0001493152-23-027263.txt : 20230809 0001493152-23-027263.hdr.sgml : 20230809 20230809080531 ACCESSION NUMBER: 0001493152-23-027263 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeterna Zentaris Inc. CENTRAL INDEX KEY: 0001113423 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38064 FILM NUMBER: 231153440 BUSINESS ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT CANADA LLP STREET 2: 222 BAY STREET, SUITE 3000, PO BOX 53 CITY: TORONTO STATE: A6 ZIP: M5K 1E7 BUSINESS PHONE: 843-900-3201 MAIL ADDRESS: STREET 1: C/O NORTON ROSE FULBRIGHT CANADA LLP STREET 2: 222 BAY STREET, SUITE 3000, PO BOX 53 CITY: TORONTO STATE: A6 ZIP: M5K 1E7 FORMER COMPANY: FORMER CONFORMED NAME: AETERNA LABORATORIES INC DATE OF NAME CHANGE: 20000503 6-K 1 form6-k.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2023

 

Commission File Number: 001-38064

 

Aeterna Zentaris Inc.

(Translation of registrant’s name into English)

 

c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form 40-F [ ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 

 

 

 

Exhibits 99.1 and 99.2 included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019) and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

DOCUMENTS INDEX

 

Exhibit   Description
99.1  

Aeterna Zentaris’ Condensed Interim Consolidated Financial Statements – Second Quarter 2023 (Q2)

99.2   Aeterna Zentaris’ Management’s Discussion and Analysis of Financial Condition and Results of Operations – Second Quarter 2023 (Q2)
99.3   Certification of the Chief Executive Officer pursuant to National Instrument 52-109
99.4   Certification of the Principal Financial Officer pursuant to National Instrument 52-109

 

(2)
 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    AETERNA ZENTARIS INC.
                    
Date: August 9, 2023   By: /s/ Klaus Paulini
      Klaus Paulini
      President and Chief Executive Officer

 

(3)

 

EX-99.1 2 ex99-1.htm
0001113423 false --12-31 2023 Q2 CA 2023-06-30 0001113423 2023-01-01 2023-06-30 0001113423 2023-06-30 0001113423 2022-12-31 0001113423 ifrs-full:IssuedCapitalMember 2022-12-31 0001113423 AEZS:WarrantsMember 2022-12-31 0001113423 ifrs-full:OtherEquityInterestMember 2022-12-31 0001113423 ifrs-full:RetainedEarningsMember 2022-12-31 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001113423 ifrs-full:IssuedCapitalMember 2021-12-31 0001113423 AEZS:WarrantsMember 2021-12-31 0001113423 ifrs-full:OtherEquityInterestMember 2021-12-31 0001113423 ifrs-full:RetainedEarningsMember 2021-12-31 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001113423 2021-12-31 0001113423 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001113423 AEZS:WarrantsMember 2023-01-01 2023-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2023-01-01 2023-06-30 0001113423 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001113423 AEZS:WarrantsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2022-01-01 2022-06-30 0001113423 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001113423 2022-01-01 2022-06-30 0001113423 ifrs-full:IssuedCapitalMember 2023-06-30 0001113423 AEZS:WarrantsMember 2023-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2023-06-30 0001113423 ifrs-full:RetainedEarningsMember 2023-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001113423 ifrs-full:IssuedCapitalMember 2022-06-30 0001113423 AEZS:WarrantsMember 2022-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2022-06-30 0001113423 ifrs-full:RetainedEarningsMember 2022-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001113423 2022-06-30 0001113423 2023-04-01 2023-06-30 0001113423 2022-04-01 2022-06-30 0001113423 2023-03-31 0001113423 2022-03-31 0001113423 AEZS:LicenseFeesMember 2023-04-01 2023-06-30 0001113423 AEZS:LicenseFeesMember 2022-04-01 2022-06-30 0001113423 AEZS:LicenseFeesMember 2023-01-01 2023-06-30 0001113423 AEZS:LicenseFeesMember 2022-01-01 2022-06-30 0001113423 AEZS:DevelopmentServicesMember 2023-04-01 2023-06-30 0001113423 AEZS:DevelopmentServicesMember 2022-04-01 2022-06-30 0001113423 AEZS:DevelopmentServicesMember 2023-01-01 2023-06-30 0001113423 AEZS:DevelopmentServicesMember 2022-01-01 2022-06-30 0001113423 AEZS:ProductSalesMember 2023-04-01 2023-06-30 0001113423 AEZS:ProductSalesMember 2022-04-01 2022-06-30 0001113423 AEZS:ProductSalesMember 2023-01-01 2023-06-30 0001113423 AEZS:ProductSalesMember 2022-01-01 2022-06-30 0001113423 AEZS:RoyaltiesMember 2023-04-01 2023-06-30 0001113423 AEZS:RoyaltiesMember 2022-04-01 2022-06-30 0001113423 AEZS:RoyaltiesMember 2023-01-01 2023-06-30 0001113423 AEZS:RoyaltiesMember 2022-01-01 2022-06-30 0001113423 AEZS:SupplyChainMember 2023-04-01 2023-06-30 0001113423 AEZS:SupplyChainMember 2022-04-01 2022-06-30 0001113423 AEZS:SupplyChainMember 2023-01-01 2023-06-30 0001113423 AEZS:SupplyChainMember 2022-01-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2023-04-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-04-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-01-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2023-04-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-04-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-01-01 2022-06-30 0001113423 AEZS:UnsatisfiedPerformanceObligationsMember 2023-03-15 0001113423 AEZS:IndicationPerformanceObligationMember 2023-03-15 0001113423 AEZS:PediatricIndicationPerformanceMember 2023-03-15 0001113423 AEZS:NovoNordiskHealthCareAGMember 2023-05-23 2023-05-23 0001113423 AEZS:NovoNordiskHealthCareMember 2023-06-30 0001113423 AEZS:PharmanoviaMember 2023-06-30 0001113423 AEZS:NKMeditechMember 2023-06-30 0001113423 AEZS:NovoNordiskHealthCareMember 2022-12-31 0001113423 AEZS:ConsilientHealthMember 2022-12-31 0001113423 AEZS:NKMeditechMember 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2023-01-01 2023-06-30 0001113423 AEZS:OtherBenefitPlansMember 2023-01-01 2023-06-30 0001113423 2022-01-01 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2022-12-31 0001113423 AEZS:OtherBenefitPlansMember 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2023-06-30 0001113423 AEZS:OtherBenefitPlansMember 2023-06-30 0001113423 AEZS:ShareholdersAndBoardOfDirectorsMember 2022-07-15 2022-07-15 0001113423 AEZS:DeferredStockUnitsMember 2022-07-15 2022-07-15 0001113423 AEZS:TwoThousandEighteenLongTermIncentivePlanMember 2023-01-16 2023-01-17 0001113423 AEZS:TwoThousandEighteenLongTermIncentivePlanMember 2022-01-16 2022-01-17 0001113423 AEZS:DeferredShareUnitMember 2023-06-14 2023-06-14 0001113423 AEZS:DeferredShareUnitMember 2022-06-14 2022-06-14 0001113423 AEZS:DeferredShareUnitMember 2023-04-01 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2023-01-01 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-04-01 2022-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-01-01 2022-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-12-31 0001113423 AEZS:DeferredShareUnitMember 2021-12-31 0001113423 AEZS:DeferredShareUnitMember 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2023-04-01 2023-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2022-04-01 2022-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2023-01-01 2023-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2022-01-01 2022-06-30 0001113423 AEZS:WarrantsMember 2023-04-01 2023-06-30 0001113423 AEZS:WarrantsMember 2022-04-01 2022-06-30 0001113423 AEZS:WarrantsMember 2023-01-01 2023-06-30 0001113423 AEZS:WarrantsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:NotLaterThanOneYearMember 2023-06-30 0001113423 AEZS:OneToThreeYearsMember 2023-06-30 0001113423 AEZS:FourToFiveYearsMember 2023-06-30 0001113423 ifrs-full:LaterThanFiveYearsMember 2023-06-30 0001113423 ifrs-full:TopOfRangeMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR AEZS:Integer iso4217:CAD xbrli:shares

 

Exhibit 99.1

 

 

Aeterna Zentaris Inc.

Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars)

(Unaudited)

 

Condensed Interim Consolidated Statements of Financial Position 2
Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity 3
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss 4
Condensed Interim Consolidated Statements of Cash Flows 5
Notes to Condensed Interim Consolidated Financial Statements 6

 

1

 

 

Aeterna Zentaris Inc.

Condensed Interim Consolidated Statements of Financial Position

 

(In thousands of US dollars)

(Unaudited)

 

   As of
June 30,
2023
   As of
December 31,
2022
 
   $   $ 
ASSETS          
Current assets          
Cash and cash equivalents   42,186    50,611 
Trade and other receivables   185    732 
Inventory   93    229 
Income taxes receivable   792    1,428 
Prepaid expenses and other current assets   2,637    2,488 
Total current assets   45,893    55,488 
           
Non-current assets          
Restricted cash equivalents   325    322 
Property and equipment   265    216 
Total non-current assets   591    538 
Total assets   46,483    56,026 
           
LIABILITIES          
Current liabilities          
Payables and accrued liabilities   3,572    3,828 
Provisions   49    45 
Income taxes payable   109    108 
Deferred revenues (note 3)   202    2,949 
Lease liabilities   145    114 
Total current liabilities   4,077    7,044 
           
Non-current liabilities          
Deferred revenues (note 3)   1,580    1,684 
Deferred gain   111    110 
Lease liabilities   85    65 
Employee future benefits (note 4)   11,381    11,159 
Provisions   170    188 
Total non-current liabilities   13,327    13,206 
Total liabilities   17,404    20,250 
           
Shareholders’ equity          
Share capital (note 5)   293,410    293,410 
Warrants   5,085    5,085 
Contributed surplus   90,654    90,332 
Deficit   (358,936)   (352,084)
Accumulated other comprehensive loss   (1,134)   (967)
Total Shareholders’ equity   29,079    35,776 
Total liabilities and shareholders’ equity   46,483    56,026 

Commitments (note 9)

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

Approved by the Board of Directors

 

/s/ Carolyn Egbert   /s/ Dennis Turpin
Carolyn Egbert, Chair of the Board   Dennis Turpin, Director

 

2

 

 

Aeterna Zentaris Inc.

Condensed Interim Consolidated Statements of Changes in Shareholders’ Equity

For the six months ended June 30, 2023, and 2022

 

(In thousands of US dollars)

(Unaudited)

 

   Share capital   Warrants   Contributed surplus   Deficit   Accumulated other comprehensive loss   Total 
   $   $   $   $   $   $ 
Balance – January 1, 2023   293,410    5,085    90,332    (352,084)   (967)   35,776 
Net loss   -    -    -    (6,772)   -    (6,772)
Other comprehensive loss:                              
Foreign currency translation adjustments   -    -    -    -    (167)   (167)
Actuarial loss on defined benefit plans (note 4)   -    -    -    (80)   -    (80)
Comprehensive loss                  (6,852)   (167)   (7,019)
Share-based compensation costs   -    -    322    -    -    322 
Balance – June 30, 2023   293,410    5,085    90,654    (358,936)   (1,134)   29,079 

 

   Share capital   Warrants   Contributed surplus   Deficit   Accumulated other comprehensive loss   Total 
   $   $   $   $   $   $ 
Balance – January 1, 2022   293,410    5,085    89,788    (334,619)   (678)   52,986 
Net loss   -    -    -    (6,856)   -    (6,856)
Other comprehensive loss:                              
Foreign currency translation adjustments   -    -    -    -    79    79 
Actuarial gain on defined benefit plans   -    -    -    8,025    -    8,025 
Comprehensive income                  1,169    79    1,248 
Share-based compensation costs   -    -    60    -    -    60 
Balance – June 30, 2022   293,410    5,085    89,848    (333,450)   (599)   54,294 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

3

 

 

Aeterna Zentaris Inc.

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

For the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data)

(Unaudited)

 

   2023   2022   2023   2022 
  

Three months ended

June 30,

  

Six months ended

June 30,

 
   2023   2022   2023   2022 
   $   $   $   $ 
Revenues (note 3)   2,246    (222)   4,374    1,295 
                     
Expenses                    
Cost of sales   139    13    156    92 
Research and development   2,929    2,398    6,941    4,788 
Selling, general and administrative   2,033    2,083    4,339    3,944 
Total expenses   5,101    4,494    11,436    8,824 
                     
Loss from operations   (2,855)   (4,716)   (7,062)   (7,529)
                     
Gain (loss) due to changes in foreign currency exchange rates   27    502    (32)   676 
Interest income   307    -    320    - 
Other finance income (costs)   3    (2)   2    (3)
Net finance income   337    500    290    673 
                     
Loss before income taxes   (2,518)   (4,216)   (6,772)   (6,856)
                     
Income tax recovery   -    -    -    - 
Net loss   (2,518)   (4,216)   (6,772)   (6,856)
                     
Other comprehensive loss:                    
Items that may be reclassified subsequently to profit or loss:                    
Foreign currency translation adjustments   3    42    (167)   79 
Items that will not be reclassified to profit or loss:                    
Actuarial gain on defined benefit plans (note 4)   83    5,276    (80)   8,025 
Comprehensive (loss) income   (2,432)   1,102    (7,019)   1,248 
                     
Basic and diluted loss per share (note 7)   (0.52)   (0.87)   (1.39)   (1.41)
                     
Weighted average number of shares outstanding (basic and diluted)   4,855,876    4,855,876    4,855,876    4,855,876 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

4

 

 

Aeterna Zentaris Inc.

Condensed Interim Consolidated Statements of Cash Flows

For the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars)

(Unaudited)

 

   2023   2022   2023   2022 
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
   $   $   $   $ 
Cash flows from operating activities                    
Net loss for the period   (2,518)   (4,216)   (6,772)   (6,856)
Items not affecting cash and cash equivalents:                    
Provisions   18    7    10    5 
Depreciation and amortization   44    35    84    71 
Share-based compensation costs   306    33    323    60 
Employee future benefits   130    98    265    197 
Amortization of deferred revenues   (794)   124    (1,554)   (704)
Net foreign exchange differences   (9)   (513)   (1)   (687)
Other non-cash items   

5

    495    5    509 
Refund (payment) of income taxes   647    (51)   647    830 
Changes in operating assets and liabilities (note 6)   (2,122)   (862)   (1,361)   264 
Net cash used in operating activities   (4,293)   (4,850)   (8,354)   (6,311)
                     
Cash flows from financing activities                    
Payments on lease liabilities   (42)   (34)   (80)   (68)
Net cash used in financing activities   (42)   (34)   (80)   (68)
                     
Cash flows from investing activities                    
Purchase of property and equipment   (3)   (42)   (5)   (48)
Net cash used in investing activities   (3)   (42)   (5)   (48)
                     
Effect of exchange rate changes on cash and cash equivalents   (36)   (513)   14    (716)
                     
Net change in cash and cash equivalents   (4,374)   (5,439)   (8,425)   (7,143)
Cash and cash equivalents – Beginning of period   46,560    63,596    50,611    65,300 
Cash and cash equivalents – End of period   42,186    58,157    42,186    58,157 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

5

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

1. Business overview

 

Summary of business

 

Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen® (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macimorelin is currently marketed under the tradename Ghryvelin™ in the European Economic Area and the United Kingdom through an exclusive licensing agreement with Pharmanovia. The Company’s several other license and commercialization partners are also seeking approval for commercialization of macimorelin in Israel and the Palestinian Authority, the Republic of Korea, Turkey and several non-European Union Balkan countries. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in North America, Asia and the rest of the world.

 

The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications.

 

These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 8, 2023.

 

2. Basis of presentation

 

These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting as issued by the International Accounting Standards Board.

 

The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

 

The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements.

 

New standards and amendments

 

Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.

 

Critical accounting estimates and judgements

 

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.

 

6

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

 

3. Revenue

 

The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories:

 

   2023   2022   2023   2022 
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
    $    $    $    $ 
License fees   795    (206)   1,554    226 
Development services   1,402    (77)   2,741    889 
Product sales   -    -    -    57 
Royalties   7    24    26    43 
Supply chain   42    37    53    80 
Total   2,246    (222)   4,374    1,295 

 

The Company recorded revenue for the transfer of services over time for the three-months ended June 30, 2023, of $2,197 (2022 – ($283)) and the six-months ended June 30, 2023, of $4,295 (2022 - $1,115). While revenue recorded at a point in time for the three-months ended June 30, 2023, was $49 (2022 – $61) and the six-months ended June 30, 2023, was $79 (2022 - $180).

 

Pharmanovia:

 

On March 15, 2023, with the Company’s consent, Consilient Health (“CH”) entered into an assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product (together, the “Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. Subsequent to the execution of the Assignment Agreement, the aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations was $1,658 (€1,540), comprised of; the combined adult indication performance obligation of $1,233 (€1,145), and the combined pediatric indication performance obligation of $425 (€395). The Company will continue to recognize revenue over time using an output method based on units of licensed product supplied to Pharmanovia. The total units that the Company expects to supply to Pharmanovia is an estimate, based on current projections and anticipated market demand, and therefore will be a significant judgement that will be relied upon when using the outputs method to recognize revenue.

 

7

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

Novo Nordisk Health Care AG:

 

On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination was effective May 23, 2023, upon the completion of a 270-day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment returned to the Company, and the Company regained full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270-day notice period, as per the terms of the Novo Amendment, Novo continued to fund DETECT-trial costs up to $10.1 million (€9.4 million). As of May 23, 2023, the Company recognized all remaining license fees associated with the Pediatric indication and development services revenue previously recorded in deferred revenue.

 

Liabilities related to contracts with customers

 

The following table provides a summary of deferred revenue balances:

 

   June 30, 2023 
   Current   Non-current   Total 
   $   $   $ 
Novo Nordisk Health Care   -    -    - 
Pharmanovia   193    1,459    1,652 
NK Meditech   9    121    130 
    202    1,580    1,782 

 

   December 31, 2022 
   Current   Non-current   Total 
   $   $   $ 
Novo Nordisk Health Care   2,914    -    2,914 
Consilient Health   35    1,556    1,591 
NK Meditech   -    128    128 
    2,949    1,684    4,633 

 

8

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

4. Employee future benefits

 

The change in the Company’s employee future benefit obligations is summarized as follows:

 

   benefit plans   benefit plans   Total   Total 
  

Six months ended

June 30, 2023

   Year ended
December 31,
2022
 
   Pension   Other         
   benefit plans   benefit plans   Total   Total 
   $   $   $   $ 
Change in plan liabilities                    
Balances – Beginning of the period   21,657    93    21,750    29,412 
Current service cost   63    6    69    142 
Interest cost   400    2    402    295 
Actuarial loss (gain) from changes in financial assumptions   143    -    143    (5,915)
Benefits paid   (380)   -    (380)   (752)
Impact of foreign exchange rate changes   261    1    262    (1,432)
Balances – End of the period   22,144    102    22,246    21,750 
                     
Change in plan assets                    
Balances – Beginning of the period   10,591    -    10,591    11,927 
Interest income from plan assets   198    -    198    120 
Employer contributions   14    -    14    45 
Employee contributions   8    -    8    10 
Benefits paid   (136)   -    (136)   (247)
Remeasurement of plan assets   63    -    63    (641)
Impact of foreign exchange rate changes   127    -    127    (623)
Balances – End of the period   10,865    -    10,865    10,591 
                     
Net liability of the unfunded plans   10,867    102    10,969    10,787 
Net liability of the funded plans   412    -    412    372 
Net amount recognized as Employee future benefits   11,279    102    11,381    11,159 
                     
Amounts recognized:                    
In net loss   257    8    265    295 
Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income   (80)   -    (80)   5,262 

 

The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 3.70% as of June 30, 2023, and 3.75% as of December 31, 2022, causing the variances in the actuarial loss (gain) on defined benefit plan during the six months ended June 30, 2023.

 

9

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

5. Shareholders’ equity

 

Share capital

 

The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.

 

   Common shares   Amount 
   #   $ 
Balance – December 31, 2022   4,855,876    293,410 
           
    -    - 
Balance – June 30, 2023   4,855,876    293,410 

 

On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of incorporation to effect a 1-for-25 share consolidation (reverse split) of the Company’s common shares. The Company’s outstanding stock options, DSUs and warrants were also adjusted to reflect the 1-for-25 share consolidation (reverse split) of the Company’s common shares. Accordingly, all common shares, DSU, warrants, stock options and per share amounts in these interim condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share consolidation (reverse split). Outstanding warrant and stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The share consolidation (reverse split) was affected on July 21, 2022.

 

Share-based compensation

 

On January 17, 2023, the Company granted 14,000 (2022 – 2,000) stock options under the Long-Term Incentive Plan. The stock options have a term of seven years and will vest over a period of three years. The fair value at grant date is estimated using a Black-Scholes option pricing model, considering the terms and conditions upon which the options were granted, using the following assumptions:

 

   June 30,
2023
   June 30,
2022
 
Expected dividend yield  $0.00   $0.00 
Expected volatility   104.46%   115.75%
Risk-free annual interest rate   3.56%   1.59%
Expected life (years)   5.45    5.72 
Share price  $3.75   $8.88 
Exercise price  $3.75   $8.88 
Grant date fair value  $2.99   $7.47 

 

The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued.

 

10

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

The compensation expense for the three months ended June 30, 2023, was $22 (2022 – $33) and the six months ended June 30, 2023, was $39 (2022 – $60) recognized over the vesting period. Option activity for the six months ended June 30, 2023, and 2022, was as follows:

 

   Stock options   Weighted average exercise price 
   #   $ 
Balance – January 1, 2023   42,030    20.05 
Granted   14,000    3.75 
Cancelled / Forfeited   -    - 
Balance – June 30, 2023   56,030    15.98 

 

   Stock options   Weighted average exercise price 
   #   $ 
Balance – January 1, 2022   43,455    22.00 
Granted   2,000    8.88 
Cancelled / Forfeited   (2,399)   10.98 
Balance – June 30, 2022   43,056    21.95 

 

Deferred share units

 

On June 14, 2023, the Company granted 100,000 (2022 – nil) DSUs under the Long-Term Incentive Plan. The compensation expense for the three and six months ended June 30, 2023, was $284 (2022 - $nil) and is presented in selling, general and administrative expenses. DSU activity for the six months ended June 30, 2023, are:

 

   2023   2022 
   #   # 
Balance – January 1,   96,920    16,920 
Granted   100,000    - 
Balance – June 30,   196,920    16,920 

 

11

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

6. Supplemental disclosure of cash flow information

 

   2023   2022   2023   2022 
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
   $   $   $   $ 
Changes in operating assets and liabilities:                    
Trade and other receivables   199    (255)   402    220 
Inventory   135    -    140    (206)
Prepaid expenses and other current assets   (748)   (1,471)   (122)   (759)
Payables and accrued liabilities   (398)   (40)   (163)   119 
Deferred revenues   (1,205)   1,001    (1,359)   1,008 
Provision for restructuring and other costs   4    -    (5)   - 
Employee future benefits   (109)   (97)   (254)   (118)
Increase (decrease) in operating assets and liabilities   (2,122)   (862)   (1,361)   264 

 

7. Net loss per share

 

The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.

 

   2023   2022   2023   2022 
   Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
   $   $   $   $ 
Net loss   (2,518)   (4,216)   (6,772)   (6,856)
Basic and diluted weighted-average shares outstanding   4,855,876    4,855,876    4,855,876    4,855,876 
                     
Basic and diluted loss per share   (0.52)   (0.87)   (1.39)   (1.41)
                     
Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:                    
Stock options and DSUs   252,950    62,375    252,950    62,375 
Warrants   457,648    457,648    457,648    457,648 

 

8. Segment information

 

The Company operates in a single operating segment, being the biopharmaceutical segment.

 

12

 

 

Aeterna Zentaris Inc.

Notes to the Condensed Interim Consolidated Financial Statements

As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

 

(In thousands of US dollars, except share and per share data and as otherwise noted)

(Unaudited)

 

9. Commitments

 

Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:

 

   TOTAL 
   $ 
Less than 1 year   7,586 
1 - 3 years   151 
4 - 5 years   37 
More than 5 years   - 
Total   7,774 

 

In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $38,887 upon achieving certain sales volumes, regulatory or other milestones related to specific products.

 

13

EX-99.2 3 ex99-2.htm

 

Exhibit 99.2

 

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Introduction

 

This Management’s Discussion and Analysis (“MD&A”) provides a review of the results of operations, financial condition and cash flows of Aeterna Zentaris Inc. for the three and six-month periods ended June 30, 2023. In this MD&A, “Aeterna Zentaris”, “Aeterna”, the “Company”, “we”, “us” and “our” mean Aeterna Zentaris Inc. and its subsidiaries. This discussion should be read in conjunction with the information contained in the Company’s unaudited condensed interim consolidated financial statements and the notes thereto as of June 30, 2023, and for the three and six-month periods ended June 30, 2023 and 2022. Our unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) applicable to the preparation of interim financial statements, including IAS 34 interim financial reporting.

 

The Company’s common shares are listed on both The Nasdaq Capital Market (“Nasdaq”) and on the Toronto Stock Exchange (“TSX”) under the symbol “AEZS”. All amounts in this MD&A are presented in thousands of United States (“U.S.”) dollars, except for share and per share data, or as otherwise noted. This MD&A was approved by the Company’s Board of Directors (the “Board”) on August 8, 2023. This MD&A is dated August 8, 2023.

 

About Forward-Looking Statements

 

This document contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation and regulations, and such statements are made pursuant to the safe-harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, these forward-looking statements can be identified by words or phrases such as “forecast”, “may”, “will”, “expect”, anticipate”, “estimate”, “intend”, “plan”, “indicate”, “believe”, “direct”, or “likely”, or the negative of these terms, or other similar expressions intended to identify forward-looking statements. In addition, any statements that refer to expectations, intentions, projections and other characterizations of future events or circumstances contain forward-looking information.

 

Forward-looking statements are based on the opinions and estimates of the Company as of the date of this MD&A, and they are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the factors described under Item 3, D. – “Risk factors” in our most recent Annual Report on Form 20-F and those relating to: Aeterna’s expectations with respect to the DETECT-trial (as defined below) (including regarding the enrollment of subjects in the DETECT-trial, the application of the macimorelin growth hormone stimulation tests and the completion of the DETECT-trial); Aeterna’s expectations regarding conducting pre-clinical research to identify and characterize an AIM Biologicals-based development candidate for the treatment of neuromyelitis optica spectrum disorder (“NMOSD”), as well as Parkinson’s disease (“PD”), and developing a manufacturing process for selected candidates; Aeterna’s expectations regarding conducting assessments in relevant PD models; the University of Queensland’s undertaking a subsequent investigator initiated clinical trial evaluating macimorelin as a potential therapeutic for the treatment of amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig’s disease, and Aeterna’s formulating a pre-clinical development plan for same; the commencement of Aeterna’s formal pre-clinical development of AEZS-150 (as a potential therapeutic in chronic hypoparathyroidism as defined below) in preparation for a potential investigational new drug (“IND”) filing for conducting the first in-human clinical study of AEZS-150; and the impacts associated with the termination of the license agreement with Novo Nordisk Healthcare AG (“Novo Nordisk” or “Novo”), as discussed below.

 

1

 

 

Forward-looking statements involve known and unknown risks and uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, among others: our reliance on the success of the pediatric clinical trial in the European Union and U.S. for Macrilen® (macimorelin); potential delays associated with the completion of the DETECT-trial; we may be unable to enroll the expected number of subjects in the DETECT-trial, and the result of the DETECT-trial may not support receipt of regulatory approval in childhood-onset growth hormone deficiency (“CGHD”); results from ongoing or planned pre-clinical studies of macimorelin by the University of Queensland or for our other products under development may not be successful or may not support advancing the product to human clinical trials; our ability to raise capital and obtain financing to continue our currently planned operations; our dependence on the success of Macrilen® (macimorelin) and related out-licensing arrangements, including the continued availability of funds and resources to successfully commercialize the product; our ability to enter into additional out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and to keep such agreements in effect; and our ability to continue to list our common shares on the Nasdaq or the TSX. These risk factors are not intended to represent a complete list of the risk factors that could affect the Company. These factors and assumptions, however, should be considered carefully. More detailed information about these and other factors is included under Item 3, D. – “Risk factors” in our most recent Annual Report on Form 20-F.

 

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Many of these factors are beyond our control. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements contained herein, except as required by applicable securities laws. New factors emerge from time to time, and it is not possible for the Company to predict all of these factors, or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement.

 

Certain forward-looking statements contained herein about prospective results of operations, financial position or cash flows may constitute a financial outlook. Such statements are based on assumptions about future events, are given as of the date hereof and are based on economic conditions, proposed courses of action and management’s assessment of currently available relevant information. The Company’s management has approved the financial outlook as of the date hereof. Readers are cautioned that such financial outlook information contained herein should not be used for purposes other than for which it is disclosed herein.

 

About Material Information

 

This MD&A includes information that we believe to be material to investors after considering all circumstances. We consider information and disclosures to be material if they result in, or would reasonably be expected to result in, a significant change in the market price or value of our securities, or where it is likely that a reasonable investor would consider the information and disclosures to be important in making an investment decision.

 

We are a reporting issuer under the securities legislation of all of the provinces of Canada, and our securities are registered with the U.S. Securities and Exchange Commission (“SEC”). We are therefore required to file or furnish continuous disclosure information, such as interim and annual financial statements, management’s discussion and analysis, proxy or information circulars, annual reports on Form 20-F, material change reports and press releases with the appropriate securities regulatory authorities. Additional information about the Company and copies of these documents may be obtained free of charge upon request from our Corporate Secretary or on the Internet at the following addresses: www.zentaris.com, www.sedarplus.caand www.sec.gov.

 

2

 

 

Company Overview

 

Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen® (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macimorelin is currently marketed under the tradename Ghryvelin™ in the European Economic Area and the United Kingdom through an exclusive licensing agreement with Pharmanovia. The Company’s several other license and commercialization partners are also seeking approval for commercialization of macimorelin in Israel and the Palestinian Authority, the Republic of Korea, Turkey and several non-European Union Balkan countries. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in North America, Asia and the rest of the world. We are also leveraging the clinical success and compelling safety profile of macimorelin to develop the compound for the diagnosis of CGHD, an area of significant unmet need.

 

The Company is also dedicated to the development of therapeutic assets and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, with a focus on rare or orphan indications, including, Neuromyelitis Optica Spectrum Disorder (NMOSD), Parkinson’s Disease (PD), chronic hypoparathyroidism and ALS (Lou Gehrig’s Disease).

 

Key Operational Developments

 

 

Macimorelin Commercialization Program

 

On March 15, 2023, with the Company’s consent, Consilient Health Limited (“CH”) entered into an assignment agreement with Atnahs Pharma UK Ltd. (Pharmanovia) to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product. Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. To date, we have received total pricing milestone payments from CH of $0.5 million (€0.5 million) relating to Ghryvelin™ approved list prices in the United Kingdom, German and Spain. We shipped initial batches of macimorelin (Ghryvelin™) to Consilient in the first quarter of 2022. Consilient launched the product meanwhile in the United Kingdom, Sweden, Denmark, Finland, Germany and Austria. More EU countries will follow pending re-imbursement negotiations. On April 19, 2022, we announced that European Patent Office had issued a patent providing intellectual property protection of macimorelin in 27 countries within the European Union as well as additional European non-EU countries, such as the UK and Turkey, for macimorelin (Ghryvelin™; Macrilen®) for use to diagnose GHD in adults.

 

3

 

 

On May 9, 2023, the USPTO issued patent US11,644,474 to the Company protecting the use of macimorelin for the diagnosis of GHD in pediatrics.

 

Since November 2020, Novo marketed macimorelin under the tradename Macrilen® through a license agreement and an amended license agreement (collectively the “Novo Amendment”) for the diagnosis of AGHD. On August 26, 2022, the Company announced that Novo had exercised its right to terminate the Novo Amendment. Following a 270-day notice period, Aeterna regained full rights to Macrilen® in the U.S. and Canada on May 23, 2023, and the sales of Macrilen® are temporarily discontinued in the U.S. commercial market for the diagnosis of AGHD, until an anticipated re-launch with an alternate commercialization partner. The Company continues to actively strategize and seek alternate development and commercialization partners for Macrilen® in the U.S. and other territories. The decision to temporarily discontinue sales of Macrilen® in the United States does not have any impact on the sales and commercialization efforts in the UK and European Economic Area.

 

On June 25, 2020, we announced that we entered into an exclusive distribution and related quality agreement with MegaPharm Ltd., a leading Israel-based biopharmaceutical company, for the commercialization in Israel and in the Palestinian Authority of macimorelin, to be used in the diagnosis of patients with AGHD and in clinical development for the diagnosis of CGHD. Under the terms of the agreement, MegaPharm Ltd. will be responsible for obtaining registration to market macimorelin in Israel and the Palestinian Authority, while the Company will be responsible for manufacturing, product supply, quality assurance and control, regulatory support, and maintenance of the relevant intellectual property. In June 2021, MegaPharm Ltd. filed an application to the Ministry of Health of Israel for regulatory approval of macimorelin in Israel, which was approved in November 2022.

 

We entered into license and supply agreements with NK Meditech Ltd. (“NK”), a subsidiary of PharmBio Korea, effective November 30, 2021, and a distribution and commercialization agreement with ER Kim Pharmaceuticals Bulgaria Eood (“ER-Kim”), effective February 1, 2022. The agreements with NK are related to the development and commercialization of macimorelin for the diagnosis of AGHD and CGHD in the Republic of Korea, while the agreement with ER-Kim is related to the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries.

 

Macimorelin Clinical Program

 

On January 28, 2020, we announced the successful completion of patient recruitment for the first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of GHD in children. This study, AEZS-130-P01 (“Study P01”), was the first of two studies as agreed with the EMA in our Pediatric Investigation Plan (the “PIP”) for macimorelin as a GHD diagnostic. Macimorelin, a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland into the circulatory system. The goal of Study P01 was to establish a dose that can both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD. The recommended dose derived from Study P01 is being evaluated in the pivotal second study, Study P02, on diagnostic efficacy and safety (the “DETECT-trial”). Study P01 was an international, multicenter study, which was conducted in Hungary, Poland, Ukraine, Serbia, Belarus and Russia. Study P01 was an open label, group comparison, dose escalation trial designed to investigate the safety, tolerability, and pharmacokinetic/pharmacodynamic (“PK/PD”) of macimorelin acetate after ascending single oral doses of macimorelin at 0.25, 0.5, and 1.0 milligram per kilogram body weight in pediatric patients from 2 to less than 18 years of age with suspected CGHD. We enrolled a total of 24 pediatric patients across the three cohorts of the study. Per study protocol, all enrolled patients completed four study visits after successful completion of the screening period. At Visit 1 and Visit 3, a provocative growth hormone stimulation test was conducted according to the study sites’ local practices. At Visit 2, the macimorelin test was performed, and following the oral administration of the macimorelin solution, blood samples were taken at predefined times for PK/PD assessment. Visit 4 was a safety follow-up visit at study end.

 

4

 

 

The final study results from Study P01 were published in the second quarter of 2020 indicating positive safety and tolerability data for use of macimorelin in CGHD, as well as PK/PD data observed in a range as expected from the adult studies.

 

On April 7, 2020, we announced the decision of the EMA to accept our modification request of our PIP as originally approved in March 2017, which covered the conduct of two pediatric studies and defined relevant key elements in the outline of these studies. We believe this EMA decision supports the development of one globally harmonized study protocol for test validation, specifically Study P02, which we expect to be accepted both in Europe and the U.S.

 

In late 2020, we entered into the start-up phase for the clinical safety and efficacy study, AEZS-130-P02 (“DETECT-trial”), evaluating macimorelin for the diagnosis of CGHD. The DETECT-trial is an open-label, single dose, multicenter and multinational study expected to enroll approximately 100 subjects worldwide (incl. sites in U.S: and EU), with at least 40 pre-pubertal and 40 pubertal subjects. The study design is expected to be suitable to support a claim for potential stand-alone testing, if successful. On April 22, 2021, the U.S. FDA Investigational New Drug Application associated with this clinical trial became active, (see: https://clinicaltrials.gov/ct2/show/NCT04786873), and on May 13, 2021, we announced the opening of the first clinical site in the U.S. Under the Novo Amendment, and following Novo’s notice to terminate the Novo Amendment, Novo will fund DETECT-trial costs up to $10.1 million (€9.4 million). Any additional trial costs incurred over $10.1 million (€9.4 million) will be paid by Aeterna.

 

On January 26, 2022, we announced that the DETECT-trial had experienced unavoidable delays in site initiation and patient enrollment due to the rise of the Omicron variant in the COVID-19 pandemic. Furthermore, in February 2022, due to the Russian invasion of Ukraine, the clinical trial activities planned in both Russia and Ukraine were halted and consequently, no patients have been enrolled in either of these countries’ clinical sites to date. On January 17, 2023, we provided a business update, highlighting that bolstered enrollment was expected by the engagement of an additional Clinical Research Organization (CRO) and the replacement of inactive countries and sites with three new countries (Armenia, Slovakia, and Turkey) as well as additional sites in the U.S. In March 2023, we received approval for and activated our first site in Slovakia and expect the approval and activation of sites in Armenia and Turkey to follow in Q3, 2023. We expect enrollment in our DETECT-trial to be completed by the end of 2023.

 

Pipeline Expansion Opportunities

 

 

5

 

 

AIM Biologicals: Targeted, highly specific autoimmunity modifying therapeutics for the potential treatment of neuromyelitis optica spectrum disorder and Parkinson’s disease

 

AIM Biologicals is based on a natural process during pregnancy, which induces immunogenic tolerance of the maternal immune system to the partially foreign fetal antigens. Fetal proteins are processed and presented on certain immunosuppressive major histocompatibility complex class I molecules to induce this tolerance. In an autoimmune disease the immune system is misdirected and targets the body’s own protein. With AIM Biologicals, we aim to restore the tolerance against such proteins to treat autoimmune diseases. Our AIM Biologics program is focused on the rare and orphan indication NMOSD and the second most common neurodegenerative disorder, Parkinson’s disease.

 

In January 2021, we entered into an exclusive patent license and research agreement with the University of Wuerzburg, Germany, for worldwide rights to develop, manufacture, and commercialize AIM Biologicals for the potential treatment of NMOSD. Additionally, we have engaged Prof. Dr. Joerg Wischhusen from the University Hospital in Wuerzburg as well as neuro-immunologist Dr. Michael Levy from the Massachusetts General Hospital in Boston as consultants for scientific support and advice in the field of inflammatory central nervous system “CNS” disorders, autoimmune diseases of the nervous system, and NMOSD. In September 2021, we entered into an additional exclusive license with the University of Wuerzburg for early pre-clinical development towards the potential treatment of Parkinson’s disease. On May 12, 2022 we announced positive pre-clinical results in an innovative mouse model of Parkinson’s disease, where treatment with α-Synuclein specific AIM Biologicals showed a trend towards improved motoric function, as well as significant induction of regulatory T cells and rescue of substantia nigra neurons. The data were presented at IMMUNOLOGY2022™, the annual event of the American Association of Immunologists, held on May 6-10, 2022 in Portland, Oregon. On June 13, 2022, we announced that we had achieved proof-of-concept for the treatment of NMOSD in both in-vitro and in mouse models. These findings were presented at the 13th International Congress on Autoimmunity on June 10-13, 2022, in Athens, Greece. In October 2022, we entered into a research and development agreement with Massachusetts General Hospital (MGH) in Boston and Dr. Michael Levy, to conduct pre-clinical ex-vivo and in-vivo studies in NMOSD.

 

NMOSD is an autoimmune disease targeting the protein aquaporin 4, primarily found in optic nerves and the spinal cord. The disease leading to blindness and paralysis has a prevalence of 0.7-10 in 100,000, more common in persons with Asian or African compared to European ancestors, and nine times more prevalent among women compared to men. NMOSD progresses in often life-threatening relapses, which are aggressively treated with high-dose steroids and plasmapheresis. Current treatment options include treatment with immunosuppressive monoclonal antibodies, which carries risk of serious infections. Our pre-clinical plans include expanding the already available proof-of-concept data for the treatment of NMOSD in both in-vitro and in-vivo assessments to select an AIM Biologicals-based development candidate; and manufacturing process development for the selected candidate.

 

Parkinson’s disease is a neurological disease commonly associated with motoric problems with a slow and fast progression form. It is the second most common neurodegenerative disease affecting 10 million people worldwide. The hallmark of PD is the neuronal inclusion of mainly α-synuclein protein (αSyn) associated with the death of dopamine-producing cells. Dopaminergic medication is the mainstay treatment of PD symptoms, but currently there is no pharmacological therapy to prevent or delay disease progression leading to alternate treatments, such as deep brain stimulation with short electric bursts, being investigated for the treatment of symptoms. For the development of AIM Biologicals as potential PD therapeutics, Aeterna plans utilizes, among others, an innovative animal model on neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice, which has recently been published by University of Wuerzburg researchers. We are continuing in-vitro and in-vivo testing of antigen-specific AIM Biologics candidate molecules for the potential treatment of Parkinson’s disease.

 

6

 

 

AEZS-150 - Delayed Clearance (“DC”) Parathyroid Hormone (“PTH”) (“DC-PTH”) Fusion Polypeptides: Potential treatment for chronic hypoparathyroidism

 

On March 11, 2021, we entered into an exclusive license agreement with The University of Sheffield, United Kingdom, for the intellectual property relating to PTH fusion polypeptides covering the field of human use, which will initially be studied by Aeterna for the potential therapeutic treatment of chronic hypoparathyroidism (“HypoPT”). Under the terms of the exclusive patent and know-how license agreement entered into with the University of Sheffield, we obtained worldwide rights to develop, manufacture and commercialize PTH fusion polypeptides covered by the licensed patent applications for all human uses for an up-front cash payment, and milestone payments to be paid upon the achievement of certain development, regulatory and sales milestones, as well as low single digit royalty payments on net sales of those products and certain fees payable in connection with sublicensing. We will be responsible for the further development, manufacturing, approval, and commercialization of the licensed products. We also engaged the University of Sheffield under a research contract to conduct certain research activities to be funded by Aeterna, the results of which will be included within the scope of the license granted to Aeterna.

 

The researchers at the University of Sheffield have developed a method to increase the serum clearance time of peptides, which the Company is applying to the development of a treatment for HypoPT. HypoPT is an orphan disease where the PTH level is abnormally low or absent, with a prevalence per 100,000 of 37 in the U.S., 22 in Denmark, 9.4 in Norway, and 5.3 to 27 in Italy. Standard treatment is calcium and vitamin D supplementation. In consultation with The University of Sheffield, Aeterna has selected AEZS-150 as the lead candidate in its DC-PTH program. AEZS-150 is being developed to provide a weekly treatment option of chronic hypoparathyroidism in adults. Recent progress includes the successful verification and reproduction of previous in-vivo data from the University of Sheffield, in a rat model of hypoparathyroidism, as well as ongoing development of the manufacturing process for AEZS-150 with the Company’s contract development and manufacturing organization, establishment of a master cell bank for a cell line expressing AEZS-150 and the development of a production process suitable for larger scale good manufacturing practices. Our next steps include working with The University of Sheffield to continue with in depth characterization of development candidate (in-vitro and in-vivo); meeting with regulatory authorities to formalize the pre-clinical development of AEZS-150 in preparation for a potential IND filing for conducting the first in-human clinical study.

 

AEZS-130 - Macimorelin Pre-clinical Program

 

On January 13, 2021, we entered into a material transfer agreement with Queensland University to provide macimorelin for the conduct of preclinical and clinical studies evaluating macimorelin as a therapeutic for the treatment of ALS. ALS is a rare progressive neurological disease primarily affecting the neurons controlling voluntary movement, leading to the disability to control movements such as walking, talking, and chewing. Most people with ALS die from respiratory failure, usually between 3-5 years after diagnosis. Currently there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. Ghrelin is a hormone with wide-ranging biological actions, most known for stimulating growth hormone release, which is demonstrating emerging evidence as therapeutic for ALS. As a ghrelin agonist, macimorelin has the potential as a treatment for ALS, which is evaluated in this research collaboration.

 

The University of Queensland researchers have filed for supportive grants to conduct such clinical studies. In July 2022, we entered a research and option to license agreement with UniQuest Pty Ltd., the commercialization company of The University of Queensland (UQ), Brisbane, Australia, to advance the development of macimorelin as a potential therapeutic for the treatment of ALS. We have developed an alternative formulation suitable for use in ALS patients and are accumulating data for positive effects of AEZS-130 treatment on survival of motor-neurons. We are continuing to evaluate AEZS-130 in transgenic mouse ALS models as well as in human patient-derived neuron cultures to demonstrate the therapeutic potential of macimorelin in this indication. Our next steps include completion of the ongoing toxicology and safety studies to support treatment over prolonged periods and following potential achievement of proof-of-concept, scientific advice with regulatory authorities to discuss program development to support first in human studies.

 

7

 

 

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss Data

 

  

Three months ended

June 30,

  

Six months ended

June 30,

 
   2023   2022   2023   2022 
   $   $   $   $ 
Revenues   2,246    (222)   4,374    1,295 
                     
Expenses                    
Cost of sales   139    13    156    92 
Research and development   2,929    2,398    6,941    4,788 
Selling, general and administrative   2,033    2,083    4,339    3,944 
Total expenses   5,101    4,494    11,436    8,824 
                     
Loss from operations   (2,855)   (4,716)   (7,062)   (7,529)
                     
Gain (loss) due to changes in foreign currency exchange rates   27    502    (32)   676 
Interest income   307    -    320    - 
Other finance income (costs)   3    (2)   2    (3)
Net finance income   337    500    290    673 
                     
Loss before income taxes   (2,518)   (4,216)   (6,772)   (6,856)
                     
Income tax recovery   -    -    -    - 
Net loss   (2,518)   (4,216)   (6,772)   (6,856)
                     
Other comprehensive loss:                    
Foreign currency translation adjustments   3    42    (167)   79 
Actuarial gain on defined benefit plans   83    5,276    (80)   8,025 
Comprehensive (loss) income   (2,432)   1,102    (7,019)   1,248 
                     
Basic and diluted loss per share   (0.52)   (0.87)   (1.39)   (1.41)

 

8

 

 

Summarized Interim Consolidated Statements of Financial Position Data

 

(in thousands) 

June 30,

2023

   December 31,
2022
 
   $   $ 
Cash and cash equivalents   42,186    50,611 
Trade and other receivables and other current assets   3,614    4,648 
Inventory   93    229 
Restricted cash equivalents   325    322 
Property and equipment   265    216 
Total assets   46,483    56,026 
Payables and accrued liabilities and income taxes payable   3,681    3,936 
Current portion of provisions   49    45 
Current portion of deferred revenues   202    2,949 
Lease liabilities   145    114 
Non-financial non-current liabilities (1)   13,327    13,206 
Total liabilities   17,404    20,250 
Shareholders’ equity   29,079    35,776 
Total liabilities and shareholders’ equity   46,483    56,026 

 

(1) Comprised mainly of employee future benefits, provisions and non-current portion of deferred revenues.

 

Critical Accounting Policies, Estimates and Judgments

 

The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.

 

Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

 

Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements for the year ended December 31, 2022.

 

Financial Risk Factors and Other Financial Instruments

 

The nature and extent of our exposure to risks arising from financial instruments, including credit risk, liquidity risk and market risk and how we manage those risks are described in note 24 to the Company’s audited consolidated financial statements for the year ended December 31, 2022. There were no significant changes in the three and six-month periods ended June 30, 2023, as compared to the December 31, 2022, disclosures.

 

9

 

 

Revenues

 

We generate revenue from license and collaboration agreements with customers (license fees, milestone revenue, royalties), the provision of development services, the sale of certain active pharmaceutical ingredients (“API”), semi-finished goods and finished goods, and from certain supply chain activities, which are comprised largely of oversight or supervisory support services related to stability studies or development activities carried out with respect to API batch production as specified in underlying contracts with customers.

 

(in thousands, except percentages)  Three month ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Revenue                    
License fees   795    (206)   1,001    486%
Development services   1,402    (77)   1,479    1,921%
Royalties   7    24    (17)   -71%
Supply chain   42    37    5    14%
Total revenue   2,246    (222)   2,468    1,112%

 

Our total revenue for the three-month period ended June 30, 2023, was $2.2 million as compared to ($0.2) million for the same period in 2022, representing an increase of $2.5 million. The increase is due to an increase in license fee revenue recognized of $1.0 million and development services revenue of $1.5 million relating to the Company’s amended agreement with Novo Nordisk Healthcare.

 

The negative revenue of $0.2 million for the three-month ended June 30, 2022, was driven by the reversal of revenue of $0.4 million in license fees and $0.8 million in development services in Q2, 2022 as a result of a change in management’s best estimate of additional costs associated to the DETECT-trial.

 

(in thousands, except percentages)  Six month ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Revenue                    
License fees   1,554    226    1,328    588%
Development services   2,741    889    1,852    208%
Product sales   -    57    (57)   -100%
Royalties   26    43    (17)   -40%
Supply chain   53    80    (27)   -34%
Total revenue   4,374    1,295    3,079    238%

 

Our total revenue for the six-month period ended June 30, 2023, was $4.4 million as compared to $1.3 million for the same period in 2022, representing an increase of $3.1 million. The increase is due to an increase in license fee revenue recognized of $1.3 million and development services revenue of $1.9 million relating to the Company’s amended agreement with Novo Nordisk Healthcare, offset by a $0.1 million decrease in product sales.

 

10

 

 

Research and development expenses

 

The following table summarizes our research and development expenses incurred during the periods indicated:

 

(in thousands, except percentages)  Three months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Direct research and development expenses:                    
Macimorelin pediatric DETECT-trial   1,154    651    503    77%
AEZS-130 – Macimorelin ALS   550    419    131    31%
AEZS-150 – DC-PTH   396    447    (51)   -11%
Aim Biologics - Parkinson’s Disease   168    161    7    4%
Aim Biologics - NMOSD   213    115    98    85%
Bacterial Vaccine Platform - Covid-19   (5)   146    (151)   -103%
Bacterial Vaccine Platform - Chlamydia   3    107    (104)   -97%
Additional programs   56    11    45    409%
Total direct research and development expenses   2,535    2,057    478    23%
Employee-related expenses   311    294    17    6%
Facilities, depreciation, and other expenses   83    47    36    77%
Total research and development expenses   2,929    2,398    531    22%

 

Research and development expenses increased by $0.5 million for the three months ended June 30, 2023, compared to the three months ended June 30, 2022, primarily driven by a $0.5 million increase in direct research and development expenses. Direct research and development expenses include expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturers, and consultants. The $0.5 million increase in total direct research and development expenses for the three months ended June 30, 2023, was primarily due to a $0.5 million increase in costs for the DETECT-trial. The Company has seen a significant increase in the number of testing sites opened and the recruitment of patients for the DETECT-trial leading to the increase in cost from the comparative period when the company was primarily focused on establishing testing sites for patient enrollment.

 

In addition to the DETECT-trial, the Company was actively working with its university research partners on the named pre-clinical programs. The fluctuation in spend on these programs from the prior year is primarily driven by the timing of various pre-clinical activities and the advancement of these projects, in particular the AEZS-150 and DC-PTH projects which were in licensed in 2021.

 

Lastly, the Company ceased its development of both the COVID-19 and Chlamydia vaccine trials in Q1, 2023, resulting in the decrease in spending on these two projects for the three months ended June 30, 2023, compared to the three months ended June 30, 2022.

 

11

 

 

The following table summarizes our research and development expenses incurred during the periods indicated:

 

(in thousands, except percentages)  Six months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Direct research and development expenses:                    
Macimorelin pediatric DETECT-trial   2,245    1,547    698    45%
AEZS-130 – Macimorelin ALS   1,644    696    948    136%
AEZS-150 – DC-PTH   959    715    244    34%
Aim Biologics - Parkinson’s Disease   358    350    8    2%
Aim Biologics - NMOSD   459    204    255    125%
Bacterial Vaccine Platform - Covid-19   113    194    (81)   -42%
Bacterial Vaccine Platform - Chlamydia   221    225    (4)   -2%
Additional programs   127    147    (20)   -14%
Total direct research and development expenses   6,126    4,078    2,048    50%
Employee-related expenses   639    618    21    3%
Facilities, depreciation, and other expenses   176    92    84    91%
Total research and development expenses   6,941    4,788    2,153    45%

 

Research and development expenses increased by $2.2 million for the six months ended June 30, 2023, compared to the six months ended June 30, 2022, primarily driven by a $2.0 million increase in direct research and development expenses. Direct research and development expenses include expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturers, and consultants. The $2.0 million increase in total direct research and development expenses for the six months ended June 30, 2023, was primarily due to a $0.7 million increase in costs for the DETECT-trial. The Company has seen a significant increase in the number of testing sites opened and the recruitment of patients for the DETECT-trial leading to the increase in cost from the previous year when the company was primarily focused on establishing testing sites for patient enrollment.

 

In addition to the DETECT-trial, the Company was actively working with its university research partners on the named pre-clinical programs. The increase in spend of $0.9 million for the six-month period ended June 30, 2023 compared to the period ended June 30, 2022 for the AEZS-130, ALS program, relates to an increase in the companies pre-clinical activities, primarily the ongoing toxicology and safety studies. The fluctuation in spending on the DC-PTH and the two Aim Biologic projects from the prior year is primarily driven by the timing of various pre-clinical activities and the advancement of these projects.

 

Lastly, the Company ceased its development of both the COVID-19 and Chlamydia vaccine trials in Q1, 2023, resulting in the decrease in spending on these two projects for the six months ended June 30, 2023, compared to the six months ended June 30, 2022.

 

12

 

 

Selling, general and administrative expenses

 

The following table summarizes our Selling, general and administrative expenses incurred during the periods indicated:

 

(in thousands, except percentages)  Three months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Selling, general and administrative expenses:                    
Salaries & benefits   1,002    455    547    120%
Insurance   250    423    (173)   -41%
Professional fees   434    939    (505)   -54%
Other office & general expenses   347    266    81    30%
Total selling, general and administrative expenses   2,033    2,083    (50)   -2%

 

Our total Selling, general and administrative expenses for the three-month period ended June 30, 2023, were $2.0 million as compared to $2.1 million for the same period in 2022 representing a decrease of $0.1 million. This decrease arose primarily from a $0.5 million decline in Professional fees and a $0.2 million decline in insurance costs offset by a $0.5 million increase in salaries and benefits and a $0.1 million increase in other office & general expenses. The increase in salaries and benefits expense primarily relates to the timing of the issuance of deferred share units of $0.3 million to the Company’s Board of Directors, which were issued in June 2023 for the current year entitlement, compared with August 2022 for the entitlement in the prior year.

 

The following table summarizes our Selling, general and administrative expenses incurred during the periods indicated:

 

(in thousands, except percentages)  Six months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Selling, general and administrative expenses:                    
Salaries & benefits   1,761    1,038    723    70%
Insurance   678    842    (164)   -19%
Professional fees   1,183    1,518    (335)   -22%
Other office & general expenses   717    546    171    31%
Total selling, general and administrative expenses   4,339    3,944    395    10%

 

Our total Selling, general and administrative expenses for the six-month period ended June 30, 2023, were $4.3 million as compared to $3.9 million for the same period in 2022 representing an increase of $0.4 million. The $0.7 million increase in salaries and benefits primarily relates to the timing of the issuance of deferred share units of $0.3 million to the Company’s Board of Directors, which were issued in June 2023 for the current year entitlement, compared with August 2022 for the entitlement in the prior year. The remaining increase is due to a $0.2 million increase in other office & general expenses offset by a $0.3 million decline in professional fees and a $0.2 million decline in insurance costs.

 

13

 

 

Net finance income

 

(in thousands, except percentages)  Three months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Gain (loss) due to changes in foreign currency rates   27    502    (475)   -95%
Interest income   307    -    307    100%
Other finance income (costs)   3    (2)   5    -250%
Net finance income   337    500    (163)   -33%

 

For the three-month period ended June 30, 2023, our net finance cost was $0.3 million as compared to a net finance income of $0.5 million for the three-month period ended June 30, 2022. This is primarily due to a $0.5 million decrease in our gain (loss) due to changes in foreign currency offset by an increase in interest earned on bank deposits of $0.3 million.

 

(in thousands, except percentages)  Six months ended June 30, 
   2023   2022   Change   Change 
    $    $    $    % 
Gain (loss) due to changes in foreign currency rates   (32)   676    (708)   -105%
Interest income   320    -    320    100%
Other finance income (costs)   2    (3)   5    -167%
Net finance income   290    673    (383)   -57%

 

Our net finance income for the six-month period ended June 30, 2023, was $0.3 million as compared to $0.7 million for the same period in 2022, representing a decrease of $0.4 million. This is primarily due to a $0.7 million decrease in gain (loss) due to changes in foreign currency offset by an increase in interest earned on bank deposits of $0.3 million.

 

Net loss

 

For the three-month period ended June 30, 2023, we reported a consolidated net loss of $2.5 million, or $0.52 loss per common share (basic), as compared with a consolidated net loss of $4.2 million, or $0.87 loss per common share (basic) for the three-month period ended June 30, 2022. The $1.7 million decrease in net loss is primarily due to a $2.5 million increase in revenue, offset by a $0.5 million increase in research and development expenses, a $0.1 million increase in cost of sales and a $0.2 million decrease in net finance income.

 

For the six-month period ended June 30, 2023, we reported a consolidated net loss of $6.8 million, or $1.39 loss per common share (basic), as compared with a consolidated net loss of $6.9 million, or $1.41 loss per common share (basic) for the six-month period ended June 30, 2022. The $0.1 million decrease in net loss is primarily from a $3.1 million increase in revenue off-set by a $0.1 million increase in cost of sales, a $2.2 million in research and development expenses, a $0.4 million increase in selling, general and administrative expenses, and a $0.4 million decrease in net finance income.

 

14

 

 

Selected quarterly financial data

 

   Three months ended 
(in thousands, except for per share data) 

June 30,

2023

   March 31, 2023   December 31,
2022
   September 30,
2022
 
    $    $    $    $ 
Revenues   2,246    2,128    2,485    1,860 
Net loss   (2,518)   (4,255)   (12,451)   (3,420)
Net loss per share (basic and diluted) (1)   (0.52)   (0.88)   (2.56)   (0.70)

 

   Three months ended 
(in thousands, except for per share data) 

June 30,

2022

   March 31, 2022   December 31, 2021   September 30, 2021 
    $    $    $    $ 
Revenues   (222)   1,517    956    1,052 
Net loss   (4,216)   (2,640)   (2,894)   (1,932)
Net loss per share (basic and diluted) (1)   (0.87)   (0.54)   (0.63)   (0.40)

 

(1) Net loss per share is based on the weighted average number of shares outstanding during each reporting period, which may differ on a quarter-to-quarter basis. As such, the sum of the quarterly net loss per share amounts may not equal full-year net loss per share.

 

Historical quarterly results of operations and net loss cannot be taken as reflective of recurring revenue or expenditure patterns of predictable trends, largely given the non-recurring nature of certain components of our historical revenues, the impact of costs associated with launching a number of significant preclinical research and development programs in 2021, and of foreign exchange gains and losses. In addition, we cannot predict what the revenues from royalties will be earned from licensing agreements.

 

The increase in net loss for the three-month period ended December 31, 2022, was due to the recording of an impairment charge on the Company’s goodwill and intangible assets for an amount of $7,642 and $372 respectively.

 

The decrease in revenue and increase in net loss for the three-month ended June 30, 2022 was driven by the reversal of revenue of $0.4 million in license fees and $0.8 million in development services which took place in Q2, 2022 as a result of a change in management’s best estimate of additional costs associated to the DETECT-trial.

 

Cash flows

 

The following table shows a summary of our consolidated cash flows for the periods indicated:

 

(in thousands)  Three months ended   Six months ended 
   June 30,   June 30, 
   2023   2022   2023   2022 
    $    $    $    $ 
Cash and cash equivalents – Beginning of period   46,560    63,596    50,611    65,300 
Net cash used in operating activities   (4,293)   (4,850)   (8,354)   (6,311)
Net cash used in financing activities   (42)   (34)   (80)   (68)
Net cash used in investing activities   (3)   (42)   (5)   (48)
Effect of exchange rate changes on cash & cash equivalents   (36)   (513)   14    (716)
Cash and cash equivalents – End of period   42,186    58,157    42,186    58,157 

 

Operating Activities

 

Cash used by operating activities totaled $4.3 million for the three-month periods ended June 30, 2023, as compared to $4.9 million in the same periods in 2022. This $0.6 million decrease in the three-month periods ended June 30, 2023, in use of cash in operating activities is attributed primarily to increase in interest income combined with decrease in selling, general and administrative expenses offset by an increase in research and development expenses, as described above.  

 

15

 

 

Cash used by operating activities totaled $8.4 million for the six-month periods ended June 30, 2023, as compared to $6.3 million in the same periods in 2022. This $2.1 million increase in the six-months periods ended June 30, 2023, in use of cash in operating activities is attributed primarily to increased research and development and selling, general and administrative expenses offset by increases in revenue, as described above.

 

Liquidity and capital resources

 

The Company’s objective in managing capital, consisting of shareholders’ equity, with cash and cash equivalents being its primary components, is to ensure sufficient liquidity to fund research and development costs, selling expenses, general and administrative expenses and working capital requirements. Over the past several years, we have raised capital via public and private equity offerings and issuances and have entered licensing and collaborative arrangements, consideration from which, together with proceeds from equity issuances, has been our primary source of liquidity. The capital management objective of the Company remains the same as that in previous periods. The policy on dividends is to retain cash to keep funds available, to finance the activities required to advance the Company’s product development portfolio and to pursue appropriate commercial opportunities as they may arise. The Company is not subject to any capital requirements imposed by any regulators or by any other external source.

 

Adequacy of financial resources

 

Since inception, the Company has incurred significant expenses in its efforts to develop and co-promote products. Our current business focus is to: investigate further therapeutic uses of Macrilen™, expand pipeline development activities, further expand the commercialization of macimorelin in available territories and fund ongoing clinical trial costs. Consequently, the Company has incurred operating losses and has generated negative cash flow from operations and in each of the last several years except for the year ended December 31, 2018, when the Company earned revenue from the sale of a license for the adult indication of Macrilen™ in the U.S. and Canada. The Company expects to incur significant expenses and operating losses for the foreseeable future as it advances its product candidates through preclinical and clinical development, seeks regulatory approval, and pursues commercialization of any approved product candidates. We expect that our research and development costs will increase in connection with our planned research and development activities.

 

As of June 30, 2023, the Company had an accumulated deficit of $358.9 million. The Company also had a net loss of $6.9 million and negative cash flows from operations of $8.4 million for the six-month period ended June 30, 2023. We believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements for at least the next 12 months. We plan to finance our future operations and capital expenditures primarily through cash on hand. We also believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements beyond the next 12 months and through 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates.

Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially as a result of a number of factors. Our future capital requirements are difficult to forecast and will depend on many factors, including:

 

  the terms and timing of any other collaboration, licensing, and other arrangements that we may establish;
  the initiation, progress, timing, and completion of preclinical studies and clinical trials for our current and future potential product candidates;
  our alignment with the FDA on regulatory approval requirements;
  the number and characteristics of product candidates that we pursue;
  the outcome, timing, and cost of regulatory approvals;
  delays that may be caused by changing regulatory requirements;
  the cost and timing of hiring new employees to support our continued growth;
  the ability to manage inflation, including rising interest rates and increased labor costs associated with attracting and retaining employees;
  the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;

 

16

 

 

  the costs of filing and prosecuting intellectual property rights and enforcing and defending any intellectual property-related claims;
  the costs of responding to and defending ourselves against complaints and potential litigation;
  the costs and timing of procuring clinical and commercial supplies for our product candidates; and
  the extent to which we acquire or in-license other product candidates and technologies.

 

Contractual obligations and commitments as of June 30, 2023

 

Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:

 

(in thousands)  TOTAL 
    $ 
Less than 1 year   7,586 
1 - 3 years   151 
4 - 5 years   37 
More than 5 years   - 
    7,774 

 

In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $38,887 upon achieving certain sales volumes, regulatory or other milestones related to specific products.

 

Contingencies

 

In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, contract terminations and employee-related and other matters.

 

Related Party Transactions and Off-Balance Sheet Arrangements

 

Other than employment agreements and indemnification agreements with our management, there are no related party transactions.

 

As of June 30, 2023, we did not have any interests in special purpose entities or any other off-balance sheet arrangements.

 

Risk Factors and Uncertainties

 

An investment in our securities involves a high degree of risk. In addition to the other information included in this MD&A and in the related consolidated financial statements, investors are urged to carefully consider the risks described under the caption “Risk Factors” in our most recent Annual Report on Form 20-F for the year ended December 31, 2022, for a discussion of the various risks that may materially affect our business. The risks and uncertainties not presently known to us or that we currently deem immaterial may also materially harm our business, operating results and financial condition and could result in a complete loss of your investment.

 

Our most recent Annual Report on Form 20-F was filed with the relevant Canadian and U.S. securities’ regulatory authorities at www.sedar.com and with the SEC at www.sec.gov. Investors are urged to consult the risk factors in these documents.

 

Disclosure Controls and Procedures

 

The Chief Executive Officer and the Chief Financial Officer of the Corporation are responsible for establishing and maintaining our disclosure controls and procedures. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under U.S. and Canadian securities legislation is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures.

 

17

 

 

Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. There have been no significant changes to our disclosure controls and procedures for the six-month period ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, the disclosure controls and procedures.

 

Internal Controls over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS as issued by the IASB.

 

Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of Aeterna Zentaris; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of Company management; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of Company assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Changes in Internal Controls over Financial Reporting

 

There have been no significant changes to our internal controls over financial reporting for the three-month period ended June 30, 2023, that have materially affected, or are reasonably likely to materially affect, internal controls over financial reporting.

 

18

EX-99.3 4 ex99-3.htm

 

 Exhibit 99.3

 

FORM 52-109F2

CERTIFICATION OF INTERIM FILINGS

FULL CERTIFICATE

 

I, Klaus Paulini, Chief Executive Officer, Aeterna Zentaris Inc., certify the following:

 

1.Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aeterna Zentaris Inc. (the “issuer”) for the interim period ended June 30, 2023.

 

2.No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

 

3.Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

 

4.Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.

 

5.Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

 

(ii)information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

(b)designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

5.1Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – Integrated Framework: 2013, issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

5.2 N/A

 

5.3N/A

 

6.Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on January 1, 2023 and ended on June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: August 9, 2023 

 

/s/ Klaus Paulini  
Klaus Paulini 
Chief Executive Officer  

 

 

 

EX-99.4 5 ex99-4.htm

 

Exhibit 99.4

 

FORM 52-109F2

CERTIFICATION OF INTERIM FILINGS

FULL CERTIFICATE

 

I, Giuliano La Fratta, Chief Financial Officer, Aeterna Zentaris Inc., certify the following:

 

1.Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Aeterna Zentaris Inc. (the “issuer”) for the interim period ended June 30, 2023.
  
2.No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
  
3.Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
  
4.Responsibility: The issuer’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings, for the issuer.
  
5.Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer’s other certifying officer(s) and I have, as at the end of the period covered by the interim filings

 

(a)designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that

 

(i)material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and
   
(ii)information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

 

  (b)designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

 

5.1Control framework: The control framework the issuer’s other certifying officer(s) and I used to design the issuer’s ICFR is Internal Control – Integrated Framework: 2013, issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

5.2 N/A

 

5.3N/A

 

6.Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer’s ICFR that occurred during the period beginning on January 1, 2023 and ended on June 30, 2023 that has materially affected, or is reasonably likely to materially affect, the issuer’s ICFR.

 

Date: August 9, 2023  
   
/s/ Giuliano La Fratta  
Giuliano La Fratta  
Chief Financial Officer  

 

 

GRAPHIC 6 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 7 ex99-2_001.jpg begin 644 ex99-2_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" R ((# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_B@G )]! MFBD/ /T- %&Y;:ZLHR2I&3\V.2!A2<98XY&"0 "<=/CK]I7]N#]GG]E6(0_% M/QG#_P )?=:?+J.C?#W0XFU;Q;J<4B/):L;* .FE6=Y(@B@OM5DM;8NQ<.8Q MN/T5\6/'.G_#/X>>.OB)JDEO%I_@3P=XA\67/VJ22&VE&BZ9=7\$$QC3?LGN M(8+=MA+'SBBAFK^=?_@G3^R+HO[Q:;J_B'2?L'VZ]UU8)HS_PC'@K2I=&\">%O#5G.VF.ND7U[=QK*L<;?$<39 MYFF&S#*>'.'Z&#KY[G4,9B85\PC4G@\JRS!2H+%9CB*>'G2KUU&IB*5.A1HU M*:5E M*480Y86/_ (P?![P1H7PV\:?! M_P .7?Q$N+3PO!=Z-I/B+PSX-2/7?%-JMM9R21VGBBV\/:??WOA'5K2.TF@U M^"P@O9EL)[B9/O3]ASXE>(_BM^R[\(?&'B^^GU'Q3=:%/H>L:K)O\[6+KPYJ M-UH\6J2M+AVN-0M+:UFNIV>3SKKS9"[,Q-?J&%X0S'!< 8/C&MQ#@.(:"XA_ MU7S18?*JV28K+8 M95FF,P<<1@\51A0KX;$0Q&$K5:D9TX_:"=!]WA0,#&1P...,#VP*=G^6<]OS M]:^&Q^WQ^SM=^./'_P ./#NL?$KQUXO^%U[IMAX^MOAO\&/BG\1-/\.RZOYEAN+_0-;ME8R:9^(U\+6^F+\#?BHOB]]6; CEF\&GPD/%%KHLK%4CUV;2(])> M218_M@*DGX["YYE.+C4>'S#"XAT7B/:1P]2>(4%A:BIU_P![2P_LFZ,VU4A& MI4FG&:Y9>TE9J^A]+ MC!.>,X]?\^M ZGGO^N /S_SUS7QQ\-?VT_@A\7/ ^I_$WP3=_$BZ^'FF^";_ M .(+^-=6^$GQ*\->%[_POHS7D>IWGA_5]?\ "NGV^O7<4EA>*NDZ6;C4)#:S M!8OER3P[^V5\+?%S^'!H'AW]H*[MO%:3;M#5'.\JJ3HPHYAAJD\2HSH04ZBG6 MIN23G!2P]G"^D9.<8R6L96)CCL%*-"4<32DL2H2H6Y[U5-J*MI-Q;=E> M+LVE=?8PSR>V1CG/ /)] /;KU]J=V_#O_6OCO7OVR?A#X?\ &WC;X;-%\6/$ M7BGX;W>GV/C5/ WP3^*_CRRT6\U2Q74]/BFU?PGX0U?2G%U8,)UCANY70!A* M$<%:[#3OVG?@MJWPN@7D.M_\ ".ZC8>(- M(U&SL=9\.ZKHNM$6'B#2];L+&[T:=7^V0@X1-HYIEU1U%2QV%G*DZT6G55-O MZO+EQ$E[503C02O>L&VU"*_M;6[L[N&YM[N MS@N[2[MKB.6WN+:>$S17<-R@:&2"2)EG295D0H%VI)D9X7X2_%/PM\:/A;\/ MOC#X!OKW4O OQ5\%^&_'O@O4;[3+[1K^[\,>+M'L];T&[N]&U01:CI][+IU] M;FXL;Z.&ZBN/-26*)L1KU*K!\D5**]I2C6A[ZDITI-1]HFG*\(\T.:2?VX6; MN;^TAS0@IQDZD7.*3;O37+>II=L$X('JJ8ZOKG!':L2YN]TQ5(9&:%LJRF,AC"C,, $$*QG )8!5:-MY M VM3Z.6RBDVV[67SW?2R3;=DDVTF72>O:4FWM:*YGKHKV3LF^:334%)JQY5^ MT7X0MOB#\#_C'X)NTD>'Q/\ "WQOIF(9/*D,TN@WS6F),$KMNHX$\GS)1\6OV@H)G(W"0V'Q7U[3S(S#!;9%9(AF+<-Y(MM2N;3SK2&X*[]U MB\_VA%8&2)0*6?3CCZ;_MK-<\K4,9G.)DLORG!8GZIE&#= M:&%Q7[.EK\3[?]J_]H?0/V-M(TCX:V7A/]E;]A+PUXILOVG? 'C+P_XA MU33-.\8?MJS^']8TRPLKJWGGOM6UJY\<:KXDU;46N9-1O+^Q:%XFM[H2?LC\ M&8_C4GAF,?';5/ FJ>-FU:Z NOAO::SI_AQM%+!M/B:#69IKMKY )!=.7\IM MRA%QS7P_8Z'X'^-O[17Q1^,'[+G[<)\$>-_&?PH^$_ASXFZ!X'\&_#/XBQ2^ M$OA%K?Q%D\$:RS>/]%UF;2%_M'XI>,;:X^QQI%>EU=SYMM')7U+^S;XNM]=\ M(:@D7[02_M-:EHOB;4=.U/QR- \%>%;RSN8Y% \-W>D>!;'2]'6:P*LL5TVG MQ7,Z$K-),B9K\[RSAC.L@Q.(I9IEG$F&GA:]2->&-IXC Y5A:./G.>%DLIKQ MK5L'+%PIN6&E7=%5&\6X2O7O+]*X>SKA[%O!2P'$>79E#'RSG^S?[,SW)\9E MN84LOJP>*>6X+ XS&5*KP"K4(XMX:MBG@IU)?6U3>)C)?#O['CR-_P $:?"! M=I'+?LU_%QG"YRV_4O'3'8IR,JA9$P& 7:%P-M>I? BW_;T3X>?!&2;7_P!F MH?#X^$OARUW;KI/CE/$W_"'RZ#IJ2P0SOJ!LFUZ2Q9+:)F0P&^D#*@X0V_A/ MI?[-/PG_ &,=?_9YLOCIIVM?"WX4>'_%WP0\;_$K4[S3TO-"U?7=8\0VNI6F MMK$#81ZWIU]J-Q9?9Q\DD]LIE0$LB^=?!/5QJ?B7X<_#7X<_\%0KGQZVAVMG M'I/PULOA%\ 7N?$OA7P/IGGZAH37]IX-AUB.!]!LVAO-3LKR+48K?SKBWN!- MO=73X3XK6$P&+JY-Q8Z&49/EV'S1993Q.#P>!J0G1Q&)>9UJN7.C&$,%7P]: M:KO"OZM/W-:D9&+XFX5CF.29?+BC(Z>88["8>A@L)AN),EIXG'3GBJF#IT\- ME]3&?6,=&KBJ&(PU&6"AB%/$4J]"FY5*=2,/*]4^.WQ1^ /[2W[9'B/P?X1\ M$ZOX'UWXR_"+PKXO\:^,M?UK1],^'&H:UX"MK30==\0P:5;R@>$9[Y[73]1U M99HFL+FXB-YY<#;QZ7\5OV?KSX-?L%_M&Z7XWUO3/&_C;XT_$W6/C5\6K[1[ M2XL?"&H>+/BKX_\ "*ZOI'A?3)Y9IK7PI9:+8:9I%G#+Z=KG4Y M7;Z1\0>#O@!\$O$OQN\4?&+QYX=&B_M<^(=$TO4_"'Q"728_#M^=-\/+X9G\ M,Z;&;/?1NUO+*-LJKMK2C_9=TX_LSZC^S?K'Q.\4^*/"5OM7 MPUXJUVTL-3\2^'? >F>(K3Q'X3\(7MS=7,L?B6W\)Z=9Q^'].UW4)$U&?0+? M35U#[5?VTM[=>11X:SC!86K4QU"M/"9G1XAHY=.OS+ X>MB,;C<-B*.!3P-& MGF$JU'%X*EBYK&R>&FX8:7)&I&H^S"PHU*^;X:.88?'8K#0QOM,MIX_!\^3T M\UYYTOKF%H.KB,.LQPC=6A4Q5-2<(U%!)237G/@36]<_8[^(?A[X->,]2N-5 M_9U^)>M0:/\ L_\ CK5KB6:3X:^--8MI9K'X$^,-3G#B'1M5N4DB^&>M7\I- MS/+#X8=WO#:*_GO[.WQ?C^ '_!(O]E?XBI9W>KZWI7['?P#T[P5H<$#OJOB7 MQQKOPZ\.:7X/T2RT\J9KG4;_ %2ZM6%DJ%\1RH1@9'T)XG_:"_8K^-NBZK\% M?%?Q-^$/C[2?'EFWA'6?!'B'5;"6P\0(S_9Y+"6*]4117D%];)/IMU T-WIV MJVUK=V$\5W;Q2#BG^#OP7^'+?L7_ C\8?$_49=,^!_V31/@UX&\8RZ=)JGQ M0\6^$_#@\/>&?$GB2[2WMI-7\3>$K S7,DRV<7V_7I9];N!'=L<>K_JGQ5E& M+IT(Y3FE'#3R+&QR_#8[ YC@JU#"RQF <<1@EBL%"6+P.!R^GC,5"=">)Y(4 M/8U*\(PA4?%A,^R&OA,9B,FXGX6,P.=99C89/F..Q&&P=#+<15P MV88E4JE3$4YT\+0Q'+B:V(A&A2C5=*7)\1?"#5(OV6_BO\!/B*?!'QG\/Z-\ M6-+A^"?[9'BKXB>!+SPSX6OOB/XP\1'Q+\'OC-?:U-?FT^W^'_B7K6M_"N\E MN1'%<>&_B-ITKR6Y\.VT%W^[MGY@94?"E,JP4#"[1D+D]5'.TY/RX(ZBOC'] MJ_XM?LLV?A#7?@1^T1\2_#WA&'XL>&-2\-R:9=WEN=;M[+6HGCM=SOTT MF\L;^UBU#1]4O(4AM]2T^WO(P9H894^E?A9);Q^ _ UO:>+?^%@6L'AC2;.+ MQT7LI7\71V6GP6R:],^GR26)N=22$7%T;9C&;EYN$.47JRWAW.L@PM.IB\)F M*R;,Z4:F5YKB'EA:]6O4DL9-4L5*8X&OF.4U:T>3_;\OP^*JXG"RQ5: MDZO/7I4TZ\ZJ<:;JTE4]/R/4?F**3=CC#''&<=:*]+VGDOOE_P#*SZOE7;_T MDI3$,4RI(#, ,\XV-T)Z>O;CWYK\?/V_OCOXOUWXT_!G]A[X6>+H_!>N?&S4 M-*O/BGXOTG4TM_$7AWP7K&N)H&F^&[&: -+I%WXBLXM:UNYN"(M3FM++3K;3 ME9-1,H_8F2(L05;;@$GH>P!XSSQW''/H:_)#_@H-^Q1\2_C%X_\ AK^TQ^S9 MXDT_PW^T!\&EM[>'3-6\JTL?&&CZ7J%[K.@20ZF5,=IK6A:G>W-M&=0AN+/4 M=%U"YTV=X6CMF7MRSBJEP7FV7<23R/\ UDCEL\3-96J=/$5X3K8'&82AFV%P M->,\-F6*X?QF*P&*SO):.,RNEB*%2E64<55I4J M]!XB=6/WW\-O _PR^ 7P^A\.^$;/2O"7@?PEID^K7MV_$SV.E6\E]J^OZ]J! M5KJ_OI;>"6\U"]NWDD9R^&=0N?ES_@G%I&H67[+VG^.=:TRZ\/W?Q]^,O[1_ M[15MIMZ8&N(_#GQH^.WC_P :_#4;+.2YCM[N\^%EYX*U2^B>\N&_M2]OP7B7 M;!;^+^"_ ?[?_P"U1I]EX+_:ML? /P)^#<8@@^(NC?#ZZDO/'?QGL()UFN- MGN$N9;3P?X5UA(S:ZX;*66]O[*2:W@:!)FK]6[32[#1M/TS3-,LK>RTG3K>V MTW3=/L88X+33=,LK:*"SM+6&(+'!;6D2"""-$54A5$ *@&OEL-F&)S_'K/,7 MALRC3I87,H?64:D87IN,*=.E$ M^ER3"X*GAL!#+,J639;E>"K8+*\OK86&"5"%2'2PSDXTJ&%I82%%PGS5* MF(5><*E1U(U*OXO_ /!1SX>?#;Q;XR^$?P,^&OP^\&1?M#?M-_$?1SJ_C>UT M*V7Q5H?@C1Y7E\4>*KK5(X9KJ"*VTZ"^U*>YE#@V^AR;4F8!7ZS_ (*:>#]! M\&?LI?!+P+X-T&/4M!\(?%CX4Z!X=\--"536+/1[62RLM'>&&.-IY-?>%;>[ MD2%)9)KV>9T#N176_%3]C;]J#Q5^TWK?[2'@#X[?#[P=K3Z4/"/@N#5O!%WX MBN/#/@:3[#]JT>U6XN!90ZCJ3VTC7&I6T?GD75Q$!ME>O0OCI^RO\:?CK^SC M\.OAIXK^+WA:[^,'A+QQHOCK5_B)+X9N;/0M8U'0[J]GL5MM"MY"ULRQRV:F M-V:*0V[JX8/BOZDR?B7*LHQ7@FZG'F2YAE/"^._M7B3#5,QXCKU,NSW-\%C* M>+K5XU*$99;D^4X%Y-D.#>4U\5B<-"ICGA,-!NC5?\>\1O"6.SSB;.,1Q%Q5BWGE! M<\8X+#9AB*O+[*'G'['*?$&+Q=X_;Q7^PMX:_95LI?AK&MMXTT*S47/B?48M M:VGPC?/'=NTMG!;2C7;=6@6-7M+R:26-T$4OYR?LB>/O%_[+&M:;^TAJ5P]] M^SO\2OC3XN^$'QC,1Q#X U+3?%(6U::2 M?6KB=75X-:T%C#=V=XC!1>0)QL9D,PX^X;R^ MIXA4,PAP]F>7<75N"\CQ^7Y!CN)\^P699/1R[/L+FV/RC,>,<17SK"YKEF)J MY9FN%JRK4J;S#"QP\8PP.)Q5(=7P@XVS=^$&-R./$_#6;\!87Q.SK*,XXIP? M!?#^+RGB2MF'#6,X>P>>Y'X?X3 \.U>'.)\-ALXR;'1PM-3QN QSQN:2EB<% MAIQ^:_\ @G+X/\$_$WPU^VKH/B[0_#OC;P7KG[87Q FDL[RVM]6T#7[%]9U7 M4=,OX6D7R+^VN(YK;5-/OE4I/!=PSIO609S?^"6WPT^'JR?'GQL/!FC#Q?X+ M_: \:>%O#'B&'2;7^U_#?ARYTJ.UN]&L+I5$EIIDMD\]JT4;Y>)Y F<,#]=_ ML,_LL:Y^REX0^(7A'Q#XST?QH_B?QO;:YI5]I&ES:5'#IFG:):Z'"E[:S22J MFIW,ELUU>+;D0(\@$0"FG_LE_LU>*?V:/#_QDL=9\7:/XCOOB1\6]=^(FCW% ME8W=C;:-!J,6[3+*^S+(\ZV<\,37TR-&L\'F0X"R&N;B[CG*:U3QIPV3<38F MO@.),SX(7#\9ULSP+SG#Y5]3P&=8G$X2E7]G&,LOPM#Z]AU@YT.:A.E0I5L/ M2A ]?P]\+,\PE/Z-.:<5< X'"9UP;D/BA+B[GPF68_%\.YMF#S/-LCP4)OB;X1 M\ ^$OV>?@]XA.AWWB?Q'I/AN#Q)\9+U;6[&BZ1+JUS ;V>(K#9R_9=TR\3+E M4Q7Z4?L-_&^/XZ_LD^#/%5]=02>,/#F@ZI\-/B+;12&1K3QGX.T6WM)KB8[I M%*Z[H5SH'BJT=&<7&G:Y9W&\B78GEWP8_P"":GPIT_1/$&J?M):+X:^.'Q5\ M5^./$?C'5?%DR:Q9V=DVNWCWJ:=I-M]M62&UA:64.9"3(OEQG"KBO2_V]%AI>@H\[+:OG3C/B?P^S3@7#<#Y)F6:UZ_ $N&Y9)BLQP&&ADF M9U*>%P.$XW658RC_ ,*^(EGV-Q%+.Z<\UC0MBLGI1A^ZK2C/A\-. _&3(/%/ M,/$SB3A[)Z>#\6*?&N%XPPV S;-ZO$.3X>KC\=F_AI//,OQM19)A*'"^'P>! MX;G3R!5JRI9Z\5F%6I2H1BOYV_#6C7GQA\ 3?LQ> O@1X+U7XE_%/XE^+9O! MGQQ\6:W:>%]5L3;:I>KJVD6NH7D"6EYI6BVT-S/-!I=_?:W) DT=EX?OK]55 M/VW_ &R8I(/VKO\ @G#;27DVKW=M\2-:LKC4[J&&.]U&6TT2V@FU&>-885AN M]0FAEO;I(8XECEF>(+M0 \V__!,GQ/;_ +/VF^ ]-^*6@Z%\:?!OQRUCXS_" M_P"*&E:-?V\'AN]U:^CN8+"6V6/ABJ69U\;+.L^ MX4CE&38_#XO,,7BYX3)\\ITL+2PG#.7T,+A+A5A^?>'7@9XC< M-\ <69-G'#.+K<19SG?@3FF5V?#N#H4>'N&^.L9G.9Y%B99;A\+3QO$G!LL1 MC:^:<3YE'%5<\P.-RJC"O[:G.,_A']L[X1:Q\%/VA_%7[6FO?"2P_:*_9[^) M?@N/P3\;O!UW:+?>)_AG8VZZ>!XIT?>7>WTR2WT6(Z5J]FDMI8:E>7VDZ^VC M6^J67B'3OU8_9OO_ (0ZI\(/AM>_ R:S_P"%4R>'83X(@LDN[6*UT>-3";"> MTO56[M-1LKE9K?4K2\ N(+V.=9TD\B[NQ'')&&#:&*XHPF:\0Y8LMP5+!996SVA&EDN M%R>.$5+B?(LP:RO"\0Y#C,3_ &%@<91-3S.,J^'P]:7[_X9\,<1\/> M,?B)B,+X>XWAW@W.)<0YI7S?/'P]C,1+BG&\286[LK67H?THW6N[4,.U=V;EJU=V;UW:LWYMEJJ;HA M9B54DOM)*@DJ0,J>.0<#(/' ]***QK?!?JI*SZK?9[KY-&E9M*-FUJ]FULHV MVMMT[="%E7,WRCY5PO ^4&(D@>@)Y('4U;=5PHP,;'.,#J%&#]1V/:BBB+;3 MNV_=ZZ](][FRVC_A7Y,0JN3\HX;(X'!!X/U'8TC*OEL=HR(D(.!D$[LD'L3@ M9-%%=$_^7/\ CC^2.6C_ ,OWU][_ -*F*$3&=JY)"D[1]TNF1TZ')R.G)I2B M8QL7&P<;1CEAGMW[^M%%-_$O*2MY;[=OE8WAK2A?6]D[ZW7OJS[JVEGIY"K& M@9L(@X!^Z.NY^>E,$:$."B$87@J,E%%)I73LKJ<+.RNKWO9VN MK];-7ZF4FW%)MM.G5NFVT_A6MV[Z::WT!%4@DJI)3DD#/0=\4]HT&XA$!P.0 MH!Y)![=QU]:**4MY_/\ *(4OAI>;L_-/GNO1V5UULNRM'M7:QP,@@@X&0=IY M'I^%2".,* (T V'@*H'0=@/<_F?6BBB27+LOXDWLMU>SVW71[KHT33Z_]>J? MXSDW][2;[M*][*R2(@*X11PW10/[H]/3CZ<4JJN$.U:5_/KKWUUUZZ[ZEP;]M5U?3J^N_WVU[];B-U/U/\ .BBBMDE9:+9=%V]# +N25EHMET79>1_]D! end GRAPHIC 8 ex99-2_002.jpg begin 644 ex99-2_002.jpg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Ȍ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ⅅ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
  •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�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end

  •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�V^HWAEBB(Z87 _7-;&I>& MK/4]>TK6)I)UN--+F%48!&W#!W @D].Q%;-%%V*R,GQ#X>M/$NGQV5Y)/''' M.DX,+ '$]R]X;,69#LI4H"#G&,[LCUQ[4[P[X;L_#-M=P64L\BW-R]RYF8$ MAFQD# ''%;%%.[_K[_S%9?U]QD67AVTL/$.I:W%).USJ"QK*C,"BA!@;1C/Y MDUC2?#C1_P"T9[JUO-5L8;AB]Q9V=XT4,S'J64<_D178447&8?A_PGIGAF74 M&TU72.]D$CQ';L3 QA0 ,#ZYK)E^&NE"YEDT_4M9TJ&5B\MMI]Z8HG)ZY7!Q M^&*[*BB[%9;&9I?A_2]'T@Z79VB+:,&WHWS>9GJ6)ZD^]<_'\,=#BD*+=:I_ M9V[=_9AO&-KG.?N=^>Q.*[.BB[O<+:6,GPWX>M/"^C1Z78R3/!&S,#,06RQR M>@ [^E'B3P]:>*-&DTN]DGC@=U#;'Q#?VU^]YJ%A?6ZE$N;"?RG*'^$G!XKHJ*2T=QF1:^';2T\2 MW6O)+.UW1SFN>"M,UR_74?.O;#4579]LT^R#D<=L5L44[O<5D9/B3 MP]:>*-&DTN]DGC@=US@+->7DQEFD [%CV^@%9]]\/-)NM2FOK6[U/3'N&W7,>GW1A2X/?>,?7IC MJ:ZVBB[O<5NAS_AWP=I7A:[OY]+$L:WGE[HF8%$V @;>,\Y).2W@GV MP3D# +ICG\ZZ.BB[%9')ZC\/M+O-2FU"SOM5TBYN#NG;3+HPB4^K#!'Y8K4T M3PSI>@6DT%G"S&X.ZXEGY5 MU+3;/5]/FL+^!)[69=KQMT/^!]ZY:W^&FC17$+7%YJM]:6[!H+&[NS);Q$=, M)CM[DUV=%";6P-7T9A^(/">E^)! ]VLT5U;Y\B[MI#'+%G^ZP_KD55T;P-I> MD:BNI27%_J>H*"J76HW!FDC![+T _+-=-10FUL#2>YDV_AZTMO$]YKZ23F[N MH5@="PV!5Z8&,YX]:3_A';3_ (2O_A(_,G^V?9?LFS>);#79))Q=64;QQHK#80PP2=IM2D6299&!52H(&W &!S MWS26GAVTL_$E_KL7>6ED+ @L6;.3S M6Y11TL'6YGZ'H]OH&BVNE6KRO!;+L1I2"Q&2>2 !W]*P]1^'NE7NHSWUI>:I MI4]R(;.UANS<1RV>#;75O)LFB. ,JWX#M6]11=A8XFX^ M%VAWUA+!J-WJE_<. JWMW=&6:, YPA(VK^72M[_A'+3^W[+66FN&NK2U-J@+ M+M93U+#&<_0@>U;%%%V%D%9.D>'K31M0U2]MY)VDU*<3S"1@0K?[. ,#GOFM M:BD,R-/\.VFFZ]JFL0R3M<:EY?G*[ HNP8&T 9'XDT1^';.+Q1<>(!),;JXM MA;/&2/+V@YX&,YX]:UZ* L<6/AGI$5Q*;34-9L[.5BTEA:WK1V[$]6H QE1C(/)ZD]:Z6BG?2P6UN9?A[0K7PUH M=OI-G)-);P;MK3$%CEBQR0 .I]*9H/ARS\.P7L5I)-(MW=/=2><0<,^,@8 X MXK7HH;;;;ZBLMC T;PAINAQZC;VQF>QOW+O9S%6A0GA@HQD ^A)Z5D#X8Z3' MF&WU77;?3V)SI\-^PMR#U&W&&K/4]>TK6) MI)UN--+F%48!&W#!W @D].Q%;-%.[%9!65XA\/6/B;2FT^_\T1[Q(DD3;7C< M=&4]C6K12&([*.VU&%G$3 M!X948I)$P[JPY!K)L/A]IMK?07E[J&K:O+;L'@&IW9F6)AW5< 9^N:ZVBA-K M8&DPK!\0>$=,\1RP7%P;BVOK?B&]LY3%-&/0,/Z@UO44AG(V?PZT>SU:PU47 M.H3W]H[.;BXG\QYR5V_O"1D@#H!BM;3_ U9:=J^KZE&\TDNJE#<)(04&T$ M*,=,'G)-;%%.[%8XJ/X8Z/#)(EOJ.M0:?(Q9M-AOF2V.>HVCG'XU.GAO3_!= MCKNIZ-82W/VB(.VFA@(VV \(-I(R"?7-==12;=K#LKW/'K"/X?3:*NHMX@NK M.Q=/-FT$:D?*#]63RN&;GTX/TK8\$^$DU+X83Z9J4<]I!J<[W&R/"NB%@5QD M$#A1VZ&NX;P_HSWWVY](L&N\Y\\VR&3/KNQFM&JA)K?UOPWI?B#3H[*^M M_P!W$P>%HFV-"PZ%".E:U%#;8))')6'P^TVUOH+R]U#5M7EMV#P#4[LS+$P[ MJN ,_7-:R>';1/%L?L>FP>5&6+N2Q9G8]69CR3 M6E11=VL%M;D5S;PW=M+;7$22PRJ4>-QD,#U!%<;_ ,*NT8 P+J.M+II/.FB_ M;[.1Z;>N/QKMZ*2T'N8^J>&=.U3PS)X?*-;6#HL86VPI0*01C(([>E:EO MM M;10(24B0(I;K@#'-244[A8R/$/AO3O$^GBTU&-R$;S(I8FVR1/V93V-83_#+ M1KJTFAU.]U;5'="D<]_=F5X0>Z9&T'WP:[2BD!@7G@[2=1\/6>C7J2SPV:(L M$S/ME0J,!@RXP>*QY?A=H]S$GVW4-7O;A)%=+J[NA+*@4YVJ2N I/7 S[UV] M%/F=[BY4U8P_$7A/3?$R0&\\^&YMB6@NK:3RY8B>NUO\:RQ\-]',]C=37>I7 M-[9W"7"W=S<>;+(5Z*S,#\OLN*["BA-K8&D]S*CT"UC\43>(!)-]KEMA:LA8 M; H;.0,9S^-4;?P98V?B>77;.]U"WDF9R"-S)CD\YZ]:Z.BA-H+ M#)G>."1XX_,=5)5,XW'' S7D6F-X+UJ&XU&XUB[\,7$DK_;])CU/R$=P2#N4 M@%LC^[CKCK7L%9]UH.CWUTMU>:38W%PN-LLULCN,=.2,T+1C>J.#^'6AVMYI MGB>6WMY+72-5G:&T"C:3 %*[ES_O'K7>:'H]OH&BVNE6KRO!;+L1I2"Q&2>2 M !W]*OJH50J@ 8 ':EIMW_#\"4K?C^)R-_\/-+NM0GOK*^U72)K@[KC^S+L MPK,?5A@C\L5M:%X>TSPY9-:Z9;^4KL7D=F+/(Q[LQY)K4HI7=K#MK#;'Q#?VU^]YJ%A?6ZE$N;"?RG*'^$G!XJW:^';2T\2W6O)+.U MWTU]Y)Q=VL#0(@8;"K=1;FY>YWP'*:G\ M/]+OM2FU&UO=3TF[N#F>33+HP^=_O#!%:>B>&-+\/V4UMI\+)YY+33.Y>25C MW9CR3S6Q12Z6#KZM/8 $16$UX7@A.."J$=1U&XQ6(GPQTD 0S:IKESIZ_=T M^:_8VX Z#: #@?6NUHIW=[BLK6,76_#%AKFGV=C,98(+.>.>);'K36=0TN]N))UDTV8SPB-@ S?[60(;B& M[G:YM;^ ;8KVSF,4R#T##J/J#U-&@^$--T![B>%[JZO;D;9KV\F,LSCT+>GT M':M^BETL/S,;0_#&GZ#X?_L2'S+BS)?<+G:Q8.22#@ $<^E80^&.DQYAM]5U MVWT]BAV6C!9;2RLYDFA2V(&"N< M Y!R.3GO[UJ:OI<&M:/=Z9E6FH07ES>ZKJ9MFW6T6H79E MC@/;8N![=<]!7744^9WN*RM8X'XG7VEZAX=F\/)/#V1Z4+1@]42UCV?ANSL_$M_KPDGEO;R-8F M\Q@5C1?X4 P.!G)-;%%+885B^'O#%EX:%\EA+<&&[G-P896!6-CU"8 ('3K MGI6U10!R-Y\.M&FNY;O3[C4=&GF.96TJZ, ?ZKR/R%3:7X T/3;Y-0F%SJ6H M)]V[U& ?<"NHHIIM":3W,C4/#MIJ.OZ7K,TDZW&F^9Y*HP"-O&#N M!&3^!%:]%%+I8?F86F^$[#2['5K2"6Y:/5)I9IB[*2K2#!VX P/3.:PK;X86 M]E;);6OBOQ5!!&,)%%J(55'L F!7=44[L5KF!H/@W2/#]S)>6Z3W%_*NV2]N MY3+,X_WCT_#%;]%%#;8)6,?Q3JYT7P[=W<8+W!7RK:,6>SISFK]%%-N[ M;$E96"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "J6KZG!HND7>IW*R/#:QF5UC +$#TR0,_C5VN<\??\B!KO\ UYR?RI2= MD-:LV-/U"+4M)MM1A5UAN(5F17 #!6&1G!QGGUKG_P#A8&D_\(8WBG[/>_85 MD\LQ[%\S._9TW8Z^]7/"SJG@+2'9@%73HB3Z#RQ7E>0W[.DQ'0W7_M<5I**4 MI)=&OSL1%WBGW_RN=_=?$[1K;]\+'5YM/!PVHQ69:V4]/OYY_ &LGXI^)?+\ M)6O]G+?20WSQR+>6JGRMF1\K,#P6!X'>NLO[:%? -S;+&HA&FL@0#@#R^E>< M:D2?@)HA))_>P]?^NAH27-;LU^+)N^6_=/\ *YV&JZUH=_:^'+O6=&U..2?4 M42SAN(S%)#,"0K.N\<<9[\=J9:_\EJO_ /L#1_\ HRH?B/\ \?O@_P#[#4-3 M6O\ R6J__P"P-'_Z,IQ[_P"+\D$MK?X?S9W%6W?RY M_P"S+,S+$WH6R!GZ9KJR0 2>@KSG1=5\1Z]'/-X0TS0]*T4W#J)KE&\R8@X: M0(F!GZ_G4+5FCT1TVB>,])U^PO+FS,ZO9 FYMIH]DL1P3@@\9X(Z]161%\4= M'NM/CN[#3=9OPR[I8[2T\QH!S_K"#M!XSC)."*YWPM'=Q>+?'J7]Y'=W0MD\ MV:.,(I.P\!>V.GX5T?PCB2/X;::R*%+M*S$=SYC#/Y 55EOY+\;_ .1-W>WF M_P!"]<^,K"]\%W.N:0EY?1[6C"6D1,L;].5X(QD$GTYKEO!^OVE[\*KJ/6]. MU2:TM;9WNII4(6Z5F8GRWW L?7DHV]EFULGK[XZBN2U$":#X7VUR ;) M_+9PP^4N(TV _F:[SQC'X=.A&7Q.!_9\,J.&_>95\X4C9\V>>U7))2=^[7X_ MG_7446VDEVO^?^1%97&B-\0=3@@LYUUE;2-KBX).QX^-H W=>G\(^M9R?$_1 MIUE2TL=6O+N*9XFM+6V\V4!3@O@-@+D\$D$^E5]&97^,6N,F2K:9 1G.<<>M M1?"6"W73M=F0+Y[ZK,LC=\#&!].3^=0EIKV_5H&]=._Z)G5>'_$^E^)+.2XL M)6!A;;/#,NR2%O1E/3^7!K%F^)6F$NVG:3KNK6Z$JUS86)>($=1N)&?PXK*: M:VTSXL>(+@H#8C11/?J%R"P/<="2OK4FA7?C+6M+MKC1++0="T64%K>-XV>5 M4YP0JX3GKCCK1:^J[?Y_Y#O;3^MD_P!39G\:Z??^#+S6M(2]O44-$4M8298W MQU*G&,9!)].:S/A9KS7O@R*.[M[^(VJ,\M[=IB*;+L25']G%6M\AC#L8C^Z9L-^A--V2E;^[^ M(*[DEYO\#K&^)NCEFE@T_6;G3T)#ZC!8LULN.IW=U#BK\OHOQL)2TO\ UMWD2"_N;-DMY6*D !_?MD"M7X:?\DZT7_K@?\ T(UH^*+>TD\&ZK!, MJ"V%E)QQA0%.,?3 Q6=\-/\ DG6B_P#7 _\ H1I*UI6\OU!WO&_G^AH^)/%. MG>%8+2?4O-$-S<" .@!"$@GA%<1!#\1OL$<$4?@W[+Y014 N=NS& ,>F*70K' MQ1X+\'V]A#I-MK5TMQ(?*MKP0I%&WS##2+SSGCWJFEJ2FW9FQX^_Y$#7?^O. M3^516>O:=X=\#:-=ZE/Y4;6L$:*JEF=B@PJJ.2:R=?U/7=1\!^)!K/AW^R E MDWEG[:EQYF0<_='&..OK4=]K,>G>&_"%I;Z1;:EK%W#$+%;@#;$PC4E]Q&1C MCIS22T:\U^3&W[R?D_S1=_X6;I<$\::GI.NZ5#(VQ+F_L3'$3Z9R3[]*WM1\ M1V>F:UI6ES1S/-J;.(6C *#:,G<2<]^P->:_$>'QB? ]U-K^H:/%;^;&/LMC M"Y\P[ACYW.1W/'I6YXA_Y';X?_\ ;;_T6M4DG;UM^%PN]?2_XG7^(?$-IX:T M^.]O(YY(Y)T@ A4$[FZ=2.*HZUXWTC0-;BTK4#.DTMOYZ.J!E;D@* #N+$C@ M 5B_%N1%\+V*LP#/J4 4>O)-0ZM%'+\<]#,B!MFFR,N>QR_-3%7W[O\ *X2= MK^G_ +=8V=,^(&EZAK$>E7%EJFEWDW^H34;4P^=_N\G]<5N(;2 M=;FZOYQNBLK.$RS./4*.@^I'0US_ ,2% U3P=*.'768E![X/7^0IGAD";XN^ M+I;D W$44"0;NJQE><>W2A)-)^OX6_S!MK\/QO\ Y'0:'XOTWQ']KMH([JTO MK=,S6=[#Y4R#L2OI]#W%<)\/?&=CHW@JWLDL=3U*[265Y8=.M3,T2ES@L> / MSS7<:@/#<'C.UDG&WQ#/:ND!7S,M$ 2@CB\!12(BJ\MS*SD# MEB&QS^ %-6LWY+\V-WT7G^AU/A_Q%IOB;3OMVF3%XPQ1U==KQL.JL.QI?$.N MV_AO2)-3NX;B6WC91)Y"AF4$XW$$C@9YKEO "+'XG\:QH-J#4@0HZ9()-=EJ MNG0ZMI5WI]P,PW,31-]",5,MDUY,(ZMI]VB/5-8M-(T6?5KES]EAC\UBG)([ M8]SQ3K[5;33]%FU:9R;2&$SEEY)7&>/K7GFGSOKFC^'/"EXA:6&XDCU!#_!IG9KE=2:RN3W^S0D/N^A7RQ^-5RWT7R].XD[6;^? MK_2.CT_7-!O?%C7L&E:@NLR:.MUO8]>B>'?$VF^*+%[K3I'/EMLEBE3;)$W]UAZ_I7,?"."./PS?RJ@$ MDFI3[VQR<$ 4O@M1'\0_'"(,+Y\#8'3)5B319/3R3_"/^8;:KN_SD=Z2%!)( M '))[5QLWQ*TPEVT[2==U:W0E6N;"Q+Q CJ-Q(S^'%=3J5S;V6EW=U=J&MH8 M7>4%B.DM?&>CW_AB[\06OX&SI.K66N:9#J.G3B:UF M&5<#'L00>A!J34=0M-)T^:^OIU@MH5W22-T _K]*XOX1J$\(7$:_=34)U4>@ MR*VO'&K6&C^&)KF_TZ/449TCCM)4#+)(3\H.01UYSCM4R6NGE^-O\QQ??S_" M_P#D9(4T_@_;VT\B#:?XLDYQ^%0?$.]M]1\(Z1>VDHEMY]1 MM7C<=&4MQ577$\>7'A?5)=2NM#TRR6TD9HK>)Y9-NT_(2QV@XXR/6L6;_DC/ MA3_K^M__ $8U4DKKR\%P;BZ&8+**(O/(<9P$'?Z\5S_BK_ )*G MX*^EU_Z *R=0;Q#-\8[\:,-)-U#IT8B_M+S,",D%BFSG.X\T)7C%>OX%2=FW MZ?B=?HOC;3=8U :=);:AIM^REDM=1MC"\BCJ5Z@_GFJM_P#$32K'6+[219:G M=:A:,B_9[6W$KR[EW90 ] .I..O>L?4?#WCS6]1TFXU&3PU$-/NTN%DM#.), M#[RC<",$=OI3O"T2-\7_ !C,5!D6.!5;T!49_D*$D_Q_"PFVE]WZFO=?$31K M"ZLK>^AOK66[M!=1K+"-P!. A4$MO)[ &G:9\0-+U#6(]*N++5-+O)O]0FHV MIA\[_=Y/ZXK&U:*.7XYZ&9$#;--D9<]CE^:E^)"@:IX.E'#KK,2@]\'K_(41 M2?+Y_P";')M7MT7Z7.@UWQ?IN@W<=E)'=WFH2)YB6=C 9I67UP. /J1571O' MNEZOJRZ3)::EINHNI:.VU&V,3R #.1R1Z_D:S=3UG4)_&MWIGA71]+;5+>!# M>:C? J%4X*IE?F;CGKBN?U"'78?BAX/.O:C9W-PWFE8K2$HL0V\\DY;)]X^*VJQR:7KABECAMXHGMS_HO3+N,_(A M/.>]=;K7C?3='U ZUTZW,TB+ZMR /SS61H7_)8?%/_7I;?^@B MN=\'MXQFO?$=QHO]@%GU65;@ZAYWF[AT'R<;0.GXT)72]/U"6C?K^B/1= \4 M:;XC69;0S17-N0)[6YC,\6?\)U%X@UI]$C46K6TJ MZ>909!G*Y#CG!]Z[I\A&*]<<4I62N-7;LSU+5;N#_ %\6 MFVQF,/\ O'( _.M+2O%&D:SHTFK6MVJVD.X3-*-AA*]0X/3%?F*1C\2::2;LO+\785W9/O?\KGHUQ\3=$MIX MS):ZH-/D<(NI_9"+4D^CGJ..H!%+??$O1;&0L;75)[!6V/J4%H6M4.RM]GU GRKA "B@+NRQSG!'3 )K.C^)6BC48[2^MM3TQ M)03#9M7\K_G_ )&A'\2='.I6]K/9ZK:P7+B.WO;FS:." M9CT"L>>?<"MG7_$VF^&X(GOY',LS;8+>%"\LS>BJ.O\ *N;^+@'_ A*G RM M[ 0?3YJR=;;7IOC#&FC_ -F&YATH-"-2W[ I;YBNSG=V^F:E)2^]_E<;;7W? MK8ZO2/'.FZIJ,>G36FI:7?2@F&WU*V,+2@=2O)!^F.]-U;5%TR6SU+3+^12T4&I6QA:4#J5Y M(/\ ]:L;5@)_C9H4=T 88M/DDMPPX\S+9(]\ ?D*W_$X\-QW>CW.O#%PET%L M''F;A*>@&SZ#KQ25M'W_ .&&[ZKM_P .1^&[G0Y-9\1+IEI-;W,5T!?R2M\L MDF#\R_,<#KV'TJE-\2M,)=M.TG7=6MT)5KFPL2\0(ZC<2,_AQ69X5N;>RU;X M@75VH:VAO"\H*YRH1B1COQ3M"N_&6M:7;7&B66@Z%HLH+6\;QL\JIS@A5PG/ M7''6DEHO1!??U9=U_P 1:;XF^%^NWVESF6$6TB,&4JR,!R"#T/(J.:XT.#P[ MX*&LV<]Q))):K9F(D".;8-K-\PX_/Z5Q^@"1?AQ\0%EN!<2"YN TRJ%$AV\M M@<#/7%;/B'_D!_#C_K^L_P#T 5I%*^G5Q_%,B3_!2_!HZK5O&G]DZE+9?\(S MXCO/+Q^_L[#S(FR >&W#/7'UJ'1/B#9:YX@_L1-(UFSO!&9'%Y;+&$4=V^8D M9[<58\8^*&T*VAL]/B^U:W?-Y=E;#G)[NWHHZ_Y)#_"7AE/#>GRR7,QNM4NS MYM]=MR9']!_LCL*A6M=_U_74TE>]D5K[X@Z;;7L]I8Z?J^KRV[^7/_9EF9EB M;T+9 S],U/I?C?2]9TJ^O+""^EFL1^_L1 1<*?[NS/)X(X/:N=T75?$>O1SS M>$-,T/2M%-PZB:Y1O,F(.&D")@9^OYU!X CNXOB/XO2_O([NZ @\V:.,(I.# MP%[8Z?A0EI9]K_D)NWW_ .8GPT\1OJ%EK-M?66K2;[FXG>YGB/EA?E'E%R>' M _A[5TWA;5O#MIX#M]2TY'T[1(U=E6Y;E!O(.?F;JV<8_!]JJU]%_=_'^OZN*]M7WE^%_Z_P"& M.^7XH:-E9I]/UFVTYR FHSV++;MGH0W7!^E:^N^,-)\/1:=->R,;>_D"13Q[ M2B@C.YB2/EQW&:T-8@M9M!OH+I4^RFW=9 1P%VFO&(-]YX*^'278,BG5O+ < M=4$A 'TQ2BE)V7=?C?\ R&VTK^3_ /0_P#A9FC1WD,5W9:O96T[!(;Z[LFC M@D)Z88\_F!79UQ'Q;17^&^I%AG:T3#V/F+77V))T^V).28E_D*6CC?S_ $'J MFC)\0^+]+\+W-A%J;21K>LX64 ;$V@$ELG/?L#6=:_$?2)]0@M;FSU33DN6V MVUS?6ABBG/;:Q/?W K*^(4-O<>,O!$5T%,+7LF0W0GY,#\\5I_%**WD^'>J- M.%S&J/$3U#AAC'OV_&DK**;[_P"7^8VFY67;_/\ R-;7O%6F^'F@ANO/FN[C M/D6EK$999<=<*/ZXK,T[XAZ7>ZM!I=W8:MI-W<'$":E:&+S3_LG)_7%9-UK> MH'5](TS1]'T^X\2G3$FGO;T8%O&< @D#<_FODB61(;:$2--N_A0 Y)X).0![UQOB;QS-<>(_#$D6B^(H((YWDDMGM=K7 M! P%50WS,ISP>F:U[:)'^/-X[*"T>D*5/H=RC^1-6/&W_(]^!_\ K[F_]!6I MBOA??_@_Y#=_>7;_ "1IZAX^TC2=0M++4([RWFN;072*\0R,G C*@[M^>-H! MINF?$#2]0UB/2KBRU32[R;_4)J-J8?._W>3^N*QM6BCE^.>AF1 VS39&7/8Y M?FI?B0H&J>#I1PZZS$H/?!Z_R%.*3Y?/_-A)M7\E^ESH]?\ %>F^'6AAN?/G MO)\^19VD1EFEQZ*/YG%0Z'XSTW6[XZ?Y%]I^H!/,^QZA;F&4KZ@=#^!KC';Q M+-\7-?;11HYN8;:%%_M+S.(B ?DV?[1YS[5HW/A[QSJVOZ+J&IOX'7Y@001VXHBDTK]?^"$FTW;I_P#6O_B)I5CK%]I(LM3NM0M&1?L]K M;B5Y=R[LH >@'4G'7O72Z?>#4=.M[Q8)X!/&'$4Z[73/9AV-<)X6B1OB_P", M9BH,BQP*K>@*C/\ (5Z)2TY5YH?5^05A^+];'A[PK?ZED>;'&5A']Z1N%'YD M5N5YE\0[R_U3Q7HN@:7IYU)[1AJ5U:B98@X4X4%FX'?\Q4VYFH]_Z?X#O97[ M?U^9!X'M)_!/BBUT6[9O+UJP2Y&]NETH_>+^1_05Z1JNJV.B:=+?ZC<)!;1# M+.WZ #N?85Y9XXO?%UY96>KS^#6TY]'G%T+I=3BFVJ/O*57!(/&?I5[Q]J4^ ML6_@NXTS[*T5[>+-&+S/DF3:"@?'..36CO*WK;_+\-/D0O=OZ7_S_P _F=!! M\2=):>,7FGZQIUM*P6*\O;(QP2$],-DXSZG%8WQ1\0SZ?=:%:06NJ,GV^&>2 M2WC)CG4$_N@0?F!K*^E26ZM]4M8I70DAB 1D$@']*(I\:MJ\OQ/\.PZ6-/,Z6LTEN-0W^47YW?=YW8 Q3O$/A_XA^)=*.GWK>%8T M\Q9%EA-P'C93D%20<'\.]3%)V;Z_YV&[['1ZUX[TK0M;.D7,%[+>&W$\:6\( MD,V6VA$ .2W!/3&!UJ"X^(FE6-MIL^I6FHZ>E_)(BB[A$;1;.I<;LC/;&2:Q MC#O^.EH9PKRQ:+NW?[6X@D?F:?\ $**.?QGX'CE0.AOG)4]#C8::2]U=_P#- M_P"0-_$^R_1?YFG%\2=(.HP6EY8ZMIZ7#;+>ZOK,Q0RD]-I)SS[@5K:]XJTW MP\T$-UY\UW<9\BTM8C+++CKA1_7%<[\8$!\ 3.1\R7,+*?0[@/ZFI->UFZ'B MVUTGP]H^GW.O?8_->]O1A8(O;];%O3OB'I=[ MJT&EW=AJVDW=P<0)J5H8O-/^R/\ BR'Q''XA\(/X@U'3Y7?5$V6M ME"55/F7)W,=Q'0=.]>P4-+E3]?T$F[V/,=2UNST+XS75U>M)AM'2...*,N\C MF0855')/!_*NGT3QWIFLZJ=*>UU'3=1*ETM=1M_)=U]5Y(/?WX-8L<,@'YTF@^-],U_49--6"^L=1C3>U MI?P&*3;ZXY'ZUARZQJ]_XJU>S\'Z/H\4MJR)?:A?!E\U\'"_(-QQZG-9%K#J MT'QJTM=9U"VO+HZ=(?\ 1X?+6-?FXZDGN33K,RQQ,.H+9'/TSTK>T77-/\0Z:M_IL_FP,2IR" MK*PZJ0>0:X+3=+\3^'_M<_@V^TC6]&GN7F^SRR?.K$_,JN#MSQC)/X5T/@?7 MK75AJ5J-#71M2M9\WULJK@NW\>0!NSCJ?UZT): VTSIKV]MM.LIKR[F6&WA4 MO)(W10*X^3XGZ;'']I&B^('T[ ;^T!IY$&W^]N)!Q^%;'C/5=/T;PK>7NI64 M=];J%'V:1 RRL2 H(((ZX[5S=XOCR[T&ZENY]"T:Q%J[>7#$\LJ)M^ZRU=M.+;?[36R;[-^#]2/< UY_=@']G73@>AN1_Z.:O4_%EO$/A_JT 11$N MGR!5 X "''\JN:4.9]G^B?ZDPO*R[K];&[!/%Z[\+VO5\R1K8N^\=6$:$$_B :(I2?S_ $;_ M $"3:5_+]5_F==:_$;29M5@L+NQU736N6V6\M_:&*.8]MISWXZ@=:U?$/BC3 M?#44)O#-)/.Q6"UMXS)+,?15'_ZJYSXM(I\,V$F/GCU. J>X.2*2,+-\<)?M M(R8-'!M@PZ9?YB/?DBDDI?C^"N#=OP_.Q:'Q-T99K2VN+/5+6^N;A(!9W-L( MI4WDA7()^[QU!/TK7\0>+M,\.R0V]SY]Q>S\PV=I$99I/HH_KBN6^*$%L=3\ M(3E5^U#5HT4]]A()_4+4OAQ5F^+WBR6X -Q## D&XY*QE-M+UN_.G>5>:?J07?]CU" PRE?4#D'\#4&DW^@Q>(O%+V5E< M17]L8WU"5CD3$(2NP%CT /9:R?B.$BUOP?23_KK_D=JOQ-T1YF:.TU633E8JVJ)9L;52#@Y?KCWQ6WX;\2V/BFPFO=/ M640Q3M 3(%^8KCD8)R#GBG:%;68\)Z?;Q(ALS9HH7'RLI09_.N2^#J11^%+Y M(#F%=2F"'_9PN/TH:2GZ#X$FM]!\.>(M(EOY(H[BYN('7>%(S\Q(M!U'PW\$;S3-2EMI)8[E63[,S%%1I5( W 'J36]\4_P#DGT/_ %\V M_P#Z$*M)+1=6E^1+;W[)_J3>'+GPMX1\*SZG'IM[H-J\FV2/4$<32.!P0I9B M<\XQ[U9MOB3I#W4,-_8ZMI23MM@N-1M#%%*3TPV3^N*S_&:K-\0O!-O= &T, MLS[6/RF0*-O'KG&*V?B-#;3?#[61=!2BVY=2W9QRN/?.*EO3F?\ 5M!QC]E? MU- R_*!P>.)KOP-=K:Z/XA MTZ2258C-/:F$( 5)W$-D!@V!Z\BH)]][KWPO:\!>1K8NV\P^7) MQWQD\'M7$_%+Q#<:==Z'9PVNJ%?M\,TCV\9\N903^Z!!^9R0#M^E>BVW_'K# M_N#^5^":2MHWU_SL59M M\J_K2YW-\+^GYHU-5\>Z9INJ2:;!9ZGJEY M" 9X]-M3,80?[QR *Y_PIJUGK?Q7UN^L)?,@?3HADJ5*D$ @@\@@]JN?"<*W MAR_N) /MLNI3FZ/\6_/0_A_.J>F)':_%OQ:UDJ^8=.20JO\ STPI_,\'\:-( MO7LW^"8G=[=TOQL;VH_$#3++4)K&TL=4U>>W.V<:9:F80GT8Y S6IIGB;2]8 MTB?4K&9I88-PE0J5D1E&2I4X(/UKSCX>#QP?!]O+HO\ PC1M99)'9KOS_.9] MQW%]O&?Z8K=TKP]XBTZ]\2:OK3Z4HU"SPT6GF3:9%4@,0X],]Z)KE3[I?B.+ MYFO7]2S%\4='NM/CN[#3=9OPR[I8[2T\QH!S_K"#M!XSC)."*FU;QI97G@"] MUG1A>W:O')$IM(B9('VGYF'!4+P2>W6HOA'$D?PVTUD4*7:5F([GS&&?R K" M\.((_#7Q$C081;R\P.P^0T5(IW_ _S"DV^5^=B70->T^\^$LO]O:5JLEC M:VR"Y:6,I]J!;K&VX%N>IR*J_$C7D71="T>SL-733[I[=G:",[982#^Y5MW, MF,?+^M6+C_DWE?\ L'K_ .A"G^+_ /D7O 7_ &$;/_T"K:3J-?WE^3,XMJ"] M&:OA35?#VC7%CH&G:)J6D-J*27445XA!+*=K [G+!L+G'3&*Z/7/$-KH"V7V MB*>:2\N5MH8H%#,S-WY(X':$^98:)9"16'0S3#(_\ '>?PJ5[S3^_Y:_EH6_=7Y>NWYZGH%;1Z1XATK6M7U'P7JFDZE:W M5TTEU97#Y,&KS5=-AOKLVY\N2U@@) MN(WZ8*''3.?H#7+?#CQ:8O -Q<:A::K)]ACEN9KN2/*3C>Q(1R?F8=\XK7\+ M^($U&\UK3[SP^FC:W%&);I4"MYP(.&W@?-U[YZ]:P/#7_)OMY_UZ7?\ Z$]- MZ*3\E^8EJTO-_D=7I/C_ $_6[VT@T_3M6FAN0/\ 2Q:_N(VV[BK/G&X=#C/- M,N_B)IL5U-!I^FZSK!@ EAM?AUHQ"A8Q9K(V!ZC M)/ZFN>T'4_$^O6/VCPKINA:-H3RL(FFC8R. Q!<(F%&<=#^=.22DTNA,6W%- M]3>@\=:;J?AR^U/38+^Z>U/ES6D-N3<1N>,;,]N^#V/I6+\)=>EO_"JP7<&H M>9"9)9+ZY0^5-EV/RR$_,1W]*H_#Y+B/Q-XY2[NTN[E9(Q+-'&$5FP^<*.F. MGX52T>6>']G:Z>WSO\J920?X3*0WZ$T.RBVNR_$:NVD^[_(ZR3XEZ1YKFUT_ M6+ZRC)$E_:63/;ICKEL\@>H!KI+;6M-N]&&KPWD3:>8S+Y^<*%'4G/3'?-<1 MH$?Q!C\.ZK0ZV'[9/J *AUCQ/X:U[X=C6M3L+V?1Y9E4P<+)N#[0?E<=QG[U=/J%I9/X9 MN;22./[#]D9"N/E";?\ "O'S_P FZ6__ %]#_P!'FB*3=NS7XNP[NR?>_P"5 MSUS7/$FE^&[&*XU"9D$K!(8D4O)(WHJCDFL[1O'>FZMJBZ9+9ZEIE_(I:*#4 MK8PM*!U*\D'_ .M6'J8$_P :- CN@##%ILDEN&''F?-DCWP!^0KHO$X\-QW> MCW.O#%PET%L''F;A*>@&SZ#KQ4I+2_7_ #L*[MIT2_*YT5K7D.//BTRU,QA_P!XY 'TS6%:10P_'+56ME42/HX>0+W?D MW?A^^UBT\^>.Q5C<6ZQ[9HRO)!1B,''\JUM-U&WU72[;4;8DV]S$LJ%N#@C/ M/O7(>'O#/B./Q7J6KZ\='$-_:"":'3S)AV!&&(Z;=&ULES\S),?W9'KC+&DUVW_ *5OR&O/;^G?\SO]/\9:3?Z'=ZT7DM=. MM9GB:>X ?:<;EP3D$\#N?2LR+XF:071[G3]9LK&0@1ZA=63);ODX&&YP#ZD M"N8\9:1/H'@WPAH=F+? OX4D^T9\IY<$_/CG:6))K;U+3_B/JNF7.GW2^$&@ MN(VC<#[3G!&./>FTE=KT^ZPD[V^\F\?,KZGX.92"IUB,@@\$8-;GB#Q=IGAV M2&WN?/N+V?F&SM(C+-)]%']<5QNL:=>:1IOP^T[4)8Y;JVU.*)WC)*G (&"0 M#TQVJ]X<59OB]XLEN #<0PP)!N.2L97)Q[9Q3LMEM>7Z$W=[OLOU-W1/&VEZ MW?G3O*O-/U(+O^QZA 892OJ!R#^!JM??$71K#6+_ $F2&^DO[1D58(81(]PS M+NQ&H.3@=%X+=_B]XPF=5-P MB0+&3U"E!NQ^2TDD]?7\+?YE-M?A^-_\CH_#_C+3/$-S-9Q1W=GJ$(W265]# MY4RKZXYR/H>XK/;XD:09KVVM[+5+N]M+AX&M+6V\V5MI +@*>I(SSQ5+Q M0@C^*?@^:V&+J03I+MZM$%SS[#)IOPUBC&I^+Y@@\QM8E4MW('('ZG\Z$DU? MR?X.PW=:>GXI_P"1?@^)>A75@)K6/4+B[WLATZ&V+W09>H*#IC/7./>M3PWX MLT[Q.EP+1;F"XMFVW%K=1>7+$3TW#GT]:YOP1;Q+\0/&\P11)]IB4''0$$G\ MS5:%Y;?XB^.9+8?OETV)T XRPCXJ79*_E?\ "X)-NWG;\;&[>_$/2[:^FM+* MPU;5FMV*7#Z;:&9(2.H9L@?EGI6I:^*-+O\ P]<:W9S-/:VZ.\BJN'4H,LI4 MXPWL<5Y_X!3QPO@RP.B?\(O]A<,RFX\_S2=QW;]O&*.:SC.ZW;:?F?H4 QR>W% M6?AA#'%\.='$:!=T3,V.Y+')KD-!41_##QU&O")=WJJ.P&P43BES+M_FD*G) MOEEW_P F=C\.M6;5/!]BKV5_ UO!'&9+N+:)SM'SH%;R]U*RCOK=0H^S2(&6 M5B0%!!!'7':G5^-V[A3^%7,>3XGZ;'']I&B^('T[ ;^T!IY$&W^]N)!Q^%:V MI>--(TWPQ#XA+2W&GS,@1X%&3N.,X8C&._I7.WB^/+O0;J6[GT+1K$6KMY<, M3RRHFW[IR=@P.XX]JXZ[ /[.NG ]#X!KH-3\1:5I&C#5KR[1;)@ICD7YO,W!=0L7L-4TVYE$;0)J-J8O/ =22AR0>.: M]2L/^0=;?]8*7CDB:(GJ&W@.]-U;5%TR6S MU+3+^12T4&I6QA:4#J5Y(/\ ]:L;5@)_C9H4=T 88M/DDMPPX\S+9(]\ ?D* MW_$X\-QW>D76O#%PET%L''F;A*>@&SZ#KQ0DK)OK_P ,#W:73_AR/6?'.F:1 MJ)TV.WO]3U!0&DM=-MS,\8]6Y 'YYJWX?\5Z7XD$RV3RQW,! GM;B,QS1'_: M4_S&17-?"M4>U\07,F#>R:M,)V)RW&,#Z MA)!.#Q3HOB7H5UIT=Q91:A>W+DC[!;6QDN4(QNW(.!C/4G'IFJ'PKB1;7Q'* M% D;69PS=R!C _4_G2?#JWB3Q%XTF5%$AU5DR!V!)Q^9-"2V\D_R_P PN]_. MWY_Y'0:/XRTO6])OK^V%PAL0WVFVFCV31$ G!4G&>#WK)/Q2T9].COK33]8O M8-F^=K6T\P6PQG$C9V@XY(!.*Q[(!?%OQ) &!]EC.!Z^2U;?P[@BC^%NG*L: M@/;R,PQU)+9S2=E%R\D_OO\ Y#7Q*/FU^7^9)F*Y?X/PQQ?#J MS9$ :665G('4[R/Y 5P\DDT'P<\1K =JG67C?' "%TS^%5**3<5Y?BTOU)BV M[-^?X)O]#OS\3M'R9ET[6GTUF:+H$6MRN\]C*R M*DEOM;(<\-R0,5S\$/Q&^P1P11^#?LOE!%0"YV[,8 QZ8KEO%.@:AX<^#)TO M4Y;:21+Y63[,S%%1GR%&X ]2:.57MYK\[ FW^/Y7/0M(\966LW1SGITK,?XI:(I::.RU>;3E8J^I163&V4@X.6Z_I3_B/ MYEK\,-32T!4+ B84=$W*#^F:V=)M-//@NSM3'&=/:Q167^$H4Y_,9I.UF^PU M=V\_^!_F9WB34?#LO_".7&H6\MZES?1'3Y8&^593RKG##(_/Z5Z7J^K+I,EIJ6F:BZEH[;4;8Q/( ,Y')'K^1K*T0QK\1O'!E4M&(;8 MN!U(\LYK"U"'78?BAX/.O:C9W-PWFE8K2$HL0V\\DY;)]YZBJEY\4[/3K>X_Y;./3T'_U\W)? MO&C.+]Q,Z/4/&.EZ7IUA=7272S7Z!K:R6 O<.2,[=@SR,\]L]ZS[+XC:7<:G M;Z??:=J^D3W+!(/[2M#$)6/8')]NOJ*C\3ZS/#XJL-*T31[&\U]X&E2ZNQA; M:+D$[A\W)SP#7(^.(?$Z3>&Y?$.HZ:^[5HMEI8PL%!S][>QW' [8_B]A4Q2; M7FRI-I/R1H:OXMGMOBW:Q_V9KDUO;6CQ"WBMRWF,6(\U%S@KCC=[5UEC<:(_ MQ U.""SG365M(VN+AB=CQ\;0!NZCC^$?6LF]_P"2W:9_V")/_0VJ.Q++\7_$ M93[XTN(K]>*E.T5Z2"7Q/_MTU=3\?Z78:E+I]K9ZGJUW!Q/'IEJ9O)_WCD 5 MIZ)XHTKQ#8S76GSL_D$K-$ZE9(F'9E/(/!KFOA D7_""1SC!N9KF9[AOXF?< M1S[XQ5:,)!\9M8CM>$FT<272J./,! !/OC'YTY+ENNMG^"N-.^OG^MB];_%+ M1[W3X[K3]-UF^8Y,D%I:>;)" 2,OAMJYQZYQBNC\/^(M-\3:=]NTR8O&&*.K MKM>-AU5AV-7^D&5FT'0M.-N62..)I98DV\ @ MD)P/3\J':W-Y)_A<2O>WFU^)O7OC?1K/PO!XB$DEQITSJBO$HR"QQR&(Q@YS M67>?$&"XTZ_>QT3Q!+&D#/#=161"2@X 9"2"0,YSCH":\[< _L\VX/0W_P#[ M4->U7\:Q>'+F-%"HEHRJ!V 0T5(J,9>7^5P@VW'^NMC@O _C6/3_ (;&^U*Q MU9DL$WRW+Q BX+R$9C9F^<@GG.*V;CXG:-!&+B.PU>YL,#S+ZWLRUO'ZY?.# MCOC-A:?;0KX"MK=8U$/]FJNP#C!CJZMDY2[?Y7)IZJ* M[_YV+XUO33H@UG[9$-.,7F_:"<+M]?\ ZW6N:3XG:.2LTVGZS;Z>3Y9'F.0'QSMR!G%=S=V?Q(OK":RG MC\'M!-&8W3%S@J1BB4>5OR=OZ^\%*Z5_ZUL;_B#Q;I?ANTL;N^9VMKR984EB MPRKN!.XG(^7 ZC/THT#Q1#XAFN$ATS5+1(E5EEO;;RDF4YP4R@KSSQ3H MEWI/@CP;HVK20W$T.JQ1.8B2A3+8 R ?ND#I7L'2DTDGUU:_(:;;7I_F%%%% M04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %96K>(M,T5?],N0).T M:_,Q_#_&LOQCXI&AVWV>V(-[*/E_V!ZFO))IY;F9I9I&>1CDLQR37%B,4J;Y M8[G-5K\FBW.\OOB9/YA_L^UCV=OM"'/Z-26/Q,G\P?;[6/9W\A#G]6KA[:RN MKQMMM;R2D=D4FII])OK5=US:S0CU="/YU%&ECJ_O4TW]R_.QYM3'JGK*7]?< M>R:3XETK6<"TN1YO_/)_E;\N_P"%:]?/J"6&021N5=3D%3@BO3_!GBQ]3 T^ M_;_2U'R.?^6@_P :[>3$4M*\''SZ'5AB%%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57O[*#4K M"XL;I-]O<1M'(OJIBBC<#AK+P!J-K:_V5)XLOI=!"E%LA"BOM_NF8?-MZ MC QQZ4@^'('PY?PB-5X:7S/M7V?I\^_&S=^'6NZHI\S%9(IW%AY^BRZ=YNWS M+

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form6-k_001.jpg begin 644 form6-k_001.jpg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form6-k_002.jpg begin 644 form6-k_002.jpg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aezs-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Interim Consolidated Statements of Financial Position (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Business overview link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Employee future benefits link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Shareholders’ equity link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Supplemental disclosure of cash flow information link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Segment information link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Basis of presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Employee future benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Shareholders’ equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Supplemental disclosure of cash flow information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Net loss per share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of revenue from transfer of goods and services (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of deferred revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of net defined benefit liability asset (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Employee future benefits (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Summary of share capital (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Summary of assumptions to determine share-based compensation costs over the life of awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Summary of number and weighted average exercise prices of share options (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of DSU activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Shareholders’ equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Disclosure of changes in operating assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Schedule of expected future minimum lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 13 aezs-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 14 aezs-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 15 aezs-20230630_lab.xml XBRL LABEL FILE Components of equity [axis] Issued capital [member] Warrants [member] Other equity interest [member] Retained earnings [member] Accumulated other comprehensive income [member] Products and services [axis] License Fees [Member] Development Services [Member] Product Sales [Member] Royalties [Member] Supply Chain [Member] Timing of transfer of goods or services [axis] Goods or services transferred over time [member] Goods or services transferred at point in time [member] Types of financial liabilities [axis] Unsatisfied performance obligations [member] Indication performance obligation [member] Pediatric indication performance [member] Categories of related parties [axis] Novo Nordisk Health Care AG [member] Collaborative Arrangement [Axis] Novo Nordisk Health Care [member] Pharmanovia [member] NK Meditech [member] Consilient Health [member] Characteristics of defined benefit plans [axis] Pension defined benefit plans [member] Other benefit plans [member] Counterparties [axis] Shareholders and Board of Directors [member] Deferred Stock Units [member] 2018 Long Term Incentive Plan [member] Deferred Share Unit [member] Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities 1 [Axis] Employee Stock Option 1 Deferred Stock Units [member] Maturity [axis] Not later than one year [member] 1 to 3 Years [member] 4 to 5 Years [member] Later than five years [member] Range [axis] Top of range [member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of financial position [abstract] ASSETS Current assets Cash and cash equivalents Trade and other receivables Inventory Income taxes receivable Prepaid expenses and other current assets Total current assets Non-current assets Restricted cash equivalents Property and equipment Total non-current assets Total assets LIABILITIES Current liabilities Payables and accrued liabilities Provisions Income taxes payable Deferred revenues (note 3) Lease liabilities Total current liabilities Non-current liabilities Deferred revenues (note 3) Deferred gain Lease liabilities Employee future benefits (note 4) Provisions Total non-current liabilities Total liabilities Shareholders’ equity Share capital (note 5) Warrants Contributed surplus Deficit Accumulated other comprehensive loss Total Shareholders’ equity Total liabilities and shareholders’ equity Statement of changes in equity [table] IfrsStatementLineItems [Line Items] Balance – Value Net loss Foreign currency translation adjustments Actuarial gain on defined benefit plans Comprehensive income (loss) Share-based compensation costs Balance – Value Profit or loss [abstract] Revenues (note 3) Expenses Cost of sales Research and development Selling, general and administrative Total expenses Loss from operations Gain (loss) due to changes in foreign currency exchange rates Interest income Other finance income (costs) Net finance income Loss before income taxes Income tax recovery Net loss Other comprehensive loss: Items that may be reclassified subsequently to profit or loss: Items that will not be reclassified to profit or loss: Actuarial gain on defined benefit plans (note 4) Comprehensive (loss) income Basic loss per share (note 7) Diluted loss per share (note 7) Weighted average number of shares outstanding, basic Weighted average number of shares outstanding, diluted Statement of cash flows [abstract] Cash flows from operating activities Net loss for the period Items not affecting cash and cash equivalents: Provisions Depreciation and amortization Share-based compensation costs Employee future benefits Amortization of deferred revenues Net foreign exchange differences Other non-cash items Refund (payment) of income taxes Changes in operating assets and liabilities (note 6) Net cash used in operating activities Cash flows from financing activities Payments on lease liabilities Net cash used in financing activities Cash flows from investing activities Purchase of property and equipment Net cash used in investing activities Effect of exchange rate changes on cash and cash equivalents Net change in cash and cash equivalents Cash and cash equivalents – Beginning of period Cash and cash equivalents – End of period Business Overview Business overview Basis Of Presentation Basis of presentation Revenue [abstract] Revenue Employee Future Benefits Employee future benefits Shareholders Equity Shareholders’ equity Supplemental Disclosure Of Cash Flow Information Supplemental disclosure of cash flow information Net Loss Per Share Net loss per share Segment Information Segment information Commitments Commitments New standards and amendments Critical accounting estimates and judgements Summary of revenue from transfer of goods and services Summary of deferred revenue Summary of net defined benefit liability asset Summary of share capital Summary of assumptions to determine share-based compensation costs over the life of awards Summary of number and weighted average exercise prices of share options Summary of DSU activity Disclosure of changes in operating assets and liabilities Summary of pertinent data relating to computation of basic and diluted net loss per share Schedule of expected future minimum lease payments Disclosure of disaggregation of revenue from contracts with customers [table] Total IfrsStatementTable [Table] Total Current Deferred Revenues Total Deferred Revenues Non Current Total Deferred Revenues Revenue Performance obligations Detect trial costs Disclosure of defined benefit plans [table] Change in plan liabilities Balances – Beginning of the period Current service cost Interest cost Actuarial loss (gain) from changes in financial assumptions Benefits paid Impact of foreign exchange rate changes Balances – End of the period Change in plan assets Balances – Beginning of the period Interest income from plan assets Employer contributions Employee contributions Benefits paid Remeasurement of plan assets Impact of foreign exchange rate changes Balances – End of the period Net liability of the unfunded plans Net liability of the funded plans Net amount recognized as Employee future benefits Amounts recognized: In net loss Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income Employee future benefit obligation Number of shares issued Number of shares issued Summary Of Assumptions To Determine Share-based Compensation Costs Over Life Of Awards Expected dividend yield Expected volatility Risk-free annual interest rate Expected life (years) Share price Exercise price Grant date fair value Summary Of Number And Weighted Average Exercise Prices Of Share Options Number of Options, Beginning Weighted average exercise price, beginning Number of Options, Granted Weighted average exercise price, granted Number of Options, Canceled/Forfeited Weighted average exercise price, cancelled/forfeited Number of Options, Ending Weighted average exercise price, ending Balance – January 1, Granted Balance – June 30, Disclosure of offsetting of financial assets [table] Reverse stock split Number of options, granted Compensation expenses Number of share units granted Disclosure Of Changes In Operating Assets And Liabilities Trade and other receivables Inventory Prepaid expenses and other current assets Payables and accrued liabilities Deferred revenues Provision for restructuring and other costs Employee future benefits Increase (decrease) in operating assets and liabilities AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis [Axis] Basic weighted-average shares outstanding Diluted weighted-average shares outstanding Basic loss per share Diluted loss per share Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: Anti-dilutive shares Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table] Total Disclosure of detailed information about borrowings [table] Minimum lease payments net Deferred revenues current. Deferred revenues non current. Deferred gain. Operating Expense Abstract Provision. Adjustments for employee future benefits. Adjustments for amortization of deferred income. The disclosure of detailed information about revenue from transfer of goods and services. Unsatisfied performance obligations [member] Indication performance obligation [member] Pediatric indication performance [member] Disclosure of detailed information about deferred revenue explanatory. Collaborative Arrangement [Axis] Deferred Revenues. Novo Nordisk Health Care [member] Pharmanovia [member] NK Meditech [member] Consilient Health [member] Detect Tria lCosts. Novo Nordisk Health Care AG [member] Other benefit plans [member] Interest income from plan assets. Assets employer contributions. Assets Employee contributions. Remeasurement of plan assets. Impact of foreign exchange rate changes assets of benefit plan. Net liability of the unfunded plans. Net liability of the funded plans. Net amount recognized as Employee future benefits. Postemployment benefit expense defined benefit plans. Employee future benefit obligation discount rate. Stockholders equity reverse split. Shareholders and Board of Directors [member] Deferred Stock Units [member] 2018 Long Term Incentive Plan [member] Description of option life share options granted expected life years. Exercise price of share options granted in sharebased payment arrangement. Weighted average grant date fair value Deferred Share Unit [member] Disclosure of number and weighted average exercise prices of deferred share units explanatory. Adjustments for decrease increase in current prepayments and other current assets. Antidilutive securities excluded from computation of earnings per share, amount. Employee Stock Option 1 Deferred Stock Units [member] Warrants [member] Disclosure of Finance Lease and Operating Lease by Lessee Explanatory. Minimum lease payments, net 1 to 3 Years [member] 4 to 5 Years [member] Disclosure of Changes in Operating Assets and Liabilities Explanatory. Disclosure of Assumptions to Determine Share based Compensation Costs Over Life of Awards Explanatory. Current assets [Default Label] Non-current assets [Default Label] Assets Current liabilities [Default Label] Non-current lease liabilities Non-current provisions Non-current liabilities [Default Label] Liabilities Equity attributable to owners of parent Equity and liabilities Operating expense Profit (loss) from operating activities Finance income (cost) Profit (loss) before tax Tax expense (income) Provision Adjustments for share-based payments Cash flows from (used in) operating activities Payments of lease liabilities, classified as financing activities Cash flows from (used in) financing activities Purchase of property, plant and equipment, classified as investing activities Cash flows from (used in) investing activities Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Disclosure of employee benefits [text block] Disclosure of share capital, reserves and other equity interest [text block] Disclosure of commitments and contingent liabilities [text block] Net defined benefit liability (asset) Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions Decrease (increase) in net defined benefit liability (asset) resulting from payments in respect of settlements Assets of benefit plan Increase (decrease) in net assets available for benefits Remeasurement of plan assets Impact of foreign exchange rate changes [Default Label] Number of shares issued Number of share options outstanding in share-based payment arrangement Weighted average exercise price of share options outstanding in share-based payment arrangement Number of share options forfeited in share-based payment arrangement Number of other equity instruments outstanding in share-based payment arrangement Adjustments for decrease (increase) in trade and other receivables Adjustments for decrease (increase) in inventories AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets Adjustments for increase (decrease) in trade and other payables Adjustments for increase (decrease) in deferred income including contract liabilities Adjustments for increase (decrease) in other liabilities Adjustments for increase (decrease) in employee benefit liabilities EX-101.PRE 16 aezs-20230630_pre.xml XBRL PRESENTATION FILE XML 17 R1.htm IDEA: XBRL DOCUMENT v3.23.2
    Cover
    6 Months Ended
    Jun. 30, 2023
    Cover [Abstract]  
    Document Type 6-K
    Amendment Flag false
    Document Period End Date Jun. 30, 2023
    Document Fiscal Period Focus Q2
    Document Fiscal Year Focus 2023
    Current Fiscal Year End Date --12-31
    Entity File Number 001-38064
    Entity Registrant Name Aeterna Zentaris Inc.
    Entity Central Index Key 0001113423
    Entity Address, Address Line One c/o Norton Rose Fulbright Canada, LLP
    Entity Address, Address Line Two 222 Bay Street
    Entity Address, Address Line Three Suite 3000, PO Box 53,
    Entity Address, City or Town Toronto ON
    Entity Address, Country CA
    Entity Address, Postal Zip Code M5K 1E7

    XML 18 R2.htm IDEA: XBRL DOCUMENT v3.23.2
    Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($)
    $ in Thousands
    Jun. 30, 2023
    Dec. 31, 2022
    Current assets    
    Cash and cash equivalents $ 42,186 $ 50,611
    Trade and other receivables 185 732
    Inventory 93 229
    Income taxes receivable 792 1,428
    Prepaid expenses and other current assets 2,637 2,488
    Total current assets 45,893 55,488
    Non-current assets    
    Restricted cash equivalents 325 322
    Property and equipment 265 216
    Total non-current assets 591 538
    Total assets 46,483 56,026
    Current liabilities    
    Payables and accrued liabilities 3,572 3,828
    Provisions 49 45
    Income taxes payable 109 108
    Deferred revenues (note 3) 202 2,949
    Lease liabilities 145 114
    Total current liabilities 4,077 7,044
    Non-current liabilities    
    Deferred revenues (note 3) 1,580 1,684
    Deferred gain 111 110
    Lease liabilities 85 65
    Employee future benefits (note 4) 11,381 11,159
    Provisions 170 188
    Total non-current liabilities 13,327 13,206
    Total liabilities 17,404 20,250
    Shareholders’ equity    
    Share capital (note 5) 293,410 293,410
    Warrants 5,085 5,085
    Contributed surplus 90,654 90,332
    Deficit (358,936) (352,084)
    Accumulated other comprehensive loss (1,134) (967)
    Total Shareholders’ equity 29,079 35,776
    Total liabilities and shareholders’ equity $ 46,483 $ 56,026
    XML 19 R3.htm IDEA: XBRL DOCUMENT v3.23.2
    Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
    $ in Thousands
    Issued capital [member]
    Warrants [member]
    Other equity interest [member]
    Retained earnings [member]
    Accumulated other comprehensive income [member]
    Total
    Balance – Value at Dec. 31, 2021 $ 293,410 $ 5,085 $ 89,788 $ (334,619) $ (678) $ 52,986
    IfrsStatementLineItems [Line Items]            
    Net loss (6,856) (6,856)
    Foreign currency translation adjustments 79 79
    Actuarial gain on defined benefit plans 8,025 8,025
    Comprehensive income (loss)       1,169 79 1,248
    Share-based compensation costs 60 60
    Balance – Value at Jun. 30, 2022 293,410 5,085 89,848 (333,450) (599) 54,294
    Balance – Value at Dec. 31, 2022 293,410 5,085 90,332 (352,084) (967) 35,776
    IfrsStatementLineItems [Line Items]            
    Net loss (6,772) (6,772)
    Foreign currency translation adjustments (167) (167)
    Actuarial gain on defined benefit plans (80) (80)
    Comprehensive income (loss)       (6,852) (167) (7,019)
    Share-based compensation costs 322 322
    Balance – Value at Jun. 30, 2023 $ 293,410 $ 5,085 $ 90,654 $ (358,936) $ (1,134) $ 29,079
    XML 20 R4.htm IDEA: XBRL DOCUMENT v3.23.2
    Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
    $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    Profit or loss [abstract]        
    Revenues (note 3) $ 2,246 $ (222) $ 4,374 $ 1,295
    Expenses        
    Cost of sales 139 13 156 92
    Research and development 2,929 2,398 6,941 4,788
    Selling, general and administrative 2,033 2,083 4,339 3,944
    Total expenses 5,101 4,494 11,436 8,824
    Loss from operations (2,855) (4,716) (7,062) (7,529)
    Gain (loss) due to changes in foreign currency exchange rates 27 502 (32) 676
    Interest income 307 320
    Other finance income (costs) 3 (2) 2 (3)
    Net finance income 337 500 290 673
    Loss before income taxes (2,518) (4,216) (6,772) (6,856)
    Income tax recovery
    Net loss (2,518) (4,216) (6,772) (6,856)
    Items that may be reclassified subsequently to profit or loss:        
    Foreign currency translation adjustments 3 42 (167) 79
    Items that will not be reclassified to profit or loss:        
    Actuarial gain on defined benefit plans (note 4) 83 5,276 (80) 8,025
    Comprehensive (loss) income $ (2,432) $ 1,102 $ (7,019) $ 1,248
    Basic loss per share (note 7) $ (0.52) $ (0.87) $ (1.39) $ (1.41)
    Diluted loss per share (note 7) $ (0.52) $ (0.87) $ (1.39) $ (1.41)
    Weighted average number of shares outstanding, basic 4,855,876 4,855,876 4,855,876 4,855,876
    Weighted average number of shares outstanding, diluted 4,855,876 4,855,876 4,855,876 4,855,876
    XML 21 R5.htm IDEA: XBRL DOCUMENT v3.23.2
    Condensed Interim Consolidated Statements of Cash Flows (Unaudited) - USD ($)
    $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    Cash flows from operating activities        
    Net loss for the period $ (2,518) $ (4,216) $ (6,772) $ (6,856)
    Items not affecting cash and cash equivalents:        
    Provisions 18 7 10 5
    Depreciation and amortization 44 35 84 71
    Share-based compensation costs 306 33 323 60
    Employee future benefits 130 98 265 197
    Amortization of deferred revenues (794) 124 (1,554) (704)
    Net foreign exchange differences (9) (513) (1) (687)
    Other non-cash items 5 495 5 509
    Refund (payment) of income taxes 647 (51) 647 830
    Changes in operating assets and liabilities (note 6) (2,122) (862) (1,361) 264
    Net cash used in operating activities (4,293) (4,850) (8,354) (6,311)
    Cash flows from financing activities        
    Payments on lease liabilities (42) (34) (80) (68)
    Net cash used in financing activities (42) (34) (80) (68)
    Cash flows from investing activities        
    Purchase of property and equipment (3) (42) (5) (48)
    Net cash used in investing activities (3) (42) (5) (48)
    Effect of exchange rate changes on cash and cash equivalents (36) (513) 14 (716)
    Net change in cash and cash equivalents (4,374) (5,439) (8,425) (7,143)
    Cash and cash equivalents – Beginning of period 46,560 63,596 50,611 65,300
    Cash and cash equivalents – End of period $ 42,186 $ 58,157 $ 42,186 $ 58,157
    XML 22 R6.htm IDEA: XBRL DOCUMENT v3.23.2
    Business overview
    6 Months Ended
    Jun. 30, 2023
    Business Overview  
    Business overview

    1. Business overview

     

    Summary of business

     

    Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen® (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macimorelin is currently marketed under the tradename Ghryvelin™ in the European Economic Area and the United Kingdom through an exclusive licensing agreement with Pharmanovia. The Company’s several other license and commercialization partners are also seeking approval for commercialization of macimorelin in Israel and the Palestinian Authority, the Republic of Korea, Turkey and several non-European Union Balkan countries. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in North America, Asia and the rest of the world.

     

    The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications.

     

    These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 8, 2023.

     

    XML 23 R7.htm IDEA: XBRL DOCUMENT v3.23.2
    Basis of presentation
    6 Months Ended
    Jun. 30, 2023
    Basis Of Presentation  
    Basis of presentation

    2. Basis of presentation

     

    These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting as issued by the International Accounting Standards Board.

     

    The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

     

    The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements.

     

    New standards and amendments

     

    Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.

     

    Critical accounting estimates and judgements

     

    The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

     

    XML 24 R8.htm IDEA: XBRL DOCUMENT v3.23.2
    Revenue
    6 Months Ended
    Jun. 30, 2023
    Revenue [abstract]  
    Revenue

    3. Revenue

     

    The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories:

     

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
        $    $    $    $ 
    License fees   795    (206)   1,554    226 
    Development services   1,402    (77)   2,741    889 
    Product sales   -    -    -    57 
    Royalties   7    24    26    43 
    Supply chain   42    37    53    80 
    Total   2,246    (222)   4,374    1,295 

     

    The Company recorded revenue for the transfer of services over time for the three-months ended June 30, 2023, of $2,197 (2022 – ($283)) and the six-months ended June 30, 2023, of $4,295 (2022 - $1,115). While revenue recorded at a point in time for the three-months ended June 30, 2023, was $49 (2022 – $61) and the six-months ended June 30, 2023, was $79 (2022 - $180).

     

    Pharmanovia:

     

    On March 15, 2023, with the Company’s consent, Consilient Health (“CH”) entered into an assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product (together, the “Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. Subsequent to the execution of the Assignment Agreement, the aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations was $1,658 (€1,540), comprised of; the combined adult indication performance obligation of $1,233 (€1,145), and the combined pediatric indication performance obligation of $425 (€395). The Company will continue to recognize revenue over time using an output method based on units of licensed product supplied to Pharmanovia. The total units that the Company expects to supply to Pharmanovia is an estimate, based on current projections and anticipated market demand, and therefore will be a significant judgement that will be relied upon when using the outputs method to recognize revenue.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    Novo Nordisk Health Care AG:

     

    On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination was effective May 23, 2023, upon the completion of a 270-day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment returned to the Company, and the Company regained full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270-day notice period, as per the terms of the Novo Amendment, Novo continued to fund DETECT-trial costs up to $10.1 million (€9.4 million). As of May 23, 2023, the Company recognized all remaining license fees associated with the Pediatric indication and development services revenue previously recorded in deferred revenue.

     

    Liabilities related to contracts with customers

     

    The following table provides a summary of deferred revenue balances:

     

       June 30, 2023 
       Current   Non-current   Total 
       $   $   $ 
    Novo Nordisk Health Care   -    -    - 
    Pharmanovia   193    1,459    1,652 
    NK Meditech   9    121    130 
        202    1,580    1,782 

     

       December 31, 2022 
       Current   Non-current   Total 
       $   $   $ 
    Novo Nordisk Health Care   2,914    -    2,914 
    Consilient Health   35    1,556    1,591 
    NK Meditech   -    128    128 
        2,949    1,684    4,633 

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    XML 25 R9.htm IDEA: XBRL DOCUMENT v3.23.2
    Employee future benefits
    6 Months Ended
    Jun. 30, 2023
    Employee Future Benefits  
    Employee future benefits

    4. Employee future benefits

     

    The change in the Company’s employee future benefit obligations is summarized as follows:

     

       benefit plans   benefit plans   Total   Total 
      

    Six months ended

    June 30, 2023

       Year ended
    December 31,
    2022
     
       Pension   Other         
       benefit plans   benefit plans   Total   Total 
       $   $   $   $ 
    Change in plan liabilities                    
    Balances – Beginning of the period   21,657    93    21,750    29,412 
    Current service cost   63    6    69    142 
    Interest cost   400    2    402    295 
    Actuarial loss (gain) from changes in financial assumptions   143    -    143    (5,915)
    Benefits paid   (380)   -    (380)   (752)
    Impact of foreign exchange rate changes   261    1    262    (1,432)
    Balances – End of the period   22,144    102    22,246    21,750 
                         
    Change in plan assets                    
    Balances – Beginning of the period   10,591    -    10,591    11,927 
    Interest income from plan assets   198    -    198    120 
    Employer contributions   14    -    14    45 
    Employee contributions   8    -    8    10 
    Benefits paid   (136)   -    (136)   (247)
    Remeasurement of plan assets   63    -    63    (641)
    Impact of foreign exchange rate changes   127    -    127    (623)
    Balances – End of the period   10,865    -    10,865    10,591 
                         
    Net liability of the unfunded plans   10,867    102    10,969    10,787 
    Net liability of the funded plans   412    -    412    372 
    Net amount recognized as Employee future benefits   11,279    102    11,381    11,159 
                         
    Amounts recognized:                    
    In net loss   257    8    265    295 
    Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income   (80)   -    (80)   5,262 

     

    The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were 3.70% as of June 30, 2023, and 3.75% as of December 31, 2022, causing the variances in the actuarial loss (gain) on defined benefit plan during the six months ended June 30, 2023.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    XML 26 R10.htm IDEA: XBRL DOCUMENT v3.23.2
    Shareholders’ equity
    6 Months Ended
    Jun. 30, 2023
    Shareholders Equity  
    Shareholders’ equity

    5. Shareholders’ equity

     

    Share capital

     

    The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.

     

       Common shares   Amount 
       #   $ 
    Balance – December 31, 2022   4,855,876    293,410 
               
        -    - 
    Balance – June 30, 2023   4,855,876    293,410 

     

    On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of incorporation to effect a 1-for-25 share consolidation (reverse split) of the Company’s common shares. The Company’s outstanding stock options, DSUs and warrants were also adjusted to reflect the 1-for-25 share consolidation (reverse split) of the Company’s common shares. Accordingly, all common shares, DSU, warrants, stock options and per share amounts in these interim condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share consolidation (reverse split). Outstanding warrant and stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The share consolidation (reverse split) was affected on July 21, 2022.

     

    Share-based compensation

     

    On January 17, 2023, the Company granted 14,000 (2022 – 2,000) stock options under the Long-Term Incentive Plan. The stock options have a term of seven years and will vest over a period of three years. The fair value at grant date is estimated using a Black-Scholes option pricing model, considering the terms and conditions upon which the options were granted, using the following assumptions:

     

       June 30,
    2023
       June 30,
    2022
     
    Expected dividend yield  $0.00   $0.00 
    Expected volatility   104.46%   115.75%
    Risk-free annual interest rate   3.56%   1.59%
    Expected life (years)   5.45    5.72 
    Share price  $3.75   $8.88 
    Exercise price  $3.75   $8.88 
    Grant date fair value  $2.99   $7.47 

     

    The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    The compensation expense for the three months ended June 30, 2023, was $22 (2022 – $33) and the six months ended June 30, 2023, was $39 (2022 – $60) recognized over the vesting period. Option activity for the six months ended June 30, 2023, and 2022, was as follows:

     

       Stock options   Weighted average exercise price 
       #   $ 
    Balance – January 1, 2023   42,030    20.05 
    Granted   14,000    3.75 
    Cancelled / Forfeited   -    - 
    Balance – June 30, 2023   56,030    15.98 

     

       Stock options   Weighted average exercise price 
       #   $ 
    Balance – January 1, 2022   43,455    22.00 
    Granted   2,000    8.88 
    Cancelled / Forfeited   (2,399)   10.98 
    Balance – June 30, 2022   43,056    21.95 

     

    Deferred share units

     

    On June 14, 2023, the Company granted 100,000 (2022 – nil) DSUs under the Long-Term Incentive Plan. The compensation expense for the three and six months ended June 30, 2023, was $284 (2022 - $nil) and is presented in selling, general and administrative expenses. DSU activity for the six months ended June 30, 2023, are:

     

       2023   2022 
       #   # 
    Balance – January 1,   96,920    16,920 
    Granted   100,000    - 
    Balance – June 30,   196,920    16,920 

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    XML 27 R11.htm IDEA: XBRL DOCUMENT v3.23.2
    Supplemental disclosure of cash flow information
    6 Months Ended
    Jun. 30, 2023
    Supplemental Disclosure Of Cash Flow Information  
    Supplemental disclosure of cash flow information

    6. Supplemental disclosure of cash flow information

     

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
       $   $   $   $ 
    Changes in operating assets and liabilities:                    
    Trade and other receivables   199    (255)   402    220 
    Inventory   135    -    140    (206)
    Prepaid expenses and other current assets   (748)   (1,471)   (122)   (759)
    Payables and accrued liabilities   (398)   (40)   (163)   119 
    Deferred revenues   (1,205)   1,001    (1,359)   1,008 
    Provision for restructuring and other costs   4    -    (5)   - 
    Employee future benefits   (109)   (97)   (254)   (118)
    Increase (decrease) in operating assets and liabilities   (2,122)   (862)   (1,361)   264 

     

    XML 28 R12.htm IDEA: XBRL DOCUMENT v3.23.2
    Net loss per share
    6 Months Ended
    Jun. 30, 2023
    Net Loss Per Share  
    Net loss per share

    7. Net loss per share

     

    The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.

     

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
       $   $   $   $ 
    Net loss   (2,518)   (4,216)   (6,772)   (6,856)
    Basic and diluted weighted-average shares outstanding   4,855,876    4,855,876    4,855,876    4,855,876 
                         
    Basic and diluted loss per share   (0.52)   (0.87)   (1.39)   (1.41)
                         
    Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:                    
    Stock options and DSUs   252,950    62,375    252,950    62,375 
    Warrants   457,648    457,648    457,648    457,648 

     

    XML 29 R13.htm IDEA: XBRL DOCUMENT v3.23.2
    Segment information
    6 Months Ended
    Jun. 30, 2023
    Segment Information  
    Segment information

    8. Segment information

     

    The Company operates in a single operating segment, being the biopharmaceutical segment.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    XML 30 R14.htm IDEA: XBRL DOCUMENT v3.23.2
    Commitments
    6 Months Ended
    Jun. 30, 2023
    Commitments  
    Commitments

    9. Commitments

     

    Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:

     

       TOTAL 
       $ 
    Less than 1 year   7,586 
    1 - 3 years   151 
    4 - 5 years   37 
    More than 5 years   - 
    Total   7,774 

     

    In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $38,887 upon achieving certain sales volumes, regulatory or other milestones related to specific products.

    XML 31 R15.htm IDEA: XBRL DOCUMENT v3.23.2
    Basis of presentation (Policies)
    6 Months Ended
    Jun. 30, 2023
    Basis Of Presentation  
    New standards and amendments

    New standards and amendments

     

    Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.

     

    Critical accounting estimates and judgements

    Critical accounting estimates and judgements

     

    The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.

     

     

    Aeterna Zentaris Inc.

    Notes to the Condensed Interim Consolidated Financial Statements

    As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022

     

    (In thousands of US dollars, except share and per share data and as otherwise noted)

    (Unaudited)

     

    Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.

     

    XML 32 R16.htm IDEA: XBRL DOCUMENT v3.23.2
    Revenue (Tables)
    6 Months Ended
    Jun. 30, 2023
    Revenue [abstract]  
    Summary of revenue from transfer of goods and services

    The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories:

     

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
        $    $    $    $ 
    License fees   795    (206)   1,554    226 
    Development services   1,402    (77)   2,741    889 
    Product sales   -    -    -    57 
    Royalties   7    24    26    43 
    Supply chain   42    37    53    80 
    Total   2,246    (222)   4,374    1,295 
    Summary of deferred revenue

    The following table provides a summary of deferred revenue balances:

     

       June 30, 2023 
       Current   Non-current   Total 
       $   $   $ 
    Novo Nordisk Health Care   -    -    - 
    Pharmanovia   193    1,459    1,652 
    NK Meditech   9    121    130 
        202    1,580    1,782 

     

       December 31, 2022 
       Current   Non-current   Total 
       $   $   $ 
    Novo Nordisk Health Care   2,914    -    2,914 
    Consilient Health   35    1,556    1,591 
    NK Meditech   -    128    128 
        2,949    1,684    4,633 
    XML 33 R17.htm IDEA: XBRL DOCUMENT v3.23.2
    Employee future benefits (Tables)
    6 Months Ended
    Jun. 30, 2023
    Employee Future Benefits  
    Summary of net defined benefit liability asset

    The change in the Company’s employee future benefit obligations is summarized as follows:

     

       benefit plans   benefit plans   Total   Total 
      

    Six months ended

    June 30, 2023

       Year ended
    December 31,
    2022
     
       Pension   Other         
       benefit plans   benefit plans   Total   Total 
       $   $   $   $ 
    Change in plan liabilities                    
    Balances – Beginning of the period   21,657    93    21,750    29,412 
    Current service cost   63    6    69    142 
    Interest cost   400    2    402    295 
    Actuarial loss (gain) from changes in financial assumptions   143    -    143    (5,915)
    Benefits paid   (380)   -    (380)   (752)
    Impact of foreign exchange rate changes   261    1    262    (1,432)
    Balances – End of the period   22,144    102    22,246    21,750 
                         
    Change in plan assets                    
    Balances – Beginning of the period   10,591    -    10,591    11,927 
    Interest income from plan assets   198    -    198    120 
    Employer contributions   14    -    14    45 
    Employee contributions   8    -    8    10 
    Benefits paid   (136)   -    (136)   (247)
    Remeasurement of plan assets   63    -    63    (641)
    Impact of foreign exchange rate changes   127    -    127    (623)
    Balances – End of the period   10,865    -    10,865    10,591 
                         
    Net liability of the unfunded plans   10,867    102    10,969    10,787 
    Net liability of the funded plans   412    -    412    372 
    Net amount recognized as Employee future benefits   11,279    102    11,381    11,159 
                         
    Amounts recognized:                    
    In net loss   257    8    265    295 
    Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income   (80)   -    (80)   5,262 
    XML 34 R18.htm IDEA: XBRL DOCUMENT v3.23.2
    Shareholders’ equity (Tables)
    6 Months Ended
    Jun. 30, 2023
    Shareholders Equity  
    Summary of share capital

       Common shares   Amount 
       #   $ 
    Balance – December 31, 2022   4,855,876    293,410 
               
        -    - 
    Balance – June 30, 2023   4,855,876    293,410 
    Summary of assumptions to determine share-based compensation costs over the life of awards

       June 30,
    2023
       June 30,
    2022
     
    Expected dividend yield  $0.00   $0.00 
    Expected volatility   104.46%   115.75%
    Risk-free annual interest rate   3.56%   1.59%
    Expected life (years)   5.45    5.72 
    Share price  $3.75   $8.88 
    Exercise price  $3.75   $8.88 
    Grant date fair value  $2.99   $7.47 
    Summary of number and weighted average exercise prices of share options

       Stock options   Weighted average exercise price 
       #   $ 
    Balance – January 1, 2023   42,030    20.05 
    Granted   14,000    3.75 
    Cancelled / Forfeited   -    - 
    Balance – June 30, 2023   56,030    15.98 

     

       Stock options   Weighted average exercise price 
       #   $ 
    Balance – January 1, 2022   43,455    22.00 
    Granted   2,000    8.88 
    Cancelled / Forfeited   (2,399)   10.98 
    Balance – June 30, 2022   43,056    21.95 
    Summary of DSU activity

       2023   2022 
       #   # 
    Balance – January 1,   96,920    16,920 
    Granted   100,000    - 
    Balance – June 30,   196,920    16,920 
    XML 35 R19.htm IDEA: XBRL DOCUMENT v3.23.2
    Supplemental disclosure of cash flow information (Tables)
    6 Months Ended
    Jun. 30, 2023
    Supplemental Disclosure Of Cash Flow Information  
    Disclosure of changes in operating assets and liabilities

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
       $   $   $   $ 
    Changes in operating assets and liabilities:                    
    Trade and other receivables   199    (255)   402    220 
    Inventory   135    -    140    (206)
    Prepaid expenses and other current assets   (748)   (1,471)   (122)   (759)
    Payables and accrued liabilities   (398)   (40)   (163)   119 
    Deferred revenues   (1,205)   1,001    (1,359)   1,008 
    Provision for restructuring and other costs   4    -    (5)   - 
    Employee future benefits   (109)   (97)   (254)   (118)
    Increase (decrease) in operating assets and liabilities   (2,122)   (862)   (1,361)   264 
    XML 36 R20.htm IDEA: XBRL DOCUMENT v3.23.2
    Net loss per share (Tables)
    6 Months Ended
    Jun. 30, 2023
    Net Loss Per Share  
    Summary of pertinent data relating to computation of basic and diluted net loss per share

    The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.

     

       2023   2022   2023   2022 
       Three months ended   Six months ended 
       June 30,   June 30, 
       2023   2022   2023   2022 
       $   $   $   $ 
    Net loss   (2,518)   (4,216)   (6,772)   (6,856)
    Basic and diluted weighted-average shares outstanding   4,855,876    4,855,876    4,855,876    4,855,876 
                         
    Basic and diluted loss per share   (0.52)   (0.87)   (1.39)   (1.41)
                         
    Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:                    
    Stock options and DSUs   252,950    62,375    252,950    62,375 
    Warrants   457,648    457,648    457,648    457,648 
    XML 37 R21.htm IDEA: XBRL DOCUMENT v3.23.2
    Commitments (Tables)
    6 Months Ended
    Jun. 30, 2023
    Commitments  
    Schedule of expected future minimum lease payments

    Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:

     

       TOTAL 
       $ 
    Less than 1 year   7,586 
    1 - 3 years   151 
    4 - 5 years   37 
    More than 5 years   - 
    Total   7,774 
    XML 38 R22.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of revenue from transfer of goods and services (Details) - USD ($)
    $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    IfrsStatementLineItems [Line Items]        
    Total $ 2,246 $ (222) $ 4,374 $ 1,295
    License Fees [Member]        
    IfrsStatementLineItems [Line Items]        
    Total 795 (206) 1,554 226
    Development Services [Member]        
    IfrsStatementLineItems [Line Items]        
    Total 1,402 (77) 2,741 889
    Product Sales [Member]        
    IfrsStatementLineItems [Line Items]        
    Total 57
    Royalties [Member]        
    IfrsStatementLineItems [Line Items]        
    Total 7 24 26 43
    Supply Chain [Member]        
    IfrsStatementLineItems [Line Items]        
    Total $ 42 $ 37 $ 53 $ 80
    XML 39 R23.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of deferred revenue (Details) - USD ($)
    $ in Thousands
    Jun. 30, 2023
    Dec. 31, 2022
    IfrsStatementLineItems [Line Items]    
    Total Current Deferred Revenues $ 202 $ 2,949
    Total Deferred Revenues Non Current 1,580 1,684
    Total Deferred Revenues 1,782 4,633
    Novo Nordisk Health Care [member]    
    IfrsStatementLineItems [Line Items]    
    Total Current Deferred Revenues 2,914
    Total Deferred Revenues Non Current
    Total Deferred Revenues 2,914
    Pharmanovia [member]    
    IfrsStatementLineItems [Line Items]    
    Total Current Deferred Revenues 193  
    Total Deferred Revenues Non Current 1,459  
    Total Deferred Revenues 1,652  
    NK Meditech [member]    
    IfrsStatementLineItems [Line Items]    
    Total Current Deferred Revenues 9
    Total Deferred Revenues Non Current 121 128
    Total Deferred Revenues $ 130 128
    Consilient Health [member]    
    IfrsStatementLineItems [Line Items]    
    Total Current Deferred Revenues   35
    Total Deferred Revenues Non Current   1,556
    Total Deferred Revenues   $ 1,591
    XML 40 R24.htm IDEA: XBRL DOCUMENT v3.23.2
    Revenue (Details Narrative)
    € in Thousands, $ in Thousands
    3 Months Ended 6 Months Ended
    May 23, 2023
    USD ($)
    May 23, 2023
    EUR (€)
    Jun. 30, 2023
    USD ($)
    Jun. 30, 2022
    USD ($)
    Jun. 30, 2023
    USD ($)
    Jun. 30, 2022
    USD ($)
    Mar. 15, 2023
    USD ($)
    Mar. 15, 2023
    EUR (€)
    IfrsStatementLineItems [Line Items]                
    Revenue     $ 2,246 $ (222) $ 4,374 $ 1,295    
    Novo Nordisk Health Care AG [member]                
    IfrsStatementLineItems [Line Items]                
    Detect trial costs $ 10,100 € 9,400            
    Unsatisfied performance obligations [member]                
    IfrsStatementLineItems [Line Items]                
    Performance obligations             $ 1,658 € 1,540
    Indication performance obligation [member]                
    IfrsStatementLineItems [Line Items]                
    Performance obligations             1,233 1,145
    Pediatric indication performance [member]                
    IfrsStatementLineItems [Line Items]                
    Performance obligations             $ 425 € 395
    Goods or services transferred over time [member]                
    IfrsStatementLineItems [Line Items]                
    Revenue     2,197 283 4,295 1,115    
    Goods or services transferred at point in time [member]                
    IfrsStatementLineItems [Line Items]                
    Revenue     $ 49 $ 61 $ 79 $ 180    
    XML 41 R25.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of net defined benefit liability asset (Details) - USD ($)
    $ in Thousands
    6 Months Ended 12 Months Ended
    Jun. 30, 2023
    Dec. 31, 2022
    Change in plan liabilities    
    Balances – Beginning of the period $ 21,750 $ 29,412
    Current service cost 69 142
    Interest cost 402 295
    Actuarial loss (gain) from changes in financial assumptions (143) 5,915
    Benefits paid (380) (752)
    Impact of foreign exchange rate changes 262 (1,432)
    Balances – End of the period 22,246 21,750
    Change in plan assets    
    Balances – Beginning of the period 10,591 11,927
    Interest income from plan assets 198 120
    Employer contributions 14 45
    Employee contributions 8 10
    Benefits paid (136) (247)
    Remeasurement of plan assets 63 (641)
    Impact of foreign exchange rate changes 127 (623)
    Balances – End of the period 10,865 10,591
    Net liability of the unfunded plans 10,969 10,787
    Net liability of the funded plans 412 372
    Net amount recognized as Employee future benefits 11,381 11,159
    Amounts recognized:    
    In net loss 265 295
    Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income (80) 5,262
    Pension defined benefit plans [member]    
    Change in plan liabilities    
    Balances – Beginning of the period 21,657  
    Current service cost 63  
    Interest cost 400  
    Actuarial loss (gain) from changes in financial assumptions (143)  
    Benefits paid (380)  
    Impact of foreign exchange rate changes 261  
    Balances – End of the period 22,144 21,657
    Change in plan assets    
    Balances – Beginning of the period 10,591  
    Interest income from plan assets 198  
    Employer contributions 14  
    Employee contributions 8  
    Benefits paid (136)  
    Remeasurement of plan assets 63  
    Impact of foreign exchange rate changes 127  
    Balances – End of the period 10,865 10,591
    Net liability of the unfunded plans 10,867  
    Net liability of the funded plans 412  
    Net amount recognized as Employee future benefits 11,279  
    Amounts recognized:    
    In net loss 257  
    Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income (80)  
    Other benefit plans [member]    
    Change in plan liabilities    
    Balances – Beginning of the period 93  
    Current service cost 6  
    Interest cost 2  
    Actuarial loss (gain) from changes in financial assumptions  
    Benefits paid  
    Impact of foreign exchange rate changes 1  
    Balances – End of the period 102 93
    Change in plan assets    
    Balances – Beginning of the period  
    Interest income from plan assets  
    Employer contributions  
    Employee contributions  
    Benefits paid  
    Remeasurement of plan assets  
    Impact of foreign exchange rate changes  
    Balances – End of the period
    Net liability of the unfunded plans 102  
    Net liability of the funded plans  
    Net amount recognized as Employee future benefits 102  
    Amounts recognized:    
    In net loss 8  
    Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income  
    XML 42 R26.htm IDEA: XBRL DOCUMENT v3.23.2
    Employee future benefits (Details Narrative)
    Jun. 30, 2023
    Dec. 31, 2022
    Employee Future Benefits    
    Employee future benefit obligation 3.70% 3.75%
    XML 43 R27.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of share capital (Details) - USD ($)
    $ in Thousands
    Jun. 30, 2023
    Dec. 31, 2022
    Jun. 30, 2022
    IfrsStatementLineItems [Line Items]      
    Balance – Value $ 35,776 $ 54,294 $ 52,986
    Balance – Value $ 29,079 35,776 54,294
    Issued capital [member]      
    IfrsStatementLineItems [Line Items]      
    Number of shares issued 4,855,876    
    Balance – Value $ 293,410 $ 293,410 293,410
    Number of shares issued 4,855,876 4,855,876  
    Balance – Value $ 293,410 $ 293,410 $ 293,410
    XML 44 R28.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of assumptions to determine share-based compensation costs over the life of awards (Details) - $ / shares
    6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Shareholders Equity    
    Expected dividend yield 0.00% 0.00%
    Expected volatility 104.46% 115.75%
    Risk-free annual interest rate 3.56% 1.59%
    Expected life (years) 5 years 5 months 12 days 5 years 8 months 19 days
    Share price $ 3.75 $ 8.88
    Exercise price 3.75 8.88
    Grant date fair value $ 2.99 $ 7.47
    XML 45 R29.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of number and weighted average exercise prices of share options (Details)
    6 Months Ended
    Jun. 30, 2023
    shares
    $ / shares
    Jun. 30, 2022
    shares
    $ / shares
    Shareholders Equity    
    Number of Options, Beginning | shares 42,030 43,455
    Weighted average exercise price, beginning | $ / shares $ 20.05 $ 22.00
    Number of Options, Granted | shares 14,000 2,000
    Weighted average exercise price, granted | $ / shares $ 3.75 $ 8.88
    Number of Options, Canceled/Forfeited | shares (2,399)
    Weighted average exercise price, cancelled/forfeited | $ / shares $ 10.98
    Number of Options, Ending | shares 56,030 43,056
    Weighted average exercise price, ending | $ / shares $ 15.98 $ 21.95
    XML 46 R30.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of DSU activity (Details) - Deferred Share Unit [member] - shares
    6 Months Ended
    Jun. 14, 2023
    Jun. 14, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    IfrsStatementLineItems [Line Items]        
    Balance – January 1,     96,920 16,920
    Granted 100,000 100,000
    Balance – June 30,     196,920 16,920
    XML 47 R31.htm IDEA: XBRL DOCUMENT v3.23.2
    Shareholders’ equity (Details Narrative)
    $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 14, 2023
    shares
    Jan. 17, 2023
    shares
    Jul. 15, 2022
    Jun. 14, 2022
    shares
    Jan. 17, 2022
    shares
    Jun. 30, 2023
    USD ($)
    Jun. 30, 2022
    USD ($)
    Jun. 30, 2023
    USD ($)
    shares
    Jun. 30, 2022
    USD ($)
    shares
    IfrsStatementLineItems [Line Items]                  
    Number of options, granted               14,000 2,000
    Compensation expenses | $           $ 22 $ 33 $ 39 $ 60
    Deferred Share Unit [member]                  
    IfrsStatementLineItems [Line Items]                  
    Compensation expenses | $           $ 284 $ 284
    Number of share units granted 100,000           100,000
    2018 Long Term Incentive Plan [member]                  
    IfrsStatementLineItems [Line Items]                  
    Number of options, granted   14,000     2,000        
    Shareholders and Board of Directors [member]                  
    IfrsStatementLineItems [Line Items]                  
    Reverse stock split     1-for-25            
    Deferred Stock Units [member]                  
    IfrsStatementLineItems [Line Items]                  
    Reverse stock split     1-for-25            
    XML 48 R32.htm IDEA: XBRL DOCUMENT v3.23.2
    Disclosure of changes in operating assets and liabilities (Details) - USD ($)
    $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    Supplemental Disclosure Of Cash Flow Information        
    Trade and other receivables $ 199 $ (255) $ 402 $ 220
    Inventory 135 140 (206)
    Prepaid expenses and other current assets (748) (1,471) (122) (759)
    Payables and accrued liabilities (398) (40) (163) 119
    Deferred revenues (1,205) 1,001 (1,359) 1,008
    Provision for restructuring and other costs 4 (5)
    Employee future benefits (109) (97) (254) (118)
    Increase (decrease) in operating assets and liabilities $ (2,122) $ (862) $ (1,361) $ 264
    XML 49 R33.htm IDEA: XBRL DOCUMENT v3.23.2
    Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) - USD ($)
    $ / shares in Units, $ in Thousands
    3 Months Ended 6 Months Ended
    Jun. 30, 2023
    Jun. 30, 2022
    Jun. 30, 2023
    Jun. 30, 2022
    IfrsStatementLineItems [Line Items]        
    Net loss $ (2,518) $ (4,216) $ (6,772) $ (6,856)
    Basic weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876
    Diluted weighted-average shares outstanding 4,855,876 4,855,876 4,855,876 4,855,876
    Basic loss per share $ (0.52) $ (0.87) $ (1.39) $ (1.41)
    Diluted loss per share $ (0.52) $ (0.87) $ (1.39) $ (1.41)
    Employee Stock Option 1 Deferred Stock Units [member]        
    Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:        
    Anti-dilutive shares 252,950 62,375 252,950 62,375
    Warrants [member]        
    Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:        
    Anti-dilutive shares 457,648 457,648 457,648 457,648
    XML 50 R34.htm IDEA: XBRL DOCUMENT v3.23.2
    Schedule of expected future minimum lease payments (Details)
    $ in Thousands
    Jun. 30, 2023
    USD ($)
    IfrsStatementLineItems [Line Items]  
    Total $ 7,774
    Not later than one year [member]  
    IfrsStatementLineItems [Line Items]  
    Total 7,586
    1 to 3 Years [member]  
    IfrsStatementLineItems [Line Items]  
    Total 151
    4 to 5 Years [member]  
    IfrsStatementLineItems [Line Items]  
    Total 37
    Later than five years [member]  
    IfrsStatementLineItems [Line Items]  
    Total
    XML 51 R35.htm IDEA: XBRL DOCUMENT v3.23.2
    Commitments (Details Narrative) - USD ($)
    $ in Thousands
    Jun. 30, 2023
    Dec. 31, 2021
    IfrsStatementLineItems [Line Items]    
    Minimum lease payments net $ 7,774  
    Top of range [member]    
    IfrsStatementLineItems [Line Items]    
    Minimum lease payments net   $ 38,887
    XML 52 form6-k_htm.xml IDEA: XBRL DOCUMENT 0001113423 2023-01-01 2023-06-30 0001113423 2023-06-30 0001113423 2022-12-31 0001113423 ifrs-full:IssuedCapitalMember 2022-12-31 0001113423 AEZS:WarrantsMember 2022-12-31 0001113423 ifrs-full:OtherEquityInterestMember 2022-12-31 0001113423 ifrs-full:RetainedEarningsMember 2022-12-31 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001113423 ifrs-full:IssuedCapitalMember 2021-12-31 0001113423 AEZS:WarrantsMember 2021-12-31 0001113423 ifrs-full:OtherEquityInterestMember 2021-12-31 0001113423 ifrs-full:RetainedEarningsMember 2021-12-31 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001113423 2021-12-31 0001113423 ifrs-full:IssuedCapitalMember 2023-01-01 2023-06-30 0001113423 AEZS:WarrantsMember 2023-01-01 2023-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2023-01-01 2023-06-30 0001113423 ifrs-full:RetainedEarningsMember 2023-01-01 2023-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:IssuedCapitalMember 2022-01-01 2022-06-30 0001113423 AEZS:WarrantsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2022-01-01 2022-06-30 0001113423 ifrs-full:RetainedEarningsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001113423 2022-01-01 2022-06-30 0001113423 ifrs-full:IssuedCapitalMember 2023-06-30 0001113423 AEZS:WarrantsMember 2023-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2023-06-30 0001113423 ifrs-full:RetainedEarningsMember 2023-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001113423 ifrs-full:IssuedCapitalMember 2022-06-30 0001113423 AEZS:WarrantsMember 2022-06-30 0001113423 ifrs-full:OtherEquityInterestMember 2022-06-30 0001113423 ifrs-full:RetainedEarningsMember 2022-06-30 0001113423 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001113423 2022-06-30 0001113423 2023-04-01 2023-06-30 0001113423 2022-04-01 2022-06-30 0001113423 2023-03-31 0001113423 2022-03-31 0001113423 AEZS:LicenseFeesMember 2023-04-01 2023-06-30 0001113423 AEZS:LicenseFeesMember 2022-04-01 2022-06-30 0001113423 AEZS:LicenseFeesMember 2023-01-01 2023-06-30 0001113423 AEZS:LicenseFeesMember 2022-01-01 2022-06-30 0001113423 AEZS:DevelopmentServicesMember 2023-04-01 2023-06-30 0001113423 AEZS:DevelopmentServicesMember 2022-04-01 2022-06-30 0001113423 AEZS:DevelopmentServicesMember 2023-01-01 2023-06-30 0001113423 AEZS:DevelopmentServicesMember 2022-01-01 2022-06-30 0001113423 AEZS:ProductSalesMember 2023-04-01 2023-06-30 0001113423 AEZS:ProductSalesMember 2022-04-01 2022-06-30 0001113423 AEZS:ProductSalesMember 2023-01-01 2023-06-30 0001113423 AEZS:ProductSalesMember 2022-01-01 2022-06-30 0001113423 AEZS:RoyaltiesMember 2023-04-01 2023-06-30 0001113423 AEZS:RoyaltiesMember 2022-04-01 2022-06-30 0001113423 AEZS:RoyaltiesMember 2023-01-01 2023-06-30 0001113423 AEZS:RoyaltiesMember 2022-01-01 2022-06-30 0001113423 AEZS:SupplyChainMember 2023-04-01 2023-06-30 0001113423 AEZS:SupplyChainMember 2022-04-01 2022-06-30 0001113423 AEZS:SupplyChainMember 2023-01-01 2023-06-30 0001113423 AEZS:SupplyChainMember 2022-01-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2023-04-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-04-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredOverTimeMember 2022-01-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2023-04-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-04-01 2022-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2023-01-01 2023-06-30 0001113423 ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember 2022-01-01 2022-06-30 0001113423 AEZS:UnsatisfiedPerformanceObligationsMember 2023-03-15 0001113423 AEZS:IndicationPerformanceObligationMember 2023-03-15 0001113423 AEZS:PediatricIndicationPerformanceMember 2023-03-15 0001113423 AEZS:NovoNordiskHealthCareAGMember 2023-05-23 2023-05-23 0001113423 AEZS:NovoNordiskHealthCareMember 2023-06-30 0001113423 AEZS:PharmanoviaMember 2023-06-30 0001113423 AEZS:NKMeditechMember 2023-06-30 0001113423 AEZS:NovoNordiskHealthCareMember 2022-12-31 0001113423 AEZS:ConsilientHealthMember 2022-12-31 0001113423 AEZS:NKMeditechMember 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2023-01-01 2023-06-30 0001113423 AEZS:OtherBenefitPlansMember 2023-01-01 2023-06-30 0001113423 2022-01-01 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2022-12-31 0001113423 AEZS:OtherBenefitPlansMember 2022-12-31 0001113423 ifrs-full:PensionDefinedBenefitPlansMember 2023-06-30 0001113423 AEZS:OtherBenefitPlansMember 2023-06-30 0001113423 AEZS:ShareholdersAndBoardOfDirectorsMember 2022-07-15 2022-07-15 0001113423 AEZS:DeferredStockUnitsMember 2022-07-15 2022-07-15 0001113423 AEZS:TwoThousandEighteenLongTermIncentivePlanMember 2023-01-16 2023-01-17 0001113423 AEZS:TwoThousandEighteenLongTermIncentivePlanMember 2022-01-16 2022-01-17 0001113423 AEZS:DeferredShareUnitMember 2023-06-14 2023-06-14 0001113423 AEZS:DeferredShareUnitMember 2022-06-14 2022-06-14 0001113423 AEZS:DeferredShareUnitMember 2023-04-01 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2023-01-01 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-04-01 2022-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-01-01 2022-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-12-31 0001113423 AEZS:DeferredShareUnitMember 2021-12-31 0001113423 AEZS:DeferredShareUnitMember 2023-06-30 0001113423 AEZS:DeferredShareUnitMember 2022-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2023-04-01 2023-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2022-04-01 2022-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2023-01-01 2023-06-30 0001113423 AEZS:EmployeeStockOption1DeferredStockUnitsMember 2022-01-01 2022-06-30 0001113423 AEZS:WarrantsMember 2023-04-01 2023-06-30 0001113423 AEZS:WarrantsMember 2022-04-01 2022-06-30 0001113423 AEZS:WarrantsMember 2023-01-01 2023-06-30 0001113423 AEZS:WarrantsMember 2022-01-01 2022-06-30 0001113423 ifrs-full:NotLaterThanOneYearMember 2023-06-30 0001113423 AEZS:OneToThreeYearsMember 2023-06-30 0001113423 AEZS:FourToFiveYearsMember 2023-06-30 0001113423 ifrs-full:LaterThanFiveYearsMember 2023-06-30 0001113423 ifrs-full:TopOfRangeMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure iso4217:EUR AEZS:Integer iso4217:CAD shares 6-K 001-38064 Aeterna Zentaris Inc. c/o Norton Rose Fulbright Canada, LLP 222 Bay Street Suite 3000, PO Box 53, Toronto ON M5K 1E7 0001113423 false --12-31 2023 Q2 CA 2023-06-30 42186000 50611000 185000 732000 93000 229000 792000 1428000 2637000 2488000 45893000 55488000 325000 322000 265000 216000 591000 538000 46483000 56026000 3572000 3828000 49000 45000 109000 108000 202000 2949000 145000 114000 4077000 7044000 1580000 1684000 111000 110000 85000 65000 11381000 11159000 170000 188000 13327000 13206000 17404000 20250000 293410000 293410000 5085000 5085000 90654000 90332000 -358936000 -352084000 -1134000 -967000 29079000 35776000 46483000 56026000 293410000 5085000 90332000 -352084000 -967000 35776000 -6772000 -6772000 -167000 -167000 -80000 -80000 -6852000 -167000 -7019000 322000 322000 293410000 5085000 90654000 -358936000 -1134000 29079000 293410000 5085000 89788000 -334619000 -678000 52986000 293410000 5085000 89788000 -334619000 -678000 52986000 -6856000 -6856000 79000 79000 8025000 8025000 1169000 79000 1248000 1169000 79000 1248000 60000 60000 293410000 5085000 89848000 -333450000 -599000 54294000 293410000 5085000 89848000 -333450000 -599000 54294000 2246000 -222000 4374000 1295000 139000 13000 156000 92000 2929000 2398000 6941000 4788000 2033000 2083000 4339000 3944000 5101000 4494000 11436000 8824000 -2855000 -4716000 -7062000 -7529000 27000 502000 -32000 676000 307000 320000 3000 -2000 2000 -3000 337000 500000 290000 673000 -2518000 -4216000 -6772000 -6856000 -2518000 -4216000 -6772000 -6856000 3000 42000 -167000 79000 83000 5276000 -80000 8025000 -2432000 1102000 -7019000 1248000 -0.52 -0.52 -0.87 -0.87 -1.39 -1.39 -1.41 -1.41 -0.52 -0.87 -1.39 -1.41 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 -2518000 -4216000 -6772000 -6856000 18000 7000 10000 5000 44000 35000 84000 71000 306000 33000 323000 60000 130000 98000 265000 197000 -794000 124000 -1554000 -704000 -9000 -513000 -1000 -687000 5000 495000 5000 509000 647000 -51000 647000 830000 -2122000 -862000 -1361000 264000 -4293000 -4850000 -8354000 -6311000 42000 34000 80000 68000 -42000 -34000 -80000 -68000 3000 42000 5000 48000 -3000 -42000 -5000 -48000 -36000 -513000 14000 -716000 -4374000 -5439000 -8425000 -7143000 46560000 63596000 50611000 65300000 42186000 58157000 42186000 58157000 <p id="xdx_808_eifrs-full--DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_ziEJeCGKO0Z7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_821_zPeT6hWchkFe">Business overview</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary of business</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen<sup>®</sup> (macimorelin), is the first and only U.S. Food and Drug Administration (“FDA”) and European Medicines Agency (“EMA”) approved oral test indicated for the diagnosis of patients with adult growth hormone deficiency (“AGHD”). Macimorelin is currently marketed under the tradename Ghryvelin™ in the European Economic Area and the United Kingdom through an exclusive licensing agreement with Pharmanovia. The Company’s several other license and commercialization partners are also seeking approval for commercialization of macimorelin in Israel and the Palestinian Authority, the Republic of Korea, Turkey and several non-European Union Balkan countries. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in North America, Asia and the rest of the world.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also dedicated to the development of therapeutic assets and has taken steps to establish a pre-clinical pipeline to potentially address unmet medical needs across several indications with a focus on rare or orphan indications.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the “Board”) on August 8, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_802_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zGpcn2IANjNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zwzkBeFxgz28">Basis of presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed interim consolidated financial statements have been prepared in accordance with IAS 34, <i>Interim Financial Reporting </i>as issued by the International Accounting Standards Board.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The unaudited condensed interim consolidated financial statements do not include all the notes normally included in annual consolidated financial statements. Accordingly, these unaudited condensed interim consolidated financial statements should be read in conjunction with the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounting policies used in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_zvaKP4O6gmf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z6bMxTyAShL2">New standards and amendments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zvxtOwlbc7u6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zF7BRhljeBDe">Critical accounting estimates and judgements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_eifrs-full--DescriptionOfInitialApplicationOfStandardsOrInterpretations_zvaKP4O6gmf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86A_z6bMxTyAShL2">New standards and amendments</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2023, the Company adopted the Disclosure of Accounting Policies (amendments to IAS 1 and IFRS Practice Statement 2). The amendments to IAS 1 require that the Company discloses its material accounting policies instead of its significant accounting policies. As a result of the adoption of these amendments, there were no adjustments to the presentation or amounts recognized in the interim financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_845_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zvxtOwlbc7u6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zF7BRhljeBDe">Critical accounting estimates and judgements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgements, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgements in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS applicable to interim financial statements. Critical accounting estimates and assumptions, as well as critical judgements used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those applied to the Company’s annual consolidated financial statements as of and for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_804_eifrs-full--DisclosureOfRevenueExplanatory_zmNTJtrvV9ub" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zJtVTLHOa0Rf">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zriJFp7jRm2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_znzmcKcDjn4j" style="display: none">Summary of revenue from transfer of goods and services</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230401__20230630_zqJlQb1F8MY8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220401__20220630_zhrJkuhL4a4e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230630_zYS2HdfTd7mf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_z5qOLzaJX283" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td></tr> <tr id="xdx_40E_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--LicenseFeesMember_zTWOcQJG55yh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">License fees</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">795</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(206</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">1,554</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">226</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--DevelopmentServicesMember_maRzpMc_zLam7nmWBdjg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Development services</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,402</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">2,741</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">889</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--ProductSalesMember_z1R8m8N8at42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Product sales</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--RoyaltiesMember_zmyNJBuZyQvb" style="vertical-align: bottom; background-color: White"> <td>Royalties</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">7</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">26</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--SupplyChainMember_zraFtP8rw2G" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Supply chain</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">53</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--Revenue_pn3n3_zpVRQh3YxOK1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,246</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,374</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,295</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A9_zaa727nXrSal" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded revenue for the transfer of services over time for the three-months ended June 30, 2023, of $<span id="xdx_904_eifrs-full--Revenue_pn3n3_c20230401__20230630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zCcrCVYbtqye" title="Revenue">2,197</span> (2022 – ($<span id="xdx_908_eifrs-full--Revenue_pn3n3_c20220401__20220630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zcxj8O3FNHoc" title="Revenue">283</span>)) and the six-months ended June 30, 2023, of $<span id="xdx_90A_eifrs-full--Revenue_pn3n3_c20230101__20230630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zgutwyONVkM" title="Revenue">4,295</span> (2022 - $<span id="xdx_907_eifrs-full--Revenue_pn3n3_c20220101__20220630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredOverTimeMember_zRZTcDmucBj9" title="Revenue">1,115</span>). While revenue recorded at a point in time for the three-months ended June 30, 2023, was $<span id="xdx_90C_eifrs-full--Revenue_pn3n3_c20230401__20230630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zaLvUQ1MxHld" title="Revenue">49</span> (2022 – $<span id="xdx_906_eifrs-full--Revenue_pn3n3_c20220401__20220630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zWHJZPjKcqKk" title="Revenue">61</span>) and the six-months ended June 30, 2023, was $<span id="xdx_90E_eifrs-full--Revenue_pn3n3_c20230101__20230630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zoH3g2GFqiGc" title="Revenue">79</span> (2022 - $<span id="xdx_904_eifrs-full--Revenue_pn3n3_c20220101__20220630__ifrs-full--TimingOfTransferOfGoodsOrServicesAxis__ifrs-full--GoodsOrServicesTransferredAtPointInTimeMember_zgmBAJwMhS9i" title="Revenue">180</span>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Pharmanovia:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2023, with the Company’s consent, Consilient Health (“CH”) entered into an assignment agreement with Pharmanovia to transfer the current licensing agreement for the commercialization of macimorelin in the European Economic Area and the United Kingdom to Pharmanovia, as well as the current supply agreement pursuant to which the Company agreed to provide the licensed product (together, the “Assignment Agreement”). Also on March 15, 2023, the Company and Pharmanovia entered into an amendment agreement, pursuant to which the Company provided its acknowledgement and consent to the Assignment Agreement and agreed to certain amended terms which do not materially differ from the previous license and supply agreement with CH. Subsequent to the execution of the Assignment Agreement, the aggregate amount of the transaction price allocated to the Company’s unsatisfied performance obligations was $<span id="xdx_903_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--UnsatisfiedPerformanceObligationsMember_ziF90oOLRcw1" title="Performance obligations">1,658</span> (€<span id="xdx_907_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_uEUR_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--UnsatisfiedPerformanceObligationsMember_zy33KFbslHgl" title="Performance obligations">1,540</span>), comprised of; the combined adult indication performance obligation of $<span id="xdx_901_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--IndicationPerformanceObligationMember_zPS32hYj22Bd" title="Performance obligations">1,233</span> (€<span id="xdx_90B_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_uEUR_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--IndicationPerformanceObligationMember_zFUsHTaqSKBi" title="Performance obligations">1,145</span>), and the combined pediatric indication performance obligation of $<span id="xdx_90D_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--PediatricIndicationPerformanceMember_zGpqmYJmI5ng" title="Performance obligations">425</span> (€<span id="xdx_909_eifrs-full--TransactionPriceAllocatedToRemainingPerformanceObligations_iI_pn3n3_uEUR_c20230315__ifrs-full--TypesOfFinancialLiabilitiesAxis__custom--PediatricIndicationPerformanceMember_zNYHgcQbxev7" title="Performance obligations">395</span>). The Company will continue to recognize revenue over time using an output method based on units of licensed product supplied to Pharmanovia. The total units that the Company expects to supply to Pharmanovia is an estimate, based on current projections and anticipated market demand, and therefore will be a significant judgement that will be relied upon when using the outputs method to recognize revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Novo Nordisk Health Care AG:</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 26, 2022, Novo provided the Company with a notice of termination of the Novo Amendment. Under the terms of the Novo Amendment, the termination was effective May 23, 2023, upon the completion of a 270-day notice period (“notice period”). Upon termination, the rights and licenses granted by the Company to Novo under the Novo Amendment returned to the Company, and the Company regained full rights to continue the clinical development and future commercialization of Macrilen™. Following the notice of termination and throughout the 270-day notice period, as per the terms of the Novo Amendment, Novo continued to fund DETECT-trial costs up to $<span id="xdx_901_ecustom--DetectTrialCosts_pn5n6_uUSD_c20230523__20230523__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--NovoNordiskHealthCareAGMember_zjbAeBVQwvE1" title="Detect trial costs">10.1</span> million (€<span id="xdx_909_ecustom--DetectTrialCosts_pn5n6_uEUR_c20230523__20230523__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--NovoNordiskHealthCareAGMember_zS2b8y1FURYc" title="Detect trial costs">9.4</span> million). As of May 23, 2023, the Company recognized all remaining license fees associated with the Pediatric indication and development services revenue previously recorded in deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liabilities related to contracts with customers</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_ecustom--DisclosureOfDetailedInformationAboutDeferredRevenueExplanatory_zbGud5qnTdYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of deferred revenue balances:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zJ4GXkUBp1xb" style="display: none">Summary of deferred revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Novo Nordisk Health Care</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zbNXXb2eQ0Dk" style="text-align: right" title="Total Current Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zMPyqdydgJlb" style="text-align: right" title="Total Deferred Revenues Non Current"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zVpC9Q91DKs" style="text-align: right" title="Total Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Pharmanovia</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zoLtc9At3dX9" style="width: 14%; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">193</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98D_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zbOYWDgxJpZ8" style="width: 14%; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,459</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zoxDrOu9XoTf" style="width: 14%; font-weight: bold; text-align: right" title="Total Deferred Revenues">1,652</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">NK Meditech</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zMWgeBeAuzNh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zEbBNsWpXRf6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">121</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zrrz3EbjWPP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">130</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630_zaY7ptnII6o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">202</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630_zngcptmvD105" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,580</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--DeferredRevenues_iI_pn3n3_c20230630_zurrP4J5rCYf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">1,782</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Novo Nordisk Health Care</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zBDocaDWarH8" style="width: 14%; text-align: right" title="Total Current Deferred Revenues">2,914</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zGJBUzA5sMHb" style="width: 14%; text-align: right" title="Total Deferred Revenues Non Current"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_z3dEtUaQUzva" style="width: 14%; text-align: right" title="Total Deferred Revenues">2,914</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consilient Health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zgqdxobnah4k" style="text-align: right" title="Total Current Deferred Revenues">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zExzLuNiDsGg" style="text-align: right" title="Total Deferred Revenues Non Current">1,556</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zrYnuT2PkT7c" style="text-align: right" title="Total Deferred Revenues">1,591</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">NK Meditech</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zlMbACepyWG9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Current Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zePp1vgJBlK8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Deferred Revenues Non Current">128</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zm1stNj3nJXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Deferred Revenues">128</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231_zRiAyXoCbdNh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">2,949</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231_z2eGGMabakU3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--DeferredRevenues_iI_pn3n3_c20221231_zZBQzwvDuhSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">4,633</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zWkwjDzGT4I7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices_zriJFp7jRm2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company derives revenue from the transfer of goods and services over time and at a point in time in the following categories:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_znzmcKcDjn4j" style="display: none">Summary of revenue from transfer of goods and services</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20230401__20230630_zqJlQb1F8MY8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20220401__20220630_zhrJkuhL4a4e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20230101__20230630_zYS2HdfTd7mf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220630_z5qOLzaJX283" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></td><td style="font-weight: bold; text-align: center"> </td></tr> <tr id="xdx_40E_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--LicenseFeesMember_zTWOcQJG55yh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">License fees</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">795</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(206</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">1,554</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">226</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--DevelopmentServicesMember_maRzpMc_zLam7nmWBdjg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Development services</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">1,402</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(77</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">2,741</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">889</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--ProductSalesMember_z1R8m8N8at42" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Product sales</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">-</span></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--RoyaltiesMember_zmyNJBuZyQvb" style="vertical-align: bottom; background-color: White"> <td>Royalties</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">7</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">26</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--Revenue_pn3n3_hifrs-full--ProductsAndServicesAxis__custom--SupplyChainMember_zraFtP8rw2G" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Supply chain</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">42</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">37</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">53</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">80</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--Revenue_pn3n3_zpVRQh3YxOK1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,246</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(222</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,374</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,295</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 795000 -206000 1554000 226000 1402000 -77000 2741000 889000 57000 7000 24000 26000 43000 42000 37000 53000 80000 2246000 -222000 4374000 1295000 2197000 283000 4295000 1115000 49000 61000 79000 180000 1658000 1540000 1233000 1145000 425000 395000 10100000 9400000 <p id="xdx_89C_ecustom--DisclosureOfDetailedInformationAboutDeferredRevenueExplanatory_zbGud5qnTdYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table provides a summary of deferred revenue balances:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zJ4GXkUBp1xb" style="display: none">Summary of deferred revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Novo Nordisk Health Care</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zbNXXb2eQ0Dk" style="text-align: right" title="Total Current Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0586">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zMPyqdydgJlb" style="text-align: right" title="Total Deferred Revenues Non Current"><span style="-sec-ix-hidden: xdx2ixbrl0588">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zVpC9Q91DKs" style="text-align: right" title="Total Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Pharmanovia</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zoLtc9At3dX9" style="width: 14%; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">193</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98D_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zbOYWDgxJpZ8" style="width: 14%; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,459</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--PharmanoviaMember_zoxDrOu9XoTf" style="width: 14%; font-weight: bold; text-align: right" title="Total Deferred Revenues">1,652</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">NK Meditech</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zMWgeBeAuzNh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zEbBNsWpXRf6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">121</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenues_iI_pn3n3_c20230630__custom--ArrangementTypeAxis__custom--NKMeditechMember_zrrz3EbjWPP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">130</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20230630_zaY7ptnII6o9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">202</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20230630_zngcptmvD105" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,580</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--DeferredRevenues_iI_pn3n3_c20230630_zurrP4J5rCYf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">1,782</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-current</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Novo Nordisk Health Care</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zBDocaDWarH8" style="width: 14%; text-align: right" title="Total Current Deferred Revenues">2,914</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_zGJBUzA5sMHb" style="width: 14%; text-align: right" title="Total Deferred Revenues Non Current"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NovoNordiskHealthCareMember_z3dEtUaQUzva" style="width: 14%; text-align: right" title="Total Deferred Revenues">2,914</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consilient Health</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zgqdxobnah4k" style="text-align: right" title="Total Current Deferred Revenues">35</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zExzLuNiDsGg" style="text-align: right" title="Total Deferred Revenues Non Current">1,556</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--ConsilientHealthMember_zrYnuT2PkT7c" style="text-align: right" title="Total Deferred Revenues">1,591</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">NK Meditech</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zlMbACepyWG9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Current Deferred Revenues"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zePp1vgJBlK8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Deferred Revenues Non Current">128</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_ecustom--DeferredRevenues_iI_pn3n3_c20221231__custom--ArrangementTypeAxis__custom--NKMeditechMember_zm1stNj3nJXc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total Deferred Revenues">128</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_986_ecustom--DeferredRevenuesCurrent_iI_pn3n3_c20221231_zRiAyXoCbdNh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Current Deferred Revenues">2,949</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--DeferredRevenuesNonCurrent_iI_pn3n3_c20221231_z2eGGMabakU3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues Non Current">1,684</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--DeferredRevenues_iI_pn3n3_c20221231_zZBQzwvDuhSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total Deferred Revenues">4,633</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 193000 1459000 1652000 9000 121000 130000 202000 1580000 1782000 2914000 2914000 35000 1556000 1591000 128000 128000 2949000 1684000 4633000 <p id="xdx_806_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_zpkaWrv3Otp4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zlNbTrODUIfl">Employee future benefits</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eifrs-full--DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_zpoV6GS1J8Ki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the Company’s employee future benefit obligations is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z9QgdfmYVLm2" style="display: none">Summary of net defined benefit liability asset</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230630__ifrs-full--CharacteristicsOfDefinedBenefitPlansAxis__ifrs-full--PensionDefinedBenefitPlansMember_zPJbvzItDyi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630__ifrs-full--CharacteristicsOfDefinedBenefitPlansAxis__custom--OtherBenefitPlansMember_zNBqMlDTRcE6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20230630_z42RRtXQJW4e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_z9RM2z8gEtfa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Pension</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eifrs-full--DisclosureOfNetDefinedBenefitLiabilityAssetAbstract_iB_zUfg8qE6tiga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Change in plan liabilities</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eifrs-full--LiabilityAssetOfDefinedBenefitPlans_i01S_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Balances – Beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">21,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">93</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">21,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">29,412</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentServiceCostNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current service cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eifrs-full--InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">295</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_i01N_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Actuarial loss (gain) from changes in financial assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,915</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eifrs-full--PaymentsInRespectOfSettlementsNetDefinedBenefitLiabilityAsset_i01N_pn3n3_di_zccj345Gn937" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Benefits paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(752</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eifrs-full--IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Impact of foreign exchange rate changes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--LiabilityAssetOfDefinedBenefitPlans_i01E_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balances – End of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,144</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">102</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,246</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,750</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--StatementOfChangesInNetAssetsAvailableForBenefitsAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Change in plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--AssetsOfBenefitPlan_i01S_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balances – Beginning of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,591</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,591</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,927</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--InterestIncomeFromPlanAssets_i01_pn3n3_zevUoVC6Hmq8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest income from plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AssetsEmployerContributions_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employer contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AssetsEmployeeContributions_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--IncreaseDecreaseInNetAssetsAvailableForBenefits_i01N_pn3n3_di_zOKk3y3xZESi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Benefits paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(247</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--RemeasurementOfPlanAssets_i01N_pn3n3_di_zg1gTuO0Djuk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remeasurement of plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(641</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ImpactOfForeignExchangeRateChangesAssetsOfBenefitPlan_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Impact of foreign exchange rate changes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eifrs-full--AssetsOfBenefitPlan_i01E_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balances – End of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,865</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,865</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,591</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NetLiabilityOfUnfundedPlans_pn3n3_z5b4RufzPD3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net liability of the unfunded plans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,787</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--NetLiabilityOfFundedPlans_pn3n3_zvXj1Bu9gtQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net liability of the funded plans</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">412</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">412</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">372</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AmountRecognizedAsEmployeeFutureBenefitsNet_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net amount recognized as Employee future benefits</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,279</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">102</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,381</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,159</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_iB_zInA3yQU4iF7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amounts recognized:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PostemploymentBenefitExpenseDefinedBenefitPlan_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">In net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">295</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,262</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A0_z62LNAqhanA9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of the employee future benefit obligation is sensitive to the discount rate assumption and other assumptions such as the rate of the pension benefit increase. Discount rates were <span id="xdx_90D_ecustom--EmployeeFutureBenefitObligationDiscountRate_iI_pid_dp_uPure_c20230630_zpSyyOv8LZAl" title="Employee future benefit obligation">3.70</span>% as of June 30, 2023, and <span id="xdx_905_ecustom--EmployeeFutureBenefitObligationDiscountRate_iI_pid_dp_uPure_c20221231_z7ZgL7ub8Fu5" title="Employee future benefit obligation">3.75</span>% as of December 31, 2022, causing the variances in the actuarial loss (gain) on defined benefit plan during the six months ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eifrs-full--DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory_zpoV6GS1J8Ki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in the Company’s employee future benefit obligations is summarized as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z9QgdfmYVLm2" style="display: none">Summary of net defined benefit liability asset</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230101__20230630__ifrs-full--CharacteristicsOfDefinedBenefitPlansAxis__ifrs-full--PensionDefinedBenefitPlansMember_zPJbvzItDyi8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630__ifrs-full--CharacteristicsOfDefinedBenefitPlansAxis__custom--OtherBenefitPlansMember_zNBqMlDTRcE6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230101__20230630_z42RRtXQJW4e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220101__20221231_z9RM2z8gEtfa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six months ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>June 30, 2023</b></span></p></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> December 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Pension</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">benefit plans</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eifrs-full--DisclosureOfNetDefinedBenefitLiabilityAssetAbstract_iB_zUfg8qE6tiga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Change in plan liabilities</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eifrs-full--LiabilityAssetOfDefinedBenefitPlans_i01S_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 40%">Balances – Beginning of the period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">21,657</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">93</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">21,750</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">29,412</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentServiceCostNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Current service cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">142</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eifrs-full--InterestExpenseIncomeNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">295</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset_i01N_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Actuarial loss (gain) from changes in financial assumptions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">143</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,915</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eifrs-full--PaymentsInRespectOfSettlementsNetDefinedBenefitLiabilityAsset_i01N_pn3n3_di_zccj345Gn937" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Benefits paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(752</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eifrs-full--IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Impact of foreign exchange rate changes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">261</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">262</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,432</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--LiabilityAssetOfDefinedBenefitPlans_i01E_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balances – End of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,144</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">102</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,246</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">21,750</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--StatementOfChangesInNetAssetsAvailableForBenefitsAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Change in plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--AssetsOfBenefitPlan_i01S_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balances – Beginning of the period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,591</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0684">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,591</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,927</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--InterestIncomeFromPlanAssets_i01_pn3n3_zevUoVC6Hmq8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest income from plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0689">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AssetsEmployerContributions_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Employer contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--AssetsEmployeeContributions_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Employee contributions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--IncreaseDecreaseInNetAssetsAvailableForBenefits_i01N_pn3n3_di_zOKk3y3xZESi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Benefits paid</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(136</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(247</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_ecustom--RemeasurementOfPlanAssets_i01N_pn3n3_di_zg1gTuO0Djuk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Remeasurement of plan assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0709">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(641</td><td style="text-align: left">)</td></tr> <tr id="xdx_401_ecustom--ImpactOfForeignExchangeRateChangesAssetsOfBenefitPlan_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Impact of foreign exchange rate changes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0714">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">127</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eifrs-full--AssetsOfBenefitPlan_i01E_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balances – End of the period</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,865</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0719">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,865</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">10,591</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--NetLiabilityOfUnfundedPlans_pn3n3_z5b4RufzPD3c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net liability of the unfunded plans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,867</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,969</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,787</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--NetLiabilityOfFundedPlans_pn3n3_zvXj1Bu9gtQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Net liability of the funded plans</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">412</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0729">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">412</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">372</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AmountRecognizedAsEmployeeFutureBenefitsNet_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net amount recognized as Employee future benefits</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,279</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">102</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,381</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,159</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract_iB_zInA3yQU4iF7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Amounts recognized:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--PostemploymentBenefitExpenseDefinedBenefitPlan_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">In net loss</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">295</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0749">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,262</td><td style="text-align: left"> </td></tr> </table> 21657000 93000 21750000 29412000 63000 6000 69000 142000 400000 2000 402000 295000 143000 143000 -5915000 380000 380000 752000 261000 1000 262000 -1432000 22144000 102000 22246000 21750000 10591000 10591000 11927000 198000 198000 120000 14000 14000 45000 8000 8000 10000 136000 136000 247000 -63000 -63000 641000 127000 127000 -623000 10865000 10865000 10591000 10867000 102000 10969000 10787000 412000 412000 372000 11279000 102000 11381000 11159000 257000 8000 265000 295000 -80000 -80000 5262000 0.0370 0.0375 <p id="xdx_806_eifrs-full--DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_zWt00nPNOpCf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_z3CUiq0esWxh">Shareholders’ equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share capital</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized an unlimited number of common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zZtfN5KdkUD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zPUplHzuuMMj" style="display: none">Summary of share capital</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iS_pid_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zi7fikLvekK9" style="width: 14%; text-align: right" title="Number of shares issued">4,855,876</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eifrs-full--EquityAttributableToOwnersOfParent_iS_pn3n3_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z5qHjNxmI2ff" style="width: 14%; text-align: right" title="Balance - Value">293,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iE_pid_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zYZA1jIfMb08" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of shares issued">4,855,876</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eifrs-full--EquityAttributableToOwnersOfParent_iE_pn3n3_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zr8yhx9lRByc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Balance - Value">293,410</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zFcwOpDErXF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2022, the Company’s shareholders and board of directors approved an amendment to the Company’s articles of incorporation to effect a <span id="xdx_90F_ecustom--StockholdersEquityReverseSplit_c20220715__20220715__ifrs-full--CounterpartiesAxis__custom--ShareholdersAndBoardOfDirectorsMember_zZC0eLtARajl" title="Reverse stock split">1-for-25</span> share consolidation (reverse split) of the Company’s common shares. The Company’s outstanding stock options, DSUs and warrants were also adjusted to reflect the <span id="xdx_908_ecustom--StockholdersEquityReverseSplit_c20220715__20220715__ifrs-full--CounterpartiesAxis__custom--DeferredStockUnitsMember_zdOFtd6jVx01" title="Reverse stock split">1-for-25</span> share consolidation (reverse split) of the Company’s common shares. <span style="background-color: white">Accordingly, all common shares, DSU, warrants, stock options and per share amounts in these interim condensed consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the share consolidation (reverse split). </span>Outstanding warrant and stock options were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased. The share consolidation (reverse split) was affected on July 21, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-based compensation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 17, 2023, the Company granted <span id="xdx_908_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20230116__20230117__custom--ArrangementTypeAxis__custom--TwoThousandEighteenLongTermIncentivePlanMember_zPLB43oi08d" title="Number of options, granted">14,000</span> (2022 – <span id="xdx_90E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220116__20220117__custom--ArrangementTypeAxis__custom--TwoThousandEighteenLongTermIncentivePlanMember_zC352DUs3GF7" title="Number of options, granted">2,000</span>) stock options under the Long-Term Incentive Plan. The stock options have a term of seven years and will vest over a period of three years. The fair value at grant date is estimated using a Black-Scholes option pricing model, considering the terms and conditions upon which the options were granted, using the following assumptions:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_ecustom--DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory_zlkHe9efIW88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z6LfHqfEvUH8" style="display: none">Summary of assumptions to determine share-based compensation costs over the life of awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pid_dp_uPure_c20230101__20230630_zh6dtoOGNxjj" style="width: 14%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zYjg51m6CrQi" style="width: 14%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20230101__20230630_zgk4RcIPRTt5" style="text-align: right" title="Expected volatility">104.46</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zaKWVyY8IpU7" style="text-align: right" title="Expected volatility">115.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free annual interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_uPure_c20230101__20230630_z8HTM54Bci39" style="text-align: right" title="Expected volatility">3.56</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zj8ySSbVimaj" style="text-align: right" title="Risk-free annual interest rate">1.59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears_dtY_c20230101__20230630_zKUrSEYyW6x5" style="text-align: right" title="Expected life (years)">5.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears_dtY_c20220101__20220630_zMDDEA9xeUU4" style="text-align: right" title="Expected life (years)">5.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_pid_c20230101__20230630_zMRhBhUG70gf" style="text-align: right" title="Share price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_pid_c20220101__20220630_zpDzDkg3mIvj" style="text-align: right" title="Share price">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_c20230101__20230630_z0VcX6q4fheb" style="text-align: right" title="Exercise price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_c20220101__20220630_zOdJOoHsQ9kk" style="text-align: right" title="Exercise price">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Grant date fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageGrantDateFairValue_pid_c20230101__20230630_z1zfFBePyBbd" style="text-align: right" title="Grant date fair value">2.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageGrantDateFairValue_pid_c20220101__20220630_znUHqVXcnqz2" style="text-align: right" title="Grant date fair value">7.47</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A4_zr8Af0QoPae8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected volatility of these stock options was determined using historical volatility rates and the expected life was determined using the weighted average life of past options issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The compensation expense for the three months ended June 30, 2023, was $<span id="xdx_903_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20230401__20230630_zrlMkEh9SJ7f" title="Compensation expenses">22</span> (2022 – $<span id="xdx_90B_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20220401__20220630_zQXDyt5kRh29" title="Compensation expenses">33</span>) and the six months ended June 30, 2023, was $<span id="xdx_901_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20230101__20230630_zj7t0M5whtq9" title="Compensation expenses">39</span> (2022 – $<span id="xdx_900_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20220101__20220630_zHHyoRw3dNDl" title="Compensation expenses">60</span>) recognized over the vesting period. Option activity for the six months ended June 30, 2023, and 2022, was as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_zfloRfEcyDY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zp4VJwH7Gh5d" style="display: none">Summary of number and weighted average exercise prices of share options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20230101__20230630_zy2Osj1P4En1" style="width: 14%; text-align: right" title="Number of Options, Beginning">42,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_pid_uUSDPShares_c20230101__20230630_zPGBgkkJImE9" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning">20.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20230101__20230630_ziZzph7aX16l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">14,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20230101__20230630_zF10TGIG2kh5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted">3.75</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled / Forfeited</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20230101__20230630_zMxbtzpmwpBj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Canceled/Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20230101__20230630_zgMz07Zy2Jm2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20230101__20230630_zUYFYpfJPxf4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of Options, Ending">56,030</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_pid_uUSDPShares_c20230101__20230630_zSI1JpFij5Ke" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending">15.98</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Stock options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20220101__20220630_zGhBTO7Zdz2l" style="width: 14%; text-align: right" title="Number of Options, Beginning">43,455</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_pid_uUSDPShares_c20220101__20220630_zUq9lnYsbVZ9" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning">22.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220101__20220630_zYZRyZeDu3ac" style="text-align: right" title="Number of Options, Granted">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20220101__20220630_zPdKOMUWykEh" style="text-align: right" title="Weighted average exercise price, granted">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled / Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220101__20220630_zdENdqXJyAw" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Canceled/Forfeited">(2,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20220101__20220630_zNT7rm75bQzf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited">10.98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20220101__20220630_zOHVO97ukUMc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of Options, Ending">43,056</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_pid_uUSDPShares_c20220101__20220630_zNAD3gFNFnN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending">21.95</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A0_z3QT05f1WZOf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred share units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 14, 2023, the Company granted <span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_c20230614__20230614__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zgKshfanWjae" title="Number of share units granted">100,000</span> (2022 – <span id="xdx_900_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_dxL_uShares_c20220614__20220614__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zIhzzAbv6Ch" title="Number of share units granted::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0851">nil</span></span>) DSUs under the Long-Term Incentive Plan. The compensation expense for the three and six months ended June 30, 2023, was $<span id="xdx_903_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zrE1dpzA7Gtd" title="Compensation expenses"><span id="xdx_90C_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zNKt9rPI59ni" title="Compensation expenses">284</span></span> (2022 - $<span id="xdx_907_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_dxL_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zBBuii6A7YM5" title="Compensation expenses::XDX::-"><span id="xdx_90E_eifrs-full--ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_pn3n3_dxL_c20220101__20220630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zVfHaLkIKvt7" title="Compensation expenses::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0857"><span style="-sec-ix-hidden: xdx2ixbrl0859">nil</span></span></span></span>) and is presented in selling, general and administrative expenses. DSU activity for the six months ended June 30, 2023, are:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_ecustom--DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory_zuMOEpgU62v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zNkDYZ1ymKQa" style="display: none">Summary of DSU activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zWer3sR0Lox" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20220630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_ztNMxIpDNTNf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_pid_uShares_zYYg5KZcihIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1,</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">96,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">16,920</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_zbpnF0ZTvxzk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_pid_uShares_zI3mMNytA0G2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">196,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zEjTanBYMm3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zZtfN5KdkUD9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zPUplHzuuMMj" style="display: none">Summary of share capital</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iS_pid_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zi7fikLvekK9" style="width: 14%; text-align: right" title="Number of shares issued">4,855,876</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eifrs-full--EquityAttributableToOwnersOfParent_iS_pn3n3_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z5qHjNxmI2ff" style="width: 14%; text-align: right" title="Balance - Value">293,410</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfSharesIssued_iE_pid_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zYZA1jIfMb08" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of shares issued">4,855,876</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98C_eifrs-full--EquityAttributableToOwnersOfParent_iE_pn3n3_c20230101__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zr8yhx9lRByc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Balance - Value">293,410</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 4855876 293410000 4855876 293410000 1-for-25 1-for-25 14000 2000 <p id="xdx_895_ecustom--DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory_zlkHe9efIW88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z6LfHqfEvUH8" style="display: none">Summary of assumptions to determine share-based compensation costs over the life of awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pid_dp_uPure_c20230101__20230630_zh6dtoOGNxjj" style="width: 14%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zYjg51m6CrQi" style="width: 14%; text-align: right" title="Expected dividend yield">0.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20230101__20230630_zgk4RcIPRTt5" style="text-align: right" title="Expected volatility">104.46</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zaKWVyY8IpU7" style="text-align: right" title="Expected volatility">115.75</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free annual interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_uPure_c20230101__20230630_z8HTM54Bci39" style="text-align: right" title="Expected volatility">3.56</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_pid_dp_uPure_c20220101__20220630_zj8ySSbVimaj" style="text-align: right" title="Risk-free annual interest rate">1.59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears_dtY_c20230101__20230630_zKUrSEYyW6x5" style="text-align: right" title="Expected life (years)">5.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears_dtY_c20220101__20220630_zMDDEA9xeUU4" style="text-align: right" title="Expected life (years)">5.72</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Share price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_pid_c20230101__20230630_zMRhBhUG70gf" style="text-align: right" title="Share price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_pid_c20220101__20220630_zpDzDkg3mIvj" style="text-align: right" title="Share price">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_c20230101__20230630_z0VcX6q4fheb" style="text-align: right" title="Exercise price">3.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_ecustom--ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_c20220101__20220630_zOdJOoHsQ9kk" style="text-align: right" title="Exercise price">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Grant date fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--WeightedAverageGrantDateFairValue_pid_c20230101__20230630_z1zfFBePyBbd" style="text-align: right" title="Grant date fair value">2.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_ecustom--WeightedAverageGrantDateFairValue_pid_c20220101__20220630_znUHqVXcnqz2" style="text-align: right" title="Grant date fair value">7.47</td><td style="text-align: left"> </td></tr> </table> 0.0000 0.0000 1.0446 1.1575 0.0356 0.0159 P5Y5M12D P5Y8M19D 3.75 8.88 3.75 8.88 2.99 7.47 22000 33000 39000 60000 <p id="xdx_896_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_zfloRfEcyDY4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_zp4VJwH7Gh5d" style="display: none">Summary of number and weighted average exercise prices of share options</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1, 2023</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20230101__20230630_zy2Osj1P4En1" style="width: 14%; text-align: right" title="Number of Options, Beginning">42,030</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_pid_uUSDPShares_c20230101__20230630_zPGBgkkJImE9" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning">20.05</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98C_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20230101__20230630_ziZzph7aX16l" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Granted">14,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20230101__20230630_zF10TGIG2kh5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted">3.75</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled / Forfeited</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20230101__20230630_zMxbtzpmwpBj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Canceled/Forfeited"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0825">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20230101__20230630_zgMz07Zy2Jm2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2023</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_984_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20230101__20230630_zUYFYpfJPxf4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of Options, Ending">56,030</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_pid_uUSDPShares_c20230101__20230630_zSI1JpFij5Ke" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending">15.98</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Stock options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iS_pid_uShares_c20220101__20220630_zGhBTO7Zdz2l" style="width: 14%; text-align: right" title="Number of Options, Beginning">43,455</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_pid_uUSDPShares_c20220101__20220630_zUq9lnYsbVZ9" style="width: 14%; text-align: right" title="Weighted average exercise price, beginning">22.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_pid_uShares_c20220101__20220630_zYZRyZeDu3ac" style="text-align: right" title="Number of Options, Granted">2,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20220101__20220630_zPdKOMUWykEh" style="text-align: right" title="Weighted average exercise price, granted">8.88</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Cancelled / Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_pid_di_uShares_c20220101__20220630_zdENdqXJyAw" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Canceled/Forfeited">(2,399</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_pid_uUSDPShares_c20220101__20220630_zNT7rm75bQzf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, cancelled/forfeited">10.98</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30, 2022</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_989_eifrs-full--NumberOfOutstandingShareOptions_iE_pid_uShares_c20220101__20220630_zOHVO97ukUMc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Number of Options, Ending">43,056</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_pid_uUSDPShares_c20220101__20220630_zNAD3gFNFnN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Weighted average exercise price, ending">21.95</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 42030 20.05 14000 3.75 56030 15.98 43455 22.00 2000 8.88 2399 10.98 43056 21.95 100000 284000 284000 <p id="xdx_89A_ecustom--DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory_zuMOEpgU62v6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zNkDYZ1ymKQa" style="display: none">Summary of DSU activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230101__20230630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_zWer3sR0Lox" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220101__20220630__ifrs-full--ComponentsOfEquityAxis__custom--DeferredShareUnitMember_ztNMxIpDNTNf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">#</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_pid_uShares_zYYg5KZcihIk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold">Balance – January 1,</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">96,920</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right">16,920</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_pid_uShares_zbpnF0ZTvxzk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Granted</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0867">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_pid_uShares_zI3mMNytA0G2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">Balance – June 30,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">196,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,920</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 96920 16920 100000 196920 16920 <p id="xdx_80E_eifrs-full--DisclosureOfCashFlowStatementExplanatory_zTDudr4AZkPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zzRdErpr93k8">Supplemental disclosure of cash flow information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p id="xdx_893_ecustom--DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory_zuRmRgUrWY79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHGFREelfOG3" style="display: none">Disclosure of changes in operating assets and liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230401__20230630_z1ibNSDSUDoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220401__20220630_z7mpwIHAKdme" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20230630_z0h1xkF4LRWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220630_zCy76162zBI8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Changes in operating assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_iN_pn3n3_di_msIDIWCz1ji_zH8SBT4z5u75" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Trade and other receivables</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">199</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(255</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">402</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eifrs-full--AdjustmentsForDecreaseIncreaseInInventories_iN_pn3n3_di_msIDIWCz1ji_zYZ8jEFj6Ts1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Inventory</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">135</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">140</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(206</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets_iN_pn3n3_di_msIDIWCz1ji_z17uLDMoxbna" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(748</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,471</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(122</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(759</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_iN_pn3n3_di_msIDIWCz1ji_zx3fSaQnt926" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Payables and accrued liabilities</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(398</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(163</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_iN_pn3n3_di_msIDIWCz1ji_z5ch4gg3x5T6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred revenues</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,205</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,001</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,359</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--AdjustmentsForIncreaseDecreaseInOtherLiabilities_iN_pn3n3_di_msIDIWCz1ji_zgo340onqXx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Provision for restructuring and other costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(5</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_iN_pn3n3_di_msIDIWCz1ji_zZfRHmFsUh7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Employee future benefits</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(109</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(254</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eifrs-full--IncreaseDecreaseInWorkingCapital_iT_pn3n3_mtIDIWCz1ji_zStaX1FUazZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in operating assets and liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,122</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,361</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z0FHo1x1DTef" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory_zuRmRgUrWY79" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHGFREelfOG3" style="display: none">Disclosure of changes in operating assets and liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20230401__20230630_z1ibNSDSUDoc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220401__20220630_z7mpwIHAKdme" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20230101__20230630_z0h1xkF4LRWi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20220101__20220630_zCy76162zBI8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Changes in operating assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_iN_pn3n3_di_msIDIWCz1ji_zH8SBT4z5u75" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 44%; text-align: left">Trade and other receivables</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">199</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(255</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">402</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eifrs-full--AdjustmentsForDecreaseIncreaseInInventories_iN_pn3n3_di_msIDIWCz1ji_zYZ8jEFj6Ts1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Inventory</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">135</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">140</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(206</td><td style="text-align: left">)</td></tr> <tr id="xdx_406_ecustom--AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets_iN_pn3n3_di_msIDIWCz1ji_z17uLDMoxbna" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(748</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,471</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(122</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(759</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_iN_pn3n3_di_msIDIWCz1ji_zx3fSaQnt926" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Payables and accrued liabilities</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(398</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(40</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(163</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_iN_pn3n3_di_msIDIWCz1ji_z5ch4gg3x5T6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred revenues</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,205</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,001</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1,359</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,008</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--AdjustmentsForIncreaseDecreaseInOtherLiabilities_iN_pn3n3_di_msIDIWCz1ji_zgo340onqXx1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Provision for restructuring and other costs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(5</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_iN_pn3n3_di_msIDIWCz1ji_zZfRHmFsUh7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Employee future benefits</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(109</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(254</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(118</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_400_eifrs-full--IncreaseDecreaseInWorkingCapital_iT_pn3n3_mtIDIWCz1ji_zStaX1FUazZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase (decrease) in operating assets and liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,122</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(862</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,361</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">264</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> -199000 255000 -402000 -220000 -135000 -140000 206000 748000 1471000 122000 759000 398000 40000 163000 -119000 1205000 -1001000 1359000 -1008000 -4000 5000 109000 97000 254000 118000 -2122000 -862000 -1361000 264000 <p id="xdx_802_eifrs-full--DisclosureOfEarningsPerShareExplanatory_zZD4d92KexY3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zA5GbNXcOKhb">Net loss per share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eifrs-full--EarningsPerShareExplanatory_zjbFWXopyPQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3c9IoGyYOf7" style="display: none">Summary of pertinent data relating to computation of basic and diluted net loss per share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230401__20230630_zV6SYQpwglK5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220401__20220630_zxoqYWIgq502" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zeCJb01eIFsi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20220630_zmk1SjMxYEhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40B_eifrs-full--ProfitLoss_pn3n3_z0IwDDjZTG0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Net loss</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">(2,518</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(4,216</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">(6,772</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(6,856</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eifrs-full--WeightedAverageShares_pid_zKNWagkN8Kig" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted weighted-average shares outstanding</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eifrs-full--AdjustedWeightedAverageShares_pid_c20230401__20230630_zVEaY638ZAq4" style="font-weight: bold; text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pid_c20220401__20220630_zB0oTgThzUd8" style="text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pid_c20230101__20230630_zTLE9t5qbDKd" style="font-weight: bold; text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eifrs-full--AdjustedWeightedAverageShares_pid_c20220101__20220630_zLn6Rw7xJ3va" style="text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--WeightedAverageShares_pid_zhu03VJAwifl" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average shares outstanding</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,855,876</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,855,876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--BasicEarningsLossPerShare_pid_zeYvfR8kBbNc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Basic and diluted loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eifrs-full--DilutedEarningsLossPerShare_pid_c20230401__20230630_zjsVvH1Nx9ed" style="font-weight: bold; text-align: right" title="Diluted loss per share">(0.52</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eifrs-full--DilutedEarningsLossPerShare_pid_c20220401__20220630_zefFbo5GoM2a" style="text-align: right" title="Diluted loss per share">(0.87</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eifrs-full--DilutedEarningsLossPerShare_pid_c20230101__20230630_zMxjixHsAkQ5" style="font-weight: bold; text-align: right" title="Diluted loss per share">(1.39</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eifrs-full--DilutedEarningsLossPerShare_pid_c20220101__20220630_zgLlHTlnNcjc" style="text-align: right" title="Diluted loss per share">(1.41</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--BasicEarningsLossPerShare_pid_zIYkzxsngPde" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Basic loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(0.52</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1.39</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.41</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_zvbTrh2s2R2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_hcustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis__custom--EmployeeStockOption1DeferredStockUnitsMember_zHu750MwkXj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options and DSUs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">252,950</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,375</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">252,950</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_hcustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis__custom--WarrantsMember_zBMHvRm0lZJk" style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">457,648</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">457,648</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">457,648</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">457,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_zEiTmi6pSZNa" style="display: none; vertical-align: bottom; background-color: White"> <td>Anti-dilutive shares</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A6_z10BrlWFqrJ1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89E_eifrs-full--EarningsPerShareExplanatory_zjbFWXopyPQb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_z3c9IoGyYOf7" style="display: none">Summary of pertinent data relating to computation of basic and diluted net loss per share</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230401__20230630_zV6SYQpwglK5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20220401__20220630_zxoqYWIgq502" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230630_zeCJb01eIFsi" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20220101__20220630_zmk1SjMxYEhd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">$</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40B_eifrs-full--ProfitLoss_pn3n3_z0IwDDjZTG0h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-weight: bold; text-align: left">Net loss</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">(2,518</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(4,216</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 10%; font-weight: bold; text-align: right">(6,772</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(6,856</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40F_eifrs-full--WeightedAverageShares_pid_zKNWagkN8Kig" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic and diluted weighted-average shares outstanding</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98F_eifrs-full--AdjustedWeightedAverageShares_pid_c20230401__20230630_zVEaY638ZAq4" style="font-weight: bold; text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eifrs-full--AdjustedWeightedAverageShares_pid_c20220401__20220630_zB0oTgThzUd8" style="text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98E_eifrs-full--AdjustedWeightedAverageShares_pid_c20230101__20230630_zTLE9t5qbDKd" style="font-weight: bold; text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eifrs-full--AdjustedWeightedAverageShares_pid_c20220101__20220630_zLn6Rw7xJ3va" style="text-align: right" title="Diluted weighted-average shares outstanding">4,855,876</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--WeightedAverageShares_pid_zhu03VJAwifl" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Basic weighted-average shares outstanding</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,855,876</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">4,855,876</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,855,876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--BasicEarningsLossPerShare_pid_zeYvfR8kBbNc" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Basic and diluted loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eifrs-full--DilutedEarningsLossPerShare_pid_c20230401__20230630_zjsVvH1Nx9ed" style="font-weight: bold; text-align: right" title="Diluted loss per share">(0.52</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eifrs-full--DilutedEarningsLossPerShare_pid_c20220401__20220630_zefFbo5GoM2a" style="text-align: right" title="Diluted loss per share">(0.87</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_981_eifrs-full--DilutedEarningsLossPerShare_pid_c20230101__20230630_zMxjixHsAkQ5" style="font-weight: bold; text-align: right" title="Diluted loss per share">(1.39</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eifrs-full--DilutedEarningsLossPerShare_pid_c20220101__20220630_zgLlHTlnNcjc" style="text-align: right" title="Diluted loss per share">(1.41</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eifrs-full--BasicEarningsLossPerShare_pid_zIYkzxsngPde" style="display: none; vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Basic loss per share</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(0.52</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.87</td><td style="text-align: left">)</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">(1.39</td><td style="font-weight: bold; text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.41</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eifrs-full--WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract_iB_zvbTrh2s2R2b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_hcustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis__custom--EmployeeStockOption1DeferredStockUnitsMember_zHu750MwkXj1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock options and DSUs</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">252,950</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,375</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">252,950</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_hcustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis__custom--WarrantsMember_zBMHvRm0lZJk" style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">457,648</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">457,648</td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">457,648</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">457,648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1_pid_zEiTmi6pSZNa" style="display: none; vertical-align: bottom; background-color: White"> <td>Anti-dilutive shares</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right"></td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> </table> -2518000 -4216000 -6772000 -6856000 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 4855876 -0.52 -0.52 -0.87 -0.87 -1.39 -1.39 -1.41 -1.41 -0.52 -0.87 -1.39 -1.41 252950 62375 252950 62375 457648 457648 457648 457648 <p id="xdx_802_eifrs-full--DisclosureOfEntitysReportableSegmentsExplanatory_zj0Y2YG1GEOb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_z4lm6up9e8ei">Segment information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in a single operating segment, being the biopharmaceutical segment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aeterna Zentaris Inc.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to the Condensed Interim Consolidated Financial Statements</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of June 30, 2023, and for the three and six months ended June 30, 2023, and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(In thousands of US dollars, except share and per share data and as otherwise noted)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_806_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zS5VJLr2iQj7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_z1pjupMLoAs6">Commitments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_ecustom--DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory_zjOkXGB3jLih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z9kVmJq2Dva" style="display: none">Schedule of expected future minimum lease payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_z3IZY6zmWgH1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TOTAL</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zGsMGrlr0Uqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Less than 1 year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">7,586</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__custom--OneToThreeYearsMember_zKT9XOyN1Mr6" style="vertical-align: bottom; background-color: White"> <td>1 - 3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__custom--FourToFiveYearsMember_z8h4uRdSAZab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>4 - 5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__ifrs-full--LaterThanFiveYearsMember_zlZ8D6UB8b59" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">More than 5 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_zDyAqFJbu7A6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,774</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zdi0YMyh1Tpe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company executed various agreements including in-licensing and similar arrangements with development partners. Such agreements may require the Company to make payments on achievement of stages of development, launch or revenue milestones, although the Company generally has the right to terminate these agreements at no penalty. The Company may have to pay up to $<span id="xdx_901_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_c20211231__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zgm05nCCiQt" title="Minimum lease payments net">38,887</span> upon achieving certain sales volumes, regulatory or other milestones related to specific products.</span></p> <p id="xdx_897_ecustom--DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory_zjOkXGB3jLih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant expenditure contracted for at the end of the reporting period but not recognized as liabilities is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BA_z9kVmJq2Dva" style="display: none">Schedule of expected future minimum lease payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 96%; margin-left: 0.25in"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230630_z3IZY6zmWgH1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">TOTAL</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zGsMGrlr0Uqh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Less than 1 year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">7,586</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__custom--OneToThreeYearsMember_zKT9XOyN1Mr6" style="vertical-align: bottom; background-color: White"> <td>1 - 3 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__custom--FourToFiveYearsMember_z8h4uRdSAZab" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>4 - 5 years</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_hifrs-full--MaturityAxis__ifrs-full--LaterThanFiveYearsMember_zlZ8D6UB8b59" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">More than 5 years</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0993">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--MinimumLeasePaymentsNet_iI_pn3n3_zDyAqFJbu7A6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,774</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 7586000 151000 37000 7774000 38887000 EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 112 152 1 false 33 0 false 7 false false R1.htm 00000001 - Document - Cover Sheet http://zentaris.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Interim Consolidated Statements of Financial Position (Unaudited) Sheet http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition Condensed Interim Consolidated Statements of Financial Position (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Sheet http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited) Statements 3 false false R4.htm 00000004 - Statement - Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) Sheet http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Sheet http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows Condensed Interim Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Business overview Sheet http://zentaris.com/role/BusinessOverview Business overview Notes 6 false false R7.htm 00000007 - Disclosure - Basis of presentation Sheet http://zentaris.com/role/BasisOfPresentation Basis of presentation Notes 7 false false R8.htm 00000008 - Disclosure - Revenue Sheet http://zentaris.com/role/Revenue Revenue Notes 8 false false R9.htm 00000009 - Disclosure - Employee future benefits Sheet http://zentaris.com/role/EmployeeFutureBenefits Employee future benefits Notes 9 false false R10.htm 00000010 - Disclosure - Shareholders??? equity Sheet http://zentaris.com/role/ShareholdersEquity Shareholders??? equity Notes 10 false false R11.htm 00000011 - Disclosure - Supplemental disclosure of cash flow information Sheet http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformation Supplemental disclosure of cash flow information Notes 11 false false R12.htm 00000012 - Disclosure - Net loss per share Sheet http://zentaris.com/role/NetLossPerShare Net loss per share Notes 12 false false R13.htm 00000013 - Disclosure - Segment information Sheet http://zentaris.com/role/SegmentInformation Segment information Notes 13 false false R14.htm 00000014 - Disclosure - Commitments Sheet http://zentaris.com/role/Commitments Commitments Notes 14 false false R15.htm 00000015 - Disclosure - Basis of presentation (Policies) Sheet http://zentaris.com/role/BasisOfPresentationPolicies Basis of presentation (Policies) Policies 15 false false R16.htm 00000016 - Disclosure - Revenue (Tables) Sheet http://zentaris.com/role/RevenueTables Revenue (Tables) Tables http://zentaris.com/role/Revenue 16 false false R17.htm 00000017 - Disclosure - Employee future benefits (Tables) Sheet http://zentaris.com/role/EmployeeFutureBenefitsTables Employee future benefits (Tables) Tables http://zentaris.com/role/EmployeeFutureBenefits 17 false false R18.htm 00000018 - Disclosure - Shareholders??? equity (Tables) Sheet http://zentaris.com/role/ShareholdersEquityTables Shareholders??? equity (Tables) Tables http://zentaris.com/role/ShareholdersEquity 18 false false R19.htm 00000019 - Disclosure - Supplemental disclosure of cash flow information (Tables) Sheet http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformationTables Supplemental disclosure of cash flow information (Tables) Tables http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformation 19 false false R20.htm 00000020 - Disclosure - Net loss per share (Tables) Sheet http://zentaris.com/role/NetLossPerShareTables Net loss per share (Tables) Tables http://zentaris.com/role/NetLossPerShare 20 false false R21.htm 00000021 - Disclosure - Commitments (Tables) Sheet http://zentaris.com/role/CommitmentsTables Commitments (Tables) Tables http://zentaris.com/role/Commitments 21 false false R22.htm 00000022 - Disclosure - Summary of revenue from transfer of goods and services (Details) Sheet http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails Summary of revenue from transfer of goods and services (Details) Details 22 false false R23.htm 00000023 - Disclosure - Summary of deferred revenue (Details) Sheet http://zentaris.com/role/SummaryOfDeferredRevenueDetails Summary of deferred revenue (Details) Details 23 false false R24.htm 00000024 - Disclosure - Revenue (Details Narrative) Sheet http://zentaris.com/role/RevenueDetailsNarrative Revenue (Details Narrative) Details http://zentaris.com/role/RevenueTables 24 false false R25.htm 00000025 - Disclosure - Summary of net defined benefit liability asset (Details) Sheet http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails Summary of net defined benefit liability asset (Details) Details 25 false false R26.htm 00000026 - Disclosure - Employee future benefits (Details Narrative) Sheet http://zentaris.com/role/EmployeeFutureBenefitsDetailsNarrative Employee future benefits (Details Narrative) Details http://zentaris.com/role/EmployeeFutureBenefitsTables 26 false false R27.htm 00000027 - Disclosure - Summary of share capital (Details) Sheet http://zentaris.com/role/SummaryOfShareCapitalDetails Summary of share capital (Details) Details 27 false false R28.htm 00000028 - Disclosure - Summary of assumptions to determine share-based compensation costs over the life of awards (Details) Sheet http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails Summary of assumptions to determine share-based compensation costs over the life of awards (Details) Details 28 false false R29.htm 00000029 - Disclosure - Summary of number and weighted average exercise prices of share options (Details) Sheet http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails Summary of number and weighted average exercise prices of share options (Details) Details 29 false false R30.htm 00000030 - Disclosure - Summary of DSU activity (Details) Sheet http://zentaris.com/role/SummaryOfDsuActivityDetails Summary of DSU activity (Details) Details 30 false false R31.htm 00000031 - Disclosure - Shareholders??? equity (Details Narrative) Sheet http://zentaris.com/role/ShareholdersEquityDetailsNarrative Shareholders??? equity (Details Narrative) Details http://zentaris.com/role/ShareholdersEquityTables 31 false false R32.htm 00000032 - Disclosure - Disclosure of changes in operating assets and liabilities (Details) Sheet http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails Disclosure of changes in operating assets and liabilities (Details) Details 32 false false R33.htm 00000033 - Disclosure - Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) Sheet http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails Summary of pertinent data relating to computation of basic and diluted net loss per share (Details) Details 33 false false R34.htm 00000034 - Disclosure - Schedule of expected future minimum lease payments (Details) Sheet http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails Schedule of expected future minimum lease payments (Details) Details 34 false false R35.htm 00000035 - Disclosure - Commitments (Details Narrative) Sheet http://zentaris.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://zentaris.com/role/CommitmentsTables 35 false false All Reports Book All Reports ex99-1.htm form6-k.htm aezs-20230630.xsd aezs-20230630_cal.xml aezs-20230630_def.xml aezs-20230630_lab.xml aezs-20230630_pre.xml ex99-2.htm ex99-3.htm ex99-4.htm ex99-1_001.jpg form6-k_001.jpg form6-k_002.jpg http://xbrl.sec.gov/dei/2022 https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full true true JSON 58 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ex99-1.htm form6-k.htm": { "axisCustom": 2, "axisStandard": 9, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 15, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 498 }, "contextCount": 112, "dts": { "calculationLink": { "local": [ "aezs-20230630_cal.xml" ] }, "definitionLink": { "local": [ "aezs-20230630_def.xml" ] }, "inline": { "local": [ "ex99-1.htm", "form6-k.htm" ] }, "labelLink": { "local": [ "aezs-20230630_lab.xml" ] }, "presentationLink": { "local": [ "aezs-20230630_pre.xml" ] }, "schema": { "local": [ "aezs-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 290, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 7, "http://zentaris.com/20230630": 12, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 56, "total": 75 }, "keyCustom": 31, "keyStandard": 121, "memberCustom": 22, "memberStandard": 10, "nsprefix": "AEZS", "nsuri": "http://zentaris.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://zentaris.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form6-k.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Shareholders\u2019 equity", "menuCat": "Notes", "order": "10", "role": "http://zentaris.com/role/ShareholdersEquity", "shortName": "Shareholders\u2019 equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Supplemental disclosure of cash flow information", "menuCat": "Notes", "order": "11", "role": "http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformation", "shortName": "Supplemental disclosure of cash flow information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Net loss per share", "menuCat": "Notes", "order": "12", "role": "http://zentaris.com/role/NetLossPerShare", "shortName": "Net loss per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Segment information", "menuCat": "Notes", "order": "13", "role": "http://zentaris.com/role/SegmentInformation", "shortName": "Segment information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments", "menuCat": "Notes", "order": "14", "role": "http://zentaris.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Basis of presentation (Policies)", "menuCat": "Policies", "order": "15", "role": "http://zentaris.com/role/BasisOfPresentationPolicies", "shortName": "Basis of presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "16", "role": "http://zentaris.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Employee future benefits (Tables)", "menuCat": "Tables", "order": "17", "role": "http://zentaris.com/role/EmployeeFutureBenefitsTables", "shortName": "Employee future benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Shareholders\u2019 equity (Tables)", "menuCat": "Tables", "order": "18", "role": "http://zentaris.com/role/ShareholdersEquityTables", "shortName": "Shareholders\u2019 equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Supplemental disclosure of cash flow information (Tables)", "menuCat": "Tables", "order": "19", "role": "http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformationTables", "shortName": "Supplemental disclosure of cash flow information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Interim Consolidated Statements of Financial Position (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition", "shortName": "Condensed Interim Consolidated Statements of Financial Position (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "lang": null, "name": "ifrs-full:TradeAndOtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Net loss per share (Tables)", "menuCat": "Tables", "order": "20", "role": "http://zentaris.com/role/NetLossPerShareTables", "shortName": "Net loss per share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Commitments (Tables)", "menuCat": "Tables", "order": "21", "role": "http://zentaris.com/role/CommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "AEZS:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Summary of revenue from transfer of goods and services (Details)", "menuCat": "Details", "order": "22", "role": "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails", "shortName": "Summary of revenue from transfer of goods and services (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30_custom_LicenseFeesMember", "decimals": "-3", "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "AEZS:DeferredRevenuesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of deferred revenue (Details)", "menuCat": "Details", "order": "23", "role": "http://zentaris.com/role/SummaryOfDeferredRevenueDetails", "shortName": "Summary of deferred revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfDetailedInformationAboutDeferredRevenueExplanatory", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "lang": null, "name": "AEZS:DeferredRevenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Revenue (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://zentaris.com/role/RevenueDetailsNarrative", "shortName": "Revenue (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-05-232023-05-23_custom_NovoNordiskHealthCareAGMember", "decimals": "-5", "lang": null, "name": "AEZS:DetectTrialCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Summary of net defined benefit liability asset (Details)", "menuCat": "Details", "order": "25", "role": "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails", "shortName": "Summary of net defined benefit liability asset (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "lang": null, "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "AEZS:EmployeeFutureBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Employee future benefits (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://zentaris.com/role/EmployeeFutureBenefitsDetailsNarrative", "shortName": "Employee future benefits (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "AEZS:EmployeeFutureBenefitObligationDiscountRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:EquityAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Summary of share capital (Details)", "menuCat": "Details", "order": "27", "role": "http://zentaris.com/role/SummaryOfShareCapitalDetails", "shortName": "Summary of share capital (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30_ifrs-full_IssuedCapitalMember", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Summary of assumptions to determine share-based compensation costs over the life of awards (Details)", "menuCat": "Details", "order": "28", "role": "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails", "shortName": "Summary of assumptions to determine share-based compensation costs over the life of awards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Summary of number and weighted average exercise prices of share options (Details)", "menuCat": "Details", "order": "29", "role": "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails", "shortName": "Summary of number and weighted average exercise prices of share options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOutstandingShareOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2021-12-31_ifrs-full_IssuedCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:EquityAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited)", "menuCat": "Statements", "order": "3", "role": "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2021-12-31_custom_WarrantsMember", "decimals": "-3", "lang": null, "name": "ifrs-full:EquityAttributableToOwnersOfParent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31_custom_DeferredShareUnitMember", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Summary of DSU activity (Details)", "menuCat": "Details", "order": "30", "role": "http://zentaris.com/role/SummaryOfDsuActivityDetails", "shortName": "Summary of DSU activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2022-12-31_custom_DeferredShareUnitMember", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Shareholders\u2019 equity (Details Narrative)", "menuCat": "Details", "order": "31", "role": "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "shortName": "Shareholders\u2019 equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "lang": null, "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Disclosure of changes in operating assets and liabilities (Details)", "menuCat": "Details", "order": "32", "role": "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails", "shortName": "Disclosure of changes in operating assets and liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory", "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Summary of pertinent data relating to computation of basic and diluted net loss per share (Details)", "menuCat": "Details", "order": "33", "role": "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Summary of pertinent data relating to computation of basic and diluted net loss per share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30_custom_EmployeeStockOption1DeferredStockUnitsMember", "decimals": "INF", "lang": null, "name": "AEZS:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "AEZS:MinimumLeasePaymentsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Schedule of expected future minimum lease payments (Details)", "menuCat": "Details", "order": "34", "role": "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails", "shortName": "Schedule of expected future minimum lease payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30_ifrs-full_NotLaterThanOneYearMember", "decimals": "-3", "lang": null, "name": "AEZS:MinimumLeasePaymentsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "AEZS:DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "AEZS:MinimumLeasePaymentsNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Commitments (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://zentaris.com/role/CommitmentsDetailsNarrative", "shortName": "Commitments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "AsOf2021-12-31_ifrs-full_TopOfRangeMember", "decimals": "-3", "lang": null, "name": "AEZS:MinimumLeasePaymentsNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "shortName": "Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows", "shortName": "Condensed Interim Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-04-012023-06-30", "decimals": "-3", "lang": null, "name": "AEZS:Provision", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000006 - Disclosure - Business overview", "menuCat": "Notes", "order": "6", "role": "http://zentaris.com/role/BusinessOverview", "shortName": "Business overview", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of presentation", "menuCat": "Notes", "order": "7", "role": "http://zentaris.com/role/BasisOfPresentation", "shortName": "Basis of presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Revenue", "menuCat": "Notes", "order": "8", "role": "http://zentaris.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Employee future benefits", "menuCat": "Notes", "order": "9", "role": "http://zentaris.com/role/EmployeeFutureBenefits", "shortName": "Employee future benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ex99-1.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 33, "tag": { "AEZS_AdjustmentsForAmortizationOfDeferredIncome": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for amortization of deferred income.", "label": "Amortization of deferred revenues" } } }, "localname": "AdjustmentsForAmortizationOfDeferredIncome", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "AEZS_AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for decrease increase in current prepayments and other current assets.", "label": "AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInCurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_AdjustmentsForEmployeeFutureBenefits": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for employee future benefits.", "label": "Employee future benefits" } } }, "localname": "AdjustmentsForEmployeeFutureBenefits", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "AEZS_AmountRecognizedAsEmployeeFutureBenefitsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net amount recognized as Employee future benefits.", "label": "Net amount recognized as Employee future benefits" } } }, "localname": "AmountRecognizedAsEmployeeFutureBenefitsNet", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Antidilutive securities excluded from computation of earnings per share, amount.", "label": "Anti-dilutive shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount1", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "AEZS_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities 1 [Axis]", "verboseLabel": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Axis", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "AEZS_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Domain": { "auth_ref": [], "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities1Domain", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "AEZS_ArrangementTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement [Axis]", "label": "Collaborative Arrangement [Axis]" } } }, "localname": "ArrangementTypeAxis", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "stringItemType" }, "AEZS_ArrangementTypeDomain": { "auth_ref": [], "localname": "ArrangementTypeDomain", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "AEZS_AssetsEmployeeContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets Employee contributions.", "label": "Employee contributions" } } }, "localname": "AssetsEmployeeContributions", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_AssetsEmployerContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets employer contributions.", "label": "Employer contributions" } } }, "localname": "AssetsEmployerContributions", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_BusinessOverviewAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Overview" } } }, "localname": "BusinessOverviewAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_ConsilientHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consilient Health [member]", "label": "Consilient Health [member]" } } }, "localname": "ConsilientHealthMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "AEZS_DeferredGain": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred gain.", "label": "Deferred gain" } } }, "localname": "DeferredGain", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "AEZS_DeferredRevenues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Revenues.", "label": "Total Deferred Revenues" } } }, "localname": "DeferredRevenues", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_DeferredRevenuesCurrent": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenues current.", "label": "Deferred revenues (note 3)", "verboseLabel": "Total Current Deferred Revenues" } } }, "localname": "DeferredRevenuesCurrent", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition", "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_DeferredRevenuesNonCurrent": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred revenues non current.", "label": "Total Deferred Revenues Non Current", "verboseLabel": "Deferred revenues (note 3)" } } }, "localname": "DeferredRevenuesNonCurrent", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition", "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_DeferredShareUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Share Unit [member]", "label": "Deferred Share Unit [member]" } } }, "localname": "DeferredShareUnitMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDsuActivityDetails" ], "xbrltype": "domainItemType" }, "AEZS_DeferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Stock Units [member]", "label": "Deferred Stock Units [member]" } } }, "localname": "DeferredStockUnitsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of option life share options granted expected life years.", "label": "Expected life (years)" } } }, "localname": "DescriptionOfOptionLifeShareOptionsGrantedExpectedLifeYears", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "durationItemType" }, "AEZS_DetectTrialCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Detect Tria lCosts.", "label": "Detect trial costs" } } }, "localname": "DetectTrialCosts", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "AEZS_DevelopmentServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Development Services [Member]" } } }, "localname": "DevelopmentServicesMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "AEZS_DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Assumptions to Determine Share based Compensation Costs Over Life of Awards Explanatory.", "label": "Summary of assumptions to determine share-based compensation costs over the life of awards" } } }, "localname": "DisclosureOfAssumptionsToDetermineSharebasedCompensationCostsOverLifeOfAwardsExplanatory", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "AEZS_DisclosureOfCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments" } } }, "localname": "DisclosureOfCommitmentsAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_DisclosureOfDetailedInformationAboutDeferredRevenueExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about deferred revenue explanatory.", "label": "Summary of deferred revenue" } } }, "localname": "DisclosureOfDetailedInformationAboutDeferredRevenueExplanatory", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "AEZS_DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about revenue from transfer of goods and services.", "label": "Summary of revenue from transfer of goods and services" } } }, "localname": "DisclosureOfDetailedInformationAboutRevenueFromTransferOfGoodsAndServices", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "AEZS_DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Finance Lease and Operating Lease by Lessee Explanatory.", "label": "Schedule of expected future minimum lease payments" } } }, "localname": "DisclosureOfFinanceLeaseAndOperatingLeaseByLesseeExplanatory", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/CommitmentsTables" ], "xbrltype": "textBlockItemType" }, "AEZS_DisclosureOfNetLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "localname": "DisclosureOfNetLossPerShareAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of number and weighted average exercise prices of deferred share units explanatory.", "label": "Summary of DSU activity" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfDeferredShareUnitsExplanatory", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "AEZS_DisclosureOfSegmentInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "localname": "DisclosureOfSegmentInformationAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_DisclosureOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Equity", "terseLabel": "Summary Of Number And Weighted Average Exercise Prices Of Share Options", "verboseLabel": "Summary Of Assumptions To Determine Share-based Compensation Costs Over Life Of Awards" } } }, "localname": "DisclosureOfShareCapitalAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_DisclosureOfSupplementalDisclosureOfCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure Of Cash Flow Information", "verboseLabel": "Disclosure Of Changes In Operating Assets And Liabilities" } } }, "localname": "DisclosureOfSupplementalDisclosureOfCashFlowInformationAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Changes in Operating Assets and Liabilities Explanatory.", "label": "Disclosure of changes in operating assets and liabilities" } } }, "localname": "DisclosureofChangesInOperatingAssetsAndLiabilitiesExplanatory", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "AEZS_EmployeeFutureBenefitObligationDiscountRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee future benefit obligation discount rate.", "label": "Employee future benefit obligation" } } }, "localname": "EmployeeFutureBenefitObligationDiscountRate", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/EmployeeFutureBenefitsDetailsNarrative" ], "xbrltype": "percentItemType" }, "AEZS_EmployeeFutureBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Future Benefits" } } }, "localname": "EmployeeFutureBenefitsAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_EmployeeStockOption1DeferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Option 1 Deferred Stock Units [member]", "label": "Employee Stock Option 1 Deferred Stock Units [member]" } } }, "localname": "EmployeeStockOption1DeferredStockUnitsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "AEZS_ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of share options granted in sharebased payment arrangement.", "label": "Exercise price" } } }, "localname": "ExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "perShareItemType" }, "AEZS_FourToFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4 to 5 Years [member]", "label": "4 to 5 Years [member]" } } }, "localname": "FourToFiveYearsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "AEZS_IfrsStatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IfrsStatementLineItems [Line Items]" } } }, "localname": "IfrsStatementLineItems", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative", "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/RevenueDetailsNarrative", "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails", "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDeferredRevenueDetails", "http://zentaris.com/role/SummaryOfDsuActivityDetails", "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails", "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "stringItemType" }, "AEZS_IfrsStatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IfrsStatementTable [Table]" } } }, "localname": "IfrsStatementTable", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "AEZS_ImpactOfForeignExchangeRateChangesAssetsOfBenefitPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impact of foreign exchange rate changes assets of benefit plan.", "label": "Impact of foreign exchange rate changes [Default Label]", "verboseLabel": "Impact of foreign exchange rate changes" } } }, "localname": "ImpactOfForeignExchangeRateChangesAssetsOfBenefitPlan", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_IndicationPerformanceObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indication performance obligation [member]", "label": "Indication performance obligation [member]" } } }, "localname": "IndicationPerformanceObligationMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_InterestIncomeFromPlanAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest income from plan assets.", "label": "Interest income from plan assets" } } }, "localname": "InterestIncomeFromPlanAssets", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_LicenseFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Fees [Member]" } } }, "localname": "LicenseFeesMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "AEZS_MinimumLeasePaymentsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum lease payments, net", "label": "Total", "verboseLabel": "Minimum lease payments net" } } }, "localname": "MinimumLeasePaymentsNet", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative", "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_NKMeditechMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NK Meditech [member]", "label": "NK Meditech [member]" } } }, "localname": "NKMeditechMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "AEZS_NetLiabilityOfFundedPlans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net liability of the funded plans.", "label": "Net liability of the funded plans" } } }, "localname": "NetLiabilityOfFundedPlans", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_NetLiabilityOfUnfundedPlans": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net liability of the unfunded plans.", "label": "Net liability of the unfunded plans" } } }, "localname": "NetLiabilityOfUnfundedPlans", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_NovoNordiskHealthCareAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novo Nordisk Health Care AG [member]", "label": "Novo Nordisk Health Care AG [member]" } } }, "localname": "NovoNordiskHealthCareAGMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_NovoNordiskHealthCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Novo Nordisk Health Care [member]", "label": "Novo Nordisk Health Care [member]" } } }, "localname": "NovoNordiskHealthCareMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "AEZS_OneToThreeYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1 to 3 Years [member]", "label": "1 to 3 Years [member]" } } }, "localname": "OneToThreeYearsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "AEZS_OperatingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Expense Abstract", "label": "Expenses" } } }, "localname": "OperatingExpenseAbstract", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "AEZS_OtherBenefitPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other benefit plans [member]", "label": "Other benefit plans [member]" } } }, "localname": "OtherBenefitPlansMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "domainItemType" }, "AEZS_PediatricIndicationPerformanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pediatric indication performance [member]", "label": "Pediatric indication performance [member]" } } }, "localname": "PediatricIndicationPerformanceMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_PharmanoviaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmanovia [member]", "label": "Pharmanovia [member]" } } }, "localname": "PharmanoviaMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfDeferredRevenueDetails" ], "xbrltype": "domainItemType" }, "AEZS_PostemploymentBenefitExpenseDefinedBenefitPlan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Postemployment benefit expense defined benefit plans.", "label": "In net loss" } } }, "localname": "PostemploymentBenefitExpenseDefinedBenefitPlan", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_ProductSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Sales [Member]" } } }, "localname": "ProductSalesMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "AEZS_Provision": { "auth_ref": [], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision.", "label": "Provision", "verboseLabel": "Provisions" } } }, "localname": "Provision", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "AEZS_RemeasurementOfPlanAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remeasurement of plan assets.", "label": "Remeasurement of plan assets", "negatedLabel": "Remeasurement of plan assets" } } }, "localname": "RemeasurementOfPlanAssets", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "AEZS_RoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalties [Member]" } } }, "localname": "RoyaltiesMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "AEZS_ShareholdersAndBoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders and Board of Directors [member]", "label": "Shareholders and Board of Directors [member]" } } }, "localname": "ShareholdersAndBoardOfDirectorsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_StockholdersEquityReverseSplit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders equity reverse split.", "label": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseSplit", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "AEZS_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basis Of Presentation" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://zentaris.com/20230630", "xbrltype": "stringItemType" }, "AEZS_SupplyChainMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supply Chain [Member]" } } }, "localname": "SupplyChainMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "AEZS_TwoThousandEighteenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Long Term Incentive Plan [member]", "label": "2018 Long Term Incentive Plan [member]" } } }, "localname": "TwoThousandEighteenLongTermIncentivePlanMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_UnsatisfiedPerformanceObligationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsatisfied performance obligations [member]", "label": "Unsatisfied performance obligations [member]" } } }, "localname": "UnsatisfiedPerformanceObligationsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "AEZS_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [member]", "label": "Warrants [member]" } } }, "localname": "WarrantsMember", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "AEZS_WeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant date fair value", "label": "Grant date fair value" } } }, "localname": "WeightedAverageGrantDateFairValue", "nsuri": "http://zentaris.com/20230630", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "perShareItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r149", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://zentaris.com/role/Cover" ], "xbrltype": "booleanItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r162" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r160" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive income [member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions", "negatedLabel": "Actuarial loss (gain) from changes in financial assumptions" } } }, "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of shares outstanding, diluted", "verboseLabel": "Diluted weighted-average shares outstanding" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r166" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "negatedLabel": "Inventory" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r168" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "negatedLabel": "Trade and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r167" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Depreciation and amortization" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": { "auth_ref": [ "r166" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 5.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in deferred income including contract liabilities", "negatedLabel": "Deferred revenues" } } }, "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": { "auth_ref": [ "r168" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 7.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in employee benefit liabilities", "negatedLabel": "Employee future benefits" } } }, "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "auth_ref": [ "r168" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 6.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in other liabilities", "negatedLabel": "Provision for restructuring and other costs" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r168" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "negatedLabel": "Payables and accrued liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Items not affecting cash and cash equivalents:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r167" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "verboseLabel": "Share-based compensation costs" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r15", "r79", "r81", "r82", "r94", "r111", "r112", "r113", "r114", "r121", "r130", "r132" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r13", "r73", "r74", "r75", "r101", "r104" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_AssetsOfBenefitPlan": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets held by retirement benefit plans. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Assets of benefit plan", "periodEndLabel": "Balances \u2013 End of the period", "periodStartLabel": "Balances \u2013 Beginning of the period" } } }, "localname": "AssetsOfBenefitPlan", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r47", "r48" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic loss per share (note 7)", "verboseLabel": "Basic loss per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r9", "r58", "r70" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents \u2013 End of period", "periodStartLabel": "Cash and cash equivalents \u2013 Beginning of period" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows", "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r52", "r59" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r52", "r59" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r52", "r59" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansAxis": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Characteristics of defined benefit plans [axis]" } } }, "localname": "CharacteristicsOfDefinedBenefitPlansAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CharacteristicsOfDefinedBenefitPlansMember": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for all defined benefit plans when disaggregated by characteristics of defined benefits plans. It also represents the standard value for the 'Characteristics of defined benefits plans' axis if no other member is used." } } }, "localname": "CharacteristicsOfDefinedBenefitPlansMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDsuActivityDetails", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Items that may be reclassified subsequently to profit or loss:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Items that will not be reclassified to profit or loss:" } } }, "localname": "ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r1", "r24", "r62", "r63", "r68", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income (loss)", "totalLabel": "Comprehensive (loss) income" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r0", "r28" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales" } } }, "localname": "CostOfSales", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r97" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "localname": "CounterpartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r162" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Payables and accrued liabilities" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r16", "r64", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets [Default Label]", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liabilities" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r17", "r66", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities [Default Label]", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": { "auth_ref": [ "r162" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]" } }, "en-us": { "role": { "label": "Prepaid expenses and other current assets" } } }, "localname": "CurrentPrepaymentsAndOtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Current service cost" } } }, "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxAssetsCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } }, "en-us": { "role": { "label": "Income taxes receivable" } } }, "localname": "CurrentTaxAssetsCurrent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxLiabilities": { "auth_ref": [ "r11" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Income taxes payable" } } }, "localname": "CurrentTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "New standards and amendments" } } }, "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk-free annual interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r47", "r48" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted loss per share (note 7)", "verboseLabel": "Diluted loss per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Critical accounting estimates and judgements" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": { "auth_ref": [ "r15" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date." } }, "en-us": { "role": { "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]" } } }, "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } }, "en-us": { "role": { "label": "Basis of presentation" } } }, "localname": "DisclosureOfBasisOfConsolidationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Business overview" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/BusinessOverview" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SupplementalDisclosureOfCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r21" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "Summary of share capital" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Disclosure of commitments and contingent liabilities [text block]", "verboseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } }, "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } } }, "localname": "DisclosureOfDefinedBenefitPlansTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r170" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative", "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Net loss per share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r41" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "verboseLabel": "Employee future benefits" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/EmployeeFutureBenefits" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for operating segments." } }, "en-us": { "role": { "label": "Segment information" } } }, "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SegmentInformation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in plan liabilities" } } }, "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Summary of net defined benefit liability asset" } } }, "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/EmployeeFutureBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Summary of number and weighted average exercise prices of share options" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": { "auth_ref": [ "r93" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the offsetting of financial assets." } }, "en-us": { "role": { "label": "Disclosure of offsetting of financial assets [table]" } } }, "localname": "DisclosureOfOffsettingOfFinancialAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRevenueExplanatory": { "auth_ref": [ "r158" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue." } }, "en-us": { "role": { "label": "Revenue" } } }, "localname": "DisclosureOfRevenueExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r22" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "verboseLabel": "Shareholders\u2019 equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r47" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Summary of pertinent data relating to computation of basic and diluted net loss per share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r54", "r55" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r43" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 equity" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r13" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r12" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent", "periodEndLabel": "Balance \u2013 Value", "periodStartLabel": "Balance \u2013 Value", "totalLabel": "Total Shareholders\u2019 equity" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDsuActivityDetails", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend yield" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } }, "en-us": { "role": { "label": "Compensation expenses" } } }, "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r163" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "totalLabel": "Net finance income" } } }, "localname": "FinanceIncomeCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesTypeMember": { "auth_ref": [ "r96", "r97" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated types of financial liabilities. It also represents the standard value for the 'Types of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "localname": "FinancialLiabilitiesTypeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r38" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Actuarial (loss) gain on defined benefit plans in other comprehensive (loss) income" } } }, "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amounts recognized:" } } }, "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAssetAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r5", "r42" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Gain (loss) due to changes in foreign currency exchange rates" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r161" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]" } }, "en-us": { "role": { "label": "Goods or services transferred at point in time [member]" } } }, "localname": "GoodsOrServicesTransferredAtPointInTimeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_GoodsOrServicesTransferredOverTimeMember": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]" } }, "en-us": { "role": { "label": "Goods or services transferred over time [member]" } } }, "localname": "GoodsOrServicesTransferredOverTimeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r26", "r29", "r30", "r31", "r45", "r72", "r100" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax recovery" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefund": { "auth_ref": [ "r56" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded." } }, "en-us": { "role": { "label": "Refund (payment) of income taxes" } } }, "localname": "IncomeTaxesPaidRefund", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r58" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNetAssetsAvailableForBenefits": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in net assets available for benefits. Net assets available for benefits are assets of a retirement benefit plan less liabilities other than the actuarial present value of promised retirement benefits." } }, "en-us": { "role": { "label": "Increase (decrease) in net assets available for benefits", "negatedLabel": "Benefits paid" } } }, "localname": "IncreaseDecreaseInNetAssetsAvailableForBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r168" ], "calculation": { "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Changes in operating assets and liabilities (note 6)", "totalLabel": "Increase (decrease) in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/DisclosureOfChangesInOperatingAssetsAndLiabilitiesDetails", "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes in foreign exchange rates. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Impact of foreign exchange rate changes" } } }, "localname": "IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } }, "en-us": { "role": { "label": "Net foreign exchange differences" } } }, "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Share-based compensation costs" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Interest cost" } } }, "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InventoriesTotal": { "auth_ref": [ "r7" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets: (a) held for sale in the ordinary course of business; (b) in the process of production for such sale; or (c) in the form of materials or supplies to be consumed in the production process or in the rendering of services. Inventories encompass goods purchased and held for resale including, for example, merchandise purchased by a retailer and held for resale, or land and other property held for resale. Inventories also encompass finished goods produced, or work in progress being produced, by the entity and include materials and supplies awaiting use in the production process. [Refer: Current finished goods; Current merchandise; Current work in progress; Land]" } }, "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoriesTotal", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r118" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Share capital (note 5)" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanFiveYearsMember": { "auth_ref": [ "r81", "r82", "r114", "r130", "r131", "r133" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years." } }, "en-us": { "role": { "label": "Later than five years [member]" } } }, "localname": "LaterThanFiveYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r13", "r73", "r74", "r75", "r101", "r105" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "auth_ref": [ "r34" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Net defined benefit liability (asset)", "periodEndLabel": "Balances \u2013 End of the period", "periodStartLabel": "Balances \u2013 Beginning of the period" } } }, "localname": "LiabilityAssetOfDefinedBenefitPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r15", "r79", "r81", "r82", "r94", "r95", "r111", "r112", "r113", "r114", "r121", "r130" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r16", "r65", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets [Default Label]", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r80" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Non-current lease liabilities", "verboseLabel": "Lease liabilities" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r17", "r67", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities [Default Label]", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r10" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "verboseLabel": "Provisions" } } }, "localname": "NoncurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "auth_ref": [ "r20" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } }, "en-us": { "role": { "label": "Employee future benefits (note 4)" } } }, "localname": "NoncurrentProvisionsForEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r14", "r81", "r82", "r114", "r130", "r133" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ScheduleOfExpectedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r90", "r169" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Granted", "verboseLabel": "Number of share units granted" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfDsuActivityDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r169" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Balance \u2013 June 30,", "periodStartLabel": "Balance \u2013 January 1," } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfDsuActivityDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r83", "r86", "r88" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Number of Options, Ending", "periodStartLabel": "Number of Options, Beginning" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Number of Options, Canceled/Forfeited" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "auth_ref": [ "r84" ], "lang": { "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of Options, Granted", "verboseLabel": "Number of options, granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/ShareholdersEquityDetailsNarrative", "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r159" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "periodEndLabel": "Number of shares issued", "periodStartLabel": "Number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r163" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "auth_ref": [ "r167" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Other non-cash items" } } }, "localname": "OtherAdjustmentsForNoncashItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r18", "r27" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "auth_ref": [ "r18", "r27", "r164" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } }, "en-us": { "role": { "label": "Actuarial gain on defined benefit plans", "verboseLabel": "Actuarial gain on defined benefit plans (note 4)" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherEquityInterest": { "auth_ref": [ "r118" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Contributed surplus" } } }, "localname": "OtherEquityInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherEquityInterestMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other equity interest [member]" } } }, "localname": "OtherEquityInterestMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherFinanceIncomeCost": { "auth_ref": [ "r163" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Other finance income (costs)" } } }, "localname": "OtherFinanceIncomeCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsInRespectOfSettlementsNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r40" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in the net defined benefit liability (asset) resulting from payments from the plan in respect of settlements. [Refer: Decrease (increase) in net defined benefit liability (asset) resulting from gains (losses) arising from settlements; Net defined benefit liability (asset); Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from payments in respect of settlements", "negatedLabel": "Benefits paid" } } }, "localname": "PaymentsInRespectOfSettlementsNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Payments on lease liabilities" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PensionDefinedBenefitPlansMember": { "auth_ref": [ "r165" ], "lang": { "en": { "role": { "documentation": "This member stands for pension defined benefit plans. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Pension defined benefit plans [member]" } } }, "localname": "PensionDefinedBenefitPlansMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r107", "r128" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r107", "r128" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "localname": "ProductsAndServicesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r2", "r23", "r53", "r62", "r63", "r101", "r103", "r125", "r136", "r137" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows", "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r92", "r115", "r116", "r134", "r135" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "totalLabel": "Loss before income taxes" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r122", "r163" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Loss from operations" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r6", "r32" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Provisions": { "auth_ref": [ "r10" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities of uncertain timing or amount, including provisions for employee benefits." } }, "en-us": { "role": { "label": "Provisions" } } }, "localname": "Provisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r123" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r76", "r88", "r113", "r126", "r127", "r170" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r76", "r88", "r113", "r126", "r127", "r170" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r51" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r162" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Restricted cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r118", "r119" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Deficit" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r4", "r117" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r25", "r69", "r92", "r98", "r102", "r107", "r108", "r109", "r115", "r116", "r125" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenues (note 3)", "terseLabel": "Revenue", "verboseLabel": "Total" } } }, "localname": "Revenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/RevenueDetailsNarrative", "http://zentaris.com/role/SummaryOfRevenueFromTransferOfGoodsAndServicesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [abstract]" } } }, "localname": "RevenueAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r71", "r99", "r106", "r161" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfChangesInShareholdersEquity", "http://zentaris.com/role/SummaryOfDsuActivityDetails", "http://zentaris.com/role/SummaryOfShareCapitalDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInNetAssetsAvailableForBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in plan assets" } } }, "localname": "StatementOfChangesInNetAssetsAvailableForBenefitsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNetDefinedBenefitLiabilityAssetDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Timing of transfer of goods or services [axis]" } } }, "localname": "TimingOfTransferOfGoodsOrServicesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_TimingOfTransferOfGoodsOrServicesMember": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used." } } }, "localname": "TimingOfTransferOfGoodsOrServicesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r76", "r88", "r113", "r126", "r127", "r170" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r8", "r19" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Performance obligations" } } }, "localname": "TransactionPriceAllocatedToRemainingPerformanceObligations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfFinancialLiabilitiesAxis": { "auth_ref": [ "r96", "r97" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of financial liabilities [axis]" } } }, "localname": "TypesOfFinancialLiabilitiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/RevenueDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_WarrantLiability": { "auth_ref": [ "r162" ], "calculation": { "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of warrant liabilities." } }, "en-us": { "role": { "label": "Warrants" } } }, "localname": "WarrantLiability", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price, cancelled/forfeited" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r84" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price, granted" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r83", "r86" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement", "periodEndLabel": "Weighted average exercise price, ending", "periodStartLabel": "Weighted average exercise price, beginning" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfNumberAndWeightedAverageExercisePricesOfShareOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Share price" } } }, "localname": "WeightedAverageSharePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfAssumptionsToDetermineShare-basedCompensationCostsOverLifeOfAwardsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r49" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of shares outstanding, basic", "verboseLabel": "Basic weighted-average shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/InterimConsolidatedStatementsOfLossAndComprehensiveLoss", "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Items excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:" } } }, "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://zentaris.com/role/SummaryOfPertinentDataRelatingToComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r116": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r117": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r118": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r122": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r124": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r125": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r126": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r127": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r128": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r129": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r131": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r132": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r133": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r134": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r135": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r136": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r137": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r138": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r139": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r141": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r142": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r143": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r144": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r145": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r146": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r147": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r148": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r149": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r151": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r152": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r153": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r154": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r155": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r156": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r157": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r158": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r159": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r161": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r162": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r163": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r164": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "13C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_13C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B51", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B51&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 59 0001493152-23-027263-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-027263-xbrl.zip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end GRAPHIC 9 ex99-2_003.jpg begin 644 ex99-2_003.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **Y/7?'$>C:I)8K8-.\6-S&78.0#QP?6K M/ASQ;%X@N9;;[(UO*B>9C?O!&0.N!ZBNIX2LJ?M7'0X(YCAI5O8*?O;6UW.C MHHHKE.\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***Y/7?'$>C:I)8K8-.\6 M-S&78.0#QP?6M:5&=:7+35V<^(Q-+#0YZKLCK**YSPYXMB\07,MM]D:WE1/, MQOW@C('7 ]171TJM*=*7)-695"O3KP]I2=T%%%%9FP4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110!6U&Y-EIEU= F&%Y #W(!- M>5GQMXAS_P A#'_;&/\ ^)KUBY@2ZM9K>3[DJ,C8]",&N&/PTYXU;C_KV_\ MLJ]7 5,-!2]LE?S5SP,WH8ZI*'U5NVM[.W^1S_\ PFOB'_H(?^08_P#XFC_A M-?$/_00_\@Q__$UT'_"L_P#J+_\ DM_]G1_PK/\ ZB__ )+?_9UZ/UC+^R^[ M_@'B?4\X[R_\"_X)S_\ PFOB'_H(?^08_P#XFC_A-?$/_00_\@Q__$UD7UM] MBU"YM-^_R)6CW8QNVDC./PK4\->'?^$AFN(_M7V?R5#9\O?G/XBNN=/#0A[2 M45;T/.IUL=5J^QA.3E_B[?/R'_\ ":^(?^@A_P"08_\ XFC_ (37Q#_T$/\ MR#'_ /$UT'_"L_\ J+_^2W_V='_"L_\ J+_^2W_V=")8E8+$Y3DY]*Z<-AWB)\B=CBQV,CA*7M9*_30]'HKSCP-K&HW M6N&VN;V>>)HF8K*Y?D8Z9Z5Z/1B<.\//D;N&!QD<72]K%6Z:A1117,=IQWCO M7+S3(K6VLI3$TVYG=?O #& /3K^E<-#XCUF"59%U.[8CL\I52!^1)KZ/ SPRPZ4[7 MZWL?%YK2Q\L8W34K:6M>WX/OW/4-.NOMVFVMUC!FB60CT)&:LU!9VRV=E!:H MS@F:XO0TD:L0'3&2,_W:^DQ'U6@DZD%KY'Q&#_M#%MJE4>G> M31RW_":^(?\ H(?^08__ (FK5OX_UN''F-!..^^/&?\ OG%=&WPXTL_=N[P? M5E/_ ++61J?P[NH(VET^Y%P!SY3C:WX'H?TKFC7R^H^6R7RL=LL+G%%))+:ZCTJZDS;RG$)8_<;T^A_G6.,RV*BZE'[O\ (ZLMSNWL]A>7#SJ(O,1I#E@00",]3U[^E8EWX$UN&X=+>!+B+)VNL MBKD=L@DW7Y>ECL:***^;/M@HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "O(?&O_(W7W_;/_P!%K7KU>0^-?^1NOO\ MG_Z+6O7RC^. M_3]4?.<1?[K'_$OR9H?#G_D8;C_KU;_T-*].KS'X<_\ (PW'_7JW_H:5Z=6> M:?[R_1&V0?[DO5_H-D<1QLYZ*"37C=YXGUB\N7F.H7$0))"0R%%4>G%>RLH= M&5N0PP:\IN_ FMPW#I;P)<19.UUD5TM?IWL]A>7#SJ(O,1I#E@00",]3U[^E=Y7'>#/"]WH]Q->7P5) M7C\M(PVX@$@DDCCL*[&N7'.FZ[=+;R._*8UXX6*KWYM=][= HHHKB/4"BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,OQ'J$NEZ!=WD! E1 M0$)&<$L!G]:\U_X37Q#_ -!#_P @Q_\ Q->I:MIR:MI<]C(Q195QN S@@Y!_ M,"N-_P"%9_\ 47_\EO\ [.O7P-7"P@U62O?JKGSF;4,?4JQ>&;Y;=';6_JCG M_P#A-?$/_00_\@Q__$T?\)KXA_Z"'_D&/_XFN@_X5G_U%_\ R6_^SH_X5G_U M%_\ R6_^SKO^L9?V7W?\ \CZGG'>7_@7_!.?_P"$U\0_]!#_ ,@Q_P#Q-'_" M:^(?^@A_Y!C_ /B:P*Z3PWX3_P"$AM9I_MOV?RWV8\K?GC/J*ZZM/#4H\\XI M+T/.H5L=B)^SI3DW_B_X)%_PFOB'_H(?^08__B:/^$U\0_\ 00_\@Q__ !-= M!_PK/_J+_P#DM_\ 9T?\*S_ZB_\ Y+?_ &=F@7TEV;PW#M'L4>7L MR02>ISTKIJ\7&SI2JWH[?[OIZA1117&>D%%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M16=KUQ+::#>SP.4E2)BK#L:\D_M_6-^[^U;W.<_Z]L?EFN_"X&6(BY)I6/(S M#-:>"G&$HMWUTL>V45G:%<2W>A65Q.^^62)2S>IK1KBE%QDXOH>I3FIP4UU5 M_O"FR.(XV<]%!)IU(RAT96Y##!J2V>-7GB?6+RY>8ZA<1 DD)#(451Z<5U7@ M/7KZ]O9["\N'G41>8C2'+ @@$9ZGKW]*Q+OP)K<-PZ6\"7$63M=9%7([9!(Y MKIO!GA>[T>XFO+X*DKQ^6D8;<0"0221QV%?28N>%>':A;RM:_P#F?$Y?2S!8 MV+J*5KZWO;K\O2QV-%%%?-GVP4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110!XEKO_(PZE_U]2_^AFNI^&W_ !^7_P#US3^9 MKEM=_P"1AU+_ *^I?_0S74_#;_C\O_\ KFG\S7U>+_W-^B_0_/;Y?S/>Q7$%"E+EIKF_!'NU%>$075Q:MNMYY86]8W*G]*['P] MX[GCF2VU=O,A8X$^,,G^]ZC]?K16RJI"/-!\WYBPO$%"K)0J1Y;]=T>C44@( M90RD$'D$=Z6O(/HPHHJEJFJVFCV;75W)M0<*HY9CZ 548N3Y8J[)G.,(N4G9 M(NT5Y7JWCK4[YV2T;['!V"??/U;_ Q7-S7,]RVZ>:25AW=BQ_6O7IY14DKS ME;\3YNOQ%1@[4HN7GLO\SWBBO!8II(7WQ2/&WJC$&M_2_&FKZ$K_@*CQ'1D[58./GO_DSUNBL[1]9M-;LQ<6K>^/=5U"SUB"WM;R>"+[.'*Q.5R2S#/ M'T%;8:@Z]3D3L M3O9-:-I)=2R0&)CL=BP!&.1GI717RMT MJ;FI7MY''A<^C7K1I.%KNVYZ312$A022 !R2:X?6OB#'"[0:5$LS#@SR9V_@ M._U_G7G4%6]_>6A!MKJ:' M'3RY"O\ *NLT/Q]=02K#JO[^ \><%PZ^YQU'Z_6LJV558*\'?\S?#<04*DE& MHG'SW1Z3134=9(UD1@R,,JP.013J\@^C"BBO%'\0ZS)(7.J7@).<+,P'Y XK MMPF#EB;\KM8\O,,RA@N7FBWS7VMT/:Z*PK/6X;+PK9ZAJ5Q\S1 DG[SMZ =S M7#ZQXYU+4&:.T8V=OT 0_.1[MV_"G1P-6K)J.RTN&)S7#X>"E-ZM726^OY'J MM%>"RS2SN7ED>1S_ !.Q)J:UU&]L6#6MU-"1_<<@?E7>\G=M)Z^AXZXECS:T MW;U_X![I17#>&O')N94L]6*B1L*EP!@$^C#M]:[FO)KX>="7+-'T6%Q=+%0Y MZ3_S7J%%%%8'4%%8?B'Q/::#&$8>==,,I"I[>I/85YUJ7BW6-2=MUTT$9Z1P M'8!^/4_B:[\/@*M=::+X^O+:18 MM3_TB G!D =?\:]&MKF&[MTN+>19(I!E67H17F8C"U,.[36G<]_!X^ABXWI MO5;I[DM%%% =1O+^PNQ=W$ MDYBD4*TAR0"/6O2KY?.C2]JVNGXGBX7.*>(Q'L(Q:>NNG0ZZBBBO-/:"BBO' M=3U[5SJET!J=VBK*RA4E90 ">P-=F%PDL2VHNUCS#V]S< M6DOFVT\L,F,;XW*G'U%6_P"W=7_Z"M]_X$/_ (T8S+Y8BISJ26@LMSFG@Z'L MI0;U;W74]MHKRCPSK>J/XCLHY;^ZFC>3:R22LP((]":]7KQ,5A98>2BW>Y]5 M@,?'&TW.*:L[:A17,>.K^ZL-"C>TG>%WN%1F0X.W:QQGMT%>>0^(M9@E61=3 MNV*G.'F9@?J":WPV7SKT_:1:1R8W.:6$K>RE%O;73J>U4445YI[844=!DUPW MB#QZ+>1[720DCKPUPW*@_P"R._UZ?6MZ&'J5Y@^&/%\>MO]DN(Q%>!M_\ KZ7_ - >NO _[S#U_P SSLU_W*KZ?Y'F->Z:;_R"[3_K MBG_H(KPNO=--_P"07:?]<4_]!%>MG'PP^9\_PU\=3T7YLLT445\\?8GGOQ$T MJ.*2#5(E"F5O*EP.IQD'ZX!_(5PJ.R.KH2K*<@CL:]1^()4>&U#8R9U"_7!_ MIFO+:^LRV;GAUS=+H_/<\IQIXUN/5)_/^D>Z:?<_;=-M;K_GM$K_ )C-6:S/ M#H*^&].!SG[.AY^E:=?+5$E-I=W^9][1DY4XR>[2_)!17D6NZ[JPUV_1-2ND M2.X=$6.4J H8@# KJOA_JE[J$5]'=W,DXA,90R-N(SNSR?H*[ZN7SI4?:MKI M^)Y.'SFE7Q/U=1:>NNG2_P#D=G1117FGMA17BC^(=9DD+G5+P$G.%F8#\@<5 MZ=9ZW#9>%;/4-2N/F:($D_>=O0#N:]'$9?4HI:WOIH>-@LWHXIR5G%15[NVQ MNT5Y5K'CG4M09H[1C9V_0!#\Y'NW;\*YJ6:6=R\LCR.?XG8DUT4LHJ25YRM^ M)Q5^(J,)6I1.3]5"$IR48J[,ZE2%*+G-V2-2BO)-4\::OJ+,(YC M:PGHD)P?Q;K6!+-+.^^61Y&_O.Q)KV*>45&KSE;\3YRMQ'1B[4H.7X?YL]ZH MKP>&YGMFW0321-ZHQ4_I72:1XZU*QD5+QC>6_0[_ +X'L>_XTJN4U(J\'?\ M JAQ%1F[58N/GNO\SU2BJNGZA;:I9I=6D@>)OS!]".QJU7CM.+L]SZ.,E)*4 M7=,*\A\:_P#(W7W_ &S_ /1:UZ]7D/C7_D;K[_MG_P"BUKULH_COT_5'SW$7 M^ZQ_Q+\F:'PY_P"1AN/^O5O_ $-*].KS'X<_\C#K?^AI7IU9YI_O+]$; M9!_N2]7^@445Y%KNNZL-=OT34KI$CN'1%CE*@*&( P*Y\+A98F3C%VL=F89A M#!0C*46[NVAZ[17&?#_5+W4(KZ.[N9)Q"8RAD;<1G=GD_05V=95Z+HU'3?0Z M,)B8XFC&M%63"BBO%)/$&LR2,[:I> DY.V9E'Y X%;X3!RQ-^5VLT[78K/PE9ZAJ=P2S)U/+.*XK6/&^IZB[);.;.W[" M,_.1[M_ABG1P%6K)Q6R=KBQ.;8?#TXRENU=+KKW['JU%>"22R3.7D=G8]V.3 M5JSU74-/96M;R:+;T"N=OY=#7>\GE;2>OH>3'B6'-[U-V]?^ >XT5R/A;QB- M6=;*^"QW>/D=>%D_P-==7D5J,Z,^2:U/H\-B:>)IJI2=T%%%%8G0%%8?B'Q/ M::#&$8>==,,I"I[>I/85YUJ7BW6-2=MUTT$9Z1P'8!^/4_B:[\/@*M=[45YIHOCZ\MI%BU/_2("<&0 !U_QKT:VN8;N MW2XMY%DBD&59>A%>9B,+4P[M-:=SW\'CZ&+C>F]5NGN2T445RG<%%%% !111 M0 4444 >!5Z1\-_^07>?]=Q_Z"*\WKTCX;_\@N\_Z[C_ -!%?5YG_NS]4?GN M0_[['T?Y':T445\H?H045'--';P/-,X2-%+,S= *X+6/B&Y=HM)A4*.//E&2 M?HO;\?RKHH8:I7=H(X\7CJ&$C>J_EU9Z#17B5UKFJ7K%KB_N'S_"'(7\AQ6? M7JQR>5O>G^!X$^)8)^Y3;7F_^ SWVBO#;75+^R8&VO)XL= LA _+I7:>'?'D MDD\=IJVT[R%6X48P?]H=/Q%<]?*ZM-%S[#UI*$TXM_=]YWU%%%>4 M?0!15/5YI+?1;Z>)MLD=O(Z,.Q"D@UX__;^L;]W]JWN8ZGK>H M:M*SW=R[*>D8.$'T%5ALOJ5];V7?_(C'9Q1PEHVYI/IV]3VVBO"+>ZN+1]]O M/)"WK&Q4_I7LVA7$MWH-C<3OOE>%2S>I]:,9@7ADI.M2OI&2R8V=OT&W[Y^I[?A6.&P=3$/ MW=NYT8W,:[QZOHMSU.BO!IKB:X;=/-)*WJ[%C^M)%-+"VZ*1XV]58@UZ? M]CNWQ_A_P3P_]98W_AZ>O_ />J*\1&N:N!@:I>@#L+A_\:7^W=7_ .@K??\ M@0_^-1_8\_YU]S-/]9:7_/M_>CVVBO// >L:A=:S+;7-Y-/$82^)7+X((Z$] M.IKT.O,Q.'="IR-W/=P6+CBZ*JQ5MU]P44R66."%Y975(T&YF8X %>?:W\0) MI':'25$DFZN MYIL]0[DC\JK E6#*2"#D$=J]19.[:S_ \"7$L;^[3T]?^ >^45XQ8>)M7TYP M8;V1ESS'*=ZG\#T_"O1?#?BRVUU?)D407BC)CSPP]5_PKCQ.7U:"YMUY'IX+ M.,/BI)RIX P,CZ_I7)0HNM45- M=3T,7B8X:C*M)72-WQ-_R+.H_P#7!J\7J[+K&ISQ-%+J-Y)&PPR/.Q!'N,U2 MKZG!85X>#BW>[/@T>&?^19T[_K@M:M>'Q:QJ<$2Q1:C M>1QJ,*B3L ![#-/_ +=U?_H*WW_@0_\ C7G5,IG*;ES+5^9[5+B*E"G&#IO1 M);KHCVVBN>\%WEQ?>'(Y+J5Y9%D9=[G)(SW/?K70UXM6FZA55:E&H MMFKA17D6NZ[JPUV_1-2ND2.X=$6.4J H8@# KJOA_JE[J$5]'=W,DXA,90R- MN(SNSR?H*[JN7SI4?:MKI^)Y6'SFE7Q/U=1:>NNG2_\ D=G1117FGMA17BDG MB#69)&=M4O 2H:G<$LR=3RSG)X [GBO1Q&7U** M3O>[MH>-@LXHXJ4E9Q45>[ML=#17E.L>-]3U%V2V1V=CW8Y-=%+**DE>RM:WDT6W MH%<[?RZ&O0_"WC$:LZV5\%CN\?(Z\+)_@:QQ&6U*,>=.Z.G!9W0Q,U3DN63V MOL_F==1117F'NA117$^)/'(LIGL]+"22KP\[:OJ-^Q-U>S2YZJ7.W\NE4@<'(ZUZTG^!\[/B6 M%_=INWF_^ >^T5X=%JVI0+MBU"[C'HDS#^M2?V[J_P#T%;[_ ,"'_P :G^QY M_P Z^YEKB6EUIO[T>VT5XI%XAUF*59%U2\)4Y >9F!^H)P:]I1BT:L>I -<. M+P+ M_P!S?HOT/SW+?^1FO\4O_;CT2BBBOE#]""BBB@#R'QK_ ,C=??\ ;/\ ]%K6 M"'90P5B PPP!ZC.<'\0/RK>\:_\ (W7W_;/_ -%K3O!FE6^K:[Y=TNZ*&(S; M.S$$ ^W/Z5]C3J*GA8SELDOR/S2M1E6Q\Z4-W)K\67/#/@N358UO+XM#:'E M%'#2>_L/?_\ 77=0^&-$@C$:Z9;L!W=-Q_,\UJ@ # '0"EKYJOC:M:5[V7 M9'W&$RS#X:'*HIOJVKG%>(_!%I):276EQ>5<(-QB4_*X[X]#7F]>^UXKXBM5 ML_$-] @PHE)4>@/('ZUZ^5XF=2].;O;8^>S_ -.ERUJ:M?1_P"9Z#X#U)KW M0C;R-F2U;RQ_N'E?ZC\*ZFO.OAM(1>W\?9HU;\B?\:]%KRIKT/ MQS>FS\-2HK8:X<1#'H>3^@(_&O)P"Q ))X %>GE-!%Q%BI.4<- M';=_H=/X3\*?VVS75T62S1L?+P9#Z#V]Z]+M-,L;&(1VMI#$H_NJ,GZGO2:9 M9)INF6UFG2*,*3ZGN?Q.:MUYF+Q]U95NM-LKV(QW M-K#*I[,@./IZ5YKXN\+#1'6ZM-S63&WIGT]*]4K+\1VBWOAV_A*[CY+ M.H_VEY'ZBG@\5.C46NCW0LRP-/$T9:>\E=/KH>5^']8DT75HKD,?*)VS*/XD M/7\NOX5[.K!U#*05(R".]>!U[)X4NC=^&+"0DDB/RSG_ &25_I7HYO15HU5Z M'B<.8AWG0>VZ_)_H;->8_$;_ )&&W_Z]5_\ 0WKTZO,?B-_R,-O_ ->J_P#H M;UQY7_O*]&>EG_\ N3]5^IS%O?3VL%Q#"^U;A DA'4KG.*U/#GAJXU^X)#>5 M:QG$DN,\^@]_Y5G:9I\NJ:E!90D!Y6QD]AU)_ U[3I]A!IEC%:6R[8XQ@>I M/MC\7]77+#XG_5_\CY[*,O>,ES5?@C^+WM^K,-? FA+$$,$K-C&\RMG M_#]*?HWA"ST34WO+>>9\H45'Q\N2.X^E=%17S[Q59IQ2738_L]R!D(#\C^V# MT_"O,F5D8JP(8'!!'(->^5XOXFA6#Q+J"(,#SBWY\_UKVLKQ,YMTYN]M3Y?/ M\%2I*-:FK7=G;[SN_A]J#76B26KMEK5\#)_A;D?KFNMKSSX:L1=:@O8HA_4_ MXUZ'7F9A!0Q$DOZN>]E%1U,%!R]/N=@KP*O?:\"KTB"*21Y!$HCB3LH] *[C0? *&);C6-Q+#(MU.,?[Q'\A3?A[H]M-%+J MLJ[Y8Y3%&".%P 2WUYKOZG'XZ4).C2TMNR\IRJ%2"Q.(]Z^R_P _NV,L>'-% M";1I=KC&.8QG\ZY/Q1X)A@M9+[2E9?+&Z2#.1CN5S_*O0*" 1@\BO,HXNK2G MS*39[N(R_#UZ;@XI>:231X%7K/@K5VU31!',Q:XMCY;D]2/X3^7'X5YOKUB- M-UV\M%&$20E!Z*>0/R(K=^'ETT6O2V^?EFA/'N""/TS7T&/A&MAN==-4?'91 M5GAL=[)]6XO\;?BOQ/3ZSM7,EQ<2&261MS, M>YKO/"W@J!K:._U5"[.-T=NW0#L6]3[5R?ANQ74?$-G;.,QE]SC'4*,D?CC' MXU[17LYGB94DJ5/3_(^:R+ PKN6(K*]GI?ONV11VMO"@2*")$'150 51U+P_ MIFJQ,MS:Q[R.)4&UQ^-:=%?/QJ2B^:+U/L)TH3CR2BFO0\5U[19M#U)K60[T M(W1R8QN7_&N@\ :TUOJ!TR5R89\F,'^%Q_B/Y"M?XC6BR:3;707YXIMF?]E@ M?Z@5YY97)L[ZWN5SF*17X]CFOJ*;^N83WM_U1\'7C_9N8IT_AT?R>Z_/\#W: MBD!! (Z&EKY0_0#PS4O^0I=_]=W_ /0C7=_#;_CRO_\ KHO\C7":E_R%+O\ MZ[O_ .A&N[^&W_'E?_\ 71?Y&OJL?_NGW?H? Y1_R,?_ +]3N****^5/O@K MPS4O^0I=_P#7=_\ T(U[G7AFI?\ (4N_^N[_ /H1KW,G^*?HCY7B7^'3]7^1 MWWPW_P"07>?]=Q_Z"*[6N*^&_P#R"[S_ *[C_P!!%=K7!C_]YGZ_Y'KY3_N5 M/T_5F)/X0T&XG>:33U+N=S%9'49^@.*\\\8:;::7KGV:RB\J+RE;;N+X:C#"\\().ZU27F5?!^FV MFJ:Y]FO8O-B\IFV[BO(QW!%=_P#\(5X>_P"@?_Y&D_\ BJXKX?\ _(S#_K@_ M]*]4IYG6J0KVC)I674,CPM"KA.:I!-W>Z7D9%CX8T;3KI;FULE29<[6+LV/I MDFM>BBO(G.4W>3N?14Z5.DN6G%)>6AR'Q&_Y%ZW_ .OI?_0'KS&O3OB-_P B M];_]?2_^@/7F-?3Y7_NR]6?!Y_\ [Z_1?J>^T445\J?H!QGCW7&L[1--MWVR MW"YE(ZA.F/Q_D*\WCC>:5(HU+.[!54=23T%:GB6]:_\ $5[,22!(8U]@O _E MG\:V?A[IZW.LRW;C*VJ97_>;@'\@:^KHJ.$PO-;6U_FS\^Q,IYCF'LT]+V7D MEO\ DV;VB> [*UA674E^TW!&2F?D3V]_QK=/AW12,?V7:?A$*TZ*^EHXU4D(F,@8_ MO5[>:4:E6,?9J]KGR^0XJCAY5'5DHWMO\SM:*XYOB/I8SMM+P^F0H_\ 9JPM M6\?WU[&T-C$+2-N"^[U>13R[$3=G&WJ?15].4,%A[?=YL^2IPJYIC')K1[^2_K\3LH(5M[>. M%!A(U"*/8#%2445\DW<_0TK:(\2UW_D8=2_Z^I?_ $,UU_PS_P"8I_VR_P#9 MZY#7?^1AU+_KZE_]#-=?\,_^8I_VR_\ 9Z^JQO\ N7R7Z'P&6?\ (S7K+_VX M[ZBBBOE3] / JL375U>B"*21Y!$HCB3LH] *KUWWP]T>VFBEU65=\LQ^7X'#3Q5948.U]_1:_,=H/@%#$MQK&XEAD6ZG&/ M]XC^0KJ1XL1INNWEHHPB2$H/ M13R!^1%>UEF*E43IS=VCY?/L!3H.-:DK)Z->9Z1X*U=M4T01S,6N+8^6Y/4C M^$_EQ^%=)7F'P\NFBUZ6WS\LT)X]P01^F:]/KR^O(M/L9KN%SPH[ >PKO?B-> MF+3+:S5L>?(6;W5>WYD?E7GUA:F]U"VM1D&:54R.V3C->KE=&,*3K2Z_DCY_ M/\3*K7CAH;*WS;_R_4ZSPEX/3485U#40WV.;1;GPO. M^W+P,LB^W.#^A-=& Q4Z=51;T>AR9O@:=?#RFE[T5>_IT.(\&ZTVEZS'"[G[ M-YZ;<_;-,M;GO+"CG\0#73F]%*4:BZZ' M!PYB'*$J,OLZKY_\$M5Y#XU_Y&Z^_P"V?_HM:]>KR'QK_P C=??]L_\ T6M9 MY1_'?I^J-N(O]UC_ (E^3-#X<_\ (PW'_7JW_H:5Z=7F/PY_Y&&X_P"O5O\ MT-*].K/-/]Y?HC;(/]R7J_T"O$M=_P"1AU+_ *^I?_0S7MM>):[_ ,C#J7_7 MU+_Z&:Z,G_B3]%^9Q\2_PJ?J_P CK_AG_P Q3_ME_P"SUWU<#\,_^8I_VR_] MGKOJX\Q_WF7R_(]+)?\ <8?/\V%>!5[[7@5>AD_V_E^IX_$O_+KY_H6)+FYO M!;P,[R")?+AC Z9/0#U)KN]!\ Q+$MQJ^7D/(MU; 7_>(ZGZ?K3/AYI-M)!- MJDB[YTE,4>>B< DCW.:[VIQ^.E&3HTM+;FF495"I!8G$>\WLO+S^[Y&6?#>B MM'L.EVN,8XC /Y]:X7Q=X2CTB,7UAN^REMLB,C**BD[:-)+4\0BD>&5)8V*NC!E8= M01T->W:3?#4M)M;P8!EC#,!V;N/SS7A]>K^ Y"_A:)3_ 2.H_//]:]?-X)T ME/JG^9\YPY5:KRI]&K_=_P .=-6=KFJIHVDS7C@%E&(U/\3'H*T:\[^)%Z6N MK.Q5OE1#*P]23@?R/YUXN#H^VK1@]NI]1F.)>&PTJBWV7JSB[FYFO+F2XN)# M)+(VYF/I]JY/PW8KJ/B&SMG&8R^YQCJ% M&2/QQC\:]HKVSTOWW;(H[6WA0)%!$B#HJH M*HZEX?TS58F6YM8]Y'$J#:X_&M.BOGXU)1?-%ZGV$Z4)QY)137H>*Z]HLVAZ MDUK(=Z$;HY,8W+_C70> -::WU Z9*Y,,^3&#_"X_Q'\A6O\ $:T632;:Z"_/ M%-LS_LL#_4"O/+*Y-G?6]RN]O\ JCX.O'^SD?#?_ )!=Y_UW'_H( MKS>O2/AO_P @N\_Z[C_T$5]7F?\ NS]4?GN0_P"^Q]'^1VM%%%?*'Z$8OBVU MN+WPU=PVR,\I"D(HR6 8$@#OP*X;1_ NHZAB2\_T.'T=?G/_ 'M^/Y5ZG17 M;1QM2C3=.'7J>7BLKHXJLJM6[LK6Z?YG/V7@O1+-1NM?M#CJTS;L_AT_2KI\ M.Z,1C^R[3_OT*TZ*PEB*LG=R?WLZX83#P7+&"MZ+_(X3Q+X(MDLY;W2E:-XP M7>#)(8=\=P?:O/:]](!!!&0:\(O(E@O9X5^['(RCZ XKW\KQ$ZL90F[V/D,_ MP5*A*-2DKPGS_ ..C M_"NTKQ,9!0KSBNY]3EU1U,)3G+>W_ _0S]=_Y%[4O^O67_T UXE7MNN_\B]J M7_7K+_Z :\2KV,G_ (<_5?D?-<2_Q:?H_P RUV."W\Q^==[6./ MQSC+V-%V2W_R.K*,;Y77KCT'N:KZ^Q?Q%J18Y/V MJ0?@&(KM?AM&HT^^D &\RJI/L!Q_,U])4E]6P:Y-[+\>I\31@L=F;5757?W+ M9?@=79:58:="(K6UBC4>B\GZGJ:2^TC3]2A,=U:12 C@[<,/H>HJ[17S'M)\ MW-=W/N_94^7DY5;M96/&?$>B-H6JM;9+0L-\3GNOO[BK_@ZUTG4KY[#4;022 M."T4GF.I..JX!';G\#6S\2U7_B6MGY_W@QCJ/E_S^-5Z^:!^!& M#7U$*DJV#YV[.SU]#X*I2AALS]FDG&ZT>NCM_F>JZ;H6F:0[O8VJQ.XPS;F8 MX],DFM&BH+ZY6RL+BZ;I#&SG\!FOEW*526KNV?>QC"E"T4DEV///'FO-:8]RJ?# MO\ELOZ\S4TOP[IFDQ*MO;(S@*_!ENMK)?Z7%Y;QC=) O1AW*CL?:N!@GEMIXYX7* M2QL&5AU!KWD@$$$9!KP[5K466KWELHPL4SJH]@>/TKZ'+,1*K&5.>MOR/C<^ MP4*$XUZ2M?>W?>Y[#HFIKJ^D6]ZH 9UPZCLPX(_.I-1TJRU: 0WUNLR*=P!) M!!]B.:Y/X;W1>ROK4D_NY%D'_ @1_P"RUW%>+B(.A7E&.EGH?3X*JL7A(SFK MW6OY/\CD-=\)Z)9Z'>W-O9;)8XBR-YKG!^A->8U[1XF_Y%G4?^N#5XO7NY54 MG.G)S=]?T/D\_HTZ5:"IQ2TZ*W4].T+PGHEYH=E_P"@?_Y&D_\ BJM>&?\ D6=._P"N"UJUXE;$UE4DE-[OJ^Y]3A\%AG1@ MW3CLNB[(@L[.WT^U2VM8EBA3[JC_ #S4]%%YS7VF)K1HT_:25['YA@<-/%5E1B[ M7W]%J/T'P#$L2W&KY>0\BW5L!?\ >(ZGZ?K73'PWHK1[#I=KC&.(P#^?6M2B MOE*N+K5)XK MDHI'AE26-BKHP96'4$=#7M^K6JWND7=LPR)(F ^N.#^=>'5]!EN(E6IM3U:/ MC\[P<,-7C.DK*7X-=CW#2;X:EI-K># ,L89@.S=Q^>:NUS/@.0OX6B4_P2.H M_//]:Z:OG*\%"K**Z-GVN$JNK0A4>[2_(Y_QCJKZ5H$AA;;/.?*0CJ,]3^6? MTKR1$:218T4L[$!0.Y-=]\2V(33%S\I,I(]QM_Q-"1"CPQLIZAE!!J6BOG:E6=27-)ZGV='#TJ,%3IQLCS[QGX4M M[6T;4].B\M4/[Z)>F#_$!VKBK.6"&[C>Y@$\(;YXRQ7(U]%EE:56BXS=['Q6>8>&'Q$9TU:ZO;I=/MYGKMIX3\..D- MU!8*RL!(A,KL"#R."<&N@K(\+,S^&-/+=?* _ ' K7KY^O*;FXR;=F]S[+"P MIJDI4XJ/,D]%;H%%%%8'4%%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 >):[_R,.I?]?4O_ *&:ZGX;?\?E M_P#]/\ C'_D;+__ 'E_] 6O8*\?\8_\C9?_ .\O_H"U M[&4?QGZ?JCYOB/\ W:/^+]&;'PW_ .0I>?\ 7$?^A5Z17F_PW_Y"EY_UQ'_H M5>D5CF?^\OY'5D7^XQ]7^9PGQ*E(M].B[,TC?D%']:\_1VCD5U.&4@@X[UW_ M ,2XV,6FR?PJTBGZG;_@:X*WV&YB\T Q[QN!..,\U[676^JQ^?YGRV=7>/E\ MOR1M_P#":^(?^@A_Y!C_ /B:/^$U\0_]!#_R#'_\37?_ /"%>'O^@?\ ^1I/ M_BJ/^$*\/?\ 0/\ _(TG_P 57%]=P7_/O\$>I_9>:?\ /[_R:7^1P'_":^(? M^@A_Y!C_ /B:;)XQUZ:)XGO\HZE6'DQ\@_\ :]!_P"$*\/?] __ ,C2?_%4 M?\(5X>_Z!_\ Y&D_^*H^O8+_ )]_@@_LK-/^?W_DTO\ (\AKUKP+N_X12WST MWOM^FX__ %ZD'@KP\#G^S_\ R-)_\56W##%;PI##&L<:#"JHP *PQV/IUZ:A M!/?J=>5935PE9U*DEM;2Y)7F/Q&_Y&&W_P"O5?\ T-Z].KS'XC?\C#;_ /7J MO_H;UEE?^\KT9OG_ /N3]5^IG^"O^1NL?^VG_HMJ]>KR'P5_R-UC_P!M/_1; M5Z]6F;_QUZ?JS'AW_=9?XG^2"BBBO(/HPJGJ&J66E0>=>W"1*>F>2WT Y-1: MYJT>BZ5+>. S#Y8T_O,>@_SZ5XY?W]SJ5X]U=RF25^YZ >@]!7I8+ O$>])V MBCQ*E>-^Z>OW(ZGX;?\?E__P!N/^OIO_0$KKZ\O'?[S/U_R/>RK_)V8#&^%&/OU']*J>#25\6V!'JX_P#'&JWX^E$GB=E! MR8X44^W?^M5O!49D\666.B[V/L-AKZR'^XZ_R_H?GM37-M/YU^:/7J\E\3E-O;OT_R/H>(K_5 M%;^9?DS'L-0NM,NA MHZ_':WL0DB=&PNXKR!GL1Z5Z%_PA7A[_ *!__D:3_P"*KT\7B,/3J_P"@?_Y&D_\ BJ/^$*\/?] __P C2?\ Q5;:AXDU;5+;[->W?FQ;@VWRT7D>X K*KU[_ (0KP]_T#_\ R-)_ M\54EOX1T*UG2:+3U$B'*EI'8 _0DBM(YIAX*T(M?)&,\AQM67-5J)^;;?Z&O M!N^SQ;_O;!GZXJ2BBOG&?:+0\,U+_D*7?_7=_P#T(UW?PV_X\K__ *Z+_(UP MFI?\A2[_ .N[_P#H1KN_AM_QY7__ %T7^1KZK'_[I]WZ'P64?\C'_P "_4[B MBBBOE3[X*\,U+_D*7?\ UW?_ -"->YUX9J7_ "%+O_KN_P#Z$:]S)_BGZ(^5 MXE_AT_5_D=]\-_\ D%WG_79^ MO^1Z^4_[E3]/U85Y7\0/^1F/_7!/ZUZI7E?Q _Y&8_\ 7!/ZUOE7^\?)G'Q! M_N?S7ZA\/_\ D9A_UP?^E>J5Y7\/_P#D9A_UP?\ I7JE&:_[Q\D'#_\ N?S? MZ!1117EGOG(?$;_D7K?_ *^E_P#0'KS&O3OB-_R+UO\ ]?2_^@/7F-?597_N MR]6?G^?_ .^OT7ZGOM(S;4+>@S2TUUW(RCN"*^5/T \%=F=V=CEF.2?>O1_A MO&!I=Y)W:8+^2C_&O-R""01@CJ*])^&[@Z5>1]UG#?FH_P *^KS/_=G;R/S[ M(O\ ?E?L_P CM****^4/T$**** "BBB@ HHHH *Y#XC?\B];_P#7TO\ Z ]= M?7(?$;_D7K?_ *^E_P#0'KKP/^\P]?\ ,\[-?]RJ^G^1YC6['X.UZ:))4L,H MZAE/G1\@_P# JPJ]TTW_ )!=I_UQ3_T$5]!C\5/#J+@EKW/CLHR^EC9351M6 MML>5CP3XA) ^P8]_.C_^*J]:_#S596'VB:W@7O\ ,6/Y#C]:]/HKR99K7:TL MOD?10X?PD7=W?S_R1SVC>#M,TAUFPUS<#I)+T7Z#H/U-=#117G5*LZDN:;NS MVJ-"G0CR4HV04445F;'B6N_\C#J7_7U+_P"AFNO^&?\ S%/^V7_L]KC_P <:O8*\A\%1F3Q998Z+O8^ MPV&O7JK-_P",O3]69\._[K+_ !?HCS3XCRDZS:Q=EM]WYL1_2N3M;J:RNH[F MW?9-&=R-@'!^AXKJ_B/&PUNUD_A:V"CZAF_Q%<]H4%O=:Y96]T@>&64(REB, MYXZBO7PCBL)%O:W^9\YF*G+,9Q3LW)6_"Q?_ .$U\0_]!#_R#'_\31_PFOB' M_H(?^08__B:[_P#X0KP]_P! _P#\C2?_ !5'_"%>'O\ H'_^1I/_ (JN#Z[@ MO^??X(]?^R\T_P"?W_DTO\C@/^$U\0_]!#_R#'_\34-WXKUJ^M9+:YO=\,@P MR^4@R/J!FO1?^$*\/?\ 0/\ _(TG_P 51_PA7A[_ *!__D:3_P"*H6.P:=U3 M_!">59FU9UM/\4O\CR&O:?#F[_A&].W=?LZ?ECBJJ>#/#Z.&&G D'/,KD?D6 MK=50JA5 P .U:?[R_1&V0?[DO5_H%>):[_ ,C#J7_7 MU+_Z&:]MKQ+7?^1AU+_KZE_]#-=&3_Q)^B_,X^)?X5/U?Y'7_#/_ )BG_;+_ M -GKOJX'X9_\Q3_ME_[/7?5QYC_O,OE^1Z62_P"XP^?YL*\"KWVO J]#)_M_ M+]3Q^)?^77S_ $/3OAS_ ,B]RK_ '*EZ?YA3)?]2_\ NFGTR7_4O_NFN5;GH/8\%KU3P!_R M+(_Z[/\ TKRNO5/ '_(LC_KL_P#2OI\U_P!W^:/@^'O][?H_T.IKR7QS*9/% M=RI_Y9JBC_OD'^M>M5Y)XXC9/%EVQZ.J,/IL _I7FY3;V[]/\CW.(K_5%;^9 M?DS'L-0NM,NAHZ_' M:WL0DB=&PNXKR!GL1Z5Z%_PA7A[_ *!__D:3_P"*KT\7B,/3J_P"@?_Y&D_\ BJ/^$*\/?] __P C2?\ Q5;:AXDU;5+;[->W?FQ;@VWRT7D>X K*KU[_ (0KP]_T#_\ R-)_\54E MOX1T*UG2:+3U$B'*EI'8 _0DBM(YIAX*T(M?)&,\AQM67-5J)^;;?Z&O!N^S MQ;_O;!GZXJ2BBOG&?:+0****!A1110 4444 >!5Z1\-_^07>?]=Q_P"@BO-Z M](^&_P#R"[S_ *[C_P!!%?5YG_NS]4?GN0_[['T?Y':T445\H?H05GZGKFG: M.@-[Y/T_PKR*>>6ZG>>>1I)7.6 M9CDDUZF"P#KKGF[1_,\'-,W6$?LZ:O/\$=]=?$F%6Q::>[C^]*X7]!G^=9S_ M !'U0M^[M+-5]&5C_P"S"H-'\"7^HPK/N.WXUT"?#C3@!OO M+HGN5VC^AKME_9U)\K5W\V>9#^V<0N=/E3]%^C9B?\+&U?\ Y]K'_OA__BJY M2>5KBXDF< -(Q<@=,DYKTK_A7.D?\_-]_P!]I_\ $UYO=Q+;WL\*$E8Y&0$] M< XKLP=3#2;]@K=]/^">9F5''4XQ^MRNNFM_T1Z%\-_^07>?]=Q_Z"*[6N*^ M&_\ R"[S_KN/_017:U\_C_\ >9^O^1]CE/\ N5/T_5F?KO\ R+VI?]>LO_H! MKQ*O;==_Y%[4O^O67_T UXE7JY/_ Y^J_(^>XE_BT_1_F>O>"O^11L?^VG_ M *,:M^L#P5_R*-C_ -M/_1C5OUXN)_CS]7^9]1@?]UI_X5^04445SG8>1>,] M/>Q\27#;<1W!\Y#CKGK^N:N^!-:BT[4);2Y<)#SO_ )K^OT/>J0D*I9B !R2>U>+V?B/6+"(16^H3+&.B MMA@/IG.*;>^(-6U&+RKJ^E>,]4!"@_4#&:\S^R*G-\2L>Y_K)0Y;\CO\OS_X M!H^,]:BUC5PMNVZWMUV(PZ,>Y'MT'X4_P+8/=^(XY\'R[93(Q]R, ?K^E8^F M:/?:O.(K.!GY^9SPJ_4UZUX?T.'0=.%O&=\K'=+)C[S?X"NS%UJ>&H>P@];6 M_P""SSLNPU;'8OZU47NWO_DE_70U:P_&$IA\*7[#NJK^; ?UK[(8QA5 M\I#@?4BL:O2_#WA?0]1T"SNIK(/+(GSL)G&2"0>A]J^JQE6E2@G5C=?>?G^6 MX?$5ZCCAY\KMW:_(Y/\ X37Q#_T$/_(,?_Q-'_":^(?^@A_Y!C_^)KO_ /A" MO#W_ $#_ /R-)_\ %4?\(5X>_P"@?_Y&D_\ BJ\WZ[@O^??X(]O^R\T_Y_?^ M32_R. _X37Q#_P!!#_R#'_\ $UBW5S->74ES_Z!_\ Y&D_^*JX9CA8.\(6^2,ZF2YA55JE1->;;_0Y MOX:[OM&HX^[L3/UR35NO&Q=95JKJ) M:,^ER_#2PN'C2D[M?JS*\3?\BSJ/_7!J\7KVCQ-_R+.H_P#7!J\7KV\H_A2] M?T/E^)/X\/3]3VCPS_R+.G?]<%K5K*\,_P#(LZ=_UP6M6O K?Q9>K_-GU^&_ M@0]%^2"BBBLC<\2UW_D8=2_Z^I?_ $,UU_PS_P"8I_VR_P#9ZY#7?^1AU+_K MZE_]#-=?\,_^8I_VR_\ 9Z^JQO\ N7R7Z'Y_EG_(S7K+_P!N.^HHHKY4_0#P M*O3OAS_R+UQ_U]-_Z E>8UZ=\.?^1>N/^OIO_0$KZK-/]V?JC\_R#_?5Z/\ M0Z^BBBOE3] &2_ZE_P#=->"U[U+_ *E_]TUX+7OY/M/Y?J?(<2[TOG^AZIX M_P"19'_79_Z5U-POX+N/EX9 X&>N#TKUOQ/K$.CZ/(\B+*\P,<<3 M#(8DE>7QHTLBQHI9V(50.I)I_[^[N/^6DTTA]V9C_ #->@>$?!\EG M.FI:D@65>883U4_WF]_:N^/L\!1LW=_FSR9^WS?%)QC:*T]%Z]SK=,M/L&EV MMIG)AB5"?4@<_K5NBBOEI-R;;/O8Q48J*V04444B@HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q+7?^1A MU+_KZE_]#-=3\-O^/R__ .N:?S-Y;_P C-?XI?^W'HE%%%?*'Z$%%%% 'D/C7_D;K[_MG M_P"BUK0^'/\ R,-Q_P!>K?\ H:5G^-?^1NOO^V?_ *+6M#X<_P#(PW'_ %ZM M_P"AI7U53_7\CJR+_<8^K_,Y;Q]9FY\.&90 M2UO*LAQZ'@_S'Y5Y77O%S;QW5M+;S+NCE4HP]C7BVL:5/HVI2VDP/RG*/V=> MQKT,IK)P=)[K4\7B+"R52.(2T>C]5L>NZ%J*:KHMK=*.^ M'?$MSH$[!5\VVD.9(B<<^H]#7H=EXRT2]0$W8@?NDPVX_'I^M>?B\#4I3;BK MQ\CVLOS:C7I)3DE-;WT^:-^BLS_A(M&_Z"EI_P!_15&[\;:':@XNC.P'W84) MS^)P/UKCCAZLG91?W,]&>+P\%>4U]Z_S.AHKS^7XC2R7L26UE&EN7 8RDEBN M>>F /UKT"JK8:I1M[16N1AL;1Q7-[%WL%>8_$;_D8;?_ *]5_P#0WKTZO,?B M-_R,-O\ ]>J_^AO77E?^\KT9YV?_ .Y/U7ZF?X*_Y&ZQ_P"VG_HMJ]>KR'P5 M_P C=8_]M/\ T6U>O5IF_P#'7I^K,>'?]UE_B?Y(****\@^C.$^)4K"#3H1] MQVD8_4!0/_0C7"V$"W.HVL#_ '9940X]"0*]%^(=@]SH\-VBY-LYW>RMP3^8 M%>:1R-%(LB'#H0RGT(KZK+FI85*.^I^?YTG''N4]M'\OZN>\HBQQJB*%11@ M= *=6'H?BBPUBU3,R176/GA=L'/MZBM:6[MH(S)-<11H.K.X %?,SI3A+EDM M3[JE7I5(*<))HFKQOQ60?%.H8.?WG]!75>(_'<:(]II#;Y#PUSCA?]WU/O7G MK%F8LY)+>C\ $#WXS7>UX(C/&RR(S*RG M*L#@@CT->@Z!X^B:);?6,I(.!<*N0W^\!T/T_2EF& FY.K3UONBLGS:G&FL/ M6=K;/I\SNJ:[K&C.Y"JHR2>PK-/B310F[^U+7&,_ZP9_*N,\5>,TO[=K#3"W MD/Q+,1@N/0#KBO,H8.K5FHV:7<]S%9CA\/3@_0"NE^'-F9-5N;L_=ABV#ZL?\ ?SKC55G8*H+,3@ #))KV+PMHYT7 M1(X9!_I$A\R7V8]OP&!7O9A4C1P_LUUT7H?)9-1GB<9[:6RNWZN]OS_ VJ\W M^(UF8]2M;P [98C&3[J?\#^E>D5D>)='&MZ-+;KCSU^>$G^\.WX]*\+!5E1K MJ3VV^\^MS/#/$X65..^Z]4>4:)?C3-:M+QON1R#?_NG@_H37MJLKH'4@JPR" M.XKP66-X97BD0HZ$JRD8(-=;X:\;/I<*65^C36R\(Z_>0>GN*]K,<)*LE4IZ MM?D?+Y)F,,,Y4:VB?7L]M3TZBL>W\4Z'<1AUU*!?:0[#^1J1O$>BHN3JEKCV MD!_E7SSH54[P8#!'\C^-8&EZE/I.HQ7D!^>,\J>C#N#7ULH_6<):/5+[U_P MQ^=QG]0S%RGLF_N=_P!&>XT5@Z?XQT:^@#M=);28^:.<[2/QZ&FZCXRT:PA+ M)F3FK^M:W>:]>B6WJ?>J% MQ;S6D[03QF.5<;E/4<9KZ3 X3ZO'WG[S/B,VS!XR2Y%[D=O5_P!:(]#^&_\ MR"[S_KN/_017:UQ7PW_Y!=Y_UW'_ *"*[6O Q_\ O,_7_(^ORG_ M=I99#M#*IVY^I_I6W7CSISA\:L?1TZU.JFZG?$;_D7K?_ *^E_P#0'KS&OI\K_P!V7JSX3/\ _?7Z+]3WVBBBOE3] /$] M>M&LM>OK=AC;,Q'^Z3D?H16_\/-06VUB:T<@"Y0;<]V7D#\B:T/B#HK.(]6@ M3.T;)P.P[-_3\JX**62"9)8G*2(P96'4$=Z^MIN.+PMNZM\T?G=92R[,.>VB M=UYI_P##M'O5%%6-*F^9MI:;* M_G_D>K4445YY[ 4444 %M_\ KZ7_ - >NOKD/B-_R+UO_P!?2_\ MH#UUX'_>8>O^9YV:_P"Y5?3_ "/,:]TTW_D%VG_7%/\ T$5X77NFF_\ (+M/ M^N*?^@BO6SCX8?,^?X:^.IZ+\V6:***^>/L0HHHH **** /$M=_Y&'4O^OJ7 M_P!#-=?\,_\ F*?]LO\ V>N0UW_D8=2_Z^I?_0S77_#/_F*?]LO_ &>OJL;_ M +E\E^A^?Y9_R,UZR_\ ;COJ***^5/T \"KT#X>:M;1P3:7(VR=Y3+'GH_ ! M ]^,UY_3D9XV61&964Y5@<$$>AK[7$T%7INFS\NP.+EA*ZJQ5[?DSWNBN%T# MQ]$T2V^L920<"X5 Z'Z?I73'Q)HH3=_:EKC&?]8,_E7R=7"5J'/&:^;2:^\TG=8T9W(55&23V%>):Q??VEK%W>?PRR$K_ +O0?H!7 M4>*O&:7]NUAIA;R'XEF(P7'H!UQ7%*K.P5068G &237NY;A94DZDU9O\CY3 M/,PAB)1HTG=+KW9V7PYLS)JMS=G[L,6P?5C_ ( _G7I58OA;1SHNB1PR#_2) M#YDOLQ[?@,"MJO%QM95J[DMMON/I\KPSP^%C"6^[]6V:KIT>JZ9/92\"1OZ1[A:745[9PW4+ M;HY4#J?8U-7D_AKQ=-H8^S3(9[,G.T'YD/?;_A7>VOBW0[M RW\<9[K-\A'Y MUY.)P-6E)V5UW/HL%FN'Q%--R2EU3T^XVZ*S#XBT8#/]J6GX2BLV\\=:):@^ M7-)51+YK_ ()TM%<+I_CVXU#7;6U6 MTBBMII-AW$L_/3G@>G:NZHK8>I1:516N&%Q='%1KR'QK_R-U]_VS_\ 1:UZ&4?QWZ?JCQN(O]UC_B7Y,T/AS_R,-Q_U MZM_Z&E>G5YC\.?\ D8;C_KU;_P!#2O3JSS3_ 'E^B-L@_P!R7J_T"O$M=_Y& M'4O^OJ7_ -#->VUXEKO_ ",.I?\ 7U+_ .AFNC)_XD_1?F9?+\CTLE_W&'S_-A7@5 M>^UX%7H9/]OY?J>/Q+_RZ^?Z'IWPY_Y%ZX_Z^F_] 2NOKD/AS_R+UQ_U]-_Z M E=?7EX[_>9^O^1[V5?[E2]/\PIDO^I?_=-/IDO^I?\ W37*MST'L>"UZIX M_P"19'_79_Z5Y77JG@#_ )%D?]=G_I7T^:_[O\T?!\/?[V_1_H=37F_Q&LS' MJ5K> ';+$8R?=3_@?TKTBLCQ+HXUO1I;=<>>OSPD_P!X=OQZ5X>"K*C74GMM M]Y]9F>&>)PLJ<=]UZH\HT2_&F:U:7C?(]%1A[]JV^I5^1S<;)=SG>9X7VD:2G=MVTU_'8[. MBBBN0] **** "BBB@ HHHH \"KTCX;_\@N\_Z[C_ -!%>;UZ1\-_^07>?]=Q M_P"@BOJ\S_W9^J/SW(?]]CZ/\CM:***^4/T(\T^(\K'6K6$_<2WW#ZEB#_Z" M*P_#%K'>>)+&&5=R&3<0>^ 3_2NG^(]@Y>TU!5RNTPN?3G*_S:N+L+V33M0@ MO(L%X7# 'O[?C7UF$]_!I0WLU\]3\]S']UF;E5VNG\M#W2BLS2]?T[5X%DM[ MA Y'S1.P#J?<5;N+^SM(C)<74,2#N[@5\LZB^@]^M<001U&*^CRS"SHISG MI?H?%Y[CZ6(<:=+7EOKT/2/AO_R"[S_KN/\ T$5VM<5\-_\ D%WG_7U+_KUE_P#0#7B5>VZ[_P B]J7_ %ZR M_P#H!KQ*O5R?^'/U7Y'SW$O\6GZ/\SU[P5_R*-C_ -M/_1C5OU@>"O\ D4;' M_MI_Z,:M^O%Q/\>?J_S/J,#_ +K3_P *_(*9*_E1/(?X5+?E3Z0@,"",@\&N M<[&>#32O/-)-(VYY&+,?4DY->M^$8K1O"MHD2HZLI,H(SEL\Y_SZ5YQXAT*? M0]1>-D8V[,3#)V9?3/J*J6&JWVF.6LKJ2$GJ%/!^HZ&OK<31^MT5[.5NI^=X M'$O+L3+V\;O9]]]]>_XGJ\_A+0;A]SZ;$#_TS+(/R4BDA\(Z#;MN338R?^FC M,X_)B:\]7QMX@4C_ $_('8PIS^E3KX]UQ3DR0-[&(5YSP.-2LI_BSV5FV6-\ MSI6?^%'J<44<$8CBC2-!T5%P!^%/KS"'XB:LC#S8+65>XVE3^>?Z5TNC^.M/ MU&18+E#:3-P-YRA/^]V_&N*KE^(IKF:OZ:GJX?.,'6:A&5GYJW_ .JJKJ=K] MNTNZM>\L3(/J1Q5JBN&+<6FCU)14HN+V9X&RE6*L"&!P0>U>F?#W44GT>2Q) M_>V[D@>JMSG\\_I7.>-]"?3M4:]B3_1;EMV0.%?N/QZU@Z9J5SI-\EW:OMD7 M@@]&'<'VKZRM".-PWN]=5ZGY[AJDLLQK51:+1^CZ_DSW&BN6TSQYI5Y&JW3& MTF[AP2I/L1_7%:P\1:,1G^U+3_OZ*^9GAJT':47]Q]S3QN'J1YH35O5?K8TZ M*Q+GQ=H5L,MJ$;GTB!?^5<]J'Q'0973K(L?[]P<#_OD?XUI3P=>I\,7\]#*M MF6$HKWYKY:O\#O**H:)?MJFC6MZZJKRIE@O0'.#C\JOUS2BXR<7NCMA-3BIQ MV>IE>)O^19U'_K@U>+U[EJEJ;W2;NU7[TL+HOU(.*\-(()!&".HKZ#)VN22\ M_P!#X[B2+]K3ETL_S/9O"[!_#&GE3D>2!^7%:]>?^"O%%G:6']FW\JP[&)BD M;[I!.2">W.?SKJ+GQ5HEM$7;487_ -F([R?P%>5B<-55:246]>Q]!@L;0EAH M2E"<9Q4HNZ9XE MKO\ R,.I?]?4O_H9KK_AG_S%/^V7_L]!5Z=\.?^1>N/^OIO M_0$KS&O3OAS_ ,B]E\_T/5/ '_(LC_KL_P#2NIKE MO '_ "+(_P"NS_TKJ:\K&?[Q/U/H(?W0/UYQ[_\ UZU/'V@SW?EZG:QF1HTV2JHR=N<@X_$Y MKSR.1X9%DB=D=3E64X(/L:][#QC7P:IQ=M+'R&-G/"9FZ]2-U>Z\U;IZ'M=[ MH>EZB2UW8PR.1@OMPWYCFJ(\%^'E8$:>,@YYFD/_ +-7GD?C'7XE"KJ+D#^] M&C'\R*L)XZUY5 -S&Q]3$N3^0KC6 Q<%:,]/5GI/.,MJ/FJ4M?\ "F>G6>F6 M.GC%I:0PYZE$ )^IZU;KRQ?B#K2G)%JWL8S_ (UK6'Q'!95U"RV@]9(#T_X" M?\:YJF78GXFK_,[Z.=8%^Y%\ORLOP.]HJO97UMJ-JMS:3++$W1A_(CL:L5YK M33LSVXR4E>+N@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** /(]>T'5O[=OI$TZYDCEN)'1HXRX(+$ MCI]:Z3P!I5_8RWDUW:R0)(JJOF#:2:[BBO2JYC.I1]DXH\2ADU*CB?K" MDV[MVTZW_P PHHHKS3VPHHHH \P\8Z+J<_B6ZN8+"XFADV;7BC+@X0 ].G(- M7O 6D:A9ZK/=75I+!%Y!C!E4J22RGH?H:]!HKTI9A.5#V-EM8\2&34HXKZSS M.][VTW_IA1117FGMA7EOB[1-3E\274\-A<312E2CQ1EP?E [=*]2HKJPN)EA MY\\5445&(KNO M4=1JQI@\+'"T51B[I!6;K.B6>N6GDW2G**]> MGF]1*TXI_@?.5N'*,G>G)Q_'_@G@8!9@J@DDX '>KUOH>JW9 @T^Y;/?RR!^ M9XKVZBM)9Q+[,/Q,H<-03]^H_DO^"SS;1O 5^US%/J#);QHP8QAMSG';C@?G M7I-%%>7B,34Q$KSZ'O8/ T<)%QI==[A7GOCW2=0O-8@N+6SGGB^SA"T2%L,& M8XP.>XKT*BEAJ[H5.=*X\;A(XNBZ4G;;\#S'P=HFIP^)+:YGL9X88@Y9I8RG M52!C/7DUZ=1158K$RQ$^>2L3@,%#!TO9P=];ZA1117*=PR6*.>%XI4#QNI5E M89!!ZBO-M<\!WEK*TVF W%N3D1Y^=/;W_G7IE%=6'Q53#N\/N.'&X"CC(\M1 M:K9K='@\]K<6K;;B"6(^DB%?YT06MQ=/LMX)9F](T+']*]XHKT_[8=O@U]3P M?]6HW_B:>G_!/-=$\ W5RZS:H?L\/7R@BN19E6]JJCUMTZ'I/)<-]7=&-U>VO73^MCAOA_IE]93 M7LMW:S0(ZJJ^:A4DY/8\UW-%%M^$[B"Z3D73%)%^\AV)R/\*P=6\(:KI_<\#(*L58$$'!![5?L=#U/47"VUE,X/\97"_F>*]MHJY9Q*W MNP_$RAPU!/WZC:\E;]616K3K2YI MN[/H\/AJ6&A[.DK(****R.@YSQ%X1M=8!D/[,/Z_SKSZ_\*:SI M['S+*21 ?OPC>#^7(_$"O9**]##YA5HKEW7F>-C,FP^*ES_#+NOU1X))&\3; M9$9&]&QQ23/LBC9V]%&37O5%=W]L.WP?C_P \O\ U:5_XNGI_P $\7M? M#6LWA'E:=. >\B[!^;8KM_"G@^?1[W[?>3(90A58X^0,]R:[&BN2OF56K%PL MDF>CA,DP^'FJEW)KO_D@HHHKS#W"EJNEVVL6#VETI*-RK#JI[$5Y=JWA#5=+ MD;; US!VEA4G\QU'^>:]>HKMPN-J8?2.J['EX[+*.,UGI)=5_6IX(Z-&Q5U* ML.H(P15^PT+4]391:V*]LHKOEG$K>[#7U/(APW!2O.HVO2W^9 MRWAOP;;Z0RW5V5GO ../EC/MZGWKD_%.B:I+XCO)HM/N98I&#*\<9<$8'I7J MM%<5+'U8575EJWH>I7RBA5H*A'W4G?3];G)^ M/N[#2[@7=O) TDNY5D&"1@ M=JZRBBN6M5=6HZCZG?AJ"P]&-*+ND%9FNZ-#KFF/:2'8^=T^45[ M4,XDE[T;OU/F*G#=-RO"HTO-7_R/*O"6A:C+KEK=-:RQ6\+[VDD4J#CL,]:] M5HHKS<5B98B?,U8]O 8&&"ING%WN[G,>.K"ZO]"C2T@>9TN%=E09.W:PSCOU M%>>0^'=9GE6-=,NU+'&7A90/J2*]JHKHPV83H4_9Q29QXW)J6+K>UE)K;33H M%%%%>:>V-DC26-HY%#HP(96&01Z5Y[KO@&9)>C$D9Y,#-AE^A/4?7]:]$H MKIP^)J4)7@SBQ>!HXN/+57H^J/"[G3KVR)%U:3PX."7C('YU756=@JJ68] ! MDU[Y17J+.';6'XG@2X:C?W:FGI_P3QFQ\,:QJ# 16,JJ?XY1L4?G_2N\\-># M8M&F6\N91-> 87;]Q,]<>I]ZZJBN3$9C5K+EV7D>E@\EP^&DIZRDN_\ D%%% M%>:>T%%%% !7->.-.NM2T)([.$RR1SK(47J1M8A91^9&*]DLXFAL;>)_O)&JG'J!BIZ*ZL7C98 ME)-6L<.7Y9#!P4445PGJA1110 4444 >1:[H6K'7;]TTVZ=)+AW1H MXBP*EB0 M)A\FI4,3]84FWKIIUO\ YA1117FGMG@5=[X1T6SUOPG<072W6XG M-I=K7_R/$K'0]3U%PMM93.#_ !E<+^9XKT'PUX,BTEUO+UEFO!R@'W8_IZGW MKK**Y\1F56LN5:([,'DF'PTE-^])=]E\@HHHKS#W K%U_P -6>O0CS,Q7*#" M3*.1[$=Q6U15TZDJ-O1U(/ZU[S17KPS>:5IQ3_ ^H07]_*B>4=RQ(=Q)]ST_G7>T45Y5?$3KRYIGOX3!TL)#DI+0*\P\8Z+J<_B M6ZN8+"XFADV;7BC+@X0 ].G(->GT5>%Q,L//GBKF>/P4<925.3:L[Z'GW@+2 M-0L]6GNKJTF@B,!C!E0J22RGH?H:]!HHJ<37=>ISR5B\%A(X2BJ47??\0KR+ M7="U8Z[?NFFW3I)<.Z-'$6!4L2#D5Z[15X7%2PTG**O*2>'M9BD9&TN\)4X)6%F'Y@8->UT5OA,9+#7Y5>YR9AEL,;R\TFK7VMU.:\ M#:?=:=H3QW<+0O).T@1N#C:HY';H:Z6BBN>K4=6;F^IVX>A&A2C2CLE8*:X+ M1LHZD$4ZBLC<\4D\/ZS%(R-I=X2#@[868?F!@UZ5X+LKFP\/K%=0M%(9&;:W M7!Q70T5Z.)S">(AR-)'BX')Z>#JNK&3>EM;!1117G'M'.>(O"-KKF9XV$%X! MCS ,A_9A_7^=>?7_ (4UG3V/F64DB _?A&\'\N1^(%>R45Z&'S"K17+NO,\; M&9-A\5+G^&7=?JCP22-XFVR(R-Z,,&ECBDF?9%&SMZ*,FO>J*[O[8=O@_'_@ M'E_ZM*_\73T_X)XO:^&M9O"/*TZ< ]Y%V#\VQ7;^%/!\^CWOV^\F0RA"JQQ\ M@9[DUV-%)@\FI82M[:,F]^W4****\T]LKWME!J%G+:7*!XI!AA_4>]> M9:SX(U+3Y&>T1KNVZ@H/G ]U[_A7JM%=>&QE3#OW=NQYV.RZCC%^\T:V:W/! MI8)8'V31/&WHZD']:DM;"[O6VVMM-,G_!//M!\ /O2XU@@*.1;HC&E%W2*>K0R7.C7T$2[I)+>1$7U) M4@"O'SH&L!BO]E7N0P\-V=M-KE[;PO<;#@RE8\^Q//Z BG2I^TFH=V3B*JHTI5'T39POBCQ M/-KEP88B4L8V^1.A<_WC_A2^&/"LNO.TTKM#9H<%QU8^B_XUSE>Y:9:1V.F6 MUM$ $CC X[G')_$U]'C*OU.BH4E:_P#7WGQ>6X=YEB95L0[I=/R7H:ZE\ M/+VVB:6RN5N@N3Y978V/;D@G\JXUE*L58$,#@@]J]\KQCQ.8CXFU#R<;/./3 MU[_KFO8R[&5*S<*FMNI\WG66T,-&-2CI=VM_D=UX"UB2_P!,DLYV+2VI 5CU M*'I^6#^E=;7G7PV1C?7[C[HC4'ZDG'\C7HM>1F$(PQ$E$^BRBK.I@X2GOJON M9#=6L%[;26US&LD4@PRGO7G>L?#^[@D:72V%Q">1$Q =?QZ']*]*HK/#XJK0 M?N/3L;XS 4,6K55JNJW/#+G3;ZS+"YLYXMO4O&0/SJK7OM%>FLX=M8?B>#+A MJ-_=J?A_P3PR#3;ZZQY%E<2YZ%(B16Y8>!=9NV!FB2UC[M*W/Y#G\\5ZO16< M\WJOX(I?B;TN'*$7>I)R_ J:98IIFFV]DC%UA3;N/?WJW117CR;DVV?1QBHQ M48[(*\^\5>#+A[N34-+C\Q9#ND@'#!NY7U!]*]!HK?#XB="?- Y<9@Z6+I^S MJ?+NCP>>VGMGV3PR1-Z2*5/ZTZWL[J[;;;6TLQSC$:%OY5[M17J_VP[?!KZG MS_\ JU'F_B.WI_P3"\(Z;<:5H$4%TNR9F9V3.=N>@K=HHKQ:DW4FYO=GT]&E M&C3C3CLE8\BUW0M6.NW[IIMTZ27#NC1Q%@5+$@Y%=5\/]+O=/BOI+NVD@$QC M""1=I.-V>#]179T5WU\%V5S8>'UBNH M6BD,C-M;K@XKH:**YJM1U)N;ZG=0I*C2C3CLE8Y#QEXI;2E^P638NW7+O_SS M4^GN?TKSNQL;G5;^.UMU+S2'N>GJ2?2GZQ:S>7#G)>9L?3. /RQ7;?#>T MC%K>7A ,I<1 ^@ S^N?TKZ11C@L+S16NGWO_ "/B92GFF/\ 9R=HIO[E^K_K M8EB^'%@(D\Z]N3)CYBFT#/MD4I^&]AGB^N8VWUVXY_7%=^!Q]:=54YNZ9Y&:Y3AJ>'E6I+E:^YG-^#]8D MTO6X8BQ^SW+".1>V3P#^!_3->N5X7IR-)J=HB?>:9 ,>NX5[I49O"*J1DMVC M3ARK.5&<'LGI\T%%%%>,?3!1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !7@5>^UXI+X>UF*0HVEWA(_NPLP_,<5[F43C'GYG;;]3Y3B.G. M:IN*;WV3?8[SX<_\B].[A:%Y)VD"-P<;5'([= M#72UYN,:EB)M=SV\MC*&#IQDK.W^84445RGH!1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M'@5>G?#G_D7KC_KZ;_T!*X.7P]K,4A1M+O"1_=A9A^8XKT;P-I]UIVA/'=PM M"\D[2!&X.-JCD=NAKZ?,ZD)8>R:>JZGPF14*L,9>46K)[I^7D=+1117S!]V% M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8WBG3I-3\/7,$(S* )$' MJ5.\$V>JRO2NFO-;H]&C\3:)*@9=3M@#_>?: M?R-*_B318UW'5+4C_9D!/Y"O)VT#6$8J=*O2? MK7GOSRR?Q.[GZDDUTEEX$UJZ8>;'';)W,K@G\AFNVT+PA8:*RSDFXNATE<8" M_P"Z.W\ZU5?"X.#5-W?]=3G>$S#,JBE77+%=]+>BW'>$=%;1M&"S+BYF/F2C M^[Z+^ _4FM^BBOGZE252;G+=GV5"C&C3C3AL@HHHK,U"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&/$NG2:9KUU$ MZX1W,D9QP5)R/\/PJQX9\2R>'[B0-&9;67&] <$$=Q7IVL:)9:W:^3=HRK:/\ KJ?%8K+,5A,0 MZ^%U5[Z;J_1KJCLK3QAH=VH(OEB;NLP*$?GQ^M6O^$AT;_H*6G_?Y:\IF\-: MW!]_3+D]OD0O_+-1?V%J_P#T"K[_ ,!W_P *S>6X9ZQJ?BC59WCHZ3HZ^DO\ MCTF_\;Z-9H?*G-U)V2(''YGBO.-;UJYUR_-S<84 ;8XU/"#_ #WJU;^$-=N6 M %@Z _Q2$*!^9S73Z3\.TC=9=4N!)CGR8L@?BW7\L5I3^IX/WE*[^]_@8UGF M696@XE0C MSU9)+S.@HK%T7Q1I^NRR16HE25%W%)5 )&<9X)]16U2G3E3ERS5F.E6IUH\] M-W7D%%%%0:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8FM> M*=/T*=(+H3/*Z;PL2 \9(SR0.QJZ=.527+!79E5K4Z,>>H[+S-NBN?TCQAIF MLWHM(%GCF8$J)4 W8&3C!/:N@IU*4Z;Y9JS%1KTZT>>E*Z\@HHHK,V"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHJMJ%_!IEC+>7+$0Q@;B!D\D ?J132*=/T*=(+H3/*Z;PL2 \9(SR M0.QJ+2/&&F:S>BT@6>.9@2HE0#=@9.,$]JW6'JN'M.5V[G(\;AU5]BYKF['0 M4445@=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%86L^+-.T. MY%O;:QQ_N/_ /%5@:[_ ,C#J7_7U+_Z M&:J);R/;2W"KF.)E5CZ;LX_D:^MI8+#JG&\5LC\[KYIC76FHS:2;T79-^7D> MJ>&O%L.O,UO)$(+M1N" Y#CU'^%=)7AVE7[:9JMM>KD^4X) [CH1^6:]OCD2 M6))(V#(X#*1W!KQ,QPL:$TX;,^HR;'RQ=)JH_>C^*Z,=1117FGN!1110 5RG MB;QDFC3_ &.TB2>Z RY<_+'Z XZG\JZ2]NH[&RFNI3^[B0N?PKP^[N9+R[FN M93F25R[?4FO5R["1K2!G683PM-0I.TI?@CJ?^%C:O_P ^UC_WP_\ M\571^%/%LNNW,MI=01QSJF]6BSM89P1@YP>1WKS.XMI+8QB4 &2-9 /8\C]* MZ/X?_P#(S#_K@_\ 2O3Q6$PZH2E"*32/"R_,<8\7"G4FVF[-/_ACU2BBBOES M[P**** "BBB@ HHHH **** "O(?&O_(W7W_;/_T6M>O5Y#XU_P"1NOO^V?\ MZ+6O7RC^._3]4?.<1?[K'_$OR9H?#G_D8;C_ *]6_P#0TKTZO,?AS_R,-Q_U MZM_Z&E>G5GFG^\OT1MD'^Y+U?Z!117'>-O$&H:/):Q6,JQ>:K,S; QX(]>*X MJ%&5::A'=GJ8K$PPU)U9[+L=C17F_AOQ;K%YKMM:W5PLT4S;2#&H(X/0@"O2 M*O$8:>'ERS,\%C:>,INI3O9.VH4445S':87BO6Y-"TD30*K3R.(TW=%X))Q^ M%< OCCQ L@8WJL,YVF%,?RS7<>-=(N=6T=!:)YDT,H?8#RPP0QZWH>I?VO MHUM>E0K2*=RCH&!(/ZBM"LOP[ITFE:#:V7VDN3 M:[L?58=S=&+J?%97];!11169L%%%% !1110 4444 %>8_$;_ )&&W_Z]5_\ M0WKTZO,?B-_R,-O_ ->J_P#H;UZ>5_[RO1GA9_\ [D_5?J9_@K_D;K'_ +:? M^BVKUZO(?!7_ "-UC_VT_P#1;5Z]6F;_ ,=>GZLQX=_W67^)_D@HHHKR#Z,* M*** "BBB@ HHHH **** "BBB@ K(\2:Q)H>D->11+*^\( QP.>]:]H;'IFO!:]WM/^/.#_KFO\J]+-*%*DHNG&U[GAY#BZ^(=159-VMO M\R:BBBO%/IPJO?7/V+3[FZV[_(B:3;G&=H)Q^E6*S]=_Y%[4O^O67_T U=-) MS2?=?FC.K)QIRDMTG^3.#;XC:J7)6ULPOH58G\]U=SH&J-K.C07SQ"-GW JI MR."1_2O%:];\#_\ (IVO^\__ *&:]S,L-1I4E*$;.Y\IDF.Q%?$.%6;:M?\ M%>1T55M0NUL-.N+MEW"&-GV^N!TJS5/5;,W^DW=HI ::)D4GH"1Q^M>%"W,N M;8^LJSMZVT/,9O'.OR2LR7:1*>B)$A _,$UVG@WQ#<:Y:W"7>SSX"N M648W*#7GE6MU/>1&*2J_,X\= M_NM3_"_R/(:]MT+_ )%[3?\ KUB_] %>)5[;H7_(O:;_ ->L7_H KVLX_AP] M7^1\OPU_%J>B_,T****^=/M HHHH **** "BBB@ HHHH I:M>OIVDW-Y'&)& MA0N%)QFO/C\1M7SQ;6./]Q__ (JO2Y8DGA>&091U*L/4'@UX=J%F^GZC<6DF M=T,A3GN!T/XBO9RRE1JJ4:D;M'S.?5\30<)TIM1=UIW^[L>O>'=:77=*6[V" M.0,4D0'(##_ZQ%:U>;_#K4/*U&XL'/RSIO0?[2]?T/Z5Z17#C:*HUG%;=#U< MLQ3Q.&C4EOL_5!1117(>B%%%0W=REG9S7,IPD2%V^@&::3;LA-I*[.-\1>.+ MG3-6DLK*"!Q%@.\H)R<9(&"*E\+^+[_6]6-GAV]%%%?.GV@4444 %%%% !1110!YC\1O^1AM_\ MKU7_ -#>L_P5_P C=8_]M/\ T6U:'Q&_Y&&W_P"O5?\ T-ZS_!7_ "-UC_VT M_P#1;5]53_W#_MU_J?G];_D;_P#;Z_0]>HHHKY4_0 HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y7Q9XIN=!G@@MH(G:1"Y:7) MYQC Q_.NJKS?XD?\A2S_ .N)_P#0J[L!3A4KJ,U=:GE9O6J4<)*=-V>GYES0 M?'-_J6L065S;6VR9MNZ,,I7@^I.:[RO&_"?_ "-.G_\ 70_R->R5KF=&%*JE M!6T.?(\35KT)2JRNT_T"BBBO,/="BBB@ HHHH **** "BBB@ HHHH **** " MO*_B!_R,Q_ZX)_6O5*\K^('_ ",Q_P"N"?UKU,J_WCY,\#B#_<_FOU#X?_\ M(S#_ *X/_2O5*\K^'_\ R,P_ZX/_ $KU2C-?]X^2#A__ '/YO]!&8(I8\ #) MKRJ\\=ZU/C @UXW=^&-9M+AX3I]Q*%) M >*,NK#UR*O+(T9.7M+7Z7,\]J8J$8>PO;6]K_+8[3P9XHO-7N9K.^9'D2/S M$D"A20" 0<<=Q795PG@30+ZRO)K^\@> &+RT2088Y()..W3]:[NN7'*FJ[5+ M;R._*95Y86+KWYM=][= HHHKB/4"BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HKS?Q)XMUFSUVYM;6Y6&*%MJ@1J<\#KD&MCP3X@U#6)+J&^D67RE5E< M(%/)/IQ7?/ 584?;.UCR:6;4*F)^K)/FNUMII\SL****X#U@KB_&7BF\TF\C ML; JCF/S'D*AB,D@ \=J[2N \=:!?W>I1WUG;//&8@CB,;F4@GMUZ'MZ5W8 M!4W72J[>9Y6;RKQPK="]]-M[=3)L/'>LPW<;7W<<+6%Q"A8;Y)8R@4=SS7L8 '05TYG&C&4?96OUL<613Q,H M3]O>VEKW^>XM%%%>0?1!1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 >):[_R,.I?]?4O_H9K>\&Z>NJ:=K=FV,R1(%)[,"Q!_/%8 M.N_\C#J7_7U+_P"AFNL^&G^NU+_=C_\ 9J^LQ4G'"8""GF/++9N M2_\ 2CA'1D=D<%64X(/8UZIX$U3[=H0MG;,MH=A]=I^[_4?A7'>-],^P>()) M47$5T/-7'3=_$/SY_&D\%:G_ &=XAB1VQ#<_NFR>Y^Z?SX_&IQ45BL+SQ]?\ M_P!33 3> S#V4]K\K_1_E]YZU1117RI]^%%%!( ))P!0!Q/Q$U3R;&'34/S3 MG?)_NCI^9_E7#Z-IS:KJ]M9J#B1QO([*.2?RS4OB'4SJVN7-T#F/=LB_W!P/ MSZ_C76?#K3,)T5P7@[Q-JNJ:P;2]G6:,QLP/EJI!&/0"N]HQ%"5 M"?)+<,'BZ>+I>UIWMMJ%>0^-?^1NOO\ MG_Z+6O7J\A\:_\ (W7W_;/_ -%K M7H91_'?I^J/'XB_W6/\ B7Y,T/AS_P C#K?^AI7IU>8_#G_D8;C_ *]6 M_P#0TKTZL\T_WE^B-L@_W)>K_0*\[^)/_'Y8?]_G\YHP0IV*N ?H!79@QNH[FV?9-&IZ]17E M%EXUUTWUN)KP21F10R&)!D9Y&0,UZO7B8G"3P[2GU/JL#F%+&J3IIJW<**RO M$FH3Z7X?NKRVV^=&%V[AD#+ ?UKS=?&_B!6!-\& [&%,'\A5X? U,1%R@T98 MW-:&#J*G43NU?3_ASUVBJVG7+7FEVETX ::%)"!T!*@_UJS7$TTVF>G&2E%2 M74**Y[QEJUWH^C1SV3JDKS"/<5#8!5CQGCL*Y?PYXLUF]UZUM;JZ66&5BK*8 ME'8]P!792P52I2=56LK_ ('G5\SHT<0L/)/F=O37;J>DT5CZYXDL="B_?L9) MV&4A0_,?<^@]Z\^U#QQK-[(?)F%K%V2(<_BQY_E3P^!K5US)67=BQF:X;"OE MD[R[+]>QZS17B0U[6 0?[5O>/^GA_P#&M?3?'6KV3*,H-QD MK,^AA.-2*G!W3"O,?B-_R,-O_P!>J_\ H;UZ=7F/Q&_Y&&W_ .O5?_0WKTT7R8_+FO3HY97J*[T7G_D>'B<\PM&7*KR?EM]Y M['17B0U[6%8$:K>Y!SS.Q_K6M8>.M9LW'G2)=1YY65<'\"/ZYK6>454KQ:?X M'/3XBP\G:<6ON?Y'J]%9&A^(K+7H"T!*3*/GA?[R^_N/>M>O*G"4)/\ _D63_P!=D_K74URWC_\ Y%D_]=D_K75@ M_P#>(>IPYC_NE3T9Y77N]I_QYP?][VG_ !YP?]U+_KUE_\ 0#6E+^)' MU7YHQK_PI^C_ "9XE7K?@?\ Y%.U_P!Y_P#T,UY)7K?@?_D4[7_>?_T,U]'F MW\!>O^9\5P[_ +T_\+_-'14445\P?=A17DDGCCQ \C,MXL8)X184P/S!-=WX M/U>ZUG1GGNRIECF,>Y1C< PT5Y#_P )KXA_Z"'_ )!C M_P#B:?%XXU])59[Q9%!R4:% &]N #4_V37[K^OD:+B+"W^&7W+_,];K \:_\ MBC??]L__ $8M;R-N16QC(S6#XU_Y%&^_[9_^C%K@PW\>'JOS/6QW^ZU/\+_( M\AKVW0O^1>TW_KUB_P#0!7B5>N1:W9:)X5TV:[DY-I%LC7EG.P=!7N9M&4XP MC%7=_P!#Y3AZI&G.K.;LDE^9T-%>5ZGX[U6\W^-<<,IJM7DTCU*O$6&C*T(N7GHOS/;:*\HT[QSK%E(//E%W%W M24 '\&'/YYKT?1]9M-;LAA@LTP^+?+!VEV M?]:FA1117$>F%%%% !1110 5YI\0].\C5(;]%PEPFUSC^)?_ *V/RKTNL#QC MIW]H^'+@*N9(/WR?AU_3-=N!K>RKQ?1Z?>>9FN'^L82<5NM5\OZ9Y9I=ZVG: MK;7B_P#+*0,?<=Q^6:]Q1UD170@JPR".XKP.O7/!6H?;O#<"DYDMR86_#I^A M%>IF]*\8U%TT/ XQP MWZ38KIFDVUFH'[J, X[MU)_/->7^"].^W^ M(X&9K>4:2Z:GF<.8>U.5=]=%\M_Q"BL;6_$VGZ& MNV=S).1D0Q\M]3Z"N'O_ (@:KOB\U MPV%?+.5WV6O_ QZC17BLGB'697W-JEV#_LS,H_(4L7B/6H6W)JET3_MREQ^ MN:[?['J6^)?B>7_K)0O\#M\CVFBO-=*^(5[#(J:E&MQ%T,B *X]\=#^E>AV= MY;W]I'=6L@DAD&585Y^(PE6@_?6G<]C!YA0Q:_=/5='N3T445RG>>8_$;_D8 M;?\ Z]5_]#>L_P %?\C=8_\ ;3_T6U:'Q&_Y&&W_ .O5?_0WK/\ !7_(W6/_ M &T_]%M7U5/_ '#_ +=?ZGY_6_Y&_P#V^OT/7J***^5/T **\W\2>+=8L]=N M;6TN%AAA8* (U8G@=20:U?!/B+4=7N;F"^E64(@=6V!3UQVP*[YX"K&C[9VM MN>33S:A4Q/U9)WNUMII\SLZ***X#U@HHKS?Q)XMUFSUZZM;6Y6&&)MJ@1*<\ M#J2#73A\-/$2<8'%C<;3P=-5*E[-VT/2**X[P3X@U#6);N*^E67RE5E;8%/) M/I@5V-17HRHS<);HTPN)AB:2JPV?<***@N[RWL+5[FZE6*%!DLU9)-NR.AM1 M5WL3T5YUJWQ#GD=H]+A6)!QYLHRQ^@Z#\55IJ\K(\"OG^%IOE@G+TV_$]IHKQ6+Q%K,3[EU2[)_VY2P_(UOZ7\0;ZW=4 MU&-;F+NZ@*X_H?TIU,IK15XM,5'B'#3=IIQ_%?@>ET56L-0MM3M$NK2421-W M'4'T([&K->4TXNS/?C)22E%W3"BBBD4%%%% !7F_Q(_Y"EG_ -<3_P"A5Z17 MF_Q(_P"0I9_]<3_Z%7I99_O*^9XN>_[C+U7YF'X3_P"1IT__ *Z'^1KV2O&_ M"?\ R-.G_P#70_R->R5MF_\ %CZ?JWTK>I@ZL*OLDKOR.6C MF6'J4'B&^6*TU.AHKR"^\8ZW?.3]L:!#T2#Y,?CU_6JO@\?0Q<;TGJMT]R2BBBN8[@H MI"0 23@#J37#ZYX_2"1K?2464KP9W^[G_9'?ZUO0P]2O+E@CEQ6,HX6'/5=O MS?H=S17C%QXGUNY;<^IW"^T;[!_X[BD@\2ZU;OO34[HG_II(7'Y-D5Z7]D5; M?$OQ/#_UDH5_$#_D9C_UP3^M;F@^/DG=;?5E2)CP)UX4_P"\ M.WU_E6%X^(;Q)D$$&!""/QJL!AZE#%JWW0OP__P"1 MF'_7!_Z5ZI7E?P__ .1F'_7!_P"E>J5AFO\ O'R1U7ZSXQ MUN#6;R""Z6**&9XU58E/"L1W!.:Y<-A9XB34.AZ&-Q]+!Q4JB>NFAZA17*>" M=>OM:BO$OG61H"FUPH4G=NZXX[5U=95J4J,W"6Z-\-B(8FDJL-F%%%5=0U&U MTNT:YNY1'&./=CZ =S6<8N3LMS:4E%.4G9(M45YIJGQ"OKAV33HUMHNSL SG M^@_6L"7Q%K,S[FU2[!_V)2H_(5ZM/*:TE>32/ K<0X:#M!.7X+\?\CVJBO%X M/$VMVS934[DG_IH^_P#]"S73Z1\0Y!(L6JPJ4/'G1#!'U7O^'Y4JN5UH*\;, MJAG^%JOEG>/KM]Z/0:*9#-'<0I-"X>-U#*PZ$&GUY6Q[R=]4%%UEYGD8G. M<+AWRM\S\O\ /8]:HKQ(Z]K#,2=5O5;?5HTB+<"=/NY_VAV^M=SU&17F5 M\/4H2Y9H]W"XRCBH<])W_-!15>_N?L>G75UC/DQ/)CUP"?Z5Y4?&WB'/_(0Q M_P!L8_\ XFM<-@ZF(3<+:=SFQV9T<$XJHFV^Q!XL_P"1IU#_ *Z#^0KH/AM_ MQ^7_ /US3^9KC+N[GOKJ2YN7WS2'+-@#)^@XJQINL7^CO(]A/Y+2 !CL5L@? M4&OI*M"4\-[%;V2_(^)P^,A3QWUEI\MV_/6_^9[?17D/_":^(?\ H(?^08__ M (FM_P (>)]5U+7!:7UP)HGC8@>6JX(YSP!7A5.YKAHTI5IJ$=V>KB< M1##4G5GLCK**\PT7QEK4VLV<%S'DHSZF M."Q]+&0QZ[17B7]NZO_T% M;[_P(?\ QJS;>*]=^*O%6KZ?X@N+.TN5AAB"X C4DY4'G(/K6WX*UN]U>R MNGOY5D:%P ^T+P1WQQ7;/!5(456=K:?B>72S2C5Q+PT4^97]--^IU-%<5KOC MV&TD:VTM%GD'#3-]P'V]?Y?6N-N?$^MW3[GU*X7GI$^P?^.XK:CEE:HN9Z+S M.?%9YAJ$N2-Y/RV^\]GHKQ>#Q-K=NVY-3N2?^FC[Q^39KLO#WCM;R9+35%2* M1CA)EX5CZ$=OKT^E%;+*U./,M5Y"PN>X:O)0=XM]]OO.VHHHKS#W0HHKC_$/ MCF'3I7M-/1;BX4X=V/R(?3CJ:VHT)UIFLHJ6UDOQ/"EQ)03LH-KY'MM M%>26?C?7+5P7N5N$'\$J _J,']:],T;4AJ^D6]\$V>:IRN6QZ>"S2AC&XT[IKHR_1117$>F%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110!XEKO_ ",.I?\ 7U+_ .AFNL^&G^NU+_=C_P#9JY/7 M?^1AU+_KZE_]#-=9\-/]=J7^['_[-7U>,_W)^B_0_/LM_P"1FO67_MQL^.], M^VZ";A%S+:-O'KM/#?T/X5Y6K%6#*2&!R".U>]2QI-$\4@W(ZE6'J#7A^J6+ MZ9JES9OUBQ:'J(U;1K: M\!^9TPX]&'!_6M"O/OASJ>V6YTQVX8>;&/?HP_E^1KT&O'Q='V-:4.G3T/I< MNQ/UG#1J==GZK<*Y_P 9ZI_9OA^4(V)KC]RF/?J?RS705Y5X[U3[=KIMT.8K M0>6/]X\M_0?A6F H>UKI/9:F.;XKZOA9-;O1?/\ X!S,<;S2I%&I9W8*H'F?;==^TN,Q6B[_\ @1X7^I_"O5*[ M6B]%_P?R/)_'G_(TS?]O5Y#XU_Y&Z^_[9_^ MBUJ\H_COT_5&?$7^ZQ_Q+\F:'PY_Y&&X_P"O5O\ T-*].KS'X<_\C#K? M^AI7IU9YI_O+]$;9!_N2]7^AS6H^!]*U*^ENY)+F.24[F$3J 3Z\@UQ7B[P_ M::!<6L=K),XE5F;S6!Q@CI@"O6J\[^)/_'Y8?]R5OF>(JTJB4)6T.3(\%AZ]"4JL$W?KZ+S.6M M? .D6MU%.);N0QL&".Z[21ZX4&NIHHKQ:E:I5=YNY]/0PU&@FJ44K]C \:_\ MBC??]L__ $8M>0UZ]XU_Y%&^_P"V?_HQ:\AKZ'*/X#]?T1\;Q%_O4?\ "OS9 M[;H7_(O:;_UZQ?\ H K0K/T+_D7M-_Z]8O\ T 5H5\[5_B2]7^;/M*'\*'HO MR1R'Q&_Y%ZW_ .OI?_0'KSJPO9=.OHKN$+YL1)7<,C.,5Z+\1O\ D7K?_KZ7 M_P! >O,:^ERQ)X:S[L^'SV3CC^:.Z4?U+L4-_KNIE4#W%W,V6)_F?05WFE_# MRSBC5]2E>>4CE(VVH/QZG]*V_#OA^#0;$(H#W+C,LN.I]!["MFO-Q68RD^2B M[11[F7Y+3A'VF)7--]]E_F^YR]SX!T2:(K"DL#]G60G]#FO/-;T2YT*^^S7& M&5ANCD4<./\ 'VKVNN<\;ZSJRN@92"K#(([B MO Z]A\'W9O/#%FS'+1J8C_P$X'Z8KJS>BK1JKT?Z'!PYB7>6'>VZ_4W*\Q^( MW_(PV_\ UZK_ .AO7IU>8_$;_D8;?_KU7_T-ZXLK_P!Y7HST\_\ ]R?JOU,_ MP5_R-UC_ -M/_1;5Z]7D/@K_ )&ZQ_[:?^BVKUZM,W_CKT_5F/#O^ZR_Q/\ M)!7 >//$+B0Z/:R%1C-PRGKGHO\ C_\ KKNKJ=+6TFN)/N1(7;Z 9KPRYN)+ MNZEN)3F25R['W)S1E>'52HZDMH_F&?XR5&BJ4'K+\O\ @EC2],N-7OX[.V7+ MMR6/11W)]J],TOP3I-A$OGPB[FQ\SR],^R],?G53X?:88V;J.G!V2%D^5TH48UJL;REKKT70RI/#6BR(4;3+8 _W8PI_,+:C:_8M2NK7G$,K(,]P#BN_^'%V9-,N[0MGR90X'H&'^*FO8S2E& M=%5ENOR9\UD.(G2Q$L-+9W^]':T445\V?;!1110 5RWC_P#Y%D_]=D_K74UR MWC__ )%D_P#79/ZUU8/_ 'B'J<.8_P"Z5/1GE=>T6NN:2MI"K:I9 A%!!N$X MX^M>+T5]-B\)'$I)NUCX3+\RG@G)QBG>V]^A[;_;ND?]!6Q_\"$_QH_MW2/^ M@K8_^!"?XUXE17#_ &/3_G?W(]7_ %EJ_P#/M?>SVW^W=(_Z"MC_ .!"?XU2 MUG6=+ET+4(X]2LW=[:1559U))*G S7C]%5'*81DGS/3T(GQ%5G%Q]FM4UN^ MH5ZWX'_Y%.U_WG_]#->25ZWX'_Y%.U_WG_\ 0S5YM_ 7K_F9\._[T_\ "_S1 MT5%%%?,'W9X%7IWPY_Y%ZX_Z^F_] 2O,:].^'/\ R+UQ_P!?3?\ H"5]5FG^ M[/U1^?Y!_OJ]'^AU]8WBC5VT;0Y;B,@3N1'%GLQ[_@,G\*V:X/XER,(M-C!^ M5FD8CW&W'\S7S^#IJI7C%['V.95Y4,).I'>WYZ' $M(Y))9V.23R2:])T#P- M9V]LD^IQ^?QFF)G3M3@[ M7/F\@P5*JI5ZJO9V5_ON9;^&]%D0J=+M0#_=C /YBN%\6^$4TB'[=8EC:[L. MC')CST.?3M7IU9^O1+-X?U%&QC[.YR>@(4D&O+PN+JTZBU;1[V/R^A6H27*D MTG9I)?Y'C-G]F^UQB\\W[.6PYB(# >HR#7I$'P_T7=',)KN5.& :1=K#\%!K MS"O9_"\C2^&-/9NHA"_@.!_*O8S2=2G&,H2:Z'S>0TJ->J_,^MQW^ZU/\+_( M\AJR/MFJ74,*^9/-M6*)1SA0, #T '^-5J]7\&Z!;Z;I<-Z0)+JYB5RY'W5( MR%']:^IQ>)CAX<[5WT/@,NP4\95]FG:.[]#-TGX>6Z1+)JDK22$9,49PJ^Q/ M4_ABM"Y\ Z)-$5A26!^SK(3^AS7445\U+&XB4N;F9]U#*\'"')[-/UU?WGB> MMZ-<:'J#6L_S#&Z.0#AU]:M^$]5?2M>@;<1#,PBE';!/!_ \_G79?$.S6;1( MKK \R"4#/^RW!'YXKS$'!R.M?18>I];P_O\ 71GQ>-HO+\;^[V5FO3M^:/?: M*BM9/.M(9?[Z*WYBI:^2:L['Z(G=7"BBBD,**** "D8!E*D9!&"*6B@#Q#6; M Z7K%U9D'$1^F*Z/X>:AY&KS63-A+E,J,_P 2\_RS^56?B-IVRXM= M10<2#RG^HY'Z9_*N.T^\?3]1M[N/.Z&0-CU'YN99Y#F25R['W)R:]-\?ZA]ET);56P]TX7K@[1R?Z#\:\R@A>XN(X M(QF21@BCU).!7TF4TN6FZCZ_DCXGB&NZE>-"/3\W_P #\STGX>Z=]GT>6]8? M/.ZGIVHZCXIOX(H)9KCSWX Z#/&3T QBNBTWX-252K[S;;UVW_ !.<7P+H*J ;61CZF9LG\C5/ M4/A[IL\1-E));2@<9;>I^N>?UKKZ*Y8XS$1=U-G=++<)*/*Z:^ZQX3>V<^GW MDMIIO'?3Z:[$QRKYB ]F'7'U'\JC^(UNJ:O:SC@RPX/U!Z_ MK^E8_A!RGBNP(_OL/S4BOHIR6)P;D^JO\U_PQ\92@\%F:IQ>BE;Y/_A_P/8J M***^3/T(\Q^(W_(PV_\ UZK_ .AO6?X*_P"1NL?^VG_HMJT/B-_R,-O_ ->J M_P#H;UG^"O\ D;K'_MI_Z+:OJJ?^X?\ ;K_4_/ZW_(W_ .WU^AZ]1117RI^@ M'C?BS_D:=0_ZZ#^0K<^&_P#R%+S_ *XC_P!"K#\6?\C3J'_70?R%;GPW_P"0 MI>?]<1_Z%7U5?_D4445\J??!7C?BS_D:=0_ZZ#^0K MV2O&_%G_ "-.H?\ 70?R%>QE'\67I^I\WQ'_ +M'_%^C.@^&W_'Y?_\ 7-/Y MFO1*\[^&W_'Y?_\ 7-/YFO1*PS+_ 'F7R_(Z\C_W&'S_ #$) !). .I->1>* MO$$FMZBRQN190G$2=C_M'W/\J[[QG?FP\-7!1MLDY$*GZ]?T!KR*N[*<.FG6 M?HOU/*XAQDDUAHOS?Z+]3=\-^&9]?G8[_*M8SB23&KE^54 M<^)O#4N@7"E7,MI*3Y-J4ZB4G=,69991K492C%*2 M5TUIMTT/-_"NNOHNJH6<_9)B%F4] /[WX?RS7L'49%>!5[1X:NS>^'+&=FW- MY01B>Y7Y3_*NS-Z*7+57HSS.'<5)J6'D]M5^O^9JT445X)]:%%%% !7F_P 2 M/^0I9_\ 7$_^A5Z17F_Q(_Y"EG_UQ/\ Z%7I99_O*^9XN>_[C+U7YF'X3_Y& MG3_^NA_D:]DKQOPG_P C3I__ %T/\C7LE;9O_%CZ?J8_/\CMSK_<9_+\T<7IVI7&EW)N M;4A9MC(K$9VY&,_6IM+TF^UZ^,5N"[$[I)7/"Y[D_P"T:3I-KHUBEK:IA1RS'J[>IKW,;BHX97BO>9\KE6 EC7:;_=Q_ M-]OU9@V/P_TF"("[,MS)W.XH/P _QJ+4_A]I\T+-I[O;S ?*K,60_7/(KL:* M^?6-Q"ES<[_KR/L'E>#<.3V:M^/W[G@T\$MK<203H4EC8JRGJ"*[?X=ZJXFG MTN1B4*F6+/8CJ/QZ_@:I?$.S6#7(KE !]HBRV.[+QG\L5E^$I3#XIL&!QERO MY@C^M?0U6L3A')]5?YH^-H*6!S)4T]G;U3_X='L=%%%?)GZ&<-X_UUH(UTFW M8AI5W3L#_#V7\>__ ->O/HHGFE2*)2\CD*JCJ2:N:W>G4-;O+K((DE.TC^Z. M%_0"ND^'FF+<:C-?R+E;=0J9_O-W_ ?SKZRFHX/"WMK:_P V?GE9SS+'\J>C M=EY)?U?YFEH_P^MTA6357:25AGRHVPJ^Q/4FM&X\!:)-$5BCF@;LZ2$_HS3]=_O/'=?\,7F@R;G_>VS'"3*./H1V-8[RR2 M;=[LVQ=JY.<#TKW6YMH;NW>WN(UDBD&&5NA%>.^(](&BZS+:(^^/ >,GKM/8 M^]>Y@,;[?W)_$OQ/E,WROZI^]I? ^G9_Y&G\/_\ D9A_UP?^E>J5Y7\/_P#D M9A_UP?\ I7JE>7FO^\?)'N\/_P"Y_-_H%>):[_R,.I?]?4O_ *&:]MKQ+7?^ M1AU+_KZE_P#0S6^3_P 2?HOS.7B7^%3]7^1U_P ,_P#F*?\ ;+_V>N^K@?AG M_P Q3_ME_P"SUWU<>8_[S+Y?D>EDO^XP^?YL:[K%&TCL%1068GL!7CGB/7)= M@>.;XV?AN1$;#W+B+CTZG]!C\:\GKT1REY\/](GC(MC-;/V(?/N+EEW7ZHP?!6__ (1. MSWY_CQGTWFM/6!,=%OA;[O.\A]FWKG:>GO5M$6- B*%51@*HP *=7'.IS574 MMUO^)Z=.AR4%1OLK7^5CQ;2?#^I:R_\ HD!\O.#*_P J#\>_X9KM+#X=642A MKZZEF?NL?R+_ (_RKM:*[:V9UJGP^ZO+_,\K"Y%A:*O-<[\]ON_XI7JO^'X5YYXBMUM?$5_$G M"B9B!Z \X_6NH^&KD7&HIV*(?R)_QKWZ?RO_ M )'H$L:31/%(NY'4JP]0>M:O\ PKG2/^?F^_[[3_XFM'1O"6G:'=M=6[3R2E=H M,K [1WQ@"MZBOFYXNO.+C*;LS[6GEV$IR4X4TFOZ[A7 _$S_ )A?_;7_ -DK MOJX'XF?\PO\ [:_^R5MEW^\Q^?Y'-G7^XS^7YHY#0O\ D8=-_P"OJ+_T,5[; M7B6A?\C#IO\ U]1?^ABO;:[,X_B0]'^9YO#7\*IZK\@KD/''B)]-MET^U2 ,G@5XAK.H-JFL75X6R)'.SV4<#],5SY;AU5J\TMH_TCLS MS&2P^'Y8.TI:?+K_ )%)59V"J"6)P !R37=Z+\/?,B6?5I70MR((R,C_ 'C_ M $'YU5^'VDK=:A+J$JY2V $>?[Y[_@/YUZ77;F&.G"?LJ;MW9YF3933JT_K% M=7OLNGJCGW\Y_\:R-5^'<#1-)I<[I(.1%*BL_P/!IX);:=X)XVCE0[65A@@UV7@/Q \-T-(N'S# M)DPD_P +=WGCFC.'C8.I M]"#D5]&N7&X;7K^#/BI*IE>-LGHOQ3_K[T>]45#:7"W=G!LI-?>V2^'O"EWKI\XGR+0'!E(SN]E'?ZUV\/@/0HXPKPRRL.KO*0 M3^6!71Q11P0I%$BI&@VJJC I]?/U\PK597B[+R/LL)D^&H0M.*E+JW^AYWX MB\"I:6DEYI;R,L8W/ _)QW*GV]*X:O?2 1@\BO$MI&.#^7 M'X5T=>=_#:4B[OX<\,B-CZ$C^M>B5XV.IJGB));;_>?3956E6P<)2WV^[0P? M%^J/I7A^62)MLTQ$49'8GJ?R!KR)$:218T!9V("@=R:]*^(T;-H=NX!*K<#= MCME37G5E.+6^M[@C<(I5?'K@YKV\KBHX=RCNV_\ @'RV?3('5 M(?\ :'(_3/Y5Z)69X@TW^U=#NK4#,A7='_O#D?X?C7S^#K>QK1ETZGV.98;Z MSAI4UONO5?U8\ATJ_;3-4MKU.3$X) [CH1^6:]OCD2:))8R&1U#*1W!KP0C! MP>M>J>!-3^VZ$+9VS+:'8?7:>5_J/PKU\VHW@JJZ:'S?#N)Y:DL/+KJO5;_A M^1MZQJ"Z5I-S>-C,:':">K= /SKQ*1VED:1V+.Q+,3U)-=W\1=4R]OI<;<#] M]+CUZ*/YG\JY70--.K:W;6F,HS;I/]T?\C3-_US3^52?# M_P#Y&8?]<'_I7TS_ -P_[=/AU_R./^WSU2BBBOE3[X\K^('_ ",Q_P"N"?UJ M/P'_ ,C3#_US?^52?$#_ )&8_P#7!/ZU'X#_ .1IA_ZYO_*OJE_N'_;I\"_^ M1Q_V^>L4445\J??!7E?Q _Y&8_\ 7!/ZUZI7E?Q _P"1F/\ UP3^M>IE7^\? M)G@<0?[G\U^H?#__ )&8?]<'_I7JE>5_#_\ Y&8?]<'_ *5ZI1FO^\?)!P__ M +G\W^@5Y#XU_P"1NOO^V?\ Z+6O7J\A\:_\C=??]L__ $6M7E'\=^GZHSXB M_P!UC_B7Y,T/AS_R,-Q_UZM_Z&E>G5YC\.?^1AN/^O5O_0TKTZL\T_WE^B-L M@_W)>K_0*\[^)/\ Q^6'_7-_YBO1*\[^)/\ Q^6'_7-_YBIRW_>8_/\ (TSS M_<9_+\SG_"?_ "-.G_\ 70_R->R5XWX3_P"1IT__ *Z'^1KV2M\W_BQ]/U.3 MAS_=I?XOT04445XY](8'C7_D4;[_ +9_^C%KR&O7O&O_ "*-]_VS_P#1BUY# M7TV4?P'Z_HCX7B+_ 'J/^%?FSVW0O^1>TW_KUB_] %:%9^A?\B]IO_7K%_Z M*T*^=J_Q)>K_ #9]I0_A0]%^2.0^(W_(O6__ %]+_P"@/7F->G?$;_D7K?\ MZ^E_] >O,:^FRO\ W9>K/A<__P!]?HOU/?:***^5/T *K:A$)]-NHF&0\+J1 M]0:LU#=2"*SGD/1(V;\A51OS*Q,TG%IGA%>F_#ERV@W"DDA;DX]OE6O,J]-^ M'*D:%<,>AN3C_OE:^HS3_=GZH^!R"_UU>C_0["O,?B-_R,-O_P!>J_\ H;UZ M=7F/Q&_Y&&W_ .O5?_0WKR,K_P!Y7HSZ//\ _O5Y#X*_Y&ZQ_P"VG_HMJ]>K3-_XZ]/U9CP[_NLO\3_)&+XMF\CPKJ#C/*!. M/]I@O]:\Q?K^AY/$;?UF*_N_JSIM/\ M'&I:;80V<%O:&.)=JET8D_7YJL_\+&U?_GVL?^^'_P#BJT-$\$:7J>C6MY+/ M>+)*F6".N 2:A?3720Y9L=*6+Q]"=!TZ=_N'E^4XJEBU7K6TNWK>][ M^7F:=%%%>"?7!1110 5RWC__ )%D_P#79/ZUU-( M>IPYC_NE3T9Y77M%KH>DM:0LVEV1)122;=.>/I7B]>[VG_'G!_US7^5>QF\I M14+.VY\UPY3A-U.9)[;I/N5?["TC_H%6/_@.G^%']A:1_P! JQ_\!T_PK0HK MP?:U/YG][_S/K?84OY%]R_R,_P#L+2/^@58_^ Z?X52UG1M+BT+4)(]-LT=+ M:1E98%!!"G!!Q6[6?KO_ "+VI?\ 7K+_ .@&KIU)\\?>>ZZONO,RKT*2I2]U M;/HNS\CQ*O6_ _\ R*=K_O/_ .AFO)*];\#_ /(IVO\ O/\ ^AFOH,V_@+U_ MS/C^'?\ >G_A?YHZ*BBBOF#[L\"KT[X<_P#(O7'_ %]-_P"@)7F->G?#G_D7 MKC_KZ;_T!*^JS3_=GZH_/\@_WU>C_0Z^N,^(UDTVE6UVJY^SR%6]@V.?S _. MNSK)\1WUG8:)H)(Y%\L19P7)[#_/:OGL+.4*T915W<^SQ]*%7#3A-V5M^ MW4\CTN].G:I;7@!/DR!B!W'XBNK>.X@O'2M32O$ M.IZ/\MI<$1$Y,3C--5B MT_09H-X\^Z4Q(G?!^\?IC^=<>_Q!UID( M4)_B6,Y'YFNKCL^HRHN%!.[TN]+$ !) R3T%>WZ-:-8Z-9VK? M?CA4-]<<_K7#^#O"@_6O1JSS7$QG)4XN]M_4U MR#!3HPE6J*SEMZ?\$*P/&O\ R*-]_P!L_P#T8M;]8'C7_D4;[_MG_P"C%KSL M-_'AZK\SVL=_NM3_ O\CR&O;="_Y%[3?^O6+_T 5XE7MNA?\B]IO_7K%_Z M*]K./XE_A7YL]TTW_D%VG_7%/_0146LWVDMM.NZ*52K#..#7SMTJEY; M7_4^U:DZ-H[VT^X\H/C;Q#G_ )"&/^V,?_Q-)_PFOB'_ *"'_D&/_P")KKS\ M.M'S_P ?%\/^!I_\31_PKG2/^?F^_P"^T_\ B:]WZW@/Y?\ R4^1_L[-_P"? M_P G.0_X37Q#_P!!#_R#'_\ $UK>&_%NLWFOVMM=W0FAE)5E,:KV/.0!6S_P MKG2/^?F^_P"^T_\ B:N:7X*TO2K^.\B>YDECY42N" >F> *SJXK!.#48ZV[& MV'P&:1JQE.>B:O[U]/0Z.BBBO!/KC(\3Z=_:?AZ[@49D5?,CQ_>7G'X]/QKQ MFO?:\7\2:=_9FOW=N!B/?OC_ -UN1^73\*]_**OQ4GZ_YGR/$>'^"NO1_FOU M/1/ ^H?;O#L<;',EL3$?IU7]#C\*Z2O,/A]J/V;6GLW.$NDP/]Y>1^F:])N[ ME+.SFN93A(D+M] ,UY^.HN&(:775?/\ X)[&4XE5L'&4G\.C^7_ /,/'FH?: M_$)@4YCM4$8_WCR3^H'X4> ].^V>(!<,,QVJE_\ @1X']3^%H^ ].^QZ +AUQ)=-O_ . CA?ZG\:]G%-8;!\BWM;_/]3YC 1>. MS)U9;)N7W;?H=1112,0JEF( R2>U?+GWH$@ DG '4FL*_\ &6BV!*FZ\]Q_ M# -_Z]/UKAO%'BN?6+A[>VD:.P0D!5./-]V]O:L33],O-4N!!9P-*_?'11ZD M]!7N4,KCR<]=V\O\V?*XO/I.I[+"1N]K[W]$=U-\2;9?]1ITS_[\@7^0-0_\ M+,_ZA'_DS_\ 855MOAQ?.@-Q>P1$_P **7Q_*K(^&AQ\VK 'VM\_^S5?+EL= M+_F9<^=SU2M_X"CG?$OB+_A(9K>3[+]G\E2N/,WYS^ IGA/_ )&G3_\ KH?Y M&G^)?#O_ CTUO']J^T>J_^AO6?X*_Y&ZQ M_P"VG_HMJT/B-_R,-O\ ]>J_^AO6?X*_Y&ZQ_P"VG_HMJ^JI_P"X?]NO]3\_ MK?\ (W_[?7Z'KU%%%?*GZ >-^+/^1IU#_KH/Y"MSX;_\A2\_ZXC_ -"K#\6? M\C3J'_70?R%;GPW_ .0I>?\ 7$?^A5]57_W'Y+]#X'"?\C;_ +>E^IZ11117 MRI]\%>-^+/\ D:=0_P"N@_D*]DKQOQ9_R-.H?]=!_(5[&4?Q9>GZGS?$?^[1 M_P 7Z,Z#X;?\?E__ -AQ7??$M&*:8^/E!E!/ MN=O^!K@[=%DN8D?.QG ;'7!->WEUEA5\_P SY7.N9X^2]+?KH_^%M>!23X4M\C&'?'O\ ,:ICX=:/ MG_CXOC_P-/\ XFNGLK*#3[..UMDV0QC"BLL?C:5>FH0ON;Y/E>(PM9U*MK6M MH[EBBBBO%/J HHHH *\W^)'_ "%+/_KB?_0J](KS?XD?\A2S_P"N)_\ 0J]+ M+/\ >5\SQ<]_W&7JOS,/PG_R-.G_ /70_P C7LE>-^$_^1IT_P#ZZ'^1KV2M MLW_BQ]/U.7AS_=I?XOT05P/Q,_YA?_;7_P!DKOJX'XF?\PO_ +:_^R5S9=_O M,?G^1VYU_N,_E^:.0T+_ )&'3?\ KZB_]#%>VUXEH7_(PZ;_ -?47_H8KVVN MS./XD/1_F>;PU_"J>J_(****\0^I//OB7_KM-_W9/_9:YGPQ_P C-IW_ %V6 MNF^)?^NTW_=D_P#9:YGPQ_R,VG?]=EKZG"_[C\G^I\#C_P#D;?\ ;T?T/9Z@ MO)#%8W$@ZI&S#\!4]5M1!.F78 R3"_'_ $U\Q'XD?>3^%GA=>H_#V$1^'7D M[RSL?R ']*\NKU3P!('\,A01\DSJ?;H?ZU]/FM_J_P T?!\/I?7->S_0ZFBB MBOEC[X*\K^('_(S'_K@G]:]4KROX@?\ (S'_ *X)_6O4RK_>/DSP.(/]S^:_ M4/A__P C,/\ K@_]*]4KROX?_P#(S#_K@_\ 2O5*,U_WCY(.'_\ <_F_T"O$ MM=_Y&'4O^OJ7_P!#->VUXEKO_(PZE_U]2_\ H9K?)_XD_1?F,G_OH5[F!TPBMV?ZGRN:ZYDT^\?T/J:C#I M.G37L_W(QT'5CV ^M.,7)I+=DRE&$7*3LD6)[B&UA:6XE2*->KNP 'XFNUZU3V>#A?Y7?W=/F=;)\2H@W[K2W8 M>K3!?_933/\ A9G_ %"/_)G_ .PJ&/X;7!0&74HE;T6,L/SR*E_X5I_U%_\ MR6_^RHMEJ_IA?/'K;_TDX[5K_P#M35;B]\KRO.;=LW;L<8ZX%=9\-O\ C\O_ M /KFG\S7)ZM8?V7JMQ9>;YODMMW[=N>,],FNL^&W_'Y?_P#7-/YFNW&8 M_/\ (\C.O]QG\OS1R&A?\C#IO_7U%_Z&*]MKQ+0O^1ATW_KZB_\ 0Q7MM=F< M?Q(>C_,\WAK^%4]5^12U>8VVBWTPZI;NP^H4XKP^O;/$ +>'=2 _Y]I#_P". MFO$ZWR=>Y-^?Z')Q*W[6FO)_F>J^ (5B\,JX',LSL3Z]OZ5U%-(?.\*7F.J;7'X,,_I MFO(:]A\82"+PI?$]U51^+ 5X]7TV47]B_7]#X;B-+ZS'OR_JSV7PK)YOA?3V MR#B+;P?0D?TK8K&\)Q^5X6T]<8S'N_,D_P!:V:^?KV]K*W=_F?882_U>%^R_ M)'D/C7_D;K[_ +9_^BUK0^'/_(PW'_7JW_H:5G^-?^1NOO\ MG_Z+6M#X<_\ MC#K?^AI7TE3_ '#_ +=7Z'Q%'_D;_P#;[_4].HHHKY4_0 KQ_P 8_P#( MV7_^\O\ Z M>P5X_XQ_Y&R__ -Y?_0%KV,H_C/T_5'S?$?\ NT?\7Z,V/AO_ M ,A2\_ZXC_T*O2*\W^&__(4O/^N(_P#0J](K',_]Y?R.K(O]QCZO\RGJFG1: MKIL]E-PLJX#=U/8_@:\;U32KO2+QK:[C*L/NL/NN/4&O<*K7MA::C 8;R!)H M_1AT^A[5."QKP[LU>+*S/*XXU*2=I+K^C/'=*UW4=&D+6D?S+^74?K4.I_#I&W2:9=;3U\J;D?@P_PKC=2T74-(DV MWML\8)PK]5;Z$<5[%L'C/7[G_P '\3YI2S++-_A^^/\ P/P/9[2]M;^$36D\ M&6&HW>F7*W%G,T4@]#PWL1W%>N>'=WL:\G&8"6']Y.\3Z/+BBBO-/:"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH \2UW_D8=2_Z^I?_0S76?#3_7:E M_NQ_^S5R>N_\C#J7_7U+_P"AFNL^&G^NU+_=C_\ 9J^KQG^Y/T7Z'Y]EO_(S M7K+_ -N/0:***^4/T$\@\8:9_9OB&<*N(I_WR?CU'YYIW@_6%TC6PTSA;:92 MDA)X'<'\_P"==?\ $#3/M6CI>HN9+5NJ7SZGJES>OUE?0027-Q'!$NZ21@BCU).*]PTZRCT[3K>SC^["@7/J>Y_$\ MUAF=54Z*I1Z_DCKR&@Z^)EB)ZV_-_P!,LT445\T?;GD_CS_D:9O^N:?RJ3X? M_P#(S#_K@_\ 2H_'G_(TS?\ 7-/Y5)\/_P#D9A_UP?\ I7U3_P!P_P"W3X%? M\CC_ +?/5****^5/OCR_XAQE?$4;8X>W4Y]>6%4?!X@*^Y#GW4X_7 M%=+\1M/:2UM;]!D1$QR<=CT/Y@_G7GT4KP3)+&Q61&#*P[$<@U]7A+5L&H>3 M1^?9@WALR=1]U+\O^">]45@Z#XJL=8MD#S)#=@?/$YQD^JYZBM:XOK2TB,MQ M_EV#E2 M?M:FC>R/D,ZS.%=>PHZI:M_Y?YG3_#__ )&8?]<'_I7JE>5_#_\ Y&8?]<'_ M *5ZI7GYK_O'R1Z_#_\ N?S?Z!7D/C7_ )&Z^_[9_P#HM:]>KR'QK_R-U]_V MS_\ 1:U>4?QWZ?JC/B+_ '6/^)?DS0^'/_(PW'_7JW_H:5Z=7F/PY_Y&&X_Z M]6_]#2O3JSS3_>7Z(VR#_*=/RVZ%_R+VF_P#7K%_Z *T*S]"_Y%[3?^O6+_T 5H5\[5_B2]7^;/M* M'\*'HOR1R'Q&_P"1>M_^OI?_ $!Z\QKT[XC?\B];_P#7TO\ Z ]>8U]-E?\ MNR]6?"Y__OK]%^I[K8WMOJ-G'=6T@>*09!]/8^]6*\<\.^([G0+HE"G0E=:Q[_P"9]3EV:4L7!)NT M^J_R-*L'QA?K8^&KK)&^=?)09Z[N#^F:T[S5+'3X3+=7442^[#)^@ZFO*_%' MB)]>O@4!2TBR(D/4^K'WJL#A95:JDU[J)S;'T\/0E%/WFK)>O4P:]?\ !EJU MKX7M PPTH,I^A/'Z8KR_1=+EUC58;./.&.78?PJ.I_SWQ7MD<:11)'&H5$ 5 M0.P%>AF]58_$;_ )&&W_Z]5_\ 0WKTZO,?B-_R M,-O_ ->J_P#H;UPY7_O*]&>IG_\ N3]5^IG^"O\ D;K'_MI_Z+:O7J\A\%?\ MC=8_]M/_ $6U>O5IF_\ '7I^K,>'?]UE_B?Y(I:Q:F]T:\ME^])"RK]<^UY'XPT9])UJ1U4_9K@F2,]@3U7\#^F*URBLE*5-]=48<1X9RA&O'IH_G MM^)V/P_ODN/#_P!ER/,MI""/]ECN!_,G\JZNO%-#UJXT/4%NH?F4C;)&3PZ^ MGU]Z]1TSQ3I.J1KY=TD4IZQ3$*P/X]?PK#,,).%1U(JZ>IU9/F-*I0C1F[2C MIZ]K&U13!-$1D2)C_>%5[G5+"T&;B]MXO]^0 UYBC)NR1[TIQBKMV+=%?TKH=+OUU/2[>]5-@F3=LSG:>XS6M3#U:<5.<;)G/2 MQE"M-TZC/*Z]WM/\ CS@_ZYK_ "KPBO=[3_CS@_ZYK_*O6SC: M'S/G>&MZOR_4FHHHKY\^P"L_7?\ D7M2_P"O67_T UH5GZ[_ ,B]J7_7K+_Z M :TI?Q(^J_-&-?\ A3]'^3/$J];\#_\ (IVO^\__ *&:\DKUOP/_ ,BG:_[S M_P#H9KZ/-OX"]?\ ,^*X=_WI_P"%_FCHJ***^8/NSP*O3OAS_P B]G?#G_D7KC_ *^F_P#0$KZK-/\ =GZH_/\ (/\ ?5Z/]#KZ\U^(MX\F MK6]IG]W%%OQ_M,3_ $ KTJO/OB'I,IGAU2)2T>P1RX'W2#P3]?3YY&8U/J3C/X?UKK[[P9HE\S.;8P M.W5H&V_IT_2O*+.]N=/N5N+29HI5Z,O^>:Z6/XAZRB@-':2'U:-LG\F%>KB\ M+B95?:49?C8\#+\?@H8?V.)A?5]+WO\ B=&/AUHX8$SWI /0R+S_ ..UK:?X M7T?3'$D%FIE'220ER/IGI^%<:GQ'U *-]E:ENY&X#^=3K\2IP?FTR,CVE(_I M7'4PV825I._S_P"&/2HXW)Z;YH12?^%_\$]#HKD;#X@Z9QKRZM"I2=IQL>[0Q5'$*]*28^L#QK_R*-]_ MVS_]&+6_6!XU_P"11OO^V?\ Z,6JPW\>'JOS(QW^ZU/\+_(\AKVW0O\ D7M- M_P"O6+_T 5XE7MNA?\B]IO\ UZQ?^@"O:SC^'#U?Y'R_#7\6IZ+\S0HHHKYT M^T.=\E M_A7YL]TTW_D%VG_7%/\ T$59JMIO_(+M/^N*?^@BK-?-3^)GW$/@7HOR"BBB MI+"BBB@ HHHH *X/XCZ=NBM=11>5/DR$#L>5_K^==Y6?KFGC5-%NK/ W.AV? M[PY'Z@5TX2K[*M&9PYAA_K&&G3ZVT]5JCQFRNGL;Z"ZC^_#(''.,X/2O1O'& MKQCPS"D#Y^W%2I!QE.&)_P#01^->9$$$@C!'45:NM0GO+:T@E;*6L9C3Z9)_ MP'X"OJ*V&56K"I_+_7YGP6%QTJ%"K1_F6GY/\!EE:27U]!:Q??F<(..F3UKW M*"".VMXH(EVQQJ$4>@ P*\V^'NG?:-8DO77*6R?*?]IN/Y9KTVO&S:MS5%37 M3\V?3\/8?DH.L]Y/\%_P0K%\67#6OA:_D3J4"=>S,%/\ZVJRO$MFU_X;0:56/-M=?F>YBE)T)J&]G^3/%Z]@\(6$5CX/UZEX)UZWO-*AL))%6ZMQL"$XWKV(]>./PKZ'-8S=%([#1(29Y \Y'R0(K5 MA2BYU'9(Y+XD_P#'Y8?]T>I6]^H_=S)Y;''1 MA_B#^E0']Y$VX>_J/Q'%?64U]8P:BNJM\U_PQ^>5I/!YFYRV4 MK_)_\/\ @>Z45E:3XBT[6(%>"=%EQ\T+D!E/T[_459O=5L-/A,MU=11*/5N3 M]!U/X5\NZ4U+D:=S[V->E*'M%)Y:DD2&)I)&"(@+,Q. !7BNO7L6HZY>7 M<&?*DDRI(QD=,_I6MXH\72ZT3:VH:*R!Z'[TGN?;VKFFC= I=2NX;ER.H]:^ MCR[!RHKGGN^A\5G691Q35*EK&/7N]ON_,[?X;?\ 'Y?_ /7-/YFO1*\[^&W_ M !^7_P#US3^9KT2O)S+_ 'F7R_(^BR/_ '&'S_,Y/XA6IF\/I.O_ "PF#'Z' MC^9%>75[K?6D=_8SVDOW)D*'VSWKQ/4+&?3;Z:TN%VR1M@^X[$>QKT\IK)TW M3>Z/"XBPSC6C76S5OFO^ >T:5?)J6E6UXA!$L8)]F[C\#FKE>4>%?%;:&QMK MA6DLG;.%ZQGU'M[5Z19:UINHH&M;V%\_P[L,/J#R*\G%X.=&;T]WHSZ++\QI M8JDO>M+JO,OT4SS8_P#GHG_?0JC=Z_I-B";C4(%(&=H?VX4445B=(4444 %>;_$C_D*6?\ UQ/_ *%7I%>;_$C_ )"EG_UQ M/_H5>EEG^\KYGBY[_N,O5?F8?A/_ )&G3_\ KH?Y&O9*\;\)_P#(TZ?_ -=# M_(U[)6V;_P 6/I^IR\.?[M+_ !?H@K@?B9_S"_\ MK_[)7?5P/Q,_P"87_VU M_P#9*YLN_P!YC\_R.W.O]QG\OS1R&A?\C#IO_7U%_P"ABO;:\2T+_D8=-_Z^ MHO\ T,5[;79G'\2'H_S/-X:_A5/5?D%%%%>(?4GGWQ+_ -=IO^[)_P"RUS/A MC_D9M._Z[+73?$O_ %VF_P"[)_[+7,^&/^1FT[_KLM?4X7_Y@:VNIK=_O1.R'Z@XKN_AO>KLO;!B V M1,HSU['_ -E_.LGQWI+66M&\1?W-W\V?1QU']?Q-8.EZE/I.HPWL'WXSRIZ, M.X-?75(K%X7W>J_$_.J,GEV/][9-KY/_ (%F>XT5E:3XAT[5X%>"=%DQ\T+L M RGZ=_K5RYU"SLXC)<74,2#NS@5\K*G.,N5K4_0(UJY9Z#)KR#QA MJ-OJ7B&66V;?&BB/=V8CJ1[5J>)_&K:@CV6FEDM3P\I&&D]AZ#]37'E&"!RI M"L2 V."1U_F*^@R[!2I/VM31OH?'9UF<*Z]A1U2U;_R_S.G^'_\ R,P_ZX/_ M $KU2O*_A_\ \C,/^N#_ -*]4KS\U_WCY(]?A_\ W/YO] KQ+7?^1AU+_KZE M_P#0S7MM>):[_P C#J7_ %]2_P#H9K?)_P")/T7YG+Q+_"I^K_(Z_P"&?_,4 M_P"V7_L]=]7 _#/_ )BG_;+_ -GKOJX\Q_WF7R_(]+)?]QA\_P V<=\1;9I= M&M[A1GR9L,?0,/\ $"O- 2I!!((Y!%>X:I81ZIIEQ92<"5, ^AZ@_@<5XG4*ZK+:2_%?\ /;M-O$U#3;: M[3I+&&^A[C\#5JO+O"/BM='S97NXV;'X8?,?]T=OKU^E30PM6N[16G?H:8O'T,+&]26O9;GHE<-\2 M;AEM+"V'W)'=SSW4 #_T(UM^#KR>]\-6\MS*\LH9E+NWN(YX_OQL'7/J#FO:=(UBUUFR2X MMI 21\\>?F0^A%=^<1FU%K;]3R.&YTTZD7\3M]W_ YH445RGB/QG;:8CV]B MR3WG3(Y2/ZGN?:O$I49U9#G5=E_6QPWBS_D:=0_ZZ#^0KH/A MM_Q^7_\ US3^9KBIYY;F=YIG9Y7)9F8\DUVOPV_X_+__ *YI_,U]/C(\F#<7 MT2_0^&RVHJF9J:ZMO[[GHE%%%?)GZ">-^+/^1IU#_KH/Y"M_X;$?;;\9Y\M? MYFLCQM;M;^*;EB,+*%D7Z8 /Z@TSPCJ\>CZXDLYVP2J8I&_N@X(/Y@5]7.+J MX*T?Y5^A^?4JBH9JY3T7,_QO_F>OT5$EU;R1B1)XFC(R&#@C'UJM;ZSIUW>M M9V]Y%+.H+%4.>!UYZ5\LH2=[+8^^=2"LFUKMKN7JX'XF?\PO_MK_ .R5WU<# M\3/^87_VU_\ 9*[WDB/1U*G\1BO"9HG@ MGDAD&'C8JP]"#@U[U7E_CO17LM5.H1)_H]T3>:>Q <,)D'J" #_ "'YUWE>&:=J%QI=_%>6 MS;9(SGV([@^QKU71_%VEZK$NZ9+:X[Q2L!S['O1F6$FJCJQ5TQY'F%.5%8>; MM*.WFC>HIGG18SYB8]=PK&U;Q9I6E1MFX2><=(HF#'/N>U>5"E.;Y8J[/H*M M:G2CS5))(Q_B+J"Q:9!8*?GF?>P_V5_^N1^5><1QO-*D4:[G=@J@=R>E6M4U M.XU?4)+RY(WOP .BCL!72^ ]#>[U :G,A%O;G]WD???_ .M_/%?44XK!8;WM MU^9\#7E+-,=:&ST]$NOZ_<>BV5LMG8V]LOW88U0?@,5/117RC;;NS]"244DC MR'QK_P C=??]L_\ T6M:'PY_Y&&X_P"O5O\ T-*S_&O_ "-U]_VS_P#1:UH? M#G_D8;C_ *]6_P#0TKZFI_N'_;J_0^ H_P#(W_[??ZGIU%%%?*GZ %>/^,?^ M1LO_ />7_P! 6O8*\?\ &/\ R-E__O+_ .@+7L91_&?I^J/F^(_]VC_B_1FQ M\-_^0I>?]<1_Z%7I%>;_ W_ .0I>?\ 7$?^A5Z16.9_[R_D=61?[C'U?YA1 M7'>,?$E_HFH6<=H4",A=U=(J<[ MT.C 8*.#H^RB[]6PHHHKF.X\J\>PR+XD>5HV$;1IM8C@\>M2?#Z&5O$!E$;& M-86!?' /'&:]1HKU/[1?U?V/+TM>YX*R9?7/K7/UO:WZW"BBBO+/>(KJVAO+ M66VG0/%(I5E/I7E&O^$K[1Y7DC1KBSS\LJC)4?[0'3Z]*]PL[ M,DVUI!!GKY487^0KU7G$;:0U]3Y]<-3YM:BMZ._YGG.@>!KN^=9]25K:V!SY M9X=_P[#Z\U/\0;);7^S4MX/+MHXV0;5^5>1Q7H]%<']HU'6566RZ'K_V-1CA MI4(.S=KO=Z?IY'EOP^C<^(C($8HL+ MC@=.]>I445SXK$?6*G/:QV9?@_J=' MV5[ZM_>%>2>-XI$\5W4+DL23I=D2>23;I_A7NPSC3WX MZ^1\G5X;?->E4T\U_D>/Z19W%]JEM#;QL[>8I.T?=&>I]!7M],BAB@39#$D: M^B* /TI]>=C,7]9DG:R1[669=)\S;[GM0CR145T5ON.0^(W_(O6_\ U]+_ .@/7F-> MG?$;_D7K?_KZ7_T!Z\QKZC*_]V7JSX'/_P#?7Z+]3T'Q+X&,CM>:0B@GE[;H M/JO^%<#+#+!(8YHWCD7JKJ01^!KWJH;BSM;M=MS;0S+Z2(&'ZUYF'S2=-@ZCK$@%I;L4)YE;A!^/^%>O1Z-I<3AX] M-LT8="L"@_RJX , 8 ["MZF<:>Y'7S.2CPVE*]6=UY+]68_A[P[;Z!:%$/F M7$F/-E(Z^P]!6S117B3G*I)RD[MGU-*E"E!4Z:LD%>:?$:*3^V[>7RV\O[,J M[\<9W-QG\17I=%;87$>PJ>TM&63Q5:R)&Q2,.78# MA@KVW^PM(_P"@58_^ Z?X5:AM+:V $%O%$!T"(%_E6SSB/2#^ M\Y8\-3O[U1?CVUDS!FB3#,!@ M$]3^IJ]17F8K&SQ"2:LD>[@,KI8)N46VWU84445PGJA1110 5S/CN*27PTPC MC9R)5)"C.!SS7345K1J>SJ*?8PQ%%5J4J3=KJQX(D;RN$C1G<]%49)KW:U!6 MTA5@00B@@]N*EHKKQF-^LV]VUCS\MRQ8'F?-S7MTML%%%%>>>N%4=9C>70]0 MCC4L[VTBJH&225.!5ZBJB^62?8F<>>+B^JM]YX(R.CE&4AAQM(YKUSP7%)#X M6M4EC9&RYPPP<%CBM^BO1Q>/>(@H+EV4+!574Y[W5MK?J%%%%>8>X>" M21R0R-'*C(ZG!5A@C\*]0^'T,L/AZ0R1LF^X9EW#&1M49_0UU=%>IBLQ>(I^ MSY;?,\# 9,L)6]KSWT:VMO\ ,*YKQ;XEBT:U^S1JDMW,O".,JJ^I'?Z5TM>) MZ]>O?Z[>7#G.965?90<#]!4Y=AE6JWELC7.<;+"T%R?%+3T[E."":\N4@@C, MDTC85%'4UVD7PVN&B1I=1C20C+*(BP!],Y&:F^'&GQ,MUJ+J#(K>4A/\/&3_ M #%=]79CLPJ0J>SI:6/+RK)Z-6@JU=7YMO3_ ()YV?AK<9XU*+'_ %R/^-5K MCX=:I&FZ&XMIC_=R5/X9&*]-HKC69XE=?P/4ED6":MRM?-GA-Y97-A&.I6H3[_G)M^N17N0DL7AKS6]_P/E*E.678]1IN]FON?1GNE87C M&.27PI?)&C.Q"':HR>'4G]*W:*^5ISY)J?9W/T"O2]K2E3;M=-?>>!JC,X15 M)8G '->WZ/&\.AZ?%(I5TMHU93U!"C(J[17;C,=]927+:QY>6Y4L%*4N;FO MIM8****\X]DP/&D4DWA:[6)&=LH<*,G 85Y$B-(X5%+,>@ R37OE%>GA,>\/ M!PY;_,\/,1>+])ET[7KEUB86TS>:C@';SU&?KGCZ5@*C.P5%+ M,>@ R37OE%>U3S:4(*+C=KS/EZ_#L:E64XSLF[VM_P $Y_P;I;Z7X?B$J%)Y MR99%(Y&>@_(#]:Z"BBO)JU'4FYO=GT5"C&C3C2CLE8****S-CSKQ1X*G6XDO MM*C\R)R6>!?O*>^WU'M7%,LD,I5U:.13R",$&O>JAGL[:Z&+BVAF'I(@;^=> MQA\UG"/+45_S/F\9D%.K-U*4N5OIT_X!XI_:VI;=O]H76WICSFQ_.K&EZ!J6 MM2_Z- Q0GYIGX4?CW_"O6TT;2HG#QZ;9HPZ,L"@C]*N@ # & .PK2>;)+]U" MS_KL84N'I.2=>K==E?\ 5L\Z\1>%X=%\*Q^2IFN/M"M--CMM;\AG%8GA"-Y/ M%%B41F"N2Q Z#!Y->PT5SPS*:I2A)7;OK?N=M3)*;Q$*U.7*HVTMV\_,**** M\L]X\T^(T4G]MV\OEMY?V95WXXSN;C/XBJ'@>&63Q5:R)&Q2,.78#A!/)E+&?6N?K>UOUOY!1117EGOE/5--M]6T^2SN0= MCC@CJI[$>]>2ZUX;U#1)6\Z(R09^6=!E2/?T/L:]FHZC!KNPN-GA]%JNQY68 M972QJ3EI)=?\SP*GQ0R3R".&-Y'/144DG\!7MLFCZ9,^^73K1V]6@4G^53V] MG:VB[;:VAA7TC0*/TKTGG$;:0U]3PX\-2YO>J*WH[G ^'? DDCI=:NNR,W\JH>/H#%KZ%8BD/D(J$+A>,\"O4Z*X89C4]M[6>OD>M4R:B\-] M7INVJ=]V[=SSWX;1N+B^D*,$** V."P5B>(O#5MK\ +'RKI!\DP&?P/J*VZ*RIU)4Y*4'9F]:C"M!TZBNF>+ZGXN>WXXK*KWVJLVF:?)6_F*]JGG#2_>1^X M^8K<-Q;O2G;U5_Q1X93XXI)G"11L[GHJC)KVL:)I*L&72[($'((MTX_2KD<, M<*[8HT0>BJ!5RSB/V8?B90X:E?WZB^2_S/*M%\':K>W4,DUN;:W#!F:88)&> MR]:]8HHKRL5BIXB2F:]%HKHPU?V%15+7./'858J@Z+=K_ *'CWA"*23Q/9,D;,J/E MB!D*,'K7L-%%:8O%?6)J5K6,M[&JJEKV-\;AOK5"5%NU_P#.YXKX=AEF\0Z>(HV?;<1LVT9P M P))KVJBBML9B_K,E*UK'-EN7K!0E'FO=WVL%%%%<1ZAP/Q)BD8Z?*$8QJ) MS < G;C)KF/"L4DGB6P*(S!906(&<#U->RT5ZE+,'3H>QY>^M^YX-?)E5Q?U MGGMJG:W:W6_D%%%%>6>\4M5TNVUBPDL[I(S6 MXZ3QC*X]_3\:]CHKNPN-J8?1:KL>7C\KHXQ7EI)=5^O<\"I55G8*H)8G ') M->X2Z3IL[[YM/M)&]7A4G]14EO86=I_Q[6D$/_7.,+_*O3><1MI#7U/!7#4^ M;6HK>C_S/-]!\#7E^ZSZBK6UMUV'B1_P[?C5SX@6*6D&F1VMOY=M$LB_*ORK MRO4UZ)17!_:-1UE4ELNAZ_\ 8U".&E0@[.5KO=Z:_=Y'EOP^C<^(C($8H(6! M;' Z=Z]2HHKGQ6(^L5.>UCLR_!_4Z/LKWU;^\*\4\01R1>(=1$B,A:YD8;AC M(+'!^E>UT5>#Q?U:3=KW,LRR_P"NPC'FM9WVN<)\-H94BU&5HV6-S&%8CAL; MLX_,5W=%%8XBM[:HZEK7.G!X986A&BG>W_#A7,^)_"<6N#[3;LL5ZHQN/W9! MZ'_&NFHJ:56=*7/!V9I7P]/$4W3J*Z9X=?Z5?:9+Y=Y;21'. 2/E/T/0U3KW MQE5U*L 5/4$9JD^BZ5(Q9],LF8]28%)/Z5[4,XT]^'W/_,^7J\-Z_NJFGFO\ MCQ D@ 9)Z"M[2O"&K:HZGR#;P'K+,-OY#J:]7M["SM?^/>T@A_ZYQA?Y58J M*N;R:M3C;U-:'#D(N]:=_):?\$I:3IL6D:9#90L66,'+'JQ)R3^=3W=K#?6D MMK<)OBE4JP]JFHKQ7.3ES-ZGT\:<(P]FEI:UO(\CUSPAJ&D2L\<;7-IG*RH, MD#_:';^58,4TL$@DAD>-QT9&(/YBO>JJSZ9873;KBQMI3ZR1*W\Q7LTLV:C: MK&Y\SB.'8N7-0GR^3_1K4\6EU*_GC,JO*Q!_ FMG1/!NHZJZR3(UK M:]3)(,,P_P!D?UZ5ZA!IEA:OOM[&VA;UCB53^@JU2JYJ^6U*-BJ'#ZYE+$3Y MO+7\VVSRGQKI,.E7]G%:P%+<6P7=C[S;FSD^O2M3X;1N+B_DV-Y910&QQG)X MKT*BN>>82GA_8M:][^9UT\GC3QGUF,M.UO*P4445YI[AS/C#PX^MVB3VH'VR M ':#QO7^[GU]/_KUY;<6\UK,T-Q$\4B]5=<$5[Q44]K;W2;+B"*5?21 P_6O M4PF8RH1Y)*Z/!S#)88N?M8RY9=>S/!ZZWX?V=Q)KWVI8V\B.-@SXXR> ,^M> MA)HNE1L&33+)6'0B!01^E754*H50 !T '2M\1FBJ4W",=SEP>0.A6C5G.]G> MR7^8M<'\2HY&CTV148HAD#,!P,[,9/X5WE%>7AZWL:JJ6O8]W&X;ZU0E1;M? M_.YXKX=AEF\0Z>(HV?;<1LV!G # DFO:J**VQF+^LR4K6LL%"4>:]W? M:P5!>V5OJ%I):W48DAD&"I_F/0U/17&FT[H].45)6>QY7K7@?4-/=I+-6N[; MJ-@^=?J._P"%TMKD8N+>*4>DB!OYU[-'-IQ5JBN M?,XGAVE.7-1ER^6Z_P SPBGQ0RSR".&-Y'/144DG\!7M7]A:1_T"K'_P'3_" MKD-O#;KMAACC'HB@?RK>6<1M[L/Q.6'#4[^_45O)/]3S?0_ =W=NLVIYMH < M^7_&_P#\3_.O1[:VAM+=+>WC6.*,855Z 5+17D8C%5,0[SV['T6#P%'!QM36 MKW;W84445RG>>2>-XY$\5W;LC*KA"K$8#811QZ\UH?#F&7^VKB?RV\H6Y7?C MC)93C]#7I=%>I+,7+#^QY>EKW/ ADRCC/K7/U;M;];^84445Y9[X5Y#XTBDC M\4WC.C*KE2I(X8;1T]:]>HKKPF)^KS<[7T/.S' K&TE3YK6=^YYU\-XI!?WD MI1O+,0 ;'&<],UZ+1148FO[>HZEK&N!PJPM!44[V_4YCQAX:EUR**>U91%S&=" M/(U='GX_):6*FZB?+)_-,\#H )( &2>@KV]M$TIV+-IEDS'J3;J3_*IK>PL[ M7_CWM((?^N<87^5=SSB-M(/[T>2N&IWUJ*WHSR[1/!FHZI(KSQM:VO4O(,,1 M[#^O2O4;&R@TZSBM+9 D48P!_4^]6**\K$XRIB'[VB['T&!RVC@U[FK>[?\ M6@4445QGI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 M_\ KZ7_ - >O,:] M1^(44DOAZ'RXV?;90PRW$RQ0QM)(QPJJ,DU]3E;7U;YL^ MSZ+>-T6Z7ZGO-%%%?+'WX4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B>O64FG MZY>6\BXQ*67W4G(/Y&O;*Q/$'AJUU^$%SY5R@PDRC/X$=Q7H8#%+#U'S;,\; M-\!+&44H?%'5>?D<+X0\31Z'++;W2L;68AMRC)1O7'3NLFI2+;Q=3&A#.?Z#]:]"LK&VTZT2VM8ECB3H!_,^IIXK&TJ5+V-# MT]/^"+ 99B*^(^M8O36^N[?33HBQ1117SQ]B%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C_ (Q^ M*7B/0O&EUH>F6%A<*C1K$'AD>1RR@X^5QDY/851N/B?\1K*!KB[\)QP0(,O) M)I]PBJ/T\:>;;26_P!DU&)=YAW[E=,]5/MQD>]=Q7SC\+5^T_%=9K!6 M2T!N), =(B"%!_-:V?$?Q0\1^'_B#J-J+H3Z=;2LJ6ABC /R?*"VW=C<0>M. M45=6ZJY,7:]^C/=:*\N^'.M^/=8UVX/B&&:+31$77S[+R1N)^4(< GKWSP/> MJ7BKXIZM/XB;P]X.M%GN%G67%W2ZE*2:;Z'KU%>&S M^-_B3X,GAF\3V2W-G*P'SI&!] \7 /USTZ5ZK;>+=+NO")\2QR-]@6%I6R/F M7'52/7/%#C9/OB)XRU.9O"]JD5M G'O3Y'H@YD>_P!%>:?%'Q7K M7AWPYH]WI5[]GGN'Q*WE(^X;,]&! Y]*XRW^(GQ#U][/^P[6=XH@D4TD5D)% MEDP-Q=MN%!/88P*(P;V[V!R22?S/?J*X+X@^,M8\*:9:QZ?IS75[*FZ6Y\AC M#%C&>G%O&TWBCP%?:L(UMKZUCE20)RH=4W!@#GCD<']:\X\,?$[QQJC7&FVL2ZMJ< M^TP%XHT6%1G<3M"CG(Y)P*.5W<>PN963/?J*\&@^)_C+PGXB^P^+8A<(,&6$ MQQJZJ>Z,F%/XYZ8XJQK?C7XEFQ'B*VL/[.T3(9%\J-R4)X+[LO@^H '-'+UZ M!S=.I[C17)?#SQ@_C+PX;RXB2*[@D\F<)]TG (8>@(/2NMI2BXNS&FFKH*** M*0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*ZE:"TFE4 LD;,,],@9J M6J^H?\@VZ_ZXO_(U,W:+94=6CSCX:_$?6/&6MW5EJ-M8Q1Q6_FJ;='4D[@.= MS'CFO3Z\ ^!'_(UZA_UY'_T-:TO$_P 2_$'A[XEW=DL[7&F0.H6R6*,%\Q@@ M;MN[[Q]:WG%%Z[XN^*FD1)K-]:I8Z>S#$0AB9!GH&ZNO MIR17IG@GQ>GBGPF-7G1+>2(LERJGY591DD>V"#4.-DWV+YM4NYU%<'\3?&VI M>"[/3YM.@M)6N9'5Q<(S 'C:P]:XBZ^)7C+Q;K\ECX,M_*A0DIMB1G91QN M=I/E4'\/K7/_ !%\0>(KZTL-(\4:8+74;5VD$JD;9488SP2,Y'4''THY7H/F M6J/;K77=2O/AXFNP6LV MD?V=)$ZB%?LTD.\$')PY.?PJMIE[<:;\%H+VTD\NX@TGS(WV@[6"9!P>#^-4 M/A%XIUGQ1I^IRZS>?:7@E18SY2)M!!S]T"K:]Z:70SO[L;]3TBBO'O$OQ/US M4?$C^'O!=JLDJ,8S/L#L[#J5S\H4>IS^%9C?$/Q]X,U2"'Q9:K/!+\Q5HXP2 MO?8\?RY'HM^@[[6ZGNU<5K7Q M%L].\867AFVMWGO9KB.*9V^5(@V.G]XX/T]^U5/AUX\O/&>CW\=Q!''J=HH^ M:+A9-P.T@'HJZ1X;N+W1+'[;?HR".#RFDW L ?E4@G R:A\$ZOK6M>'_M> MO:?]@O?-9?)\EXOE&,':Y)]:Y?5-9\8Z#\)[G4=6G\C7HYE'F;(6PAD '"@I MT)K6^&/B#4-?\&'4M8NQ-.L\BM*45 % '90!ZTDK*7E8&[N/G<[6BO%M2^*' MB;Q-KLFD^![(;%SMF,:L[ 'EOF^55^OK^%11?$;QOX-U2"V\9V'G6\IR7V(K M[>^QH_D./3]1246QN21[=16!KNM$>!;_ %K2K@9^PO<6\P4'^'(.#Q^!KR7P MU\2?'6M6DNFZ=;#4]59]_P!H>.-%ACP!C VKG.>6-"BVVNPW)))]SWFBO";+ MXE^,O#'B:/3?%R++&S*)5>)%9%/\2-'@']>G:O=@JGVXR/>NXKYQ^%J_:?BNLU@K): W$F .D M1!"@_FM;/B/XH>(_#_Q!U&U%T)].MI65+0Q1@'Y/E!;;NQN(/6G**NK=5_1GNM%>7?#G6_'NKZ[<-XAAFBTP1&0>?9>2,D_*$. 3^.>![UEZW\2_$>O M^(I=$\#VRMY9(^T;%9GP>6&[Y57MD]<]JEQ=[%*2M<]EHKQ6R^)'B[PGK<&G M^-[,-!+R9=B*Z@G[RE/D8#N.OO7HGC/QE:>$/#XU%U%Q+,=EM$#CS&(SG/H! MR30U97&G=V.FHKPJ'Q1\6=:L6UO3K?9IX!8)%!%A@.NT/EV'TS78_#3XCR>+ MS/I^I111:E OF Q A94S@G!Z$9&?K3Y&3SHJ>&?B/K&L_$>Y\.W%M8K9Q23H MKQHXDPA.,DL1VYXK8\?^)/%.@2V*^'-%_M%9E+]=\+SZ2NC7WV83K*9/W*/NP5Q]Y3CJ>E#6D/,$_ M>GY'I=A+-/IUK-Y5Q'C_ ,2>*= EL5\.:+_:*S*YF/V66;81C'W",9R>OI7& M>$/B9XDM_%\7AWQ4BR/+-Y!=HECDB<_=^[A2,X[=\YK7^+WB_7?"\^DKHU]] MF$ZRF3]RC[L%4XZGI2<;->8U*]_(]+L)9I].M9KF/RYY(D:1-I&UB 2,' MD6/T_*FU[S7847[J?<]THKROX>_$Z^UK6FT#Q#!'%?_,(I%386 M9?O(R]FX/3'3I5SXB>.-?T348-*T#2I7FEV@W4D#,A9CA53L3G'//I2<6FEW M&I)IOL>D5F>(]1FTCPWJ6HVZHTUK;/*BR E20,C."#C\:\9U/Q9\5?"20WVN M!#;.VP"6*!D+=<$QXKT"\\0)XH^$&HZND7E&>PFWQYSM8 @C/ID4I1:B MVAQDG))C/AEXUU+QI9:A-J,%I$UM(B(+=&4$$$\[F/I7>5X_\ _^05K7_7>/ M_P!!->P5=1)2T(IMN.O=A11169H%%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X MEJ?Q;\61^*;[1M,TFPNVAN9(HHTMY9)'"D]E?DX&>!7MM?/?A7_DOTW_ %_7 M?_H,E735YV?9BF[0OZ&I<_%;Q]IB+<:IX6BM[4, S2V4\0/L&9L UZ-X'\<6 M?C737FBC-O=P$">W+9VYZ$'N#S^5:/BN^TZP\,:A)JDD2VS6[J5-G?$6-MJY45R_@OQ)]6N;?P[IC6,6\*!PIR! MN:7C)P>F.GM2Y7SVT5XIX<^)?BC3/%\/A[Q9"DC23+"[%%22-FQM M.4^4KR.W3O71_$;XAWOAK4;31=%MHYM2N55BT@W!0QPH R,DD4.+TMK<%):W MZ'I%%>)F_P#C18!;J>V:XB! ,0BMWSG@96/YO\\UZKX:O]5U'1(KC6],_LZ^ MR1)%O# X_B&"< ^AY_G0XV5[@I:V->BO&M;^)?B/7_$4NB>![96\LD?:-BLS MX/+#=\JKVR>N>U167Q(\7>$];@T_QO9AH)>3+L174$_>4I\C =QU]Z(Q;MYA M*25_(]JHIJ.LB*Z,&5AD$=Q5;5!=MI-XM@<7A@<0'CA]IV]>.N.M2]"EJ(=5:\U5I(P%1BRKE@#ECR>.P ]Z]$^#/_). MX/\ KXE_G6BBN5]]#-R?,NVIZ!11169H%%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !7C_C'XI>(]"\:76AZ986%PJ-&L0>&1Y'+*#CY7&3D]A7L% M?/?BC_DOT'_7_:?R2JIKFFDQ3=H-FM233[A%4>Y+ M8%=MX!^(]IXT\VVDM_LFHQ+O,._5 M@% [YS7SS\+5^T_%=9K!62T!N), =(B"%!_-:J%I-JW0B5XI.YW]W\1]8M_B MJOA9+:Q-B;F.+S"C^9AE!/.[&>?2O3Z^O\ B[XJ:3&NM7EFEAII88A$43J,] _5QZ.]8\33Z/X7TJ6T6/=L::W M D=5."Y,OR@'CMW'>DXM2Y1J2<>8]CHKPE/B3XX\(:]%9>+8$FC?#NC1QJP0 M\91H_E/?KGICBN\^(_C]O!VF6OV*%)KV]R8C)G8BC&6('7J,"AQ:2?<:=W8[ MJBO$O[1^,_DC41 6MB/-$*Q6QRO7 4?/^'6O2?!FJ^(=4TIF\1Z1_9]TA 5@ M0%E&.NW)*D=\_P#U@W&PE*YTE%>3^,_B9JJ^(SX9\(VRSWP;RWFV;SOQR$!X MX[D\<'TK';QY\0O!=[;GQ;8K<6DS=62,''<*\?RY[X-*,;J_<;=G8]PILDB1 M1/)(P5$!9F)P !U-0:=?V^J:=;W]J^^"XC62,^Q&:6_LH=1T^XLK@,8;B-HY M IP2I&#S4M-:=1IIZ]#R34OC+JE_JDEEX1T+[;L)P\D;RM(HZD(F"!TZFM#P ME\7)-0UN/1/$>FC3[V1_+5T#*N\]%9&Y7L.IY]*Z[PKX'TCP<]Z^F>>3=$%O M.<-L SA5. <<]\UXYXUN8?%/Q@M8='(E99(8#+'R&93EFSZ <9_V:UARN2CW M,Y\RBY=CZ(HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR MWXD?$G6?!_B].M;&6*2V64FXC=FW%F'\+#C@5ZE7S[\2#4OCA%-HI!MWU,. MC1C@J#ER/8X8_0U<+2ERV,I74.:YZ)X[^(^L>&/&5IH]E;6,EO-'&[-,CEP6 M8@X(8#MZ5Z?7SY\99A;_ !'LIF!*QVL+D#J0'8UL:YXM^)\MDVO66G'3=&4> M8H\N)W\OL7#9;\0 .?QJ4KP3]2FVIM>2/:Z*XGX:^-Y?&>CSM>11QWUHX67R M^%<$?*P';H1^%<_XT\<>+5\3#P_X9TJ6-RWEK3GIGI2< M6I!-;\6:K#*GB;1#9[5#17&-F_G[I0G(/OC']7R,7,CL MJ*\G\9_$S55\1GPSX1MEGO@WEO-LWG?CD(#QQW)XX/I6.WCSXA>"[VW/BVQ6 MXM)FZLD8..X5X_ESWP:48W5^XV[.Q[A15;3K^WU33K>_M7WP7$:R1GV(S5DC M(P>E2TUH"=]3R?Q)\7KN/7)=&\+:1_:%Q$Y0R,K2!V'W@J)@D#US^'JOA;XN MW%UKD>B^)],73[J1_+$BJR!7/161LE<\^\1P:6ENT,!$K6X M^9ER#@*2%R3CGCZUXZQD^*WQ,2YLXEM+5!'O\QU#B-3R<9Y8^V<<5I3LVH_> M14;2;7R/HJBCM169H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 ?-WQ T_^UOC)/IWF^5]JN+>'S-N[;N5!G&1 MGK74I\ $$BF3Q*S)GY@MC@D>Q\PX_*I=>\#^([WXO1:[;Z=OTU;NWD,WGQCY M5";CM+;N,'M7L=:)VIQMN3)7F[G-^$?!&D^#;62/3UDDGEQYMQ,07?'0<< > MP_6O&KRU2\^/QAD4,AU-&(/? !_I7T37CP\$>(O^%R_V_P#V=_Q+/MGF^?YT M?W=N,[=V[]*4)/VB;\R9Q_=M(]0>*/A7JUOXB?Q!X/NT@G9S*8"^QE<]=AZ$'T.!SZ4H-*3O MU5BIKFCIT=SJOBQ]G_X5QJ?VC'_+/R_7?O&,5Y9I0N?^%!ZWC=Y?]H)C_=S' MG]:UYO!'Q)\9SPP^*+Y;:SB;/SO&1]0D7!/UQUKU ^'-$TSP4^@S,D.EB Q2 M22N%Z]6+'C))SGUIVY8ON[?@%^:2\KG*_ _R/^$'F\O;YOVQ_-QUSM7&?PKB MOCKY'_"7V.S'G?8QYF/3>V,_K5BP\#_$#PIJ4W_")7T-Q9SM@SQ2Q%2!TW(_ M<9[ URWQ"T#4-&UBS_M?4C?ZM>0^=V![?2KTE4C)?UH1&\8./] M;G??&O\ Y%'P_P#]=/\ VG7:_#&U2U^'6CJB@>9$9&]RS$YK#^*7A76/$?A[ M2+71[,W,EN^9%,J)@;,?Q$5UO@W3[K2?!VE6%[%Y5S! $D3<&VGTR"0:F_NR M]0MK'T.5^(7Q(N?#.I0:+H]I%<:E.JL7FR53<<*, C)/UP..M[$GVJ5; MD\S1WY_(?\)@?^%:>)3C@M+_ .B15+X"1J=6UF4CYE@C4?0L?\!70?#OPOXB MT/PIK^DZGIA@>Y1FMSY\;;V9"I7Y6..@Z^M)\(O!^O>%[S5)-9L/LRSQQK&? M.1]Q!.?NL<=:T;7/)^2,K>XEYG(_'!1_PG-GP.;),^_SO7K/CY%3X;:NBJ J MVF /3&*XCXJ>"/$7B3Q7:WNDZ=]HMTMEC9_/C3#!F)&&8'H17H7C#3KO5?!6 MIZ?91>;=36Y2./<%W'CC)(%92_@I>;-O^7M_(X/X"_\ (!U;_KZ7_P!!KUNO M._A'X8UCPQI&HP:Q9_9I)IU=%\U'R-N,_*37HE74=Y:&=-6CJ%%%%9F@4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 57U#_D&W7_7%_P"1JQ4-Y&TME<1H M,N\;*H]214S^%E1^)'@WP(_Y&O4/^O(_^AK4>LPK/^T(D;@%3?P$@C/1$/\ M2ND^$W@GQ#X9\0WEUK&G_9H9+4QHWG1OEMRG&%8GH#1?>"?$,WQF37X]/SI8 MNHI#/YT?W0B@G;NW=0>U=7,O:Q?D^L-69$<,A11_"2.QK&/P37H=#W@_4YKX!^1]G MUO[OVC?%GUVX;^N:/CYY'D:)]W[1NEQZ[<+_ %Q52]^&OC#PGX@DU#P5<>9# M(2$42HKHIYVL)/E8#CU^E5/$7PV\>:W;1ZIJ4PU+57<)Y"RQJ(8\$]257.>R M_6JDU)J7H9Q3BG'U.[B_Y(/_ -P4_P#H!KG/@9O_ +!U_P O[^]-OUVMBNSC MT/45^$O]B&W_ .)C_9AM_)WK_K-N,;LXZ]\XK(^$7A;6?"^GZG%K-G]F>>5& MC'FH^X '/W2:=]C;&>N=ZYKVC7M3\/Z6;6; M79+2(NS)!)<(#@XR<''' ]NU>;>)OA?K>G^)'\0^"[E8Y6=I/(WA&1CU"D_* M5.3P--3MY?%MVD$$/&6>,L%/78L?RY/JP[5$/U:J'B X_:#@S_S^VW_H*5T_PI\(^(O">N:DNIZ;Y=G< M1 ).)XV!96XX#$\@GM5?XB?#[Q%?>+X_$?AU4FE/EML\Q4>.1.C#=@$<#O\ MA6KDE4C+I8A1?LY1ZG3_ !?_ .2;:C_OQ?\ HQ:Y;P09A\"-:-N2)=MSC'7[ MHS^E:NIZ'XSUOX57FG:M&MUKDTZ.J+)$OR!E.,C"@C!K7^&7A[4-!\%MINLV M@AF:>1FB+JX*L!W4D>M96M&KL;.R$N%D4$_<.[ MY6'U]*CB^'/C;QEJD-SXSO\ R;>$XV;T9\=PBQ_(N?7K[&KE:;3O;;\!1O!- M;[FWX?$H_9\N/-S_ ,>-SMS_ '=SXK.^ <*BSUN? WF2),XYP Q_K7HVO:.7 M\#W^C:5;C)LGM[>%2%'W<*,GC\ZY7X1>%M9\+V&IQ:S9_9GGE1HQYJ/N !S] MTFCF3BUVWT[?IJW=O(9O/C'RJ$W':6W<8/:O8ZT3M3C;GK))/+CS;B8@N^.@XX ]A^M>-7EJEY\?C#(H9#J:,0>^ #_ $KZ M)KQX>"/$7_"Y?[?_ +._XEGVSS?/\Z/[NW&=N[=^E*$G[1-^9,X_NVD>JZMY MG]C7WD_ZW[/)L^NTXKYQ^&=GXGO-3OE\+ZG9V-TL(,IN5!W)GME&[X]*^FCR M,&O%];^&/B/0O$J_-\K+[']:4':3OU14U>.G1B:_\ M#?XA^*/(_MG7-'N?(W>7U3;G&?NPC/05E_%^RO=.T7PE8W;I(UO:M%(T9)4N MH0$C('I6E9>!?B#XCUV'4/$NJR6 B&PO%,HDV9!P@B^49/?/;/->B^,O!EKX MN\/+ILLK130D-;SGYRK 8YSR01U_.JD[)>MQ+5OT+OA+RCX.T7R=OE_8H<;> MGW!4.B:[X6NKE[#1KNP%PI8&WA C;Y2<_+@$X.?YUY3;>%_BSH5F=%TV<-I_ M*AXIX=J@]=I?#KZ\8KL?AM\-V\(--J.I313:G,FP"/)6)>I )ZD\9-.5G)RO MH2KJ*C8X3P'_ ,ERO_\ KO=_S:M'X^_\?6A?[DW\TJ_X2\$^(=,^*MWK5YI_ ME:?)+@45I>,/#^J:K\+ MUT:RM?-OQ#;KY7F*O*E=W)('&#WI_P +M!U+P[X/%AJMM]GN?M#OLWJ_RG&# ME21VJKKW_-D).U/T_0\O\9@+\=[&(->\$0Z%J2F,_9HT++@F*15'([<$?C7EMKX.^*' M@_SK+P]JVVN^%H]PW$^V6^WK&\UQR-Y&< 9 X' M4GWXIOP_^&%[H^MMX@\13QS:AEFCB5M^UVZNS=VY/3/7.:SO'?PTU^;Q6_B/ MPS())I'64QB01R1R# RI8@$<9Z_G4VBI)/YE7;3:^1D?$G1O%]KX8AOO$WB* M*[!N51;.WC"HI(8YR N< >G?K70>%@1^S[?Y'6VNB/S:LO5? /Q \4Z/+=>( M-066[@7-I8*T8W-D9W%<(.,\Y/X5TOAKPYK]I\)=3\/WNFF&_,<\<$?G1MYF M\9'(8@@+XXLR?@'_ ,@K6O\ KO'_ .@FO8*\W^$7A;6?"]AJ M<6LV?V9YY4:,>:C[@ <_=)KTBBHTY:>1-)-1U[L****S-0HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "OF%_#__ E'Q9U#1_M7V;[1?7'[WR]^W:6;ID9Z>M?3 MU>.:!X'\1V7Q>DUVXT[9IINKB03>?&?E8/M.T-NYR.U73MSZ]F*?P:=T,@^ M,*S*9_$;O%_$L=F$8_0ESC\J]-\->%],\)Z6+#3(F5"=TDCG+R-ZL?\ #BMF MBDY-JPE%+4^?=8A2?]H1(W *F_@)!'HB'^E>H_%0 _#;5\C/RQ_^C%KD;[P3 MXAF^,R:_'I^=+%U%(9_.C^Z$4$[=V[J#VKN_'VE7NM^"=2T[3X?.NIE01Q[@ MN<.I/)('0&E+^'%?UNAP_BR?]=3A/@]J<&C_ ZUG4;HMY%KY MINC>+/'OQ"FN6T%]/TBPA=5:5UWN,]N0HSV^@S1+;SD![A)8C&P&<$J_(/T&>: MUE9S=^RL9JZ@K=SGM9T^_P!/^+%K::CJ3:E>"[MC)<%=NXG:<8SVSBO5_B-\ M-9/%UQ#J>G726^HPH(R);QKX. MU25K=8-1M8F1UC)VL2A*L,],D'CGI7&76B?&'6[1M*U"7;9RC9(SRVZ@KZ,4 M^<@_KWKT7P#X*C\%Z(]LTPGN[AM]Q(HPI.,!1[#]7U M3;G&?NPC/04NM_#'Q'H7B.36_!-RJ[F++ '5'3/5?F^5E]C^M,LO OQ!\1Z[ M#J'B759+ 1#87BF42;,@X01?*,GOGMGFJNI68KMZ#97&G>'].L;MTDN+ M>WCBD9"2I95 )&0#CBM"FQH(XU0%B% +,23]2>M.K*3NVS1*RL<%\8_^2<7 MG_7:+_T,4SX,_P#).X/^OB7^=:7Q*T74/$'@JYT_2[?S[IY(V6/>JY 8$\L0 M*;\,M#U'P]X,BL-4M_L]TLTC%-ZOP3QRI(IP^&7R)E\4?F=A1114EA1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 5\W?$#3_[6^,D^G>;Y7VJXMX? M,V[MNY4&<9&>M?2->.:]X'\1WOQ>BUVWT[?IJW=O(9O/C'RJ$W':6W<8/:KI MV]HK["G\#L1)\ $$BF3Q*S)GY@MC@D>Q\PX_*O1/"/@C2?!MK)'IZR23RX\V MXF(+OCH.. /8?K7244N=VL+E1\^ZQ"D_[0B1N 5-_ 2"/1$/]*]1^*@!^&VK MY&?EC_\ 1BUR-]X)\0S?&9-?CT_.EBZBD,_G1_="*"=N[=U![5W?C[2KW6_! M.I:=I\/G74RH(X]P7.'4GDD#H#2E_#BOZW0X?Q9/^NIQWP-E6'P7J4DC8CCO M&8D] !&N:IVGC_Q?XZUFZL/"45E86T*[OM%R-S!_-;_PM\+:G MH/A74-.UNT^SR7%PS!/,1\H449RI([&N'C^'/CWPAKTD_A:598WRBSI)&/D) MZ.DG&?H#TK633J._;\3-74-.YSOQ-TO5]+\0VL>M:R=4NY+8/OV;!&-S#:!Z M<9Z#K7L'C;P"OC30-/$5P+:_M(AY3N"48$#*MCIT'/:O/_$OPK\9WZ0:G/<# M5]5G8BX19558E&-H!8J#WX 'ZUW'C#P7K/BSPWI[6][-IVHQ6X2>S><^2^1 M\P.TD9SWYSWJ7\"7F4OCOY'#'2OBOX.B(M9[FXM(5R/*D6X0 #H$;+ 8[ "N MY^&?Q%N/&/VFQU"WBCOK=!)OBR%D7..AZ$<=^<]JY,:3\95M?[*$[?9,>3YO MG6^=O3.__6=/QKL_AM\/6\&03W-[.DVHW*A6\O.R-!SM!/4YZG_)IV:?-_P2 M;-6Y3R#PU;Z_=?$B\BT2^MK+5C+.1+U=SKO@+XE>);)+/5]? MT>Y@1Q(J[=F& (SE80>YJQXU^&&JR^(V\2>%+A8;QF\UX=^QO,[LC=.>X.!R M?6LIO!WQ/\57UL=>O_L4=NV4E\V,%<\$JL/4XXYQUZU,7>,5V*DK2;[GI_@C M1+WPYX2LM)U"6&6XM]X+0L2N"Q(P2 >A]*Z&JNG60T[3;>S$TT_DQA/-F68]T0]L=S]?>NC^'?PW@\(P_;KTK/J\J89ARL(/55] M_4_Y/E-G\-?B+IUS]IL;"XM9\$>;!?Q(V#UY$F:U8/"_Q<6XC,EQJ^P."V=8 M4\9Y_P"6E:QBDK)[[LSDVW=K8^@**0=!FEK$U"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ KY\^.0W>-[-?6R0?^/O7T'7CWQ4\$>(O$GBNUO=)T M[[1;I;+&S^?&F&#,2,,P/0BJA;VD;[ _A967X [E!_X2;J,_\>'_ -LKNO!_ MPYT;P=*]S;&6YO7&TW$V,JOHH' _G77("$4'J!3J;FR%%61\_?&.-9?B581M M]U[:%3]"[5[3XH11X.UA HVBQF &./N&O./B/X)\0Z]X[LM2TS3_ #[2**)7 MD\Z-<%78GAF!Z$=J].UZUFO?#NI6MNF^>:UECC7(&6*D 9/'6IE_!2]2H?Q[ M]-#R/X!$^?KHSQMAX_%ZT[_XC^(=?\7R^'/"%M:(8V=#=7/.=O!;T !]B3Q] M*L?"'PAKOA>;5FUFQ^S"X6(1_O4?=C=G[K''4=:P-;^&GBW1/%LNM>$I!+YD MK2QE941XMV25(OKJ4\ MQDVQ1QA$BP%SC&,YS_='2O1XO"$/C'X2:'ITLQMYDMHI8)<9VMM[CN"#7'^( M/AKXZU[31JFJWJZAJP94CLU=%"1\Y.?E0'..!^9KKV\':WK/PTTO2I+FXT;5 MK)-@5+C,;XX ?83D$8/M4OX&O,I?&GY'$IX3^*7A!1'I-U+/;+T6VG$B#Z1O M_1:Z?X<_$W4=>UIM UVV1;P*VR9$*$LO577L>O3'3&*PK71/C!H=HNEZ=+OL MXAMC9);=@!Z R?, /T[5TWP[^&MWX=U6;7=U=SKO@ M+XE>);)+/5]?T>Y@1Q(J[=F& (SE80>YJQXU^&&JR^(V\2>%+A8;QF\UX=^Q MO,[LC=.>X.!R?6LIO!WQ/\57UL=>O_L4=NV4E\V,%<\$JL/4XXYQUZU,7>,5 MV+DK2;[GI_@C1+WPYX2LM)U"6&6XM]X+0L2N"Q(P2 >A]*WY9$AB>61@J(I9 MB>P'6J^G60T[3;>S$TT_DQA/-F<<5Y!\8-&L/#/B#2;[1(4L)I49R MML-@5D(PP Z'GMZ5IZI\+_$_AOQ#)J_@FY4H23'%YBH\8)Y3Y_E9?J>W3BET M[X9>*?%&O1:KXWNPL:8#1!U9W /"C9\JK]/7I5Q2NI)V[DR;LTU<];T*\FU# MP_IU[<+MFN+:.5QC&&9036A3418T5$4*JC ["G5$FFVT5%-))A1112&%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 54U33;;6-+N=.O$+V]Q&8W .#@^GO5NBAJX'B;?!SQ/H] MW(_AOQ,L$3>P.1N= M\$CVQ7K5%6IR1#@F%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110!5^V?],_UH^V?],_UJK171R1.3VDNY:^V?\ 3/\ 6C[9_P!, M_P!:JT4@44451 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 5;7_7W/^]_4U:JK:_Z^Y_WOZFK53'8N>X44451 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %63_D)1?[O M^-6JJR?\A*+_ '?\:M5*ZERV7H%%%%40%%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% %6U_P!?<_[W]35JN3UW7KK1;D"V MCA?S6;=Y@)Q@]L$>M9/_ G>J?\ /"S_ .^&_P#BJZJ."JU(*<;6?F>?BLTP M]"JZ%G_ -\-_P#%4?\ "=ZI_P \+/\ [X;_ .*K M;^SJ_9?><_\ ;6$[O[CT*BO/?^$[U3_GA9_]\-_\51_PG>J?\\+/_OAO_BJ/ M[.K]E]X?VUA.[^X]"HKSW_A.]4_YX6?_ 'PW_P 51_PG>J?\\+/_ +X;_P"* MH_LZOV7WA_;6$[O[CT*BO/?^$[U3_GA9_P#?#?\ Q5'_ G>J?\ /"S_ .^& M_P#BJ/[.K]E]X?VUA.[^X]"HKSW_ (3O5/\ GA9_]\-_\51_PG>J?\\+/_OA MO_BJ/[.K]E]X?VUA.[^X]"HKSW_A.]4_YX6?_?#?_%4?\)WJG_/"S_[X;_XJ MC^SJ_9?>']M83N_N/0J*\]_X3O5/^>%G_P!\-_\ %4?\)WJG_/"S_P"^&_\ MBJ/[.K]E]X?VUA.[^X]"HKSW_A.]4_YX6?\ WPW_ ,51_P )WJG_ #PL_P#O MAO\ XJC^SJ_9?>']M83N_N/0J*\]_P"$[U3_ )X6?_?#?_%4?\)WJG_/"S_[ MX;_XJC^SJ_9?>']M83N_N/0J*P/#WB6/6%,,P2*[7G:.CCU&?Y5OUQU*S^T-0M+3S,[/M$RQ[L=<9(SU%7*\?^.771/\ MM_[)2;L5&-V>D?\ M)9X;_P"A@TK_ ,#8_P#&M*VN[:]A$UK<13Q'H\3AE/XBO,=*^#_A^_T:RNY+ MS4UDG@21@LD> 64$X^3IS7)ZOINJ_"KQ/;7-A>--:S?,I(P)5!^9''3//7WS MQ5/27*Q).O#.C71MK[5H4F!P MR(K2%3Z'8#C\:3T=F):['1452TS5].UFV^T:;>0W46<%HVSM/H1U!^M4+SQA MH5AKD>C7-]Y>H2,BK#Y+G);[OS!<(D=M*OX[DIRR@%64>I5@#C\*T+N\MK"V>YN[B*"!!EI)6"J/Q-#TW$3 M45RT?Q'\(RW?V9=;A$F2,LCJG_?9&W]:Z>.1)HUDC=71AE64Y!'J#0 ZBL1O M%^A)KYT-K\#4@=IA,3]=N[[V-O3GK52;XA^$[>]^R2:U!YN<9569 ?\ ? V_ MK0.S.FHID,T5Q"DT$B21.-R.C AAZ@CK7/ZGX\\+Z1OG&F:E![4HHG9X?+?@;B?O8QT([UO6_COPS=7%U!%JJ>9:JSS;XW0(%.#RR M@=2!5-6=B5=G145CZ)XJT3Q&95TF_2X:+EUV,C >N& ./>J-_P#$+PIIMP8+ MG68?,4D$1(\N".H)0$"D.QTU-=UC0N[!549+,< "L[1_$.D:_$TFEW\-R% + M*IPRY]5/(_$5XW\3?%JZGXB@L[#4I'TZWP)X@K(OFJYW9! W8P/4>E'5+N"5 MTWV/=Z*RM"\1Z5XCMY)M)NOM$<3!'/ELF#C/\0%0:QXP\/Z!*(=3U.&&7C]V M SN/JJ@D?C0]!+4W**S-'\0Z1K\1DTN_AN0HRRJ<,OU4\C\15V[N[>QMGN;N M>."",9>21@J@?4T/3<":J%KK>DWURUM9ZI97$Z@DQ0W".P Z\ YK,T_QUX9U M:]^Q6>KPO<$[51E9-Q]%+ _A7E?PK_Y*3>?][445BZ MYXLT3PY+#'JU[]G>8$QCRG?6UA;/!< M;I)G"*,\#)/%9.D>,_#NN3"'3M5@EF)PL; QNWT5@"?PJ/QM!H]QX6N8M=NI MK73RR>9+",L#N&,?*W?':D]$-*[L;-G?6>HP>?8W4%S#DKYD$@=<^F1Q4V]0 MX0L-Y&0N>2/6N+\-ZAX6\,^"'NM.U2>324F8?:)XV+!S@8P$!ZX[5YWX!\:6 M]GXLO]4\2:G)F:W,:RR*[Y.X$ !0<#&>V*K[5@L^6Y[=?:OIFEE!J&HVEH9, M[!<3K'NQUQDC-6D=)8UDC971@&5E.00>A!K@/B%;>#]1_LR;Q%JMW9@QNUM] MG0G>IVDD_(WMZ=:WKOQ3X>\,:?IT5[?M%#+ OV=FAD8N@ Y^5>N"/3K2Z:]P MMM8Z.BH[>>*ZMHKB!P\4J!T8=&4C(-8S^,=!37QH9O\ .I;Q'Y*PR'YB,XW! M<=/>CK872YNT55U#4K+2K4W-_=16T ."\K!1GT^M8FG_ ! \*ZIW5G#J:>=:JS3B2-T5 IPQ+ M, .#[U#:_$'PI>7WV.'6H#,3M&Y612)<1(<.0"I4^X8 BLR[^(?A.QNS:SZS#YH.#Y:/(H.<0K' M3457LK^TU*U6YLKF*X@;I)$X8'\15B@ HHK U;QMX;T.X-OJ&K0QS X:- TC M*?<*#C\:!VN;]4;O6M*L+E;:\U.RMYV *Q37"HQ!X& 3FHM'\1:/K\9?2]0A MN=HRRJ<,H]U."/Q%>/\ Q4_Y*3I__7&'_P!#:A?$H]PZ-]CVF]U*QTR)9;^] MM[2-FVJ\\JQ@GT!)ZU+;W,%Y;I<6TT<\+C*21.&5A[$<&N4^(=KX=N]&MD\2 M7]Q9VHN 8W@4DE]IX.%;C&>U:.A3Z-I'@NWN+*[DDTBV@+K<2J2Q0$DD@*#Z M]J%LVP:VL;]%8%MXV\-W>F2ZC%JL(M(G\MI)%:/YL9P P!)QZ4:1XU\.:[<_ M9M.U2*6?M&RM&S?0,!G\*/(1L7=Y:V%NUQ>7,-O N-TDSA%&>!DGBDL[ZSU& M#S[&Z@N8[L?.<^;."&W<9'*K[=J%K<'I8Z>BL;6?%F@^'V":GJ<,$A M&?+Y=\>NU03C\*-&\6:#K[[-,U.&>3!/E\H^!WVL #)*P49]*YQ/B9X/DG$*ZT@8G&6AD5?^^BN/UH'9G651@UO2KJ M]:RM]3LI;I208([A6<$=?E!SQ5J">&Z@2>WE26&0;DD1@RL/4$=:\0\#_P#) M9K[_ *[77\VH6LN4'\+D>YT45EZWXBTKPY;QW&K77V>*5]B-Y;/DXSCY0:!& MI17/7OCKPSIUM;SW6K1(EQ&LD:A69RK#()4 L!]16CI.MZ9KMK]HTR]BN8AC M)0\K[$'D'ZT :%%8FM^+=#\.3PPZM??9Y)E+(/*=\@''\*FHI_''AJVU5=,E MU:%;LD+LVL0">Q;&T'V)H6NP['0454U#4['2K;[1J%W#;0YQOE<*"?09ZFL. MR^(?A/4+D6\&M0B0]/-1X@?Q< 4;BMU.GHHZC(K)UCQ/HF@ ?VIJ4-NQ&1&2 M6[U6QMY_^>W3^*=5NK4$ QM"I9I')YR=K?Y-?26FV,.FZ M9:V-N6,-O$L:%NI &!GWJK:78/1V1:HHK#U?QCX>T*4PZCJL,4PP#$N7P6YSM\EKE ^?3;G-:((( MR#D&OG#P3H_A35W\C7=4N[>^EG6*V@@4X?..IV,.2<=17T%=,N3;W6LPB520PB1Y<'T)0$ TAV9TM%4M,UC3M:MS<:;>P MW40."8VSM/H1U!^M3W=Y;6%L]S=W$4$"#+22L%4?B:'IN+-T"!3AB68!>#[U6C^(?A.6]^R+K<'FYQDJP3_OLC;^M&X[,Z>BD M!# $$$'D$5@ZMXV\-Z'<&WU#5H8Y@<-&@:1E/N%!Q^- DKF_169H_B+1]?C+ MZ7J$-SM&653AE'NIP1^(J[=75O96SW-U/'!!&,O)(P55'N30]-P)J*Y>'XB^ M$KB[^S)K< DSC+HZ)_WV0%_6NE::-83,7'EA=VXE&E^.O#.LW8M+'5HI)R<*CJT98^@W M9_"@#H::KJY8*P)4X8 ]#Z&N,^)7B>/0O#DUM!?/;:IC6R>)+^XL[47 ,;P*22^T\'"M MQC/:DV"5V=7;W,%Y;I<6TT<\+C*21.&5A[$<&I:P-"GT;2/!=O<65W))I%M M76XE4EB@))) 4'U[46WC;PW=Z9+J,6JPBTB?RVDD5H_FQG # $G'I5.R;$KM M&_16!I'C7PYKMS]FT[5(I9^T;*T;-] P&?PK?I (2%!)( '))JC9:[I&HSF" MQU6QNI@-QC@N$=L>N >E6KG_ (]9O]QOY5\K:'K%QH.MVVIVI_>0/N*YP&7N MI]B,BA.\K,KE]VZ/JXG R>E4;+6=+U*1X[#4K.ZD0998)U0_!7_D8]5_Z]Q_Z&*:7O.+%]GF\SUR\UW1].G\B M^U6QM9L;O+GN$1L>N":L6=]::A )[*Z@N822/,AD#KD=LCBO"/C I;QVJCJ; M6,#\VKJ_@U>R0QZOH5P<2VTWF!<]/X6Q^*C\Z4/>5QS7*>DWVJ:?IB(^H7UM M:*YPIN)EC#'VR1FFV.L:9JC.NGZC:790 N+>=9-N>F<$XKQ[XPW*+32H M,-]DMFE89Z$@L?\ QU15CX'?\?VL_P#7*+^;40]ZX2CRJY[-6;<^(M$LYC#= M:QI\$HZI+=(K?D37EOQ*\6ZAJ.O+X4T:1T7>L4QC.#+(W\&?[HSS^.>E:.G_ M 3TP62?VEJ5X]T1EOLY54!]!E23]>*2NU?H#26CW/4(IHIXQ)#(DB'HR,"# M^(I]>!:G::U\)_$<,EE>--8S_,H/"RJ#RK+TW#CD>O'I7I/B[Q6]O\.3K>EL M5>ZC01/WCW]3]1S^-#:Y>9!ROFL=->ZSI>FN%O\ 4K.U9N@GG5"?S-36E]:7 M\0EL[J"YC/\ '#(''YBO%/ GP^T[QAI /AUI'BKP\^H7US?1RB=HL0.@7 /=3SS22=VNP67*GW/9;+5M-U M+=]@U"TNMO7R)E?'Y&KE>&>,_AU)X.MH]HKE;;XD>$+N<0Q:U$&/0RQR1K_ -],H'ZUU!D0 M1>9N!3&[<.1BCI/? M"^IWHL[76(6G)VJKJR!CZ L #^!H\@.CHH)P,GI7-3?$'PI;WWV.36K<39P= MH9D!]W VC\Z/(+&M/K>DVMX+.XU2RANB0!!)<(KDGI\I.>:OUX/XVD2;XO6< MD;J\;R6I5E.01\O(->\4+6-QR5G89--%;PO--(D<2*6=W8!5 ZDD]!65_P ) M9X;_ .A@TK_P-C_QH\6_\B?K/_7E+_Z :\4^''@K3?&']H_VA/=Q?9O+V?9W M5<[MVVG@>0]7PF03[X(I-^ZVN@U'5+N=A_P )9X;_ .A@TK_P-C_Q MJS9ZYI.HR&.QU2RNG'58+A'(_ &O#OAQX'TSQ?#J#ZA/=Q&V9 GV=U7.0@445E>(M?M?#.C MR:G>QS20HRJ5A4%LDX'4@?K5-V)2N:M%8?ACQ7IOBRPDNM/\U1$^QXY@ ZGL M2 2,'ZU%XJ\8Z?X0AMI=0ANI5N&*I]G56(('?+#UH>FXDK['0T5!97<=_86] MY$&$<\:RJ&'(##(S[\U/3:MHP3N%%%%( HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **Y?1/'FEZ_P"(+G1K6"\2YMPY=I44(=K!3@AB>I]*-7\>:7HW MB6VT&X@O&NK@QA'C12@WG R2P/Z4+6WF.SU\CJ**S]8US3= LC=ZE=)!$.F3 M\SGT4=2?I2ZCJT&FZ)/JLR2-!##YS*@!8KC/ )QG\:5]+A9E^BL/POXJL?%N MGRWMA%<1QQ2^41.J@YP#V)XYK(-,T5H$OKI$FN'6.&(QJT5F>']C0ZI9QS)!*6"K, M&&"02%%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 ^*5X95EB(TU:(03D)>*.1T#CU'^%=!7S52G*G)QDM3[FC6A6@JE-W3"BBBLS8**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ KQ_P".771/^VW_ +)7L%>/_'+KHG_;;_V2 MIET-*>[]#TWPY_R+&E?]><7_ * *\]^-X7^R-*; W"=P#[;:U]%^)7A*TT+3 M[:?5MDT5M&CK]FE.&"@$9"UP7C;Q$WQ#\0Z?IFAP2R11$K&67!=FQEL=E Z M^]747-.R[_YDTO=5WV.H&N76B_ RTN8)&2YDC\B-^A7Y&: MX+P#XA\&V>D267B73K,7$1(> 5Y^O;OQ7,>.O\ DL5K_P!=K7^:TDKN M"95_C:[&QXY^'6A:%X(DO;&&1;RV,>Z9I6)ERP4Y&<#KG@#I5'X9>#-.\3Z7 M/?:T)KJ*"0V]O 9F54& Q/!!ZMTZ=:[SXH_\D\U+_MG_ .C%K(^"W_(GW7_7 MZW_H"4XZ\UQ2TC$XGP_:CP]\9DT^S=Q ET\(W'DH5/!]>WY5=^(-Y=^*/B); M>&HYS';12QPA?X=[ %G([D X_#WJ%?\ DO7_ &_G_P!!J7X@VEWX7^(UOXD2 M$R6TLLTAFBO53Y+DS M,Q+8[J3MP?8"N>^#>N78O;SP_>(;E66*1##$6'^L)(+,/;@# M\_2JC?F=]K$R^#7>YS7B^Q;4_B]_TZWDBNK783(96;S 6"G()QWSP!6-J'_)?$_Z_8O\ T!:]'^)G_)/=5_W4 M_P#1BU&U),M.]6QRGP\N=1NOA5K$%FSM=0F9+8*>02@( _$G\ZX+PG<^$;9I MX?%6FW<\C/\ )(CL!&.X8*P/7Z_2N^^%%]_9G@+5KW[--<^3=,YB@ +MA%Z MU5/B_P"'OBF:Y;7M(6RDR"DY1B\O'4M&,@^QR/Y5NW*;6 M.,9QU[XS7 S6^G2>/+.+P8UU)%YL9B9P&M(@\.Z=KD=IMU*6)U>;S'.1N(^[G;T M[5Y3I&A-XD\?2Z5YK11S7,IE=>H122?Y5ZE\+_%.E3^'M-T%;@_VE&LFZ'RV MZ!BV=V,=#ZUQWPW /Q5NR1T^T$?]]5;7[WRLR$VJ;[GI&E?#W2]#T?4K"PN[ MZ,WZ;9+AG4R*H'0$* !R>W>N'30/AGX=%Q%JVK#4YBY""-W)C 'W?W1QG.>3 M].U=K\4);N'P%?-:%P2464IU\LL-WX>OM7GOP^\0>"]%T:1]8MXQJB2,RR/; MF5G7' 0X(7N.U0G=OR*V2\S*\!7$$'Q1M?[,:5;*6:6.,2'#&,JV WY#\JF^ M)VBZ?I7C6"&RM_*CN8UFE&]FW.SMD\DX_"H_"E^NH?%VVOVB:)+F[DE1&X(# M*Q7^8K5^,JM!XPT^Y*G8;5<''!*NV1^HJE]BY3^*:78]&NK#3/ ?A'5;O1;0 M6Y6(R[3([@OC"GYB>^*\=\('PE=W-[>^,[Z1YG;]W&1*=Y/+,S(,^G>O7[C4 M]-\?>$M6L]&N?/8P;#NC9 '(RH^8#N*\L\!:MX'/&UKJ/A*]DDL5*LRD.NWG#)\P!((^O6N ME^,6K7%[K>G:)"Y$(C64KGAG";_P 1II6G^#[6[25U2*>* MRB! MQTW_ J'P\NA_9PDO]H"/B\\UL[\==N=N,]L?C7#?"%'C\>RI)]];:4-]=RU MW)^+WA[^POM(>7^T/+_X\_*;._'3=C;C/?/3MVKAOA$SOX_F:4$2-;2E@1C! MW+FG&_._0E_P]3WNO&/CA_R$='_ZY2?S6O9Z\7^.'_(1T?\ ZY2?S6HENO7_ M #*AU.AT3X5:#/X=@DU.*:?4+F(2R7'G,"K,,\#.#C/<'-'R6)D*C&00,<^Y M%]=A>_"+PW)H[V]I#-%>JGR7)F9B6QW M4G;@^P%<=\0;2[\+_$:W\2)"9+:66.93V+* &0GL<#/X^U=C>_%WPW'H[W%I M--+>LGR6QA92&QW8C;@>Q-9K^'YZEN_.K;:'-_"#7+X7&H>'I'9ECB::!6/^ MK8'!'T)(/X'UKC->:R\07J^--.O+IRY#!7*LDF?F+ ,"?S_.NT^$.C7<4F MH>)KB&5HVB:.%5'S3'.YBN<9Z ?4^U6+CQUX(\1ZE-;^(M"-L%7:+F:,F3(/ M*G8-RX^OKTJW\2[V%IK;:Y)H>B?#'6-5BETRYDCN 5\NU>XDC.X'.5W?,3]& M-='\5O\ DGM]_OQ?^AK7C?BJ#PVVKVL?@]KJ8/PP(;&\GY0FX!L__6Q7K7Q$ M6X3X4R+=G-R$MQ*?5]RY_6IEK"_F-:31G_#C2+'6_AC)9:C!YUNUU(Q3>R\C M!'*D&N)^&/A[2O$/B"]M=5M?M$,=N71?,9,' B/6XE'\J M\\^'.O:?X6\57[ZO,UO$T+Q;O+9L.''!"@GL:O3VC]"%?V>G?]6;GQMC2&30 MHHQA$BE51GH!LQ70>.M#_M?X86=Q&F;BQMXIUP.2NP!A^7/X5SWQJGCN3H%Q M$NYN<'Z M# _"K3NW4\O^'%)+(/ATVAL_AR[=-1C*[4VSD2C(!SO& <<\8J3QO9#PU\35U2^L5NM.N)1 M/L= RR+@!UP>,@YZ^U=%J?C3X<6EI%+8Z!I]]*[ -"-/6,HO.W>YF>?8<$HK$X_$@5 MV'Q"^'&B:5X8EU32('MI;8J77S6<.I(!^\3@\YXKC=(UW_A&_B3=:DT;R0)= M3K,J#)V%B"?PX/X5V?Q!^(^B:KX7ETS2)WN9KHJ';RF01J""<[@,GC'%9_\ M+N-OZV-]?:N^W_#FQ\/]9N-7^&MVMRY>6T66W#MU*A,KGZ X_"O+O /A5/%V MN/97$\L-I%&993%C<>< #.0#SUP>]>I?#_1IM(^&ETURC)+=I+<;&X(4IA?S M S^-O8 MIO$V@6\SPSZYIL4L;%71[N-64CJ"">#7'>!O$'AWQ#JSKIOA*&QN+=2_VF.W MBP@S@?, ""1V'O\ 6K&I?"30-5U.ZOY[O4EEN96E<))&%!)R<90\53O9(G2[ M-'Q=XIM[3P/J.IZ1?6]PZ@0I+;RJX1V('4'J FW6DZU)):XF,B2&)F&2 "I"@D'(].]*-N:7R&[\JMW-_3/A;BC[[G&"!]?0>M8_Q4_Y*3I__7&'_P!#:G&_-#U% M+:=^QT_QL_Y%>P_Z_!_Z U6=/_Y(6W_8-E_]FJM\;/\ D5[#_K\'_H#59T__ M )(6W_8-E_\ 9JC[$ROM0.%^%_A"P\43WLNJ!Y;6TVA8%D*AF;/)QST7M57Q M_H=KX.\8VIT??!&8TN(UWEC&P8C@GG^'O78_ _\ Y!FK_P#7:/\ ]!-87QJ_ MY&RP_P"O,?\ H;5H])QMY"A[W,GYG>?%)M_PXO'_ +QA/_CZUD?#K4#I/PGO MM0 !:W:>10>Y"@C]:UOB=_R36Z_[8_\ H:UD_#K3SJWPGOM/! :X:>-2>Q*@ M#]:CI.PEM"YROPY\,6OC75=3U+7FDNA&5+*9"ID=L\DCG QV-=/>?",P>)(= M0\/ZBNG6\6UU5MTC(X/..>1CU/K7+_#GQ/;>"=6U/3M>66U64J&8QEC&ZYX( M S@Y[>E;>N?%*_O?$MK9>$-MS"X$>)8#B60GJ <, !].]7I>/*#YO>N=3X^\ M+:=KUI!2>W6O./%D?PYMM$DM]":675$VA)4:1E)! M&=Q;Y<$9^Z*D^+,]V/%]@FI O:QV\;;(\A6Y_>;?J1C\JT?%7BSP@_@Z;2?# M5HGGW07YUY?\;O^1>TW_K[/_H!KU"O+_C=_R+VF_P#7 MV?\ T UC+IZHN&Y#X&^&^BZIX7M]2UF*2[N;M=RYF91&@X4#!&> .MD6_,-5!^Y&GWL#U8CK[^U=9XL^%F@Q>&[JYTFWDMKNVB:52)6<2;1D@AB> MH';'-X8))8#H#VSS4?\ +M6W_4TU]IY?H4OAOXPN(_!6L+=LTQTB M+S(2QR2A!POX%?R-87P_\,1^.M7U#5M?EDN4C8;TWD&5VSU(Y '08[>E;WP MY\'7+^!]8:Z4Q/J\)CA##!"@':Q^I/Y#WK ^'OBB+P-JVH:5KT4EO'(P#OL) M,3KGJ!R00>WMZUJ[<[OO;_AS/['N]RW\2/!%CX6MK36M!\ZU"S!&02,VQL$J MRDG(Z>OI77HMGXY^&,&HZO;^=/#;R2 [V7$J!EW?*1UQG'3FN0^)'C>Q\56U MIHN@^==!I@[.(V7>V"%501D]?3TKT#2M%D\/_#-].F(,T=E*TF.@9@S$?AG% M9N_LY7^1?VX]_P#@GF'PJ\-:1XCO-275K3[0($C:/]XZ;22<_=(STKVJZ\0: M)I\YMKO5]/MID S%-,+*T\(:E?Z1J-K=3Q*J*UO,L MGELYP"<$X[G\*X'X;>!-/\2V-SK6N"2Z#S,B1F5EW'JS,002G M>#]9L='ENYKBZ5)%6X=3EHR2 ,*.N2*YKX:^/-.\-V%QHVMF2U5)6D27RV;! M. 58 $@Y'I4QM=^B*=^56[E+Q[X<7P#KNG:KH$LMO'*6**6+>6ZXR,GD@@]# MGO7:>.+/3?$7P[7Q%<6N;M+-)8&WL/+W[21@'!_$&N+\=^(E^(&O:=I.@1RS MQQL51RI7S&;&3@\A0!U/O7HGBZP&E_"B[L%;<+:SCBW>NTJ,U+O[-W[Z%+^) M'\3C_A%X9TC5;";4[VT\V\M+Q3#)YCKLP PX! //J*]0F\3:!;S/#/KFFQ2Q ML5='NXU92.H()X-<+\$O^1[U)9;F5I7"21 MA02Y%\2?%<,/@IGT;4(9C=3BV,UM,'VC!9AE3P<8'XUC> M /AQH6J^%(=2U6![F>ZW%<2L@C4$@8VD9/&>Z^ MV$2D,Y&W:V-H'08/X&H/A_\ $;0]*\*PZ9JUP]M-:E@A\IG$BDDC&T'!YQS4 MJWO?(IWM&WF:WA'X<7_A7Q))?Q:LALV+I]G"$F2/^'<> ".#T/ZURGQ!O+OQ M1\1+;PU'.8[:*6.$+_#O8 LY'<@''X>];GA3Q[X@\3^-I;6TCB.D>8SL9(OF MBB' Y!')/KGJ>PK"^(-I=^%_B-;^)$A,EM++',I[%E #(3V.!G\?:CK#FV#7 MWK;G8WOPB\-R:.]O:0S17JI\ER9F8EL=U)VX/L!7/?!O7+L7MYX?N79HHXS- M$K'_ %9# ,!['.?P]ZZ&]^+OAN/1WN+2::6]9/DMC"RD-CNQ&W ]B:Y_X-Z% M=&[O/$-RK+%(AAB+#_6$D%F'MP!^?I3C?F=]K"E\&N]SDM/T5/$/Q1N],ED> M.":]G,NPX)569B/QQ71_$[P-HGA[0K74-)MWMW\\12*96<.""<_,3@\=O6JW M@?\ Y+-??]=KK^;5U_QG_P"1+@_Z_$_]!:HVIQMY&B=ZK7];,J6'B.[T[X'1 MZBDI^U)&;>)R>1^\* _@/Y5B?#/P-I7B/3+K5M:C>Z)F,:(9649 !+$J02>? M6M31='FUWX%_8K==UP?,DC7^\RREL?CC'XUE?#/QSI?AO3;K2=:DDM<3&1)# M$S#) !4A02#D>G>M';GE,5U72]56VLHY R0LI=V0CYD M/(XZCOV/6N=^,&LRW7B2UT5IS%90(KR8R1N;^(@=<#&/J:TXOB1K6N^.TT_P MZL4NG2.J@3P]%'WW.,$#Z^@]:S/B]I4]CXHL]<\@2VLJHK;AE=Z'[K?48_6H M_EOME019'3U0@^A?9M_$9KJ M/"U_I&K^&[[4-)T%=+C=60E8$C\W /(*]0,GK[T2^&?H);Q]3R7X;^%X/%.M MS07S2?8;=!++$C%?,;.%!Q]3SU_.M[XF^!=,\-Z?:ZMHT*(?"VO23WBR?89X_*F=%W>6?2G/9(!;>)OA!;>(;^+S-3MHQ$DV M]A@^:$8X!PU6]5T.?2? M@:]A(C">.%995QDJ3('(_#/Z50^$GBG2K'2!HES<%+^>\/DQ^6QWA@O<# Y! MZFK5N>21#_AQ^9ZY7F?QL_Y%>P_Z_!_Z U>F5YG\;/\ D5[#_K\'_H#5E+_( MJ&Y9T_\ Y(6W_8-E_P#9JX7X7^$+#Q1/>RZH'EM;3:%@60J&9L\G'/1>U=UI M_P#R0MO^P;+_ .S5F? __D&:O_UVC_\ 036G_+R1"=J:]3CO'^AVO@[QC:G1 M]\$9C2XC7>6,;!B.">?X>]?0L;;XD?\ O*#7AWQJ_P"1LL/^O,?^AM7M]O\ M\>T7^X/Y4H_!\V747O+T$N?^/6;_ '&_E7SW\/O#L/B<:WI\@ E-J'@D/\$@ M;@_3L?8U]"7/_'K-_N-_*O%O@E_R']3_ .O8?^A"IBKR:\A-VA==T6OA9X@F MTR^O?">IYC?'*.5,1=3R&4[E_F?RJ8OEC%^;_$;7-)Q\D9VED^(O%WB M_6L;HX+*Y\LCW4HG_CH-7_@=_P ?VL_]Z61%/JJ MH?ZDU4^!W_']K/\ URB_FU5%+?F8OA[]Y\:R9^3_:%P?F]?GQ_2 MOH"O#?B'H>H>%_&*^)]/C)MI)EG$@&1'+W#>Q_7)KMM-^+GABZL$EO;B6RN, M?/"T+OS[%001]<4HOW$NP33<[]S,^-H3_A'-.) WB[P/7&PY_I5OP/I$'B'X M2P:9? ^3-YBJPZKB0D,/<&N%\7>(;OXD>(K33=%M96MXB1"K#!8GJ[>@_I]< M5WWBC3]:\,?#RS@\.W+QO8!?M!B0$NN#N89!_BYX[9I+2#;ZL;^**6Z.!O\ MX;^,/#=V\^D/+.@SB>QE*28]UR#^ S4FF?%#Q5H%\MOK<3W,8/SPW,7ERJ/8 MX!S]0:Z/P3\5-.CT9+/Q'=S)=PDC[0Z-)YH)R,E03D=/RK#^)OC'2?%2V.GZ M,CW4D\/ M^%WL]4U#[/<&Y=PGDR/\I"X.54CL:I63FEY$.[A'YG>_$ *W@+6 P!'D$\^N M1BN,^![/]@UA23L$L9'IG#9_I57XA_$?2]8T)]'T1Y+EKAE\R7RV10H.< , M220.U=?\,O#DWA[PJOVM"EW=OYTB'J@QA0?PY_&IA]ICG\*1V=>?>._".AZG MJ4&JZWX@>RC7:@AE=0A4')"#@Y/KS7H-?/WC*[C3XL2/K\,#*4*8.<^8>N<=*]2^&]Q)&M1T"#2/#5NGEI*)I'AMC$B C&" H,P;GON/_P!:C[$QO>)Y9\.?#5MXH\126E\S_8X8C-)&C%?, M(( '_CU:?Q2\(Z7X8GTZ?28G@CN X:/S&8 KC!!8D]_7M5WX)?\ (?U/_KV' M_H0K2^./^HT7_>F_DE.>G+;^MP@[SDGYESQKXBNX/A/I4B2L+C48H8Y) ><% M,M^>,?C57P#\-M$U/PO#J6KP/4O\ Z :\(\#> M.O\ A"_MW_$N^V?:MG_+?R]NW=_LG/WJ]W\6_P#(GZS_ ->4O_H!KSCX&]-; M_P"V/_L]*'Q2]!NW(K]S"\1^-M:^(5O'I.FZ-)'#YBLZ0DRLQ[9; '4].WM M7?V/AR3PQ\)]2L9V!N6M)Y9MO0,4/'O@ "N]K'\6_P#(GZS_ ->4O_H!J9:0 M:74<7>0$'_=->,?"KQ7HGANWU-= M6O?LYG:,QCRG?=@-G[H/J*Z/QE\4]#F\/W5EHT\EU(]14$[#:9/IG>,?UKW"O-/@_P"&Y]+TFXU6[C,< MM[M$2L,$1CO^)/Z"O2ZN71$=6PHHHJ!A1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% % M63_D)1?[O^-6JJR?\A*+_=_QJU4KJ7+9>@5P_P 6O^1 NO\ KK%_Z$*[BN'^ M+7_(@77_ %UB_P#0A2GM_7=!#XCR;X?^(Y/"WB2":?#RYLC@KG $?\ A)/A!I]S;)G4+(S/'C_EHN]MR?ID>_UK ME-:\3MK7@[2-/N6)N]/E="3_ !1[1M/U&,?@*N?\O5-?<.._,NM_O/;TUZS\ M-^ -/U*])\N.SA"HOWG8H,*/>N"_X6SXGE5M1M_#<9TE#\TGE2L!ZYE'RC\J MC^)CRCP#X5C&?*:)"W^\(UQ_,U=T>]^(J^&;.TL?#6E2Z!UIRNY2?FR8)*$?-';Z#XPM?$?AFXU6R3RYH$;S()#DQN!G!QU!]:Q_ MAQXUU+QA_:/]H06D7V;R]GV=&7.[=G.6/H*PO /A?Q!X;M=?_M6Q^S6\]F=O M[Y'!8 ]E8]B:@^!K#=K:]\0G_P!#IJW,_3]1-6C\S=\6>/-4T+QO8:+:P6;V MUP(B[2HQ<;G*G!# =!Z5<^(WC'4/"%I82Z?#:RM<.RO]H5F Z88>M<5\1' M#?%K2 #ROV8'_OX3_6M7XX?\@[2/^NLG\A6=_<3\S1)<]O(CT[XM:GJ_BJRT MZQTRV:UGD6,[]PD.?O,#G Y.,'@=:W?&7Q+B\/:A_96FVGV[4N RY.V,GH, M#ECTX&/K6_X(LX;'P5I$<"*H>V21L#JS $D_B:\Q\ (ES\7-4DO0&N$-PR;N MQ1>*/#YM893PZ0R0L!W(5R=WYBN ML\;>,)M"\*6VLZ1]FN5N)45&E#,I1E)R,$'L*K_%J*WD\!7+S!?,CEC,)/4- MN X_ FO/M0DF?X&:9YI)"Z@53/\ =^?^N:ENZ?DT7&*NO._Y&U)\6=>N],6? M2?#_ )WDQ@W=RT,CQ(V,L %/R@>I:KEG\8#>Z.J0:/+<:ZS[$M80S*PQG>, MG'^SU]^];_P\@B3X9685 !)%*S\?>)9NM<-\$H8VUW4Y2@+I;J%;'0%N?Y"J M:]YQ(NN7F-WPK\4=0OO$4>B:_ID=I<2OY:M&K1E&QPK(Q)Y]<]QQ5K4O'VK: M1\1X=!O+>R&G32H$F",)-CC .=V/O<'CM7,>,45?C;IA4 %IK4M[GPL-<@7$EJ_E2,.H4\J?P(_6DFK1D^^I3CJXKL=OXOU\^&O#-WJ:*CS1 M@+$K@D,Y.!G!''?\*R_"WBVZO?! MT\8V2[)-(ZAG.XY MS^]7OQT[5=\!>%?$^D^-I]4U+2TM+:Y27S/+FC*J6.X *&)QD5:5G8F6US.^ M&W_)5=9_W;C_ -&BMOQ;XC^P?$K3=._L;1[CS6@_TFXM=\Z;GQ\K9XQU''%8 MGPV_Y*KK/^[HZG=^)1;7EGY M-I:EEM)?*9?.4A2QR3AL'TKM]+\2:]=> ];N]A^ M\H&<'C)IWP819?".H1N,JUVRD>Q1:R)/A]XQ\)WT]SX4U$2P.OUXJYZ2UVL2K6?>YU'ACQOK5]KS:)KV@R6MTN0TUNC&-6QD!NN 1WW'] M:[RO*= ^(^NV?B*WT+Q78+'+,RQB4)L<%N 2.A!/<8KU:CHF2]SS/XR:]-8: M):Z7;NR-?,QE*\9C7&5_$D?E5SP-\/M%L_#UK=ZAI\%Y>W42RN;A X0$9"A3 MP, ]>M<_\<+24MI%X%S$/,B)]&."/Y'\J])\+ZA#JGA?3;N!@R/;H#CLP&"/ MP((I0^%OS*G]E>1YW\4O ^F66BG7-*M8[.6!U$T<(VHRDX! ' ()'2K-EX^U M&V^%$6LQB&>_MIQ:R&<%@WN<$'.".];?Q7OX;3P)=0.ZB6Z=(XU)Y.&#']!7 MG4=K);_ V>5Q@7&HB1..W"_S4U-_=E\OS1=D^6_F;J_%CQ#J-C%_8_A\75Q& M@-U*L$CQJ>> JG(&,7$@5CT7)]/SKC9_B MQXAU.XE/ASP[YUK$3N9X9)FQV)V$!?UJJ[2+^S['LS@S8?'IYQ_^M77?")8E M\!PF,+O:>0R8ZYSW_#%:-7E+R(T45YW)? WQ"@\722V<]L+2_B7?L#;ED7H2 M.XQZ5E^*/B==V6NR:)X=TP7]Y$=KL59P6'551>3CUSU^E=?INB^'+34Y[G3[ M6R%_OAV\ ? M>YXXJ7JT"6[*>D?%?58M M*K!_$+VANFC0HMKG:B;S@<]\Y[FOH<=!36L;BDK2MY"T444A!1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GWC3_C[ M@^LG\Q7+UU'C3_C[@^LG\Q7+U]+E_P#NT?G^;/A\Y_WV?R_)!1117<>2%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 /BE>&598G*.IRK X M(->C>'/$::M$()R$O%'(Z!QZC_"O-J?%*\,JRQ.4=3E6!P0:Y<3AHUXV>_1G M?@<=/"SNM4]U_74]FHKG_#GB--6B$$Y"7BCD= X]1_A705\U4IRIR<9+4^YH MUH5H*I3=TPHHHK,V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'USPMHWB3R/[7L_M/ MD9\O]ZZ;';-[32 MK;[/ [F1E\QGRQ &PK2HH PO^$-T :]_;GV#_B9>9YGG>=)][&,[=V/T MK6N[.VO[9[:\MXKB!_O1RH&4_@:GHHZ6"^MSEH_AQX1BN_M*Z)"9,DX9W9/^ M^"=OZ5TZ1I%&L<:*B*,*JC ] *=10!A2>#M!EU\:X]AG4@XD\[SI/O 8!V[ MMO0>E:6IZ99ZQITMA?P^=:R@!TW%@%9^H^ O"VJSF>[T: RDEF:(M$6)ZD[",_C71T4 M/4+V,C1O"^B>'P?[+TZ&W8C!D&66=MJ%I):WD$<\$@P\U/TWP;H&D:J^IV-AY5 MX^[=)YTC9W#- O=9CU>?3P;Z,H4E25TP5^[PK <8':KFL^' M]*\06ZP:K91W**'M>E\[4M+AFE[R*2CGZLI!/XUN44/42=C)T;PQHGA\'^R M].AMV(P7&6.10RL/<&I:*'KN!S=EX!\ M+:?>_;+;1H!.&W NS.%.'=RYPX8[F97= Q]2% M(!/U'-='11Y@M##U;P=H&N1VL>HZ>)4M$V0*)70(O''RD>@K8@ACMK>.")=L M<:A$7.< # %244 8.J^#/#VMZDNH:CIRSW2A0'\QUR!TR 0#^(K> P,#I111 MY!N5=0TRQU6V-MJ%I#"*]5M_ 'A6UO\ M[;#HMN)LY&XLR@^R$[1^ K5M]$TFTO#>6VEV4-T229H[=%3?<9+$D\+PR+F-U*L,XR#P:R-#\):'X;EFETFQ^SO,H5SYKOD#_>8UM4 M4"\@(!!!&0>U?#OPE?W)N)]%A$AZ^4[Q@_@I _2NHHH'=E33],L=)MOLV MGVD-M#G.R) H)]3ZFK=%% @K U;P3X;URX-QJ&E0R3$Y:1"T;-]2I&?QK?HH M'>QF:/X>TC0(C'I=A#;!AAF499OJQY/XFJNJ^#M!UO4H]1U&P\Z[C5563SI% MP TOQ':QVVJVOVB&-_,5?,9,-@C.5([$TZ/0M-BT( MZ*EMC3C$8O)WM]P]1NSGOZUHT4>07,G0_#6D>&XIH])M/LZ3,&D'F.^2.GWB M:@UKP=H/B*[CNM5L/M$T:>6K>=(F%R3C"L!U)K=HH!:;%'5-'L-9TQM.U"#S MK1]NZ/>RYPA>'V+Z7IL,$A&/,Y=\>FYB3C\:V:*%IL# M=S/U?0M+UZV%OJEE%$EW'T9B2*UYX([FWE@F7=%*A1USC((P1Q4E%#UW#S,70 M_">B>&Y)GTFR^SM, )#YKOD#I]XGUK:HHH *P]7\&^'M=E,NHZ5!+*3DR+F- MS]64@G\:W**!WL96C^&M&\/H5TO3X;8L,,X!9R/0LNXEH9>B>'M*\.6TEOI-K]GBD?>Z^8SY;&,_,3Z5J M444 %6\5Q _P!Z.5 RG\#4]%#UW%L7?NSLTOG2');[W!;'.?2KFM:%IOB&R6SU2V^T0*XD";V3Y@",Y4@]S6C11 MTL.[O3:QDE4WLV,G)Y8D]36;JW@GPWKEP;C4-*ADF)RT MB%HV;ZE2,_C6_10]=Q)VV,S1_#VD:!$8]+L(;8,,,RC+-]6/)_$U=NK2VOK9 M[:[@CG@<8:.10RG\#4U%#UW Y6/X;^$([K[0NBQ%\DX:1V3G_9+;?PQ6_=11 MP:3/%%&L<:0,JH@P%&.@%6Z1E5U*L 5(P01P12DKQ:&GJFSPOX.6=M?ZKJUM M=P1SP26@#QR+D$;AVKU33/ WAK1[W[98Z3#'< Y5V9GVGU7<3M_#%:=CHVE: M9(TEAIEG:.XVLT$"QDCT) J]5-[6%W&2Q1SQ/%*BO&ZE61AD,#U!%<]9> ?" M^GZDNH6NDQQW*-O5O,8[Y(Z?>)K6HH\P\C"UKP=H/B*[CNM5L/M$T:>6K>=(F%R3 MC"L!U)K<50JA5& !@4M%'D#U$90Z%6&588(K%T3PAH7ARXEGTFQ^SRRKL=O- M=\C.?XF-;=% >1#=VD%_9S6EU$LL$R%)$;HP/45DZ)X0T+PY<2SZ38_9Y)5V M.WG.^1G./F8UN44!Y&'J7@[0=7U6/4[ZP\V\CV[9/.=<;3D&SGDG/<]ZJ:'X3T3PW),^DV7V=I@!(?-=\@=/O$^M;5%'6XO(9+%'/$T4L: MR1L,,CC((]Q7,7/PV\(74QEDT6)6/:*1XU_)6 KJJ*!W90TO1-+T6(QZ;806 MJM][RT +?4]3^-7Z**!'-ZAX!\+:I,9KK1H/,))+1%HLD]SL(S5G2?!_A[0I M!+IVE00RKG$IR[C/HS$D?G6W10M-AMWW*>J:59:UITMAJ$/G6LN-Z;BN<'(Y M!!ZBN;_X5;X-_P"@-_Y-3?\ Q==A10%V8&E>"?#>B3":PTF".93E9'S(RGV+ M$D?A6_110(*R=:\,:+XA5!JNGQ7!3A7)*L!Z!E(./QK6HH"]C"@\&>';;2I] M,ATJ%+6X 6903N< Y&7SN.#[U9T?P]I>@64EGIEL8+>1BS)YKN"2,'[Q..!V MK4HH Q-$\(:%X&-'\2+ NK6?VD0$F/\ M>NFW.,_=(]!6O10]03L06=G!864-G;1[+>%!'&F2<*!@#)Y-8-S\/_"EW??; M)M%@,Q.3M9E4GW4$*?RKI:*.MP.?N?!/AR\U"WOI=,3[1;!%A*2.BH%.5 52 M%X^E=!110!#=VL-]9S6ERF^"9#'(N2-RD8(R.:S=#\+:-X:\_P#LBS^S>?M\ MS]Z[[L9Q]XG'4UL44!Y!4-W:PWUG-:7*;X)D,>>.OA?JD_B&2\\/62S6US^\D MC$J)Y;]\;B.#UX]Z]IHIRU=PB['):KX/7Q#X%LM'O#]GNH((]C\-Y-Z/W'L#[5[;11UN"=E8\2G^'7BW_ (2C3M3NB-1E:6.:[G$J 1D/]T;B M"<*!T&.PKJ_BIX:U?Q)9:;'I-I]H:&1VD'F(F 0,?>(KT*BDU=)#YG>YF^'[ M6:Q\.:9:7*;)X;6..1<@[6"@$9'%<)XO^'6I3>(/^$A\,72V]Z6WO&6V'?W9 M3TY[@\=:]-HIR=Y#?$OB35 VF:PMOISPK'+;27$BJ MQRT6V\0:+U\+?$KPJ);'0KA9K-F+!HWBV_7$G*GZ5W7@G1O%&G12R M^(]8:Z+C$=OD/LYSDL1DGV''].NHH3&W<\O\$>$=@]*/%OA'7-3^)6FZO9V/FV,+0&27S47&U\MP6!Z>U>H44EIR^ M0-WOYG ?$_P;J'BBULI],"/<6I<&)G"[U;'0GC.1WQUJ'3M+\9W?@;6[#75$ MMW-!Y5G%OB!Q@C!*_+Z![26>=B/ M+F4MM**,AD)P>#[US,GA#XA^&M1N)= U(WL,CV)KV*BF]7 M<2=E8\GT#X?^(M4\30:_XNN5\R%E<1!U9V*GY1\ORJO?BO6***=]+">KN9?B M'0+/Q)H\NFWRGRWY5U^\C#HP]Z\LA\%_$'PC+)'XBIMK=%+/%.IQ7GB[4/+B7JGF*S@9Z*%^1<^OZ5T7Q1L[?3_ M (;"SM8Q'!#+$B(.P!KT*N:\=^'KOQ/X9?3;*2".9I4<-,Q"X!]@3^E*7PV0 MXOWKL\Q\,:'XVM?"MMJ7A2_W0WNXS6I* JP8KD;^.@Z@@UU?P_\ A_?:/J#=$N?#OA6STN[>)YX-^YHB2IRY/&0 M#W]*WJT;M)V(O=6/,?B/X)UK6-U2ZIHG MB_6OAI/8ZI&MSK,EPKA \:_("#@D87CFO2:*BVEBN9W3.,\+>%91\.$\/ZY; M>4[B19$#JQ7+D@@@D9Z&N)@\'?$3PE+/;^';E9[25BKN).RL>;>!/AY>Z1K$FO:].DNH-N*(K;MK-]YF;N>2./6L&]\!>,/#OB> MXU+PJZR1S,Q5UDC#*K')5E?@\_7IVKV>BCJGV#F>M^IXAK_PY\8WDEKJD\PU M74Y&)G42(JQ*,;0"Q4>O &!7MD+.\$;21F-RH+(2"5..G'%/HIWTL)ZNX444 M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** //O&G_ !]P?63^8KEZZCQI_P ?<'UD_F*Y>OI(TU:(03D)>*.1T#CU'^%>;5>TBRO+[4 M(X[+*RJ=WF#@)[DUR8JA"K"\M+=3T>18XHU M+.[G 4#J2:DKB?BNET_@*Z^S!BHD0S;?[F>?PSBB3LKBBKNQ6O?C#X7M)S%& M+V[ _P"6D$(V_P#CS*:Z'P[XQT3Q0K#3;K=,@W/!(I5U'K@]1[C(KSCX>WO@ M+^PH[75H-/74MQ,KW\2L&YX*LPP!C''']:T[+X>SVOCBW\0>&[W3UT@2JX19 MF)V$?.JX!!!!..>]:6L[/[Q.UKH]2HKS_P"('CO4/".JZ?;VL%K)!.A>4S(S M, &QQAAVKG[[XL>(_P#D(67AP)HV[ FGBD.X9_O@A03^./>H3N/E9[!17/>% M_%]AXFT%]33_ $?R[*N!UQGD$>AIW MC?XA6_A.6*R@MOMFH2C<(]V%1>Q/?)["AZ DWH=K4=Q<0VEN\]Q*D,,8W/)( MP55'J2:\CB^+/B'2[J+_ (2+P\(;>7[I6&2%L=R-Y(;]/K5OXKZY>7/AJT33 M[83Z/?1K++=")CLPRE/F!PN?0TGHKC4=;,]&TC6++7+'[;I\AEMB[(K[2-VT MX)&>U7Z\A^$VM:]BUTDZ9_Q)0)7%YY#_ 'N3C?G;UXZ55/QGU.W-_%<6%F\R M-LMO+5U&03DOECGC' Q3=D["2;/:**\Q3XBZVWPYE\1/8V27*W0@0$.8W7N= MN[(].O:NP\&ZW<^(O"MGJEVD23S[]RQ A1AR.,DGMZT[;^7ZB-ZBO//"_CS5 M-;\>7^AW,%FEK;F8(\:,'.QL#)+$?I53Q+\3KWPYXWFTN6UMY-.A"EBJ-YQR MF< [L=3Z=*F^WF5RN[78].HKQZX^+?B+3[Z&74/#BVVGS!8W4]B"H%2K\JD6U%2L;&G:E9: MO8QWMA<)<6\@^5T/Z>Q]C6"GCS2W\8GPP(+S[:'*>9L7R\A=W7=GI[5YY\*+ MVXTCQEJ/AV60F)O,&WMYD9QD?49_(5MQ>(]WQA;2/[&TV\1>&$,BZ M1-J=ZYCMXE#'*_,<] !ZD\8KRU_BMXGU&22?1/#8EL8CAF,,DQ'U92 O'UI7 MUL"3:N>PT5QW@GX@6?BX26[0_9-0B&YH2VX,OJI_F.ULT5POP^\;:CXIL]1N=3M;6WAM2,3 M0[E!X)(()/0#.<]ZYR\^+>KW^K/;>&-$%W"A/WHI)))%'\6U"-H^N:'H[ E> MYVGB'Q]I7AK6;?2[RWO))YU5U:%%*@,Q49RP/4>E=37SGXK\1'Q+XMTRZDLI M;*XB6.&>"3JKB0GO@]QU%>O^-O'5KX/MXE\G[3?3C,< ;: O]YCV'\Z/LW?< M;7O678ZVBO'X?BQXBT^:&77_ [Y5C,1L=(9(F(]07)#BN*SO8Z&BO$I/C7JO]GP"+3[(WI9C,S*_E@9 MX"C=G/J<_A7L.E74][I-I=7, @GFA61X@<["1G&:=M+B>A:=UC1G=@J*,LQ. M !6%H/B[3_$5M?7-C#=?9[-RAED0!9"!GY.3GC'7'45B_%?6GTGP;)!"VV6^ M<6X(/(7&6_08_&K7@S2UTKX;VT0&'FM6G?U)<9_E@?A4-^[*7;\RK?"N_P"0 MOAGXC:)XIU)K"S2ZAN A=1<(J[P.H&&/-;^M:M!H6CW.IW22/#;KN=8@"Q&< M<9('?UKY_%.KV^N_">]U*U/[N>V5 ML=U.X94^X.153TAS(:C[Z3V9M:#XLL/$.A3ZO:17*6\+.K+*JASM )P 2._K M7.Z?\7O#VI:C;64=MJ,-^NI]4W$\=K;2W$IQ'$A=CZ # M)KA-/^+N@:EJ5M8PV>IK+<2K$A>*,*"QP,X?IS3_ !KXC4_"LZA$P#ZC!'&G M_ Q\P_+=7D>DZ6TF.1C[^UOZT17O\K] M[G,?2EQ<0VEO)<7 M$J10QC<\CMA5'J37"WWQ@\+VDYCB^VW8'5X(1M_\>9:YOXRZU<2WUCX>MV81 MLHFE4?QL3A0?I@G\17:^'_AYX?T?2XH9],M;RY*@S37,0D+-WQNS@?2I5VK] M =E9/)9!#8WFVY(S]GF78_X=C^!-=!//%;023SR+'%&I9WTG,48O;L#_ ):00C;_ ./,IKH?#OC' M1/%"L--NMTR#<\$BE74>N#U'N,BO./A[>^ O["CM=6@T]=2W$RO?Q*P;G@JS M# &,<*?%MAX1LX+J_AN9$FD\M1 JD@XSSDCTKE?\ A=?AO_GRU7_OU'_\GW1%PJ[FMY5V.!_(X]B:?X@\6Z?X:N[&'4(KD)> M/L2=%!C0\?>._$ MJTCUOXW)MY#GD[>A/_ 2*ZVJDK.QFG<****0PHHHH **** "BBB@ HHHH \^\ M:?\ 'W!]9/YBN7KJ/&G_ !]P?63^8KEZ^ER__=H_/\V?#YS_ +[/Y?D@HHHK MN/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBKFFZ;< M:K>+;VZY)Y9CT4>II2DHJ[V*A"4Y*,5=L--TVXU6\6WMUR3RS'HH]37IVDZ3 M;Z19B" 98\NYZN?6C2=)M](LQ! ,L>7<]7/K5^OG,7BW6?+'X3[;+LNCAH\T MM9O\/)!1117 >L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2.ZQHSNP55&2Q. !2UY3 M\9O$,]K:VFB6TA07*F6XVGED!P%^A.?RI-V*C&[-W4_BUX6TZF6\5Y="XFBB"RSE=N\@7R]OG>7C@G.=ISTH>BN%G>QU%%>87_QITZVM[?[+ILEU MFV=_:Z9X3M+V\F6&WAM(V=VZ ;127PMON$EJDN MJ->BO*;OXWV4=V4M-&FGMP<>;).(V//4+M/\Z[+P]XUTOQ-IEQ=6!<36Z%I; M:7 =>/;.0?44=+A9WL:.H>(=+TR^M;&YNT%W=2+'% O+DDX!([#W-6-3U"+2 MM+NM0G5VBMHFE<( 6( R<9(YKYQOO%WVWQXGB?[#LVS1R_9O-SG8 ,;MO?'I M7M5CXNBUSX?WNO3Z6AB2.7?9O('60*.025Z'Z4?8N-JTDB_X5\8:?XO@N9M/ MANHEMV"L+A54DD9XPQKH*XGX<^(-/U^SOI-/T&UTA8I%5DM]N)"0>3A5Z5G) M\7;&'6]0L=0T]K:&T,BB99O,:1E;: %VCD_7BF]'8E)NYZ/17E,?QPLFO=DF MBSI:Y_UHG!?'^YC'_CU>F6NI6EYID>HPSJ;22/S1*3@;<9R?2ETN.VMBU17E MVI_&O3;6^,-AIDUY K8:9I1&#[J,'/XXJ34_C-IUM;6UWYZMYL;S^4\ M+#'!&ULYSUH6H^5GIM%1P2>=!'+C&]0V,],BI*'H2M0HKSSQ'\7-)T6]DL[* MUDU&:)MKLL@2,'N V#DCZ8]Z/#?Q;TK7+^*QO+233YYFVQLT@>,GL-V 03]* M%KL-IK<]#HJIJ6IV>CZ?+?7\ZPV\0RSM_(>I]J\SO/CA9QW&VST2:>'^_+.( MS_WR%;^=*^M@Y7:YZO17->%?'&D^+8W6S9XKF,9>WF #@>HQP16/X@^)D/A[ MQ:NBW&G PYC\R[-QC8K8R=NTYQ]>:>SL"5[^1WM%>5W7QNL([[R[;2)Y[4'! MF:8(Q&>H7!_4C\*T]5^+N@V6FV]Q9+)>SSIN%N"$,?LYYP?IG\J.EPY7>QZ# M17#^#_B7I_BJ]^P/:O97I4LD;/O5P.N&P.<8)7T.SHKR_5OC3IUG=F'3]-DOE4X:4S"-2?]GY22/? MBNN\*>,M,\76LDEEOBGB_P!;!+C.H]Z%J#5MSHJ*\[U#XKVNE^*[K1[S M32EO;LRM="?).%R,)MZDX'7O5GP?\2D\6ZU+IZ:3+;JD9D$OG!QM!Q\PP,=1 MTS0M=@::W.[HKSCQ!\8=*TJ]>UT^S?47C;:\@E$<>>^#@Y_+'O6AX3^)ND^) M[I;%XI+&^8?)'(P97/HK<9/L0*%KL#36YM>*/%5CX2L(;R_BN)(Y9?*40*I. M<$\Y(XXJ_HVJP:YI%MJ=LDB0W"[D64 ,!G'."1V]:X'XV?\ (KV'_7X/_0&K M*TGXH:;X9\':3816SWUZD/[Q%?8B?,>"V#SCT%)/1W[C<7I8]AHKCO!WQ$T_ MQ=,]H+>2TOD7?Y+L&##OM;C./<"KOBOQMI7A&%/MA>6YD&8[>+!8CU.>@IO3 M<23;LCI**\KT_P"-UA-&KC6[7;= MP1V[7";'P) !GK@X_*AZ*X6=[&I17F-M\:-,?2I+FZT^2*Z$FR.UBE\PL, [ MBQ '..]2>'_ (Q:=JVI165]I\E@9F"1R"82)D]-QP,?K32N[ TTKGI5%9VN M:Y8^'M+DU'4)2D*< *,L['HH'+AX::WO3>F58MX1?+R0".=V<<^E2>$_'6E>+A*EH)8;F( M;G@F SM]01U%<]=>*]*C^)JZ,WA>R>]-PB?VB2OF E00WW,Y&[55O>2%] MEL](HKA-5^(_]C>-(] O-)*1/(BK=_:."K8PVW;TSQU[&NSO[V'3M/N+VX;; M#!&TCGV S4W]WFZ#L[V+%%<;X(\=2^,YKL#2?LD-L%S(;CS-S'.!C:.P/>JO MBKXIZ5X4[49I \9/8;L#!/TQ[UZ%3L(**S]7NV[L=LX. M/RK@(OC3IQTAKJ?39$NS(4CM8Y@^0 #N9BHP,G'0]*FX^5GI]%><^'/B]IFL MZA'97UD^G22MMCP)P,9^F/>MSQOXR_X0VRM;C[!]L\^0IM\[R]N!G/ MW3FF]-6"3;L=517EMU\:K&)[5+?29+@R1HT^)\>6Q )5?E^8C\.:[77_ !9I MWAK28[_4B\;2C]W;C!D9L9P!G''<]*'HKA9WL;M%>3P_'"S:[VSZ'.EMG_6) M4<,.H/<$=B/2G;2XGH7:**I:MJUEH>F MRW^H3B&WC')/4GL .Y/I2;L"5R[17DUQ\<;5;G;;Z'-)!G[\EP$;'^Z%(_6N MY\*^,-,\6VCS6)=)8B!+!* '3/0\=0?6A*XVK;E32OB!I6K^)I= M[>]6ZB: M12\B*$RF<\AB>WI1X@^(&E>'-;ATF\M[UYY55E:%%*@,2!DE@>WI7F_@?_DL MU]_UVNOYM75^-?%>E:/XNM;"\\+V6HSR1QLMU,5W("Q RA/&,]>]$=5#S"2 MLY+L>D45S/C;Q=_PAVEV][]A^U^;-Y6SS?+QP3G.T^E_&C3+>RMVM]/DN M;N2-7EB$NU(B?X=^.2/9:5PY6>G5S7BOQQIGA"2U34(+N4W(8I]G16QMQG.6 M'K5+P=\1=.\73-:"WDL[Y5W^2[!@P[[6XSCZ"J?Q'\2Z9X?FT]=0\.6FKF97 M*&X*_N\;\C7JD=1^54_%GQ-TOPO>-8+!)>W MJ#+QHP54/8,W//T!I/3<:39V]5-3U"+2M+NM0G5VBMHFE<( 6( R<9(YKS73 M_C=8SW*QW^D36L1('FQS"7;[D;5X^F:[7Q;-'<^ ]6GA=7BDL9'1U.0P*Y!% M*5U&XXKWDF'A7QAI_B^"YFT^&ZB6W8*PN%5221GC#&N@KRGX'_\ (,U?_KM' M_P"@FO5JN2L0NH5#=W*6=G/=2!BD,;2,%ZD 9.*P?%OC;3/"$$9NP\US+S'; MQ8W$>IST%<7'\8-.UBPOK*^L)+!Y;>1(W$OFJ6*G /R@C\JS;T=C2,=5?8[+ MPKXYTSQ?+\:P6"2]O4&7C1@JH>P9N>?H#5RLK$I-MV.WIDTT5O"\TTB1Q(,L[L %' MJ2:\MT_XW6,]RL=_I$UK$2!YL/IFI?BUXHCB\/P:7# L\6J1"5+ ME9,!0K*PP,M:% M>(_"SQI_9\EKX:_L_P S[5?N^M=OXL^)NE^%[QK!8)+V]0 M9>-&"JA[!FYY^@-5*R$DV[';T5Y5I_QNL9[E8[_2)K6(D#S8YA+M]R-J\?3- M>HP31W,$<\+J\4BAT=3D,#R"*+:7$]-"2BBO-8_C!8QZIJ-K?Z8%D2 M?>TK*VT*%VCD]>O&*5];#2;/2J*\JM?C?8R7WEW.CSPVI.!,LP=@,]2N!^A/ MXUZ2NJV+:3_:@N8_L/E>=YV?EV8SFCI<+:V+E%>4W_QOLH;@I8:--9+ M.(L^X&UJZ+PA\2=,\5W7V'R)+.^V[EB=@ROCKM;C)'N!0M=@::W.THKG_%/C M'2_"5JDE\SO-+_JK>( N_OST'N:X:W^.-JUSMN-"FC@S]^.X#M_WR5 _6A.X M%?'>E^+[BXAT^"\B:! [&X15!!..,,:TX=5 ML]:\./J%A,);>6%RK=".#D$=B*\J^"!QJNK$]/(3_P!"-"^)I]@?PW7<]JHK MSQOB@;OQ2=#T/13J1W[!/]I\M3C[S?([>'E MFQU/..!ZTKZ7"SO8Z&BO(T^.4)G DT!UASRRW8+8^FP?SKTG0-?L?$FDQZCI M[LT3':RL,,C#JI'K56TN)JVYIT5P?BOXI:9X;OGL(+9[^\CXD5'"(A]"V#S] M!6>GQFTR30Y[M;!UOHBO^AR3 !P3@E7VG./3%2G=7*Y6>F45@^&/$T?B'PRF MM2P+91DON5I=P0*2"2V!Z>E<9JOQKTZUNVAT[3);Z-2097E\H'W4;22/KBF] M'823>J/4:*Y3PEX_TGQ:6@@$EM>(-S6\N,D>JD=1^OM75TVK""BBBD 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !17B'C7XEZ[:>*[RST:_%O:6S>5@0QON8?>.64GKQ^%:'PW^(6KZOXE.FZW M>BX6>,^0?*1-KCG'R@=1G\J(^]L5*+CN>OT45P/Q3\2:MX;TRPFTF[^SR2S, MKGRT?(VY_B!I-V$E<[ZBN"^%GB/5O$>E7\VK7?VB2*<(A\M$P-N?X0*YKXC^ M./$>@^+7L=,U'R+80HP3R(VY/7EE)IO1I=P2O?R/8J*\9^'OQ#UW5?%L&GZQ M?_:(+A&5%\F-,.!D'*J#V(_&O9J;5E<76P45X+XE^)WB2'Q+J$.F:F(;**=H MXD$$;<+QG)4GDC/XUUOPK\6:WXDN]235KW[0L*(8QY2)@DG/W0/2E'WE=%2B MX[GIM%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% %63_ )"47^[_ (U:JK)_ MR$HO]W_&K52NI+/%6G>%;&*74[6YG@N&,6(45ATS@AF'!&:Z&L?Q M/X=M?%&B2Z;=$IN(:.4#)C<="/\ /0FG*]M!1M?4Y _#;PCXITZWU735N;%+ MI!*H@<8&>Q4Y QTP"*X;4++4/A9XPM/L>HF>"8+(R@%?,3<05=_UJHVYDUL#^%J6IG_ !L(;6=()Z&!O_0J]:FM[,^'9+3?&T;M;TA?6!A_X]4^H>%?B-;V?]A6.H?:]&<;%?S(T*H>S% MOGQCL"1C\JA:TVN[97VHM]D6SSGS)9V ?<%'R_ZQ> /;N:]%\(^ [;0/#%SIEX4N)KY2+M ME^Z01C:/89//O7%)X)\>>$+VX'A:[$]K,>SQ@X'3 M&/&3?$:V\1:AHT-JKS;KCR)X]H!7:3C>3[]ZHW&)?CXHNL;1=KM#=.(QM_7% M=MX+T;QI;WK7OB366,3 G['N5R6/J0,*!Z*?_KU?'OP\N==U&+6M$G2#4DV[ MU9BN\K]U@PZ,/Z#TI?"XOL+XN9=SL=.F*Y"Y\(_$?Q68+/7[A(K2)@P:5XL# MMG$?+''K^==[JO@N.7X>/X9T]PI2-?+>3@,X8-DX]3G\Z4E[K'%I215^$_\ MR3ZT_P"NDO\ Z&:X#X6V<-U\1KR29%1G#;P,_D373?#[0_&^A:A'8 MZBJQ:)%O/E[XFW,0<$$9;KSSBF?#SPAKNA>,=0O]2L?(MI89%1_.1LDNI'"L M3T!J_P#EYS>1/V&O,V/B]_R(*50R-<@P%"@_*6SV/:JCHX>02?Q^9-\;%'_",Z>V.1>8!_X U;7A:VA7X3V\8C M4))82,PQU+!B:A^*/A[5/$>@VEMI5K]HFCN1(R^8J87:PSEB.Y%:^A:7>6?@ M&VTRXAV7B69B:/<#AL'C(./UJ'\$U_6P7]Z']=3@O@;TUO\ [8_^SUZ_7G'P MJ\+:SX:_M3^U[/[-Y_E>7^]1]V-V?NDXZBO1ZUET]$1U9XI!_P G!-_UW;_T M2:]K) &3T%>,^(?"/C1?B!>:]H5CC,FZ"?S8?[@4_*[?7J*?-IWQ5M^[NW=?:JCI**[)B;NI/N/\7?#O5[GQ*WB+PWJ"P7CD M,Z,Y0A@,95AV(Z@^_P!*Q6\<^._"$L*^)=/6>V=MN^15!/LKI\N?J#6SXL\% M>*1XB.N>'-4ED;)=8)9SF-B,$+NRI4^AQCITK&F\&_$'Q?<00^);I(+2%LY= MHN_4A8^"?KCK4QO9)%.W4T?BYJ(U'P3H]Y:LWV2ZF67GCJA*Y_6NV\#PV\/@ MC1UME4(ULC';W8C+'ZYS1JOA&PU3PDOAYMR011*D,G5HRHPK>_O]37G%OX7^ M)GAJ)M-T:[66Q9B0T%SW DY7U^6G=)R2ZLG=+R(852U^/A33P C7!WA.G M,>7_ %S56SLX;[XZRPW"!XQ>ROM89!*J6'Z@5W'@/X?2^'KN75]7N%N=4E! MVDL$SU.X\ECZ_7K67IOA#7;?XNRZY+8[=-:>5Q-YR'AD8 [=V[J1VIP5I179 M,*[MI;>= \4J%'4]P1@BO'/^$$\;>$M7FD\*7 EMIN-P>,';V#K)P2,] M1G\,U,79OS%O&W8J?%..!/B/I[1!1(\<)EQZ[R!G\ *C^(CWK_%:W6"".>=/ M(%M%*?D<]0#D@8+$]ZFU'X;^+YM6LM1N2-1NY9!)=2"9 (\,,#YB,\>@P.E= MI\0? $OB=X-1TV9(=2@7;\Y($B@Y'(Z$'H:%[J7DV4VG)^A@>(8/B5XFT>33 M+[PUIRPNRMNBE0,I!SD$RD>W3O5HZ7J>C?!+4;#5H#!<1!MJ&17^4N".5)'< MU1BTOXMWDD5M/?&UBC((F::$#CU*99OQS[UVVOZ+JEU\/;K21.VHZD\ 7S&V MQF1MP)] /QHDO<=NH)^]&_0YKX*6<*>'K^]"+Y\ESY9?'.U54@?FQKT^N)^& M&@ZGX=\-W%IJMM]GG>Z:15\Q7RI51G*DCL:[:M)[Z&7<\A^.+-MT1,G83,2/ M?Y*]-553PVJI]T6F!CTV5Q/QETMKOPM!?HN6LIP6]D;@_KMKIO#=V=7\!V,T M9WR2V00^[A=I_4&LO^7(],NN$ECAVOCE&!< MAA]#65!JMUX:T?Q'X0U3*[U_==P) 1T]F7G\!ZUZ#\*O"NM>&Y=4;5K+[,)U MC$?[U'W8W9^Z3ZBI?B;X$G\1QP:CI,"R:E'B.1-RKYJ?4D#(_D?I53\NJLPB M]=>]T5OA?_R3+4O^ND__ * *XWP'IG]J>$/&%N%W,;:-D&/XEWL/U%>B^ _# MVJZ-X%O=-U"U\F[E>4I'YBMD,@ Y!(Z^]4_A9X4U;P[!JJZQ9_9S<^6$!E1P MP ;/W2?6G+64O3_(F+M%>IYD-8EU_0O#OA=2VZ*[96SW#, GY!FKH_%4(M_C M1I<:J%19;0*!Z J/Z5<\)?#C6=+\>Q7EY9!--MI9'CE\U&W=0G )/<'I6MXF M\(ZYJ'Q0T[6;6R\RPB>!I)?-0;=K?-P3D\>U.+]Z+\[O[@>G,O*WXG._%N.2 MP\=Z?J+)F)H8V4^I1SD?R_.O;+6YAO+2&YMW$D,J!T8="",@UB>+_"5GXNTG M[)<,8IHSN@G49*-].X/<5YQ;>&?B=X70V6BW2SVF25\N2)E'X2],^U1%V7*Q MR7-9HV/C7?PQ^'['3]Z^?+<>;MSR%52,_F14VC>(+/P3\,]$.KVES-%=*XVP MQJWWBS ,&8=0:R])^&&M:SK"ZKXQO1)T+0B3>[X_A)'RJOTSWZ=:]#\2>&K/ MQ)H,FE3_ +I.#$Z#_5,.A _3'I1JHONPNFTNB.2/PV\(^*=.M]5TU;FQ2Z02 MJ('&!GL5.0,=, BN&U"RU#X6>,+3['J)G@F"R,H!7S$W$%77.#WP?QXK8M/" M_P 3/"JM9Z)*Y1E:47HUY@U=(/C?<))?Z/:*094CDQ$?^(KD_#GPWU:ZU^/7O%UV)IT*NL&_>68=-Q' ]!G_ !ZKXD7RV'@+ M5&)^:6,0J,]2Q _EFIEI3:[E)WJ*W0YCX(LYT+4U/W!OI+;VZY)Y9CT4>II2DHJ[V*A"4Y*,5=L--TVXU6\6WMUR3RS'HH]37IVDZ3 M;Z19B" 98\NYZN?6C2=)M](LQ! ,L>7<]7/K5^OG,7BW6?+'X3[;+LNCAH\T MM9O\/)!1117 >L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X5\:8G7Q992E3L M:T 4^I#MG^8KW6N1^('@W_A+M'18&5+^V):!FZ-GJI^N!S[5+T::Z%P=G8Z7 M3YDN--M9HR"DD*,I'3! J/4-8T[23#_:%[#:B=MD9E;:&/U/%>.Z1X_\0^!K M)=(UO1))HX?DA,K&)@!V#8(8>F/SJE>+XG^*NM6\@L6M;",81RI\J)2>3N/W MFX[>G:K>LO=)4;+WCTWXE:A):?#^_FMG_P!<%BWJ?X68 \_3/YU@_!K2+./P M]-JOE*UY+.T?F$%+2Y\%/X;B/EPB 1QN1T8>R>3<,L40OTW))@@Y Z>W:DFE*7F.SE%6-#XT:3:V=YINJ6 MT:0W$Y=92@P7*X(;Z\]?I3/B;>2W_@CPI=SG,LT6]SZDHN352>/Q#\6->M9F ML6L]*AX$F#L12?F(8@;V..WMTK9^,UM%9Z'H-K"NV*%FC0>@"J!4M6A9]S1. M\EZ,ZSP-H]E#\.K2'[-'MO+8O/E<^86!Z^O'%>8?"33K:]\:N;B)9!;6[RQA MQD!MR@'\,FO7_!O_ "(6D?\ 7DG\J\K^#/\ R.=[_P!>;_\ H:5K_P O7Z&2 M_A?,F^-EO%'K^G3)&JR2VYWL!@MAN,UK?%PEO!6A,3DF123_ -LS6;\;_P#D M,:5_U[O_ .A5H_%K_D2-!_ZZ)_Z+-8KX/^WC3[:]#J?AII-G9>![&2*)#)=H M9)WP"7))X/L!QBO-=4MX_#WQJ@33E$49NX2$3@*) -P^GS'\ZM^'/&VN>"_" MUK'=Z*;S3IE,EI<"0H%!)RI.".N>.#S4G@O1-7\7>-_^$JU6V,5JD@G#,A57 M8#Y%3/4#@Y]JVWJ*71?U8S6D&GU+'QQ_X^=%_P!R;^:U-\4;N6+P#X>M49A' M.J%\=#MC& ?Q.?PJ'XX_\?.B_P"Y-_-:ZCQ3X7E\4?#S3X+7!O+>"*:%2<;S MLP5_$'\\5E]A^I=_?CZ'*>%/%&I:-X8M[&T\ 7UY Z$O<('VW&>YQ$01VZGB MJW@'3]:L?B*MW_8&H:?87)E5DDMW"1H06"EBH'! ':H]$^)&K^#-+70]2T1I M)8,B$RN8F49/!!4[AGTQ7;?#_5O&6LRRW&N01PZ> =AD@\N1V)X"CC@>I'Y\ MFM%\7,B'I&S.*US_ )+Q#_U^6_\ Z"E>K^,_^1*UK_KSE_\ 037DWQ%AO= ^ M),7B 6KO;EX9HWY"L5 !4MV/R_K7=2>(I/%'PNUG4I+%K/=;S*L;,6R O!R0 M,YSZ5GO2]+FC_BI][&)\#_\ D&:O_P!=H_\ T$UROAK3;?5/C#/#=1++"EY< M2E&&02I8C([\XKJO@?\ \@S5_P#KM'_Z":PO _\ R6:^_P"NUU_-JU_Y>+T, MOL2]3J/C1:0'PK:7/E()HKI45P.0I5LCZ<#\JR5O9K?]GX&-B"Y,)/\ LF8@ MC\N*W?C/_P B7!_U^)_Z"U0^$M%7Q#\&4TLL%:82[&/17$A*G\P*R7P3]4:Z M+D?J)\&=+M8O#4^I"-3=33LAD(Y55 P!^9-<;\7]+M=/\60S6L21?:H!)(J# M +!B"<>_%'AOQ5K?PXGN='O]'DG663JW4)(ECM9&0CJ#M/-:-HI6R@4]1&H_2FW]G%J.GW-E,/W5Q$T3X]",45%> M]C.F[6;\CR/X):?;33ZI?RQ*]Q#Y:1LPSL!W$X]S@5WFK_#_ ,/ZYK']IWMO M(9]H#".0QAB#G<=N#GMG/:O+-.N-?^$^MW8N---U8S *7R5CD )VL'P<'D\' MUJ1[[Q-\2O$]M<:?;W&G6D:^7YL3L%B7.6)?C"_"VL^(?%[>*_$%N]NBR>?$W3K2+X;W,45O&D= MJ8C"JJ $^8#CTX)%8_P5TZV&A7NH&)#:E_ MVS_]&+61\%O^1/NO^OUO_0$IP^T_0F7P1.-M88[3XZB*W18XQ?-A5& ,J<_S M-:/QP_Y".C_]F> M'-%T^Q\*6=A%;Q-!);J9 5!$I*@DGUS7D?@]!HOQEEL+0[;?SYX-H/\ Q M_# _*M&W^(?B#P?H5KIFI:&)76%1:W;2$(R$?+G .[ ]".E6?AAX7U.?7Y_% M.L0/$6WF(2KM9W?[S8[#!/YUM_R\J\9_2O6?$]C8>'/!6L7&D:?;64IMBA>WA5&.>.2!DXS7FR_\ )>O^W\_^ M@U[5JVG1ZOI%WITQ(CN8FC)';(ZUC;]RDBV[5=?(\(^'>M7F@K=W-CX3NM8F M=@OVB$-^Z&/N\(V,YSU]*/$":_K'BB#7++P=J>FS(49E2WD;6U]I37%G,P&22B.1G#(^".G;'Y5TWAWQEXT\5>(EDL+"*WTAV M7<9HBR1H.N'^4LQ]/T'-:IWDFN@G[J=RQ\:26\*:?\B#H_P#UQ/\ MZ$:F&TO4F7V4>5^&8TL?C:]O;*(XEO+A%1> %VOQ]*I^*+V6Y^+-Q++I\NI> M19RX[@+MX!/?\ 7O7=:FVKO\,-2?7%@74&LI3(D(P%^4X!Y.3Z MXXHEI"7F2OBBCBO@GIEO++J>HRPJ\T12.)V .S.2<>AX%97QBMHK7QG;30HJ M/+;*[E1CO-?S_0[SXC^'+_Q-X3@CT\;[F"19O*SCS!M(('OSFO/](^(NN>$; M&'1]3T*,P1+M5)8V@D([YR"#](,.TK>5N/8M&4//TQ^%1U:01UBKG<>"/&F@ M>( UGIUF-/N43<;7RU4%1W4KP0,^Q]J\_P!0_P"2^)_U^Q?^@+5[X7^%M4;Q M/)XAN[(V%JH?RXRA0,S9&%4\A0#_ "JCJ'_)?$_Z_8O_ $!:M?'$E_#,WOC3 MH?G:=9ZW$OSV[>3*1UVMRI_ _P#H54_%?C+[?\)=.P_^E:@1!* >?W?WS^)" M_P#?5>HZYI<>M:'>:;+]VXB* ^A['\#@U\Z^'-'O-9\3V'AVY#B*"Y\<8P4> M!-5NM.URYU*'P]XF(DY+G"MR?7CO7T8\2/ T)4>6R[2OMC%>$)! MKGPI\47%TEB]UID@*>800DD>.Z:VC,J2*0P;:,Y!Z'- M>76?Q!\9>*=:A7P_I<<%KC8ZR+YL:G()9I,+C [#U[G%>OIO$:B0J7P-Q48! M/? IK2-A2=V8/CG_ )$;6O\ KT?^5>?_ 3TNTD74M3DC1[F-UBC9ADH""21 MZ9_I7H'CG_D1M:_Z]'_E7B_@'6=;\-PWVJV&FG4-/RL=U$I(*GDJW .._."* MF+M*7H4TW%)=SH?C7IEK;W6F:C#&D<\^])2HP7VX()]^3S2?$FZDO?A[X5N9 MB6EE16G'':ND^,=K'8^ M&-#M(1B*"3RT'L$P*35H6?3YF,TT(=E.X M[<$CC Z5POQ9NI;GQ_#;/')-'!%&J0J3E]QR0/' MIM&;X;:A% T12+".1"<<,H\KM5CX6?VGX>T77#J^G7UM:VZBY198&0MA6W;= MV,G"BLJ7XO:[=6']FVFC^7J^-AF0ESN'4B(KU^I->D^%7UW4= 9_%%O;++/D M"W$6#Y9'1P21D^GYT:ZM [:)G,_\+K\-_P#/EJO_ 'ZC_P#CE8'Q@U@ZCIGA MYH!(EK=1-=!7&#R%VYP<9 8_G7I__")^&_\ H7]*_P# */\ PKF_B1X,D\0: M!;#2H8UN;#/DP* H:,@ JO8=!CZ5$MOF5!JYM^%='L(/!5A9+;1&">U1IE90 M1(64%BWKUIGAWP-HGA>Y>YTZ.?SW38SR3$Y&<].!Z=J\RTSXHZQX=T>+0[O1 M"][;H(HGE9HV Z+N3;DXZ=1G%;OPLT+Q EY/K&KS7D%NX816TKLHD9CDL4[# MKCCOFM'K)M;?UH9V<8V9@>!_^2S7W_7:Z_FU'Q4_Y*3I_P#UQA_]#:CP/_R6 M:^_Z[77\VH^*G_)2=/\ ^N,/_H;5,/\ EV5/>H=/\;/^17L/^OP?^@-6O\+] M+M;3P+9S+ @ENPSS.5&7^8@ ^V .*R/C9_R*]A_U^#_T!JZ;X>?\B#H__7$_ M^A&B&TO44_LGE7AF%+'XVM;VZB.)+RX157@!=K\5K_''_CYT7_M/XX_\ 'SHO^Y-_-:G[$#5_Q)%_XF7!+.:.%/-NM[S.5&7^8C!]L"E\0>&G\4_#JSLH2JW4< M$,T!;@%@G0_4$BO/M!\?:SX!T\Z'J>AN_E,QA$KF(KDY/\)##//'KUK1M*4T M^K,HIN$+=#T[2_ &@:/K3:M:02K=;W=?WI"INZ@*,#'.,'-[L[%I&F:/'_P"RH\.(=[[I'^Z2#T(QQU ZFO1U8M\$\DY/]CG_ - KS?QU MJNO^*].M]:N](:PTJW?RX0Q)+,_);) R/E'.,5Z%:W45Y\$'>)@P32WC;'9E M4J1^E)_PY(K[43)^!_\ R#-7_P"NT?\ Z":]6KRGX'_\@S5_^NT?_H)KU:KE MT]$8KKZL\&\31#7?C2MC>Y-O]IA@VG^X #C\?_$SPMJEIXBB\5:/%)*04>41KN:-TQAL=P0!^55[CXA^( M/&6CS:1IFA^7+-&4N;I'+(JX^;MA,C/4G\ZRWI\O77_AS;_EXI=-!WP._P"/ M[6?^N47\VK;\0>(_!VE>*1]ET(ZEKTORFI?P2]2T_?B2?!K_D2I/^OQ_P#T%:K^(/$?@[2O%(^RZ$=2UZ.0 MG_18NDF.Y_B;\#CZBN:^&/BZZTFXC\,MI;R&>[RTI8@P@X!RNWMCU'6LNXDU M;X=_$"?4[BP,T;2R%&?(69')/#X.#_G%5)WFGT_X8B*LFNH_XDZIK.L?V==: MIX?_ +*CPXAWOND?[I(/0C''4#J:]C\%,6\$Z*2@;P9ZU\5-+M+OP1=W,D2>?:;'BDQR MOS $9]"#TK$^&E]8GX:Z@NMF)M-MKAU<3+N780K8QWY/'N:YSQ-X\UKQI;?\ M(]::%);R.X\Z)2TDC8(P,;1M&<=?SKI[KP)?V?PD?1K=!)J)<7,T:'[[9!*C MUP ![XHVC)][%:>[%D&D>,[*%KBW\#^#+JX620F20?(F<<$GYL#CH2/S-#O'FK>&=/D\/PZ"]Y=>8S1I\RNI/ M4,@4D_I531/M^D?%FREUY!!=S7'F2CC ,JG'ZMCVJX_&A/X)%SQ4!K7QGCLK MP%K<7,$&P_W,*2/H/[IQQZ?2O./B5X M2U6'Q#%XIT6%YF4H\J1KN9'3&&V]Q@#\JRM9^)VK^*-(DT.ST1H[N<;)6A9I M&(SR%3;D>G4U"^!1ZC:;ES)Z'J]AX>T[PWH%W9Z;&\<+*[D/(SY8K[GCH.E? M.NB:UJ&F6FHV>G(YEOXA$SH"65!DM@#U'?L,U[CX,T35-&\&W(UBZGEO)U>0 MQRRE_)&WA>3U[G']*X;X)V\,NM:G))$CNENH5F7)4$\X^M.UYM>0D[1OYFU\ M%3I3:7>^5&!JBOB9F.28S]W'H,YS[_A6YX_U+P?IZ1?\)#8)>W;(1%$B9EVY M_O9&T9]_7%>?Z@DOPR^):W,*M_9LYWA1T:%C\R_53T^@JU\4]-OSK]IXFLHC M\,;),@WJA7D9] 1@^E#?-RR_I HVDU_3+/B[Q+K&N>#KF*+PC)8Z1'L(N M+@X*J&&THI QU XSU-:?P;F:+PCJKCGR[AF ]]@_PK%U;QCXB\>^'+BPT_03 M#;+'YEW7U\JS30Q-,H<9^=F&6^O)_.NJ^,^EVLGAVWU/RD6[BG6 M/S .64@\'UY -!]:Z3PMX M?_X2/X,KIN\))*TCQ,>@<2$C/XC'XURWA_QCK?PWAFTC5-%>2(R%XUD:>"?$GC3Q)K33W-K%!HK,7+2P$84CY50\%OKS_(5Z71M%(F3O M)L****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *S/$6K+H?AZ_P!2;&8(2R@]VZ*/S(K3KRKXU:SY.G6.C1OAIW,T MH!_A7@ _4G/_ &IEM;N7!79POP[TH^(?'5NUR/-CB+74Y;G=CIGZL15'5(9 M_!OCN80##6-T)(L]TSN7\U(KO?A%-HNCZ9>7]_JVGV]UF:C9W321F*9;>='(*]"0#W!Q^%7)\KC8:][F3/<;.ZBO MK&"[A;=%/&LB'U!&17F?QO\ ^0+I7_7PW_H-:7PAUK^T?"1L9)-TUA(8\$Y. MP\K_ %'X5F_&_P#Y NE?]?#?^@U-56>G=$TM]?,7X(_\@/5/^OE?_0:X[XO? M\CY)_P!>\?\ (UV/P1_Y >J?]?*_^@UQWQ>_Y'R3_KWC_D:=3XH_UT'3^U_7 M4PYXW\-:UHNHP@@-!;WB>_3=^JG\Z^B]9U:/3_#-YJJME([9I4/K\OR_KBO& M_'NFC_A!/".IHH&VU6!R!ZJ&'\FJSK/B<7/P6TVUW@SRRBU<9Y"Q\_R"?G1/ MX91[.WWC2O*+[_H<)::HV?]E6"C]0:U?@=_Q_:S_URB_FU5'237E^A,G>-_/] M3V:BBBI)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JR?\ (2B_W?\ &K559/\ MD)1?[O\ C5JI74N6R] HHHJB HHHH \]^(?@35/%NI6%S83V<:6\95Q.[ DD MYXPIKT%1A0/04M%"T5AMW"BBB@04444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[^Q@U+3 M[BRN4WP3QF-Q[$8KG? GAW4_"^EW&FWUQ;SVZS%[5HF8D*>H8%1CUX)ZFNJH MH6@7TL%%%% !1110 4444 %%%% !1110 4444 %%%% !7(>.O"VH^+$TZRM[ MF"#3XYO,NM['>W8;0 0>"W4CG%=?10--K8BMK>*TM8K:! D42!$4=@!@"I:* M*-Q!1110 4444 %%%% !1110 4444 >?>-/^/N#ZR?S%8Y57KXF52%K. MW7R1YQ17H_\ PA6D>D__ '\_^M1_PA6D>D__ '\_^M75_:5'S^XX/[#Q7E]_ M_ /.**]'_P"$*TCTG_[^?_6H_P"$*TCTG_[^?_6H_M*CY_<']AXKR^__ (!Y MQ17H_P#PA6D>D_\ W\_^M1_PA6D>D_\ W\_^M1_:5'S^X/[#Q7E]_P#P#SBB MO1_^$*TCTG_[^?\ UJ/^$*TCTG_[^?\ UJ/[2H^?W!_8>*\OO_X!YQ17H_\ MPA6D>D__ '\_^M1_PA6D>D__ '\_^M1_:5'S^X/[#Q7E]_\ P#SBBO1_^$*T MCTG_ ._G_P!:C_A"M(])_P#OY_\ 6H_M*CY_<']AXKR^_P#X!YQ17H__ A6 MD>D__?S_ .M1_P (5I'I/_W\_P#K4?VE1\_N#^P\5Y??_P \XHKT?\ X0K2 M/2?_ +^?_6H_X0K2/2?_ +^?_6H_M*CY_<']AXKR^_\ X!YQ17H__"%:1Z3_ M /?S_P"M1_PA6D>D_P#W\_\ K4?VE1\_N#^P\5Y??_P#A--TVXU6\6WMUR3R MS'HH]37IVDZ3;Z19B" 98\NYZN?6G:;I=II4!AM8]H)RS$Y+?4U=KS,7BW6? M+'2)[N79='"KFEK-_AZ!1117 >L%%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 5YS\8--O\ 4]"T^.PLKF[=;DLRP1-( M0-IY( KT:BDU<:=F<[X$MI[/P1I5O-)KGQ2\/3O#>37MU%-:-/L#>Z0@ '04M%% @HHHH **** "BBB@ H MHHH *\D^,6CZGJ=_I3:?IUY=JD4@5"HN(6C+#!Z9 S7I=%"T;?<;U204444""BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ KQCP3HFK6GQ4N;RYTN]AM3)<$326[JAR3CYB,'O#UEI:,'\A,,X_B8G+'\R:U:**IN[N0E8****0 MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "OFCQQJC>)/'%W);DR)YHMK<#N!\HQ]3D_C7T7JL5W/I-W%8-&EW) M$RQ-*2%5B, D@$\?2O+/"WPEU72O$MEJ&IW-A+;6[^84A=V8L!\O50.N#U[4 MDKS5]BT[1=MS&'P5\2$ _;=*'MYLG_Q%0WGP>\165E/=-V@E+N?/7PHUH:5XRCMY&(AOD\@^F[JI_/C\:[/XW M_P#(%TK_ *^&_P#0:R+GX/Z]#KNS\?^ M$=4\7Z1IUO;2V<5Q ^^7S78+DK@[2%)//J!1+WHHI64WV,3X(_\ (#U3_KY7 M_P!!KCOB]_R/DG_7O'_(UZA\.O"-_P"$=-O+>_FMI'GF#J;=F( QSE16!X[ M^&VL>*/$KZE97-A'"8D3;-(X;(^BD?K3GK)-?UH*#M>_]:ES7M,&H?!.V11E M[>P@N%]MJ@G],UX49Y6MTMS(QB5BZIG@,< G]!^5?5&GZ5Y'ABVTBX*OLM%M MI"O0X3:<>U>26/P8UJ'5+:6YO-->U296D"R2;F0'G V=<>]-V=1]F$96AYHZ M/Q=I_P#97P5CLB,-%%;AO]XNI/ZDUB? [_C^UG_KE%_-J]'\9Z'<>(O"MWI= MH\*3S;-K3$A1A@>< GH/2N>^'/@;4_"%S?R:A/:2BX1%3[.[-C!.M"?O M2;ZDOX$CT"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K)_P A*+_=_P : MM55D_P"0E%_N_P"-6JE=2Y;+T"BBBJ("BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@"K:_Z^Y_WOZFK55;7_7W/^]_4U:J M8[%SW"BBBJ("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH JR?\A*+_=_QJU6!K&E75_JL36^IS6@\K;B//7+'/#"J_\ PC&J M?]#+>?DW_P 76T*5-J[FE\F.IT]%?DW_P 7 M1_PC&J?]#+>?DW_Q=:>QI?\ /Q?QI?\ /Q??DW_Q='_",:I_T,MY^3?\ Q='L:7_/Q??DW_P 71_PC&J?]#+>?DW_Q='L:7_/Q? M?DW_ ,71_P (QJG_ $,MY^3?_%T>QI?\_%]S#ZS7_P"?+^^)T]%?DW_Q='_",:I_T,MY^3?_ !='L:7_ #\7W,/K-?\ Y\O[XG3T5S'_ C& MJ?\ 0RWGY-_\71_PC&J?]#+>?DW_ ,71[&E_S\7W,/K-?_GR_OB=/17,?\(Q MJG_0RWGY-_\ %T?\(QJG_0RWGY-_\71[&E_S\7W,/K-?_GR_OB=/17,?\(QJ MG_0RWGY-_P#%T?\ ",:I_P!#+>?DW_Q='L:7_/Q??DW_P 71[&E_P _%]S#ZS7_ .?+^^)T]%QI?\_%]S#ZS7_Y\O[XG3T5 MS'_",:I_T,MY^3?_ !='_",:I_T,MY^3?_%T>QI?\_%]S#ZS7_Y\O[XG3T5S M'_",:I_T,MY^3?\ Q='_ C&J?\ 0RWGY-_\71[&E_S\7W,/K-?_ )\O[XG3 MT5S'_",:I_T,MY^3?_%T?\(QJG_0RWGY-_\ %T>QI?\ /Q??DW_Q='_",:I_T,MY^3?\ Q='L:7_/Q??DW_P 71_PC&J?]#+>?DW_Q='L:7_/Q??DW_ ,71_P (QJG_ $,MY^3?_%T>QI?\_%]S#ZS7_P"? M+^^)T]%?DW_Q='_",:I_T,MY^3?_ !='L:7_ #\7W,/K-?\ MY\O[XG3T5S'_ C&J?\ 0RWGY-_\71_PC&J?]#+>?DW_ ,71[&E_S\7W,/K- M?_GR_OB=/17,?\(QJG_0RWGY-_\ %T?\(QJG_0RWGY-_\71[&E_S\7W,/K-? M_GR_OB=/17,?\(QJG_0RWGY-_P#%T?\ ",:I_P!#+>?DW_Q='L:7_/Q??DW_P 71[&E_P _%]S# MZS7_ .?+^^)T]%QI?\_% M]S#ZS7_Y\O[XG3T5S'_",:I_T,MY^3?_ !='_",:I_T,MY^3?_%T>QI?\_%] MS#ZS7_Y\O[XG3T5S'_",:I_T,MY^3?\ Q='_ C&J?\ 0RWGY-_\71[&E_S\ M7W,/K-?_ )\O[XG3T5S'_",:I_T,MY^3?_%T?\(QJG_0RWGY-_\ %T>QI?\ M/Q??DW_Q='_",:I_T,MY^3?\ Q='L M:7_/Q??DW_P 71_PC&J?]#+>?DW_Q='L: M7_/Q??DW_ ,71_P (QJG_ $,MY^3?_%T> MQI?\_%]S#ZS7_P"?+^^)T]%?DW_Q='_",:I_T,MY^3?_ !=' ML:7_ #\7W,/K-?\ Y\O[XG3T5S'_ C&J?\ 0RWGY-_\71_PC&J?]#+>?DW_ M ,71[&E_S\7W,/K-?_GR_OB=/17,?\(QJG_0RWGY-_\ %T?\(QJG_0RWGY-_ M\71[&E_S\7W,/K-?_GR_OB=/17,?\(QJG_0RWGY-_P#%T?\ ",:I_P!#+>?D MW_Q='L:7_/Q??DW M_P 71[&E_P _%]S#ZS7_ .?+^^)NVO\ K[G_ 'OZFK5?DW_Q=3&C2M_$7W,N>)Q%_P""_P#P*)T]%?DW_P 71_PC&J?]#+>?DW_Q=5[&E_S\7W,CZS7_ .?+^^)T]%QI?\_%]S#ZS7_Y\O[XG3T5S'_" M,:I_T,MY^3?_ !='_",:I_T,MY^3?_%T>QI?\_%]S#ZS7_Y\O[XG3T5S'_", M:I_T,MY^3?\ Q='_ C&J?\ 0RWGY-_\71[&E_S\7W,/K-?_ )\O[XG3T5S' M_",:I_T,MY^3?_%T?\(QJG_0RWGY-_\ %T>QI?\ /Q??DW_Q='_",:I_T,MY^3?\ Q='L:7_/Q??DW_P 71_PC&J?]#+>?DW_Q='L:7_/Q??DW_ ,71_P (QJG_ $,MY^3?_%T>QI?\_%]S#ZS7_P"?+^^) MT]%?DW_Q='_",:I_T,MY^3?_ !='L:7_ #\7W,/K-?\ Y\O[ MXG3T5S'_ C&J?\ 0RWGY-_\71_PC&J?]#+>?DW_ ,71[&E_S\7W,/K-?_GR M_OB=/17,?\(QJG_0RWGY-_\ %T?\(QJG_0RWGY-_\71[&E_S\7W,/K-?_GR_ MOB=/17,?\(QJG_0RWGY-_P#%T?\ ",:I_P!#+>?DW_Q='L:7_/Q??DW_P 71[&E_P _%]S#ZS7_ M .?+^^)T]%QI?\_%]S#Z MS7_Y\O[XG3T5S'_",:I_T,MY^3?_ !='_",:I_T,MY^3?_%T>QI?\_%]S#ZS M7_Y\O[XG3T5S'_",:I_T,MY^3?\ Q='_ C&J?\ 0RWGY-_\71[&E_S\7W,/ MK-?_ )\O[XG3T5S'_",:I_T,MY^3?_%T?\(QJG_0RWGY-_\ %T>QI?\ /Q?< MP^LU_P#GR_OB=/17,?\ ",:I_P!#+>?DW_Q='_",:I_T,MY^3?\ Q='L:7_/ MQ??DW_P 71_PC&J?]#+>?DW_Q='L:7_/Q M??DW_ ,71_P (QJG_ $,MY^3?_%T>QI?\ M_%]S#ZS7_P"?+^^)T]%?DW_Q='_",:I_T,MY^3?_ !='L:7_ M #\7W,/K-?\ Y\O[XG3T5S'_ C&J?\ 0RWGY-_\71_PC&J?]#+>?DW_ ,71 M[&E_S\7W,/K-?_GR_OB=/17,?\(QJG_0RWGY-_\ %T?\(QJG_0RWGY-_\71[ M&E_S\7W,/K-?_GR_OB=/17,?\(QJG_0RWGY-_P#%T?\ ",:I_P!#+>?DW_Q= M'L:7_/Q??DW_P 7 M1[&E_P _%]S#ZS7_ .?+^^)T]%QI?\_%]S#ZS7_Y\O[XG3T5S'_",:I_T,MY^3?_ !='_",:I_T,MY^3 M?_%T>QI?\_%]S#ZS7_Y\O[XG3T5S'_",:I_T,MY^3?\ Q='_ C&J?\ 0RWG MY-_\71[&E_S\7W,/K-?_ )\O[XG3T50TFPGT^U:*XOI+QRY8229R!@#')/I^ MM7ZYY))V3N=D).44Y*S[!7'^.?'7_"%FR_XEWVS[5O\ ^6_E[=N/]DYZUV%> M/_'+KHG_ &V_]DK-NUC:"3>HO_"\_P#J7/\ R>_^UU8T_P"-/V[4K6T_X1_9 MY\J1;_MF=NX@9QLYZUK>'_B1X3L?#FF6ESJVR>&UCCD7[/*=K!0",A<5N:;\ M0/"^KZA#86.I^;*Y4_%;7+^PB_L3P^UW<1QJ;J802/$CXY 53G'N6J+ MCY6>M5SWB7QGI/A?RXKN1I+N7'EVT8RQ!.,GL![G\,USO@3XEGQ/?G2]0M([ M>]V%D:(G9)CJ,')!QSU/>O,?'VJ:OJ'BXRZE8_9I8#Y=NGDNGF1J[;6PQYSZ MCBG]I)]02W\CZ1'(S17'^%/$^KW>AZAJ'BFP&EK:G(S;R190+DG#DD_A7(W' MQ8U_4[R5?#/A[[1;Q'EGADF8CL2$(V]_6A[V$DVKGKU%<)X*^),'B:\;3+VU M^Q:D 2J DK)CJ!GD$>A_.J_Q%\>:IX1U"Q@L(+.1)XF=S.C,00<<884/2WF" M3>AZ'17D=I\6]4U7Q5;:?IFEVSVD\JQ*)-WF-GJV0< =^AX%;?C+XF)H.H_V M1I5F+[4N P.=J,>@P.6/3@8^M';S"SO8]!HKR2S^+.L:;?Q0>*=!-I'(>'2* M2)E7UVOG=^!%>D:CKVGZ9H+ZS/,#9K&)%9>=X/W0/8\2^?]HVXWX_AVGIGUKF(?BSXEU*]DDTKPVMQ91GYT2.2 M1P/=EX'Y5RVKZ[#XC^)%AJ4$,D(>:W5HY!RC @$?G1%7E%#M:+/HNJ.M:C_9 M&B7NH^5YOV:%I?+W;=V!G&<''Y5>K-\0:A+I7A[4-0@5&EMK=Y4#@E20,C." M.*4G9"BKLQO _C3_ (3.UNYO[/\ L?V=U3'G>9NR"?[HQTKJZXGX<^,-0\7V M=]-J$-K$UO(JJ+=64$$$\Y8US/\ PMZ]LO$6HV5_8V\EM;R210+;HPDD<-A0 M26(^O%4][ DW=GKE1SSQ6T$D\\BQQ1J7=V. H'4FO(+GXM>)M,O8VU/PY';6 MDG*1RQR1NP]F;@_]\UT7C;Q->W?@"&_T.S-S;:A&R7!,3.88RAW$[3\I!XR> M*EZ1NAJ/O),Z/P[XMT[Q1<7R:;YCPVC*IF88$A.?NCKCCO6]7SS\.M<\0:3< MRP:-I7VRWN)HAZ260E88$/S2' M^@'&HSI:G)D\B5@ .O[P$+^.*[OP;XX ML/&%L_E(;>]B&9;=FS@?WE/<4) U8ZFBBN>\8>+;3PAI(NYXS--*VR"!3@NW MN>P',O\4O&9MSJ$?AR(:;][SC;3%=O_ %TW!?QQ7>>"/&L' MC&PFD%N;:ZMR!-%NW#G."#Z'!JDK@U8ZJBO(_P#A;U[9>(M1LK^QMY+:WDDB M@6W1A)(X;"@DL1]>*@N?BUXFTR]C;4_#D=M:2H/N#D5=JFK:$K4\W\4?%?\ X1OQ#=:3 M_8OVCR-O[W[5LW94'IL..OK61_PO/_J7/_)[_P"UUC>)/^2Y0_\ 7]:_R2O= MV("DM@+CG/2DO@4BY64K6.*\)_$S2O%%XM@89;.]9DS MZYX1U'3[8XGDCR@SC<5(8#\<8_&DW[BD@Y4I\K.%O/C?9QW12ST6:> '_623 MB-C_ ,!"G^==SX5\7:;XML7N+$NDD1"RPR@!T)Z=.H/8UX]X(\;VGA'2M6T[ M4--:29R60;0"[8VF-\]!_P#7KJO@[H5];"_UJYA-O;W:A8(\8W#).X#T[#\: MI+\MQ25E\STG5K_^R]'O=0\OS?LT+R[-VW=M!.,\XZ5Y9_PO/_J7/_)[_P"U MUZ/XM_Y$_6?^O*7_ - ->>? [_CUUG_?B_DU*.K?D#LHI^9-8?&^QEG"W^CS MVT9(&^*82X^H(7^M>FV-]:ZG917EG,DUO*NY)%/!%8'CGPY9:_X;O/.MT-U# M"TD$VWYE8#.,^AQ@BN(^"6K2LNI:0[YC0+<1*>V3AO\ V6G'6ZZH4E9*2/7J M**X3QO\ $>/PO>)IME:"\U!E#,I8A8P>F< MQKT5Y!-\6]\CTB@>X+1C;*I*_-UX!!_6O/ M9_C7J@T^U$%A9&].XW#.C^6.3@*-V>F,DFCJUV$DVDSVRBN*UKX@1^'O#%A? M:C:8U.]B#I9(W3C/)(X R*Y$?%?Q5:JM_?>&D&F.?D?R98P0>F)#E3^5'6P) M-JY['161X?\ $=AXCT5=4M'*QY/X4/1V!*ZN>KT5YQX5^*)U+5UT;7=/\ [/OF;8K ,%+_ -TJ MW*GTY-:'Q&\8ZAX0M+"73X;65KAV5_M"LP '3##UH>EF"3;L=O17D5Q\6-= MNM/2XT70#.D,:F[NG@D>)7VY8 *?E /B>)O M%%AX7T?^T+LEPYVPQ)]Z1B,X'^-#T5PL[V-NBO&_^%K^*WC.HQ^&XSI0.3)Y M,I '?]YG;U]J]"\(>+[+Q?IK7-LC0SQ$+/ QR4)Z<]P?6G8&K'145Y;KGQ1O M=!\TDCNW\-K;:;(?D-Q%*" MX]GX7I[&I3NKCY7L>Q$@#)Z5SND^,])UW7[C2M-D:X-O$9))U'R=0, ]^O7I M]:RY_&EWJG@ Z[X?T\W%X7$;6K1M*4.<-PN"< YS7CO@O6M=T;5KF?0M,^W7 M+Q%9(_(>7:NX'.$((YQ37Q-,+7C='TQ145J\DMI#)*FR1HU9UQC!(Y&*XGXC M>,-8\("QFT^WLY;>XW*YG1B588(QAAU&?RH>CLQ17-L=W17/ZGXE2S\#2>(8 M0C9M5FB5\[2S ;0<>Y%+=0O+/48;2*2*(21?9U93M/)/;M1#WDQR5DC=N/B+Y'CY?"_]E;L MS)%]I^T8^\H.=NWW]:[FO O$>HP:3\:)M0N2WD6]S'(^T9.!&O2MW4?BOXFM M)8[L^&A;:9(?D:ZBD!D'L_"Y(]C^-*+O%,)1?,['L%%8_ACQ#;^*-"AU.W1H MPY*O&QR48=1GO]:V*IJVA)YGXB^+?]@>(+S2O[#\_P"S.%\W[7MW< ]-AQU] M:[7PSKT?B7P_;:K'%Y7G [HMV[8P)!&<#/3TKP[Q38#5/BY=6#'"W%Y'&3]5 M45VWP8U!Q8:IHTQ(DM9O,"D] >"/P*_K2AK'4J:L]#6\:?$J/PCJ\6GKIGVQ MVB$KM]H\O;DD ?=/I6KX)\7_ /"8Z;<7?V'['Y,OE;/.\S/ .<[1ZUXUXGSX MD\2>*-4!)AL5&PYXX=8Q^8R:[[X)?\BWJ/\ U]_^R"B&L;OM<=1);>AZ=17E MFM_%>];69=,\,:2+^2-BOF,CR;R.NU$P<>^:JZ?\7-4L]62R\3Z,MJ&8!C'& M\3Q@]"4%U%@/G+FSG V?[^<=.^,4KARL]BHKGO"7B=_$NEO=3Z;K$W^L:)Y2X'<(F"!]33>CL)*ZN M>KT5Y;HOQ,U\ZM'I^N>&9T=R,FVMY%>-3P"4;)(SGO7>^(M?L_#6BS:G>;BB M8"HOWG8]%%#T5PL[V-6BO&_^%I^,+^-[O2_#4;V2YR_V>:8+CKEU('Z5UO@/ MXAQ^+Y)K.>U%M?1)YF$;F"1Q32N#5CMZ*X/QI\2H/#-X-,L;7[;J. M!N4MA8\] <#[UY/\/O%TGAW3+^UL=-GU'4 MKF56B@B4GY0#DG )_ 4UNTQ6O%-=SW^BO)-&^+>I)KD>F^)-)CM=[A"8T>-H MB>A97)R.1Z?C74_$3Q;?^$=*M+JPBMI7FG\MA.K, -I/&"/2AZ*X6=['945C M^%=5GUSPQ8:GR6S6XFB#H MCB3"!L<[L9X':G;WN7J):QYCTNBO/_&7Q);0=6_L;2=/-]J6!N!R50D9 VCE MCT..*P$^)OC*QGC.K>%2(9&VJJVTT+,WH"V,4D[E.+1Z_15+3M134-)A MU PS6R21[S'<(49/7(->:ZG\6=1O-3>R\*:-]N$9_P!8\3R%P.I")@@>Y/X4 M/1V$E=7/5ZQO$?BG2O"UD+C4IRI?/E1(,O(1V _J>*Y'PK\43J6KKHVNZ?\ MV??,VQ6 8*7_ +I5N5/IR:XKXMZEJMWX@6TO;+R;*U9A:3>4R^<"%+'<3AL' MTI2OI;J5&-WJ>YV%XM]IMM>A2BSQ+*%)^Z&&?ZUC:3XSTG7=?N-*TV1K@V\1 MDDG4?)U P#WZ]>GUKA=%\7>-%\*3[?#V1:V\*6G^A3?OE.%)^]\WR\\5P?@O M6M=T;5KF?0M,^W7+Q%9(_(>7:NX'.$((YQ5:<[70E)\E^I],45PWB[XAKX7@ MLK<61N=4N8ED,&2JQY]>ISG( ]JY8_$OQQ9A;C4/"RI:Y )-I-%G/3#$D=<= MJ74+.USV*BLKP[K1U[1X[YK&YLG8E6AN$*D$>A(&1[UJTVK",W6]>TWP]8&] MU.Y6&+.%'5G/HHZDUYQ=?'&U2;%IH4TL7]Z6X$;?D%;^=<[XKFF\:_%--(\U MEMHI_LJ '[H'WV'OP?R%>W:7I%AHMDEII]K';PH ,(O)]R>I/N:F.JYBY6B^ M4X[P[\6=$UN[BL[F*73[B3 7S2&C+>FX?U KOJX?Q-\,-)\1ZI%?+*UB^TB8 M6\8_>GL?0$<]N?PKJVDM]$T;S+JY_K71^"OB3!XFO&TR]M?L6I $J@) M*R8Z@9Y!'H?SH6H-6.[HKS?QM\1-0\+>++;3HX+1K)HXY)7DC9G +$-C# =! MQQ61J7Q7\1"/[?IWASR])SQ<74,C!AV^8$*/UI)W5Q\K/7Z*YGP5XP@\8:7) M<+ ;>X@8)-%NW $]"#Z'^E8OC+XF)H.H_P!D:59_;M2& P.=J,>@P.6/3@8^ MM-Z.PDKGH%%>26?Q9UC3;^*#Q3H)M(Y#PZ121,J^NU\[OP(KLO&?BF;0O"(U MK2Q;SEVC\LR@E&5N_!!Z4/17"SO8ZFBO$Y_C7J@T^U$%A9&].XW#.C^6.3@* M-V>F,DFNPU_XC?\ ".^']-N+NP#:K>PB46@['&?PQUSZ4/17#E=['>4 M5XS+\4O&=G&E[>^'(HK!B,2/;3(&!Z8XY'-.PGH8>A_$7^V?&<_A[^RO)\IY4\_[1NSL)_AVCKCUKN:\,\#_ M /)9K[_KM=?S:OEI_A MSXAT2Q\":=;W>L:?;SIYFZ.6Y1&7,C'D$YHCJI7')64;&WXV\7?\(=I<%[]A M^U^;-Y6SS?+QP3G.T^E:/AK6O^$A\/6FJ_9_L_VA2?*W[]N&(ZX&>GI7G7Q> MUO2M3\.645AJ=E=R+=AF2"X60@;&Y(!Z5U?P\GBMOAOIL\SK'%'$[N[' 4!V M))HC\,F^@I+X;=3KZ*\FO_BWJ5]J$EIX5T0W@0\.\;R,ZCJ=B8('U-6O#WQ8 M:;5%TOQ+IPTZX9MGF@,JJQZ!D;E?KDT+4&FCT^BL3Q3XFM/"NBOJ-TK2?,$B MB4X,CGH,]NAYKS@?$SQO>(;K3_"ZM9,,JXM)I1CO\X(!_*E1](CD9HKB_#7BS59/#VHZIXJT_^S5M#E1]G>(LN.P*-5FD;P_X;$UO&<$F"6=AZ9*$ ?2F][$I-JY[#7#>*OB+_ ,(S MXDM]'_LK[3YR(_F_:-F-S$=-I]/6J?@GXFMXBU4:1J=BMK>L#L:(G:S 9*E3 MRIX/2/ZT M>R^V7@956+RFDR"<$X4@\"I;LK@E=V(M)\9Z3KNOW&E:;(UP;>(R23J/DZ@8 M![]>O3ZUT5?,_@O6M=T;5KF?0M,^W7+Q%9(_(>7:NX'.$((YQ7NGB+QA:>%M M"@OM11C=3(/+MDX9WP"1ST SR3TJG9),;7O-(Z2BO&_^%J^+98SJ$'AJ,Z6I MR9/(E8 #K^\!"_CBN[\&^.+#QA;/Y2&WO8AF6W9LX']Y3W%"0FK'4T444A!1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %<-K7Q4T/0M8N=,NK347FMV"NT4:%2< \9<'OZ5W-?-'Q%_ MY'_6/^NH_P#05J6]4BXI-,]/_P"%U^&_^?+5?^_4?_QRI[7XR>%[B79(FH6R MX^_+""/_ !UB?TK/T[X.^'KO3+2YDO-4#S0I(P66/ ) )Q\E9/C'X4:?HOAV MYU/3+V[9[8;WCN"K!ESS@@#!_.JE[NXH\LMCUZPU"SU2SCO+&XCN+>0?+)&< M@_\ U_:LKQ3XML/"-G!=7\-S(DTGEJ(%4D'&>E>7_ 5U*X37+W3-Y-M) M 9MIZ*ZD#(^H/Z"N\^(EKX;N]*M%\2ZAU MF\N+[;=C^_!" O\ X^RFMSP_XZT#Q)((;"\Q#^!-):[#:MN M='7"I\5M"DUQ=(%IJ/V@W/V;<8TV[MVW.=^<9]J[JOF2V_Y*7'_V%Q_Z.HCK M-1';W6SZ;HHKGM?\;Z!X;D\K4+T?:,9\B)2[_B!T_'%*]A)-['0T5Y_:?&/P MO%[&Y,,9O+P X,EO$"N?JS#/X47Z#LV=[17 M-P>/?#5QHTNJKJ2BUB8++F-BZ$G RH&>?7&*NZ'XGT?Q(DS:3>?:! 0)#Y3I MMSG'W@/0T".>UGXJ:'H>L7&EW-KJ+SV[!6:*-"I. >,N#W]*[9&#HKCHPR,U MY'XJTOX=S^*;Z75]>U&WU!I 9HHD)53@=/W1[8[FO6X@HB0(9!EH74HX'K@]1]*-P:MN6/$6OVOAG1Y-3O8YI(495*PJ"V M2<#J0/UK/\*>-]-\8/=+I\%W$;8*7^T(JYW9QC#'TK,^+7_(@77_ %UB_P#0 MA7*? W_7ZU_NP_S>B&K=^A4E:*9['16=K&NZ9H%G]KU2[2WBSA=V26/H .2? MI7&2_&?PS'*R+;ZE*HZ.D*8/TRX/Z47%9GHE%8'A_P ::%XF=HM-O TZC)AD M4H^/4 ]?PS6_1804444 %%%% !1110 4444 %%%% !1110 4444 59/^0E%_ MN_XU:JK)_P A*+_=_P :M5*ZERV7H%%%%40%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% %6U_U]S_ +W]35JN9U7Q#_8= MR1]E\_SF;_EIMQ@_0^M4?^$__P"H9_Y'_P#L:Z*.$K5(*45H<>)S'#4:CA.5 MFK='V.THKB_^$_\ ^H9_Y'_^QH_X3_\ ZAG_ )'_ /L:U^HXC^7\4<_]K8/^ M?\'_ )':45Q?_"?_ /4,_P#(_P#]C1_PG_\ U#/_ "/_ /8T?4<1_+^*#^UL M'_/^#_R.THKB_P#A/_\ J&?^1_\ [&C_ (3_ /ZAG_D?_P"QH^HXC^7\4']K M8/\ G_!_Y':45Q?_ G_ /U#/_(__P!C1_PG_P#U#/\ R/\ _8T?4<1_+^*# M^UL'_/\ @_\ ([2BN+_X3_\ ZAG_ )'_ /L:/^$__P"H9_Y'_P#L:/J.(_E_ M%!_:V#_G_!_Y':45Q?\ PG__ %#/_(__ -C1_P )_P#]0S_R/_\ 8T?4<1_+ M^*#^UL'_ #_@_P#([2BN+_X3_P#ZAG_D?_[&C_A/_P#J&?\ D?\ ^QH^HXC^ M7\4']K8/^?\ !_Y':45Q?_"?_P#4,_\ (_\ ]C1_PG__ %#/_(__ -C1]1Q' M\OXH/[6P?\_X/_([2BN+_P"$_P#^H9_Y'_\ L:L6/CFWN+M(KFU^S1MQYGF[ M@#[\#CWI/!5TKN)4YAD@F2+#QRH593N/4'D5$-I>H2 M^R>4>'U$/QSD2,;5%] MI9F]G;[0UNXCP0V#NQC!R*O_ !;\*ZMJ6HV>K:9:2W2QP^5(D*[G4AB0<#D] M>WI1%V5-OH:RUG-=T;WQ;EDC\ S+'G:\T:OCTSG^8%<7X#O/'%GX< \.Z'I] MU9/*S&:5P'9NAS^\7I@=J[#2(]<\<^%-3T_Q1IW]G[PJV[>0T9R.=Q#$G((' MI7&Z6OQ!^'S3V-II#7UM(Y9=L#SQY_O#801GC@_E0M&T^I"UBO(FM_"OC>Z\ M>VOB&\T6&V8W,]U02S.([E@ ,DACRR\C/K7T+IRLFF6B.I5EA0$$8(.T5Y/XI\%Z_H M/BQO$OA>)IE9S,8XP&9&.=PV_P 2GGISS52=JE_4B&M.W709XHTWXC>+;"*T MU#PY8(L4GF(\$R!@<$8R93QS5?QC:ZMI/PET33M2C,,Z7125-X;@;RHR"1TQ M^53-J?Q/\47MND-C-I(B/+B)[=#GNV\G=CT&?IFO0/$'A63Q#X.&D7EYYUZB M*RW3*!F4#J0!P#R/H:EKW7ZEI^\KE?X9V\%OX TTP* 95:20CNQ8YS^6/PKS M#QC;06WQBC$ 50]U;R,%[,=I/^/XU=T.X^(O@Y7T6UT1[F(N3&7@:2-">ZNI M /7DUFW'A;Q4GC6PO=2L;NZGFGBN+B:&%G2,E^5+*-O Z<"KO>HI+8E+EA M)/\ K<^@JP_&?_(E:U_UYR_^@FMRL;Q;!+<^$-7@@B>662TD5(T4LS$J< = M36<_A80^)'!? _\ Y!FK_P#7:/\ ]!-A/V)>IO?&B-6\'VSD#,JR[F;!(//?-9_8F:W2<'_6YSGP._X]=9_P!^+^35C_%R1[CQY8VL[$6Z MP1@#. SG%(?''@[5+BRM= FD%RZ+*[V[.@"YY5P0O0GJ:[SXC^!9 M?%5M#>:>474;92H5S@2IUVY[$'IVY-7)ZQET1$59RCW.W@MX;>UCMX8U2%$" M*BC@*!C%>&^%473_ (URVM@<6_VFXC*J.-F&./H"!^57X?$/Q/L;)='&BS/* MJB-;HVC.P]/G!V''J?QKHOASX!NM"N)=:UHJVI3 A(]VXQ@\L2>['V_K0OCY MN@GI#E/1JY7QOXNTSPMI\?VZU%[-.3Y5M@8;'4DG.!SZ'K755YK\5O!^I>(( M[._TR+SY+9622$'YBI(((]>_%1(J%KZE*\U/QUK'A>Z>#1].TC1_L;$!_OF+ M86(9KNXMVB/I6B^)^@G\'S, M+PA;1W/QGN/,4,([JYD /J"V#^==G\:(U;P?;.0-RWBX/IE6K!\':)JMK\6; MR]N-,O8K5I;DB>2W94()./F(QS74?%K3[W4O"4,-C:7%U*+M&*01EV VMS@# MI6;_ (Z=D]&E'_D1J[*N2^&MG=6'@6QM[RVFMYU: M3=',A1AER1D'FNMK6?Q,Q1\]^.K#^U/BW/8>9Y7VF>"'?MW;=RH,XXSUI?%_ MPPOO"^G?VA#=B_M5.)66(HT?H2,GCWS6UK^AZM-\9(KZ+2[U[,7ELQN%MW,> M $R=V,8LMQ!%=6\EO/&LD4JE'1AD,#P0:S2_=JVYM*5I^6AY=\(;7PS-; MO=6D4G]M0KB;[0P8J#WCP -I_,=,^K?BUXMU"QN;?0-.E: SQB2>1#AF!) 4 M'L.#G\*YV;PWXA\">.A=:-IM[>VB-NC:&%W#Q-U1B >>WX UUWQ#\%W?BRWL M]WF'ENR]0.<88$G@X_2G)J23Z=28KEDU]QROB#X376D^%X]1M; MA[J]B7?=P@F=V=GXXQ6*?A=XLM=/35XU3[5^%;S MQMX0CNDT_P ,74HN2I?[183-C&<8QCUIK2XZ].EKX>U&>0X1+:1B M?^ FO(O@C;NVNZG< ?(EL$)]V;(_]!-&I7OQ(\:VYTR31GLK9R!*/(:!6&>[ M2')'L*])\$^$XO".ABTWB6ZE;S+B4=&;T'L*(JSM>@UXKXU\*>(]+\;/XDT6UENE>59D," M>8R-@ @J.2/Z5/VE?8(K1D/Q"E\:7?AR&X\0V]A9V?VA0MO _ M?I4\=+=,)&[\ 8'Z_K7'_&>W@B\66LL842S6H,F.Y#$ G\./PIV MD6_C[P!?7%C8:2U[!.^>(&EB8] P*D;?Q(]^E8'CNTUV/5K:\\0RH;^\B\SR M4Z0J"0%IM\THM!!B,>?<7#!GQSM4 9] M,Y_.KWQ(T^[O?A^MK96L]U,'A_=PQEV('4X'-3?"ZRN]/\$PV][:S6TPFD)C MFC*, 3QP>::WF9_8@>;?%1[B;XCQQ"-9"L<*Q1N?E;)S@\C@DFNIU&X^)VJ: M7<:=<>&-+\B>(Q-MD7(!&./WW45=^)G@2[\0M!JND@-?P+L>(L%,B@Y&">X. M?SKFI?$'Q/O;#^QAH]U%+C8;Q+9XY#COYF=@^HQ41^'E9J]U)#]'T'Q%X6\ M>*X]2M#;I+ IBQ,CYZJ_W2<<$5D_#FY\6V=G?2>&='L;U'D4323N RD#@#,B M\[5ED0;?W2D8VY Y/O^5>;6NC^-_ASJER=(L6U M"SF.WY(FE60#.TE5.Y2/R^M5>TG?L2M8Z=Q-?\,?$#Q%K<&K7.@6T%S$JJ#; M3QJ#M.03F0\UL_&W=_9>C;AAO,?(]]HI_AU/B+KOB)=0OYI]*L"RF2)DVKM' M\*1OD@GU/UR>*M?&+2]0U.PTI=/L+J[9)7+BWA:0J,#K@'%*6D4O,<7[_P C MI/ ]K%#\/-,B5%"R6N]@!U+9)S^=>6_!RWBD\;7#N@)AM79,_P )W*,_D37K MOA.WFMO!6EV\\,D4R6BJT;J593CH0>0:\V^$VB:MIOBV[FOM+O;6)K5U#SV[ MHI.]>,D=>*T_Y>OT9"_A?,A^-R@:UI;8Y-NP)_X%5?XN2RM_PCL1SY8LMP]V M.,_R%:WQAT;5-3U73'T_3;R[5(&#-;P-(%.[H<#BNA\:^"IO%/A?3_LP":E9 MQ+Y:R?*&!4;D/H>!^58KX/G_ )FE_>7H9-E?_$M-(M[6W\,:2UF(%1!YBX*; M<#_EMZ5'\,?"?B3PYX@NIM3L/LUI-;E21,C#<&!'"L3TS63;:Y\2],TQ="31 M+ABB^3'E?$Z-7^'NI[@#M$;#V.] M:XJ^T357^-B7ZZ9>M9?:XF^T"W8QX"+D[L8Q7>_$*UN+WP+J=O:02SSNJ;8X MD+,WSJ> .36;_A)?UNC1/]]]QS/P9)/@[4!G@7;?^@+7-_!?_D:]1_Z]3_Z& MM=?\(M-OM.\,WL-_97%K(]V6"7$3(2-BC.".E<+I^E>,O OBJZDTS19;LR!H ME?[.TD3H6R#E2,'@=2,5HW:I\B+7@UYGOE[4W2VN+A/;;][_ M ,=+5U%B\\NGVTERFRX:)3*F,;6QR/SJ6:))X9(I!E'4JP/<'BHFM&A0E9IG MSY>>)_/^$MCHPD!G6\:-U[F-?F'ZL!^%7]$M#X"^)&F1W#[8;FT3S&;I\Z<_ MDXK,TSP%K"^-H+&?2[S[%'>8>X:!O+:-6SG=C&"!^M=O\8?#E[J:Z9>Z=8W% MU+'NAD6WB+L%/() '3K^=-NUIKJ_TL797Y/+];F5\+X7U_Q[JWB&;)$>YUSV M:0G'Y*"*J?%3_DI.G_\ 7&'_ -#:N]^%NA3:)X14W5O)!=W4K2R)*I5E X4$ M'D<#/XUR/Q*T75;_ .(%CF7MQ L4(:6&W9U!#L3D@8JK)3@ET(;NIOO0"X ((&>^#G\*YOX9WOBRUEM=#OM%EM]*@5R9YK9T<$Y(&6(!&?05,/ MM(<_AB^USFM:MH[SXYB"50T;7L.X'H0%4X_2O2_BMC_OA:]*KSWX0Z=?:9X:O(K^RN M+21KLL$GB:,D;%YP1TKT*M9[_=^1CW/![U-_QW4$X_XF$9_)5-/NM3/@7XG: MZ^&6*XAE* ="77>O_CW%:$VA:H_QL%]_9E[]B^V*_P!H$#>7@(.=V,8S3_B] MX9U"^URRO]-TZZN_,@,%I-I4\9P#C(;]*R7P1^:^\VTX1E/\ -C^5=7\%&">&M29B HNLDGM\@JY_PC]S9_!9]+2U MF:\>U\QH5C))D)!0#(! JWH MYV[(B]XJ_&H;RZ12#>387*YY)Z84D#JPSQQ7!_$9?$']O M6S^(FM/M3VX*):_=1-S<'WSGN:T=-TGQO\/]>F.G:3)>"0&/&O&NJ26^M:I82SW,^4%M:1&0P(O(R%S@')[GWJ5;W66M&T=[X_\ M%7GBK1=-N-/=3>6D6!$[;1(I R >QR._%U'[:\OM0D^S7UU%Y4:)AC"O7<>H)SCCVK&N)_B?X8U>:8I-K,#?(I$9EC8 MK;>)-)"KGYFC1HI%'KM;K^E>B>)?% M&EZ#X?74[L?:()MHAC4 ^:2,CKQC'->5WFC>-OB-JMK)JNFC3[>'*;WA,*H# M@DA6.YC^GTYKM_B#X-N=9\)V5GI0WS:>1Y<;$ R*%VX!Z9Z42OR^?Z#27.9F MF:_XVU^P5O#V@:;I6FN&*2S'CD\D 8]2<[>>:Y/X0!AX\F#'+"VDW$?[RU?T M&]^),>E+X"- 8UNKFW:,Q*3V[4,XN[A@&[,N['Y8_2O9=< MT[1M1M(DUN*W>W2563SVVKOZ#N,YSC'>O./&7@;6[#Q3_P )/X84RR-)YSQ) MC>C]R ?O ]QUY-9&K2_$+QY%#IEUHCVD".'8FW>!">F6+GG'/ _*H6L(QZHJ M2]]ROHSTSQ':65C\/-6@TZ&&&U6REV)" %^Z?2N(^!]M'Y.L714>9NCC![@8 M)_P_*NJ;PP=!^%]]HMHKW%Q]DEW>6I)ED8'. .?8#Z5C_!W2]0TS3M474+&Z MM&>5"HN(6C+#!Z9 S5+XI>A#^!>IROQH55\7V3J &:S7)]<.U=%\9R3X7TDG MJ;@?^@&LWXN:)JVI>)K*6PTR]NHUM0K/!;LX!WMP2!UKLOB!X7NO$_A**WLP M#>6[+-&C'&_"D%?TJ/\ EW\S5M3SAR0A&3GO3/!WA;7-'^* M%N][973C/>M5K4YO4RMRTW$U_&_@;Q OBL^)?#; M&29R'*JP62-@,9&>""!T]^E9D?Q/\9:#(B:]I(D0':3/ T#L?9A\OZ5O^,;3 MX@6.N_VCHMY/>Z>K>8EO&%^3CE&08+C\_P \&N>U?4?B'XULO[(G\.M;0NP9 MS]D>$'!XRTAQU].:RC>UD6[/5G;ZSXE@\0?"O4]5TX.H>W9&1OO(H\BB:2=P&4@< 9D7CDUZIX8\'1:/X*;0KQQ,;E7^ MTE>F7&"!]!CGVKSBUT?QO\.=4N3I%BVH6&=1U[2[*XTVW: MXDM'??$@RY5@.0._W>@]:4M(I>9<7[_R.OT'_D4]-_Z\HO\ T 5Y)\%_^1KU M'_KU/_H:UV/PYU+Q1=0_V?K6DO:65I;+%#));M&SD8'.X\\>@K@]/TKQEX%\ M574FF:++=F0-$K_9VDB="V0-]TS.*_=\O9H[#XD>!=5UK4[ M?7-$8/=PHJ-#O"M\I)5E)XSSZ]JYT?$'Q[X<(76M-,L2'#/,+'Q[/'97^BWLP5HHVGLHBJ-%( "?]X9ZC)_$5SFH>(OB/X@TZ71Y/#CQ+ M<)Y;R"QD0D=_F<[1G_\ 54*ZND7H[-GI/@_Q=:>+]+>Z@B:":)MDT+'.TXSP M>X/KQTKHJXSX<>$)_">BS"]93>W3AY$0Y" #A<]SRF),X/_CPKVCQ-HG_"1>'KO2OM'V?[0%'F[-^W# ],C/3UKF?B M%\/O^$J5+ZP=(M3B7;\_"RKZ$]B.Q_R.5MO$/Q.\/6R6$VAR7NQ=J2/;/.0! MQ]Z-L'\>:A6Y%%]#5WZ\>VOB&\T6&V8W,&P@C/'!_*NF\$VGCR\UIM2UR\GM-/9C(; M60#+DCA0IR44?@?Q)-6G>2DB7HFCE/BW$)OB#9Q'H]M$OYNU>N>)+>)?!FJ6 MXC41)8R*J@< !#BO-?B5HNJW_P 0+&YL],O;B!8H0TL-NSJ"'8G) Q7J7B&* M2?PUJD42-)(]I*JH@R6)0X ']U02S.([E@ ,DACRR\C/K7*--^(WBVPBM-0\.6"+%)YB/!,@8'!&,F4\W0Y[MO)W8]!GZ9KJ?B%I>I MW'PZ2Q07&IWRO%YC10Y:0CJVU1TJ):0?FU^8T_>15^#6GPP>$YKT1CS[BX8, M^.=J@ #/IG/YU?\ 'GC73- :+3I=,35+V9=RV[@%5!.!G(/7T YQVJ7X765W MI_@F&WO;6:VF$TA,.#S7+?%#P=K5WKL6OZ1 ]SMC4.D0S(C+D@A>X MZ=*N;]Y=B(+?YD7C"[\=ZEX1OI]3L+#3=+ 4O#G=*R[EQW/ZYUXWX.T35;7XLWE[<:9>Q6K2W)$\ENRH02J7=UJ"3S[]RQ2(%&'(XRA/;UKIOBYI MU[J7A>UAL+.XNI5NU8I!$SL!M;G '2M7XI4GI&QYE\0_A_I7A+1K:\L+B]DDEN!$PG=2,;2>,*.>*V[B>:#] MGZ$PDC>H1B/[IF.:V?B]IM]J?ARRBL+*XNY%NPS)!$TA V-R0!TJ_P"%] ^W M?"ZVT75+>: RPNDB2(5=#O)!P>A'!I:N$EYH+I2B_4S?@S:V\?A&:Y1%\^6Y M99'[X &!^OZUA_'"VMUDTBZ 47+B1&P.648(S]"3^=4;'3/'OPZN[B/3;#^T M;.5O^6<33(Y[-M4[E./\GBIK?PKXL^(&O0:AXFA:RL8\#8R^60N>51#\PSZG M]>E.7OM-!'W+MG4ZOX:NO&GPTT>-9@E_'!%.ADX#MLP0?3.>M<9:ZM\1_!=M M':26$LMI",(LEOYR*!VWI_4UZ=XNTS79M"CB\+WOV.>WX$*A0)% P%#$?*1V M[5Y];>*?B;I%J-/DT&>[>,;1<2V0?;GZUP6HP6]S\]<9XGLKC4?B[=6EG,(;F6[012 M'^%MJD'\Z>TXL7V9);'MWBVW@N?"&K17"J8_LDCK6K>'[G1G42#9)/;VY E'O)DH ?;%=]\/_"3>$]! M,-PRM>W#^9.5Y"G& H/?'\R:(Z-L)?"H^9YQX'_Y+-??]=KK^;4OQ>_Y'S3_ M /KVC_\ 1C5>\':)JMK\6;R]N-,O8K5I;DB>2W94()./F(QS5OXM^%=6U+4; M/5M,M);I8X?*D2%=SJ0Q(.!R>O;TJ8NRIOL5O.:[GI&MZO9Z%HMQJ-^3]GB7 MYE R6)X"@>I/%>?:5XL\4>($E?PGX9L;.R:4[[B-K57B:(2; S!Y[NW@=X\R [CN QP6.?I6E\2M%U M6_\ B!8W-GIE[<0+%"&EAMV=00[$Y(&*HYN_/Z'LE,E_U+_[II](1D$> MM3)731*W/#_@O_R->H_]>I_]#6F_%R1[CQY8VL[$6ZP1@#. SG"+SQ?H]A?P*D6L00@ M/$_RA\C)7/8@YQVY--O2,NQ;^.2OO<[Z"WAM[6.WAC5(40(J*. H&,5X;X51 M=/\ C7+:V!Q;_:;B,JHXV88X^@('Y5?A\0_$^QLET<:+,\JJ(UNC:,[#T^<' M8<>I_&NB^'/@&ZT*XEUK6BK:E,"$CW;C&#RQ)[L?;^M-?'S="'I#E/1J***0 M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "OFCXB_\ (_ZQ_P!=1_Z"M?2]?-'Q%_Y'_6/^NH_]!6H? MQ+Y_H:0V9M6OQB\0VEI#;1V>EE(8UC4M%)D@# S\]9OB+XE:_P")=.:PN?LU MO;.1YB6R%=^.<$DDXKVK1_"WAZ71+"230=+=VMXV9FLXR22HR2<5!K_@3PU? M:1;_#_4I],\;Z8T#-B:80 M2*I^\K''/TZ_A7I'QN_Y%[3?^OL_^@&BIJDQP5I-$OP4_P"15OO^OT_^@+7' M_%GQ+/J7B-]'BD86=D0I0='DQDD^N,X_/UKL/@I_R*M]_P!?I_\ 0%KR_P 9 MQM9_$#5?-!XO#)R.Q.X?H:I%/^M@AHI,]2\-?";0XM&@?6K=[N]E0.^97 M18R1]T!2.GJ:X#Q_X1_X0K6K6XTV:86LV7@1D>F00?\*^A+>5+BVB MFB8-'(@92.X(R*\J^.%S$++2;7]^-=>;PWX5O-0C_ M -> (X'][^!UQ$&UBV) E/E2 >JC<#_,?G40UE)OH.3M!6ZF MWX@^$F@W&DR_V1;O:7J*6C82LZN0.C!B>OMBN%^%GB6YT;Q-'I,SM]CO7\MH MV/"2=B/0YX/_ -:O?9'6*-I'8*B@LQ/8"OF7P\C:E\0[$VP/[S4!*N.RA]Q/ MY"B'\2W<'K3;?0](^-&NS6NGV6CP.4%T6DFP>JKC"_0DY_"LOX;_ YTW6M' M_MC6HWGCE9E@@#L@P#@L2I!SG/?M4'QMA==?TV8D['M2H'N&.?YBO0/AA.DW MP^TT(03'O1AZ$.?_ *U%/X9,)NW*D>;?$OP-;>%XXM0TEI([&Y?RI8&//&934+B0B3=<7,@/S%1V'IR0/:O3/$?PET270YO[#M'@U&-=T7 M[]F$I'\)WG SZ\5QWP8F2/QC<1MC=)9N%^H93_*O=;BXBM+:6XG<)#$A=W/1 M5 R35R2441S/G9YU\-O"/B3PM>7 OVMA83H"T2S%F#]B!C'J#SZ>E+XX^&^I M^*]9;4(M7A5%14BMY8V C'?D$]>3G'M77Z;XLT#6)HX;#5K6::092(/ASQG[ MIPA M;;T]P:[O2_@C(Z))JNK!"1EH;:/)'_ S_A7!:-;1P>/[&UA=C%'J:(C-R2!( M ":J'\1 [?R%='X?T?X6ZII\$1E07;(%?[5=212;R.PR%)SZ9%==XX\+:!XB@5]3O M8[&YA7Y+DR*I5?1@3@C/_P"NO,]3^#GB"UW/836M_'_"%?RW/X-Q_P"/5,=% M9E.SLTSH-/\ A'>V'B!-2T[7(H;>&826S!#(Y3T;D#U'7D?E7K=?,>G:SXA\ M"ZRT"O-;2Q,/.M)#E&S@\KTY')9 #V# '^M7]G38S ME?FU+%%%%(04444 %%%% !1110 4444 %%%% !1110!5D_Y"47^[_C5JJLG_ M "$HO]W_ !JU4KJ7+9>@44451 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 >?>-/^/N#ZR?S%-/^/N#ZR?S%O53V(^AP:O44FKZ#3MJ>-)X;^*'AZ=TTK4'O(G)&[[0 MCKCL=LW0GVJ73?AYXG\0>((-5\87*!(B"T9=6=P#D* GR@?X]*]@HJD[.X-W MT"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ KR:X\&:^_Q;&N+89T[[6DGG>=']T* 3MW9_2O6:*%HU(.C7<**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFCXB_\ (_ZQ M_P!=1_Z"M?2]%*VMRE*Q\V0?$OQ?;6\<$6K[8XU"(OV:(X & /NU%>^./%NO MVYTZ;49[A)1@PPPHI<=Q\B@D>U?3%%-Z[@I6V1XS\,/ &H1:M%KNK6[VT4&3 M;PRKAW8C&XCL!GOWK6^-W_(O:;_U]G_T UZA11+WK(479W/-/@I_R*M]_P!? MI_\ 0%I?B7\/I_$$BZOI"JU\B;9H2<>:HZ$'IN'3W'TY]*HHE[SN$79GSWIO MC[Q;X-LUTJ>U79'Q&E_ X9!Z Y!(_.DM/#WBOXBZV+Z_66.%L;KF:,I&B=<( M._7H/Q/>OH6BGUNQ\W1:%/2M,MM&TJVTZT7;!;H$7/4^I/N3S7SA;?\ )2X_ M^PN/_1U?3=%"?O\ .*]HN)4U33;;6-+N=/NUW07"%& ZCW'N.M>"7GAGQ7\/ MM<%_81RRQQD[+J!"Z.GHX[>X/X'O7T-14VL[H:EI9GSYJ'Q#\7>+;-M*M[9 M)1B1;"!R[J>,'EL#Z8KN/AK\/)M D.L:NJB^9=L,(.?)!ZDG^\>G'0?7CTNB MJ3ML)NZMT.1^(/A$^+-"$=N56^MF,D!;@-ZJ3VSQ^(%>.:+XE\3^ +J:R6V, M?F-EK6[B8J6Z;A@@_B#@^]>M_$;6/$&@:?:ZGHK*8(F9;I&B#C! VL>X .>A M'45R>@?&ID61/$%D7QCRY+*,9/KN#-C\JF.[L6[\JNKG+^+%\4ZYI@\1^((_ MLUNL@@MX#&4ZY)*J>0..IZ\5V'P.'^B:R>V^+^35SOQ!^(MKXLT^#3]/M)XK M=)1*\D^ S$ @ $XZGO7??"70KC2/"KW%U&T(8[G3Q!,H>.2+8ZGN",$58HI+2'* M$G>5SY\UWP9XA\$:\-1TF.>6VC??;W,"[R@_NN.W'!SP?TINI?$;Q5XJT]]( MCMX<2KB06<#&21>X/)X^@%?0M%*VEF/FUO;4\O\ A?X"N]%F?6M6B\JZ9"D$ M!^\@/5F]">F/K7&_$/P?J>B^([K5+6":2QGD-PL\2D^4Q.2&Q]W!Z'TKZ"HI MO5IKH*+M>_4\*LO'OCOQ-9C2M-M8Y)&'EM=00D...27)VK]<"N2-I/X3\:00 MWY!EL;J)Y"AR" 0W'X5]144T[24@OI8X7XKNLGP\N'1@RM)$01W&X5RWP-_U M^M?[L/\ -Z]CHI1T;?<3=XI'C_Q,^'E]=:E)KFC6[7 E&;FWC&7##^)1WSZ# MG/Z<_9?%/Q5H5I'IL\%M(\*A0;R%Q(!CC.&';U%?0%%)*RMT*-/\,^ M)?B!XB-_?P3113,&FNI(]B!,O'3'XU]!6UO':6L5O"NV.) B#T &!4M% M5?2R(;N[L****0!1110 4444 %%%% !1110 4444 %%%% %63_D)1?[O^-6J MJR?\A*+_ '?\:M5*ZERV7H%%%%40%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% 'GWC3_C[@^LG\Q7+UU'C3_C[@^LG\Q7 M+U]+E_\ NT?G^;/A\Y_WV?R_)!1117<>2%%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 =7X8\3FS*6-\^;<\1R'_EG['V_E].G? @@$'(/> MO%JZOPQXG-F4L;Y\VYXCD/\ RS]C[?R^G3R,;@N:]2FM>J/I,KS3EM1K/3H_ MT9WU% ((!!R#WHKPSZH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKR/XP^)+ MR*XM?#UG*T:31^9/M."X)(5<^G!SZ\4F]DNI45<]*_X2'1/M7V7^V-/^T9V^ M5]I3?GTQG-:749%>1S_!:W7P^7AOKA]7$6X*2HB9\9VXQD>FVM(S+ JREV0 $E>F,=,<^M-V2=^@K7M;J=K=WUII\)FO;J"VB'5Y MI B_F:99:G8:DA>POK:Z13@M!*K@'\#7AWAK0K[XH:_>:CK-]*MM#C=Y?49S MA$SD*!CT_G4OC'P;-\/)K/6]"U&Y$?F>7F0C>C8SR0 "IP>,?G1M;FZCY4W: M)[E-/%;0///*D44:EGD=@JJ!U))Z"JUMJ^F7EM)W0UZ!\7?$ESINAV=A9RM$]_N,CKP?+ & M1GW)'Y4F_=YEZ%Q_P"2\M_U M_P G_H+5K>'O@_:7OA^VOK[4+N&_GC$J"':%BR,KD$9)Z=Q7+^$H;NW^+=K! M?RM+=Q74B2R,,_'#_D(Z/_URD_FM>KZ3_P BW8_]>D?_ M * *F_N.7835FEW'66MZ3J4S0V.J65U*HW%(+A'8#UP#TYJY--%;Q-+-(D<: MC+.[ ?4FO#?@S_R.=[_ ->;_P#H:4GB"YOOB!\2?[!%RT5C#.T2*.BA =SX M[DX/Z536R74IQ2>)3X<\-7,UM M=VT6HE1]GCE8%F^8 E5)YP#FN%U_X.26B6TWAJZN))Q(-XN9%7;WWA@!C!'3 MD\U:\>^'+J?X?V^J:].6UC3HA'F!P8WW.HRV5R3CTQSZU$OA'%+F1I_"WQ)% M>Z)(FIZO%)J<]XY$BUXY\)_!^GW]K#XBEFNA>6MTRH MBLOEG"CJ-N>Y[U['6DC(JWVI6&F1K)?WMM:(QVJT\JQ@GT!)J.?6=+M;6*YN M-2LX;>4 QRR3JJ.#TP2<&O/?C=_R+VF_]?9_] -9/A3X:1^*/#]OJNMZC>!Y M8PELD3*!'&ORKG(/IT&/UJ%JGY%M)6OU/8;>Y@NX%GMIXYH6&5DB<,I^A%5I M]:TJUO5LKC4[.&Z<@+!).JN<],*3GFO%?#5Q?> ?B4=!>X,MI-.L$@Z*P<#8 M^.QY'ZBH/BO)+#\1/,@9EF2&)D9>H8="*?\ +;J'+JT^A[G'J^FRWS6,>HVC MWB_>MUF4R#ZKG-3W%S!:0M-M:AJ0N+B- M3(;<0\+(1UWEN<9]!S7&:SJ0\=?$![+4]5CL-(@D=$:6155%7(R,D#*M"T7PM]CU3PKXE2YF M24*42ZCDD0X)##9CCC!X[UW6O>.[F/X66>L6S>7?WP$&]1]Q^0[#_ODX^HH; M]VZ#EU2[G=7FN:1ITHBOM4L;60C(2>X1#^1-7(9HKB)989$DC;D.C @_B*\7 M\&_#"U\2Z -8U:_NUENF9HQ$RYX)&YBP.22#Z5N> _!OBCPKXAG#S0'1W9U= M6EYD ^ZX49P>G4],T[:V8G:UTAV.O:-;6] M_K=OI,:7 =9I]N&.TC:,LO/.>O:O//BI_P E)T__ *XP_P#H;5T_QL_Y%>P_ MZ_!_Z U1_P NUZE_\O/D=AX;M[/0_"-G"NI07-G;1'_3 P6-ER26SD@#\:OV MVKZ9>6TES:ZC:3P1G#RQ3JRJ?<@X%<3I_P#R0MO^P;+_ .S5Y]\//";^,%N[ M6ZO[B#2[9ED>*$@%Y&X'7(Z+UP:MW+'5],U,L+#4;2[*?>\B= M9,?7!KF_B'H=CKVC6UO?ZW;Z3&EP'6:?;ACM(VC++SSGKVKR3Q1HS_#SQG:' M3+N9E54N(GUC)P&GE5 ?Q)K MEO"-^NE_"JSOW&Y;:S>4CUP6.*\U\)^'KCXF:[J&HZW?SB.+&XQD;LMG"KG( M4#![54KN;1$4N7F9[G9:C8ZC&9+&\M[J,<%H)5/O">J>*K."*WU:&TMX ME+20.IVNWJ6'8?2D]KHJVMCH4\2Z#+.((];TUYB=HC6Z0L3Z8S5^YYM)B/\ MGF?Y5X1XL\'^$="T21[+Q$;C58]H\CS4<,<@,-JC*]SR>U=I\)M1N;WP1>0W M$K2"UE:.(L<[4V @?0(_!+_ )#^ MI_\ 7L/_ $(5[=6DMEZ?YD?:?J%4KW6-,TTJ+_4;2U+?=$\ZIGZ9-<]\1/%, MGA?PV9K4@7MP_E0$C.TXR6Q[#]2*\_\ !GPW3Q=I;ZYKE_>9N7;R_+8;VP<% MF9@<\Y_+K4*[O;H59)7?4]IM[F"[A6:VFCFB895XV#*1[$54;7='2^^POJMB MMYN"?9S<()-QZ#;G.?:O'O!TEYX.^*,OAU;@RVDTIB=3T;Y=R-CL>GZU?^,6 M@/:WEIXELP48D1SLG!5QRC?IC/L*=UH^C!1U<>IZ[D:1X&\/I UQ!;Q@CSKF=UC\QSW)/Z"G;2[$^BZ MG0U0?6])COQ82:I9+>%@HMVN$$F3T&W.TMW8A55;R,DD] M !FO)/B;'_8_Q*T_55&%<0SD^I1L'] *2^)+N"6C\CW'I6?::[H]_ 53'S-^1Q]363\.- 7PQX M1N_$5ZFVZG@:4;ARD2C('X]?RI7T;>R';16W9-_PBFDZM\2/[;7Q197-S'.) M?[/C",XV #&0^>"!VKN8=;TFXOC90:I92W8)!@2X1I 1U&T'/%>2?!>T:ZU[ M5=4ER6CB";C_ 'G;)_\ 0?UJO=H-!^.T;XVQS7:L/<2K@_JQJDK.,.X2UYI= MCV^66."%YII$CB12SNYP% ZDD]!56QUC2]3=TT_4K.[9!EA;SK(5'O@G%>>_ M&#Q*;338M M6/VB\PTVWJ(\\#\3^@-5T1_AA\-?/1%&LZ@P!8C.QB"0/^ J# MQZU*>C?]7#EV75GI=[JVFZ9M^WZA:6F[[OGS+'GZ9-2VM[:WT(FL[F&XB/1X M9 ZG\17BW@SX='QA92:YKM_=A;ASY?EL/,DQP6+,#QGCIVK.U6UNOA;XYM_[ M/O)9+5U64JV,R1DD%& X)X/.*I+51?4+73<>A] T$@ DG '>D5@Z*PZ$9%'9)$I.0A.[./K@52UNNP-65ST[^V=+&H?V?\ MVE9_;>OF9QG&W.>G--EUS2(+L6DVJ64=R3@0O<('/\ P$G->%>+HKR? MXO75O83M!=37$<4K:+:Z?X3\*V=M+J%NMK;H ;J1EC1RQSG).! MDGUK035M-EL3?1ZA:/9C.;A9E,8QU^;.*\^^,]Z+7PO8Z?&=OGS@[1_=0?XE M:Q_"/PYF\2>&;2?7-0NH;(*39VL!"[0227.0>22>W3'/:G=RNPY4DK]3URRU M"RU&(RV-Y;W48."\$JN,_4&K->"_#!9[#XE36-K.9+91-'*>@=5S@X^H'YU[ M/<>)-"M+AX+G6M.AF0X>.2Z164^A!.13TLFNHFFFUV+MU>6UC;M<7EQ#;P+C M=),X11G@9)XIME?V>I0&>QNX+J(';YD$@=<^F0>M8'B:2P\2^"=8BT^\MKP" M!CFWE60!U&X#Y3UX%,NR[=U9' .["D ML >GK7F%Z9OB=\2A;PLW]F6YV[A_#"IY;ZL>GU'I5[XS3QQ7.BZ+;*$C@A+B M-1P 2%4?^.FIWBO-EI6E9=#O/"ECH_@KPM%%)K=E+;32M(MX[K$DI/0 [B#P M/7M746UU;WMNEQ:SQ3P/RLD3AE;Z$<&N!\>:&(OA.EHBY;3XX6'']W"L?R)H M^%FK0Q?#IY;B0)%822B1CV7[_P#[-5MW;'Y7F[U\O&[?GC'KGTKPSPW8S?$?XA7&KWJ'[! XD93TV MC[D?Z<_CZT[Q=J^I>.?&Z^&=/E,=E',850<*2OWG8=\8./I[TM=%U932N]=$ M>QP^(-%N;G[-!K&GRSY(\I+E&;(]@7]GI\/G7MW!;1?WYI B_F:L5\ZZM< YKA].^'7A'4[V&30_%3],43V'!+F)/A;XDBO=$D34 M]7BDU.>\!,;I)G"*,\17,?%'_DGFI?]L_\ T8M8WP9<1^#+QV.%6\UBSC?/($'YDUP?Q8N[:]^'ZSVEQ%/"UU'B2)PZG@]Q7!:; M9W?Q2\Y_FU0?!:9 M;?0]I7E]9Z?#YU[=06T7]^:0(OYFDLM1L= M1B,MC>6]U&#@O!*KC\P:\!L)(/B#XLN;KQ+K4>GV:*6023HF!GA$W<=.IP>G MO1KMM9>!M=L=0\*>(([Q&SN"3I(RXQE7V<%3GT'2I72_4MQW2Z'T/67/XET* MVF:&?6]-BE7JDETBL/P)KB_B;KEV_P /;*\T]I(X;]H_-9#R$9"V">V3@?I7 M#^'/#_@'5=+A_M#Q#=6FHE?WJ2,L:*WL64@C_@7Y4:W:["LK)]SWZ.1)4#QN MKH>C*<@TZN0\#^#[?PQ;R26FLSWT-PH^4%?))_O*!GG\:Z^FR3@?B/X:TSQ! M-I[:AXCM-(,*N$%P%_>9VYQEUZ8]^M=C:&WT_18"]U$;:"W4&X9@J%0H^;.< M 8YZUY1\45Y&];:OIEY; M27-KJ-I/!&1.LF/K@UX/\//";^,%N M[6ZO[B#2[9ED>*$@%Y&X'7(Z+UP:@\4:,_P\\9VATR[F955+B)W(W 9(*G& M>A[=#56]Y)]0M=.W0^BZP_&?_(E:U_UYR_\ H)K:1M\:L/X@#6+XS_Y$K6O^ MO.7_ -!-1/X6$/B1X1\/O%!\,>)8Y)7(LKG$5P.P'9OP/Z9KWKQ60W@W6&4@ M@V4I!'?Y#7@V@^%#K_@S5[VV0M?6,JN@'5TVGNX\*>*?[9^&.LZ9< MR9O+"QE49/+Q;#M/X=/R]:J>L&NJ7X%1^-27A?"75/[0\$10,V9+.5H3]/O#]#C\*\W^+%^^I^-;B&, M%HM/@6-L=!W)_-@*Z#X;W*^'?&7B+19V*Q('D7/_ $S8_P#LIS^%5_T+A'E;CYV_4[OX*,$\-:DS$!1=9)/; MY!7/ZUXL\0>._$QT7PW/);V08A3&Y3>HZN[#D+[?3@FK'@"5X/A9XIEC.UU$ MI!]/W0H^!\,;7^L3D#S$BC53W ))/\A5MB(VBVM[DK?!?488S=6WB)?M MXRP_2DLIR\3] "W\2GU]QVKV*O MOBZBVOCY)H?DD:WBD)'7<"0#^0%2G:271CMS)]STGXE^*+KPSX=1K$[+NZD\ MI),9\L8R2/?M^-<)HOPRU/Q=I,&M:EX@97N%W1AT:=MN3U)88^G->A^,_"Q\ M8^&(H%=8KR/;-"S]-V.0?8YKR**?QWX +1*MY;6J-N(:,2P'GL<%1GV(-)63 M:D";<5RFGI^KZ]\.O&<6C:A?/F*Z[XT_P#(HVG_ M %^K_P"@/67X:^,K7%W%:Z_:11JY"_:H,@*?5E.>/4@_A6G\:"&\(69!R#>* M01_N/1._*K]QP^,Y/PU\)O\ A(?#UIJO]M_9_M"D^5]DW[<,1UWC/3TJ#4K# MQ/\ "O4;:>WU$W%A(Q"@$^4_T2TU.WXCN$#;!]C'(CNI%7V& ?YDUZ!3DK,A;!1114C"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&5 M74JP#*1@@C((KF;SX>>$K^023:) K<_ZEFB'/LA KIZ*!W9SNF^!/#&DRB6T MT:W$BMN5Y@445QWQ/O;K3_ 11S3;LKDI M7=CL:*\+\/>'_'OB71X]3L_%4T<$C,H6;4)PW!P>@(_6G6GBGQ9X$\40Z;XA MNY+NU)9/,RC'&]'//'/!],8JK:\H6TNCW*BF/+'%$9)'5(P,EF. /QJA; M>(=$O9Q!:ZQI\\S=(XKE&8_@#2$:5%17-S!9V[W%U/'!"@R\DKA54>Y/ JFW MB#15M$NVU>P%M(Q1)CZU"STZU2>_O(+6(X7S)Y0BD^F2>M"UC?SL-JS2+5%7O([DS M(PW$_?/7 X]L4=_(+;'0T52MM9TN]@EGM-2LYX8O]9)%.K*GU(/%+8ZMIVIA MC8:A:W>S[WD3+)CZX- BY14<\\-M$TL\L<4:\L\C!0/J35*TU_1K^;R;/5[" MXEQG9#JZ[8 M:]=WZQIFFE1?ZC:6I;[HGG5,_3)JFK6%UL M7:*KV=_9ZA#YUE=P7,7]^&0.OYBK%( HKSGXP:E?Z9H6GR6%[)/"7B>/0_%DC3V[E4\R0AF0'@.'_B7US_ #KM/B)!?W&E6@T_Q#;:*XFR MTT]ZUL'&T_*".OKBF]DT*VMF=E16=H"2Q^']/2>[2\E%N@>X20R+*<#+!C]X M'KFFW'B/0[26MC 9[RYAMX1UDF<(H_$ MTVRU"RU&(RV-Y;W48."\$JN,_4&@"S1165XEUJ/P]X>O-3D /DI\BG^)SPH_ M,BDW97&E=V-6BN)^&)U.\\.RZMJM[ M+?$GC+4=*TWQ%>0,DLSJ);V54"J^,#;GU':F[J7*"5TV?0-%>&ZUIGQ$\'6@ MU6;7YKF!" Y2[>94R>-RR#&,^QKLH/%MQX@^%&HZLC-;7T,$D*+B..*7RB)]0G!S@'L#QS5R] MU'Q[\.[NWFU*^;4+*1\$R2F9'/==S#B9V5%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** // MO&G_ !]P?63^8KEZZCQI_P ?<'UD_F*Y>OI]>+5U?ACQ.;,I8WSYMSQ'(?^ M6?L?;^7TZ>1C<%S7J4UKU1])E>:]%>&?5!1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 5XA\9;":U\36&JA"8980F[MO1B'4\.MJ<>IVS2B'E8>A>)=2^(OA?7+*33([?%L8EFCD.UY"#\N"./7KQD5/\ \*;\ M,?:O-\S4-F<^3YR[/I]W=^M=OIFEV.C6,=EI]LEO;Q_=1?YD]2?-?"?Q+8^'[S4-*U:5;,S,I628[55UR"K$]/Q]#6A\6?%VEZEI5OH^F7 MD5Y(TPED:!@ZJ #@;AP22>WI7;>(/AYX>\1SOV;8S?48()]R M*AT'X9^'- NENHH);JX0[DDNG#[#[ #/OC-#]ZW,4FHMM&?;:3/HOP6N;.Z M4K.+"9W4_P );%?!^G^$(+F'3YKJ5;A@S&X96((&.,**=_>DWU(?PI>9Y9\:O^ M1LL/^O,?^AM6K\9M-FDTW1]21"8H0T4A'\.X KG\C79^*/A_I/BS4(KV_N+V M.2*,1*('4#&2>>:Z*YL+6]L'LKJ%9[=TV.CC(85-OK=.,9KS#PSJ*ZO\ &(U*I<7DD MB@]=I5L?I7HR_![PLM[]H(O6CSG[.9_D_/&[_P >K0MOASHEGXGCUZV>ZBGC M;A:=XAT\V6IVXFASN')!4^H(Y!KE] M,^$OAC3;L7#)=7A4AE2ZD!4$>R@9_'-2E[KB^I3:T?8X/X+G=XQO#ZV3G_Q] M*@MYD\&_&*6;408[;[3(2Y'1) =K?3YA^1KU7P_X#TKPWK=SJMG/>//<*RLL MKJ4 9@QP H/4>M7?$/A/1_$\*)J=KO=/]7,AVNGT([>QR*J^L6NB$VGS)]3 M\6_$O3-$TV*72;NRU&[DD \J.4. G#V'UZ50\2:O=^(_@Y=ZG\ME1(N&Z#K5S3_A#X7L;D32"\O-I!$=S*"N?HJKGZ'BNUN;"UO-/DL)X$ M>UDC\MHL8&W&,<=*EKW6NHU)*2?8\V^#^LZ;!X;?3YKVWBNWO&V0/( [Y5<; M5ZGOTKU&N(TOX5^'M(UF+4[>2^,D+^9'&\P**<\=%!/XFNWJV[ZD6L]#R_XW M?\B]IO\ U]G_ - -6OAUXUT4>$+6RO\ 4;:TN;-3&RSR!-RY."N>O'IZ55^- MW_(O:;_U]G_T T:!\/M!\4>"-&N;R*6&Z\C!GMF"LPW'KD$'ZXS40O:7J7*W MNW.4:X3QE\98+C3BSVPN8W$FT_A^S@_G7K/AOP M?H_A6%UTVW/FN ))Y6W2/]3V^@ %4=:^'NDZ[XACUJZN+U+F/9A8G0)\IR." MI/ZTUHXVV0G*_-YJQUE?.5OIVDZ5\1[K3_%%N38>=(I+,RA=QRCY4@XZ?G7T M;6!XC\&:)XI"MJ-L?/5=J3Q-MD4?7H?H0:6TK@GHTS@]5M?A+I,D"/!'<^;G MYK.[DF" =VVRE.T+XF7.O>,VT>RTV.>R: M5MERKE2L0'WR,'^G4"K6H?"'PO?7+31B\L]Q),=M* N?HRG'T'%='X>\)Z/X M8A=-,M=CR?ZR5V+._P!2>WL,"G>[YF)I)61Y-\5/^2DZ?_UQA_\ 0VKI_C9_ MR*]A_P!?@_\ 0&KH?$'P_P!*\1ZW#JUY<7J3Q*JJL+J%(4DC(*D]_6KWBCPI M8^+;"&SOY;B..*7S5,#*#G!'.0>.:BWN)>95USW\CF=/_P"2%M_V#9?_ &:L MOX'@?V;JYQSYT?/X&N^A\-6<'A0^'%EG-F8&@WEAYFTYRD^YG]A+S/+/C5_R-EA_UYC_T-JZ/XR?\ MB=I?_7TO_HMJZ7Q1\/\ 2?%FH17M_<7L$K#Q5I ML%A?37,<4$@D4P,H8D CG(/K46]RWG>_H:]BT;2H-#TBVTRV> M1X;==J-*06(SGG [^E8'B#X<>'O$=TUU<02V]T_WYK9PA?Z@@@GWQFJ;]]M M=2(VY.5F%XD^*T>G:[!8:)!;ZK&R@.T/;N*YCXKZQ>S^)+/3+ MR26VT\0QR2PQMD98_,?]HC&!]/>O1?#WPY\/>'+I;JV@EN+I/N37+ABOT M/OC-7O$O@_1_%42+J4+>;&"(YXFVR*/3/0CV(-3;;J4FKOT/-/%D'@#2?!DT M.B&RN-0N @B=)/.E'())))V< \<=>E:_PR1W0&]9W5@",C( MPHYYIO:2[H+Z+R9YM\$O^0_J?_7L/_0A7MUQJS16\S+)CH-P&"?Q&/QKE_#WA?P!J M6@0WFH>(;BUNPG[^%KF)"&'7:I3)'IC->YW-M!>6TEOA%< M)/\ !WPO-=^"+SQ#'=:+>:S)= MV9,@2Y50F.1DD)WZCD']157XC^,)O$-^OA70E,\9D"2M'SYS@\*/8'J?;T'/ MI,'A'2['09M(TP2Z=#,,22VS#S6]?F8'Z>W;%4O#'P]T3PK>27EF;B>X9=JR M7+*Q0=]N%&,TW9NSV0D[7:W/./A9?-X=\9WFAZC"L4UQ^YRP&Y9$)(7/H>?K MQ7IWC3PJ_B[2(M/74/L:K,)6;RO,W8!&,;AZU5UKX=:/K>OC6I+B^MKP%3NM MG1067HW*GG@?E76@8 &2?)Y=H_P:32]9L[^36_M"VTRR^5]D MV[MIR!G>*-).G7SS)$7 M60-"0&!'ID$?I2E=I>1479W9XUX?M[SXE^,K::_3%C801B50F?$R^&F^ +]4(4S!;=![,1D#_ ("#6MX9\+:=X4TY[/3_ #65W+O),078 M^Y X^E-\4>%K+Q9I\5E?3W,44VTRT,A@@4JID(+'DG)P ._I6=XJ\'Z=XOM[>'4)+F,0.61H&4'D8(.0 M>*2:Z"A97OUN>:^!M-N/'/C:Z\4ZG&/LT$@94/*E_X%'J%&#^7K6]\:K* M>?PW974:EH[>X_>8'0,, G\>/QKN]"T2S\.Z1#IMBK"&+/S.068GJ20!DUYB2:&1=KQNN0P]"*4DK)+H.,O>YF<'X!\9>'XO!=E;W.IVMI/:1^ M7)%/($;()Y /WL^U MXN#+&U_;*?\ EE#,"O\ X\I/ZUU.A>&=(\-V[1:79K#O^_(26=_JQY_"G>\N M9BV34364!5"CH!@5Y-\:=7O[9=/TZ"5XK6='>782/,((&T^W/3WKUJLK7_#F ME^);$6NIV_FHIW(P.&0^H/:HDKC@TF>7FW^'>E^!I+J![2ZU&:T*J))/,F\T MJ1]S^#!/7 Z4? ['VS6>>?+B_FU=?H_PJ\,Z/=BY\J>]D4Y3[6X95/\ N@ ' M\@4'CMS6B?O-]Q-^[8\VU$ _'M 1 MG_38O_0%KT?XF?\ )/=5_P!U/_1BTLWP_P!*G\7#Q*UQ>B]$JR[ Z^7D <; M,@CMZ5FU^[42E)>TYNFAYC\.+!] M4^%_B"QB&9)Y)40>K&-8[%#+D%23T/U]# M7J?A?PK8^$M/ELK"6XDCEE\TF=E)S@#L!QQ67X@^&GA[Q#>M>3QSVURYS)): MN%WGW!!&??&:MOWKKJK"T:L^]SS[XO>)]-UF>PL--N8KI;;<\DL3;ER< $< M'IVKU+P1_P B1HO_ %Z)_*L:?X4>&9M*CL(TN8%63S&FCD!DD.,?,64\<] ! M76Z7IT.D:5:Z=;L[0VT8C1I""Q ]< 4*R30I.]O(MUX7X8SXA^-,]Z\EFF3RV-PZM@9SQA1Z M4HZ2N#?NM=SSKXP7#ZCXPTW28CDQQ* !_>D;_ "O6-1FC\/^%;B5,*EE:'8. MGW5X'Z"LF\^'VDW_ (K7Q%<7%ZUVLB2"/>OEY0# QMSCCUK;US1X-?T>XTRY MEFBAG #M"P#8!!QD@CMZ5-OW?+U=RKKG3Z(\I^"=B9=2U74Y 24C6)6/OF%-"FTW[3]K,TC2/(8]F<@#&, MGL/6O!8=6O/"T^OZ5;##7.ZT=\X*A7P2/J,C\:^GJXZ;X::%<>)VUZ5[MYVF M\\PEU\HM]-N<9YZU.\KOT&FDOQ&?#7PK_P (WX=66XCQ?W@$DV1RB_PI^ Z^ MY->?Z_\ \5%\;(;0$/'%<118_P!E!N8?^A5[I7*:9\/]*TOQ/)X@CN+V6\D> M1R)70H"^]5?WU+L):1:ZLV]=L1J7A_4+(C/GV[H/J5.*^:]/UJ_30 M+GPW:1EA?W*,=I^9B.-@'N=OY5]25QVD?#30M&U\:Q"]W+<*S.B3.I1">X 4 M'C/'-2E[VNQ7-:/F:/@WPW'X7\.06("FX8>9<./XI#U_ =!]*\?\-WL'A/XK M7/\ ;!,*"6:)I&'"[C\K'V/'/O7T!7.^(_!&A^*")-0MB+@+M6XA;8X'\C^( M-.[YN8E6Y7%G.?$+Q[I$'AFYL=-O[>\N[Q#$/L\@D"*>&)(X'';KS3/@[H,^ MFZ!<:E<(4:_93&I'/EKG!_$D_I5_2_A+X7TVY$[QW-ZRG*K=R!E'X* #^.:[ MA5"J%4 *!@ =!36E_,).Z2%KR[6]5^''BC7/LFHAXKP;HS>%6@"E>,,QQ^&X M8X[5ZC7*^(/AWX>\1W#W5U;20W3_ 'I[=]C-[D'()]R*E[CBTCQOQEH'A[P_ M]FF\/^(1?2L_,:2+(T8'(;>G Y[=:]"UN>^O_@8+B_+-=-;Q,[/U8"08)]R, M&M+3/A)X7TZY$[I=7I4@JMU("H/T4#/XYKLKNRMKZQELKF%9+:5#&\9Z%3VH M?P-#4O>3['FWP?UG38/#;Z?->V\5V]XVR!Y '?*KC:O4]^EW M?R0QWD4C-CHA5>:]&TOX5^'M(UF+4[>2^,D+^9'&\P**<\=%!/XFM3Q-X'T7 MQ64DU"*1+A%VK<0-M<#TY!!_$&J;]Y2)5K./1G*_$[Q=HESX/FT^QU&VN[BZ M9,+!('V@,&)..G3O3O@Y&)O!%]$>CWNWC:#VSBMOPQX7LO">FR6-A+<21/*929V4MD@#L!QP*22M)/J-O16Z' MCOP\U2#P=XVO;+66%LKJUNTC\!'# @GT!QU]Q70?%KQ;I-_HD&E:=>P7DKS" M5V@<.J* ?XAQDD]*[;Q+X!T+Q3*)[V&2*Z ^T6[!7(]#D$'\16<1'GZHPKO['PC8:?X3E\.137+6'HO$=UIGB^W5 M 8T:65XUCD4\@E2,9]3QQ78:A#\)-.U!+1K7S]R[O-M;B66,<]"5<\_2NV\1 M?#_0/$TYN;R"2&Z( -Q;MM<_7((/IR*JZ'\,/#>A7:74<,UW/&VZ-[IPVP^P M _,4EK:Y3:U:+>N:IX:\->&[6TU*%O[,EC$,4#0O("H' .>AQZ\UP#>&?AK MKE@M]9:W_9)8$F"6Y4,I]"CDG/T.*];U+3++5[&2RU"W2XMY/O(_\QW!]Q7# MS_!GPS+,72;485/2..92H_[Z4G]:6[=P321Q?PFN;NV\;S6%G[UD:#X8TCPU;O%I=H(O,YD*_ ^F>+Y+5]0GNXC;!@GV=U7.[&!_9NKG M'/G1\_@:P_C5_P C98?]>8_]#:O4_"O@_3_"$%S#I\UU*MPP9C<,K$$#'&%% M5/%'P_TGQ9J$5[?W%[')%&(E$#J!C)/.5//-6W>47VL$':]^MSI[?_CVB_W! M_*L?QG_R)6M?]>Z:/+L-2BD0 #Y M1N&'3]L?$VDOIV MH*_E,P97C(#HP[J2#CTZ=Z<]6FAP=F[GGWP/_P"09J__ %VC_P#037/W()^/ M2X&?]/3_ -!%>K>%?!^G^$(+F'3YKJ5;A@S&X96((&.,**J'X?Z4?%__ DI MN+W[;YHEV;U\O.,=-N37=LS1_;;;<6'?W#*IMW5< M@XZY4^E7Y?#EE+X6_P"$>W3)9^0+?K3?#GQIKQ.L#CR9R!G SE9!ZC^A MKV7PMX3L/"-E-:6$MS)'-)YC&=E)!P!Q@#TJ77?"^C^)(535+))BGW) 2KK] M&'/X=*MOWN9=B4U9IE>7QQX7ALS=-KMBR!=VU)@SG_@ ^;/X5XV/M'Q+^) F MA@<69==V?^6<"^I]3S^)KT%/@SX96?S#/J3IG/E-,NWZ<+G]:[+1]"TS0+3[ M+I=G';Q'EMO+,?4D\G\:%9/F[ W9-+J%K2SFTE8!;2[HY)'BW%& MQ\O?'3/;M5[PS\0M#U;1+>6]U6TM;T(%GCN)5B.\#DC. 0>O%=3>65MJ%I): MWD$<\$@P\%[F;?$U_:K_SSAF!7_Q]6/ZU*NKIAHTCS[XFW>A: MMXBM8_#T<,LY79/);+\LKDC:!CAC[CU%=;\5();7X<:/;SG,T4L*.?\ :$3 MUUF@?#[P]XR\6:='8W\MQ'%'*)08& M4-D CN#QS0U[O*N]QJ7OW?8YWX?^(M#LO VF6]UK.GP3HC!HY;I%9?G;J"WI6Y_PI3PW_P _NJ_]_8__ M (W6WH/PV\-Z!<)=V*+4=B;X?Z)+H/@VR MM+A2MPX,TJGJK,@5P_ MQ:_Y$"Z_ZZQ?^A"NXKA_BU_R(%U_UUB_]"%*>W]=T$/B.-\$?$S1O#7A>#3+ MRUOY)XW=BT,:%>6)'5P?TK&U>^N?B?XYM1864L<"JL7/)2,$EG8C@=3^E=W\ M,O#^C7_@>UN+S2+"YG:20&2:V1V.&..2,UZ!9V%GI\/DV5I!;1?W(8P@_(5J M])7?0E/1I''>/O!U_P")X[1(M7AM+"WQOAD4@$YQN)SS@=!C\>>/,/&?ASPI MH=C!)H6O&]O/,"R1>-8W,:$C8#N MQ[>@Y]:?\:QN\1Z8/6V(_P#'S4?C;PI_P@T^C:YH>\1P[5D9CG]Z.0Q_WAD' MMQ[U,7HG+:[^\T:Z1WL=C\2M/M=+^&,EE90K%;PO$J(O8;A^M.\ ?\DE3_KE MIE? MEJ7_ *T9,?L6[GFGP]\+-XON;JRN;VX@TV ++*D) +NN1Z\X/ZU8U'2&\ M!?$O3X-.NYFC+Q.K.1N*,VUE;& >A[5O_ W_ %^M?[L/\WJI\3?^2HZ5_N6_ M_HPUKM.%A;J1+\6KB1?&6F1:H+AM%5%?RXCC=\QWX[;L8'Y>M2#0?AIXB^SQ MZ/JG]E7*N"P>1PSYZ*/,.,YQT)KI_&WC71]*U*/1M:T*6[MY-KF25%,>T]64 M&WF&H-(#Y:+((P.^=XX_#^591=E\R]W\CUOQ1JLOA M'P--<1SR7%Q!$L,4LV"S.<*&;C!]?PKSGP;\.D\8Z;)KNNZA=EKF1MGE,-S8 M."S%@>^1CVK>31M4USX)16DZ2/>K'YL*O]YE5\J/Q7I^%9WPZ^(>CZ-X=72- M9E>UDMG;RW\IG#@DG'R@D$$FKLN:5]R%?D5C.TXWOPT^(L.DB[>;3+MDR&X# M(YP&QV8'N/2H/B4MT_Q1ACLI6BN9$A2)U."K-P#G\:DFNF^(WQ2M)M/AD%C: MF/,C+C$:-N+'TR20/J*F\7^=$=5)>A,MHLWM$\/1^' M=.NEMYI;J^N&:6:YFY>63'&?;T%>'^&[KPW+K.H-X[CNY;J1^)'+X1@3NW!" M&ST]N*^B)Y3#;R2B)Y2BEA''C(='-FZ@!9Y(V, MC'N"8QN&/QI?:^0U\/S-?P=X6\-1>('UCPWK[R18_P"/.*0':I'1P?FQGGG! M_*O1J^>-/6P3XG:G\?4 [=N>OO7T/5?93)>DCR_XW?\B] MIO\ U]G_ - -=KX._P"1+T7_ *\HO_017%?&[_D7M-_Z^S_Z :N>&OB-X4T_ MPQIEG=:KY=Q!;1QR)]GE.U@H!&0N*4/AEZ_H.2^$Y_XXQ(+K1I@!YC)*I/L" MI'\S4OQ2E>?X?^')I/ON8V;ZF*L7Q1JC?$SQG8:?H\4AM8AL$C+C@D%W([ # M'Y>]=+\9H4MO"VD01C"1W 11[!"!4[0]67]M>2+^JS7]O\$K:33FD646,&]H M_O!,#<1^&?PKA_":_#FYT:.VUU9H=38E7GD>0+DG@J5.T #'WAZUZ79Z['X< M^&.E:C-9SW426D(=80"5!4%M"N[JPUN34[-E,IVLIC4J#DKC.#Z\]J\LT2"Q\ M=^(;_4?%6O1V,:X*JTZ1LG?WK2^%EK/>ZKKMI:&;^R9K22-C)Z MDX3/;=C/ZUB^%X?#6F:Q?:=XUL9 4.U)-TH\MAG((0Y(/&#@]/>E]J[[%;)V M[FGIMS#X&^(MM;Z-JZ:AI5TR)(8Y5<%6.,-MXW*><\?K7HGQ \(7_BI;41ZO M#:6,',D,BD DGEB<\X'08_'GCFM*3X5W^N0V-AI]P]PTBB%P;C:S=>/FSQCN M!^59GQ5OI'\=65GJ;3C1XUCWGF!9(O.20;<'Y@4 Q@@=3WKO+S5=6NO@A'?6TLK79@5995R7V!]K M'/7H.3]:XOQKJ'@N31(+'PK9(95D$DMP(7!1!D8+/\QR6'M^E=[X:UZ+P[\) M-.U*6TGNXHU976#!V@NPRDL6C@CD!SZY0;3GW%0?!P7'_"3ZF+,S'2O*.3)Z[ALSVW8S M^M4KMOT^1,EI?$&Y76]8CL-,MRXC,DJH BG 5=W&X]3^/I46JI9> M ?$UAJ'A?78[^W;F14G20@ C*OLX((/' _2H(=/T;P_X^O;#Q98R26!9PC N MNT$Y5_D()&../7VKIU?X127T=K#8W$QDP%=#*&% M=L4:!$7G@ 8 YKRGXX6[FTT>Z ^1))(S]2%(_P#034SM==KDTM]>QZ1X>M%L M/#>FVJ](K:-?QVC->%>'O$EGX5^(FJ:C?13R0F2>/; H+9+^Y'I7O6D3K=:+ M8W"'*RV\;@_50:\6\"V%GJ/Q2U2"^M(+J'-PWESQAUSYG7!K1W]J_F3&WLM? M(M^-OBC8^(O#\NDZ78W:M<%0[SA1@ @X 4G)) K7T?0KG0_@OJZWD;13W4,L M[1L,%05 /O@9_&O0[30-&L)O.L](L+>7IOAMD1OS JAXY_Y$;6O^O1_Y5G+ M2#\RHN\DNQRGP4_Y%6^_Z_3_ .@+6O\ %:))?A]?,X&8WC9?8[P/Y$UQ?PO\ M9:!X=\/W5KJM_P#9YI+DR*ODR/E=JC.54CJ#3OB-X_TWQ#I,>B:$TMT9Y5,D M@B90<'A5! ))..W:JJZZ+R_0(:2N_,Z?X/R--X%\M^52YD1<^G!_F37*_#"0 MZ9\1]8TI.(6$J;>>J/Q^F:]&\"Z%)X=\(V=C.,7!!EF'HS'./P&!^%>_%O5[Q1E(S<%+-#R>AD/H/;U-'ASPX^K2B><% M+-#R>AD/H/;U->C11)#$L42!$0855& !7EXW&^S_ '=/?\O^">_EF6>UM6K+ MW>B[_P# _/T%CC2&)8XU"H@"JH' [4ZBBO /K]@HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,O M6_#NE>([>.WU:U^T11/O1?,9,'&,_*15K3M/M=*T^&QLHO*MH5VQIN+8'7J2 M35JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** *LG_ "$HO]W_ !JU563_ )"4 M7^[_ (U:J5U+ELO0*HZOH]AKNGO8:E!Y]LY#,F]ER01;(253>S8).3RQ)J]110!F:SX>TGQ! L.JV,5RJ_=+9#+]&&"/P-4 MX/!/ARVTF?3(=*B2TN !*H9MSX.1E\[N#[UOT4#NS&A\*Z-;Z!)H<=H1ILF= MT!F<]3DX);(Y]#4^BZ#IGAVS>TTJV^SP.YD9?,9\L0!G+$GL*TJ*!&)K7A#0 MO$5S%<:K8_:)8EV(WFNF!G/\+"K^I:59:QITEA?P">UD #1DD9PCZ=K-N(-2LH;J,'*B5,[3 MZ@]1^%8ME\._">GW*W$&C0F1>GFN\H'X.Q%=/10M OT#H,"N?U7P1X:UJX-Q M?Z3#),3EI$+1LQ]RI&?QKH** O8HZ7HVG:+;?9]-LH;6(\D1K@L?4GJ3[FJ- M]X0T+4M9BU>[L?,OXBA27SG&"IRO ;''TK=:R$% MDWLN<'(Y4@]13=(T:PT&P6QTV#R+96+!-[-R>O+$FK]% !6!JO@CPWK3^)IFM^'=*\1V\=OJUK]HBB?>B^8R8 M.,9^4BM2BAZ[B6A7M;&VL]/BL((@MK%&(DC)+ *!C'.<\>M<[<_#?PA=SF:3 M18E8]HI'C7_OE6 _2NJHHZW"]BKI^FV6E6HMK"UAMH0<[(D"C/K]:S]9\):# MX@<2:IIL,\@X\P$H^/3K^E:)IVBZ;_9UA;^7:9)\IG:0<]?O$\>U:%% '*W M/PW\(7$;NTB7-R@$T QU=>OK5JJ;N[B\N@57OK&WU*Q MFLKN/S+>="DB;B-P/;(YJQ12 X__ (5;X-_Z W_DU-_\76GI'@WP]H,WG:=I M4,4PZ2,3(X^C,21^%;M% ;F9XBU2/1?#U_J,C >1"S+GNW11^)(KBO@]H;V. M@7&K7"$37[Y3(Y\M\MH;F!B"8YHPZG'3@\5)%%'!$ MD44:QQHH5408"@= !V%"T;8V]$A]%%% @HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** //O&G_'W!]9/YBN7KJ/&G_'W!]9/YBN7KZ7+_ /=H_/\ M-GP^<_[[/Y?D@HHHKN/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "N@\.>''U:43S@I9H>3T,A]![>IH\.>''U:43S@I9H>3T,A]![>I MKT:*)(8EBB0(B#"JHP *\O&XWV?[NGO^7_!/?RS+/:VK5E[O1=_^!^?H$420 MQ+%$@1$&%51@ 4^BBO /KTK!1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1S3 MQ6T+S3RI%$@W.[L%51ZDGI0!)17*3?$KP?;SF%]:C+#O'%(Z_P#?2J1^M;^G M:K8:O;^?I]Y#=1 X+1.&P?0^E /0N4444 %%%85CXQT'4M:?2+2_\R_1G5HO M)D&"OWN2N.,>M'D'F;M%%% !1110 4444 %%5[2^M+]96M+B.=8I#&[1MN 8 M=1GUYK*D\8Z#%KXT-[_&I%Q'Y/DR?>(R!NV[>A]:/(#=HJM?ZA9Z7:-=7US% M;P+UDD;:*Q=-\>^&-7NQ:6.JI).02$,3H3CDXW*,_A0.S.CHK$T3Q?H7B.XE M@TF^^T2Q+O=?*=,#./XE%;= @HHHH **** "BBB@ HHK"O\ QEH&F:RNDWE_ MY=\Y55B\F0Y+?=Y"X[^M'D!NT444 %%%85CXQT'4M:?2+2_\R_1G5HO)D&"O MWN2N.,>M'D'F;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 457A MO[2YN9[:"XCDFM\"9$;)C)Z ^AXZ5E:KXQT'1-2CT[4;_P F[D566/R9&R"< M#E5(ZB@#=HHHH **** "BBB@ HHHH **** "BBB@ HHK,UOQ#I?ARUCN=5NO ML\,C^6K>6SY;!.,*#V!H TZ*JZ=J%KJNGPWUE+YMM,NZ-]I7(Z=" :<+^T-^ M;$7$9NPGF&$-E@N<9([#FCR L45C:YXKT7PVT"ZM>_9C."8_W3ONQC/W0?45 MJP31W-O'/$VZ.10Z-C&01D&@"2BBB@ HHHH **** "BBB@ HHHH **** "BL M;7/%>B^&V@75KW[,9P3'^Z=]V,9^Z#ZBM6":.YMXYXFW1R*'1L8R",@T 244 M44 %%5[V^M=.MFN+RXC@A7@O(V!GL/K[58H **** "BBB@ HHHH **** "BB MB@ HHHH ***1F5$+NP55&22< "@!:*@L[RVO[9;FTF2>!\[9$.5;!P<'OR*R M;'QCH.I:T^D6E_YE^C.K1>3(,%?O.>)MT4BAT;&,@C(- $E%5 M[2^M+]96M+B.=8I#&[1MN 8=1GUYK*U7QCH.B:E'IVHW_DW0&[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 457%_:&_-B+B,W83S#"&RP7.,D=AS5B@ HHHH ***R=<\2Z1X;CADU:[^S MK,2L9\MWR1U^Z#0%KFM15>QO;?4K&&]M)/,MYT#QOM(W*>AP>:L4 %%0W5W; M6-N]Q=W$4$*#+22N%4?B:YF3XE^#XYS"VM1E@<96&1E_[Z"X_6@=F=91533] M3L=5M_/T^\@NHLX+0N& /H<=#5N@0451U?6=/T*P:^U.Y%O;*P4N5+& - %^BBH+N\M=/MGN;RXB@@09:25@JC\ M30!/17+1?$?PC-=?9EUN$29(RZ.J?]]E=OZUTZ.DB*\;*R,,JRG((]10 ZBL M76?%V@^'Y%CU34HH)3SY8!=\>I502![U9TC7=+UZV-QI=[%1^ M(H6H/0T:*9+-%;PO+-(D<:#+.[ !1ZDFN8?XD>$$NOLYUN$OD#*QN4_[Z"[? MUH'9G545%;7,%Y;I<6TTQ%9FL^*M#\/D+JFI0V[D9$?+/CUV MJ"NH\:?\ 'W!]9/YBN7KZ7+_]VC\_S9\/G/\ OL_E^2"B MBBNX\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KH/#GAQ]6E$ M\X*6:'D]#(?0>WJ:/#GAQ]6E$\X*6:'D]#(?0>WJ:]&BB2&)8HD"(@PJJ, " MO+QN-]G^[I[_ )?\$]_+,L]K:M67N]%W_P"!^?H$420Q+%$@1$&%51@ 4^BB MO /KTK!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D'QNU&Z0Z9IRNRVL M@>5P.CL" ,_3^M>OU@^*_"=AXMTP6EX6CDC.Z&=/O1G^H/<5,EIR7AG MP!X&U?0+>6%?MTK1@RS"Y<,K$<@J" N#V(K,\-^"O$OA/Q]YUC;/+HK2&-Y3 M/&-\1Z$KNR2/IVK"O_A-XITB8W&F2Q7>PY1[>7RI ,>AQC\":L>%_B!XAT#7 MXM)\1-<2P-((Y%N@?-BR.E:)WE="::BUN>VW5W;V-K)=74R0P1+ MN>1S@**X2X^,?A>&Y\I$OYTSCSHX0%_\>8']*QOC;J4T=II>FHY$4S/-(!_% MMP%_F:Z/PSX$\.GP?91W&EVT\MS;+)+/)&#)N9EW2SQ@[6&"&0^A!Y%<5X?X?RK7\'_#ZV\(7QT8*J'G(..3D?7N:\]\#_ /)9K[_K MM=?S:J5N=6["?POY'KNO>)-*\-6BW&J70A5CA$ +,Y]@.37,:?\ %[PO?7(A MD:[L]Q $ES$ N?JK''U->;>-M5M[WXG3-JXFETZTF6)HHL;O+7J!DCJ<]^]3 M^+/$G@?6-#:WTG0I[&_0J895MHXQUY#%6R>,]0>:A/3F+<=>4]SU#4[?3M(N M-3DW26\$)F/E8)90,\K(^$'AK3=8GU"]U*TCNA;[$CCE7 M1QT-C_ !0M+6X\ W5Y+;0O M^T(!=!SY>_:,''F=,8_AJ'X/:7I\WA@WTMA:R7D=VX2X:%3(ORKT;&1U-P6%K%=2V \R=(55WR,G+ 9 M-91=H2?];&DMXK^MS)^'=]X.N]4O%\-:3>65PL(,K3N2&7=T&9&[UV6M^(-, M\.V7VK5+I8(R<*,$LY] !R:\D^"7_(?U/_KV'_H0JKXU=O$?Q;ATJXD;[*DT M5LJ@]%."V/M3PMX:A\*Z1_9T%W<7$7F%P9L?+GL,#@=_P Z%8'Y&W7)>(/B1X>\.W;V MEQ--<728WQ6R!BOU)(&?;.:ZVO)M4/PS\-Z_/9:C-PF\GDG?QNZ M]6XY[XJ>HTM#I-%^*7AO6[U+19+BTFD;;&+J,*&/ID$@?CBNREEC@A>:9UCC M12S.QP% ZDFOFKQK=V5WKD5SIVA2Z/"T0VQ/$(O,()^<*.!Z<>E>G_%C4Y[; MP):0HQ!O9$20@XRH4L1^8%#?NW^0^7WK%R;XO^%H;[[,&O)4S@W$<(\L?F0W MZ5Y]XLO[74_BM8WEE.D]O)):E)$.0>5KM_AQX,T1_!]M?7NG6UY>Z[HMOH'Q4AL;1=MM]K@DC7.=H8JQW32K&)2B^62V,'.[..1VKI[BXBM;:6XF<)%$A=V/0 #)- M>3_&C160V&OVX(9#Y$K+V[H?SS^E7/%_C%;OX36MU&^+C4U6!@.Q'^L_]!(_ M&HO[C?7;_(?*N9=G_3.J\+>.M.\7W%Q%I]K>QBW4,[SHBKR>!PQ.>#^5<]X< MO_!?X?RK0^%6A_P!D>#H;B10)[X^> MQ[[>BC\N?QKA/ __ "6:^_Z[77\VK2UJEO(C[#?F>P:WX@TSP[9?:M4NE@C) MPHP2SGT ')KD;?XR>%YKGRG2_@3/^MDA!7_QUB?TKB/&KMXC^+<.E7$C?94F MBME4'HIP6Q[DD_I7I.M_#CP]JND"RMK&VL)5*[+F"$;QCKD\%LC(Y/O4*_+S M%M13Y3J;6[M[VTCNK:9);>1=R2(<@CUKC-5^+/AC2[MK97N;QE)#-:QAE!^K M, ?PS67XHTW_ (0/X7W=A87US*)YA&'E(R@<_,%P. 0#^9KA_!GB#P9HNF2+ MK>BS7]](Y)=K>.5%7L%W,,=^U/=NW0$M$V>U^'O%FC^)X7?3+K>\?^LB=2KI M]0>WN,BMJOG30]8L+3XGVEYH,4]OI\]RD:PR@ A7PK#@GC))'/I7T73MHF0U M9V,?Q+XCL_"VE?VC?1SR0^8(]L"@MDY]2/2N?F^*_AF#2K>^9[DO."5M513* M &(RPW;1TSR>E0?&+_D1O^WJ/^1K*^%7A/1KSPJVHW^GV]W/<2LH-Q&'"JO& M%!ZM9 MMO\ %[PM/J M2UW$A.!<20@1G\CN ^HKRW1?#UE>_%(Z)*A-DEY,I3)Y1-Q MS^ %=1\8/#^DZ58:95%@5=YD+#:%QG.?2N%N_C!X7M;LP)]MN5!P9H81LZ_P"TP)_ 5R?B_5KF M+X1>'+59&'VM%60_WE0=/SQ^59WAOQ+X"TOP_'9ZGH%Q>7C ^?,UM&^2?[K% M\@ >F*;W?D2E[J?<]IT37],\167VO2[I9XP<,,$,A]"#R*CU[Q)I7AJT6XU2 MZ$*L<(@!9G/L!R:\7^&>IQ6GQ(,&G^:NGWOFQHDGW@@!9<\GD8]?6J_C;5;> M]^)TS:N)I=.M)EB:*+&[RUZ@9(ZG/?O0^ENH*.KOT/2=/^+WA>^N1#(UW9[B M )+F(!<_56./J:T?'WB:VT+PM*Y,Y>^C>&WEMR/E8H2&SD8'N,UY9XL\2>!] M8T-K?2="GL;]"IAE6VCC'7D,5;)XSU!YKHO"TL6L_!S4X[Z"*X;3DG6!I4#& M/Y-P*YZ$;CR*4M8OR*BK27F8/PP\96'AR6[M;Z*ZEEOYHEC:)58 \CYLL/[W MO79^-;_P7;^+K6+7-(O;K4C'&8YH7(4#<=N?WB]#GM6%\&=+T^_BU26\L+6Y MDADB,;S0JY0_-T)''0=*H_%3_DI.G_\ 7&'_ -#:M'\<5Z&?23]3U;Q1XKL? M"5A#>7\5Q)'++Y2B!5)!P3SDCCBL:]^*OAFQLK>=I;B62>-9!;Q(&D0'INYV M@^V:R?C9_P BO8?]?@_] :I/AQX.T2;P;;7M[IMM=W%V&9GN(@^!N( 7/3@= MJS5VF^Q3LK>9T_AKQKHOBL.NG3.L\8W/!,NUP/7N"/H36EJ^LZ?H.GO?:E-SL03^0%/=1Y>H^6TFGT.VTWXL>&-1U 6GF7-L6;:DMQ&%1C]03C\<5 M?T3Q]I6O>(9]%M8+Q;F#?N>1%"':<'!#$_I0WP\\-'0O[-_LNWSY>W[3Y8\[ M=C[V_KG//I7EWPBB,/CZ:(G)2VE4_@RBFK.7*2U[O,CU+Q%\0= \,W!MKR>2 M:Z4 M!;IN89]N":S=-^+GA?4+@0R/=61) #7,0"G/NI;'XXKS/65G\)? M$&]O=;T:/4H)II)(TN!^[E5CD$$@C(^AQ736'BGX:ZM=P_;O#T.GR@;0QMU$ M7/KLZ_4KQ4PU294HI:'L"L&4,I!4C(([U5U34(]*TNYU"6*66.WC,CI$ 6(' M7 ) _6IK;[.+6'[+Y?V?8/*\K&S;CC&.,8I9X4N+>2"0;HY%*,/4$8-$KZV) MC;2YB>%O%VG>+K2>XT^.XC$#A'2=5#>*X7X:W!\,^.M9T2Y?;'MD&3W,1)!_P"^=QKAKZ.\U8ZI MXE4$1"\&X]P7+,.?; _,4[JZ?2U_T*Y=UU/HWQ'XBLO"^DMJ-\LKQ!U0+"H+ M$GTR0/UKD_$GB;PKK'@ZQU;6M*U"?3IKDK#%PCAP&&X[9!QP>_X5ROQ,UXZ[ MI7AFSMOGDNX5N60==S *H_/=6E\4M.72?AYH>GH!BWF2,X[D1MD_GFDU9._> MP16J]+G6P^(]$T'X>VNK6EI=1:4$"PPKAI%!8@=6]?>O(O ?C&T\->(+W4M4 M6[N/M$13,8#N6+ Y.YAZ>M>M^"[.UO\ X::7!>6T-Q"8"3',@=20QQP>*\U^ M$FFV&I>)K^*_LK:ZC6V+*D\2N =Z\@$5=OWC]"4U[+7N:7QJF6X.@3H"%DAD M< ]<'8:ZF7XE^'?#VFV%G-)/#[2*YTJVFFN+97EFDC!DW,N3ACRN,\8-0G[K:VN4[7 MC?L;WA[Q1I7BBS:XTRX+["!)&Z[7C)]1_4<5L5X7\&I'A\97ULK'RVM6R/4J MZX/ZG\Z]TJVEHUU(::;3Z&!XJ\7:?X1M;>XU"&YE2=RBBW56((&>M3#6]^C*=DEYG=ZQXITC0=.BO=1 MNO)CF ,:%27?Z+U[_A7-:?\ %[PO?7(AD:[L]Q $ES$ N?JK''U->;>-M5M[ MSXG3-JXFETZTF6%HHL;O+7J!DCJ<]^]3^+/$G@?6-#:WTG0I[&_0J895MHXQ MUY#%6R>,]0>:2=US%^JZ/&)%961AN# Y!'KFN(U/XL^&--OC:B2YNBK M;7DMHPR*?J2,_AFN/TKQ%=Q_ _4 LC>;!-]C1\\A&*_T8BKWPE\)Z3?:#/JN MH65O>2R3&-%GC#JBJ!V/&23U^E5;WFNB(T4;OLM \ M3QC3XEAM[J$2^4O1&R0<>@X'%>C_ !-_Y)BWU@_F*EOW.9=RN7WDO(ZCPWXC ML_%.D_VC8QSQP^8T>V=0&R/H2._K63>_$/2;#Q6OAV6WO3>-+'$'5$\O+XQS MNSCD=JSO@]_R(H_Z^I/Z5POB3_DN4/\ U_6O\DJ[?O%'^MB8ZQD^W^;-3XX_ M\?.B_P"Y-_-:]/T^[M['PM9W5U,D,$5I&SR.8?''_CYT7_ ')OYK7> M7MEH]_X#M(M>D$>GK;0N[&4Q@$*,<@\\]JA? _44?0Q;GXR^&()C''%J% MPH_Y:10J%/\ WTP/Z5U'A[Q5I'BBW>73+G>T>/,B==KIGU!_F.*\UM]8^']E M:-I>C^'+C7)F#$2&T#N2?%:QM+3QQ9I;6L$*2P(\BQQA0[%VR3CJ3ZUZ/XT:V\* M> ]2ET>SM[)Y0L>;:)8^6(7=\HZX)YJ4[4[_ -7*DKS27;\!=;^)_AK0[I[5 MYYKN>-MKI:H&VGW)('Y&K?AWQ_H'B:86]GI>*O%VG^$;6WN-0AN94G5&K>2& (#_-UP>0,UR_Q1OGU/P-X:OY !)<8D8#U,8)K M0^'OP]T&\\,66JZG9_:;N=C*I:5@J ,0!@$ ],\YZT).[OT8.UD^YT.C?$K1 MM;UY-&BMM0M[IRP'VF)4&5!)!^8D'CTKI=6U2WT72;G4KO=Y%NA=@H!)]AGN M>E>.?$FTD\,_$&PU^V&U)V6;CCYT(##\1C\S71?%_7(U\*65E;N&_M%Q(,=X MU .?S*TF_<36^P^7W[=-SK_"WBVR\76L]S86UW%#"X0M<(J[FQG PQZN]N2/PZ?A715(_'>A>%Y!#?W#O< ME=PMX%W/CWZ ?B16/I_Q>\+W]RL$AO+/<0!)*H/AYI7B5 MM0U=Y)]2W^9+:JS3!SC@.IR!VP"1V[5Y_P".]2TG5#8W&D>')=*@PP\UH%B6 M?H1@+P<>N>]0GW->5,]X\0>(;/PYHKZK=I++;J5&( &8[C@8R0/UI/#?B.S\ M4Z3_ &C8QSQP^8T>V=0&R/H2._K7!>)W:3X%V#.]-XTL<0=43R\OC'.[..1VKDOC'XD MA%M'X>B^TI<[DGD88$;1D,-IYR><'&,<5@^)/^2Y0_\ 7]:_R2NI^--E:CP] M:WHMH1=FZ6,SB,;RNUCMW=<>U0]81;-DK3LNQ)\+?&&GW.F6'AI(;H7L,3LS MLJ^61N)X.[/?TKD/"E[;:?\ %O4KN\F2&WBENV>1S@ 9->B?#/2]/C\&Z7?I M86JWKQN&N%A42,-Y'+8SVKR_1-&MM>^+5S97B;[;[9<22)_>"ECC\\5H[^U\ M[,R5O9OMH>D)\8/"SWWVK'G'VAH/W?\]W_CM=W#-%<0)-#(LD4BAD=3D, M#T(->4?%OPWH^G>&[6]L-.MK29;D1DP1!-RE6.#CKT%/L];N=.^ Z743L)]K M6Z.#RH,A7(^@J+^ZWV*Y=5YG2ZW\3_#6AW3VKSS7<\;;72U0-M/N20/R-6_# MOC_0/$TPM[.X>*Z()%O<+L<_3D@_@37$_";PCI-_HLVKZC:0WDKS-%&DZ!T1 M0!D[3QDDUE_%3P[:>&M3T[5=&B%F9F;*P_*%=<$,H[=>W'%-^ZTI"24K\IZW MXC\0VGAC2&U*]CGDA5U0K"H+9/U('ZUS,_Q<\-0:?:W16]=KC<1 D:F1 "1E MOFP,XXYS6?\ $"^?4_A':7\@ DN!;R,!ZD9-8GPQ\!Z-KVA3ZEJ]LUR6F,<2 M>:R!0 ,GY2#DD_I0D[R3Z!IRI]S>\:Z[X+NK/1[[7=,OKZ*YB>2U,64*K\N< MC>O7CUIOQ'\36>G>#+?2[5+J%]0MD:V*8 2,%HS[5+LX-]+E1^. M/H87PG\8:?86L/AV6&Z-Y=73,CJJ^6,J.IW9['M6WXUO_!=OXNM8M+T.>U0_![2]/F\,&^EL+62\CNW"7#0J9%^5>C8R.IKFOB MI_R4G3_^N,/_ *&U:OXXK^NAFOADUY_J>UWM]:Z;9R7=Y.D%O$,O(YP *X=O MC'X7%WY(6_:/.//$(V?7&[=^E<[\;M2F$NF:8KD0E6G=1_$)_ MAS%X>339O#UW)+Y062Y^S1>87QRP??N'-9)W39?+L>TZ9JECK-C'>Z?,;3M'U(%>L#IQTI]"'N%'[MK2:6:ZN$.)([5 MVP^Y) _#.:U?%^HRZ5X1U2]@8K-' VQAV8\ _K7A7@K6O"^CO=3^(=,FU&=R M!$/)25%'9=KX]NQ_ FJ?B M+XBZ7X7U46&HV.HAF4.LL<:%&4]P=X/'TKQC6-=TA/%]KK'ABUGL8HV21HG1 M5 <'G 5B ",U-Z14@27-RLT M=7\3Z9HWA\:U/*9+1@IC\K!:3=T"@D9]:K>'/&-EXFT^ZOK.SOHK:WX+SHJ[ MR!DA<,AHTGXK^&=6OEM-]S:.Y"HUU&%5B?<,\0SOJ$*SP6D0 M<1.,JS$X&1W'7BNC^+?A32=/T:VU73K*"TE6812+ @164@D' XR"/UHE[MFQ MI)MI'K^0!G/%<-JOQ9\,:7=M;*]S>,I(9K6,,H/U9@#^&:Y^^\1WA^!=O2H8J>?=5Q7)^#/$'@S1=,D76]%FO[Z1R2[6\ M:["2]U-]3VOP]XLT?Q/"[Z9=;WC_ -9$ZE73Z@]O<9%3ZWX@TSP[9?:M4NE@ MC)PHP2SGT ')KP?0]8L+3XGVEYH,4]OI\]RD:PR@ A7PK#@GC))'/I6GXU=O M$?Q;ATJXD;[*DT5LJ@]%."V/%YKGRG2_@3/\ MK9(05_\ '6)_2NEUKQ3IVD>&CKA9[FS8+L:VPQ;<< C) _6LS6_AQX>U72!9 M6UC;6$JE=ES!"-XQUR>"V1DGK7O-_KVFZ5I"Z MI?W M[9E# OU.1D =3["O%_A)IMAJ7B:_BO[*VNHUMBRI/$K@'>O(!%.^+F MH>;XPMM.D++8V<*#RXP.-W+$#IG&!^%5+:*[CM>%Y;OR7%]"F<> M?)"-GUX8M^E=U:W4%[:QW-K,DT$J[DD0Y##VKP_5_$_P\O/#TVGV?AZYM[@1 M$03BWC5U<#@LX?<1GKG-7/AOX@N;'P-XF16)-C$9X,_PEE;^J@TNC\AZN$.)$M4#;#Z$D@9]@:X+XH^)M*\3:'I-QIER)-LT@>- MAM=#@=1_7I2?"/PUI^MW&H:EJEO'=^051(YAN7\,Z=HUQI M]]IMM%:K<;TDBB4*F1@@@#@=3^53)62N5"W,[>9ZEX(_Y$C1?^O1/Y5OU@>" M/^1(T7_KT3^5;C0_";PC':"%[*:63;@SM<.')]< A?TKSKX.LJ>.95?AS:R M 9]=R_X&O?*+)12+DWSOR/GW4K>_^%?C:-K*X>6T=%GE6[9'//T->^ M6MS'>6<-U"V8ID61#Z@C(KR#XXM&;S1D&/,$PY1O)>:.4^)OB>7Q)K,EM9[VTS3C MM++]UG)P6/X\#\?6O1_A'_R(4'_7>7^=%_A"ZS+B_N9XI+D^ASPOX M#]V2:;&DFGQ 93S M0IWDG+$$C( Q[\FO2Z;)(D4;22.J(@+,S' '4FI=MV)-K8\O\4?#/PYI?@N M[N;>*2.\M(/,%PTS$R,.Q!.WGV IGPHUN>#P3J[W+,]OIQ:2/)Z#:6*C\1^M M8WC/Q=>^.=33PYX;BDEM"WS,HP9R.Y]$'O\ 6NS'AA/"OPKU73T827#6DLD\ MB_Q.5YQ[ #'X47?+*7.=:U74]?#W2H02OF,NYW)[@@X M'2@0#X?_ !<@MK)W6QG=%V,V?W(/$.E6UGHR))"K%YXS*$,AXVCG ( M')Y/I5"'X3Z##X3Q>PR+J0MR\ESYS?(^,G@';@'CI7I5>0?$'Q[)JLS>&/#> M^=Y6\J>6(9,AZ%$]O4UF]G%;LN+;:;V1%\$K^Y-QJFG[RUL(UF53T5\XX^O] M*U;3X4/=^*+G4_$=['J%O-NQ$I'KGU-?0U>!W%E>?"3Q5:SD6VHP3I ME9'BVM@'#!>3M;GJ">M>[6EU%?64%W =T4\:R(?4$9%"^!!/XB:BBBD(**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@"K)_R$HO\ =_QJU563_D)1?[O^-6JE=2Y;+T"BBBJ( M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@#D]=T&ZUJY!MI(4\IFW>82,Y/; /I63_P ()JG_ #WL_P#OMO\ XFNXM?\ M7W/^]_4U:KJHXVK3@H1M9>1Y^*RO#UZKJ33N[=?(\]_X035/^>]G_P!]M_\ M$T?\()JG_/>S_P"^V_\ B:]"HK;^T:_=?<<_]BX3L_O//?\ A!-4_P">]G_W MVW_Q-'_"":I_SWL_^^V_^)KT*BC^T:_=?<']BX3L_O//?^$$U3_GO9_]]M_\ M31_P@FJ?\][/_OMO_B:]"HH_M&OW7W!_8N$[/[SSW_A!-4_Y[V?_ 'VW_P 3 M1_P@FJ?\][/_ +[;_P")KT*BC^T:_=?<']BX3L_O//?^$$U3_GO9_P#?;?\ MQ-'_ @FJ?\ />S_ .^V_P#B:]"HH_M&OW7W!_8N$[/[SSW_ (035/\ GO9_ M]]M_\31_P@FJ?\][/_OMO_B:]"HH_M&OW7W!_8N$[/[SSW_A!-4_Y[V?_?;? M_$T?\()JG_/>S_[[;_XFO0J*/[1K]U]P?V+A.S^\\]_X035/^>]G_P!]M_\ M$T?\()JG_/>S_P"^V_\ B:]"HH_M&OW7W!_8N$[/[SSW_A!-4_Y[V?\ WVW_ M ,35FQ\"W NT:^GA-N.66)F+-[<@8KN:*3S"NU:_X#CD^$BT[/[QD420Q+%$ M@1$&%51@ 4^BBN ]=*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%>2?%W2M;2Y@U>QGNWL!&%FBCD8K$RG(8KTP>.?45ZW12:ZHJ+L>6:;\:],^ MP1C4]/O1=A<.;<(R,?498$9]*Y-C??%#Q]%=V]DT%G&45WZB.-3G+-TW')P/ M\,U[7/X:T*ZF,MQHFFRRMU>2U1B?Q(K0A@BMXA%!$D48Z*BA0/P%4G[W,*^E MD>>_%OPS=ZUHUK?6,3336);?&@RS1MC) [X('ZUAZ!\8++3?#-O97MA=27MM M$(D,>W8^T84DDY'&,\&O8JSI_#^BW5S]IN-(L)I\Y\V2V1FS]2,U*NKKHQW3 MM?H>??"_4/%6MW]QJ&HWL[:2 VU)%!#N3G"DC.%Y[^@KGO __)9K[_KM=?S: MO:I:23\A-W37< M\=\>:??^$OB!%XHMX#+:R2K,&Q\H<##(Q[9_K[5L:E\;+8VT(TC2YVNBX\Q; MH +CN%VL23Z=/IVKU9XTE0I(BNC<%6&0:H6F@:-83^?9Z386\O3S(;9$;\P* ME:*W0;:;O;4P=3O[_4_AAJ5YJ-A]AN);*5C!O+%1M.,Y P?;M7,? _\ Y!FK M_P#7:/\ ]!->I3017,#P3Q)+%(I5XW4,K ]00>HJ"QTO3],5UT^QM;17.6%O M"L88^^ ,U2T;?N%96/Z UOWNB:3J4JRW^F65U(HVJ\]NKD#T!(Z5= & !TQ4V]SE\R^?W ME+L>,?"KQI8Z9;1>'KB"=KFZO/W4B!=@W #DDYZCT-5-0_Y+XG_7[%_Z M>R M0Z'I%M=F[@TJQBN2 S2MHFE/?_ &]M,LFO=P;[0;=3)D=#NQG- M5?WE)]"'LTNIYM\*[2$R6[21RLX&0DB8&&] <#]:]=L=&TO3)& MDL--L[1W&&:"!8RP]"0*NLJNI5U#*1@@C(-4WJFN@D]7?9GCWB'XQ6]_X?DM M=)M;VVU"8!3*Q $7J5(.2?3@5VOP]_X2"3P]]J\0W,LD\[[HHY4"LB8XS@ \ M]>?:MRW\/Z+:7/VFVTBPAGSGS8[9%;\P,UHT+2X/6R(;M9'LYTA.V5HV"'T; M'%?//@KQ#;^"?$MW)K6G322;3&V$!EB?.> Q'7ZU]&51O-%TK4)EFO=,L[F5 M?NO- KL/H2*E:2N.ZY;,^?/'NOS>*=4@U@6$UM8%/(MFE'^LVG+'/3JW;->L M>.M#D\4^ 8#IX$DT*QW,*K_RT&WD#\#Q76WFDZ;J$4<5[I]K4F3=6:74K>)]&37_#=]IK ;IHSY9/9QRI_,"OG?1;6]\0:EI7AI]PCCN7XQ MR@;&_P#(*:^GZHP:+I5M>M>V^F6<5VQ):>.!5@.!^M6?$/QB MM[_P_):Z3:WMMJ$P"F5B (O4J0JLK$8YY_&O^Y=SR_5O#ESK_P=T5[*,R7-G$LRQJ,EUP0P'OW_ JEX2^*UGH7 MAV+2]4L;MY[4&.-H0I##L&R001T[U[';V\-K D%O#'#"@PD<:A54>@ X%4KO M0-&OY_/O-)L+B;IYDULCM^9%4WJ[;,E-62?0Y7P'XVUCQ;<3?:-'CALXPGF0VR(WY@5HT-)Q:[C3LTUT/ /AKXSL_"DM];7]O<.;MXPGE!? ME89!W9(P.?>KGQ4_Y*3I_P#UQA_]#:O9'T+2)+W[:^E6+76<^>;="^?7=C-+ M=:)I5]2ZG _&S_ )%>P_Z_!_Z MU=-\//\ D0='_P"N)_\ 0C6Y>Z;8ZG$L5_96]W&K;E2>)9 #Z@$=:EM[:"SM MTM[:&."%!A(XD"JH]@.!2CHFNX2UMY'ANB?\EVD_Z_[C_P!!>M?XQ^'[O[7: M>(;6-GCC013E>?+(.58^W)&?I7J*:'I,5^;^/2[)+PL6^T+;H),GJ=V,Y.37 M,>/M0\5:0L%[H,*7=GL*7-N8/,(.>&P.<8X-3M&*[%WYIM]S @^,,=[I<5I: M:3=S:W*@C5% ,9?&,@YSCOC'X]ZYKX0I*/'L_F#]XMM+OR>^Y<_K5BS^*46G MADM?!MA;ZH_R/+;@1[G_ -P)NZ]MU;?PE\+ZE9WMYKVIV\EN9D,<*2+M9LG+ M-@\@<#%7'XG+R)EI#E%U?XGW>E^(9-+\0>'$2R4L'0'S&@?&S_D5[#_ *_!_P"@-7?6.BZ5IDC26&F6=I(PVLT$"QDC MT) J2^TVQU.)8K^RM[N-6W*D\2R 'U (ZTY:I(2=I7,'X?#=\/M)7U@(_P#' MC7CO@SQ%#X%\5W[:G;7#+L>W9(E!=6# ]"1Z&OH6WMH+.W2WMH8X(4&$CB0* MJCV X%5;K1-)O;E;F[TNRGG7&)9;='88Z?]>LG_ *&M M>[50L]$TG3[@W%EI=E;3,"IDAMT1B#U&0,U?IWT2[#D[RRUL7VF:?J:(FH6-M=HARJW$2R!3ZC(XJ:WMX;6!(+> M&.&%!A(XU"JH] !P*4=$UW"3O;R/$_'FGW_A+X@1>*+> RVLDJS!L?*' PR, M>V?Z^U;&I?&RV-M"-(TN=KHN/,6Z "X[A=K$D^G3Z=J]6>-)4*2(KHW!5AD& MJ%IH&C6$_GV>DV%O+T\R&V1&_,"DM%;H-M-WMJ<_J=GJ7C/X.ISWCW7;OQ+K,&IRV4EK:21;;19.K("?F_$DU[%X\TN MYU/X,UYI.-8^*?BBRGCTMK2PB41EUR4CC#9/S MX )]AZ5[VJA5"CH!@4^7W+>8.7OI]CPKP#\2+'PKH4GT)NK-+J>4?'' M_CYT7_<*,X'EX!/L#_ #KTJ^TC3-4*'4-. MM+LQYV&X@63;GKC(.*LK%&D(B6-1$%VA . .F,>E3;W;>=Q\WO)^5CQCPO\ M$W3]%\)P:3;Z/.^IJ"B")5V2N3P2<[LG/3!K/^% >S^(DUO>)Y5R8)8RC\$. M""1]>#7MEKHNE6-PUQ::996\[9W210*C'ZD#- T325O_ +>-,LA>[MWV@6Z> M9GUW8SFJ3][F$W[KBCQ[XSP2P>)]-OMC>6UN%5NQ96)(_45V)U:R^*/@_5;# M3XIH)8U0#[0%'[S[PZ$\97&:[>[LK6_@,%Y;0W,)Y, OM6B:[I]T(UD+A44>9&W0C! M(!!P#G/YYJ/Q!JU]\5/$EG9:392Q6D&0&DYVAB-SOC@=.F>WO7N%[IFGZD@2 M_L;:Z53D">)7 _,4^TLK2P@$%G:PVT0Z1PQA%'X"GNTY!>U^4\J^+]E'IOA3 M0;&'/EV[^4N?14Q7=> N/ FC?]>RUL7VF:?J:(FH6-M=HARJW$2R!3ZC(XJ: MWMX;6!(+>&.&%!A(XU"JH] !P*$][]7<3Z6Z''_%'1/[8\&7$B+F>R/VA/H/ MO#\L_E7E?A;[5XT\4Z!I]T,V^FP@-WS&A+<_7Y5KMO'7Q)O-,U'4/#EII(,Y M41I<&4MG>HY";>O..M6/A)X3N=&L+G5-0MVAN;H!(D<898QSDCMD]O844]W+ MIO\ ,J>D;/?]#TJBBB@@^=H-1/A+XFW5[KEB]QMGE9@R@MAB<.N>#[5/\0O% MC>,HK:[LM.N8=,LW,?GS*/FD<9P<9 X7IDU[M?:5IVIA1?Z?:W87[OGPK)CZ M9%+-I6G7%DME/86LMHN-L#PJR#'3"D8J4O=2[&G.N9R[GG]]8RZW\#K6*Q0R MRI:Q.$3DDH1N'UX-!Q5=M#TAKW[:VEV)NLY\\VZ;\_P"]C-6W[S?< MA6Y4GT/ 1?7>J_%'3M3O+5[9[R]@ECB;J(]P"_H*],^,5K+<>"EDC1F$%TDC MX[+AES^9%=I-HVEW-ZE[/IMG+=H05G>!6D7'3#$9&*N,JNA5U#*1@@C((J6O M<45T*4O>YCR_X6^-+&;3].\,&"<7L:R'S"%\L@$MPRV>BZ5ITK2V.F65K(W5X(%0G\0*(-$TJUO6O;?3+**Z8DF>.W57)/7 MY@,\U5_>YB/LN*.)^,__ ")<'_7XG_H+55\,Z&?$7P573$(6642&(GIO60D9 M_$8KT6]T^RU*$0WUI;W40;<$GC#J#ZX(ZT^TL[6PMUM[.VAMX%SMCA0(HSR< M <5*6C7 M*M?"+_D0H/\ KO)_.NSO+&TU"W,%[:P7,)()CFC#KD=\'BBSLK33[<6]E:PV MT()(CAC"*">O XH3UDWU$]DNQY%\@%*WNN/F/F]Y2['C/PJ\:6.F6T7AZX@G:YNKS]U(@78-P Y).>H]#53XJ?\ ME)T__KC#_P"AM7LD.AZ1;79NX-*L8KDG)F2W17)_W@,TMWHNE7]RMS>:997$ MZ@!99K=78 O5FR>'M$ENOM4FCZ>] MQD-YK6R%\CHW.C1P*B_N'$A59WQR " M#@9[Y/XURGZDH6_L;:Z4<@3PJX'YBF]Q)KJ?/'B*;2?%.NVD'A+0Y;9G&QD"@&1B> MNT$A0/7/UZ5]$Z=;R6FEVEO,^^6*%$=LYR0 ":;9:7I^FJRV%A:VJLU>]U4O=+T_4U5;^QM;M5.5$\*R ?3(J5H[H=U:S/. M])^*6H^(/%"V&D:'YUF[+AI&*/&O\3.1D ?YYS1\6O&)T^R&@6,N+JY7-PRG ME(S_ _5OY?6O1[.PL]/A\FRM(+:+^Y#&$7\A5:;P_HMQ=F[FTBPDN2P8S/; M(7)'0[B,YH:3L@4K.YX3K'P\U'0O"-CKZO)]HR)+F(#!@!Y0COD=_0GVKU/P M=XM3Q5X/G:5A_:%M"T=ROJ=IP_T/\\UV,L,5Q"\,T:21.I5T=058'J"#U%9C M:+I6F6=W+8:996DC0,K/! L9(QT) HF_=EV_X XZN/<\"\ ^(+GPQK$^I)9R MW5FL6R[6/JJ$C#?@<=:V_'/CI?'*66CZ-876PS!\2*-\CX( "J3QR>]6?@FJ MOKFJ*P#*;4 @C(/S"O8K/1],T^5Y;+3K.VD?[[PP*A;ZD#FJDMKB4K-VW./O M?!$S_"F/P]%M-[%$)0,\&7.XC/N217%>!_B)%X.T^?1=9L+O]U*63RE&]2>J MLK$8YY_&O( M)+6#1$&GAB3<;R#$F.-W!!8^@Q^F:YKXEZ/J&@^,H/%=I"9+=I(Y6<#(21,# M#>@.!^M>S6]M!:0K#;01PQ*,*D:!5'T J1E5U*NH92,$$9!H>Z:Z#3WOLSQ[ MQ#\8K>_\/R6NDVM[;:A, IE8@"+U*D')/IP*[3P /$$WAMKCQ#A(]#70_%#2[N2[TWQAI\3-;R0QLY R8F' MS*3CM@@9]O>O6KK1-)O;E;F[TNRGG7&)9;='88Z)(H8QM2.-0JJ/0 =*DJI.[;,TK(\+\6>'M6\#>+O\ A)-(B+V1E,RN MJY6,G[R.!T!R>??UJ/Q9\1K?Q#9V5Q93:KINIVN66.(J86)QGY@P;MZ?AS7O M! (((R#VK+D\-:%+.9Y-$TUYBSU?3M;CAM%MEAB$=OY@(4GO MN&.N,8[5UVN>%-&\16BV^H62.(QB-T^5X_H1V]NE:&G6%OI>G6]C:IL@MXQ& M@]AZ^]/2UA.3O='A?B_X7_\ "*Z"^J?VQ]JVR*GE_9MG4]<[S_*MOX3>#][6 MOBG[?C8TL?V;R>O!7.[=[^E>MWEC::A;F"]M8+F$D$QS1AUR.^#Q19V5II]N M+>RM8;:$$D1PQA%!/7@<4XMJXI.ZL3UY#\8O%,\+Q>';20HCQB6Z*]6!/RK] M.,G\*]>K.N_#^BW]PUQ>:187,[8!DFMD=CCIR1FI:N.+MJ>'^$?B'8>$=.\B MW\."6Y?_ %UTUWAI#_WP<#VS7IOA/Q:GQ!TS58)-.^QHB"%AYWF;@X8?W1CI M6Y_PB?AO_H7]*_\ */_ J[8Z5IVEAQI]A:V@DP7%O"L>['3. ,U3LT[BO; M5'B'A;79?AAXBU+3M:LYVBE &80,G:3M9@)%5?^$3\-_\ 0OZ5_P" 4?\ A4QNKC;321S7@_XA-XUO;O3TTTV#);F0 M2BX\PYR!TVCUS7%V/C7Q!X,\87$'BF2]O(2IC*[N,9^62,'"G/X?I7L=EHNE M:9*TMAIEE:2,-K/!;K&2/0D#I4UYI]EJ,7E7MI;W,?\ X4 ?THL]/LM.B\JQL[>UCZ[((P@_("K--:*R!N[N%%%%(04444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M8O\ PENA_P#/]_Y"?_"C_A+=#_Y_O_(3_P"%;?5ZO\K^XY?KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T;5%8 MO_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K^X/KF'_Y^+[T:$G_ M "$HO]W_ !JU7.OXHT8WL<@O/D"X)\I_?VJQ_P );H?_ #_?^0G_ ,*2P];7 MW7]QOM5C_A+=#_Y_O_(3_P"%*.'K6^%_ M<7/&8:_\1?>C:HK%_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "G]7J_RO M[B/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%8O_"6Z'_S_?\ D)_\*/\ A+=#_P"?[_R$_P#A1]7J_P K M^X/KF'_Y^+[T;5%9=IXBTJ^NDMK:ZWS/G:OEL,X&3R1Z"M2LY0E!VDK&U.I" MHKP::\@HHHJ30**** "BBB@ HHHH **** "BBB@#%_X1+0_^?'_R*_\ C1_P MB6A_\^/_ )%?_&MJBMOK%7^9_>'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M M?'U/#_ M //M?' MU/#_ //M?:_O[U8_X1+0_^?'_ ,BO_C6A)_R$HO\ M=_QJU26(K:^\_O+E@\-I^[7W(Q?^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QK M:HI_6*O\S^\CZGA_^?:^Y&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U1 M1]8J_P S^\/J>'_Y]K[D8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%' MUBK_ #/[P^IX?_GVON1B_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6 M*O\ ,_O#ZGA_^?:^Y&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J M_P S^\/J>'_Y]K[D8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ M #/[P^IX?_GVON1B_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ M,_O#ZGA_^?:^Y&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S M^\/J>'_Y]K[D8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[ MP^IX?_GVON1B_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O# MZGA_^?:^Y&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J M>'_Y]K[D8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX M?_GVON1B_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_ M^?:^Y&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y M]K[D8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GV MON1B_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^ MY&+_ ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D M8O\ PB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B M_P#"):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ M ,(EH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D8O\ MPB6A_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B_P#" M):'_ ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ ,(E MH?\ SX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D8O\ PB6A M_P#/C_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B_P#"):'_ M ,^/_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ ,(EH?\ MSX_^17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D8O\ PB6A_P#/ MC_Y%?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B_P#"):'_ ,^/ M_D5_\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ ,(EH?\ SX_^ M17_QH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D8O\ PB6A_P#/C_Y% M?_&C_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B_P#"):'_ ,^/_D5_ M\:/^$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ ,(EH?\ SX_^17_Q MH_X1+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D8O\ PB6A_P#/C_Y%?_&C M_A$M#_Y\?_(K_P"-;5%'UBK_ #/[P^IX?_GVON1B_P#"):'_ ,^/_D5_\:/^ M$2T/_GQ_\BO_ (UM44?6*O\ ,_O#ZGA_^?:^Y&+_ ,(EH?\ SX_^17_QH_X1 M+0_^?'_R*_\ C6U11]8J_P S^\/J>'_Y]K[D<[;^%]&>696L\A6P/WK\=?>K M'_"):'_SX_\ D5_\:T+7_7W/^]_4U:I1Q%:WQ/[RYX/#7_AK[D8O_"):'_SX M_P#D5_\ &C_A$M#_ .?'_P BO_C6U13^L5?YG]Y'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M M?'U/#_ M //M?' MU/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M M?'U/#_ M //M?' MU/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M M?'U/#_ M //M?' MU/#_ //M?'U/#_ //M?'U/#_ //M?'U/#_ //M?"?0UJ445G*< MIN\GQWE%>.1?$3XA3P)-% MX622)U#*Z:?<%6!Z$'=R*U/"?Q9.J:M'I>MV4=I<2-Y:RQDA=^?NLK#[**2XBDGN)]WD0IP&(QG+=AR/7Z4F[#2;V.EHJII=VU_I-G M>.H5IX$E*CH"R@X_6K=4U9V9*=U<****0PHHHH **** "BBB@ HHHH ***\U M\2?$+5M'\>PZ%;V]DUJ[PJ7D1R^'QGD,!W]*.J7<=M&^QZ51110(**** "BB MB@ HI"0H)/0*/$EUIVGV[BUMX3)Y\G!<[@.%[#GOS["A:NP=+G M84444 %%07LS6UA<3H 6BB9P#TR!FN$^'/CO5/%]]?0ZA!9Q+!&KJ;=&4DDX MYRQH6KL.VEST*BBN>\;:[=>&_"USJEG'"\\3(%68$KRP!S@@]_6DW8$KNQT- M%/; I"X&/4D]_6LW0_$OBN^\9SZ;J&B?9]*1Y0 MEU]DE3<%)VG>3MYX[BN=M1110 444 M4 %%%% !1110 4444 %%%K8[#ZUY39_%3Q;JUVSZ9 MX;CN;16 98H99&7/8NIP#^%"U=D.SM<]CHIJ%BBE@ Q R!V-.H$%%%% !111 M0 4444 %%%% !15#6M8M-!TF?4KTN+>$ ML7).3@ #ZD5F^#O$__ EFDS:B MMM]GC6X:)$+9.T 'M0U"!4:6VMWE0."5) R,X(XKF_ASXPU#Q?9WTVH0VL36\BJHMU90003 MSEC0M;^0/17.VHKS>Z^(&JP?$U?#2V]D;(W"1;RC>9@J">=V,\^E>D4+57!Z M.P45S7COQ#=^&/#+ZE91P23+*B!9E)7!/L0?UI? OB"[\3^&8]2O8X8YFD=" ML*D+@'CJ2?UH6M_(;5K>9TE%%% @HHHH **** "BLOQ)J4VC^'-0U&W6-IK: M!I$60$J2!WP16!\.O%U_XNTV\N+^&VC>"8(HMU8 @C/.6-"UNNP-65SLZ*** M "BBB@ HHHH **** "BBN(^(WC'4/"%I82Z?#:RM<.RO]H5F Z88>M)NPT MF]CMZ*S/#NHS:OX/--\(QK M'*K7-](NY+:,X./5C_"/S/M7$+\3/'%ZANM/\+H]F1E7%I-*,=_F! /Y5*=R MN5GL5%><^%?BO;:SJ2:9JEE]@NI&V1N&RC-_=.1E3^=='XXU^Z\,^%YM3LHX M9)D=%"S*2N"V#T(/ZTWHKB2;=CHZ*\E\'?%75-<\3VFF:C;6,<%QN4-!&X8- M@D=6/IZ5Z3KVJ#1= OM2(4FWA9U#="V.!^)Q0]%=@E=\IHT5XEI?QA\07NK6 M=I)9Z8(YYTC8K%)D L ,]9O/&-[%I>J7T%O%)]GBCMIW0,5X)P MIY).?TK2^%_C'4F\6+8:GJ-W=PWB&-/M$[/L<<@C<3C."/Q%97PLT@ZQXVAG ME&^*S4W#D\Y;HOZG/X5F>)[*;PIX[N5MOW9M[D3VYQT4G]>W0^FJ\Y^,&I7^F:%I\EA>W-H[7)5F@E:,D;3P2#7=Z7?QZII5K?PG]W<1 M+(OMD9Q7G7QN_P"1>TW_ *^S_P"@&HFFM/,FGJSS6QU3QOJ:NVGWWB&[5#AC M;S32!3[X)Q5O_BX__4U?^3%=9\'=8TO3-.U1=0U*SM&>5"HN)UC+#!Z9(S7I M?_"6>&_^A@TK_P #8_\ &K:L'-Y'DG@[_A.?^$NTW^TO^$B^Q>;^]^T^?Y>, M'[V[C'UKNOBC_;G]@VG]@_VC]H^TC?\ 8-^_;M;KLYQG%=39Z[H^HS^18ZK8 MW4V-WEP7".V/7 -:%)ZI(2=G<^2K%;PJ6=SV'^/M7SCXM\47WC;7U,<OJ?PKC/C;ITXOM-U,!C;F,P,>RL"6'Y@G\J=3HB86Z@@B[B%_ =*9=:=XM\#O%+*+S3@SY5XILHS>A*DJ>.QKK? M?Q0LM!T>#1]4M)!#$3Y=Q >"2?F7CIGJ,_2N\N=7\(^/M)?2?[6C(G(P@;R MI0P.?E#CK^![TVK?"'-_,5_AOXWD\56$MM?;1J-J 791@2J>C8['L?P]:[FN M1\,_#O2?"FIM?V%U?22M$8BL[H5()![*/05UU-M,@***XGXG7FL6OARWCT1[ ME;JXN1$1;*3(RE6) P,CH.14-V'%7=BA\2O'D.C:?+I.FW.=4F&UWB?!MU[G M(Z,>PZCKZ5E_!S6-3U2\U5=0U&[NPD<907$[2;ZCH_A&YUW M6)/*N-Z".V!#-\S $N?Z?GZ5TGP._P"/[6?^N47\VJH+5W*G;E5CV:O /B'X MJUF+QOJ$%CJ]];6\)6-8X+ET4$*,\ XZYKW\G R:^9K;4[.3XC?VKJ$Q2T&H M-<.X4MP&+ 8'T J-YI#CI%LH_P#"6>)/^A@U7_P-D_QKU'X.:OJ6J3:N-0U& M[NQ&L6S[1,TFW.[.,DXZ5K0?&+PO-=&%Q?0IG'G20@I_XZQ;]*[FTO+:_M8[ MJTGCG@D&4DC;@"C^N: M^A=/L(+'2;>PCC ABA6(+CC &*B*O'G+DU%J)YY\-?B)_\ /TZOF>W_ .)!\2U6'Y$M=3V 9Z)YF,?E7TQ57YHJ1$ER MR<0HHHI""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JR?\ (2B_ MW?\ &K559/\ D)1?[O\ C5JI74N6R] HHHJB HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH JVO^ON?][^IJU56U_U]S_O M?U-6JF.Q<]PHHHJB HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\?^.771/^VW_L ME>P5X_\ '+KHG_;;_P!DJ9=#2GN_0](\*D+X/TP^HK;TGX-?VIH]E?\ ]O>5]I@2;9]CW;=P!QG> M,]:[3PK\,=)\,WB7S32WMZ@^220!50XY*J._U)K5_P 3F?1D)I1:74K_ !2\ M1ZOX;TK3Y=*N_L\LLQ21O+1\@+G^(&N,@\?>/=<>U_L:VG>*()%,\=F)%DDP M-Q=MN%!/88P*W_C?_P @72O^OAO_ $&NJ^'%LEMX!TI44#?&9&]RS$U$-;M] M&.6B2\C*\<_$)_"D4&GVT45SJ\D89\@^7&.F< Y))S@9_P#K\M-K_P 5-/M3 MK%U;9L0/,,301$*ONJ_O ![_ (UGZV5/QSC^W8\K[;#C?TQM7;^N*]SG\O[/ M)YN/+VG?GIC'-+['/ZC=E+EMV.:\$>-+?QAIKN(Q!>P8$\.<@9Z,I]#C\*XK MQ#\1]>U/Q&^B>$81N1S&)1&'>1AU(W?*%X/4>]8GPF$G_"5:K]DW>5]BEQ_W MTNVIO@MY7_"57_FX\_[*=F>OWAN_I56O)>EQ-U-^,_D_\(=!OQYOVM/+]?NMG]*RM%_Y('>_]*=0T#X?1:SXH0F_/"P^7Y M;NQ/R@CL<#)X&!VKF_@?;(+'5[K:-[21Q[O8 G^M3?&_S/[%TO'^J^T-N^NW MC^M5/W5;O84;2EZ7,JV\3_$WQ#$VJZ1;*E@"<)'%%M;![;_F;TXKJ_ 'Q D\ M333:9J=NMOJ<"EOD!59 #@\'D,.XKG?"VE_$2?PS82:/X@TR'3VCS#&\:EE& M3P?W1YSGN:N>&/AWXDTKQK%KVHWVG2@O(\_DLP9RP.<#8!U/M5)6E;H2]8WZ MD.M^/O$NK^)[G0?"-L@:!F0R%5+L5.&/S_*!GCFFV>K_ !6TR^C2^TO[>C\[ M"D6 !U^>/ 4\]_RI?$WPNU9==GUGPS?B)Y7:4Q^:T4B,>3M8=B<]2*QI/%WQ M"\&RQ'6XGEMV;:!Y^E1%V2ON7)7VV/6=?\0+X?\ #$VL75LX M:.-3]G+#.]L *2,CJ>HS7F5GXB^*'B>'^T='BCCLV)51&D 7(/\ TT))]*]" MDBLOB#X&7>'AAOH@PQR8G!_7##\:\T_X0?X@>%6;^Q+UIH,D[;:? /N8WP,_ M3-#TD[BC9Q5CMO!6M>,[N\:T\1Z,R0J"/M>T1D,/5<_,#ZJ/TZ8?C_QCKVB> M-[/3M.O_ ";22*)FC\F-LDN0>64GH*C\(_$C6_\ A)(O#_B6W!FDD\GS3'Y< MB/VW <$'CH!USS6-\5/^2DZ?_P!<8?\ T-JI:RAYLEZ*7H=U\4?$.J>'-!M+ MG2KK[/-)\*Q[I9 /F(#87 M\ #6M\;/^17L/^OP?^@-71?#>)8?A_I(4 ;HV8X'C6=O_"]$^V8\O[=#][IC:NW^E->]R>8Y)0< MO(V[?Q3\0O#UH=0\1:<]QISC!DV1"2+/0X3IS_>%:'PK\6:WXDN]235KW[0L M*(8QY2)@DG/W0/2NW\3^3_PBNK?:,>5]DEW9_P!TUY?\#O\ C^UG_KE%_-J< M7>37D3)>Y?S/9J\#^+?]N_\ "0+_ &E_R#=S?8/N?=PN[[OS=KWRO'_CE MUT3_ +;?^R5$MT53W9T'PY?Q9'9L_B%@NEK:QFS)\K 7'^QS]W'WJY_4/B1X MB\1:U)IG@VT&Q<[9B@9V /WOF^55^M=E>F7_ (5*Y@)\S^R!@C_KF,_I7(_ M_P C[/K'W?M&Z//KMPWZ9K22O-KM_F9Q=H*5MRO'X_\ &/A+4H;?Q=9>=!*< ME]B*V.^UD^4X]/U%=7X_U_4K3P=;:[X=O_+C+HS.(D<-&XX/S XYQ^=4/C1] MG_X1*U\S'G?:U\KU^ZV?T_I4_A#3'UCX.QZ=,,FX@F6/=V^=MI_/%0W>#?8T MLE*+[FKX<\4F^^'B:[=R!YH;=VG; &73.>!@#. <>]_ M$\%Q&X1/)1<.!D)&TWP!K>@2,R3S7";%/4 _ZP?\ C@'XU;GT ML^$&\':ZH*F=1-,???N_] 8#\*M6Y[]'9?>B6K0:ZZ_@=K\0/%^NV7B[3]"T M"\\B254$G[I'R[M@?>!Z#T]:VO'OBW5/"]A;Q:=8R75S(N7N7A8QQ@=2<<9/ MIVKB_"@7Q9\8;W5C\]M;,\R$<@A?DC_H?PKJ_'GQ!N/#NHP:/I-K'/J$R@EI M?NIN.%& 1DGZ\<=:C[,>[&[)O!MUJ?E+!>6ZND@3E=X7(89[.N>E=[HOBK7-(\#7FM>+8Y/.CEV01/ M!Y,C^F1@8R?;H,\UR'P3MDD\1:A<,H+16VU3Z;F'^%=+\:Q)_P (O8E?]7]L M&[_OAL4YZ+U%&TI6[?Y&#IGBWXD^)9I+_1[:-K.-L&)8HQ']-SG<3]#7-:GK M-QKOQ'L;N[LS:70N((IH2?NNK &O8_AIY/\ PK_2_)VXV-NQ_>WG->7^-/)_ MX7)'Y.,_:;;?C^]\N?Z55K5(H2=X2?D>^52U;5+;1=*N=1O&VP0(6;'4^@'N M3Q5VN$^+OF?\('-L^[Y\>_Z9_P <5G)V015W9G)Q>,?B%XNFFG\-VBP6<38P MB1'\"TG!/T]:W?!7Q$O[_7&\/>(K58-0!*HX39E@,E67L?0CBN;\!Z=XYN?# M2R>'M;T^UL?-<>5*@+!N^?W;>W>M*#X<>+I?%UIKVI:GIDT\=Q')*Z,RE@I' M0",#.!BM$K2MT!V:?\*TC*&8N5SA0>!@ZLOMB.VT1F*%QGKR8B"/J3BM/QO\ #2\UC6SKFAWB07CX,D#(Q-J)FEM$(4MM.$+0,T;;!GYAEOEZ?C^->'^"_P#A*?[6N?\ A%O^/SRCYO\ MJON;A_STXZXZ5[OX4\2IXK\,KJ0A\F3YHY8\Y"L/0^G(/XUY?\%S_P 57J/_ M %ZG_P!#6J2]]KR)O^[OYG;^-_%VK^&=)LTLM.DGO98PTT[1%HHL 9SMX)SG MOQ7&WVO_ !3T:R&K:@-ED""P>* @ ] 0OS#KWQ76>//B#<>'=1@T?2;6.?4) ME!+2_=3<<*, C)/UXXZUSWC#2?&K^$KZ_P#$&O6ZVZ;6-C;1C:V64 %@!T)_ MVNE1?1R*BMHLZ_PWXJ/BWP/>WLL*PW$4..#))_P"BA63\$FA&OZD&V^<; M8;,]<;AG'Z5=OWC]";VA\R27QUX[\):I"/$UNLL$QSY;)&,J.NQX^,\CKFNN M^(U_;ZI\+9[ZU??!/Y,B'V+K^M4OC5Y7_"*6>['F_;!L]<;6S_2L:X$@_9[B M\S.=PVY]//XJ'K!^31:5I1?-[ MJR^V([;1&8H7&>O)B((^I.*T_&_PTO-8ULZYH=XD%X^#)'(Q3Y@,!E8=#P./ MUKEY]:^)7@R,3:B9I;1"%+7 6=#Z9<'*_A3JNI"'R9/LLT-%9%/\2LG!'Y]".*[KXDZYJ&@ M>%/MVEW'D7'GHF_8K_*E^,_'_ (DT9(=$M!+/;@_:;XK&"S$D@*&P@P,#&":C MT/XM:[$L^GZC8?;]1)\NVV)L8R9QM=1_0 \>^1V7PDC5/ -NP'+S2L?KNQ_2 MO/O#4:-\<) 5&!?7) ]" ]:6]_E(7P.78N:GXV^(?AC4()];AC2")IIM,U.W6WU.!2WR JL@!P>#R&'<5SOA;2 M_B)/X9L)-'\0:9#I[1YAC>-2RC)X/[H\YSW-7/#'P[\2:5XUBU[4;[3I07D> M?R68,Y8'.!L ZGVK1*TK="'K&_4B^(7CC6_#?C.UMK.\*6'DQRRPB)"7^8[N M2I(R!CK5+5O%/Q*DL#KD%B-/TH#>%6.-SL[%@V6_' K/^+,8E^(=E&>CV\*G M\7:O7_$J*/"6K)@;192C'_ #6>U/F]331S4>]CD_#'C/5O%W@[5#9Q)'KMJF MV/R]H5F(.U@&X'0]>.*\HTG_ (2C_A.)?[._Y&#S9=_^J^_SO^]\GK_2NV^! MO^NUK_=A_F]9_A,_\7ONO^OJZ_\ 9JTM^\7FB+VA+R9[%H/]I?V%9?VQ_P A M'RQ]H^[][O\ =X_*K-]>P:;83WMT^R"!#([>@%6*XSXJ&4?#Z_\ *S]Z/?C^ M[O&:B;TN$%=I'&GQ]XT\7:A/#X3LA#!$<@[$+;>VYG^4$^@_6I]+^).OZ!K2 M:5XSM JM@&<1A77/1OE^5E^GZ]*VO@UY'_"&R^7M\W[6_FXZ]%QG\*P_CC]G M_P")-T^T_O?^^/E_K_6G+W&D./OW6QK_ !9;Q ^C!M,(.C&$F^(\OD;EV]?F M_P"^:XWX9_\ "7^='_8O_('^V)]M_P!5TXW?>^;[OI7>:T)1\$_WV?,_LV'= MGK_#5#X)?\BYJ/\ U]_^R"G%FMKUA9? M8-&4;E8)&[%/[S!LL1[@ 5-IWQ.\2^(=/CT[1M(276N3),,>6J#HP!. ?J([SPWHHGT_3Y;RZD;:FV M-F2/C)9L=O;C->7?$7_DK%I];?\ G7H?C_QU_P (?;6\=O;I/?7.XH)"=B*. MYQR>3TX[\U-[P3\QV]^R['#OKWQ4;3#K84II^SSN(8,!.N=I^?&/TKM/AYXX ME\5Z==B_BCBN[/!D:/A74YP<=CP:AJNN6UA9&T:8VMO&-S+ ML)*DX&,_[QZUG?!% ]UK0890Q1J?Q+52O>2\A.W*I>8]_'GC/Q;JES;^$K5( MK> Y!"QERO(!8R?+SZ"M+1=:^)EEJT=KJVC-?0D@R-MC0JIX^5U(3(]#^E96 MH_"WQ'HFI2WOA74#Y9.41)S%*!G[I/1A]3SZ56C\?^-O"-_%!XCMC/$_.R=% M5BO?:Z\'\QTGQ@_MW^QD^Q_\ ('V?Z;]S[VY=G7YNO]W\:YWX M6?\ "7>9:_8?^1>^TM]I_P!5UP,]?G_N]*[CXCW,=Y\,;RZB),0I.\(^92\7?$74QKY\.^%K=9KT-Y;S;=YWX MY"CIQW)XX-9+>-_'?A"\@/BFS$]K,W4I&#CN%:/Y<^QKE_#L&NW/Q!NX]'O; M>TU0R3GS+A01U.XS BO.X/B+XXU:Q@M]*CG MGN8 3"=06B)*X+DC!(!Z M'TK8^#ELD/@II@H#S7+LQ]<8 _E325Y=D3>T8G9Z,U^^C6;ZF%%\T2M.$7 # M$G7%_=OL@@0NY]AZ>]6:XSXJ>;_PK[4/+Z;H]_\ N[Q2F]&T M$%=I,XM/''COQ?>S_P#"+VBP6T)_A2,D#MN:3Y<^PQ5_PM\2-9A\2)H'BJ!5 MF9Q")=@1T<]-P'!!XY '6M+X,&/_ (0ZXVXW_;&WXZ_=7%=3*_B5X66._UVU6:R=@")(XL#VS'RI^OY5A:U'J4WQAN8[&X MBM[]KW$$LPRJG VYX/;'8UV6J>$OB3K6G2V&H:_I,UK+C>A3;G!R.1"".16< M;\JEW+=E+EZ'2:IK=MXB^%^I:G:Y$&:A_R7Q/^OV+_P! 6O:Z;9P6.0!O(4?CG\ M*[SXO?\ (AR_]?$?\ZC^#S0GP/B/;Y@N9/,QUSQC/X8I07Q?(J3LH_,PO#/Q M(UJQ\1+H7BV,!V<1^<8PCQL>FX+\I4Y'('OS73_$'Q?J7AFTA32].DGGE!9I MVB9HHE'KC@G\>*\^^,.P^.+,0?Z_[-'NV]=V]L?TKL_''Q!NO#MY;:-I=K'/ MJ4R*6>7.U"QP !QDGZ\<=:/BBGUO8;5I?*YRU]K_ ,4]&LAJVH#99 @L'B@( M /0$+\PZ]\5Z-X%\5'Q;X?%[+"L-Q%(8IE0_*6 !R/8@UPGC#2?&K^$KZ_\ M$&O6ZVZ;6-C;1C:V64 %@!T)_P!KI6G\$@?^$:U XX-W_P"R+51UNNQ,EHF8 M"?$KQ+:>+M1L03J*B:6"UM!$@^;?A&KF&[UB***WF/R M0M%&T9]LI\P/U;-5O!D2R_&BZ+ '9T3_D@ES_ ->]Q_Z&U>7:3H^MZUH]\MBCO868-S,.B[@, M<>K8SQZ9JI:2DD3%7BK]SU#P3KGC+QCK4MZ]_P#8]$BD)9$@C.?2-6*Y/N:] M4KSWX2>(8=3\,C2V")SKA8X8D+98]S@< =S7EL&O?%36[5M2T^+R[3YAM2&%?N]<"3+'T[]* M]$\;>+8_"&BK>&'SYY7\N&(G )QDDGT KE=,'Q!\7Z='J#ZQ9Z183H658(LN M1GKW(_[Z%9]V6M$KECX1=UKQ5\3-*B35KVV2SL&88B$4;*,] W M5QZ8?A#XG$1.[,V/^_2YJ;^[+R'RWY7W8VY^(?BWQ3KDEEX1@\N)"2F(T9F4 M?Q.7^50?PK!\?:[K][:V.E^)-.%M?VS-()%(VRJPQGC([=0?NEQZ[?E_K1-./BA+GW>/:O=[N^L=+MUEO;NWM(.T@Y[9SVJ?XKLK?# MRX9&#(9(BI!R"-P[UY1\0O"]AX3UNWLM/FN)8W@$C&=E9@2Q'8#L!7I_Q'_Y M)4O^[;_S6I=O9Z=QK2:OV/([:W?2]#TCQ% /WD>H.K'W4(RC_P!"KU3XMZV@ M\$VL,# _VE(C#GJ@&[/Y[?SKE++3!?? R[D5P^HK;TGX-?VIH]E?_V]Y7VF!)MGV/=MW '&=XSUKM/"OPQTGPS>)?-- M+>WJ#Y)) %5#CDJH[_4FM'_$YGT9DFE%I=3MER%&>N*6BBH$%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y#\;-9&W M3]%C?G)N)@#^"_\ LU>ND@ DG '4U\R>)M0D\6>-[F6WR_VFX$-N/]G(5?SZ M_C4M_!*6VL;B># M7//ECC9TB^R;=Y R!G><9^E.;OJ^@0LGIU-WX-:T+SPY/I;OF6RDRH_Z9MR/ MUW5#\;O^1>TW_K[/_H!K@?AEK7]B^-;4.<0W?^C29/3TW_K[/_H!IU=4GZ"@K2:/-_"O@75/%\%S-I\]G$MNP5A<.RDDC/&%-=#_P MI3Q)_P _NE?]_9/_ (W4_P *_%NA^&[#48]6O?L[S2HT8\IWR #G[H->@?\ M"TO!O_09_P#)6;_XBF[=!)R,#P#\.=8\*^(SJ-]E>F MR2)%&TDCJB("S,QP !U)KEK?XE>$;JYBMX=6W2RN$1?LTHRQ. .5KB_C#XKN MX9E\.6V8H7C$MQ(#S("3A?IQSZ_S4F[(%&[U.:^(WCE_$U^;&RJ1#[?*N8(F'^I4]S_M']!]37GWP_;PO9ZE_: M?B._6,P,#;VQAD?OZ^N_\+2\&_P#09_\ )6;_ .(II0@QQ^31M3,0.2L%TNX ^F\ /$7AV%[B\LP]JG6>!PZCZ]Q^(%>J> M _B'H]WH%K8ZG?0V=[;1B)C<.$60 8#!CQT[>M6O&GCSP]:^'+VW@U"VOKFY MA:*.*WD$@RPQDD9 SFB:Y=AP;;LSE/A-XTO9-27P]J$S3Q2(QMG7:J M\LC#H!M('YDBO9?%?@?3/%\EJ^H3W<1M@P3[.ZKG=C.R9"MS-'.?\ M+K\-_P#/EJO_ 'ZC_P#CE=_I]['J6FVU]"KK%<1+*@< , PR,X[\UP'_ I3 MPW_S^ZK_ -_8_P#XW7?Z?91Z;IMM8PL[16\2Q(7(+$*,#.._%+2P/R.0^+7_ M "(%U_UUB_\ 0A7(_ [_ (_M9_ZY1?S:NN^+7_(@77_76+_T(5R/P._X_M9_ MZY1?S:E3WE_70(:7\&];GU01:I M+%;V87&%O(<=0^./UKPOPY\1]8 MTOQ.MQKMY>75MM,,T+,?DY^\$X&X$?7K2C;F'KR:'0>*OA#9:9H5SJ&DWMT\ MMM&97BN-K!U')P5 P4R",,,$DL!V],US?P9T>:X\0W&K%2+>UB,8;L7;M^ M S^8JH7YGV_K_@!/X//^O^"5'TKY_P#BWI$N MG^,GO@A$%\BR*W;S2KJ,<0#VXB8EW [-C;@G MU-3!_N[=@J)N=UU/*]AG6Q-&$W&4TGZKL;5%8O_"6Z'_S_ '_D)_\ "C_A+=#_ .?[_P A M/_A5_5ZO\K^XQ^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PH_P"$MT/_ )_O_(3_ M .%'U>K_ "O[@^N8?_GXOO1M45B_\);H?_/]_P"0G_PJQ9:_I>H7 @M;L/*1 MD*59<_3(%)T*J5W%_<5'%4)/EC--^J-*BBBLCH"BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ KS?XJ^%M9\2'2_[(L_M/D>9YG[U$VYVX^\1GH:]( MHI-7*C*QF^'[6:Q\.:9:7*;)X;6..1<@[6"@$9'%:5%%4W=W(2L<#\4_#>K> M)-,L(=)M/M$D4S,X\Q$P-N/XB*Z3PE87.F>$],LKR/RKB& )(FX-M/U&16U1 M26B:[E-WMY'!>/\ X>#Q4\>H6$R6^I1KM._.R51TR1T(]:Y6;0/BIJ%J='NK MG%B1Y9E:>(!E]V7]X0??\:]GHI)=!\S.7\$^#+?P?ICQ"03WDY#3S;< XZ*/ M85P.L>!M4M_$3Z[X'OH)R[F01PSH&B)/S 9.TKG/!^F*]FKRO7OA+=/K,NJ^ M'-56SE=S(L9RLXC))=5N(_ M^$B\2":!"",323MCN!O ^O->KZ=86^EZ=;V-JFR"! B#V%.RY6NX.6JMT.+ M^%GAS5O#FE7\.K6GV>26<.@\Q'R-N/X2:Z3Q3XW$G9W1XK:^&/B;X9BDT[1IUDLV)(:*6(J,^GF8*GOQ76> /!. MJ^'I);S5]3DEE<$);1S,T:Y.2S9X))]O_K=]133!NYY+KG@7QAI_B!]8\.:M M+=/ ]2%BZGZXZ M]:]IHI)6T&Y-ZG.7OA*.3P='X?L+ZYLA"@$4\3D-N'][&,@GJ*\[M?#WQ2\- MJ]II5PLUNS%RR2Q.N2>?];R,]?QKV>BCJWW$G96/+?"/PZU9/$:^(O$]RLET MK>:L0?>Q?'!8CCCT&>GI4?C_ ,':]K?C>SU'3K#SK2.*)6D\Z-<$.2>&8'H: M]6HIWU3[!>][]3AOBCX>U3Q'H-I;:5:_:)H[D2,OF*F%VL,Y8CN16YX-T^ZT MKPAIMC>Q>51Y+I?@SQ!;?%A];EL-NG&[F MD$WG1GY6#8.W=GN.U7_B'X*C\2:BMYI-];)K$*JDEL\H4N.JGV;TSU_"O2ZX M3QQ\-X?%EVE_;7?V2]50CEEW)(HZ9]"/6I>R78T4KR;?4Y:;P_X^U31+F/Q1 MJ;6VEVL+2-'OC9Y=JY )3J,CJQ_"E^!T9\_6I,' 6)<]NK4-\,O'%Y$MI?>) MT>S/#(;N:0 =OE( ->B>$?"EIX1TC[%;R--([;YIF&"[=.G8>U6M&V3)Z)&_ M7#?$SP?>^*M+M6TXH;JT=F$;MM#JP&0#TSP.M=S14M7%%V=S@/ &F^,+1)+/ MQ*%&G1VX@MX6:-B,8'\&KN"=M#QN+P!XQ\6ZE#<>+K[R8(CC9O1FQWVJGRC/K^AKUZUM8; M*TAM;:,1PPH$1!T P!4U%.^EA/5W9X=XD^&&NW?C.ZFL+(/IMQ<"3SO.0;0 MQ!;@MG@D]J[OXC>%KG7O"D%II=N);FUE1HH]RKE<;2,D@=#G\*[:BIM[O*5S M/FYC@?A=X3OO#.F7KZI;""\N)0-N]7(11QRI(ZDU0^(_P^U'7]2CUC1W1KE8 MPCP,^PG;G!5CQGZXKTVBG+5I]A)VOYGC[^#OB!XFTUX/$.I>5!"A,5N60M*X M'RY*<$9[L2:U_AYXG&!IP7@/G1MO)0J1\K''0=?6O2:*'JFN MX^;;R/,/A7X2USPWJ&HRZM8_9TFB54/FH^2#_LL:[KQ'H-MXDT.XTRZ)591E M7'5&'1A6K11+WE9B3L[H\5T[PE\2?#,TEAHUR@LY&R95DC,8]]K_ #*?7 _. MH'^&?B>U\4Z?>%#?CS8I[JZ\Y!\^_+8W$,<#OCFO<:*:=FF#>C7<*I:OI=MK M>DW.G7:EH)TVMCJ/0CW!P:NT5+5] 3L[H\6@\&?$+PA<31^'+I)[:4Y)C>, MXZ$I+P#],_6M[P3X'\0V6M-K6OZI*LC,9#:Q3D^8Y')?'R\>@ST]!7I=%4G8 M&[GF/C'P+XCN==_MK0-6E9PWFK;S7!!C<#^#/&#TP<=<=*Q;SPW\3_%$2Z?K M,R16F0S&22%5)![B+D^O/I7M%%2E96'S,Q?"WAV#PQH$.F0N9"N6DD(QO<]3 MCM7E:> _''AKQ)<7/APH8Y2RK<"2/_5ELX97[\#H#[5[=13>KYA)V5CRKQU\ M/-9UUK+5[&1)-22V2.XA+A2SJ/O*W SGUQ51_!WQ \3::\'B'4O*@A0F*W+( M6E<#YP446W&I/0\V^'GAS7M$\.ZSINIZ<8&G!> ^=&V\E"I'RL M<=!U]:Y+P_\ #3QC9/-?P,-,U" J;,G:>NQ8^,\#DXKNO&7AN>Z^'SZ'HMMYCH(DBBWJO MRJP[D@=!77T4/56'S.]SD/AMHFH:!X4%EJ=OY%QY[OLWJW!Q@Y4D5S'A7P=K MVF_$VZU>[L/+L'EN&67SHSD,3MX#9YSZ5ZM13O[W,3]GE/,?&/@7Q','I@XZXZ5BWGAOXG^*(ET_69DBM,AF,DD*J2#W$7 M)]>?2O:**E*RL5S,Y!/")T?XK6GV=YI4:,>8CY !S]TFO0:*J^K?4_$_P=KWB+Q#:76E6'VB&. MV$;-YT:8; #GEB!79T5-O=Y? MF5S.Z?8Y;X>Z1?:'X/MK#4H/(N4>0LF]6P"Q(Y4D5QVA>#/$%G\59-:N+#9I MYNKB03>=&?E8-M.T-GG([5ZU157][F%?W7'N<#\4_#>K>)-,L(=)M/M$D4S, MX\Q$P-N/XB*MQ>#O[5^&UEH&J)]GN8H5PP(8Q2#.#P<'KZ]#79T5-M&NX^9W M3['BMKX8^)OAF*33M&G62S8DAHI8BHSZ>9@J>_%=9\/_ 3JOAZ66\U?4Y)9 M7!"6L"2?;_ .MWU%4F)N^AY3X_\':]K?C>SU'3K#SK2.*)6D\Z M-<$.2>&8'H:]&URVEO/#^HVL";YIK:2-%R!EBI &3Q6A14V]WE'S>\I=CS7X M5>%=:\-RZHVK67V83K&(_P!ZC[L;L_=)]16-XA\">++#QM/KOAM5E,LK31N) M(PT98?,"'P#U/K7L=%-N[3["3M?S,WP^FIQZ%:IK+J^HA3Y[*1@G)] !TQTJ MU?V-OJ=A/8W2;X)T*.OJ#5BBAZB6AXS_ ,(#XU\(W\TWA6^6>&4XP&16([;E MD^4D>H_2K.D_#?7]>UN/5O&=V&"D$P;P[/@_=^7Y57Z>O:O7:*%H-NY@^,M- MN=4\':CI]A")+B6(+'&&"YY'&20!TK"^%OA[5?#FB7MOJUK]GEDN-Z+YBOE= MH&?E)]*[NBA:-ON#=TD%>6?%'PAKOB/6;&XTFQ^T110%';SD3!W$X^9A7J=% M*VJ8U*QCZQ8W%UX0O+&&/=[8KF=[GCVG^$? MB'J]A'HVLZB;'2$ 1E9XW=D'8%,D_P# C5[X;^$=>\/:EJD&IV+P6EU#L6XC MN$R""<8VMD9!)SCC%>IT57?S%?2QX[<>"?'OAW5YKWP_J;WHD^0.\RF0IR0' M$GRG']:C7P!XS\6ZG!<>++M888CM(+H6V\9"K'\HSZ^W>O9J*2T&Y-F)XA\/ MKJ_A*ZT2W80AX1'$3T4K@KGVX%>>>"O#7C[P[JL-F52'1_M DN/WL3"0< XZ ML,@#TZ5Z]10M'<5_=Y3RWQ?\.-3DU]O$'A>X6*Z9O-:'?L82=RIZ<]P<=3ZU MEMX2^(_B:]MSKE]]CCMS\DOF1@KG@E5BZG''..O6O9J*$K#X7J2S$<_C5GX=:-?Z#X1BL=2@\BY65V*;U;@GCE217 M644+KYDO9+L%5M1L+?5-.N+"[3?!.A1Q['T]ZLT4FKZ#3MJ>,+X&\=>$+Z<^ M%KM9[>8]5:,$CMN63Y<^XS5_PQ\-]8N?$:Z_XLG1YE<2^3O#L[CIN(^4 <<# M/3TKUBBFG;4&[Z'G7C[X=3Z_J$>L:-.D&HJ '5V*A\?=8,.C#^@Z5S<_AOXH M>(5ALM5N/)MHF#K))-$ ".A/EY8D=>:]IHI)6'S,Y>?P[=6GP]O-$AN)]0O' MM9$$DTG,CL#T+'@>@SQ6-\*_#6K^&[#48]6M/L[S2HT8\Q'R #G[I->@T55] M6^Y/1(\IO/!VO2_%U=<2PSIHN8Y/.\Z/[H4 G;NW=1Z5ZM1126B2!ZNYR7Q& MT;4->\)26.F6_GW)F1@F]5X!YY8@5P>D^"/'OAO3$N]$N1!=3 BYLF>-L$,0 MI&.>H(KVFBDE:_F5S:6/)?#'PXUJ\\1+K_BV8&5'$HAWAW=QTW$?*%&!P M/TJ[\1_A]J.OZE'K&CNC7*QA'@9]A.W."K'C/UQ7IM%-]/(.9W;/'W\'?$#Q M-IKP>(=2\J"%"8K4^%?!VO:;\3;K5[NP\NP>6X99?.C.0Q.W@-GG M/I71_$W0M2\0^&(K/2[;[1.MRLA3>J?*%89RQ [BNSHJ;>ZH]AJ34G(X'2O# MFK6WPCGT.6TVZDT,RB'S$.2S$CYL[>_K1\+?#>J^'=)OX-7M/L[S3!D7S$?< M-N/X2:[ZBJOJWW)Z6/(H/!?B+PM\0FU/0=/^T:6TG*K-&O[MOO)AF!X[?05Z M[1126R0V[NYR?C_PE)XNT-+>WF6*Z@D\V(O]UCC!4^F?6N$TCPI\2DLO["-Z M-/TOE2[2QMA2>=I7+_AD?A7L]%)*UQ\SL>2>"O!&O>%?'CSM9&72RLD(NO-C M!*GE6V[L]0.,5+>>#M>E^+JZXEAG31=YT?W0H!.W=NZCTKU:BJ3U3["; MO?S.>\:QX-U"PL(?.NI54(FX+G#@GDD#H#6+\,_#>HZ%X;O;'6;,0O-< M,WEEU<,A11_"2.QKNZ*2TOY@V[)=CQF[^'GBOPOKLE]X0GWPN2% D1653SM8 M/\K ?C]*JZ_\//&VL6\>I:A*-0U-W">0LJ*(H\$]3M7KV6O<**5M+#YG>YD> M%K*XTWPMIEE=Q^7<06Z)(FX':P'(R.*UZ**IN[N0E8X3QU\.(/%4@O[.9;74 ME7:68'9*!TW8Y!]QGZ5RXTWXN:?#]BMKEIX%&!()8&./9G^:O8Z*E*Q?-W/& M-.^#VKZC?-=^(M45=[;G\MS+*_U8\#Z\UW7CW0KS5O!$FEZ5 9Y@T01"ZKE5 M([L0.@KK:*;U5A7=[G$>#/#%Y8_#V?1-5MO)GG\Y73>K<,, Y4D5RGPY^'^N M:-XL34-7L1!#!$_EMYR/ESQT5B>A->Q44[^]S"^SRGE'B[P9KNI?$BUU>RL/ M-LE>!GE\Y!C:1G@L#T'I5_XJ^%M9\2'2_P"R+/[3Y'F>9^]1-N=N/O$9Z&O2 M**FVB78KF=[_ ",WP_:S6/AS3+2Y39/#:QQR+D':P4 C(XK2HHJF[NY"5@HH MHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH J:I:2W^E75I!&_A'%H.OVNJ2ZO]K%N MQ98OLNS+8P#G>>G7I7I5%"T=T.^E@HHHH$>5WOP86?5I[VUUTVRO,98XQ:;O M+R<@ [QT^E=3XQ\&R>+](LK*74A;R6[AVE$&[>=N#\NX8ZYZFNKHI6TL/F=[ MGD'_ HS_J8__)'_ .V4?\*,_P"IC_\ )'_[97K]%,.9GE&G_!;[#J5K=_\ M"0;_ ")4EV?8\;MI!QG?QTK7\8_#+_A+-<_M+^U_LO[I8_+^S;^F><[QZ^E> M@44/4+O<\@_X49_U,?\ Y(__ &RC_A1G_4Q_^2/_ -LKU^B@.9GEFD_!K^R] M8LK_ /M[S?LTZ3;/L>W=M(.,[SCI7?Z_X?T_Q)ICV&HQ;XSRKKPT;?WE/8UJ M44/5687=[GBNH_!&_60G3-6MI4+<+F1_.LCP/X!_X0R>\E_M/[9]I55QY' ME[<$_P"T<]:[.BA:;#;NK!7%>*?AEHWB6Y>]#265Z_WI80"KGU93U/TQ7:T4 MFK@FUL>4V/P0LHIPU]K,]Q$,?)% (B?J26KTO3-,LM'L(K&PMT@MXQA47^9/ M<^]6Z*J_03U,S7= T[Q'IS6.I0>9$3E6!PR-ZJ>QKSF3X'6QNMT6NS+;Y'[M MK8,^._S;@/TKUFBIMU'S.UC"\,>$=+\)V;0Z?&QDDQYL\AR[X]3V'L*W:**I MNX@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5D_Y"47^[ M_C5JJLG_ "$HO]W_ !JU4KJ7+9>@44451 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 >?>-/^/N#ZR?S%-/^/N# MZR?S%H]_:NBKQA'>*19(V*NIRK X(->B^&_$B:I&+:Y(6\4?02#U'O[5X.-P7) M^\I[?E_P#Z_+,S]K:C6?O='W_P"#^9T5%%%>4>^%%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%8FM>+]"\.W,5OJM]]GEE7>B^4[Y&'_$$S0Z9J4<\P&?+*LC$>H# $_A6O_9%UN#SI9ZI?\ V>X= M ZIY,CY4DC.54CJ#65\1/$]GHOANZM3>&&_NX&%LJHV6Z D$# X/]:MXAT;P["G]IW\-J-OR(QRQ ]%&2?P%4U9:BMK M9&K17-:?\0/"NJ7*V]KK$)E8@*LB/%N)Z %P,FNEI""BN:U#X@>%=,N3;W6L MPB520PB1Y<'T)0$ UKZ9K&G:U;FXTV]ANH@<$QMG:?0CJ#]:-P:MN7'=8T+N MP55&2S' IU>$?$WQ:NI^(H+.PU*1].M\">(*R+YJN=V00-V,#U'I7K5CXPT M'4=)N]3M;_S+.S'[^3R7&SC/0KD_@*%K'F')-.QNT5DZ'XETCQ)%-)I-W]H2 M%@LA\MTP3T^\!4&L^,M \/WJ6>J7_P!GN'0.J>3(^5)(SE5(Z@T>0MS=HK*U MOQ)I/AV"&?5;O[/',VV-O+=\G&?X0:H7/C[PO9FV%QJ\2&YC62,;'/RMT+8' MRYS_ !8H'8V+[5],TLH-0U&TM#)G8+B=8]V.N,D9JTCI+&LD;*Z, RLIR"#T M(-W%TR:=% M%&JS,C,2I "D@#//':CI=AU5C6HK /C;PVND1ZHVJPI:2EA&SJRLY7@X0CA^(69=+U&*X=1DQX*/CUVL <>^*!&S14-W=V]C;/KPO<$[51E9-Q]%+ !OPH\@\SH:*P].\7Z%JVK2Z78 MWWFWL6[?%Y+KC:<'DJ!U]ZW*/,/(**** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHKR/XB:C+XD\9:9X/M7/DB5#<[3U8\_^.KD_C1U2 M74:6C?8]GI0M;VZ#LDDWU/=:*\#U*P\3_"O4;:>WU$W%A(Q"@$^ M4_T2TU.WXCN$#;L?_ *"*%JK^8WHTB_169<^(M#LYC#=:SI\$HZI+=(K# M\":T(9HKB)989$DC;D.C @_B*!#Z*H6VNZ1>79M;75;&>Y&?W,5PC/QUX!SQ M5R::*WA>:>1(HHU+.[L%50.I)/04!Y#Z*IV.JZ=J@)989$DC895T8$'Z$42R MQPQM)*ZQQJ,LS' 'U- #Z*P[_5M-U/P]JGV#4+2[VVLN[R)EDQ\IZX->:_ [ M_C^UG_KE%_-J%JVO(;5HW/9J***!!16;_P )#HGVK[+_ &QI_P!HSM\K[2F_ M/IC.:NW/-I,1_P \S_*DW97&EK8EHKQ'X)?\A_4_^O8?^A"O:;BY@M(6FN9H MX8E&6>1PJCZDU35K"ZM$M%4['5M-U/=]@U"TN]OWO(F63'UP:N4@"BL^\UW2 M-/E$5[JMC;2'^":X1#^1-6K6\MKZ$36EQ#<1'H\3AU/XB@":BJ,^M:5:WJV5 MQJ=G#=.0%@DG57.>F%)SS3H]7TV6^:QCU&T>\7[UNLRF0?5(=7F<(H_$U7L]*A75],:P^WKJ-H;/G_2!.OE\=?FSB@"[15:RU&QU*,R M6%[;W48."T$JN ?J#5F@ HK-_P"$AT3[5]E_MC3_ +1G;Y7VE-^?3&ZC!P7@E5Q^8- %FBBB M@ HHHH **** *LG_ "$HO]W_ !JU563_ )"47^[_ (U:J5U+ELO0****H@** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / M/O&G_'W!]9/YBN7KJ/&G_'W!]9/YBN7KZ7+_ /=H_/\ -GP^<_[[/Y?D@HHH MKN/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z/O_ ,'\ MSHJ***\H]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ#XV_\C#IO_7J?_0C7 MM]>(?&W_ )&'3?\ KU/_ *$:E[KU-*?7T_R-B]^&FB6OP]GO7CE?5$LS*KF[756EEL;(*RVPD95+OD9X/'"]L=J]>U__ M )$#4?\ L&O_ .BS7 ? WIK?_;'_ -GK1?'(B[]FFO^-O#MGXBT81:AJDFGVL+>8[AE5#QQNW=A]17EWQ M%_Y*Q:?6W_\ 0JU?C?+=A])A!<61#L0.AD&.OOC^9K.]Z:OW-+?O/D9FK6?P MSTWP_+:07,E[JRPD)<0F0[I,<'KL SVYXK3^!]Q)YFL6Q8F(".0+G@-\P)_E M^5,'B[P78>"'M-(LE&JW-IY!B6V/F;V7:2SD<\D]":;\#RHOM94_?\N(@9[9 M;/\ 2M(_%+T(E\"]3F-/T5/$/Q1N],ED>.":]G,NPX)569B/QQ71_$[P-HGA M[0K74-)MWMW\\12*96<.""<_,3@\=O6JW@?_ )+-??\ 7:Z_FU=?\9_^1+@_ MZ_$_]!:L]J<;>1HG>JU_6S*^G72>RL0/T JK\#_\ D&:O M_P!=H_\ T$U9\,6LM[\#I[>%2TKV]P%4#))W-Q7*_"SQCI/AI=1MM6F:W2XK1_P 27H96]Q6[B_&7_D=+/_KT3_T-J[WXF:)IU]X0N=2N M;??>6<'[B3>PV99<\ X/XBO*/'_B*#Q/XI2^LTD%FB+#$[KC?M))/YM7L_Q! M_P"2>:K_ -<%_P#0A6;_ (/S-/\ EY'T.$^$7AG2-5L)M3O;3S;RTO%,,GF. MNS ##@$ \^HK8\5^$/"__"2?VQXA\0.BRMO>TFD +J!PJ[<, /8'\SFF_!+_ M )%S4?\ K[_]D%<';W]A%\3KNX\6Q-- +B59!(I8*#S/;?\ ")I*J@,)RV_8>F"-YW9ZUZ#XI\1WEE\(-)DCF=;J_BBA:4-\ MVW9ECGU.,?C7(_$CQ)HNN?8+70( +*SW;I$A\I,MC P.R^@KJ?$&C3:U\&= M&DLHS+)9PQ3%%Y)4*5;'TSG\*E_PWZE_;B,\ ?#C0M5\*0ZEJL#W,]UN*XE9 M!&H) QM(R>,\YK6\(_#B_P#"OB22_BU9#9,73[.$),D?\.X\ $<'H?UK)^'_ M ,1M#TKPK#IFK7#VTUJ6"'RF<2*22,;0<'G'-3^%/'OB#Q/XVEM;2.(Z1YC. MQDB^:*(<#D$I["M'\?NF>O*[G(_$[1=/TKQK!#96_E1W,:S2C>S;G9V MR>2'-*\.?#[7H=)M?L\"=;CT2=KEUM65AY3*=Q4D+@@9/':LO^73MYFC_B1^ M7WG-? __ )!FK_\ 7:/_ -!-<_\ &7_D=+/_ *]$_P#0VI/A9XQTGPTNHVVK M3-;I.4=)!&SC(R""%!/<5C>/_$4'B?Q2E]9I(+-$6&)W7&_:22?S:M=ZD/D3 M!6YK^9W?QK_Y .D?]=V_]!K/\#_##3M1Y[\<%"W& MB*HP!'* !]4KHO'?_)'U_P"N%M_-*Y[XX_\ 'SHO^Y-_-:Z'QW_R1]?^N%M_ M-*G_ )=OU+7QQ]#E_AEX&TKQ%I$^I:Q&]RJRF&&'S655 )/RD'JWK6/+8)X M2^+]M9Z>[K"EY"$!;)V/MRN>_#$5Z+\'O^1%'_7U)_2N&\7_ /);(/\ KZM? MY)6NU6*_K8F.L)7_ *U+WQDU2YNM=L-"B"_"$R/X^F>0'>;:4OD=#N7->]5H_A1$OC=@HHHJ M1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 '@9KQ#X?F"_7@"IU4)LKK! M,\[\-Z=IWC/4;[4O%GB-+4[@%#W$<;N3D\;^BCT [TX74/P_\<0-H>LQW^F2 M[#*8I5<,A."K;3C<.H/'6CX>VO@^\>[M/%$<4=P"&AEGN'A7'=20P&?K73_9 M_A.=;&EQV,DLI=426&:>2-V;LI5SG\N]:+22L)NZ=RO\<"#<:(1T*2_S2N_N M],OM8\"6MAI^H?89I;6(&;86.W:,@8(QGUK@/C>H6?1%48 CE _-*U/B)J]_ MIGP[T:.RE>$7*1QRR1D@[1'G&>V?Z5GIR/U#7GCZ&,?AOX7TC3G'B#Q.D.H# M<0L,R!0,G'R$%C[]/3WJO\&=1N(O$UUIRS,UI+ TFS/R[E(PV.QP35SPE;?# MRS\*Q:GJ.I6 V@VLA4#_>6M(_&U MY"EK"_F2^(X3X*^+<&I1J4M9YA<>VU^)!^K?F*[KXM:N+#P4]NCXDOI%B7'= M?O-^&!C\:J_&+0_M_AF+4XDS-8298C_GFW!_7:?SK@IM2E^(&K>%='^9C!"L M=P3Z@_.W_?"@_C4)YEE(6-KN-)#_ +3;\GGZ=J],^)NDO>> ;F*T MBR;4I*J*/X5X./H,_E7GO@"R\!ZEI$D7B%;>+4(G.7N+MX0Z'ICY@..1CK3O M>4G_ %8G:"&^$=3;PA\1!HUIJB7VDW,RQ%XG#(^X#:PP2 P) ./>K7Q*U._\ M1>.(/"]I*5@C>.()T5I&P2Q]< C\C6SH47PQN_$L5GIEA-]NBG_<.'F9&9>0 MP.XC''?T]*YWQGO\,_%R+5YXV-L\T5RI ^\H #8]Q@_I1HW!2#^9K>QMZQ\* M8M"T"XU'2-5O1J%O S/N*A9%Q\P R,C/!)JK\#O^/[6?^N47\VKL/%'CSP] M%X3O)+75+6YFN(&CAABD#.2PP,J.5Z\YQ7'_ ._X_M9_P"N47\VIQOS/T%+ MX%ZGLU>1_&'Q)>17%KX>LY6C2:/S)]IP7!)"KGTX.?7BO7*\0^,MA-:^)K#5 M0A,,L(3=VWHQ./R(J7;F2>UQPZVW-.?X+6Z^'R\-]:7QPNS.>O'I5'P3XUO_&%CJ#7.F1V\=O'CSXW)5W(Y !'X]?2B5[2 M7D*-_=;[G&?!+_D/ZG_U[#_T(5G:SJ0\=?$![+4]5CL-(@D=$:6155%7(R,D M#>*O <-U:W0M+VZMROG[-VR0?*Q R.X./2N)U6U^$NDR0(\$=SYN?FL[ MN28(!W;;)Q_.MKQ+=V_A[X5&;PNLEM:R!?);YPR*[9+#=\P)S^O%2W[CN&\E M8YI/ACH6FBXD\5>)DCF9R8S'.D988R2P<$DY/0?UK#^'MX=*^)4=EI]X\UA/ M+)"6' F0!BK$?@#6AX L_!$^DS:AXBN;=]165BZ7DY''8A<_/GGUYK*\(SV= MU\7;>>RC$5G)=RM BKM 7:VT8[<8JXZ32!ZP;+'Q7DEA^(GF0,RS)#$R,O4, M.A%=GX0^%1T75[/6M0U(7%Q&IA^S@_G M7N]33T@GYL51ZV\CS/Q9\/;G7?$G]J:MX@BCTL-CRR/+,,8'1225SD#G 4%^=QX/<]:E:1BT:?: M:9W/B^]EU'X*17D[%IIH;=G8]VW+DURG@'P*/&.C-/JFH7:6%M(T5O!"P&&^ M\QY! Z^E='XAQ_PH>TP=V-K M/X'^+%OI]K+_\ DMD'_7U:_P DJQ\9;":U\36&JA"8980F[MO1B >9 %E+M&H&64\8QZ<^M69?B)X=3PZVIQZG;-*(=RVID'FE\<+LSGKQ MZ5G>#O%M_P"/-+U."YTV.VC6'RO/C<[6=@00 1^/7CBFV_>L9K5+F/-K"2#X M@^++FZ\2ZU'I]FBED$DZ)@9X1-W'3J<'I[T:[;67@;7;'4/"GB".\1L[@DZ2 M,N,95]G!4Y]!TJ#P99>'HO$=UIGB^W5 8T:65XUCD4\@E2,9]3QQ78:A#\) M-.U!+1K7S]R[O-M;B66,<]"5<\_2A:JZ=>)J.F6M[&,)<1+*H] P MS_6K-5M/MK:STZVM[.,QVT4:K$ASE5 X'S<]/7FK--VN[&2V"BBBD,**** * MLG_(2B_W?\:M55D_Y"47^[_C5JI74N6R] HHK \9^(AX8\,W.HJH:<8CA4]" MYZ9]AR?PIMV5R4KNQJWNI6.G1B2^O;:U0]&GE5!^9-+9:C8ZC&9+&\M[J,<% MH)5.X9-?\0ZE=%)G*Q["-[X/)R00%!R ,?E4FN_#G5_"FIV M>H>$9[VY9GVX&-\9Z_,1@%3CN!ZW4,X'F-R%O&VE^+A<_V>ES&UOC>L\87@]#D$CL>^:R]7 M^*WAG2;MK827%Y(A*N;6,,JGZL0#^&:'H"39V]%8?AWQ=HWBB)FTRZW2(,O" MZ[73ZCN/<9%5O$GCC3/"U_:6=]#=.]T,HT*J5'..A^M)OW6T.VJ3)['5]-U0N-/U&TNS'C?]GF63;GIG!..E7*\U^%7_"- M>;JG_"/_ -K9VQ^=]O\ +_VL;=GXYS[5U7B3QIHGA8*NHW#>>Z[D@B7<[#UQ MT'XD54K($FW9'045QFA_%#PWKMXEI'+/:3R-MC6Z0+O/H""1^9%=G2L(@N[V MUT^W-Q>W,-M"" 9)I B@GIR>*+2]M;^W%Q9W,-S Q($D,@=3CKR.*X[XM?\ M(@77_76+_P!"%.^$_P#R3^S_ .NLO_H9HCK?R&U9)]SJ[[5-/TQ4;4+^UM%< MX0W$RQAC[9(S5F.2.:))8G5XW 974Y# ]"#W%>5?'#_D':1_UUD_D*WI_'&G M>$/#N@IJ%K>R"XLHRCP(K#A5R#EASR*%JF_.PVM5;M<[FBHX)X[FVCN(VS'( M@=3[$9%625D0(54XX.[//;@4/31DK571UE%<)! M\6_#,VG37CF[@\M@BPR1KYDAQGY0K'CW) J]X<^(V@>)KL6=M)-;W39V0W*! M2^/0@D'Z9S18+:7.MHJ"\O+;3[22ZNYDA@B&YY'. !7#2?&+PNEWY*B^DCSC MSU@&SZX+!OTH\AV>YZ!15+2]6L=:L$O=.N4N+=^C+V/H0>0?8URT/Q4\-O-? M1SM=6OV0D,9HU^<[MN$"L23^'2AZ.P)7.VHKBM%^*?AO6K];)'N;261@L9NH MPJN3V!!./QQ76WU]:Z992WE[,L-O$NYY&Z 4/1786UL6**\\D^,WAB.X,:PZ MC(@./-6%=I]^6!_2NST;6]/U_3UOM-N!- 3M)P05(Z@@\@T=+B>FYH45PJ?% MGPX4O6D6\A-J<%9(US*:L*[3[\L#^E;EYXZT>+PG)X M@MI9+FT5A'^Y4;U<\8(8C&,BDW97"SO8Z7>GF>7N7?C=MSSCUQ5.?6M*M;U; M*XU.SANG("P23JKG/3"DYYKQ+P#X\CTK7+^YUM[V\N-0\M%D3#$')ZY88'/: MK?CMUC^,>G.[!55[4EB< #<*JVL5W';?R/<**X2X^+OA:WU$VHDNI4!P;B.+ M,8_72..:72XK.]C:HK)\.>(;/Q M/I"ZE8K*L+.R;90 RD>H!(_6LW4/'>EZ?XIA\.M!>3WTK(H,**44MTR2P/3D M\=*+:V%TN=117*:I\0=&T?Q)_8EZMS'-M#-.57RE!7.2=V>GM2^'/B#HOBC4 MYM/L%NUEC4N#+$ KJ#C(()QU'7'6A:[#::W.JHKD=?\ B3X=\/736D\TUS6_E? M8/+QC(SNW_ATKT62YM[/3S-Y;EE=3D,"3@@T+5V!JT6_0]D&LZ6=0_L\:E9F]SC[-YZ^9G&<;< MYZZLV=@JM=1@*2?=2Y''%#TU8DFW8VJ*X:\^+/ABSM;>7 M?;\9V[?7]/>@ M+,ZFBN2\.?$;0/$U[]BM7G@NFSLBN4"E\#)P02/PSFNMHL(**** "BBB@ HH MHH **** "BBB@#S[QI_Q]P?63^8KEZZCQI_Q]P?63^8KEZ^ER_\ W:/S_-GP M^<_[[/Y?D@HHHKN/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "G([Q2+)&Q5U.58'!!IM% )VU1Z/X;\2)JD8MKDA;Q1]!(/4>_M715X MPCO%(LD;%74Y5@<$&O1?#?B1-4C%M*/H)!ZCW]J\'&X+D_>4]OR_X!]? MEF9^UM1K/WNC[_\ !_,Z*BBBO*/?"BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#UOPA MH7B.XBN-6L?M$L2[$;SG3 SG'RL*W**!WL5[BQM[K3Y+&:/=;21F)TW$94C! M&1STK/T/PMHWAKS_ .R+/[-Y^WS/WKONQG'WB<=36Q10+I8PM1\&Z!JVK)JE M]8>;>IMVR>=(N-O3@,!^E:>HZ99:M:-::A:Q7,#TL/+OW9V:7SI#DM][@MCG/I5S6M"TWQ#9+9 MZI;?:(%<2!-[)\P!&YK1HHZ6'=WN4M*TFRT33H[#3H/)M8R2J;V;&3D\ ML2>IK(O? 'A;4+XWMSH\+3EMS%&9 QSG)52 ?Q'-=)11UN*]CGM0\#>&M36V M2ZTJ,I;*4A2-WB5 3GHA ZUKZAIMIJNG2V%[%YMK*NUTW%H7L84O@SP[-HXTEM*A6R#B3RXR4)8# )92"3CN36CI6E66BZ? M'8:?$8K:/.Q"[/C)R>6)/4U+<3W(0@ M$UL:9I&G:-;?9]-LX;6+.2L:XW'U)ZD_6KM%"T!N^YFZSX?TKQ!;K!JME'@JQ?Z%INIZ.-)O+ M;S+$*J^5O8<+C'(.>P[UHT4>07ZF?H^B:?H%C]BTRW\BWW%]F]FY/4Y8DU1O M/!GA^_UM=9N;#S-05T<3>=(.5QM. V.,#M6]11UN'D<+\1/$=[X?@B\S1;?4 MM'N$*3B4'Y7SP">1@CIQUKB=+\:> =)Q?6?A:YBU+&X L)$1O]EF?CZA17M[ MHKH4=0RD8((R#67_ ,(QH'G>=_8>F>;NW;_LD>[/7.<=:215U8\P^#FDWH&/UKV2D5510JJ%4# & *6J;V2Z$MMMM]0HHHI M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7CWB&#_A$/B]8 M:T1LL;]\N_8%AL?/YAOQKV&LW6M TOQ#:+:ZK:+<0J^]0692#Z@J0:%I),:> MC3ZE;Q/X7L?%NFQV5]+<1Q)*)08&4'(!'<'CFN2_X4IX;_Y_=5_[^Q__ !NO M188D@@CACR$C4*N6+' XZGD_C3Z++H',['):#\-O#>@7"7,-M)U<+O/N""/Q JQX=^'WA_P MU.MS:6\DUTH(6>X;>R_3 'ID"NIHH6FPVV]SFO%?@?3/%\EJ^H3W<1M@P3[ M.ZKG=C.Z1IGBAM?LY[R*X9V8PJR"+YAR,; M:Y,A"(OD0$C@D\L1].!^)KT+4O OAO5]4;4K_3%FNV*EG,K@-@8&5#8/3TK MNXD[:HX?2OA1X9TN[E-PJJ_VAU;&,XQA1ZUTU%%PW"J> MIZ78ZS8R66H6R7%N_5'_ )@]0?<5J[4GB;;(H^O0_0@UOT4/7<$[.YP MNF?"3POIMR)W2ZO2I!5;J0%01[*!G\M?#W2==\0QZU=7%ZES'LPL3H$^4Y'!4G]:ZR MBBA:*PGKJSI<6URYS(]JX7>?4@@C/OBHY?A;X9?1?[,C@F MA!D61KA'!F8@$M9*1B0NOF ! MMP&=N,9]NE7O#?ARS\+:3_9UC)/)#YC2;IV!;)^@ [>E:]%5??S$()[B]6[62.0(CH(\IC'!4GL.]=#J>EV.LV,EEJ%LEQ;OU1_Y@]0?<5< MHI=+#N[W//?^%-^&/M7F^9J&S.?)\Y=GT^[N_6NWTS2['1K&.RT^V2WMX_NH MO\R>I/N:MT4>0GJ)IS&]"N MTNHX9KN>-MT;W3AMA]@ !^8KLJ*%IL-MO<****!!1110 4444 59/^0E%_N_ MXU:JK)_R$HO]W_&K52NI(?$OPP$VFZGI#7-AO)0EBJY/=),$8/7&,_2F:EJ' MB3XK7]I;6NFFTTZ-BV_EHU/0LSD $@= />KD^9WB2H\JU.Z^+A#> 964@@SQ M$$=^:S/AAX2T2[\'1WU]IUM=SW3ON:>,/M )4!<].FIP>2?J>:U?A5_R3W3_]Z7_T8U**7O\ R&V^6)P/PWB6P^*NH6=O ME8$%Q$%SGY5?@?H*S;C1HM?^,EUIMP2();V0R;3@E5!8C\<8K5\!_P#)8]3_ M -^Z_P#0Z31_^2^3?]?4_P#Z+:B&KA?LRI:<]O(ZSQAING^"/A_J8T&V^R&Z M9(W82,QY.#RQ)'&1^-4_A?X/T6?PG%J=]86]Y<73/S<1B0(JL5 / Z9SUYK MM_%6AKXC\-WFEEPCRKF-CT5PB>,-?^&]M)H^K:(\L"N3#OT;6_'7C:+Q-K%HUK8P,KHK*5#!>45<\D9Y)Z=:9\;?\ MD-:3_P!<&_\ 0J+:03[E)IR;78ZC7?!.@V'PYNUCTVW%Q;V9E%R(QYI=1G.[ MKR>W2LGX0.Q\'ZXA/RK(2!]8_P#ZU=QXK_Y$'5?^O!__ $"N%^$'_(I:[_UT M/_H%$O\ EYZ?YD1^&'J5O@=_K];_ -V'^;UF>'K6'Q;\7+]M63[1%&\SB*3H M0AVJI'H!CCVK3^!O^OUK_=A_F]5-?TO6/ 'CN7Q'I]F]SI\KO*2%)4!N61B/ MN\\@_3WJY-*<6^P;J26YVFO?"S1-9O[>YML:8(U(=+.)4#G(P?0$<]N<^U=O M#&8H8XR[R%%"[WQN;'.?%OC;4[2'PW9SV"H2KF*3>N3W=BH 'M7 ML]I'-#9PQW$QGF5 ))2H7>V.3@<#)I)/E%+>>$ M_"7C/5O#\-WHWB#['9,S!(?MLT>"#@_*H(ZUZ'\6O^1 NO\ KK%_Z$*=\)_^ M2?V?_767_P!#-3%?%\BF[*)Y5XX\.^)]#MK-]?UG^T$E=A$OVJ2780!D_.!C M\*]!\9:*-5^$MC.BYGL;6&=/]T( WZ<_A5+XX?\ (.TC_KK)_(5Z#H,23>$M M-BD4,CV4:L#W!09HU<'Z_H#=I1?D<+H?BP0_!B>[WYN;*)K0>H8\)^C+^5)\ M,]%%C\/]2U)UQ-?1R$$_\\U4@?KN->;WUEJ6GZM=^#(V/ERWZ;5_O'D*?Q# M_@*^A);*+3?"LMC H6*"S:-0/0)BB;O"4^Z_37\02Y91AV?ZZ'C_ ,(?#NFZ MU?ZA=:C;1W(M501Q2KN3+;N2#P?N]_6E^*>BV?AGQ!IFH:1"EHTH,FR(;55T M(PP X'4=/2L?P#K.M>'GOM4T[3S?V2!$NX5)! .=K< D8P><'K6C-+K'Q9\4 M6CK8M;:?!\C,"62)=T!E9B.3OZC\#67\3O!UQXAT:UF MTV/?=V.0L0."Z'&0/<8!_.N5MOBQKVGZ?'I-SH3/JJ((TDD+*Q/0$Q[ M?^';S6--\;:EJ&C6ANY+9I7G@'5XM^"!CGJ0>/2FM)*_1 ]5+E[G4_%[PQI6 MEV%CJ6G6<-I(TWDND"!%88)!P.,C'ZUUKR:/K?PSTZZ\43E+5H(WD?S&4LX& M/X>6)].:\[UW7];^*&H6FF6.DM;Q0/EU#%PC'C<[8 SV]>M=9\2?"][_P@ M^E6>F1R7$6F[5DCC4EF 7;NP.O\ ]>EM!WZL>\DO(P+O5?!9\-W6F:%X8NM1 M>.%E^WM:KN4X)WF3[PQUZ <>E:OP/D8V&L1D_*)(V ]R&_P%9.D>--.KJUOU9[6+S9G0,5WX; &1R.3V]*];UCPYX2TKPB] MA?I]BT=)/-($SY+_ %R2Q]N?TKSWX2_\E!U7_KWE_P#1BUU?Q>T?4=5\.VLE MA%).MM,7EBC!+$$8W8'7']:EZ4X^B+>M5G*W>J^"SX;NM,T+PQ=:B\<++]O: MU7^"SKY>O6+,%G(0[3UQ\P/ MY$C\Z;7Q>A+V7J4/@WIMAJ&H:J;VRMKGRDC:/SHE?86$^D2SW%R5B,9)1EPQ^8#:=PY/^-:OC MC_DLNF?]=+7_ -"%/1RAV_X .ZYSHOB3X4T+3? DL]EI=M;S6SQA)8HPKG+! M3N/5N#WS5GX>62:U\*3IURF[ S^M>CW?A_2/ OAG5]2T.S\B[6T8>:9&3?"3 MPOI>K6%[J^IVL5[-YYA1;A0ZC@$G!X).>I]*H_$[1K7PEXBTK5M%C6S>4E_+ MB^55=".0.P.>@XXJ+2M4\0_"F\O+2]TIKK3Y7W!LE48] RN 0,CJ#STZ5(+? M7?BMXEM;NXL6L](@P-W.T)G) 8@;F/3CIQ5[RBXBVYN8F^,LWVBXT"?&/,MV M?'IDJ:W_ (PWLL'@VPMHV(6XF428[A5)Q^>/RK$^-BJFH:(BC"K#( /096NV M\?>&9_$_@](+0!KRW*S0J3C>0,%?Q!_/%2_@=OYAK24;]BIX+\$>'V\%V+76 MF6UU-=P"66::,,^6&< ]5QG'&*X7X?V*:9\7)[&,DI;M<1*2>PR!4WA_XCZ[ MH6F)X=;0I+F_@!C@#;E=1V#)MRV/J.*@^'L%[;_%=H]27;>[9FF&+=,U[PY\1'\46FF?VA;,P=3Y9D5 M?EVD,!RI'8].GTJ.#_DX)O\ KNW_ *)-;OBSQ9XR\+^(C*]A%Z'''HO?B7/F M?: J_7TKK?B5I[Z5\+M)T^1Q(]M+#$S#H2$8&B7P?, M)G6]Q2:C;1W,=K"&2*50R%B< M9(/!XS^=>F_#_P#Y)GI__7"3_P!":N&^"'_(7U?_ *X)_P"A&M'_ !'Z&5W[ M/YE/7M/MM%^,^G1:=$EM$]Q;N(XEVJNX@$ #H#S^=>ZUXIXR_P"2V:5_UUM? M_0J]KJ(_PU\_S*G\?R04444$A1110 4444 %%%% !1110!Y]XT_X^X/K)_,5 MR]=1XT_X^X/K)_,5R]?2Y?\ [M'Y_FSX?.?]]G\OR04445W'DA1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5?T?3KO4;]([3*NI# M&7H(QZYINEZ7<:M>+;VZ^[N>B#U->GZ7I=OI-FMO;K[NYZN?4UP8O%JBN5:R M9Z^6Y=+$RYY:17X^G^?ZEJ)62)%=R[!0"Y&-Q]:?117S9]N%%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 445Y"GQ@O[76M2M;ZPMI8H&DCM MTMT8/(X?:H)+$8QG/%*^MAI-JYZ]17CK_%GQ+IEZC:UX<6WLY#\J-%)%(1[, MW!X]A^%>I:?K5CJ6BQZO;S#[&\9DWMQM ZY]",'/TI]+@UK8T**\CNOBUK6I M7\L'A?0?M4<9SN>*25V7UVH1M_6K?AGXK7=WKL6C^(-,6TN)9/*#QJR;'/0, MC9(^N?PH6H-6/4:*\\^(OCS5/".H6,%A!9R)/$SN9T9B"#CC#"L:T^+>J:KX MJMM/TS2[9[2>58E$F[S&SU;(. ._0\"B/O; TTKL]6/KR*Q4^+7B+2KV./Q%X>2")^=HBD@?&>2-Y.?T^M"=Q MN+1Z]//%;023SR+'%&I=W8X"@=2:Q?#OBW3O%%Q?)IOF/#:,JF9A@2$Y^Z.N M..]87Q!UV_'@F.YT6T^UVU_$1,_DNWEPLA._@_+]3Q7FGPZUSQ!I-S+!HVE? M;+>XFB%S)]GDD\H9(SE2 .">OI3BKR:?],37N\QZ;XJ^(O\ PC/B2WT?^ROM M/G(C^;]HV8W,1TVGT]:[FO"OBS(L/Q#LI7.$2WA9C[!VK9U;XJZ^JF^TKPZR MZ0#@75U!(1(,X!W A5_6IB_=&XOFT['KE%<;H7C6;Q1X1O\ 4-,M4CU2U0@V M\N70N!D=,$@_AS5+X=>/;OQ;/?6VHPVL-Q JO&(%90R]#G+'HR6PBMY;JY9B1.K%0@'/0CG)'ZU3\4^-]=\.>$]&U%K:Q-] M>\S1M&^Q,KN W9STSR:F^E_D5RO8]$HKQ>;XSZI+/9PZ?IEK(S*@F#J^7D. M,A &X&>!G-=SXN\>VGA&R@%Q!Y^I3(&6U1\!?4EL<#.1TYIO17%9WL=?17CA M^*OBVW1;^Z\-(NELC^%O%5AXLTS[79$HZ';- _WHV]_ M4>AIV$]#"N/B+Y'CY?"_]E;LS)%]I^T8^\H.=NWW]:[FO-[KX@:K!\35\-+; MV1LC<)%O*-YF"H)YW8SSZ5T7C/QG:>#]/266,SW4Q(A@#8W8ZDGL!4W]U,II M\S2.FKA/"OQ'_P"$F\2S:/\ V5]F\M';S?M&_.T@=-H]?6N=TWXK>(<"^U/P MXQT=CS<6T$@"#/7"9AGT+"G%7E;R!JT6SWBBBB@ MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *LG_(2 MB_W?\:M55D_Y"47^[_C5JI74N6R] HHHJB HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ KFO&VKZ[HVE0W&@:<+ZX:8))'Y#RD+@G.$(/4 M#\ZZ6BDQIV/)/ ?A;7;_ ,7R>*O$=O)"XW/&LR[69R,#Y>H 'K[5ZCJ:-)I5 MXB*69H' 4#))VGBK5%$E>/*";YN8\L^#>DZEI?\ ;']H:?=VGF>5L^T0M'NQ MOSC(&>HKU.BBJ;N(****0!7D7PWT;5+'X@:M2%%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %7=+TNXU:\6WMU]W<]$'J:-+TNXU: M\6WMU]W<]$'J:]/TO2[?2;-;>W7W=SU<^IKAQ>+5%Y]M"$8148JR04445)04444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %8^N>*=&\-^1_:]Y]F\_/E_NG?=C&?N@XZBMBO'_ (Y= M=$_[;?\ LE)NUBX1NSL/^%I>#?\ H,_^2LW_ ,16UHWB;1?$"DZ7J,-R5&2@ MRK@>I4X(_*N3\/\ PW\)WWAO3;JXTK?//:QR2/\ :)1EBH). V.M>;Z_8GX? M_$.+^RYI"D92:,$Y;:W5#Z]Q]*NUI\C)M>-T>[ZWXATOPY:QW.JW7V>&1_+5 MO+9\M@G&%![ U9T[4+75=/AOK*7S;:9=T;[2N1TZ$ UYY\:SGPMIY];P?^@- M72_#]TC^'NDR2,%18"69C@ ;CR:E:IM] ?2W4ZBBN!O_ (O^%[*X,,?VR[P2 M"]O$-OYLPS^%;?AOQQH?BEFBT^=UN%7&W1[J[P<-);1@H/Q M8C/X9H"S.[HK/T;6]/\ $&GK?:;<": G:3@@J>X(/(-<[!\3?#\NK7NGS&XM M6L]_FS3JHC^1MIQAB22>@Q1L[ E?8[*D9@B%F.%49)K@H_C#X6DO?LY-ZD>< M?:&A&S]#N_2NW$\%Q9>>CB6W>/>&0Y#*1G@_2D]KA;6S,O1/%^A>([B6#2;[ M[1+$N]U\ITP,X_B45MUYU\.[[P==ZI>+X:TF\LKA8096G^)OAW0+UK.6 M2>ZN$.V1+5 VP^A)('X TRZ^*7ARWT:'4XWN+B*27RC'"B^9&V"?F5F&!QUY MI7TN.S.THJII>HPZOI5KJ-NKK#O>O=O#WB*S\2:,NJ6B316Y9EQ. K#;US@D8_&A?#<B MN%U/XM^%].N#"DES>E20S6L8*@CW8@'\,UN>'?&.B>*%8:;=9F1=SP2+MD4? M3O\ 49%"UV!IK2UF12_ MEW:A"5 R2""1P/?-,+,ZVBN"E^+_ (6BO_LP:\DC!P;A(1Y?\]WZ5V]K=V][ M:1W=M,DMO*H=)%.01ZT=+B:MH345PVJ_%GPQI=VULKW-XRDAFM8PR@_5F /X M9K?\/>+-'\3PN^F76]X_]9$ZE73Z@]O<9%"UU0VFMS:HJCJ^LZ?H5@][J5RD M$"\9;DD^@ Y)]A7&P_&+PO+=^2XOH4SCSY(1L^O#%OTHW=@L[7/0*KB_M#?F MQ%Q&;L)YAA#98+G&2.PYK+UKQ1IVD>&SK;,]S9L%V-;88MN. 1D@?K7B'@/Q MC:>&O$%[J6J+=W'VB(IF,!W+%@N",USOBKQQIWA"6V34+6]D%P&*/ BL.,9!RPYY%#T=F2M=CIJ*H7FKVMCH MW5687"*N0<],,?3]:.M@Z M7.FK"U7QCH.B:E'IVHW_ )-W(JLL?DR-D$X'*J1U%4M5\?Z5I'B6'0)+>]FO M)2BCR44J"YX!)8']*P?&M_X+M_%UK%KFD7MUJ1CC,ASVH6K M79C:LGZ'H[,J(7=@J@9))P *AL[RVO[9;FTF2>!\[9$.5;!P<'OR*\L^,?B2 M$6L?AZ+[2ESN2>1A@1M&0PVGG)YP<8QQ5_X6^,-/N=,L/#20W0O88G9G95\L MC<3P=V>_I1'WKA)62.ND\8Z#%KXT-[_&I%Q'Y/DR?>(R!NV[>A]:W:\*U21( M?CN)975(TNXF9F. $7DFNXN/B_X6M[[[,K7DR X-Q%"#&/S()_ 4+6*?5C: M:DTCO:*K6&H6NJ6,5[93K-;2KN21>A']/I5F@D**X^X^)6A6GB.?1+E;J&6! MF$D[JHB&U=Q.=V>@].M2>'/B)HOB?57TZPCO%F52P,L0"LHZD$$X[=<=:%KL M-IK'/#]VUI-+-=7"'$D=J@;8?$"/^>[]*.M@L[7.]HKDX?B'HUQXJ3P]#'=/-=-\8?:O[/@NXOLVW?]H15SNSC&&/H:%J%M+D\ MGC'08M?&AO?XU(N(_)\F3[Q&0-VW;T/K6[7AFH?\E\3_ *_8O_0%KU_7/$.F M>'+(7>J7(AC8[5&"6<^@ Y-"^%2?4;7O.*-2BO.T^,_AEYQ&T&I(I./,:%-H M]^')_2NCU+QCI-EX5/B".22ZL6PJM;@%LDXZ$C&#USS2>BN%G>QLB_M#?FQ% MQ&;L)YAA#98+G&2.PYJQ7SIX#\8VGAKQ!>ZEJBW=Q]HB*9C =RQ8')W,/3UK MWZYU>QLM)_M.\G6WM-@]8NT5Y\_P 9/"Z77DJE^\>0 M//6$;/K@L&_2NRTC6=/UVQ6]TVZ2X@)QN7@J?0@\@^QI>8GIN7Z*Y36?B#I& MA^(HM$O(KOSY-G[U53RUW' ))8' [\5FO\7?#@NY[>&'4;@Q!B'A@!63')V_ M-GIDY( P#2N/E9WM%MPJJ2#G!&&/'!J3Q3XNT[ MPC:07&H)/()W*(D"J6X&2>2./\:;TW!*^B-^BJ6D:E'K&DVVHQ0S0Q7";T28 M -M/0D D<]>M7:&K;B"BN)UCXJ^&=(NWM?,N+R6-MK_98PP4_5B ?PS5KP[\ M1?#_ (ENEM+6::"Z;.R&Y0*6QZ$$@_3.:%KL-IK.M,\(36T6H07 MDK7"LR?9T5@ ,=QRQQ&4F=$"X! [,>>:\E^(_B M>#7/%D36_P!I6WLOW+1RX WJYW%0"1SQSP>*.J7?\BE'?R/?[R\M]/L9KVZD M\NWA0R2/@G:H&2<#FJ&A^)=(\2132:3=_:$A8+(?+=,$]/O 5S-SXML/%WP^ M\0W%A#,(H&YG.T\ #K0 MMW<5M$UW/:Z*XS0OB?X=UZ_2RB>YM9Y#MC6Z0*'/H""1GZXKK[BXAM;>2>XE M2*&-2SNYP% [DT/3476Q)17 7GQA\+VMQY48OKI?^>L,(V_^/,#^E=3H7B72 M?$ELT^EW:S!#AT(*LA]U//XT+4;5MS6HKE_%/CO2_"-U;V]_!>2/.A=3 BD M XYRPJE)\4O#B:XFE(;J:1W$?G11!HPQXQG.3SQP#0M=@::-B3QCH,6OC0WO M\:D7$?D^3)]XC(&[;MZ'UK9N+B&TMWGN)4AAC&YY)&"JH]237G=U?^"Q\35M MI=(O6U[[0@%T'/E[]HP<>9TQC^&N5^,'B2'4=3AT>W^THUB["<-@(Y(4J1@\ MXYZ@=:5]%YE*-Y-'ML5S#-:I"Z62PLXUF,JJ%;"[3M(8GMWQ5'X=WW@Z M[U2\7PUI-Y97"P@RM.Y(9=W09D;O5M>\UT(^S?J>BT5@^(_&.B^%D7^TKD^< MXRD$2[I&'T[?4X%9&C?%/PSK-VMJ);BSE=MJ"[C"AC]02!^)%2M=AM-*YVM% M1SSQ6T$D\\BQQ1J6=W. H'4DUP=Y\8O"]K<&*-;ZZ4?\M(85V_\ CS*?THOT M!)L] HKGO#GC;0_%#&/3KD_:%76IN (T@8@A]IY.&7C&>]:WAFXTU_"EE<:5;RP:?Y1:&*0Y95R>#R M??O0MFWT&UM;J;5%<1IWQ6\-7]O=3N]S9QVP4G[2B@N3G 4*Q)/%1Z?\6_#% M_?"U+7=KN;:LMQ$ A.>.021^(%'6P6:.[HH!R,CI10(ANKNVL;=[B[N(H(4& M6DE<*H_$US,GQ+\'QSF%M:C+ XRL,C+_ -]!0746<%H7# 'T..AJW7S[J5O?_"OQM&UEV5@I M7Q)K,EM9[VTS3C MM++]UG)P6/X\#\?6O1_A'_R(4'_7>7^=*.J;'-6NGVSW-Y<100( M,M)*P51^)J>O-/B;X7\2^)KVR338TDT^(#*>:%.\DY8@D9 &/?DTG?9 DGN= M%%\1_",UU]F76X1)DC+HZI_WV5V_K73HZ2(KQLK(PRK*<@CU%>7^*/AGX6D'F"X:9B9&'8@G;S[ 4SX4:W/!X)U=[EF>WTXM)'D]!M+%1^( M_6G=6?D%MK=3N]9\7:#X?D6/5-2B@E//E@%WQZE5!('O5G2-=TO7K8W&EWL5 MS&/O;#ROU!Y'XBO&OAYX=MO'.M:KJ>OA[I4()7S&7<[D]P0< #I0(!\/_BY! M;63NMC.Z+L9L_NY.,'UP>GT%-+5)[L&E9M=#V^[O+73[9[F\N(H($&6DE8*H M_$USL7Q'\(S77V9=;A$F2,NCJG_?97;^M<[\3?"_B7Q->V2:;&DFGQ 93S0I MWDG+$$C( Q[\FH/%'PS\.:7X+N[FWBDCO+2#S!<-,Q,C#L03MY]@*F]ES,?* MKI'J".DB*\;*R,,JRG((]163K/BK0_#Y"ZIJ4-NY&1'RSX]=J@G'X5Q?P8O[ MJY\-WMK*Y:.VG AW?PAADCZ9Y_&F6GPH>[\47.I^([V/4+>;(0W]EZC#<,HR4&5<#UVL <>^*UZ^>=:M+?P]\ M3K>#PK(Q*2Q[$1R^USPR9ZD>N?4U]#4*SBI()*TK!5>&_M+FYGMH+B.2:WP) MD1LF,GH#Z'CI7.?$'Q'!X>\,S^8+@2WB/;P/!C*.5."3D8'N.:\O^&'C*P\. M2W=K?174LM_-$L;1*K 'D?-EA_>]Z4?>;0-6C<][HK/UC7--T"Q-YJ=TEO#G M )Y+'T ')/TKCH_C'X7>[\EEOXX\D>>T(V?7 8M^E 6=KGH-%5[&_M=3LX[R MRG2>WD&4D0Y!JQ0(**H:OK.GZ#I[WVI7*P0+QD\ECZ #DFN4T[XL^&-1OA:& M2YM=QVK+,M UO4GT[3K_SKM S-'Y,BX .#RR@4 M2>,=!BU\:&]_C4BXC\GR9/O$9 W;=O0^M>3?"H@_$B[(.089L$?[PKKKJ_\ M!:_$U;:72+UM>^T(!=!SY>_:,''F=,8_AIK7E\QR5G)+H>D45GZQK>G:!8-> MZG;Y*;<>OW\X_#/M0*SW/1**S MM%UW3?$-B+S3+I9X<[6P""I]"#R#69XC\=:%X7<0W]PSW)7<+>!=SX]^@'XD M4/3<$K['245Q.C_%3PSK%VEJ);BSED;:@NHPH8_520/QQ6QXI\6V'A&S@NK^ M*YE2:3RU%NJL0<9YR1Z4/3<+.]C>HJCHVJP:YI%MJ=LDB0W"[D64 ,!G'."1 MV]:P+'XAZ3J'BIO#L5O>K>++)$7=$$>4SGG=G'![4[:VZBZ7.MHK(U_Q/I/A MFV2;5+H1>8<1H 6=_H!_.N2A^,WAF694>#4H5/622%2H_P"^6)_2DM1V>YZ) M1533]3LM5L([ZQN4GMI!E9%/'OGT^AKD-3^+?AC3;IH$>ZO2I(9K6,%01[L1 MG\,T/1V!)O8[JBN5\/?$/P]XDN4M;6XDANG!VP7";6;Z$$@GOC-=51804444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X+X'@MY_B_/ M]H"DI/]5\W:99:I??$2\719EBU"*YGFA+="58G'XCCGBE% MVG\F5O!GL'Q1MX)_ &H-,%W1%'C)[-O X_,C\:POA'J"6?@/4+B\DV6MKBO;1!P9"D#1QN1W9V)! ZX!_#BO0K/P4ME\.YO# M4;'!D;G/TS@?04*ZC)]QNWNQ9S-AXXUG7[VY'@WPM:JN566[N"%R M.<;L%?4\9/?UKA]735D^*%L-:>!]0-U;F0VX^09VX X'08K3\/1^/_!-W%]-M8(PBK;H6P,98@ M$D^Y->;_ !?TC5-5U/2Y=/TR]ND6!MQ@MW?:2>AP.#7JVG(R:9:(ZE66% 01 M@@[12AI!^HIZM>AY]K/C])?%']E>'= CU35(69!<28&U@,':>N!R"5VC>*(RJ MRL22KJO(_3ZT>+-&\=>)M/BUC5=/(\IA'#8VT1+J&Y+;!DCH!R9>%(?''@[5+BRM= FD%RZ+*[V[.@"YY5P0O0GJ:V_Y> M2\S+_EVO)COBW$)OB#9Q'H]O$I_%V%>N^(X(D\&ZI $41+8RJ%QP $.*\T^) M.BZK?^/[&YL],O;B!8H0TL-NSJ"'8G) Q7J7B&*2?PUJD42-)(]I*JH@R6)0 MX 'GX M!OY5M?!S2-2TN;5SJ&G7=H)%BV?:(6CW8W9QD#/6I/C/I&_3+'6XOEFMI/*= M@<':W(/X$?K6DGRRC(E*_-'N9.OQMXR^,D&F8WVED520'D;4^9_S)V_E6I\; M@!HNE # %PW_ *#2?!S3))EU/Q%=Y>XN9#$DC#D\[G/XDC\JN?&'3-0U/2=- M33[&YNW2=BRV\32%1MZG XK.2Y8QB5%WFW\C:^&>GPV/@33VCC"R7"F:1L;Z^JZG\;TMK\!X/M<,>QNA7:I ^A/\Z]9\%6\UKX,TF"XADAF2W M>.12K*?0@\BN1^(W@"^U?4(]=T(C[>@421;MK,5^ZRG^\/Z"KD[5%+L1#6+7 M<]&NK>&YLY;>=%:"1"CJ1P5(P:\3^#DCQ>,M0MX7+6[6SY]#AUVG]3^=6KCQ M!\3M2LVT8Z+-%(ZF)[E;1D9AT/SD[!GU&/:NR^'?@<^$K"6:\9'U*YQYA3D1 MJ.B@]_4G_"B*M)R\AOX>4X+4/^2^)_U^Q?\ H"TWXN,T_CVR@G8B 6\8'/ ! M=LG_ #Z5HWVB:J_QL2_73+UK+[7$WV@6[&/ 1GU-2M(P?9E/XY+NCNC:6YL#9^4GV;RO+\O'R[,8QCTQ M7AOPE18_B%<(ARBV\H4^H#"M.RU;XG7]A_8*Z6\/R^2U[/;M&P7IG>3M/'< MFF?#'PYJVC>.[@WFGW<4$<,L8N)+=T1SN&""1CG&:J/QW\B7I3L>TT444B0H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JR?\A*+_ M '?\:M55D_Y"47^[_C5JI74N6R] HHHJB HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH \^\:?\?<'UD_F*Y>NH\:?\?<' MUD_F*Y>OI+;VZ^[N>B#U-&EZ7<:M>+;VZ^[N>B M#U->GZ7I=OI-FMO;K[NYZN?4UPXO%JBN6/Q'K9=ETL3+GGI!?CY(-+TNWTFS M6WMU]W<]7/J:NT45\Y*3D[O<^VA",(J,59(****DH**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ KQ_XY==$_P"VW_LE>P5X_P#'+KHG_;;_ -DJ9=#2GN_0IZ7X MV\?VNC6=M9>&#+;1P(D,HT^=MRA0 V0V#QWZ4:%X'\2>*/%*ZWXFA>WAWK*_ MF@*[XZ(%ZJ. .P_Z_!_Z MU5;NTO+SX#6D=DCNXB5W1!DL@@8D@C'XUG^&KBX_P"%MVEWJ=N;2>YN6E,4 M@(VF125'/^\*TBO?0/X)%WXP1F;QY;1#J]K&H_%FKT#7/ OAZT\#WT,.EVRR MV]H[I<>6/-WJN\3?\BKJ__7E-_P"@ M&L_^73^92_BQ7H>:_ Z9\:U#D[!Y3@>_S#_"N7T71K;7OBS<65XA>V-[L_P/_P EFOO^NUU_-JU_Y>+T,WI&5NYL_%OP MUH^G>'+2]L-.MK29+@1$P1A-RE6/('7H.:Z;X!+J>RTNUMIK78TNJ_#W6M/< MX6YFDBSZ9C49J-6I^A>EHM]S(^$?AK3];N-1U'5+>.[\DJB1S+O7F?%[PQIVC7%A?:;;1VJW.])(HEVID8(( X'7M5+P?XEG^&^MZAI^LV4YB MDP)$C W*RYPRY(!!!]?2H?B'XKF\6BSNX+&>WTJ)GCADF !DS>"/^1(T7_KT3^5;S*KJ58 J1@@C@BL+P4I7P3HH/7[)'_*MZ MKG\3,8['@6LZ;8Q?&F*PCLK=+,W<"FW6)1'@JN1MQC!KMOBG<1^'_!":?I=O M%9Q7DXC9;=!&H7!9N!ZX&:XWQW,V@_%R/5)HG,(D@N!CJZJ #C_ODBNR\0^5 M\3O ,EUH\,RRV]P6BCFVAG*CD<$CD-QSZ5GO27X_>;/2I?\ K83X;^"]$/A. MVU"]L+:]N;P%V:XC$@09( (P.E<7XWTZ/P+X]L[W1@8(V5;A(U;A3N(9?\ M=..GO6AX-^)T7AC2/[%UNPNRUJQ6,Q*-P&<[65B,8.:I;+[XJ^.H[I+1X--A MVH[GD1QJ_MFM-ZB:V_0A:1?,>[HV^-7_O &N9^(O_(@:O\ ],D[3QGD5S?B30;-/BF^C6\8AM)KN% B# 0/M) ].IKOO@E_R M+FH_]??_ +(*Y7Q)_P ERA_Z_K7^25K;]Y%"3]V;.E^*'A;1-,\%I<6&FV]M M-!,BK)$@5F!X(8]6_'-9%MJUS8? =O*D97EN&M@PZA61^-8ZN,_E^A2T#-%TR1=;T6:_OI')+M;QRHJ]@NYACOVJ'0]8L+3XGVEYH,4]OI\]RD:P MR@ A7PK#@GC))'/I6SX'^(D7@[3Y]%UFPN_W4I9/*4;U)ZJRL1CGG\:ZSPC\ M1-5\5>()+6#1$&GAB3<;R#$F.-W!!8^@Q^F:U7Q)HEZ1:9QWQ?U)KGQE;V$[ MO]CM8D)5.N6Y8CWQC\J75_$_P\O/#TVGV?AZYM[@1$03BWC5U<#@LX?<1GKG M-:GQ277'WL M$# ]/6O%O!GB*'P+XKOVU.VN&78]NR1*"ZL&!Z$CT-:7]_7L1O!V[GT2JJB* MB*%51@ # K@OB[I/]H>#3=J,R6,HE'^Z?E;^8/X5V]GV-O=1@A)HUD4' MT(S_ %IFI64>I:9=64PS'<1-&P]B,5G-.S[A!I-/H>.ZGXF\_P""-E;[\SR2 MBR;V"'=_Z"%_.J7PZ6X\,_$&VLKS*?;K0>P^9!(O\L5R6GZ==W>OVOAZ5G ^ MV^6T?96)"L?R7]*]!^,5E)INJ:/K%F3$PC, =1]TKROZ$_E5\UGS]_\ +_,K ME_Y=]O\ ,@\&H?%/QW]R/\ 3G\*@^*G_)2=/_ZXP_\ H;5U M7P9TD6GAFXU)A^\O9L*?]A.!^I:N5^*G_)2=/_ZXP_\ H;4TN64(]B6^93?D MSI/C196H\.VMZ+:$79NEC,XC&\KM8[=W7'M6S\,]+T^/P;I=^EA:K>O&X:X6 M%1(PWDC_$S M_DGNJ_[J?^C%J7_"7]=BUK6MZ&)\%YWD\'W,;$E8KQ@OL"JG^9->CUYI\%/^ M15OO^OT_^@+7I=:SW^[\C%=3YU\0Z:-8^+=UIQ8JMS?+&S#J <9(_"O4]2\/ MZ/X%\+ZOJ>AV?V>[%J4$QD9VYX'WB<Q(X/YXK'_ )%]'>ZG\0Z9-J,[D"(>2DJ M*.Y(=AR3[=JAUC7=(3Q?:ZQX8M9[&*-DD:)T50'!YP%8@ C''UK;\&>+)?AW MJ&H:5K=A<>6[AF6,#>C#C(!(!!'?/:NLTGXI:CX@\4+8:1H?G6;LN&D8H\:_ MQ,Y&0!_GG-:K646A/12N4?C7JUU*TB:62Q+>8BC)\ML9./ M8@?G61X>^+UK9>';6PN].NY]0@C$,?DA2DN.%R]N/B[;2W\1BO M)+J22:,_P$JQ(_"M;XQ6%U:>*;+5UC8V[Q(JR8X#J2<'\,'\Z<7;V;8Y*[FE MV/5_%G_(GZS_ ->4O_H!KSGX&]-;_P"V/_L]+K/Q2C\1^'YM(TG2KQM0NX3' M)N"[44CYB""2>,]0*3X&]-;_ .V/_L]."UEZ$R^!+S,O4/\ DOB?]?L7_H"U MWOQ T[PC/##=>)KF2!T4I!YAN M[;QE:7\\+2V1B01[A\A*DEE_SZU"^""*?QR]$,\4:WX4U+PU<6WA_P +2+Y1 M4#4%M5C$>".2PR3D''S8ZUT'PCMK?4/!>IVM[;PW-N+LMY.U9OB M;XAP>*/#$NB:'H]V&:,//E%VPQIACC:3QQU.*U_@I)&_AS4X 1Y@N=S#O@H M/Y&JMI/T$]H^IRWPDTVPU+Q-?Q7]E;74:VQ94GB5P#O7D BKOQ?O9;GQ'INA M1'R[:*-6"#A=S' ./8#]36%X,\10^!?%=^VIVUPR['MV2)075@P/0D>AKJOB MEH5UJD.G>+-,BD=/LZ>:J#+(OWE;CZG/IQ0VK0?32X[-3DNNMCN;7X?>&+?1 MUT]])MI1LVM.\8,K'N=_4'Z&O,O 4D_AKXIW&AQR,UM))+;LI/4*"5;Z\?J: MW;7XV6*Z.OVG3;EM25,$(5$3-Z[LY /T-4OACX?U#5?$T_B[48FCC+.\19<> M:[YR1G^$ GG_ -4K\]^A+TIV9A_%B)I_B&8E^\\,2CZGBO5]"^'WAW0C%-; MV.^[6(QM/)(S%LC#'!.T9YZ"O,OB-S\5[3ZV_P#Z%7NU1#^'\V$V^;Y(\.\& MA_"'Q9N-&D;$,S/ ,]"#\T9^O0?C5CXB,WBGXDZ;X>@)*0[8W*_PEOF<_@N/ MRJW\8--DT_5-*\2VORR(XC2Z_TSUJ"&.W@C@B4+'&H10.P P*)XTF@DCESY;J M5;#%>".>1R/K4E8WBRWNKOPEJMO9!C.@^HXI2>C9$5JD>;BZ^&/ MAO4)UMK235YWVQB$1"X13_LE^"3QR"?;O7&S7$3?$FTN;/2Y-*C:\@9+5UVE M.5YQC@'KCIS6C\/?&FG>#C?QZEITTDLI&V6%%+KC@J=Q&!_G%4=4U:?4_B#9 M:[>V;V<%S<0S1++WB5@H;/?[O6KC\<2G\,CJ/CA_R$='_P"N4G\UKU?2?^1; ML?\ KTC_ /0!7FOQLTRXF@TS4XHV>"'?'*P&0F[!4GZX-,L/BU#_ ,(U;:9; M:9=S:P(%MT"@%&;&T$'.[WQBLU\$EUN#7O1?2QD?!G_D<[W_ *\W_P#0TJ+X MK6-I:>.+-+:U@A26!'D6.,*'8NV2<=2?6IO@W&\/C6^BE!61+1U8'L0Z9J7X MSP2P>)]-OMC>6UN%5NQ96)(_45HVDX,>\IGI'B33+#3/ NN)86-M:(]G(66" M)8PQVGDX'->;?"#PUINL3:A>ZE:170M]B11S+N0$Y))!X/0=:[&;QC8^+_ 7 MB*2RAN(OL]FRN)@H))0],$\<5D? _P#Y!FK_ /7:/_T$THKWI7[$-^XO4Y;X MI:79Z#XQM7TNWCM5D@2;9"NU5<,1D <#H.E=+\9]7G33=+TV-BL=SF:7!^]M MQ@'VR2?P%8WQJ_Y&RP_Z\Q_Z&U=7\4O"]UKGAZROK")IKBR4EHE&69& S@=R M,#CZU'_+M>IK]M>AI^%? ?A^U\,6:W.F6MW//"LDLT\0=B6&>">@&>U>=) ? M!'Q@BM-/9EM9)XXPA;.8Y,?*?7!/&?05M>'?C!::=H,%CJUC=O=VR")7A"D. M ,#=D@@^O6L_PGINH>._'[>)[NV:&QBF$V<94E#OA[H-AIFE:E-9^=J8C2"?^@BHIZ1;\QSW2\CQ?4/\ MDOB?]?L7_H"U<^-EE:V]SI=Q#;0QS3^:99$C :0C9C<1R?QJGJ'_ "7Q/^OV M+_T!:VOCA:RO9:1=JC&.-Y(W8= 6"D?^@FI_Y=Q+7\1^AVWAS2]/LO"MK<6E MA:V\TUBAEDBA5&?Y ?F(&3SZUYI\$O\ D/ZI_P!>P_\ 0A78>!O&ECK^CKI, M,$Z7-E8+YK2!0K8 7Y<$D_B!7'_!+_D/ZG_U[#_T(5J_XDK=G^;,?^7:3[HY MHZWIMU\0;K5?$<,]W9B=SY,:@DXX12"1P.._:K/C77?"&MVD#:#H\VGWD;_, M1!'$C)@\$(QYSCM6A?K>_#7XD/J3VK2V,TCLA' >-^2H/36DVRX!J7BOX)1I;;I;PQ!2H/S M2"-\$>Y(7\:X+POXIT30;5M/UOPG;7DBNVZ>2)6E!_NE7';ZCZ5[5JNKZQ8> M%!J<.C">_"*\MFLV=@[X('S$>@KSF+XI>']7M67Q3X=6><.=AAA20!>W+L"# MVX_3I5-^](B/PHZ?P5?^ M0OM^A64-KJ/S,(YH]LHSUVDDCIGA3P/:N^KY]\ M'6!USXDQ7^AV$EGIL$_G$%B1$@[$^I]/?T%?05/HF0_B:/,_C9_R*]A_U^#_ M - :NA\"_P#)-M-_Z]6_FU<]\;/^17L/^OP?^@-70^!?^2;:;_UZM_-JC_EW M/^NA;^*!Y+\+- LM>\42C4(%G@MH#+Y;#*LV0!GU')XK6^,.@:9I,VEW.G64 M%H9A(DBP($4[=N#@<9Y-+\$O^0_J?_7L/_0A6E\B>%)GG\(Z/+(27:SB))[G:*U)P3;RA?O%#C'TK(\'?\B7HO_7E%_P"@ MBMNJJJ[DO4RAHD>!_!UE3QS*K\.;60#/KN7_ ->^5X7XL\/:MX&\7?\))I$ M1>R,IF5U7*QD_>1P.@.3S[^M1^+/B-;^(;.RN+*;5=-U.URRQQ%3"Q.,_,&# M=O3\.:GFO%&CC>3?1FG\<6C-YHR#'F".4GZ97'\C5_7_ !1+X?\ AEHNF6[- M_:E]91HFW[T:;1D_7G _^M7FTFN-XE\265UXGO'-NNR.62.,9"#V'KSG'KT[ M5ZQXB\!67CV>SU?3M;CAM%MEAB$=OY@(4GON&.N,8[4N7W+=V.ZYEY+\3GM< M\*#PO\(769<7]S/%)%_ ?KFNN^$?_(A0?\ 7>7^=>>>+_A?_P (KH+Z MI_;'VK;(J>7]FV=3USO/\JV_A-X/WM:^*?M^-C2Q_9O)Z\%<[MWOZ547=R(D MK11[%39)$BC:21U1$!9F8X ZDTZO(?C%XIGA>+P[:2%$>,2W17JP)^5?IQD M_A4-V'&-V9_C/Q=>^.=33PYX;BDEM"WS,HP9R.Y]$'O]:[,>&$\*_"O5=/1A M)<-:2R3R+_$Y7G'L ,?A7G/A'XAV'A'3O(M_#@EN7_UUTUWAI#_WP<#VS7IO MA/Q:GQ!TS58)-.^QHB"%AYWF;@X8?W1CI5./NM1'?WDWL;' M_(UA_%#YOB=IXC^_Y< XXYWFH/"VNR_##Q%J6G:U9SM%* ,P@9.TG:RY(!4@ MGO4^CK<_$/XGKK*6TD>G6TB2$L/NJGW5)Z9)'3W/I5)\TXM;":Y8R3_JY[C) M(D4322.J(@+,S' '4FO$_&?BZ]\0=&<]<>PX ^E7?$.E/K MF@7FF)>,C/'O6#X-\:-XWL]1V61L&@"H&$WF'+ \_=&,8K MS^Q\:^(/!GC"X@\4R7MY"5,97=QC/RR1@X4Y_#]*J6KM+J1%-*ZZ%2XLKSX2 M>*K6) M?#7QG9^%);ZVO[>X0Y?P_F6O&KR>*/BQ!HL MTK);1RQVR@'H" 6(]SG]!7IM[\/O#-UH[V":3:PG9M2>.,"53C@[^I_'K7GW MQ)T74="\7P^+=/B9X"Z2.P&1'(N!AO8@#GZUHWOQKL7T=Q9Z;=+J+I@"0KY2 M,>^0TUY M9\(O"EWIXN-=U")XI+A/+@C<88KG)8CMD@8KU.M)=+[F;LY-K8\0^,-W->^+ M=/TD/MACB4@9XW.Q!/Y 5Z*?AYX:_L+^S1I=OGR]OVGRQYV['WM_7.>?2N,^ M,7AZ[:YM?$-HC.D,8BGVC)CP25;Z<8]L]ZS7P-=;FCOS)K:QSGPBB,/CZ:(G)2VE4_@RBK&H?\E\3_K]B_\ M0%J#X2)+'\09TG!$RV\HD#=0VX9S^-3ZA_R7Q/\ K]B_] 6M%\4"9[3L;_QG MTG4;VRT^^MHGEM;7>)@@SLSC#$>G!Y[5SNF>-_!DFGI9ZMX-MH_D"--;1(S' MC[V3M8'\2?>O1/'OBS5_"EM%<6.DQW-NX(>X=R5B?L&4=O?/M7#:GX_\%ZSI MKM?>%W?4GB(++&BC=C_GH#NQ^%9IV3L7O:YZ)X4NO"S:1<7/AF.V2%1F98TV MN" <;P>?7&?>O*?AYI]OXP\=7EYK*"Z 1KEHY.59BP R.X&>GTK<^#&C7J/J M&I31O'8S1"%-W D.?KQBMWXE:-JT_P[T][J1KN]LG62[=5'.5(8X Z D?AS4._+Y7*C\23['5?# MS_D0='_ZXG_T(UY;X9_Y+C+_ -?MU_)ZO^$OBK8Z'X4M]+N+"ZFN[<%(O*V[ M'R21DDY'7' -8W@8W;_%RWDOHFBNI)9I)8V&"I9&;'ZUJM:M_4A*U-IFU\8- M-OX_$-EK+6QN-.2)$.02BL&)*MCH#D5#:>-O 6H0);ZKX/AM,D9>VB0@8[[E MVMC\_P :Z_QWXZU?PG>Q1QZ+%-8R;<7,CDAO[RX ^4XZ9)]>>E<1XG\9>"M: MTBX6V\-R1ZG*ORS>4D>QO[Q96RV/<,^&]:L/"=SR%_F-Q&/,B]@&!!_3ZUWOP MPL-9T3P9J>HI8M-+.1):VLC[#)M'7IQGMZX_&L]/BMIM\]S:^+/#BNJMB.-( M5D*>H82$%=8^'>JZNDEEID%CJ;N&CCN(0OSCILP M2H/H!@^U>EU\X?9K;Q7XZMQX5TN6RM]Z-M_N8.2YQD+] >WO7T?3^RF1+25@ MHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y-X1\&Z M_I?Q(N-6O+#RK%WG*R^=&V0Q.W@,3^E>LT4+1W![6"BBB@ HHHH **** "BB MB@ HHHH **** &N&*,%.&QP?0UXMJ/A/XD^*IH[36Y46UC?#0-$M=,MB3';IMW$I/XDDUHT453=W=DK0*** M*0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 59/^0E%_N_XU:JK)_R$HO\ =_QJU4KJ7+9>@44451 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M<)XNM;BYNHO(@EEVE\^6A;'(]*YS^R]0_P"?&Z_[\M_A7JEK_K[G_>_J:M5Z M&'Q\J5-04=CR,;E$,17=5S:O;HNR/(?[+U#_ )\;K_ORW^%']EZA_P ^-U_W MY;_"O7J*W_M27\J./^P*?\[^Y'D/]EZA_P ^-U_WY;_"C^R]0_Y\;K_ORW^% M>O44?VI+^5!_8%/^=_H?\^-U_P!^6_PKUZBC M^U)?RH/[ I_SO[D>0_V7J'_/C=?]^6_PH_LO4/\ GQNO^_+?X5Z]11_:DOY4 M']@4_P"=_0_ MV7J'_/C=?]^6_P */[+U#_GQNO\ ORW^%>O44?VI+^5!_8%/^=_7*3D[O<]^$(PBHQ5D@HHHJ2@HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ JG?:3INJ;/[0T^TN_+SL^T0K)MSUQD''05V@L[=+>V@C@A082.) JJ/8#@5+10!030])CO?ML>EV2W6<^>MN@?/^]C M-+<:)I-W>+>7&F64UTN")I+=&<8Z?,1GBKU% %&[T72K^Y6YO-,LKB=0 LLU MNKL .1@D9JW+%'/$\4J+)&ZE61QD,#U!'<4^B@"G8Z1INEESI^G6EH9,;_L\ M*Q[L=,X SUIL&B:5:WK7MOIEE%=,23/';JKDGK\P&>:O44 5KW3[+4H1#?6E MO=1!MP2>,.H/K@CK3K:RM;*U%K:6T,%N,XBBC"H,]>!Q4]% %&QT;2],D:2P MTVSM'<89H(%C+#T) H;1-*>_^WMIEDU[N#?:#;J9,CH=V,YJ]10!#=6MO>V[ MV]W!%/ _WHY4#*W?D'@U7BTNVL+">WTFVMK N&*^1"J*'(P&( P>WY5>HI-# MN>(:EXSU[2[W[/XQ\+6&HQQ'8KS6P7)]5<@J0>3P/RK.UG5]7^)EQ86&E:%] MFMK9B%$9+(A.,EFV@ >W>OH"BFO,?-V*FE6*Z7I-G8(VY;:%(@?7: ,U;HH MIMW=V0E8JWNFV&IQK'?V5M=(IRJSQ*X!]@14EM:V]E L%K;Q00KTCB0*H_ 5 M-12&4KW1M+U)E:_TVSNF7[IG@5R/S%68+>&UA6&WACBB485(U"J![ 5)10 5 M%_P!,L[IE^ZT\ M"N1^8JS;VT%I"L-M!'#$HPJ1H%4?0"I:* $(# @@$'@@UG1^'M$BNOM4>CZ> MEQDMYJVR!\GJ=<8EEMT=ACIR1FK]% "*H50 MJ@!0, <"EHHH H)HFDQW_V]-+LEO-Q;[0+=!)D]3NQG-2WVFV&IQ+%?V5M= MQJ=RK/$L@!]0".M6J* (K:VM[.W2WM8(H(4&$CB0*J_0#@56N]%TJ_N5N;S3 M+*XG4 ++-;J[ #D8)&:O44 (RJZ%'4,I&"",@BJ5GHNE:=*TMCIEE:R-U>"! M4)_$"KU% %%M$TI[_P"WMIEDU[N#?:#;J9,CH=V,YJQ=6MO>V[V]W!%/ _WH MY4#*W?D'@U-10'F5K+3K'3(FBL+*WM(V;<4@B6,$^N .M6:** *']B:3]O\ MM_\ 9=E]LW;OM'V=/,SZ[L9S5^BB@"I>Z7I^IJJW]C:W:J9VOQ/CTV=I+WP;IZZL"=]Q&H@;)Z9!0MZ=Z]SHI+0JZML>-_#W0=7U?QO/ MXKU*SDM8=TDJ[U*[W8$84'D@ GFO8)[>&ZA:&XACFB<89)%#*P]P:DHJNB71 M";;=RE::1IEA%)%9Z=:6\% M8]V.F< 9ZFKE%(11;1-*>_\ M[:99->[@WV@VZF3(Z'=C.:L7-K;WL#075O% M/"WWHY4#*?J#4U% %2UTK3K&W>WM+"UMX9,[XXH516SZ@#!IMCH^F:6SMI^G M6EH7 #FW@6/=CIG &:NT4 4+K1-)O;E;F[TNRGG7&)9;='88ZXR#YS6R%\CH7 M8N[K2[*>Y7&)I;=&<8Z?,1GBKKDJC,!D@9 ]:=11TL!X+XH\>:IXZMDT.QT1 MXCY@9TCL^"?#Y\->%K6PD"BXP9)RO=VZ_7' _"NAHH6BMW' M)W"BBB@10FT/2;B\%Y-I=E)= Y$SVZ%Q_P "(S2WNC:7J;H]_IMG=N@PK3P+ M(5'H,CBKU% #3'&8O***8\;=I'&/3%4[/1=*TZ1I+'3+.U=OO-! J$_4@5>H MH I6NC:78W+W-GIMG;SR AY88%1FR:FN[*UOX#!>6T-S">3'-&'4_@ M>*GHH IPZ3IMO9R6<&GVD5K("'A2%51@>H*@8-+8Z7I^F*ZZ?8VMHKG+"WA6 M,,?? &:MT4 4;W1-)U*59;_3+*ZD4;5>>W5R!Z D=*N@ # '0"EHH S[K0 M='OI_/O-)L;B;_GI-;H[?F15Y$6- B*%4# "C %.HH I7VC:7J;H^H:;9W;( M,*UQ LA4>@R.*N*JHBHBA548 P *6B@"BVB:4]_]O;3+)KW<&^T&W4R9'0[ ML9S5J>"&ZA>&XBCEB<89)%#*P]P>M244 4[/2--TY76QT^TM5?[P@A5 WUP. M:;8Z-I>F2-)8:;9VCN,,T$"QEAZ$@5>HH BN+:"[A:&YACFB889)$#*?J#5: MRT72M-=GL-,L[5FZM! J$_D*O44 %9UWH&C7\WG7FDV%S+TWS6R.WYD5HT4 M16]M!:0K#;01PQ*,*D:!5'T J6BB@"K?:;8ZG$L5_96]W&K;E2>)9 #Z@$=: ME@M;>UMEMK>"*&!!M6*- J@>@ XJ6B@"C8Z-I>F2-)8:;9VCN,,T$"QEAZ$@ M4Z^TK3M4"#4-/M;L1YV?:(5DVYZXR#BKE% #(88K:%(8(DBBC4*B(H55 Z M=!3Z** @$$$9![5ER>&M"EG,\FB::\Q.3(UJA;/KG%:E% &-KGA31O$5HMO MJ%DCB,8C=/E>/Z$=O;I6AIUA;Z7IUO8VJ;(+>,1H/8>OO5FB@""\L;34+*+.RM-/MQ;V5K#;0@DB.&,(H)Z\#BIZ* "LZ[\/Z+?W M#7%YI%A5 M>VEO;="^?7=C-7Z* $(# @@$'@@UGQZ!HT-W]KBTBP2YR6\Y;9 ^3W MSC-:-% !1110 A 8$$ @\$&J5MHNE65RUS:Z9903M]Z6*!58_4@9J]10!1MM M&TJSNWN[73+."Y?.Z:*!5=L\G+ 9.:&T32GO_M[:99->[@WV@VZF3(Z'=C.: MO44 (RAE*L 01@@]ZS/^$:T$W'VC^Q--\[=O\S[*F[=ZYQG-:E% " !5"J M!@ =JBNK.VOH#!=V\-Q">L#1=.BE7D2):HK#\0*T MZ* "J-[HVEZDX:_TVSNF7H9X%&>! M_P#DLU]_UVNOYM7N=?.5AI]YJWQ.OM/L[M[1KB[N$DF3JL>6+8_ 8HC\>G9E M?8?R/?EUO27O?L2:I9-=YQY N$+Y_P!W.:OUX/\ $'X=V/A/2;;4=.N[J0-, M(I%G*DY()!! &.E>D>$_$+M\,[?6;YVD>WMY#(Q.2WEDCD^IP*+KE;[ XNZM MU.IN[ZTT^$S7MU!;1#J\T@1?S-,LM3L-20O87UM=(IP6@E5P#^!KP[PUH5]\ M4-?O-1UF^E6VAQN\OJ,YPB9R% QZ?SJ7QCX-F^'DUGK>A:C7UII]N9[VZ@MH00#)-($7)[9/%57U_1H[2.[ M?5[!;:4E8YFN4".1U ;.#7GOC36AXA^#MOJFT*\TD?F*.@<,0V/;(-; R,#YOUHL[M=@LK)OJ>Z76NZ18F,7>JV-N9 M5W1B6X1-X]1D\BG7FLZ7ISHE]J5G:N_W5GG5"WTR>:\1^*^G0Z/=Z%I]O_J[ M:Q$:GN<,>?J>M:NH_#%&\&W&O7NIW<^L?9OM3EF!0\;BIR,GCC.?PI7T;Z)C MY=4NK/8GN(8X#.\T:P@;C(S *!ZYZ8J"QU73M3#&PO[6["_>,$RR8^N#7A7@ M'0;SQK%+I5[JEU'HUB1)Y,;#EVS@#(('0GO^M17>G/X#^)UI;:?=2M&LL15F M.&9'(!5L<'O56]Y)]2;:-]CZ%K/NM>T>QG\B\U:QMYO^>E2M;OHAV2M?J>O(ZR('1@RD9!4Y!JI1G_ .M47Q=>6+Q_ M:R0,5F6VB*,.H8.V/UI_RVZARZM/H>TW>M:5I\RPWNIV=M*WW4FG5&/T!-75 M974,K!E(R"#D&O(-8^$MO;^&+O4YM3NYM6C@:XE9R"CL!DC&-WKSFK7P3U.X MGT_4M/ED9H;=D>($YV[MV0/;C/YTTKW75":T4EL>HW%S!:0M-.OB ]EJ>JQV&D02.B-+(JJ MBKD9&2!N8_S]JC\5:%HOA;['JGA7Q*ES,DH4HEU')(AP2&&S''&#QWJ4]$WU M*<=;+<]4^)>BC6/!ETR+FXL_])B(Z_+]X?\ ?.?TI/AOXF;Q)X7C-P^Z]M#Y M,Q[MQ\K?B/U!K4\,:K_PDGA*SOI@-UQ"5E Z;AE6_4&O+OA#.]CXSU32\YC> M)L_5'P/T)JDK2<7Z_<2]8*7;]3VVBBBD(**** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH JR?\A*+_=_QJU563_D)1?[O M^-6JE=2Y;+T"BBBJ("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@"K:_Z^Y_WOZFK55;7_ %]S_O?U-6JF.Q<]PHHHJB H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH *\O^*?B[7/#>I:?#I-]]GCEA9G'E(^2# MC^)37J%>*?&__D,:5_U[O_Z%4RW7J7!7N>QV$CS:?;2R'+O$K,<=20,U8KQL M:7\1_$FD0:E;:BMA;"(&WM(;AH79 , _*.<]?F/?M6I\-/'>H:KJ$N@ZVQDN MT5FBE9<,=OWD;W'K[&M'K)HBUHIGJ%%>0^)_&>O>(/%C>&?"TI@".T33(=K. MP!W'=_"HYZ<\5G7]UX^^'4UM=ZAJ?]H66+MXL8/]V-<#\:>MVNPDM+GN%<#X]^($WAF_M]*LK57NYU5S-)]U%+$<#N> M#[?6I/!5GX[L+QH?$%Q!<6 !4-)+NE!'0J0.0?\ :.?QZ^4>/M+U?3_%QBU* M^^TRSGS+=_.=_+C9VVKEAQCT'%'VDOZ]"DM'_7S/I =!2URW@?1->T2PN8M? MU/[?+)(&C?[1)+M7'3+@8_"NIILS05@^--1NM)\(:C?6,OE7,,8:-]H;!W = M""*\[\:^-==U3Q4?#/AJ62$K)Y+/"F.AJCXCL_'7AKPM=0ZQ? M1ZEIMV!'(QE:5H23D'^.F MV4!! 29HE3.< LHW,3^7TJY;V78A+=ON>W45XWI'BWQ-X.\5PZ#XHN/M5M*5 M42N^\J&. X?J1GJ#Z=J7Q]JNM>%/'UI?QZE?-ILY2;[/Y[>6<$!TVYQ[_P# MJ7;S#E>J['L=%87B77X](\(7>L0NI_<;H#V9FX7]2*X_X1OJU[87^KZKJ=[< MPEO*A6XN'=1CEFP3CT&?8T+=KL%M$^YZ;17BUUXI\4^/_$<^F>&;HV-E%DAU MS@;AD]AZU&VO^,OASK-K!KUX=1L9N3NE,H89Y*NPW C/0\4+6U]+C M<;7\CM/BCXAU3PYH-IR^ M;)@T?$:\N9-+OCIUE$W&R5HD3T M7WTXJ2'Q5XM^'^NPV'B69KZQDYW,_F$KGED<\DCT;].#0NST&UVU/ M:Z*XOXDZE/;^ 9;[3;R6%F>)HYH)"C;2PZ$<\BN!\.7'CWQCHRVFFZH]O;6N M5ENYKAP\KD[L;P"W (&!V^M"UNNP6T3ON>Y45XIHOB_Q)X-\5IHGB:XDN;9V M"LTK^85#'AU<\D>Q_2K7Q>UO5-+U[3TL-2O+6-K-X='UK4) M;R)Y42599C*"KX 96;D?YXKT#XB>,V\):5$MHJMJ%T2(MXR$ ZL1WZCCWH;L MKCY7S*0Z)\3+S3%U]-;F!=/.6V^U,&9<?Q3:3VF MH[?[0M0"748\U3QG'8@]<>HIVW743VOT.\HKP*W\4^*H_'FHV.F7MS=3S7$U MO;PSS,\,9M5FE@CMX(&C6 M&-3D@'=G<>YX]JQO$-QJWC'X7VFK6%V+,K')+>HLKH)%565E Y!(Z'BN'^' M6A^(-6N99]&U7[';V\T1N8_M$D?FC).,*"#P#U]:J*]YI_UYDNW(FOZ\CZ&H MHKCOB?>W6G^"+FXLKF:VF$L8$D,A1@"PSR.:ENRN"5W8[&BO#?#EQX]\8Z,M MIINJ/;VUKE9;N:X)KB2YMG8*S2OY MA4,>'5SR1[']*JVM@:TOV/:Z*XKX@7_BNWM(8?#-C*X<%IKF(*[+Z*J]<^^/ MI7!ZQHOQ$\.:4VMW7B*9HXBK21)>R.4W''*D;3R>@S4WZC4;GN-G8#(]S]*3PIKNK>-OA]?(MPL&K)NMUN%8Q_-M! M5\J,J>>WI7DVDZ-KEWXXETRSU+R=76656N_/=:2Y$;-Y:OE=K'&&![@5N>#=0NM5\(:;?7LOFW,T6 MZ1]H7)R1T KS_XG6E[8?#K1+74;C[1>17"K+-O+[VV-SEN3^-9_A^T\=>)/ M"=I#HU[%IFFVJ&)&$S1O.P)).Y03UX[#ZTEM+U!J_*]CVVBO'OAQXPUP>*G\ M-ZW<27&=Z*9CN>.1,DC=U(X/7/:O8:=M$^Y+T=F9OB#5AH?A^^U,H)#;Q%PA M.-Q[#\\5Y)HOBKXE>)II+S2?*DMHY KQB.%8U/IE_F/X&NE^+6E:Q=Z1]NL[ M_P G3[:)OM5OYSKYN6&/E PV/>N,^&>A>(=0FCO]-U7[-IUO>(;FW^T2)YN, M$_*HPXI7NK]!&O&"^*_!]Y>*OD7MO$Z3(A^ZVTD,O?![5Y#H/B3QIJ1GTC2[^_N[JZP= MSW#,\:KG.UF.$SD9/'04_M64\\D'J<5U?A?Q0TWPN.KW$S2W%G!(LKNQ9F=,XR3U)&W\Z'HF^P[; M>9W%%>#_ T\6:M-XVM[;4=4O;J&Y1XPD\[.H;&0<$X!XQ^-;/Q#UO5;OQ]I MV@:1J5W:<)&_V>=DR[GJ=I'08ZT[:I=Q6W\CU^BN(\>WGBNRL+>U\,V<\N5_ M?728=QC@ \Y/'-*;6[KQ%,T<15I(DO9'*;CCE2-IY/09J;C4 M;V[GN-%<+X*\57GB3P+>W5VP%[:K)$TJ?*6PF0W'0\]O2O*M!\2>--2,^D:7 M?W]W=76#N>X9GC5O^!O %W?\ B2:6 MYU!IMEM#/,)2N>F6!.>YZ]!VKFM!M_B+XO5M:M-;>WB#$)YD[1QN1U"HH((' M3D?RHZV%;2[-CQ9XRU_3/B5!I-G?^78O) K1>3&_K7K%?-VH7NJ7 MWQ'LVUF%(M0BNH(9@@P"58#/XCGCBOI&B/P+YCG\7R"BBB@D**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O# M/!'_ "6:]_Z[77\VKW.N4TKX?Z5I'B:77[>XO6NI6D8I(ZE,OG/ 4'OZT1TE M<;^%HQOC/_R)<'_7XG_H+4WP;I[ZK\&&L(O]9/#<(G^\6;'ZUUGB;PS9>*], M6POI;B.)91*# P#9 ([@\17DC3"61H&#JH .!N'!))[>E=MX@^'GA[Q'.]S=6SPW3_>GMFV,WU& M""?I_P#0C7I^O\> -0_[!K_^BS57Q3X!TKQ;>075_<7D;PQ^6H@= M0",YYRIK>O--AO='FTR1I!#- 8&92-P4C''&,_A46]QQ-.9<\7V/+/@;TUO_ M +8_^SUD?$7_ )*Q:?6W_P#0J]2\*>"M-\'_ &K^SY[N7[3MW_:'5L;*4C^'=@J?T(_*ND\*^//#]UX8LVN=3M;2>"%8Y89Y0C J,< ]0<= MJ["YMH+RVDM[F))H9%VO&ZY5AZ$5PMY\'O"]U<>;&;ZU7_GE#,-O_CRD_K4* MZ30W9V;Z'"Q2GQS\8([S3U9K2*>.3>1C$<>/F/U(X^HJ;XJ@'XD:>",@PP\? M\#:O7M"\-Z3X;M6@TNT6$-R[Y+._U8\FLGQ!\/\ 2O$>MPZM>7%ZD\2JJK"Z MA2%)(R"I/?UJE9.-MD#=^;S5C6\2_P#(JZO_ ->4W_H!KS'X'?Z_6_\ =A_F M]>MWUG'J&GW-E*66.XB:)BAP0&&#CWYK"\*>"--\'O=-I\]W*;D*'^T.K8VY MQC"CUI1T;;ZH&_ MA^A!K$TSX2>%]-N1.Z75Z5(*K=2 J"/90,_CFE'9)]!RDFVSI?#MOI5IX?M5 MT:)HM.9/,A5M^<,D+=V>BT444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% %63_D)1?[O^-6JJR?\A*+_ '?\:M5*ZERV7H%%%%40 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M %6U_P!?<_[W]35JJMK_ *^Y_P![^IJU4QV+GN%%%%40%%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !7BGQO_ .0QI7_7N_\ Z%7M=>>?$7P'JGB[4+&>PGLXT@B9 M'$[LI))SQA34M7:]2X-*]SL= NX+SP[I]S;NIA:V0@CH,*,C\*\8\)%;_P"- M,MS9G=!]IN9=R\C;AAGZ'(_.MV^^%7B"U$EMH/B(Q:?+DO;2SR1J,]OE!#=^ MH%=;X(\!6G@^*24S?:;^8;7FV[0J_P!U1_7O6E[S<_7\2=H<'O7<:I\-+V>.*WU?X@7$D2!FM7QE\,8]?U(ZMI=X++4#@N&!V.PZ-DG/-84/PF\0:K=QOXE\1>?# M'TV323/CN 7 V_K417NI=BY/5RN=OI_A&RLO H\.ZC="[M-K!IBOE\%BP(Y. M,$C'->=R?";4(V:\\,>(+>X0,RAA(8V&#@KN3()'0]*]0U+PGI6I^&5T!X3' M9QH%BV'YHR.C ^O\^:\Y7X5^+=*=XM#\3+%;L"CV-;KGYS*\'123?"+Q M2D6=V\MQZ!5)_0&J/PZ\.W_B"UO5T_Q3=Z2\+J7@@W?.".&.'7TQ7IGP^\(7 MGA;1KRQU*2UF-Q-OQ"S,NW:!@[E'I7,ZE\)-0L]3>]\*ZS]BWDX1Y'C:,'J MZ9)'MBK?Q7[I$IW5O,9>?"R34=1"7WCEKJ]B50%GBWR*#DC@RY ZUT/Q4T+^ MU/!;SH-]QIY$P;N5QA_TY_"LOP[\*)H=8CU;Q)J0O[E&$GEJ6<,PZ%G;ENW& M*],FB2>%X9%#1NI5E/0@\&IDO=L"E:5SYVU3Q/-JGP^T/0D8O.D[I(H/)"X\ ML?\ C_\ X[7MFG:&=&\#+I$&!,EFRDJ.LA4Y/YFN%\._"2]TGQ;!J%W=6DMA M;RF2-$9C(V/N9!4 =B>>U>M4Y>]%^87M)6V7^9\Y?#S1;S6]5N[2R\07.C3K M$&S!NS* >1PR],^]=GJ?PPN+V>&VU7Q[+/, 6BBND+L!P"5#2_3I[5;\2?"F M6XUA]7\.:B+"Y=_,\MBR!6/4JZ\KWXQ573OA)J-[J27GBK6OMFPC*)(\C2 = M 7?! ]L4+6UQMVNTP^*M@=+^'^B6#3><;:9(O,V[=VV-AG&3BEU"&6;X 6_E M G9$CL!_=$O-=/\ $#PC>>*="M-/TQ[6 P3!\3,RJ%"D8&T'U%:OAW0FTWPA M::+J AG,<)BF"9*,"3D<@<8/I2=VI>;$FDX^1ROP9NK>3PC-;(Z^?%V],DC\*N>'?A0\&JIJOB34?[0NE8/Y:EF5F'0LSH/R\5;^#=W!-X.DMHR/.@N6\Q>_S8(/]/PJW M\6O^2?W7_76+_P!"%<#X.\#W^L>%EU?0]8FT[4O->)\2,BR*,8Y7D?K34KN; M$U[L4+\8'2[\;V5M;8>X6W2-@O7<6) ^O(_.G_&A2NN:4K=19X/_ 'T:Z;PE M\+)-,UA-8UZ^2]NXV\Q$0LR[\\,S-@L>_3K4_P 1/ .J^+=5M+JPN+.-(8?+ M83NP).XGC"FIM917G^&+K3(VC$TUHT"LQ.T,5QSQG'X5R_PX\%:EX/_M'^T)[27[3Y M>S[.[-C;NSG*CU%6G[\GW,_^7:1POQ%_Y*Q:?6W_ /0JN?&^*0:MI,ISY30. MH^H89_F*Z'Q7\/=6UWQO!K5K<626T?E965W#_*HK-+W%Y,OF7/?R.'T_P "ZU=Z1;7L/Q$U)+:2%9%QOVJN M,_\ /7&!6EX#\!0>'=5DU6V\01ZE'+ 8\1Q Y((;<';/3]:YP?"GQ;!&VGV MWB.)=+8X:/SY4!!ZYC *_AFN\\%^"+/P=:2".4W%Y/CSIV7' Z*H[#^=:7U; M1#VL>9^"D#_&>[)_AGNB/S8?UKL/C/\ \B9!_P!?B?\ H+4SPY\/]5TCX@7& MOW%Q9-:RR3,$C=B^')QP5 [^M;OQ \,WOBOP_'86,MO'*MPLI,[$+@!AV!YY MK-_PXHM->U;Z?\!G/^%@3\#KD 9/V2Z_F]9_P.(^SZTN>=\1Q^#5VOA;PS+I M/@E-!U)XI&*RI(86)4JY/0D ]#Z5PEA\*/$ND:J6T[7XH;-G&]DDDC>11SAE M48/_ 'U6E_WC[,C>%NSN>PUP_P 6O^1 NO\ KK%_Z$*[BN'^+7_(@77_ %UB M_P#0A64]OZ[HJ'Q%3X-W<$W@Z2VC(\Z"Y;S%[_-@@_T_"N-^,#I=^-[*VML/ M<+;I&P7KN+$@?7D?G2>#O ]_K'A9=7T/6)M.U+S7B?$C(LBC&.5Y'ZUU7A+X M62:9K":QKU\E[=QMYB(A9EWYX9F;!8]^G6M7\:;Z"B^5.W7_ #(?B#XXU;2= M5M?#^D21V\[QIYMRX!(+' SP!ZG'?M6=XR\&7MAX2O-4UOQ1>W]TA4QPEML M6XL!@*2<]^F*Z7Q[\.1XLN$U"RNDM[Y$\LB4'9(!G&2.0>>N#6);?"?6+ZU9 M/$'B&2Y,4;+;0),[HC8PI);H!Z ?C6>Z=]RDTFK;%SX)C_BFM0/K=_\ LBUS M/A4[?CA=!N";JZ S]&KO?AUX3U;PC:7MKJ,UG+%,ZR1FW=B0<8.O/IUK1NTT_(E6<91+/QL_P"17L/^ MOP?^@-72?#I G@#2 HZQ$_FQK%\2>!M9UKP3I>CC4+>:^M9?,EN+AWQ)PW?# M$GYAUKJO"NE3Z'X8L-,N7C>:WCVNT1)4G)/&0#W]*4=%)>8I._+\SR#1/^2[ M2?\ 7_::=\/-6M/B4_B.2XLC9FYEFV*[^9A@P'&W&>1WKTNDO@B MAU'>;:.7^(O_ "(&K_\ 7(?^A"N9^"7_ "+FH_\ 7W_[(*[7Q7I,^N^&+_3+ M5XTFN$"HTI(4'(/. 3V]*Q_AWX3O_".DW5I?RVTDDT_F*8&8@#:!SD#THCHY M!)^ZEYGG'A:1-,^,]PM^P1FN;A%9_P"\V=OYY_6O7O%UU;VGA#5I;HKY7V61 M<,<;B5( _$D5@>-/AK9^*;H:A;W)LM0P S[-RR =,CCGWKEU^%/BC4Y(X=<\ M2++9QG*J)Y9B/HK@ <=ZFUX*!5US\Y7^$D$HT/Q-<%2(6A" ]BP5R?T(_.HO M@C"K:]J4Q W);!0?3+?_ %J]6L?#UIH_AI]&TU D?E.@9SRS,/O,?7-$+Z^FU">SE6>-446[LQ!!SSE16E_?;\K$/6'S.UU?3TU71KRPDQMN(6C MSZ9&,U\Y6^NS:5X3UKPW*&66>Y3C^[M)WC_QU17TU7DGB#X2W^J>+KC4+6YL MH]/N)A*Z.S!QG&_ "D=];HRXR27H=2T,)>5"1TS\J#_ +YS^5>@>._"DGBGPVFGV;0Q M7$4JR1-*2%&.",@$]#Z5!\//!UQX0TJZBO9+>6ZN)=S- 25V@8 R0#Z]N]5% MZM^MOF0W[J772_R,#XC>.M5TO6H-!T:2.VED53)<.H)!8X &> /4X[]JS/&7 M@R]L/"5YJFM^*+V_ND*F.$MMBW%@,!23GOTQ72^/?AR/%EPFH65TEO?(GED2 M@[) ,XR1R#SUP:Q+;X3ZQ?6K)X@\0R7)BC9;:!)G=$;&%)+= /0#\:BWN^9H MFDUV#X4#_B@M=/K))_Z*%97P1A5M>U*8@;DM@H/IEO\ ZU=AX'\&:QX:T75M M.OIK&1;L$Q-"['#%2IW94<=*C^'/@35/"%]?3:A/9RK/&J*+=V8@@YYRHK2_ MOM^1F_AMYE?XU0R/X5LI%!*1W8WX'3*L!6Y\,[F"X\ ::(64F)6CD [,&.<_ MF#^-=#J^E6FMZ7/IU['O@F7:P[CT(]P>:\KC^$WB73+R1-'\2+;V4I^=EEDB M&_.HCI==QNS2\C#\8W$%S\8HV@8,$NK='(_O#:#_A^%>^UY!_PI^_L] M>T^ZL;ZVDMX&CDF:=V61W#98@!2 /3FO7Z:T@D$W>5PHHHH)"BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S-:\/Z9XB MM4MM5MC<0H_F*GF.@W8QGY2,]36A%%'!"D,2*D:*%55& H'0"GT4 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% %63_D)1?[O^-6JJR?\A*+_ '?\:M5*ZERV7H%%%%40%%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %6U_P!?<_[W]35J MJMK_ *^Y_P![^IJU4QV+GN%%%%40%%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110!A^+?#O_"4^'Y=*^U?9?,=6\WR]^-ISTR/YTSP?X9_X1/0AIGVO[5^ M]:3S/+V=<<8R?3UK?HH6E_,'K8**** "BBB@ HHHH **** "BBB@ HHHH *P M_%OAW_A*?#\NE?:OLOF.K>;Y>_&TYZ9'\ZW**35QIVU1@>#_ S_ ,(GH0TS M[7]J_>M)YGE[.N.,9/IZUOT453=Q!1112 **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7_A+=#_Y_O\ MR$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QKM_V3 M^]^!Y?\ PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ MY\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ M (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9 M/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K M_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P ) M;H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/ M]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1 M_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S M_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ M<_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_ M\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D) M_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=# M_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^ M/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ M (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y M_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH M_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_ M^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ MX4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V M3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\? M_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_ MPENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_P MH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT M?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ M '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_ MW/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB M6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^ M0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0 M_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/ M_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_ MX1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^ M?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17 M_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/ M_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_ M^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[ MWX!_PH_W/Q*[^*-&-['(+SY N"?*?W]JL?\ "6Z'_P _W_D)_P#"J[^%]&%[ M'&+/Y"N2/-?W]ZL?\(EH?_/C_P"17_QJ5]4U^+\"Y?VCI?D_$/\ A+=#_P"? M[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5 M_P#&J_V3^]^!'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X M1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\ MA/\ X4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ MQH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ M )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/ M_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[W MX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#( MK_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z M'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ M H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C M1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ MS_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_ MX2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ M ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ M H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2 MW0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ M .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^ M$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ M "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C M_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ MY\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ M (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9 M/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K M_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P ) M;H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/ M]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1 M_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S M_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ M<_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_ M\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D) M_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=# M_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^ M/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ M (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y M_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH M_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_ M^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ MX4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V M3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\? M_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_ MPENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_P MH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT M?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ M '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_ MW/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB M6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^ M0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0 M_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/ M_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_ MX1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\2O;^*-&2 M69FO,!FR/W3\]?:K'_"6Z'_S_?\ D)_\*KV_A?1GEF5K/(5L#]Z_'7WJQ_PB M6A_\^/\ Y%?_ !J8_5+?:_ N7]HWUY/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W M_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QJO]D_O?@1_P */]S\0_X2 MW0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ M .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^ M$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ M "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C M_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ MY\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ M (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9 M/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K M_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P ) M;H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/ M]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1 M_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S M_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ M<_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_ M\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D) M_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=# M_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^ M/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ M (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y M_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH M_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_ M^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ MX4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V M3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\? M_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_ MPENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_P MH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT M?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ M '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_ MW/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB M6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^ M0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0 M_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/ M_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_ MX1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^ M?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17 M_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/ M_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_ M^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[ MWX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ M "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4? M\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX M!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"- M'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ M #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0 M_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1_P ( MEH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ MD)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/ M^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ M )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#" MC_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"? M[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5 M_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+ M0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ MR$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D M_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ M ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\ M);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ M ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ M .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA M_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/ MQ#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(E MH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D M)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q# M_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\ M^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_P MH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G M^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_ M\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0 M_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R M$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P : M/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_ M\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ M ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_ MPH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_ M^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H M?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH M_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_") M:'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_? M^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$ MMT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ M #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\ M*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT M/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%? M_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$ MM#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$ M_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#& MC_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ MGQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^ M%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@ M'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO M_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H? M_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ M"C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-' M_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/ M]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A M+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ MSX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ M"C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+= M#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ MY%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1 M+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ M(3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/] MD_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#G MQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ MA1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_ MO?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ M (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ EN MA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W M/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ M B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/] M_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S M\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_S MX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ M ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ M )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_ M^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ MA$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^ M_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ M &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y M\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A M1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/ M[WX!_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\ MBO\ XT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_" M6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C M_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_ MPB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ M?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_< M_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"): M'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y" M?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ M .?[_P A/_A1_P );H?_ #_?^0G_ ,*/^$2T/_GQ_P#(K_XT?\(EH?\ SX_^ M17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O_(3_ .%'_"6Z'_S_ '_D)_\ "C_A M$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ ,:/]D_O?@'_ H_W/Q#_A+=#_Y_ MO_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M#_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ M !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#(3_X4?\);H?\ S_?^0G_PH_X1+0_^ M?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^]^ ?\*/]S\0_X2W0_P#G^_\ (3_X M4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ R*_^-'_"):'_ ,^/_D5_\:/]D_O? M@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PENA_\_P!_Y"?_ H_X1+0_P#GQ_\ M(K_XT?\ "):'_P ^/_D5_P#&C_9/[WX!_P */]S\0_X2W0_^?[_R$_\ A1_P MENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ XT?\(EH?_/C_ .17_P :/]D_O?@' M_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ ,_W_D)_\*/^$2T/_GQ_\BO_ (T? M\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$/^$MT/\ Y_O_ "$_^%'_ ENA_\ M/]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ M (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G_P */^$2T/\ Y\?_ "*_^-'_ B6 MA_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^$MT/_G^_\A/_ (4?\);H?_/]_P"0 MG_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX_P#D5_\ &C_9/[WX!_PH_P!S\0_X M2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C_A$M#_Y\?_(K_P"-'_"):'_SX_\ MD5_\:/\ 9/[WX!_PH_W/Q#_A+=#_ .?[_P A/_A1_P );H?_ #_?^0G_ ,*/ M^$2T/_GQ_P#(K_XT?\(EH?\ SX_^17_QH_V3^]^ ?\*/]S\0_P"$MT/_ )_O M_(3_ .%'_"6Z'_S_ '_D)_\ "C_A$M#_ .?'_P BO_C1_P (EH?_ #X_^17_ M ,:/]D_O?@'_ H_W/Q#_A+=#_Y_O_(3_P"%'_"6Z'_S_?\ D)_\*/\ A$M# M_P"?'_R*_P#C1_PB6A_\^/\ Y%?_ !H_V3^]^ ?\*/\ <_$/^$MT/_G^_P#( M3_X4?\);H?\ S_?^0G_PH_X1+0_^?'_R*_\ C1_PB6A_\^/_ )%?_&C_ &3^ M]^ ?\*/]S\0_X2W0_P#G^_\ (3_X4?\ "6Z'_P _W_D)_P#"C_A$M#_Y\?\ MR*_^-'_"):'_ ,^/_D5_\:/]D_O?@'_"C_<_$/\ A+=#_P"?[_R$_P#A1_PE MNA_\_P!_Y"?_ H_X1+0_P#GQ_\ (K_XT?\ "):'_P ^/_D5_P#&C_9/[WX! M_P */]S\0_X2W0_^?[_R$_\ A1_PENA_\_W_ )"?_"C_ (1+0_\ GQ_\BO\ MXT?\(EH?_/C_ .17_P :/]D_O?@'_"C_ '/Q#_A+=#_Y_O\ R$_^%'_"6Z'_ M ,_W_D)_\*/^$2T/_GQ_\BO_ (T?\(EH?_/C_P"17_QH_P!D_O?@'_"C_<_$ M/^$MT/\ Y_O_ "$_^%'_ ENA_\ /]_Y"?\ PH_X1+0_^?'_ ,BO_C1_PB6A M_P#/C_Y%?_&C_9/[WX!_PH_W/Q#_ (2W0_\ G^_\A/\ X4?\);H?_/\ ?^0G M_P */^$2T/\ Y\?_ "*_^-'_ B6A_\ /C_Y%?\ QH_V3^]^ ?\ "C_<_$/^ M$MT/_G^_\A/_ (4?\);H?_/]_P"0G_PH_P"$2T/_ )\?_(K_ .-'_"):'_SX M_P#D5_\ &C_9/[WX!_PH_P!S\0_X2W0_^?[_ ,A/_A1_PENA_P#/]_Y"?_"C M_A$M#_Y\?_(K_P"-'_"):'_SX_\ D5_\:/\ 9/[WX!_PH_W/Q)K3Q%I5]=); M6UUOF?.U?+89P,GDCT%:E9=IX=TJQNDN;:UV3)G:WF,<9&#P3Z&M2N>K[._[ MN]O,[:'MN7]]:_E?]0HHHK(W"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** *LG_ "$HO]W_ !JU563_ )"47^[_ (U:J5U+ELO0****H@**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *MK_K[G_> M_J:M55M?]?<_[W]35JICL7/<****H@**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBH+R\M["TEN[N9(;>)=SR.8IIVEW%XH;&^200@CU'# M'\P*L:+\9-&OYTAU&TFTYG./,+"2,?4X!'Y4+4;31Z3138Y$EC62-U=& 964 MY!![@TZ@04444 %%%% !1110 445QOCGQY_PADMDG]F_;/M*N<^?Y>W;C_9. M>M*]AI-['945!8W/VRPMKK9L\Z)9-N%_B/:^(-, MU.^N;%[&+3T$DI\SS 0<].!SP>,4)W38[,[>BO)S\;[8WHCCT*9K9XXW\PW&S;N)&,;3G&/6FE>WF#5KG=T4 M44A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%'=7_ +>T"SU3R/(^TIO\K?NV M\D=<#/3TK3JFK:$IW"BBBD,**** "BN=U/QII.F:[::*9&FU"XE2/RH_^6>[ MNQ[=>G6K'BOQ!_PC'AZ?5?LOVGRF4>5YFS.Y@.N#Z^E*^EQV=[&U16!X/\3? M\)9H0U/[)]E_>M'Y?F;^F. MM)NRN"U'45Q'@CXA?\)CJ%U:_P!E_8_(B$F[[1YF[G&,;1BNWJK!Y!1112 * M**Y[Q+XSTGPOY<5W(TEW+CR[:,98@G&3V ]S^&:/(+'0T4#D9HH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HK%\5^(/^$8\/3ZK]E^T^4RCR MO,V9W,!UP?7TJ+P?XF_X2S0AJ?V3[+^]:/R_,W],.8O!D M-H39_;)KEFQ'YOEX4=3G![D56\$?$2+QC>W-HVG_ &*6&,2*//\ ,WC.#_", M8X_.A:[#::5V=M103@$UPW@[XB_\)9KEQIO]E?9?)B:3S/M&_.& QC:/7UH6 MKL%M+G++.Y(_ M=RV@53[JS9'ZC\ZE[I,TI]3T_P %>%;'PWH-JL=O']MDC5[B? +,Q&2,^@S@ M"L?XH^%K/4_#5SJD<")?V:^:)5&"Z#[RMZ\9/X5V6E7<5_I%G=PL&CFA1U(] MQ6/X_O(K+P+J[RL!O@,2Y[LWR@?K3J]2*6Z.7^#6MRWVA76F3NSFR=3&2>B- MGC\"#^=9_P#PMZ]LO$6HV5_8V\EM;R210+;HPDD<-A026(^O%-^!]I(%UB\* MD1L8XE/J1DG^8_.L3PA;1W/QGN/,4,([JYD /J"V#^=6]9I>0:*+?F:US\6O M$VF7L;:GXS-P?^^:]0LM?L+SP['K@E\NR:$S,S_P =0?< M8(KC/C1&K>#[9R!N6\7!],JU8'GRQ_L^+Y;$;I"C$?W3,.O7FMSX,V\$?A":=%'G2W3"1N_ &!^OZUQ_P 9[>"+Q9:RQA1+-:@R M8[D,0"?PX_"FURM1%&TKGKVK^([+0- &JZB^U-BX1!R[D9"J/6O-3\5?%6HE M[C1O#2R64?#,899L?5E( X]JA^,<\WV3P];Y(A,+/CL6PH_D?UKU+PO:V]GX M6TN&U15B%M&PV]R5!)_$G-.U[OSL2FDHKNCG_!7Q&LO%DK6M<+KT::;\;H3IYV MEKR!F5!T+[=P_')_.M3XX_\ 'SHO^Y-_-:EN\8R74M1M)KR.Z\2^);S1O 8U MVWB@:Z,<+[)%)3+E<\ @]_6N-M/BUK&H:9'%I^A&^U?#-*((G,<8R=OR@ECQ MC/(K9\=_\D?7_KA;?S2F_!FVCB\'S7 4"2:Z;$?BICZY816UQ*YC22(,H5^RLK$D>F<]>U=5XS\9VG@_3TEEC,]U M,2(8 V-V.I)[ 5Y9XK41?&V$H-N;RU8X]3LJ3XN,9_'UE;SL1 ((P!GH"YR? M\^E+XE&W5FCBHR=]DKFSIWQ6\0 B^U3PXW]C,W_'S;PR (,]=Q)5OTK3\%_$ M74?$_BZXTR2&S%BJ2/%)'&ZNP# +G+'L?2O03:6_V V?E)]F\KR_+Q\NS&,8 M],5X=\)$2/X@SI&\UGZUK-GH&DSZC?.4@B'.!D ML>P ]2:T*\M^-TLBZ'ID0SY3W#,WU"\?S-1)V005WJ9[?%;Q1?O)=:1X;633 MXS\[&&64@#U92 ./:NO\(?$"V\665RL=N;?4K>,N;&'8J>,C...O-)?%OC.^\(2PZAX?^S03ETN'^QS)Y:#85.2<#))'/I53QU_R6*U M_P"NUK_-:].^(O\ R(&K_P#7(?\ H0J+_NKE_P#+Q+T/*_AEK>OZ?F:0 M+FPN;M!=7/V:1S&#@'YE.!@<\UVGC7X@:KX<\76NDV=O9/!+'&S-,C%@68@X M(8#MZ5#\$O\ D7-1_P"OO_V05S7Q4_Y*3I__ %QA_P#0VK5_'%&?23]3USQ' MXBL?#&D/J%\QV@[4C7[TC'HHKS%OBOXKNDDOK#PY&=-C/S2&&60*!US("%'Y M4_XXRR^9HT//E8E;ZM\H_P _6O2O"T$,7A#28HD41&SC.!T.5!/YY-9J[3D4 M[*R[F3X(\>6OC""5/(^RWT S)#NW K_>4^G\JYK6_BO>MK,NF>&-)%_)&Q7S M&1Y-Y'7:B8./?-=MHNC>&=+>2?1[:Q215*O+$P9@ >06R3U'/TKBV^(%SJ^N MSP>#O#4-Y=(I!O)L+E<\D],*2!U89XXIO5JPDMRGI_QH:IJMGHVES:C>R[+:%=S-U)] /4GI7S_ /$9?$']O6S^ M(FM/M3VX*):_=1-S<'WSGN:[WXNRRIX&TN-Q7*N=+R, MZ3XL>)=3FE?0/#@EM8OO%H9)V [$E" OTKH_!GQ)3Q5)+I\MLEGJ@C+1#<6C MDP/P(QZ>G>KWPPABB^'^FF)0#)O=R.[;R.?R%:=CH?AFWUB:ZL[2Q_M(2LTC MJ0TBN>6[DJ>?;K5-6;B1=-7.3\%?$/5-;\4SZ)K-M9V\J*X00HRGS%/*G+'M MG\JZ#Q[XJE\)>'Q>6R1274DJQ1)*"5]22 0>@/>O.?'%N?"7Q1L==B4K;W$B MSL1Z@XD'Y<_\"JU\3IY/$GC/1_#MFVY<*20>-TAZ_@H!_&IUE&-MWH79*3?2 MUST;P9JNI:YX:M]3U2*WBFN"61(%90$S@9R3R<9_$5O.ZQHSNP55&23T J*U MMHK.TAM8$"10H(T4=@!@5A^/)9(? NL/%G=]G*\>AX/Z$TYNUVB(*[29Q6I_ M%G4;S4WLO"FC?;A&?]8\3R%P.I")@@>Y/X5H>%?BB=2U==&UW3_[/OF;8K , M%+_W2K(M M;@U:YT"V@N8E50;:>-0=IR"/_ !QK?A#6+1+>TLI=/N$W M!I$8OD'YAD,!T([=Z[N&^MYM.2_20&V>(3!^VW&<_E7)?$W0SK/@F:0)FZLL M7"X&3P/F'Y9_(5PMEXQ:/X,W5FS_ .E)+]AC]=C_ #?^@[A^%1?W9+JOU'9- MQ?3>1UVHF#CWS6K\)]%&D>#_MTR[);YO.8MV0<+^F3^-9C?$"YU?7 M9X/!WAJ&\ND4@WDV%RN>2>F%) ZL,\<5G_%S5+/5DLO$^C+:A MF 8QQO$\8/0E'))'Y5H?&L@^%K CH;P?^@-7G_Q&7Q!_;UL_B)K3[4]N"B6O MW43L$_,M*T].QL^']2FT?X.V^HVZQ MM-;632(L@)4D$]<$5)\.?&&H>+[.^FU"&UB:WD55%NK*""">/_B%JWA7Q#;Z?8V]E)%) LA, MZ.6R68=F''%=IX@\06GAO0Y-3O:8+CKEU('Z5U'@OXBCQ7%=VSV8@U&"(RJB$LD@'IW')''OUK,T MS7_&VOV"MX>T#3=*TUPQ268\6J2N MW'R$[O6[CQAK]E\-YM M>OM.AMM3CE"?9YH)$7:7"Y*EMW0^M<5KG_)>(?\ K\M__04KO_BM_P D]O\ M_?B_]#6IO^[3_K=#:O4M_6Q=\!>([SQ3X;&HWT<$_K6#X ML^*46CZFVDZ/9?VA?*=CL2=BO_= '+'/4#%.^$[M'\.Y'09=9IBH]\"N/^#L M,5[XOOKNZ DN8X&D0MR0S,-S?7G]:IJ\[>5R(Z1YGW-6#XLZ[I=Y''XF\/&W MBD/!2*2%P.Y ZL\A$4-I&^T)@-HL]V5B21^5-^!]M'Y6L714&3='&&[@I4?RI+G_ (]9O]QO MY5$]$R8:M'G_ ,._'NJ>+M4O+:_M[.-((1(I@1@2=V.B4F^AKW_Q8\3VDD=V_AM;;39#\AN(I07'L_"]/8UZ3 MX7\16WBG0XM3MT,>XE)(F.2CCJ,]_K[UD_$Z-7^'NI[@#M$;#V.]:Q/@H2?" MEZ,\"]/_ * M$=;KL$EHI'I5?-WC[5-7U#Q<9=2L?LTL!\NW3R73S(U=MK88 M\Y]1Q7TC7AOQ>_Y'S3_^O:/_ -&-27QQ''X9>AV6G>+O$I\%ZSJ^K:3'97EF M,P1R6\D:N,#DAFR?P(KDQ\:]4&E!U&[)).>XKTCQ[_P B M%K'_ %['^E<+\$=/A9-5U!HP9E9(4E^&HWLESE_L\TP7'7 M+J0/TKTCQ7XCT_PSHK7FH1F9&8(D*@$R-UQSQVS7&:9K_C;7[!6\/:!INE:: MX8I+,>.3R0!CU)SMYYI-W;:&E9*YL> _B''XODFLY[46U]$GF81MR.N0"1Z8 M)'%8FN?%&]T'QS:_0U[_P"+'B>TDCNW\-K; M:;(?D-Q%*"X]GX7I[&O0]"\6V&M^%SKO,$,:L9U8Y,9498>_'/XUG_$Z-7^' MNI[@#M$;#V.]:Y?X5Z>NK_#S6=-D&S<6\9(+-#),V.Q.P@+].:V/"GQ%U;4]772M8\/3P3%MC2P0N! M&W4;U.2HQWS[].G'6^D?$'P!+.NFP23V;/N;R(Q,DGOM^\OZ5O>'OB](M.6!W<1F:(%-A.,;D;]3G\*<;/1"DM&=_XH\2V?A71WU"\R_.R*)3\TC> M@_QKSFS^*_B:YD:]7PR)M)0_.T$4A*#OF3E?T%,^.,TGGZ-#D^5ME?'8G*BO M3?#%M!:^%M+AME A%K&1COE02?Q))J8W:<@=E9=S@]'^*-YK?CJWTJT@M3I= MP^$=HW$H&S//S8SGCI6]XV^(5KX2:.TB@^UZC(NX1;L*B]BQ]^PKS;1+>"U^ M-P@MP!"E_*%"]!PW%5]=EU&7XP7+V5M%=7R7@\B&:-J^@^ M#[NQUBW\B199&B3S%?Y"H_NDCKFA_#+R)LKHY72?C+J,RW$=YI<-Q=MM6T@L MT=2['.=V2WMT&:5/B[KNFZJL.OZ"EO"W/EB.2*55)Z_.3G\AFLWX+VT^?PHT+XM77]L)IGB;2UL9'<(9$5D\LGIN1L MD#WS^%5/@=#$1K,^T&8>4@;N%.X_S'Z5Z'JFB>&K_58Y]5M;*:],>U!<,"2@ M/92>>3UQWIVY6KZ@VGK3Z%X8O]3M4C>:W0,BR@E2<@V<_P"- M3?!&WC&CZI<[5\QIUCW8YP%SC]:Y;Q1;0S?&L0.@,4M[;!U['(3-:6]]1[@K M--]C:OOBWXCLYXKJ3PXEOIDI_=?:(Y%:0>S\*?P!KTW1_$-EK'AV+6XV\JU: M,N_F''E[<[@?I@US'Q>53X#DX'RW$>/;DUR-K/-!\ KDQ$C?<%&(_NF09_S[ MU%_=EY6':[CYFE?_ !;U*^U"2T\*Z(;P(>'>-Y&=1U.Q,$#ZFK7A[XL--JBZ M7XETX:=<,VSS0&558] R-ROUR:L_!FUMX_",URB+Y\MRRR/WP ,#]?UK#^.% MM;K)I%T HN7$B-@;4[*.&29'10 MLP)7!;!Z$']:C\!>([SQ3X;&HWT<$_K7,>,II;CX*6&U+ENI/R\U?\ @]_R(P_Z^I/Z4TK.2?0A_#%]RGJWQ#U:P^)$?AV*WLC9 MM3VK7\;_ ! A\)206<%H;S4)UW+'NPJKG )[DD] *\[\ M1D'XY0X.?].M?Y)76?$CP+JNM:G;ZYHC![N%%1H=X5OE)*LI/&>?7M4_8B_O M-&ESM>1DGXE^.+,+<:AX65+7(!)M)HLYZ88DCKCM7IF@:X-;T1-1EL[BP//F M17*%2I'4@D#(]Z\G'Q!\>^'"%UK33+$APSW-L4R/9UPOX\UU5YXSA\5?#'6[ MVSB>"XBA,23,S4_BSJ-YJ;V7A31OMPC/^L> M)Y"X'4A$P0/H\BB:2=P&4@< 9D7CDUZIJT5W/<3)MC,"*V"QRQ.YAZ#]:=\1?%> MC^+;RSO-.@NXIHD,LG_HQ:]1\$ZQ_;G@VPO&;=*(O*E_WUX/YXS^->7?!W_D>-0_Z] M9/\ T8M5%6J->3(O>D_5'N=<;\4H+J?P#>K;*S;61Y O78&!/Y=?PKLJHZIJ MVF:3;A]4O+>VBD.T>